trial_id	trialacronym	phase	recruitmentstatus	recruitmentstate	approvaldate	actualstartdate	actualenddate	drug_list	drug_classes	combo_list	combo_classes	secondaryid	studytitle	healthcondition	postcode	ext_weblink
ACTRN12617001190392	PIT-Study	Phase 1 / Phase 2	STATUS_UNKNOWN	SA	2017-08-15			Irinotecan; Irinotecan + Panitumumab; Panitumumab; Trifluridine/Tipiracil	antimetabolite; topoisomerase_inhibitor; anti-EGFR_monoclonal_antibody + topoisomerase_inhibitor; Tipiracil Hydrochloride; anti-EGFR_monoclonal_antibody; Trifluridine; thymidine_phosphorylase_inhibitor	Irinotecan + Panitumumab; Trifluridine/Tipiracil	Tipiracil Hydrochloride; Trifluridine; anti-EGFR_monoclonal_antibody + topoisomerase_inhibitor; antimetabolite; thymidine_phosphorylase_inhibitor	None	An open label phase IB/II, non-randomised, dose-finding, safety and tolerability study of Panitumumab, Irinotecan, Trifluridine/Tipiracil in RAS wild-type patients with metastatic colorectal cancer	colorectal cancer	5042 - Bedford Park; 5000 - Adelaide; 5011 - Woodville	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12617001190392
ACTRN12619000566134	OXTOX	Phase 2	RECRUITING	NSW, VIC	2019-04-10	2021-01-28		Ibudilast; Ibudilast + Oxaliplatin; Oxaliplatin	platinum-based_antineoplastic_agent; PDE4_inhibitor; PDE4_inhibitor + platinum-based_antineoplastic_agent	Ibudilast + Oxaliplatin	PDE4_inhibitor + platinum-based_antineoplastic_agent	None	OXTOX: Can Oxaliplatin neurotoxicity be reduced with ibudilast in people with metastatic colorectal cancer – a phase II randomised study	Neurotoxicity caused by oxaliplatin in patients with metastatic colorectal cancer	2444 - Port Macquarie; 3128 - Box Hill; 2139 - Concord; 2747 - Kingswood; 2640 - Albury; 2500 - Wollongong; 2109 - Macquarie Park; 2065 - St Leonards; 2250 - Gosford; 2800 - Orange	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12619000566134
ACTRN12619001298101	ASN-002-IL	Phase 2	NOT_YET_RECRUITING	QLD	2019-09-20			Fluorouracil; Fluorouracil + Gusacitinib; Gusacitinib	Fluorouracil; SYK/JAK_inhibitor + fluoropyrimidine; SYK/JAK_inhibitor	Fluorouracil + Gusacitinib; Gusacitinib	SYK/JAK_inhibitor; SYK/JAK_inhibitor + fluoropyrimidine; Fluorouracil	SP-002	A Phase IIa Study to assess the Efficacy and Safety of ASN-002 alone and in combination with chemotherapy in adult participants with Low-Risk Basal Cell Carcinomas	Basal Cell Carcinoma; Basal Cell Nevus Syndrome (BCNS)	4000 - Brisbane	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12619001298101
ACTRN12620000583943	EOHC-1001-01	Phase 1 / Phase 2	RECRUITING	VIC	2020-05-20	2021-09-02		EO1001	EGFR_inhibitor,second_generation; ERBB2_inhibitor,second_generation	EO1001	EGFR_inhibitor,second_generation; ERBB2_inhibitor,second_generation	EOHC-1001-01	An ascending single and multiple dose study of the safety, tolerability, pharmacokinetics and anti-tumour activity of once-daily oral treatment with EO1001 in patients with advanced cancer.	ErbB-1(EGFR) positive cancer; ERbB-4 (HER4) positive cancer; ErbB-2(HER2) positive cancer	3168 - Clayton; 3144 - Malvern; 3004 - Melbourne	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12620000583943
ACTRN12620001198910	MODERN-LUNG	Phase 2	RECRUITING	NSW	2020-11-10	2021-04-15		Carboplatin; Carboplatin + Paclitaxel; Durvalumab; Paclitaxel; Radiotherapy	radiotherapy; platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent + taxane; anti-PD-L1_monoclonal_antibody; taxane	Carboplatin + Paclitaxel; Durvalumab; Radiotherapy	anti-PD-L1_monoclonal_antibody; platinum-based_antineoplastic_agent + taxane; radiotherapy	CMNDRO-2005	Phase 2 Study of a Moderately Hypofractionated Schedule of Chemoradiation followed by Immunotherapy for Unresectable Locally Advanced Non-Small Cell Lung Cancer	lung cancer	2148 - Blacktown; 2560 - Campbelltown; 2145 - Westmead; 2298 - Waratah; 2500 - Wollongong; 2170 - Liverpool	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12620001198910
ACTRN12621000156886	ACE-IT001	Phase 1 / Phase 2	RECRUITING	NSW	2021-02-15	2021-08-30		Ipilimumab; Ipilimumab + Nivolumab; Nivolumab; Perindopril	anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; ACE_inhibitor; anti-CTLA4_monoclonal_antibody	Ipilimumab + Nivolumab; Perindopril	ACE_inhibitor; anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	NONE	A pilot study of Perindopril in combination with first line Ipilimumab and Nivolumab for patients with unresectable or metastatic melanoma- ACE-IT 001	Melanoma - Metastatic; Melanoma - Unresectable	2298 - Waratah	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621000156886
ACTRN12621000273886	ADELE	Phase 2	RECRUITING	NSW, NZ, QLD, SA, VIC, WA	2021-03-11	2022-06-03		Carboplatin; Carboplatin + Paclitaxel + Tislelizumab; Paclitaxel; Tislelizumab	platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; anti-PD-1_monoclonal_antibody; taxane	Carboplatin + Paclitaxel + Tislelizumab	anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane	ANZGOG 1910/2020  CTC0299	The effect of adjuvant tislelizumab plus chemotherapy on failure free survival after post-operative pelvic chemoradiation in high risk endometrial cancer - ADELE: a randomised phase 2 trial	Endometrial Cancer	2298 - Waratah; 2250 - Gosford; 3052 - Parkville; 3199 - Frankston; 3168 - Clayton; 2065 - St Leonards; 2145 - Westmead; 4814 - Douglas; Wellington; Auckland; 6009 - Nedlands; 5042 - Bedford Park; Northland; 3121 - Richmond; 3000 - Melbourne; 4029 - Herston; 2050 - Camperdown; 5000 - Adelaide; 2031 - Randwick	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621000273886
ACTRN12621000611820	PICAASO	Phase 2	RECRUITING	NSW, VIC	2021-05-21	2021-11-02		Dasatinib	YES1_inhibitor; PDGFRA_inhibitor; SRC_inhibitor; KIT_inhibitor; BCR-ABL1_inhibitor,second_generation	Dasatinib	BCR-ABL1_inhibitor,second_generation; KIT_inhibitor; PDGFRA_inhibitor; SRC_inhibitor; YES1_inhibitor	Nil Known	Prostate-Specific Membrane Antigen (PSMA) Intensity Can be Altered by Androgen and phospho-SrC Obstruction	metastatic castration-resistant prostate cancer	3000 - Melbourne; 2010 - Darlinghurst	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621000611820
ACTRN12621000639820	PARAGON-II	Phase 2	RECRUITING	NSW, NZ, QLD, SA, TAS, VIC, WA	2021-05-28	2022-08-04		Alpelisib; Alpelisib + Letrozole; Letrozole; Letrozole + Ribociclib; Ribociclib	PI3K_alpha_inhibitor; CDK4/6_inhibitor + aromatase_inhibitor; PI3K_alpha_inhibitor + aromatase_inhibitor; aromatase_inhibitor; CDK4/6_inhibitor	Alpelisib + Letrozole; Letrozole; Letrozole + Ribociclib	CDK4/6_inhibitor + aromatase_inhibitor; PI3K_alpha_inhibitor + aromatase_inhibitor; aromatase_inhibitor	None	The activity and tolerability of Aromatase inhibitor plus PI3KCA inhibitor or CDK4/6 inhibitor in women with hormone receptor positive recurrent/metastatic gynaecological neoplasms (PARAGON-II) .	Granulosa cell tumours; Platinum resistant high-grade epithelial cancers of fallopian tube; Low grade epithelial cancers of ovary; Other gynaecological cancers (excluding endometrial cancers); Endometrial cancer; Platinum resistant high-grade epithelial cancers of primary peritoneum; Platinum resistant high-grade epithelial cancers of ovary; Endometrial stromal sarcomas; Leiomyosarcomas	2050 - Camperdown; 4029 - Herston; 3000 - Melbourne; 2640 - Albury; 2031 - Randwick; 2500 - Wollongong; 2485 - Tweed Heads; 5042 - Bedford Park; 2145 - Westmead; 6009 - Nedlands; Auckland; 2305 - New Lambton Heights; 4101 - South Brisbane; 2065 - St Leonards; 7000 - Hobart; 3168 - Clayton	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621000639820
ACTRN12621000762853	ACTRN12621000762853	Phase 1	RECRUITING	QLD	2021-06-18	2021-07-21		Cyclophosphamide; Cyclophosphamide + Fludarabine + Tisagenlecleucel; Fludarabine; Tisagenlecleucel	alkylating_agent + antimetabolite + autologous_CAR-T-cell_therapy,CD19-targeting; antimetabolite; alkylating_agent; autologous_CAR-T-cell_therapy,CD19-targeting	Cyclophosphamide + Fludarabine + Tisagenlecleucel; Tisagenlecleucel	alkylating_agent + antimetabolite + autologous_CAR-T-cell_therapy,CD19-targeting; autologous_CAR-T-cell_therapy,CD19-targeting	None	Phase I Clinical Trial of MB.CART19.1 CD19 Chimeric Antigen Receptor (CAR) T Cells in Relapsed or Refractory CD19-Positive Haematological Malignancy	B cell blood cancers, including non-Hodgkin's lymphoma and leukaemia.	4029 - Herston; 4029 - Royal Brisbane Hospital	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621000762853
ACTRN12621000802808	LU-TEMP	Phase 2	RECRUITING	NSW	2021-06-25			177Lu-edotreotide; Temozolomide	177Lu-DOTA-radioconjugate; alkylating_agent	Temozolomide; 177Lu-edotreotide	alkylating_agent; 177Lu-DOTA-radioconjugate	Nil	A pilot open label study of [177Lu]Lu-octretotate and temozolomide in the treatment of succinate dehydrogenase-associated locally advanced or metastatic pheochromocytoma and paraganglioma in adults.	Cancer	2065 - St Leonards	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621000802808
ACTRN12621000848808	EQ143-101	Phase 1	RECRUITING	NZ	2021-07-01	2021-06-21		Almonertinib	EGFR_inhibitor,third_generation	Almonertinib	EGFR_inhibitor,third_generation	EQ143-101	A Single Dose Phase 1 Study in Healthy Participants to Evaluate the Comparative Pharmacokinetics of Orally Administered EQ143 in Caucasian and Ethnic Chinese Populations	Non Small Cell Lung Cancer	Auckland	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621000848808
ACTRN12621000991819	PDCCiHNC	Not Applicable	STATUS_UNKNOWN	NSW	2021-07-28			Carboplatin; Ceralasertib; Cisplatin; Crizotinib; Dactolisib; Dasatinib; Docetaxel; Doxorubicin; Erlotinib; Etoposide; Fluorouracil; Gemcitabine; Itraconazole; Methotrexate; Paclitaxel; Palbociclib; Pemetrexed; Ruxolitinib; Sorafenib; Vinorelbine; Vistusertib	antimetabolite; PDGFR_inhibitor; EGFR_inhibitor,first_generation; JAK1/JAK2_inhibitor; anthracycline; Fluorouracil; CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor; vinca_alkaloid; platinum-based_antineoplastic_agent; ALK_inhibitor,first_generation; SMO_inhibitor; YES1_inhibitor; CDK4/6_inhibitor; fluoropyrimidine; gemcitabine; mTORC1/mTORC2_inhibitor; ROS1_inhibitor; ATR_inhibitor; doxorubicin; PDGFRA_inhibitor; KIT_inhibitor; VEGFR_inhibitor; topoisomerase_inhibitor; antifolate; CRAF_inhibitor; taxane; SRC_inhibitor; BCR-ABL1_inhibitor,second_generation; FLT3_inhibitor; PI3K/mTOR_inhibitor; MET_inhibitor,type_1	Carboplatin; Ceralasertib; Cisplatin; Crizotinib; Dactolisib; Dasatinib; Docetaxel; Doxorubicin; Erlotinib; Etoposide; Fluorouracil; Gemcitabine; Itraconazole; Methotrexate; Paclitaxel; Palbociclib; Pemetrexed; Ruxolitinib; Sorafenib; Vinorelbine; Vistusertib	ALK_inhibitor,first_generation; ATR_inhibitor; BCR-ABL1_inhibitor,second_generation; CDK4/6_inhibitor; CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor; CRAF_inhibitor; EGFR_inhibitor,first_generation; FLT3_inhibitor; JAK1/JAK2_inhibitor; KIT_inhibitor; MET_inhibitor,type_1; PDGFRA_inhibitor; PDGFR_inhibitor; PI3K/mTOR_inhibitor; ROS1_inhibitor; SMO_inhibitor; SRC_inhibitor; VEGFR_inhibitor; YES1_inhibitor; anthracycline; antifolate; antimetabolite; fluoropyrimidine; mTORC1/mTORC2_inhibitor; platinum-based_antineoplastic_agent; taxane; topoisomerase_inhibitor; vinca_alkaloid; Fluorouracil; doxorubicin; gemcitabine	Nil known	A Feasibility Trial of Patient Derived Cell Culture (PDCC) Chemosensitivity in Head and Neck Carcinoma (HNC)	Head and Neck Carcinoma	2050 - Camperdown	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621000991819
ACTRN12621001444875	The-SOCRATES-HCC-Study	Phase 2	RECRUITING	ACT, NSW, QLD, SA, VIC, WA	2021-10-25	2022-11-29		Radiotherapy	radiotherapy	Radiotherapy	radiotherapy	TROG 21.07	A randomised controlled trial of Standard Of Care versus RadioAblaTion in Early Stage HCC (The SOCRATES HCC Study)	Early Hepatocellular Carcinoma	6009 - Nedlands; 2145 - Westmead; 6150 - Murdoch; 3050 - Parkville; 4102 - Woolloongabba; 5000 - Adelaide; 2747 - Kingswood; 4029 - Herston; 2050 - Camperdown; 2305 - New Lambton; 3128 - Box Hill; 4215 - Southport; 5042 - Bedford Park	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621001444875
ACTRN12621001458820	CHARMM	Phase 1	NOT_YET_RECRUITING	NSW	2021-10-26			Carfilzomib; Carfilzomib + Dexamethasone; Carfilzomib + Dexamethasone + Hydroxychloroquine; Dexamethasone; Hydroxychloroquine	proteasome_inhibitor; glucocorticoid; anti-malarial_agent; anti-malarial_agent + glucocorticoid + proteasome_inhibitor; glucocorticoid + proteasome_inhibitor	Carfilzomib; Carfilzomib + Dexamethasone; Carfilzomib + Dexamethasone + Hydroxychloroquine; Hydroxychloroquine	anti-malarial_agent; anti-malarial_agent + glucocorticoid + proteasome_inhibitor; glucocorticoid + proteasome_inhibitor; proteasome_inhibitor	none	Phase I Clinical Trial to Determine Dosing Schedule of Hydroxychloroquine in Participants with Multiple Myeloma and Partial Response or Less to Carfilzomib	Myeloma; Cancer	2170 - Liverpool	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621001458820
ACTRN12621001537842	NOX66-IS-002--CA209-66P,	Phase 1 / Phase 2	RECRUITING	NSW	2021-11-10	2021-10-25		Idronoxil; Idronoxil + Nivolumab; Nivolumab	anti-PD-1_monoclonal_antibody + idronoxil_suppository; anti-PD-1_monoclonal_antibody; idronoxil_suppository	Idronoxil; Idronoxil + Nivolumab; Nivolumab	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + idronoxil_suppository; idronoxil_suppository	NOX66-IS-002  CA209-66P,	Safety and Efficacy of NOX66 in combination with Nivolumab for patients with solid tumours – a pilot study (IONIC-1).	Patients with solid tumours	2228 - Miranda; 2148 - Blacktown; 2217 - Kogarah; 2076 - Wahroonga	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621001537842
ACTRN12622000016730	HER2Pro-1B	Phase 1	RECRUITING	NSW, QLD	2022-01-11	2023-06-20		Dexamethasone; Dexamethasone + Paclitaxel + Pertuzumab + Prochlorperazine + Trastuzumab; Paclitaxel; Paclitaxel + Pertuzumab + Prochlorperazine + Trastuzumab; Paclitaxel + Pertuzumab + Trastuzumab; Pertuzumab; Prochlorperazine; Trastuzumab	antihistamine; anti-ERBB2_monoclonal_antibody; taxane; anti-ERBB2_monoclonal_antibody,dimerization_inhibitor; glucocorticoid; anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor + antihistamine + taxane; anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor + antihistamine + glucocorticoid + taxane; anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor + taxane	Dexamethasone + Paclitaxel + Pertuzumab + Prochlorperazine + Trastuzumab; Paclitaxel + Pertuzumab + Prochlorperazine + Trastuzumab; Paclitaxel + Pertuzumab + Trastuzumab; Prochlorperazine	anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor + antihistamine + glucocorticoid + taxane; anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor + antihistamine + taxane; anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor + taxane; antihistamine	None	Addition of prochlorperazine to paclitaxel, trastuzumab, and pertuzumab for previously untreated HER2-positive metastatic breast cancer: a phase 1 dose de-escalation study	Metastatic HER2-positive breast cancer	4102 - Woolloongabba; 2010 - Darlinghurst	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12622000016730
ACTRN12622000083796	20)	Phase 3	RECRUITING	QLD	2022-01-21	2022-12-14		Placebo; delta-9-tetrahydrocannabinol	placebo; tetrahydrocannabinol	delta-9-tetrahydrocannabinol; Placebo	tetrahydrocannabinol; placebo	Nil Known	Medicinal Cannabis (MedCan 3) – a randomised, multicentre, double blind, placebo-controlled trial to assess THC/CBD (1:20) to relieve symptom burden in patients with cancer	Cancer	4101 - South Brisbane; 4300 - Springfield Central; 4163 - Cleveland; 4169 - Kangaroo Point	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12622000083796
ACTRN12622000993796	ACTRN12622000993796	Phase 1	RECRUITING	NSW, VIC, WA	2022-07-14	2022-11-15		AXA-042; Cemiplimab	anti-PD-1_monoclonal_antibody; TLR2/TLR6_agonist	AXA-042; Cemiplimab	TLR2/TLR6_agonist; anti-PD-1_monoclonal_antibody	None	A Phase 1a/1b, first-in-human, open-label, non-randomised, multicenter, dose-escalation and dose -expansion study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of AXA-042 as monotherapy and in combination with an anti-PD-1 monoclonal antibody (cemiplimab) in subjects with advanced solid tumours: phase 1a	Advanced solid tumors	6009 - Nedlands; 3175 - Dandenong; 3000 - Melbourne; 2031 - Randwick	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12622000993796
ACTRN12622001003763	X22-0072	Phase 2	RECRUITING	NSW	2022-07-18	2023-03-08		Evolocumab	anti-PCSK9_monoclonal_antibody	Evolocumab	anti-PCSK9_monoclonal_antibody	Protocol Number: X22-0072	A multi-centre, open label phase 2 trial investigating the effect of evolocumab in addition to chemotherapy or androgen receptor signalling inhibitor therapy on the circulating lipid profile of men with metastatic castration-resistant prostate cancer	Metastatic Castrate Resistant Prostate Cancer	2145 - Westmead; 2010 - Darlinghurst; 2050 - Camperdown	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12622001003763
ACTRN12622001201763	TRAS-GB	Phase 2	RECRUITING	NZ	2022-09-07			Celecoxib; Metformin; Propranolol; Radiotherapy; Radiotherapy + Temozolomide; Temozolomide	biguanide_antihyperglycaemic_agent; COX2_inhibitor; radiotherapy; alkylating_agent; beta-adrenergic_blocker; alkylating_agent + radiotherapy	Celecoxib; Metformin; Propranolol; Radiotherapy + Temozolomide	COX2_inhibitor; alkylating_agent + radiotherapy; beta-adrenergic_blocker; biguanide_antihyperglycaemic_agent	none	Efficacy of Treatment Targeting the Renin-Angiotensin System in Glioblastoma (TRAS-GB) Trial	Glioblastoma		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12622001201763
ACTRN12622001378718	TheraPb-phase-I-II	Phase 1 / Phase 2	RECRUITING	QLD	2022-10-26	2023-11-01		212Pb-ADVC001	radioligand,PSMA-targeting	212Pb-ADVC001	radioligand,PSMA-targeting	none	Phase I/IIa Dose Escalation and Toxicity Study of [212Pb]Pb-ADVC001 in Metastatic Prostate Adenocarcinoma (TheraPb – Phase I/II)	Metastatic Prostate Cancer	4029 - Royal Brisbane Hospital; 4029 - Herston; 4102 - Woolloongabba	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12622001378718
ACTRN12622001514796	KARPOS	Not Applicable	RECRUITING	SA	2022-12-06	2023-05-17		Bevacizumab; Bevacizumab + GD2-iCAR-PBT; Cyclophosphamide; Cyclophosphamide + Fludarabine; Fludarabine; GD2-iCAR-PBT; Ifosfamide	antimetabolite; anti-VEGF_monoclonal_antibody + autologous_CAR-T-cell_therapy,GD2-targeting; alkylating_agent; autologous_CAR-T-cell_therapy,GD2-targeting; anti-VEGF_monoclonal_antibody; alkylating_agent + antimetabolite	Bevacizumab + GD2-iCAR-PBT; Cyclophosphamide + Fludarabine; GD2-iCAR-PBT; Ifosfamide	alkylating_agent + antimetabolite; anti-VEGF_monoclonal_antibody + autologous_CAR-T-cell_therapy,GD2-targeting; autologous_CAR-T-cell_therapy,GD2-targeting	Nil Known	KARPOS - A Phase 1, Single-Centre, Non-randomised, Open-labelled, Escalating Dose Study of Autologous GD2-Specific Chimeric Antigen Receptor-expressing Peripheral Blood T cells in Patients with Recurrent GD2-positive Glioblastoma Multiforme	Glioblastoma Multiforme	5000 - Adelaide	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12622001514796
ACTRN12623000073606	SLAP-trial	Phase 0	NOT_YET_RECRUITING	NSW	2023-01-23			Lu-177 vipivotide tetraxetan	radioconjugate,PSMA-targeting	Lu-177 vipivotide tetraxetan	radioconjugate,PSMA-targeting	None	A Single-Arm, Open-Label, Prospective, Phase 0 Trial Evaluating the Safety and Efficacy of Salvage 177Lu-PSMA-I&T in Prostate Specific Antigen (PSA) Biochemical Failure After Radical Prostatectomy for High-Risk Prostate Cancer	Prostate cancer	2076 - Wahroonga	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623000073606
ACTRN12623000096651	LUMOS2	Phase 2	RECRUITING	NSW, QLD, SA, TAS, VIC, WA	2023-01-27	2023-09-11		Cadonilimab; Cadonilimab + Niraparib; Niraparib; Paxalisib; Selinexor	dual_PI3K/mTOR_inhibitor; XPO1_inhibitor; PARP_inhibitor + bispecific_PD-1/CTLA4_antibody; bispecific_PD-1/CTLA4_antibody; PARP_inhibitor	Cadonilimab; Cadonilimab + Niraparib; Paxalisib; Selinexor	PARP_inhibitor + bispecific_PD-1/CTLA4_antibody; XPO1_inhibitor; bispecific_PD-1/CTLA4_antibody; dual_PI3K/mTOR_inhibitor	CTC0378  COGNO2201	LUMOS2: Low & Anaplastic Grade Glioma Umbrella Study of Molecular Guided TherapieS	Grade 2 Glioma; Grade 3 Glioma	4029 - Herston; 3000 - Melbourne; 2010 - Darlinghurst; 3084 - Heidelberg; 2170 - Liverpool; 5042 - Bedford Park; 6009 - Nedlands; 4102 - Woolloongabba; 2298 - Waratah; 3168 - Clayton; 7000 - Hobart; 3065 - Fitzroy; 2065 - St Leonards	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623000096651
ACTRN12623000174684	APG2449OG101	Phase 1	RECRUITING	NSW, QLD	2023-02-21	2023-08-08		APG-2449; APG-2449 + Doxorubicin; Doxorubicin	anthracycline; FAK_inhibitor + anthracycline; FAK/ALK/ROS1_inhibitor + anthracycline; ALK_inhibitor,third_generation + anthracycline; ALK_inhibitor,third_generation; FAK_inhibitor; doxorubicin; FAK/ALK/ROS1_inhibitor	APG-2449; APG-2449 + Doxorubicin	ALK_inhibitor,third_generation; ALK_inhibitor,third_generation + anthracycline; FAK/ALK/ROS1_inhibitor; FAK/ALK/ROS1_inhibitor + anthracycline; FAK_inhibitor; FAK_inhibitor + anthracycline; doxorubicin	APG2449OG101	A Phase Ib/II Study of APG-2449 in Combination with Doxorubicin Hydrochloride Liposome in Patients with Ovarian Cancer	Ovarian Cancer	2050 - Camperdown; 2148 - Blacktown; 4101 - South Brisbane	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623000174684
ACTRN12623000216617	RESCUE	Phase 1	NOT_YET_RECRUITING	NZ	2023-02-28			177Lu-DOTA-rosopatamab; Lu-177 vipivotide tetraxetan; Radiotherapy	radiotherapy; radioconjugate,PSMA-targeting; radioligand,PSMA-targeting	177Lu-DOTA-rosopatamab; Lu-177 vipivotide tetraxetan; Radiotherapy	radioconjugate,PSMA-targeting; radioligand,PSMA-targeting; radiotherapy	Nil Known	A pilot, feasibility study of 177Lu-DOTA-Rosopatamab (TLX591) therapy in castrate resistant prostate adenocarcinoma patients showing progression on radioligand therapy using PSMA small molecule ligands	Metastatic Prostate Cancer	Auckland	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623000216617
ACTRN12623000223639	iLSTA	Phase 1	RECRUITING	WA	2023-03-02	2023-04-03		Certepetide; Certepetide + Durvalumab + Gemcitabine + Nab-paclitaxel; Durvalumab; Gemcitabine; Nab-paclitaxel	antimetabolite; anti-PD-L1_monoclonal_antibody; taxane; gemcitabine; tumor-homing_peptide_iRGD; anti-PD-L1_monoclonal_antibody + antimetabolite + taxane + tumor-homing_peptide_iRGD	Certepetide + Durvalumab + Gemcitabine + Nab-paclitaxel; Durvalumab	anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + antimetabolite + taxane + tumor-homing_peptide_iRGD; gemcitabine	Nil known	A Phase 1 single-blind study evaluating LSTA1 in combination with durvalumab, gemcitabine and nab-paclitaxel as a first-line treatment in locally advanced pancreatic ductal adenocarcinoma (PDAC)	Cancer	6008 - Subiaco	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623000223639
ACTRN12623000307606	NP-105	Phase 1	RECRUITING	NSW, VIC	2023-03-21	2023-06-15		RX108	sodium-potassium_ATPase_inhibitor	RX108	sodium-potassium_ATPase_inhibitor	NP-105	A Phase I, Open-Label Study of the Safety, Tolerability and Pharmacokinetics of RX108-A Tablet in Patients with Locally Advanced or Metastatic Solid Tumors	Locally Advanced or Metastatic Solid Tumors	3144 - Malvern; 2747 - Kingswood	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623000307606
ACTRN12623000652673	ELVN-002-002	Phase 1	RECRUITING	WA	2023-06-16	2023-05-02		ELVN-002; ELVN-002 + Itraconazole; Itraconazole	ERBB2_inhibitor,exon_20_selective + SMO_inhibitor; SMO_inhibitor; ERBB2_inhibitor,exon_20_selective	ELVN-002; ELVN-002 + Itraconazole; Itraconazole	ERBB2_inhibitor,exon_20_selective; ERBB2_inhibitor,exon_20_selective + SMO_inhibitor; SMO_inhibitor	ELVN-002-002	A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ELVN-002 in Healthy Adult Volunteers: Part C Open-label Drug-Drug Interaction	Non-small Cell lung cancer	6009 - Nedlands; 6027 - Joondalup	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623000652673
ACTRN12623000874617	Biomarcer-2	Phase 2	RECRUITING	ACT, NSW, QLD, TAS, VIC, WA	2023-08-15	2024-10-08		Cetuximab; Cetuximab + Fluorouracil + Irinotecan + Leucovorin; Cetuximab + Irinotecan; Fluorouracil; Irinotecan; Leucovorin	topoisomerase_inhibitor; Fluorouracil; anti-EGFR_monoclonal_antibody + topoisomerase_inhibitor; folinic_acid; anti-EGFR_monoclonal_antibody; anti-EGFR_monoclonal_antibody + fluoropyrimidine + folinic_acid + topoisomerase_inhibitor	Cetuximab + Fluorouracil + Irinotecan + Leucovorin; Cetuximab + Irinotecan	anti-EGFR_monoclonal_antibody + fluoropyrimidine + folinic_acid + topoisomerase_inhibitor; anti-EGFR_monoclonal_antibody + topoisomerase_inhibitor; Fluorouracil	None	Phase II single arm study to explore the efficacy of cetuximab (in combination with irinotecan based treatment) in advanced stage RAS/BRAF wild-type right-sided colorectal cancer with high AREG/EREG expression	Advanced RAS Wild type right sided Colorectal cancer	3844 - Traralgon; 6150 - Murdoch; 2605 - Garran; 2298 - Waratah; 2305 - New Lambton Heights; 3280 - Warrnambool; 3144 - Malvern; 3076 - Epping; 3000 - Melbourne; 3084 - Heidelberg; 3011 - Footscray; 2340 - Tamworth	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623000874617
ACTRN12623000956606	Australia	Phase 1	RECRUITING	NSW, QLD, SA, VIC	2023-09-04	2023-11-15		AT-0174	dual_IDO/TDO_inhibitor	AT-0174	dual_IDO/TDO_inhibitor	Antido Therapeutics (Australia) Protocol No. AT-0174-001	A Phase I Study to Evaluate the Safety, Tolerability, Pharmacology, and Preliminary Efficacy of AT-0174 in Subjects with Advanced Solid Malignancies	Locally Advanced Solid Tumours	3065 - Fitzroy; 2228 - Miranda; 3350 - Ballarat Central; 4575 - Birtinya; 5000 - Adelaide	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623000956606
ACTRN12623001072606	LuCape	Phase 1	RECRUITING	WA	2023-10-06	2023-10-13		Capecitabine; Lu-177 vipivotide tetraxetan	radioconjugate,PSMA-targeting; fluoropyrimidine	Capecitabine; Lu-177 vipivotide tetraxetan	fluoropyrimidine; radioconjugate,PSMA-targeting	Nil known	A phase 1a/b dose-escalation and dose-expansion study to evaluate Lutetium-177-PSMA I&T (Lu-PSMA) with radiosensitising Capecitabine in patients with metastatic castration-resistant prostate cancer (mCRPC)	metastatic castration-resistant prostate cancer	6150 - Murdoch	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623001072606
ACTRN12623001077651	EMITT-1	Phase 1 / Phase 2	RECRUITING	NSW, QLD, SA, VIC	2023-10-10	2024-04-18		Cemiplimab; Cemiplimab + GRWD5769; GRWD5769	ERAP1_inhibitor; ERAP1_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody	Cemiplimab + GRWD5769; GRWD5769	ERAP1_inhibitor; ERAP1_inhibitor + anti-PD-1_monoclonal_antibody	GRWD5769-ST-01 Module 2	A Modular, Multi-part, Multi-arm, Open-label, Phase I/II Study to Evaluate the Safety and Tolerability of GRWD5769 Alone and in Combination with Anticancer Treatments in Patients with Solid Malignancies - Module 2.	Advanced solid malignancies	5000 - Adelaide; 2500 - Wollongong; 3084 - Heidelberg; 2010 - Darlinghurst; 5042 - Bedford Park; 2148 - Blacktown; 4101 - South Brisbane; 3004 - Melbourne	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623001077651
ACTRN12623001126606	TCaP	Phase 1 / Phase 2	RECRUITING	QLD, VIC	2023-11-01	2024-05-14		Cytarabine; Cytarabine + Pembrolizumab; Ifosfamide; Pembrolizumab	antimetabolite; alkylating_agent; anti-PD-1_monoclonal_antibody + antimetabolite; anti-PD-1_monoclonal_antibody	Cytarabine + Pembrolizumab; Pembrolizumab; Ifosfamide	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + antimetabolite; alkylating_agent	Nil known	Phase I/II clinical trial evaluating the safety and efficacy of allogeneic cytomegalovirus-specific T cells in combination with pembrolizumab for recurrent and newly diagnosed glioblastoma multiforme	Glioblastoma multiforme/astrocytoma grade 4	3084 - Heidelberg; 4006 - Bowen Hills; 4029 - Royal Brisbane Hospital; 4102 - Woolloongabba	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623001126606
ACTRN12623001164684	ACTRN12623001164684	Not Applicable	RECRUITING	QLD	2023-11-09			Atorvastatin; Hydroxychloroquine; Melatonin; Metformin	biguanide_antihyperglycaemic_agent; HMG-CoA_reductase_inhibitor; anti-malarial_agent; melatonin	Atorvastatin; Hydroxychloroquine; Melatonin; Metformin	HMG-CoA_reductase_inhibitor; anti-malarial_agent; biguanide_antihyperglycaemic_agent; melatonin	Nil	Assessing treatment effectiveness of the 'Repurposing-Drugs-in-Oncology' (ReDO) protocol for adult cancer by Circulating Tumour Cell (CTC) analysis: A case-series	Cancer	4209 - Willow Vale	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623001164684
ACTRN12623001217695	ACTRN12623001217695	Phase 1	NOT_YET_RECRUITING	NSW	2023-11-27			IMD-101	IL2_conjugate	IMD-101	IL2_conjugate	AFB-105	An Open-Label Dose-Escalation Phase Ia Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of IMD-101 Injectable in Participants with Advanced Malignant Solid Tumours.	Advanced malignant solid tumours		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623001217695
ACTRN12623001333606	CCaLM	Phase 2	NOT_YET_RECRUITING	NSW	2023-12-19			Labetuzumab	anti-CEACAM5_monoclonal_antibody	Labetuzumab	anti-CEACAM5_monoclonal_antibody	Nil known	The Novel use of Labetuzumab as Adjuvant Immunotherapy in Patients with Primary Colon Adenocarcinoma with Intact PELPK Binding Motif in their CEACAM5 gene in a Phase II clinical trial regarding the Development of Metachronous Liver Metastases (i.e., those at ‘high-risk’ of metachronous CRCLMs)	Colon cancer	2217 - Kogarah	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623001333606
ACTRN12624000110583	SOCRATES-PILOT	Not Applicable	RECRUITING	NSW	2024-02-08	2024-08-19		Abiraterone; Anastrozole; Apalutamide; Atorvastatin; Bevacizumab; Darolutamide; Enzalutamide; Letrozole; Lomustine; Nab-paclitaxel; Niraparib; Olaparib; Paclitaxel	HMG-CoA_reductase_inhibitor; CYP17A1_inhibitor; anti-VEGF_monoclonal_antibody; aromatase_inhibitor; antiandrogen,nonsteroidal,second_generation; taxane; alkylating_agent; PARP_inhibitor	Abiraterone; Anastrozole; Apalutamide; Atorvastatin; Bevacizumab; Darolutamide; Enzalutamide; Letrozole; Lomustine; Nab-paclitaxel; Niraparib; Olaparib; Paclitaxel	CYP17A1_inhibitor; HMG-CoA_reductase_inhibitor; PARP_inhibitor; alkylating_agent; anti-VEGF_monoclonal_antibody; antiandrogen,nonsteroidal,second_generation; aromatase_inhibitor; taxane	CTC 0393	SOCRATES PILOT: Standard of Care Randomised Treatment Evaluation Studies	Cardio Vascular Disease; Cancer	2050 - Missenden Road; 2050 - Camperdown; 2031 - Randwick; 2139 - Concord	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12624000110583
ACTRN12624000268549	LEPO	Phase 1	NOT_YET_RECRUITING	NSW	2024-03-15							ADRI002	LEPO: A phase 1 study of Leptospermum petersonii extract for patients with mesothelioma	Mesothelioma		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12624000268549
ACTRN12624000288527	REZOLV3R	Phase 3	RECRUITING	NSW, QLD, VIC	2024-03-20			Bevacizumab	anti-VEGF_monoclonal_antibody	Bevacizumab	anti-VEGF_monoclonal_antibody	CTC 0398	Efficacy of intraperitoneal bevacizumab for decreasing or delaying re-accumulation of recurrent malignant ascites in chemotherapy resistant solid tumours: a randomised trial (REZOLV3R)	Recurrent malignant ascites; Chemotherapy resistant solid tumours	2139 - Concord; 2060 - North Sydney	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12624000288527
ACTRN12624000532505	INTER-EWING-1	Phase 3	RECRUITING	NSW, NZ, QLD, SA, TAS, VIC, WA	2024-04-29	2024-02-23		Cyclophosphamide; Cyclophosphamide + Doxorubicin + Etoposide + Ifosfamide + Regorafenib + Vincristine; Cyclophosphamide + Vinorelbine; Doxorubicin; Etoposide; Ifosfamide; Radiotherapy; Regorafenib; Vincristine; Vinorelbine	radiotherapy; topoisomerase_inhibitor; alkylating_agent + vinca_alkaloid; vinca_alkaloid; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor; alkylating_agent; doxorubicin; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + alkylating_agent + anthracycline + topoisomerase_inhibitor + vinca_alkaloid	Cyclophosphamide + Doxorubicin + Etoposide + Ifosfamide + Regorafenib + Vincristine; Cyclophosphamide + Vinorelbine; Radiotherapy	KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + alkylating_agent + anthracycline + topoisomerase_inhibitor + vinca_alkaloid; alkylating_agent + vinca_alkaloid; radiotherapy; doxorubicin	ISRCTN17938906  RG_21-151	International clinical research programme to improve outcomes in newly diagnosed Ewing sarcoma – Trial 1 (INTER-EWING-1)	Ewing Sarcoma	6009 - Nedlands	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12624000532505
ACTRN12624000588594	PORCUPINE2-Australian-Extension	Phase 2	NOT_YET_RECRUITING	NSW	2024-05-08			Denosumab; Denosumab + Zamaporvint; Zamaporvint	PORCN_inhibitor + anti-RANK_L_monoclonal_antibody; anti-RANK_L_monoclonal_antibody; PORCN_inhibitor	Denosumab + Zamaporvint; Zamaporvint	PORCN_inhibitor; PORCN_inhibitor + anti-RANK_L_monoclonal_antibody	None	A Phase 2, Open-Label, Multicentre Study to Assess the Preliminary Efficacy and Safety of RXC004, in Patients with Advanced Pancreatic Cancer that have Progressed following Therapy with Current Standard of Care	Pancreatic Cancer		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12624000588594
ACTRN12624000644561	ACTRN12624000644561	Not Applicable	NOT_YET_RECRUITING	NSW	2024-05-20							None	A randomised controlled trial comparing animation-based with written patient information for educating patients about robotic-assisted radical prostatectomy	prostate cancer		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12624000644561
ACTRN12624000911594	CICAFU	Phase 3	NOT_YET_RECRUITING	QLD	2024-07-26			Fluorouracil	Fluorouracil; fluoropyrimidine	Fluorouracil	fluoropyrimidine; Fluorouracil	Nil known	CICAFU Trial: Randomised, controlled trial of CICAPLAST Baume B5+ versus standard of care on tolerability and observance of topical 5% 5-fluorouracil in Patients diagnosed with Actinic Keratoses (AK)	Skin Cancer	4102 - Woolloongabba	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12624000911594
ACTRN12624000917538	CetPro	Phase 2	NOT_YET_RECRUITING	QLD	2024-07-29			Cetuximab; Cetuximab + Prochlorperazine; Prochlorperazine	antihistamine; anti-EGFR_monoclonal_antibody + antihistamine; anti-EGFR_monoclonal_antibody	Cetuximab; Cetuximab + Prochlorperazine	anti-EGFR_monoclonal_antibody; anti-EGFR_monoclonal_antibody + antihistamine	none	Efficacy and safety of cetuximab and prochlorperazine combined for solid organ transplant patients with advanced Cutaneous Squamous Cell Carcinoma: CetPro study	skin cancer; solid organ transplant recipients	4102 - Woolloongabba	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12624000917538
ACTRN12624000964516	RATIONAL-PT	Phase 2 / Phase 3	NOT_YET_RECRUITING	ACT, NSW, SA, VIC	2024-08-08							TRU-RPT-22	A randomised platform trial evaluating the role of interventions to prevent infection in patients with acquired hypogammaglobulinemia secondary to haematological malignancies - RATIONAL-PT (Start-Ig Domain)	haematological malignancy; hypogammaglobulinemia		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12624000964516
ACTRN12624001067561	ACTRN12624001067561	Not Applicable	NOT_YET_RECRUITING	SA	2024-09-03							Nil known	Evaluate the effectiveness of implementing a supportive care navigation tool for people diagnosed with pancreatic cancer.	unmet needs; survival; pancreatic cancer	5042 - Bedford Park	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12624001067561
ACTRN12624001101572	EXHIBIT	Not Applicable	NOT_YET_RECRUITING	VIC	2024-09-12							None.	The safety and feasibility of exercise in patients with melanoma undergoing adjuvant immunotherapy with immune checkpoint inhibitor therapy – the EXHIBIT Study	Cutaneous melanoma	3000 - Melbourne; 3144 - Malvern	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12624001101572
ACTRN12624001119583	ACTRN12624001119583	Not Applicable	NOT_YET_RECRUITING	VIC	2024-09-17							Nil	Transperineal prostate biopsy under local anaesthetic in adults with suspected or confirmed prostate cancer: an analysis of cost, efficacy and patient tolerability in Australia	Prostate cancer		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12624001119583
ACTRN12624001120561	PECAN	Not Applicable	NOT_YET_RECRUITING	WA	2024-09-17							None	Patient Initiated Follow Up (PIFU) in Endometrial Cancer (PECAN) – a Randomised Pilot Feasibility Study	Endometrial cancer	6008 - Subiaco	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12624001120561
ACTRN12624001123538	ITM-2221-01CT	Phase 1	NOT_YET_RECRUITING	NSW, QLD	2024-09-18							ITM-2221-01CT	A Multicentre, Open-label, Interventional, Repeated Dose Escalation/De-escalation Phase I Trial to Determine the Optimal Biological Dose, and Evaluate Safety, Pharmacokinetics and Preliminary Efficacy of Actinium (225Ac) Ibu-DAB-PSMA for the Treatment of PSMA-positive Progressive Metastatic Castration Resistant Prostate Cancer	Progressive metastatic castration resistant prostate cancer (mCRPC)		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12624001123538
ACTRN12624001188527	G-DISCO	Phase 1	RECRUITING	WA	2024-09-30	2025-01-10		Docetaxel; Docetaxel + Gemcitabine; Gemcitabine	antimetabolite; antimetabolite + taxane; taxane; gemcitabine	Docetaxel + Gemcitabine	antimetabolite + taxane; gemcitabine	ANZUP 2403	G-DISCO: A Phase 1 study of feasibility, safety and tolerability of synchronous intravesical administration of gemcitabine and docetaxel - ANZUP 2403.	High risk non muscle invasive bladder cancer		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12624001188527
ACTRN12624001330538	The-Ginger-MAP-Study	Not Applicable	NOT_YET_RECRUITING	QLD	2024-11-01							Nil	The effect of low dose versus high dose ginger supplementation compared to standard care (no ginger) on gastric motility (measured by body surface gastric mapping) in patients receiving chemotherapy classified as at moderate to high risk of emesis.	cancer; chemotherapy-induced nausea and vomiting	4000 - Brisbane	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12624001330538
ACTRN12624001340527	PaxPlus-ABC	Phase 1	NOT_YET_RECRUITING	QLD	2024-11-05			Carboplatin; Carboplatin + Gemcitabine + Nab-paclitaxel + Paxalisib + Pembrolizumab; Gemcitabine; Nab-paclitaxel; Olaparib; Olaparib + Paxalisib; Paxalisib; Paxalisib + Pembrolizumab; Pembrolizumab	dual_PI3K/mTOR_inhibitor; anti-PD-1_monoclonal_antibody; taxane; gemcitabine; PARP_inhibitor + dual_PI3K/mTOR_inhibitor; anti-PD-1_monoclonal_antibody + dual_PI3K/mTOR_inhibitor; platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + antimetabolite + dual_PI3K/mTOR_inhibitor + platinum-based_antineoplastic_agent + taxane; PARP_inhibitor	Carboplatin + Gemcitabine + Nab-paclitaxel + Paxalisib + Pembrolizumab; Olaparib + Paxalisib; Paxalisib + Pembrolizumab	PARP_inhibitor + dual_PI3K/mTOR_inhibitor; anti-PD-1_monoclonal_antibody + antimetabolite + dual_PI3K/mTOR_inhibitor + platinum-based_antineoplastic_agent + taxane; anti-PD-1_monoclonal_antibody + dual_PI3K/mTOR_inhibitor; gemcitabine	KZA-0084-ABC001	A Phase 1b, Multi-centre, Open-label, Randomized Study to Evaluate the Safety, Tolerability, and Clinical Activity of Combining Paxalisib with Olaparib or Pembrolizumab/Chemotherapy in Patients with Advanced Breast Cancer	Breast cancer		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12624001340527
ACTRN12624001342505	ACTRN12624001342505	Not Applicable	NOT_YET_RECRUITING	QLD	2024-11-05			Cytarabine	antimetabolite	Cytarabine	antimetabolite	Nil known	A Prospective, Open-Label, Randomized, Controlled Post-Market Clinical Trial Investigating the Safety and Effectiveness of Human Amnion Membrane (AM) in a Cohort of Patients with Loss of Full Thickness Skin Graft Following Reconstruction of a Cutaneous Nasal Defect Secondary to Skin Cancer Resection.	skin cancer; Failed full thickness skin graft following resection of a cutaneous nasal defect	4102 - Woolloongabba	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12624001342505
ACTRN12624001458527	DARO-LIPID	Phase 2	NOT_YET_RECRUITING	NSW, QLD, VIC, WA	2024-12-16			Darolutamide; Darolutamide + Opaganib; Opaganib	sphingosine_kinase-2_inhibitor; antiandrogen,nonsteroidal,second_generation + sphingosine_kinase-2_inhibitor; antiandrogen,nonsteroidal,second_generation	Darolutamide + Opaganib	antiandrogen,nonsteroidal,second_generation + sphingosine_kinase-2_inhibitor	ANZUP Cancer Trials Group Ltd: ANZUP2205	Randomised Phase 2 study of sphingosine kinase inhibitor (opaganib) in addition to darolutamide in people with poor prognostic metastatic castration resistant prostate cancer (mCRPC) based on a companion circulating lipid biomarker, PCPro (ANZUP2205)	Prostate Cancer	2010 - Darlinghurst; 2050 - Camperdown; 2830 - Dubbo; 3630 - Shepparton; 2065 - St Leonards; 2298 - Waratah; 4102 - Woolloongabba; 6009 - Nedlands; 2145 - Westmead	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12624001458527
ACTRN12624001484538	GBMI12	Phase 2	NOT_YET_RECRUITING	NSW, QLD	2024-12-19			Ifosfamide; Radiotherapy; Radiotherapy + Temozolomide; Temozolomide	radiotherapy; alkylating_agent; alkylating_agent + radiotherapy	Radiotherapy + Temozolomide; Ifosfamide	alkylating_agent + radiotherapy	Nil known	Phase 2 Trial examining IMMUNE-12 for patients with Glioblastoma Multiforme (GBM).	Glioblastoma multiforme	4120 - Greenslopes; 2050 - Camperdown	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12624001484538
ACTRN12625000197437	NIL-Known	Phase 2	NOT_YET_RECRUITING	QLD	2025-02-20			Cemiplimab	anti-PD-1_monoclonal_antibody	Cemiplimab	anti-PD-1_monoclonal_antibody	NIL Known	A single arm, phase II trial of Cemiplimab in Head and Neck Cutaneous Squamous Cell Carcinoma with Large Nerve Perineural Spread	Cutaneous Squamous Cell Carcinoma; Skin Cancer	4102 - Woolloongabba	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12625000197437
ACTRN12625000203459	ENG19	Phase 1 / Phase 2	RECRUITING	NSW, VIC	2025-02-20	2025-04-22		PNU-159682	EnGeneIC_Dream_Vector-nanocells-delivered,EGFR-targeting	PNU-159682	EnGeneIC_Dream_Vector-nanocells-delivered,EGFR-targeting	EGFR EDV-D682/GC Trial	An open-label, multicenter, Phase I/IIa study assessing the safety and efficacy of EGFR targeted EDVsTM carrying cytotoxic drug PNU-159682 plus concurrent immunomodulatory adjuvant non-targeted EDVs carrying a-galactosyl ceramide in subjects with advanced EGFR-expressing cancers who have failed second-line therapy or where first- and/or second-line therapy is not appropriate (EGFR EDV-D682/GC Trial)	EGFR expressing solid tumors; Lung cancer (NSCLC and Mesothelioma); Pancreatic ductal adenocarcinoma (PDAC); Bladder/Kidney cancer; Colorectal cancer; Triple negative breast cancer (TNBC)	2060 - North Sydney; 3199 - Frankston	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12625000203459
ACTRN12625000334404	EIK-1005-001	Phase 1	NOT_YET_RECRUITING	VIC	2025-04-17			EIK1005	WRN_inhibitor	EIK1005	WRN_inhibitor	EIK 1005-001	Healthy Participant Study to Assess Safety, Tolerability and Pharmacokinetic Profile of EIK1005, a Werner helicase inhibitor.	MSI-H Solid Tumors	3004 - Melbourne	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12625000334404
ACTRN12625000361404	ACTRN12625000361404	Phase 1	NOT_YET_RECRUITING	QLD, SA, VIC, WA	2025-04-24							None	A Phase 1, Multicentre, Open-label, Non-randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of 177Lu-FO-004 in Patients with advanced solid tumours.	Advanced solid tumours	6150 - Murdoch; 4509 - North Lakes; 3000 - Melbourne; 3084 - Heidelberg	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12625000361404
ACTRN12625000697482	DULCE	Phase 2	NOT_YET_RECRUITING	NSW, NT	2025-07-01			Placebo	placebo	Placebo	placebo	Nil known	A parallel-group, 2-arm, Phase 2, multisite, stratified, double-blind, randomised, study to investigate the safety and effectiveness of doxycycline or placebo in conjunction with standard of care in adults with metastatic adenocarcinoma of the lung undergoing targeted anti-cancer therapy.	Lung cancer	2050 - Camperdown; 2010 - Darlinghurst; 2500 - Wollongong; 2145 - Westmead; 0870 - Alice Springs	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12625000697482
ACTRN12625000779471	ENG20	Phase 1 / Phase 2	NOT_YET_RECRUITING	NSW, SA, VIC	2025-07-24			Doxorubicin	anthracycline; doxorubicin	Doxorubicin	anthracycline; doxorubicin	EDV-GBM Trial	A Phase I/IIa Study of EGFR-targeted EDVs Carrying Doxorubicin (E-EDV-Dox) Combined with EDVs Carrying a-Galactosyl Ceramide (EDV-GC) in People with Recurrent Glioblastoma.	Recurrent Glioblastoma	2145 - Westmead; 3199 - Frankston	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12625000779471
ACTRN12625000863437	ACTRN12625000863437	Phase 1	RECRUITING	NSW, VIC, WA	2025-08-08	2025-01-23		AXA-042; AXA-042 + Cemiplimab; Cemiplimab	anti-PD-1_monoclonal_antibody; TLR2/TLR6_agonist; TLR2/TLR6_agonist + anti-PD-1_monoclonal_antibody	AXA-042 + Cemiplimab	TLR2/TLR6_agonist + anti-PD-1_monoclonal_antibody	None	A Phase 1a/1b, first-in-human, open-label, non-randomised, multicenter, dose-escalation and dose -expansion study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of AXA-042 as monotherapy and in combination with an anti-PD-1 monoclonal antibody (cemiplimab) in subjects with advanced solid tumours: Phase 1b	Advanced solid tumours	2031 - Randwick; 2050 - Camperdown; 3000 - Melbourne; 2298 - Waratah; 6009 - Nedlands; 3175 - Dandenong	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12625000863437
ACTRN12625000906459	ACTRN12625000906459	Not Applicable	ACTIVE_NOT_RECRUITING	ACT, NSW, NT, QLD, SA, TAS, VIC, WA	2025-08-20	2024-12-27	2025-06-10					Nil known	Testing the feasibility, acceptability and impact of an online delivered stress management program for Australian with breast and colorectal cancer: a pilot study	breast cancer; colorectal cancer		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12625000906459
NCT02336451	Ascend-7	Phase 2		NZ	2015-01-13	2015-04-01		Ceritinib; Crizotinib	ROS1_inhibitor; ALK_inhibitor,first_generation; MET_inhibitor,type_1; ALK/ROS1/IGF1R_inhibitor	Crizotinib; Ceritinib	ALK_inhibitor,first_generation; MET_inhibitor,type_1; ROS1_inhibitor; ALK/ROS1/IGF1R_inhibitor	2014-000578-20  CLDK378A2205	A Phase II, Multi-center, Open-label, Five-arm Study to Evaluate the Efficacy and Safety of Oral Ceritinib Treatment for Patients With ALK-positive Non-small Cell Lung Cancer (NSCLC) Metastatic to the Brain and/or to Leptomeninges	ALK-positive Non-small Cell Lung Cancer	- Auckland	https://clinicaltrials.gov/ct2/show/NCT02336451
NCT02338245	ASLAN001-003	Phase 2		NZ, WA	2015-01-14	2014-12-29		Capecitabine; Capecitabine + Lapatinib; Capecitabine + Varlitinib; Lapatinib; Trastuzumab; Varlitinib	EGFR_inhibitor,type_II + fluoropyrimidine; anti-ERBB2_monoclonal_antibody; fluoropyrimidine; EGFR/ERBB2_inhibitor + fluoropyrimidine; EGFR/ERBB2_inhibitor; ERBB2_inhibitor,first_generation + fluoropyrimidine; EGFR_inhibitor,type_II; ERBB2_inhibitor,first_generation	Capecitabine + Lapatinib; Capecitabine + Varlitinib; Trastuzumab	EGFR/ERBB2_inhibitor + fluoropyrimidine; EGFR_inhibitor,type_II + fluoropyrimidine; ERBB2_inhibitor,first_generation + fluoropyrimidine; anti-ERBB2_monoclonal_antibody	ASLAN001-003	Randomized Phase 2A/2B Study to Compare the Efficacy and Safety of ASLAN001 + Capecitabine to Lapatinib + Capecitabine in Patients With HER 2-Positive MBC That Has Failed on Prior Trastuzumab Therapy	Metastatic Breast Cancer	Tauranga; 6000 - Western Australia; Christchurch	https://clinicaltrials.gov/ct2/show/NCT02338245
NCT02340221	SANDPIPER	Phase 3		NSW, QLD, VIC, WA	2015-01-16	2015-04-09		Fulvestrant; Fulvestrant + Taselisib; Placebo; Taselisib	placebo; PI3K_alpha_inhibitor; selective_estrogen_receptor_degrader; PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader	Fulvestrant; Fulvestrant + Taselisib; Placebo	PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader; selective_estrogen_receptor_degrader; placebo	2014-003185-25  GO29058	A Phase III, Double-Blind, Placebo-Controlled, Randomized Study of Taselisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy	Breast Cancer	2109 - Macquarie Park; 3084 - Heidelberg; 2170 - Liverpool; 4101 - Brisbane; 6150 - Murdoch; - St Albans; 2298 - Waratah	https://clinicaltrials.gov/ct2/show/NCT02340221
NCT02341456	D6011C00003	Phase 1		NSW, VIC	2015-01-19	2015-01-16		Adavosertib; Adavosertib + Carboplatin + Paclitaxel; Carboplatin; Carboplatin + Paclitaxel; Paclitaxel	WEE1_inhibitor + platinum-based_antineoplastic_agent + taxane; platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent + taxane; WEE1_inhibitor; taxane	Adavosertib + Carboplatin + Paclitaxel; Carboplatin + Paclitaxel; Paclitaxel	WEE1_inhibitor + platinum-based_antineoplastic_agent + taxane; platinum-based_antineoplastic_agent + taxane; taxane	D6011C00003	A Phase Ib, Dose Finding Study Evaluating AZD1775 in Monotherapy, in Combination With Carboplatin and Paclitaxel, and in Combination With Only Carboplatin in Adult Asian Patients With Advanced Solid Tumours	Advanced Solid Tumours	3004 - Melbourne; 2170 - Liverpool	https://clinicaltrials.gov/ct2/show/NCT02341456
NCT02341625	2014-002485-70--CA008-002	Phase 1/Phase 2		NSW, SA, VIC, WA	2015-01-19	2015-06-19		BMS-986148; BMS-986148 + Nivolumab; Nivolumab	anti-mesothelin_antibody-drug_conjugate; anti-PD-1_monoclonal_antibody + anti-mesothelin_antibody-drug_conjugate; anti-PD-1_monoclonal_antibody	BMS-986148; BMS-986148 + Nivolumab	anti-PD-1_monoclonal_antibody + anti-mesothelin_antibody-drug_conjugate; anti-mesothelin_antibody-drug_conjugate	2014-002485-70  CA008-002	A Phase I/IIa Study of BMS-986148, a Mesothelin Directed Antibody Drug Conjugate, in Subjects With Select Advanced Solid Tumors	Advanced Cancer	6009 - Nedlands; 3168 - Clayton; 5000 - Adelaide; 2170 - Liverpool	https://clinicaltrials.gov/ct2/show/NCT02341625
NCT02343120	2016-003364-39--BGB-3111-AU-003	Phase 1/Phase 2		NSW, NZ, QLD, TAS, VIC, WA	2015-01-21	2014-11-26		Zanubrutinib	BTK_inhibitor	Zanubrutinib	BTK_inhibitor	2016-003364-39  BGB-3111-AU-003	A Phase I/II, Open-Label, Multiple-Dose, Dose Escalation and Expansion Study to Investigate the Safety and Pharmacokinetics of the BTK Inhibitor BGB-3111 in Subjects With B-Cell Lymphoid Malignancies	B-cell Malignancies	- Westmead; - Parkville; - Hobart; 3050 - Parkville; Auckland; - Sydney; - Concord; - Heidelberg; - Clayton; - Brisbane; - Melbourne; - Nedlands	https://clinicaltrials.gov/ct2/show/NCT02343120
NCT02343406	INTELLANCE-2	Phase 2		NSW, QLD, SA, TAS, VIC	2015-01-22	2015-02-17		Depatuxizumab Mafodotin; Depatuxizumab Mafodotin + Temozolomide; Lomustine; Lomustine + Temozolomide; Temozolomide	alkylating_agent; anti-EGFR/PBD_antibody-drug_conjugate; alkylating_agent + anti-EGFR/PBD_antibody-drug_conjugate	Depatuxizumab Mafodotin; Depatuxizumab Mafodotin + Temozolomide; Lomustine + Temozolomide; Temozolomide	alkylating_agent; alkylating_agent + anti-EGFR/PBD_antibody-drug_conjugate; anti-EGFR/PBD_antibody-drug_conjugate	2014-004438-24  M14-483	INTELLANCE-2: ABT-414 Alone or ABT-414 Plus Temozolomide Versus Lomustine or Temozolomide for Recurrent Glioblastoma: A Randomized Phase 2 Study of the EORTC Brain Tumor Group	Glioblastoma	7000 - Hobart; 3220 - Geelong; 2298 - Waratah; 2500 - Wollongong; 2031 - Randwick; 3052 - Melbourne; 5000 - Adelaide; 2065 - Saint Leonards; 4029 - Herston; 2444 - Port Macquarie	https://clinicaltrials.gov/ct2/show/NCT02343406
NCT02349633	B7971001	Phase 1/Phase 2		NSW, QLD	2015-01-29	2015-05-14		Avelumab; Avelumab + Mavelertinib; Mavelertinib; Mavelertinib + Palbociclib; Palbociclib	EGFR_inhibitor,third_generation + anti-PD-L1_monoclonal_antibody; CDK4/6_inhibitor + EGFR_inhibitor,third_generation; CDK4/6_inhibitor; anti-PD-L1_monoclonal_antibody; EGFR_inhibitor,third_generation	Avelumab + Mavelertinib; Mavelertinib + Palbociclib	CDK4/6_inhibitor + EGFR_inhibitor,third_generation; EGFR_inhibitor,third_generation + anti-PD-L1_monoclonal_antibody	B7971001	PHASE 1/2 OPEN-LABEL STUDY OF PF-06747775 (EPIDERMAL GROWTH FACTOR RECEPTOR T790M INHIBITOR) IN PATIENTS WITH ADVANCED EPIDERMAL GROWTH FACTOR RECEPTOR MUTANT (DEL 19 OR L858R ± T790M) NON-SMALL CELL LUNG CANCER	Non-Small Cell Lung Cancer	2050 - Camperdown; 4032 - Chermside	https://clinicaltrials.gov/ct2/show/NCT02349633
NCT02357147	ARTEMIS	Phase 2		NSW, QLD, VIC, WA	2015-02-06	2015-11-03		Amatuximab; Amatuximab + Cisplatin + Pemetrexed; Cisplatin; Cisplatin + Pemetrexed; Pemetrexed; Placebo	placebo; anti-MSLN_monoclonal_antibody; antimetabolite; platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; anti-MSLN_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent	Amatuximab + Cisplatin + Pemetrexed; Cisplatin + Pemetrexed; Placebo	anti-MSLN_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; placebo	2014-004489-85  MORAb-009-201	A Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma	Mesothelioma, Malignant	- Camperdown; - Perth; 3121 - Richmond; - Auchenflower	https://clinicaltrials.gov/ct2/show/NCT02357147
NCT02358356	CONTROL-NETS	Phase 2		NSW, QLD, VIC, WA	2015-02-09	2015-11-01		Capecitabine; Capecitabine + Temozolomide; Temozolomide	alkylating_agent; fluoropyrimidine; alkylating_agent + fluoropyrimidine	Capecitabine + Temozolomide	alkylating_agent + fluoropyrimidine	CTC0120 / AG0114NET	Capecitabine ON Temozolomide Radionuclide Therapy Octreotate Lutetium-177 NeuroEndocrine Tumours Study	Midgut Neuroendocrine Tumours; Pancreatic Neuroendocrine Tumours	2065 - St Leonards; 8006 - East Melbourne; 6150 - Murdoch; 4029 - Herston	https://clinicaltrials.gov/ct2/show/NCT02358356
NCT02361723	2017-003646-25--BGB-290-AU-002	Phase 1		NSW, SA, VIC, WA	2015-02-12	2014-07-03		Pamiparib	PARP_inhibitor	Pamiparib	PARP_inhibitor	2017-003646-25  BGB-290-AU-002	A Phase 1A/1B, Open Label, Multiple Dose, Dose Escalation, and Expansion Study to Investigate the Safety, Pharmacokinetics, Food Effect, and Antitumor Activities of BGB-290 in Subjects With Advanced Solid Tumors	For Participants With Advanced Solid Tumors Failed With Previous Lines of Treatment	SA 5042 - Bedford Park; VIC 3000 - Melbourne; VIC 3004 - Melbourne; WA 6009 - Nedlands; VIC 3084 - Heidelberg; NSW 2559 - Hamlyn Terrace	https://clinicaltrials.gov/ct2/show/NCT02361723
NCT02364999	2014-003878-16--B7391003	Phase 3		NSW, QLD, VIC	2015-02-18	2015-04-01		Bevacizumab; Bevacizumab + Carboplatin + Paclitaxel; Carboplatin; Paclitaxel	platinum-based_antineoplastic_agent; anti-VEGF_monoclonal_antibody; taxane; anti-VEGF_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane	Bevacizumab + Carboplatin + Paclitaxel	anti-VEGF_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane	2014-003878-16  B7391003	A PHASE 3 RANDOMIZED, DOUBLE-BLIND STUDY OF PF- 06439535 PLUS PACLITAXEL-CARBOPLATIN AND BEVACIZUMAB PLUS PACLITAXEL -CARBOPLATIN FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER.	Non-Small Cell Lung Cancer	2485 - Tweed Heads; 3084 - Heidelberg; 2480 - Lismore; 3021 - St Albans; 4224 - Tugun	https://clinicaltrials.gov/ct2/show/NCT02364999
NCT02366143	IMpower150	Phase 3		NSW, QLD, SA, TAS, VIC, WA	2015-02-19	2015-03-31		Atezolizumab; Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel; Atezolizumab + Carboplatin + Paclitaxel; Bevacizumab; Bevacizumab + Carboplatin + Paclitaxel; Carboplatin; Paclitaxel	anti-PD-L1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; anti-PD-L1_monoclonal_antibody; taxane; platinum-based_antineoplastic_agent; anti-VEGF_monoclonal_antibody; anti-VEGF_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane	Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel; Atezolizumab + Carboplatin + Paclitaxel; Bevacizumab + Carboplatin + Paclitaxel	anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; anti-PD-L1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; anti-VEGF_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane	2014-003207-30  GO29436	A Phase III, Open-Label, Randomized Study of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) in Combination With Carboplatin+Paclitaxel With or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer	Carcinoma, Non-Small-Cell Lung	5037 - Kurralta Park; 2139 - Concord; 3021 - St Albans; 2050 - Camperdown; 5000 - Adelaide; 4810 - Townsville; 4032 - Chermside; 3084 - Heidelberg; 4102 - Woolloongabba; 3199 - Frankston; 3181 - Prahan; 7000 - Hobart; 3144 - Malvern; 2747 - Sydney; 7250 - Launceston; 6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT02366143
NCT02367794	2014-003208-59--GO29437	Phase 3		NSW, QLD, SA, VIC, WA	2015-02-20	2015-06-11		Atezolizumab; Atezolizumab + Carboplatin + Nab-paclitaxel; Atezolizumab + Carboplatin + Paclitaxel; Carboplatin; Carboplatin + Nab-paclitaxel; Nab-paclitaxel; Paclitaxel	anti-PD-L1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent + taxane; anti-PD-L1_monoclonal_antibody; taxane	Atezolizumab + Carboplatin + Nab-paclitaxel; Atezolizumab + Carboplatin + Paclitaxel; Carboplatin + Nab-paclitaxel	anti-PD-L1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; platinum-based_antineoplastic_agent + taxane	2014-003208-59  GO29437	A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) in Combination With Carboplatin+Paclitaxel or Atezolizumab in Combination With Carboplatin+Nab-Paclitaxel Versus Carboplatin+Nab-Paclitaxel in Chemotherapy-Naive Patients With Stage IV Squamous Non-Small Cell Lung Cancer	Squamous Non-Small Cell Lung Cancer	3021 - St Albans; 2050 - Camperdown; 4810 - Townsville; 5000 - Adelaide; 3084 - Heidelberg; 4032 - Chermside; 2298 - Waratah; 4102 - Woolloongabba; 3144 - Malvern; 6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT02367794
NCT02369198	HREC-13-CRGH-199	Phase 1		NSW	2015-02-23	2014-09-01		TargomiRs	miR-16_miRNA_mimic	TargomiRs	miR-16_miRNA_mimic	HREC/13/CRGH/199	MesomiR 1: A Phase I Study of Intravenously Administered Epidermal Growth Factor Receptor -Targeted, EnGeneIC Delivery Vehicle (EDV)-Packaged, miR-16 Mimic (TargomiRs) for Patients With Malignant Pleural Mesothelioma (MPM) and Advanced Non-Small Cell Lung Cancer (NSCLC) Failing on Std Therapy	Non-Small Cell Lung Cancer; Malignant Pleural Mesothelioma	2050 - Sydney; 2039 - Sydney; 2065 - Sydney	https://clinicaltrials.gov/ct2/show/NCT02369198
NCT02369874	EAGLE	Phase 3		NSW, QLD, SA, VIC	2015-02-24	2015-09-09		Durvalumab; Durvalumab + Tremelimumab; Tremelimumab	anti-CTLA4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; anti-CTLA4_monoclonal_antibody	Durvalumab; Durvalumab + Tremelimumab	anti-CTLA4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody	D4193C00002	A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy and MEDI4736 in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)	Recurrent or Metastatic PD-L1-positive or -Negative Squamous Cell Carcinoma of the Head and Neck SCCHN	3084 - Heidelberg; 5000 - Adelaide; 2065 - St Leonards; 4102 - Woolloongabba; 3004 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT02369874
NCT02371369	ENLIVEN	Phase 3		NSW, QLD, VIC	2015-02-25	2015-05-11		Pexidartinib; Placebo	placebo; CSF1R_inhibitor; KIT_inhibitor; FLT3_inhibitor	Pexidartinib; Placebo	CSF1R_inhibitor; FLT3_inhibitor; KIT_inhibitor; placebo	2014-000148-14  PLX108-10	A Double-blind, Randomized, Placebo-controlled Phase 3 Study of Orally Administered PLX3397 in Subjects With Pigmented Villonodular Synovitis or Giant Cell Tumor of the Tendon Sheath	Pigmented Villonodular Synovitis; Tenosynovial Giant Cell Tumor; Giant Cell Tumors of the Tendon Sheath	2050 - Sydney; 4102 - Woolloongabba; 3000 - East Melbourne	https://clinicaltrials.gov/ct2/show/NCT02371369
NCT02374242	ABC	Phase 2		NSW, QLD, SA, VIC	2015-02-27	2014-11-04		Ipilimumab; Ipilimumab + Nivolumab; Nivolumab	anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-CTLA4_monoclonal_antibody	Ipilimumab + Nivolumab; Nivolumab	anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody	ACTRN12614001315606  CA209-170	A Phase II Study of Nivolumab and Nivolumab Combined With Ipilimumab in Patients With Melanoma Brain Metastases	Melanoma; Brain Metastases	2060 - North Sydney; 4102 - Woolloongabba; 3002 - East Melbourne; 5000 - Adelaide	https://clinicaltrials.gov/ct2/show/NCT02374242
NCT02375204	U10CA180821--A031102	Phase 3		NSW, QLD, VIC	2015-03-02	2015-08-06		Carboplatin; Cisplatin; Dexamethasone; Dexamethasone + Paclitaxel; Etoposide; Filgrastim; Filgrastim + Pegfilgrastim; Ifosfamide; Ifosfamide + Mesna; Mesna; Paclitaxel; Pegfilgrastim	granulocyte_colony_stimulating_factor; glucocorticoid; alkylating_agent + sodium_mercaptoethanesulfonate; topoisomerase_inhibitor; sodium_mercaptoethanesulfonate; taxane; glucocorticoid + taxane; alkylating_agent; platinum-based_antineoplastic_agent	Carboplatin; Cisplatin; Dexamethasone + Paclitaxel; Etoposide; Filgrastim; Filgrastim + Pegfilgrastim; Ifosfamide; Ifosfamide + Mesna; Paclitaxel; Pegfilgrastim	alkylating_agent; alkylating_agent + sodium_mercaptoethanesulfonate; glucocorticoid + taxane; granulocyte_colony_stimulating_factor; platinum-based_antineoplastic_agent; taxane; topoisomerase_inhibitor	U10CA180821  A031102	A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) As First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors	Seminoma; Non-seminomatous Germ Cell Tumor; Extragonadal Seminoma; Teratoma; Germinoma; Mixed Germ Cell Tumor; Yolk Sac Tumor; Childhood Teratoma; Choriocarcinoma; Germ Cell Tumor; Malignant Germ Cell Neoplasm	3000 - Melbourne; 2050 - Camperdown; 3128 - Box Hill; 4102 - Woolloongabba	https://clinicaltrials.gov/ct2/show/NCT02375204
NCT02381886	CIDH305X2101	Phase 1		VIC	2015-03-06	2015-03-06		IDH305	IDH1_R132_inhibitor	IDH305	IDH1_R132_inhibitor	CIDH305X2101	A Phase I Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations	Advanced Malignancies That Harbor IDHR132 Mutations	3050 - Parkville; 3004 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT02381886
NCT02383212	2015-002132-41--R2810-ONC-1423	Phase 1		VIC	2015-03-09	2015-02-02		Carboplatin; Cemiplimab; Cemiplimab + Cyclophosphamide + Radiotherapy; Cemiplimab + Radiotherapy; Cyclophosphamide; Docetaxel; Paclitaxel; Pemetrexed; Radiotherapy	radiotherapy; antimetabolite; alkylating_agent + anti-PD-1_monoclonal_antibody + radiotherapy; anti-PD-1_monoclonal_antibody; taxane; alkylating_agent; platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + radiotherapy	Cemiplimab; Cemiplimab + Cyclophosphamide + Radiotherapy; Cemiplimab + Radiotherapy; Carboplatin; Docetaxel; Paclitaxel; Pemetrexed	alkylating_agent + anti-PD-1_monoclonal_antibody + radiotherapy; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + radiotherapy; antimetabolite; platinum-based_antineoplastic_agent; taxane	2015-002132-41  R2810-ONC-1423	A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies	Advanced Malignancies; Advanced Cancer	- Melbourne	https://clinicaltrials.gov/ct2/show/NCT02383212
NCT02387996	CA209-275	Phase 2		NSW, SA	2015-03-13	2015-03-09		Nivolumab	anti-PD-1_monoclonal_antibody	Nivolumab	anti-PD-1_monoclonal_antibody	CA209-275	A Phase II Single Arm Clinical Trial of Nivolumab (BMS-936558) in Subjects With Metastatic or Unresectable Urothelial Cancer Who Have Progressed or Recurred Following Treatment With a Platinum Agent	Various Advanced Cancer	5112 - Elizabeth Vale; 2298 - Waratah	https://clinicaltrials.gov/ct2/show/NCT02387996
NCT02393625	2014-005054-19--CLDK378A2120C	Phase 1		VIC	2015-03-19	2015-05-27		Ceritinib; Nivolumab	anti-PD-1_monoclonal_antibody; ALK/ROS1/IGF1R_inhibitor	Ceritinib; Nivolumab	ALK/ROS1/IGF1R_inhibitor; anti-PD-1_monoclonal_antibody	2014-005054-19  CLDK378A2120C	A Multi-center, Open-label Study to Assess the Safety and Efficacy of Combination Ceritinib (LDK378) and Nivolumab in Adult Patients With Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC)	ALK-positive NSCLC	3084 - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT02393625
NCT02395172	2014-005060-15--100070-004	Phase 3		NSW, QLD, SA, VIC, WA	2015-03-20	2015-03-24		Avelumab; Docetaxel	anti-PD-L1_monoclonal_antibody; taxane	Avelumab; Docetaxel	anti-PD-L1_monoclonal_antibody; taxane	2014-005060-15  100070-004	A Phase III Open-Label, Multicenter Trial of Avelumab (MSB0010718C) Versus Docetaxel in Subjects With Non-Small Cell Lung Cancer That Has Progressed After a Platinum-Containing Doublet	Carcinoma, Non-Small-Cell Lung	6008 - Subiaco; 4102 - Woolloongabba; 3050 - Parkville; 2450 - Coffs Harbour; 2480 - Lismore; 3128 - Box Hill; 5112 - Elizabeth Vale; 4120 - Greenslopes; 3350 - Ballarat	https://clinicaltrials.gov/ct2/show/NCT02395172
NCT02400476	2015-004374-15--PUMA-NER-6201	Phase 2		NSW, SA, WA	2015-03-27	2015-02-01		Neratinib	EGFR_inhibitor,second_generation; ERBB3_inhibitor; ERBB2_inhibitor,second_generation	Neratinib	EGFR_inhibitor,second_generation; ERBB2_inhibitor,second_generation; ERBB3_inhibitor	2015-004374-15  PUMA-NER-6201	An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide	Early Stage HER2+ Breast Cancer	6009 - Nedlands; 5037 - Kurralta Park; - Wahroonga	https://clinicaltrials.gov/ct2/show/NCT02400476
NCT02407990	BGB-A317-Study-001	Phase 1		NSW, NZ, QLD, SA, VIC, WA	2015-04-03	2015-06-02		Tislelizumab	anti-PD-1_monoclonal_antibody	Tislelizumab	anti-PD-1_monoclonal_antibody	BGB-A317_Study_001	A Phase 1A/1B, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activities of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Subjects With Advanced Tumors	Advanced Cancer	4102 - Woolloongabba; 3004 - Melbourne; - Woodville South; 3144 - Malvern; - Sydney; Wellington; Hamilton; - Clayton; - Heidelberg; - Adelaide; - Melbourne; - East Melbourne; 2050 - Camperdown; - Nedlands; 4216 - Southport	https://clinicaltrials.gov/ct2/show/NCT02407990
NCT02408861	NCI-2015-00461--NCI-2015-00461	Phase 1		NSW	2015-04-06	2015-10-21		Ipilimumab; Ipilimumab + Nivolumab; Nivolumab	anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA4_monoclonal_antibody; anti-PD-1_monoclonal_antibody	Ipilimumab + Nivolumab	anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	NCI-2015-00461  NCI-2015-00461	A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV Associated Solid Tumors With an Expansion Cohort in HIV Associated Solid Tumors and a Cohort of HIV-Associated Classical Hodgkin Lymphoma	Refractory Classic Hodgkin Lymphoma; HIV Infection; Anal Carcinoma; Unresectable Solid Neoplasm; Kaposi Sarcoma; Lung Carcinoma; Recurrent Classic Hodgkin Lymphoma; Metastatic Malignant Solid Neoplasm; Advanced Malignant Solid Neoplasm	2010 - Darlinghurst; 2052 - Sydney	https://clinicaltrials.gov/ct2/show/NCT02408861
NCT02410512	2015-000516-18--GO29674	Phase 1		NSW, VIC, WA	2015-04-07	2015-04-24		Atezolizumab; Atezolizumab + Vonlerolizumab; Vonlerolizumab	anti-OX40_agonistic_antibody; anti-PD-L1_monoclonal_antibody; anti-OX40_agonistic_antibody + anti-PD-L1_monoclonal_antibody	Atezolizumab + Vonlerolizumab	anti-OX40_agonistic_antibody + anti-PD-L1_monoclonal_antibody	2015-000516-18  GO29674	A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors	Neoplasms	6009 - Nedlands; 3000 - Melbourne; 2050 - Camperdown; 3084 - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT02410512
NCT02420821	IMmotion151	Phase 3		NSW, QLD, SA, VIC, WA	2015-04-20	2015-05-20		Atezolizumab; Atezolizumab + Bevacizumab; Bevacizumab; Sunitinib	VEGFR_inhibitor; KIT_inhibitor,first_generation; anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; PDGFR_inhibitor; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody	Atezolizumab + Bevacizumab; Sunitinib	KIT_inhibitor,first_generation; PDGFR_inhibitor; VEGFR_inhibitor; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody	2014-004684-20  WO29637	A Phase III, Open-Label, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Bevacizumab Versus Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma	Renal Cell Carcinoma	6150 - Murdoch; 2298 - Waratah; 4101 - South Brisbane; 2050 - Camperdown; 2109 - Macquarie Park; 3084 - Heidelberg; 5037 - Kurralta Park	https://clinicaltrials.gov/ct2/show/NCT02420821
NCT02422615	MONALEESA-3	Phase 3		NSW, QLD, VIC, WA	2015-04-21	2015-06-09		Fulvestrant; Fulvestrant + Ribociclib; Placebo; Ribociclib	placebo; selective_estrogen_receptor_degrader; CDK4/6_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor	Fulvestrant; Fulvestrant + Ribociclib; Placebo	CDK4/6_inhibitor + selective_estrogen_receptor_degrader; selective_estrogen_receptor_degrader; placebo	2015-000617-43  CLEE011F2301	A Randomized Double-blind, Placebo-controlled Study of Ribociclib in Combination With Fulvestrant for the Treatment of Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer Who Have Received no or Only One Line of Prior Endocrine Treatment	Advanced Breast Cancer	6009 - Nedlands; 2065 - St Leonards; 4029 - Herston; 3002 - East Melbourne	https://clinicaltrials.gov/ct2/show/NCT02422615
NCT02425891	2014-005490-37--WO29522	Phase 3		NSW, QLD, VIC, WA	2015-04-24	2015-06-23		Atezolizumab; Atezolizumab + Nab-paclitaxel; Nab-paclitaxel; Placebo	placebo; anti-PD-L1_monoclonal_antibody + taxane; anti-PD-L1_monoclonal_antibody; taxane	Atezolizumab + Nab-paclitaxel; Nab-paclitaxel; Placebo	anti-PD-L1_monoclonal_antibody + taxane; taxane; placebo	2014-005490-37  WO29522	A Phase III, Multicenter, Randomized, Placebo-Controlled Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Patients With Previously Untreated Metastatic Triple-Negative Breast Cancer	Triple Negative Breast Cancer	2747 - Sydney; 4101 - South Brisbane; 3199 - Frankston; 6008 - Subiaco; 4102 - Woolloongabba; 2050 - Camperdown; 3000 - Melbourne; 3021 - St Albans	https://clinicaltrials.gov/ct2/show/NCT02425891
NCT02426125	RANGE	Phase 3		NSW, SA, VIC, WA	2015-04-24	2015-07-13		Docetaxel; Docetaxel + Ramucirumab; Placebo; Ramucirumab	placebo; anti-VEGFR2_monoclonal_antibody + taxane; anti-VEGFR2_monoclonal_antibody; taxane	Docetaxel; Docetaxel + Ramucirumab; Placebo	anti-VEGFR2_monoclonal_antibody + taxane; taxane; placebo	I4T-MC-JVDC  15679	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ramucirumab Plus Docetaxel Versus Placebo Plus Docetaxel in Patients With Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma Who Progressed on or After Platinum-Based Therapy	Urothelial Carcinoma	6008 - Subiaco; 3011 - Footscray; 2031 - Randwick; 5000 - Adelaide	https://clinicaltrials.gov/ct2/show/NCT02426125
NCT02435433	REACH-2	Phase 3		SA	2015-05-06	2015-07-20		Placebo; Ramucirumab; Sorafenib	placebo; VEGFR_inhibitor; anti-VEGFR2_monoclonal_antibody; CRAF_inhibitor; CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor; FLT3_inhibitor; PDGFR_inhibitor; KIT_inhibitor	Ramucirumab; Placebo; Sorafenib	anti-VEGFR2_monoclonal_antibody; CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor; CRAF_inhibitor; FLT3_inhibitor; KIT_inhibitor; PDGFR_inhibitor; placebo	I4T-MC-JVDE  15755	Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ramucirumab and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (AFP) Following First-Line Therapy With Sorafenib	Hepatocellular Carcinoma	5037 - Kurralta Park; 5011 - Woodville	https://clinicaltrials.gov/ct2/show/NCT02435433
NCT02435680	TNBC	Phase 2		WA	2015-05-06	2015-08-10		Carboplatin; Carboplatin + Gemcitabine; Carboplatin + Gemcitabine + Lacnotuzumab; Gemcitabine; Lacnotuzumab	antimetabolite; anti-CSF1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; gemcitabine; anti-CSF1_monoclonal_antibody	Carboplatin + Gemcitabine; Carboplatin + Gemcitabine + Lacnotuzumab	anti-CSF1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; gemcitabine	2015-000179-29  CMCS110Z2201	A Randomized Phase II Study of MCS110 Combined With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC)	Advanced Triple Negative Breast Cancer (TNBC) With High TAMs	6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT02435680
NCT02437318	SOLAR-1	Phase 3		NSW, QLD, SA, VIC	2015-05-07	2015-07-23		Alpelisib; Alpelisib + Fulvestrant; Fulvestrant; Placebo	placebo; PI3K_alpha_inhibitor; selective_estrogen_receptor_degrader; PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader	Alpelisib + Fulvestrant; Fulvestrant; Placebo	PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader; selective_estrogen_receptor_degrader; placebo	2015-000340-42  CBYL719C2301	A Phase III Randomized Double-blind, Placebo Controlled Study of Alpelisib in Combination With Fulvestrant for Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment	Breast Cancer	5112 - Elizabeth Vale; 3000 - Melbourne; 4102 - Wooloongabba; 2076 - Wahroonga	https://clinicaltrials.gov/ct2/show/NCT02437318
NCT02437916	NCT02437916	Phase 1		VIC	2015-05-08	2015-04-01		AMG-228	anti-GITR_monoclonal_antibody	AMG-228	anti-GITR_monoclonal_antibody	20140131	A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 228 in Subjects With Selected Advanced Solid Tumors	Colorectal Cancer; Squamous Cell Carcinoma of the Head and Neck; Tumors; Advanced Solid Tumors; Advanced Malignancy; Oncology Patients; Melanoma; Non-small Cell Lung Cancer; Oncology; Transitional Cell Carinoma of Bladder; Cancer	3050 - Parkville	https://clinicaltrials.gov/ct2/show/NCT02437916
NCT02438007	ARMOR3-SV	Phase 3		NSW, QLD, SA, VIC	2015-05-08	2015-06-01		Enzalutamide; Galeterone	antiandrogen,steroidal; antiandrogen,nonsteroidal,second_generation	Enzalutamide; Galeterone	antiandrogen,nonsteroidal,second_generation; antiandrogen,steroidal	ARMOR3-SV	ARMOR3-SV: A Phase 3, Randomized, Open Label, Multi-Center, Controlled Study of Galeterone Compared to Enzalutamide in Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic (M1) Castrate Resistant Prostate Cancer (CRPC)	Prostate Cancer	3002 - East Melbourne; 2031 - Randwick; 3165 - East Bentleigh; 4215 - Southport; 5037 - Kurralta Park; 4102 - Kippa-Ring; 2109 - Sydney; 2444 - Port Macquarie; 3128 - Box Hill; 2217 - Kogarah; 4102 - Woolloongabba; 3144 - Malvern	https://clinicaltrials.gov/ct2/show/NCT02438007
NCT02442349	AURA17	Phase 2		NSW, QLD, WA	2015-05-13	2015-06-22		Osimertinib	EGFR_inhibitor,third_generation	Osimertinib	EGFR_inhibitor,third_generation	D5160C00017	A Phase II, Open Label, Single-arm Study to Assess the Safety and Efficacy of AZD9291 in Asia Pacific Patients With Locally Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed With Previous Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Whose Tumours Harbour a T790M Mutation Within the Epidermal Growth Factor Receptor Gene.	Non-Small Cell Lung Cancer	4102 - Woolloongabba; 6009 - Nedlands; 2217 - Kogarah	https://clinicaltrials.gov/ct2/show/NCT02442349
NCT02443883	I4T-MC-JVDB--15608	Phase 2		NSW, NZ, SA, VIC, WA	2015-05-14	2015-07-07		Ramucirumab	anti-VEGFR2_monoclonal_antibody	Ramucirumab	anti-VEGFR2_monoclonal_antibody	I4T-MC-JVDB  15608	Randomized Phase 2 Trial Evaluating Pharmacokinetics and Safety of Four Ramucirumab Dosing Regimens in Second-Line Gastric or Gastroesophageal Junction Adenocarcinoma	Gastroesophageal Junction Adenocarcinoma; Gastric Adenocarcinoma	Auckland; 6009 - Nedlands; Christchurch; 2747 - Kingswood; 5000 - Adelaide; 3144 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT02443883
NCT02449681	TH-CR-602	Phase 2		NSW, VIC	2015-05-20	2015-08-01		Tarloxotinib	pan_ERBB_inhibitor,hypoxia_activating	Tarloxotinib	pan_ERBB_inhibitor,hypoxia_activating	TH-CR-602	A Phase 2 Study of TH-4000 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Skin	Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Skin	2050 - Camperdown; 3002 - East Melbourne	https://clinicaltrials.gov/ct2/show/NCT02449681
NCT02450539	I3Y-MC-JPBX--15806	Phase 2		NSW, QLD	2015-05-21	2015-08-06		Abemaciclib; Docetaxel	CDK4/6_inhibitor; taxane	Abemaciclib; Docetaxel	CDK4/6_inhibitor; taxane	I3Y-MC-JPBX  15806	A Randomized Phase 2 Study of Abemaciclib (LY2835219) Versus Docetaxel in Patients With Stage IV Squamous Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy	Non-Small Cell Lung Cancer Stage IV	2050 - Camperdown; 2013 - Randwick; 2500 - Wollongong; 4102 - Woolloongabba; 4101 - South Brisbane	https://clinicaltrials.gov/ct2/show/NCT02450539
NCT02451943	ANNOUNCE	Phase 3		NSW	2015-05-22	2015-09-14		Doxorubicin; Doxorubicin + Olaratumab; Olaratumab; Placebo	placebo; anthracycline; doxorubicin; anti-PDGFRA_monoclonal_antibody; anthracycline + anti-PDGFRA_monoclonal_antibody	Doxorubicin; Doxorubicin + Olaratumab; Placebo	anthracycline; anthracycline + anti-PDGFRA_monoclonal_antibody; doxorubicin; placebo	I5B-MC-JGDJ  15677	A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Doxorubicin Plus Olaratumab Versus Doxorubicin Plus Placebo in Patients With Advanced or Metastatic Soft Tissue Sarcoma	Soft Tissue Sarcoma	2050 - Camperdown	https://clinicaltrials.gov/ct2/show/NCT02451943
NCT02454842	TH-4000	Phase 2		VIC	2015-05-27	2015-06-01		Tarloxotinib	pan_ERBB_inhibitor,hypoxia_activating	Tarloxotinib	pan_ERBB_inhibitor,hypoxia_activating	TH-CR-601	A Phase 2 Study of TH-4000 (Tarloxotinib) in Patients With EGFR-Mutant, T790M-Negative, Advanced Non-Small Cell Lung Cancer Progressing on an EGFR Tyrosine Kinase Inhibitor	Non-squamous NSCLC; Non-small Cell Lung Cancer; NSCLC	3002 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT02454842
NCT02460224	CLAG525X2101C	Phase 1/Phase 2		NSW, VIC	2015-06-02	2015-06-17		Ieramilimab; Ieramilimab + Spartalizumab; Spartalizumab	anti-LAG3_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody	Ieramilimab; Ieramilimab + Spartalizumab	anti-LAG3_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody	CLAG525X2101C	A Phase I/II, Open Label, Multicenter Study of the Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 Administered to Patients With Advanced Malignancies	Advanced Solid Tumors	2145 - Westmead; 3084 - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT02460224
NCT02470585	VELIA	Phase 3		NSW, NZ, QLD, SA, VIC, WA	2015-06-12	2015-07-14		Carboplatin; Carboplatin + Paclitaxel + Veliparib; Paclitaxel; Placebo; Veliparib	placebo; platinum-based_antineoplastic_agent; taxane; PARP_inhibitor + platinum-based_antineoplastic_agent + taxane; PARP_inhibitor	Carboplatin + Paclitaxel + Veliparib; Placebo	PARP_inhibitor + platinum-based_antineoplastic_agent + taxane; placebo	2014-005070-11  M13-694	A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP Inhibitor) in Subjects With Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Ovarian Cancer; Ovarian Neoplasm	6008 - Subiaco; 2298 - Waratah; 2250 - Gosford; 3052 - Parkville; 3144 - Malvern; 3168 - Clayton; 2065 - St Leonards; 4101 - South Brisbane; 2145 - Westmead; 4814 - Douglas; 2217 - Kogarah; 2450 - Coffs Harbour; Auckland; 6009 - Nedlands; 2305 - Lambton Heights; 4029 - Herston; 2500 - Wollongong; 2031 - Randwick; 5000 - Adelaide	https://clinicaltrials.gov/ct2/show/NCT02470585
NCT02474355	ASTRIS	Phase 3		NSW, SA, VIC	2015-06-17	2015-09-18		Osimertinib	EGFR_inhibitor,third_generation	Osimertinib	EGFR_inhibitor,third_generation	D5160C00022	Open Label, Multinational, Multicenter, Real World Treatment Study of Single Agent AZD9291 for Patients With Advanced/Metastatic Epidermal Growth Factor Receptor (EGFR) T790M Mutation-Positive Non-Small Cell Lung Cancer (NSCLC) Who Have Received Prior Therapy With an EGFR Tyrosine Kinase Inhibitor (EGFR-TKI)	Lung Cancer	5037 - Kurralta Park; 5042 - Bedford Park; 2031 - Randwick; 3002 - East Melbourne; 2298 - Waratah	https://clinicaltrials.gov/ct2/show/NCT02474355
NCT02481830	CheckMate331	Phase 3		NSW, QLD, SA, WA	2015-06-25	2015-09-14		Amrubicin; Nivolumab; Topotecan	topoisomerase_inhibitor; anthracycline; anti-PD-1_monoclonal_antibody	Amrubicin; Nivolumab; Topotecan	anthracycline; anti-PD-1_monoclonal_antibody; topoisomerase_inhibitor	2015-001097-18  CA209-331	An Open-label, Randomized, Phase 3 Study of Nivolumab or Chemotherapy in Subjects With Relapsed Small-cell Lung Cancer After Platinum-based First Line Chemotherapy (CheckMate 331: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 331)	Lung Cancer	5037 - Kurralta Park; 6150 - Perth; 5112 - Elizabeth Vale; 4032 - Brisbane; 2298 - Waratah; 6150 - Murdoch	https://clinicaltrials.gov/ct2/show/NCT02481830
NCT02484443	NCI-2015-01001--NCI-2015-01001	Phase 2		NSW, NZ, QLD, SA, VIC, WA	2015-06-29	2016-02-04		Dinutuximab; Dinutuximab + Sargramostim; Sargramostim	anti-GD2_monoclonal_antibody; Granulocyte-Macrophage_Colony_Stimulating_Factor + anti-GD2_monoclonal_antibody; Granulocyte-Macrophage_Colony_Stimulating_Factor	Dinutuximab + Sargramostim	Granulocyte-Macrophage_Colony_Stimulating_Factor + anti-GD2_monoclonal_antibody	NCI-2015-01001  NCI-2015-01001	A Phase 2 Study of Human-Mouse Chimeric Anti-disialoganglioside Monoclonal Antibody ch14.18 (Dinutuximab, NSC# 764038) in Combination With Sargramostim (GM-CSF) in Patients With Recurrent Osteosarcoma	Metastatic Osteosarcoma; Recurrent Osteosarcoma; Metastatic Malignant Neoplasm in the Lung	2145 - Westmead; 6008 - Perth; Auckland; 3052 - Parkville; 3168 - Clayton; 4101 - South Brisbane; Christchurch; 2310 - Hunter Regional Mail Centre; 5006 - North Adelaide; 2031 - Randwick	https://clinicaltrials.gov/ct2/show/NCT02484443
NCT02485652	2015-001435-21--HM-EMSI-202	Phase 2		NSW, QLD, SA, VIC	2015-06-30	2015-08-31		Olmutinib	EGFR_inhibitor,third_generation	Olmutinib	EGFR_inhibitor,third_generation	2015-001435-21  HM-EMSI-202	A Single Arm, Open-label, Phase 2 Study Evaluating the Efficacy, Safety and PK of HM61713 in Patients With T790M-positive NSCLC After Treatment With an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor	Non Small Cell Lung Cancer	- Kogarah; - Woolloongabba; - Frankston; - St Albans; - Darlinghurst; - Fitzroy	https://clinicaltrials.gov/ct2/show/NCT02485652
NCT02491892	BO16934	Phase 2		NSW, VIC	2015-07-08	2003-02-01		Pertuzumab	anti-ERBB2_monoclonal_antibody,dimerization_inhibitor	Pertuzumab	anti-ERBB2_monoclonal_antibody,dimerization_inhibitor	BO16934	Open-Label, Phase II, Multicenter, Randomized Study of Efficacy and Safety for Two Different Doses of a Recombinant Humanized Antibody to HER2 (rhuMAb 2C4) Administered Every 3 Weeks to Patients With Metastatic Breast Cancer With Low Expression of HER2	Breast Cancer	3065 - Fitzroy; 3220 - Geelong; 2050 - Camperdown	https://clinicaltrials.gov/ct2/show/NCT02491892
NCT02492789	INCSHR1210-101	Phase 1		NSW, VIC, WA	2015-07-09	2015-09-01		Camrelizumab	anti-PD-1_monoclonal_antibody	Camrelizumab	anti-PD-1_monoclonal_antibody	INCSHR1210-101	An Open-Label, Multicenter, Nonrandomized, Dose-Escalation and Tumor-Expansion Phase 1 Study to Evaluate the Safety and Tolerability of INCSHR01210 (Formerly SHR-1210) in Subjects With Advanced Solid Tumors	Solid Tumors and Hematologic Malignancy	- Blacktown; - Nedlands; - Melbourne; - Camperdown; - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT02492789
NCT02503033	2015-523-00AU1	Phase 1		ACT, NSW, QLD, SA, VIC, WA	2015-07-20	2015-11-01		HMPL-523	SYK_inhibitor	HMPL-523	SYK_inhibitor	2015-523-00AU1	A Phase I, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of HMPL-523 in Patients With Relapsed or Refractory Hematologic Malignancies	Hematologic Malignancies	- Canberra; - Liverpool; - Frankston; 4814 - Townsville; 3220 - Geelong; 2640 - Albury; - Fitzroy; 3350 - Ballarat; 3144 - Melbourne; - Heidelberg; 6000 - Perth; - Adelaide	https://clinicaltrials.gov/ct2/show/NCT02503033
NCT02504489	DUBLIN-3	Phase 3		NSW, QLD, VIC, WA	2015-07-22	2015-12-01		Dexamethasone; Dexamethasone + Docetaxel; Docetaxel; Docetaxel + Plinabulin; Placebo; Plinabulin	placebo; taxane; glucocorticoid + taxane; taxane + tubulin_polymerization_inhibitor; glucocorticoid; tubulin_polymerization_inhibitor	Dexamethasone + Docetaxel; Docetaxel + Plinabulin; Placebo	glucocorticoid + taxane; taxane + tubulin_polymerization_inhibitor; placebo	BPI-2358-103	Randomized Blinded Phase III Assessment of Second or Third-Line Chemotherapy With Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced Non-Small Cell Lung Cancer and With at Least One Measurable Lung Lesion	Non-Small Cell Lung Cancer	3121 - Richmond; 6000 - Perth; 2640 - East Albury; 4101 - South Brisbane; 2250 - Gosford; 6008 - Subiaco; 3199 - Melbourne; 2148 - Blacktown; 6150 - Murdoch	https://clinicaltrials.gov/ct2/show/NCT02504489
NCT02506556	PIKNIC	Phase 2		VIC	2015-07-23	2015-09-07		Alpelisib	PI3K_alpha_inhibitor	Alpelisib	PI3K_alpha_inhibitor	LL14/02	A Phase II Exploratory, Open-label, Single Arm Study of BYL719 Monotherapy, a Selective Phosphatidylinositol 3-kinase (PI3K) Alpha Inhibitor, in Adult Patients With Advanced Breast Cancer Progressing After First Line Therapy.	Metastatic Breast Cancer	3002 - East Melbourne	https://clinicaltrials.gov/ct2/show/NCT02506556
NCT02512237	ZMC-ARX788-101	Phase 1		NZ, QLD, VIC	2015-07-30	2016-03-01		ARX788	anti-ERBB2_antibody-drug_conjugate	ARX788	anti-ERBB2_antibody-drug_conjugate	  ZMC-ARX788-101	A Phase 1, Multicenter, Open-label, Multiple Dose-escalation Study of ARX788, Intravenously Administered as a Single Agent in Subjects With Advanced Cancers With HER2 Expression	Stomach Neoplasms; Breast Neoplasms	Christchurch; 4101 - South Brisbane; 3168 - Clayton; 4102 - Woolloongabba; Auckland; Wellington; 3121 - Richmond	https://clinicaltrials.gov/ct2/show/NCT02512237
NCT02517398	2015-004366-28--EMR-200647-001	Phase 1		NSW, QLD, SA, VIC, WA	2015-08-07	2015-08-31		Bintrafusp Alfa	anti-PD-L1/TGF-beta_fusion_protein	Bintrafusp Alfa	anti-PD-L1/TGF-beta_fusion_protein	2015-004366-28  EMR 200647-001	A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, PK, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications	Solid Tumors	4120 - Greenslopes; 4216 - Southport; 3002 - East Melbourne; 2444 - Port Macquarie; 3690 - Wodonga; 2170 - Liverpool; 5011 - Woodville South; 6009 - Nedlands; 2148 - Blacktown; 6150 - Murdoch; 2217 - Kogarah; 2065 - St Leonards; 3144 - Malvern; 2298 - Waratah	https://clinicaltrials.gov/ct2/show/NCT02517398
NCT02521493	NCI-2015-00324--AAML1531	Phase 3		NSW, NZ, VIC, WA	2015-08-13	2015-12-23		Asparaginase; Cytarabine; Cytarabine + Daunorubicin + Thioguanine; Cytarabine + Mitoxantrone; Daunorubicin; Etoposide; Mitoxantrone; Thioguanine	antimetabolite; topoisomerase_inhibitor; antineoplastic_antibiotic; anthracycline; anthracycline + antimetabolite; asparaginase; antimetabolite + antineoplastic_antibiotic	Cytarabine + Daunorubicin + Thioguanine; Cytarabine + Mitoxantrone; Asparaginase; Etoposide	anthracycline + antimetabolite; antimetabolite + antineoplastic_antibiotic; asparaginase; topoisomerase_inhibitor	NCI-2015-00324  AAML1531	Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome	Myelodysplastic Syndrome; Acute Myeloid Leukemia; Myeloid Leukemia Associated With Down Syndrome; Myeloproliferative Neoplasm; Down Syndrome	Auckland; 6008 - Perth; 6009 - Perth; 2145 - Westmead; Christchurch; 3052 - Parkville; 2031 - Randwick; 2310 - Hunter Regional Mail Centre	https://clinicaltrials.gov/ct2/show/NCT02521493
NCT02538666	CheckMate-451	Phase 3		NSW, QLD, SA, VIC	2015-09-02	2015-10-13		Ipilimumab; Ipilimumab + Nivolumab; Nivolumab; Placebo	placebo; anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-CTLA4_monoclonal_antibody	Ipilimumab + Nivolumab; Nivolumab; Placebo	anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; placebo	2015-002441-61  CA209-451	A Randomized, Multicenter, Double-Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination With Ipilimumab, or Placebo as Maintenance Therapy in Subjects With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based First Line Chemotherapy (CheckMate 451: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 451)	Lung Cancer	4575 - Birtinya; 4102 - Brisbane; 2500 - Wollongong; 5000 - Adelaide; - Kogarah; 3165 - East Melbourne	https://clinicaltrials.gov/ct2/show/NCT02538666
NCT02544633	265-109	Phase 2		NSW, QLD, SA, TAS, VIC	2015-09-09	2015-10-01		Glesatinib	MET_inhibitor,type_2	Glesatinib	MET_inhibitor,type_2	265-109	Phase 2, Parallel-Arm Study of MGCD265 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor	Non-Small Cell Lung Cancer	2217 - Kogarah; 3165 - Clayton; 4102 - Woolloongabba; 7000 - Hobart; 2065 - Saint Leonards; 3084 - Heidelberg; 2485 - Tweed Heads; 5042 - Bedford Park; 2139 - Concord	https://clinicaltrials.gov/ct2/show/NCT02544633
NCT02545504	GAMMA-1	Phase 3		ACT, NSW, QLD, SA, TAS, VIC	2015-09-10	2015-10-13		Andecaliximab; Andecaliximab + Fluorouracil; Fluorouracil; Leucovorin; Oxaliplatin; Placebo	placebo; anti-MMP9_monoclonal_antibody; Fluorouracil; fluoropyrimidine; platinum-based_antineoplastic_agent; folinic_acid; anti-MMP9_monoclonal_antibody + fluoropyrimidine	Andecaliximab + Fluorouracil; Fluorouracil; Leucovorin; Oxaliplatin; Placebo	anti-MMP9_monoclonal_antibody + fluoropyrimidine; fluoropyrimidine; Fluorouracil; folinic_acid; placebo; platinum-based_antineoplastic_agent	2015-001526-42  GS-US-296-1080	A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5745 Combined With mFOLFOX6 as First Line Treatment in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma	Gastric Adenocarcinoma	- Hobart; - Richmond; - Westmead; - St Albans; - Brisbane; - Kurralta Park; - Garran; - Camperdown; 2485 - Tweed Heads; - Wahroonga	https://clinicaltrials.gov/ct2/show/NCT02545504
NCT02550678	ASN-002-001	Phase 1/Phase 2		NSW, QLD, VIC	2015-09-15	2015-09-01		Fluorouracil; Gusacitinib	Fluorouracil; fluoropyrimidine; SYK/JAK_inhibitor	Fluorouracil; Gusacitinib	SYK/JAK_inhibitor; fluoropyrimidine; Fluorouracil	ASN-002-001	A Phase 1/2a Study of the Efficacy and Safety of ASN-002 Alone or in Combination With 5-FU in Adult Patients With Low-risk Nodular Basal Cell Carcinoma	Nodular Basal Cell Carcinoma of Skin; Skin Neoplasm; Basal Cell Nevus Syndrome	3002 - Melbourne; 4102 - Brisbane; 4000 - Brisbane; 2217 - Kogarah	https://clinicaltrials.gov/ct2/show/NCT02550678
NCT02551991	2015-003086-28--MM-398-07-02-03	Phase 1/Phase 2		WA	2015-09-16	2015-09-01		Fluorouracil; Fluorouracil + Liposomal Irinotecan + Oxaliplatin; Gemcitabine; Leucovorin; Liposomal Irinotecan; Nab-paclitaxel; Oxaliplatin	antimetabolite; topoisomerase_inhibitor; Fluorouracil; fluoropyrimidine; taxane; platinum-based_antineoplastic_agent; folinic_acid; fluoropyrimidine + platinum-based_antineoplastic_agent + topoisomerase_inhibitor	Fluorouracil + Liposomal Irinotecan + Oxaliplatin; Gemcitabine; Leucovorin; Nab-paclitaxel	fluoropyrimidine + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; Fluorouracil; antimetabolite; folinic_acid; taxane	2015-003086-28  MM-398-07-02-03	A Randomized, Open-label Phase 2 Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-Paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma	Pancreatic Cancer	6008 - Subiaco	https://clinicaltrials.gov/ct2/show/NCT02551991
NCT02562755	PHOCUS	Phase 3		NSW, NZ, QLD, SA, VIC, WA	2015-09-29	2015-10-01		Pexastimogene Devacirepvec; Pexastimogene Devacirepvec + Sorafenib; Sorafenib	thymidine_kinase-deleted_oncolytic_vaccinia_virus_expressing_human_GM-CSF; PDGFR_inhibitor; KIT_inhibitor; CRAF_inhibitor + thymidine_kinase-deleted_oncolytic_vaccinia_virus_expressing_human_GM-CSF; VEGFR_inhibitor; CRAF_inhibitor; CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor + thymidine_kinase-deleted_oncolytic_vaccinia_virus_expressing_human_GM-CSF; FLT3_inhibitor + thymidine_kinase-deleted_oncolytic_vaccinia_virus_expressing_human_GM-CSF; CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor; FLT3_inhibitor; VEGFR_inhibitor + thymidine_kinase-deleted_oncolytic_vaccinia_virus_expressing_human_GM-CSF; KIT_inhibitor + thymidine_kinase-deleted_oncolytic_vaccinia_virus_expressing_human_GM-CSF; PDGFR_inhibitor + thymidine_kinase-deleted_oncolytic_vaccinia_virus_expressing_human_GM-CSF	Pexastimogene Devacirepvec + Sorafenib; Sorafenib	CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor; CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor + thymidine_kinase-deleted_oncolytic_vaccinia_virus_expressing_human_GM-CSF; CRAF_inhibitor; CRAF_inhibitor + thymidine_kinase-deleted_oncolytic_vaccinia_virus_expressing_human_GM-CSF; FLT3_inhibitor; FLT3_inhibitor + thymidine_kinase-deleted_oncolytic_vaccinia_virus_expressing_human_GM-CSF; KIT_inhibitor; KIT_inhibitor + thymidine_kinase-deleted_oncolytic_vaccinia_virus_expressing_human_GM-CSF; PDGFR_inhibitor; PDGFR_inhibitor + thymidine_kinase-deleted_oncolytic_vaccinia_virus_expressing_human_GM-CSF; VEGFR_inhibitor; VEGFR_inhibitor + thymidine_kinase-deleted_oncolytic_vaccinia_virus_expressing_human_GM-CSF	JX594-HEP024	A Phase 3 Randomized, Open-Label Study Comparing Pexa Vec (Vaccinia GM CSF / Thymidine Kinase-Deactivated Virus) Followed by Sorafenib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC) Without Prior Systemic Therapy	Hepatocellular Carcinoma (HCC)	- Fitzroy; - Footscray; - Melbourne; - Adelaide; - Brisbane; - Clayton; - Perth; - Camperdown; - Concord; - Heidelberg; - Sydney; Auckland; Christchurch; - Parkville	https://clinicaltrials.gov/ct2/show/NCT02562755
NCT02569476	BGB-3111-GA101-Study-001	Phase 1		NSW, QLD, SA, VIC, WA	2015-10-06	2016-01-13		Obinutuzumab; Obinutuzumab + Zanubrutinib; Zanubrutinib	BTK_inhibitor; anti-CD20_monoclonal_antibody; BTK_inhibitor + anti-CD20_monoclonal_antibody	Obinutuzumab + Zanubrutinib	BTK_inhibitor + anti-CD20_monoclonal_antibody	BGB-3111_GA101_Study_001	A Phase 1b Study to Assess Safety, Tolerability and Antitumor Activity of the Combination of BGB 3111 With Obinutuzumab in Subjects With B-Cell Lymphoid Malignancies	B-cell Lymphoid Malignancies	3144 - Malvern; 3220 - Geelong; 2217 - Kogarah; 5037 - Kurralta Park; 3181 - Melbourne; 6000 - Perth; 3002 - East Melbourne; 4120 - Greenslopes; 2640 - Albury	https://clinicaltrials.gov/ct2/show/NCT02569476
NCT02569801	HydranGea	Phase 2		NSW, SA, TAS, VIC	2015-10-07	2015-12-04		Brilanestrant; Brilanestrant + Fulvestrant; Fulvestrant	selective_estrogen_receptor_degrader	Brilanestrant; Brilanestrant + Fulvestrant	selective_estrogen_receptor_degrader	2015-000106-19  GO29689	A Phase II, Open-Label, Randomized Study of GDC-0810 Versus Fulvestrant in Postmenopausal Women With Advanced or Metastatic ER+ /HER2- Breast Cancer Resistant to Aromatase Inhibitor Therapy	Breast Cancer	3121 - Richmond; 2444 - Port Macquarie; 5037 - Kurralta Park; 3011 - Footscray; 2010 - Darlinghurst; 7000 - Hobart; 3199 - Frankston	https://clinicaltrials.gov/ct2/show/NCT02569801
NCT02573324	Intellance1	Phase 3		NSW, NZ, QLD, SA, VIC, WA	2015-10-09	2015-01-04		Depatuxizumab Mafodotin; Depatuxizumab Mafodotin + Temozolomide; Placebo; Temozolomide	placebo; alkylating_agent; anti-EGFR/PBD_antibody-drug_conjugate; alkylating_agent + anti-EGFR/PBD_antibody-drug_conjugate	Depatuxizumab Mafodotin + Temozolomide; Temozolomide; Placebo	alkylating_agent; alkylating_agent + anti-EGFR/PBD_antibody-drug_conjugate; placebo	2015-001166-26  M13-813	A Randomized, Placebo Controlled Phase 3 Study of ABT-414 With Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance1)	Glioblastoma; Gliosarcoma	2170 - Liverpool; 5000 - Adelaide; 2031 - Randwick; 2500 - Wollongong; 3084 - Heidelberg; 3065 - Fitzroy Melbourne; 5006 - Adelaide; 2065 - St Leonards; Christchurch; 4102 - Woolloongabba; 6008 - Subiaco; 2298 - Waratah; Wellington	https://clinicaltrials.gov/ct2/show/NCT02573324
NCT02576431	NAVIGATE	Phase 2		NSW, NT, WA	2015-10-15	2015-09-30		Larotrectinib	TRK_inhibitor,first_generation	Larotrectinib	TRK_inhibitor,first_generation	LOXO-TRK-15002  20289	A Study to Learn How Well the Drug Larotrectinib Works in Adults With Different Solid Cancers With a Change in the Genes Called NTRK Fusion	Solid Tumors Harboring NTRK Fusion	2109 - Sydney; 810 - Tiwi; 6008 - Subiaco	https://clinicaltrials.gov/ct2/show/NCT02576431
NCT02576509	CheckMate-459	Phase 3		NSW, SA, VIC, WA	2015-10-15	2015-12-07		Nivolumab; Sorafenib	VEGFR_inhibitor; CRAF_inhibitor; anti-PD-1_monoclonal_antibody; CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor; FLT3_inhibitor; PDGFR_inhibitor; KIT_inhibitor	Nivolumab; Sorafenib	CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor; CRAF_inhibitor; FLT3_inhibitor; KIT_inhibitor; PDGFR_inhibitor; VEGFR_inhibitor; anti-PD-1_monoclonal_antibody	CA209-459	A Randomized, Multi-center Phase III Study of Nivolumab Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma (CheckMate 459: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 459)	Hepatocellular Carcinoma	3168 - Clayton; 6009 - Nedlands; 5000 - Adelaide; 3181 - Prahran; 3084 - Heidelberg; 2050 - Camperdown	https://clinicaltrials.gov/ct2/show/NCT02576509
NCT02576574	2015-001537-24--EMR-100070-005	Phase 3		NSW, NZ, QLD, SA, VIC, WA	2015-10-15	2015-10-29		Avelumab; Carboplatin; Cisplatin; Gemcitabine; Paclitaxel; Pemetrexed	antimetabolite; anti-PD-L1_monoclonal_antibody; taxane; gemcitabine; platinum-based_antineoplastic_agent	Avelumab; Carboplatin; Cisplatin; Gemcitabine; Paclitaxel; Pemetrexed	anti-PD-L1_monoclonal_antibody; antimetabolite; gemcitabine; platinum-based_antineoplastic_agent; taxane	2015-001537-24  EMR 100070-005	A Phase III, Open-label, Multicenter Trial of Avelumab (MSB0010718C) Versus Platinum-based Doublet as a First-line Treatment of Recurrent or Stage IV PD-L1+NSCLC	First Line Non-Small Cell Lung Cancer	2640 - Albury; 4120 - Greenslopes; 3350 - Ballarat; 2480 - Lismore; 4215 - Southport; 5011 - Woodville South; Tauranga; 2450 - Coffs Harbour; 6150 - Murdoch; Dunedin; 2800 - Orange; Palmerston North; 2217 - Kogarah; Auckland; Hamilton; 3550 - Bendigo; Wellington; 2298 - Waratah; 2065 - St Leonards; 3280 - Warrnambool	https://clinicaltrials.gov/ct2/show/NCT02576574
NCT02580058	2015-003091-77--B9991009	Phase 3		NSW, QLD, VIC	2015-10-20	2015-12-21		Avelumab; Avelumab + Pegylated liposomal doxorubicin; Pegylated liposomal doxorubicin	anthracycline + anti-PD-L1_monoclonal_antibody; anthracycline; anti-PD-L1_monoclonal_antibody	Avelumab; Avelumab + Pegylated liposomal doxorubicin	anthracycline + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody	2015-003091-77  B9991009	A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY OF AVELUMAB (MSB0010718C) ALONE OR IN COMBINATION WITH PEGYLATED LIPOSOMAL DOXORUBICIN VERSUS PEGYLATED LIPOSOMAL DOXORUBICIN ALONE IN PATIENTS WITH PLATINUM-RESISTANT/REFRACTORY OVARIAN CANCER	Ovarian Cancer	4215 - Southport; 4101 - Brisbane; 2305 - Newcastle; 3000 - Melbourne; 4029 - Herston; 4032 - Chermside; 2305 - New Lambton Heights; 3052 - Parkville; 3144 - Malvern; 4101 - South Brisbane; 3186 - Brighton; 3050 - Parkville; 4066 - Auchenflower	https://clinicaltrials.gov/ct2/show/NCT02580058
NCT02582697	P3BEP	Phase 3		NSW, NZ, QLD, SA, TAS, VIC, WA	2015-10-21	2014-02-01		Bleomycin; Cisplatin; Etoposide; Filgrastim; Pegfilgrastim	topoisomerase_inhibitor; platinum-based_antineoplastic_agent; granulocyte_colony_stimulating_factor; antineoplastic_antibiotic	Bleomycin; Cisplatin; Etoposide; Filgrastim; Pegfilgrastim	antineoplastic_antibiotic; granulocyte_colony_stimulating_factor; platinum-based_antineoplastic_agent; topoisomerase_inhibitor	ACTRN12613000496718  ANZUP1302	Phase 3 Accelerated BEP: A Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours	Germ Cell Tumor	2139 - Sydney; 3084 - Heidelberg; 2485 - Tweed Heads; 5000 - Adelaide; 3002 - East Melbourne; 5042 - Bedford Park; 2751 - Sydney; 3021 - St Albans; 3128 - Box Hill; 2109 - Sydney; 3690 - Wodonga; 2298 - Newcastle; Dunedin; 2050 - Sydney; Palmerston North; 6847 - Murdoch; Auckland; 4029 - Brisbane; 2031 - Sydney; 2076 - Wahroonga; 4102 - Woolloongabba; 2145 - Sydney; 2065 - St Leonards; 4101 - South Brisbane; Christchurch; 7000 - Hobart	https://clinicaltrials.gov/ct2/show/NCT02582697
NCT02584634	2015-001879-43--B9991005	Phase 1		NSW, QLD, VIC	2015-10-22	2015-12-18		Avelumab; Crizotinib; Lorlatinib	ALK_inhibitor,third_generation; ROS1_inhibitor; ALK_inhibitor,first_generation; anti-PD-L1_monoclonal_antibody; MET_inhibitor,type_1	Avelumab; Crizotinib; Lorlatinib	ALK_inhibitor,first_generation; ALK_inhibitor,third_generation; MET_inhibitor,type_1; ROS1_inhibitor; anti-PD-L1_monoclonal_antibody	2015-001879-43  B9991005	A PHASE 1B/2, OPEN-LABEL, DOSE-FINDING STUDY TO EVALUATE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB (MSB0010718C) IN COMBINATION WITH EITHER CRIZOTINIB OR PF-06463922 IN PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER	Non-Small Cell Lung Cancer	3050 - Parkville; 4032 - Chermside; 3000 - Melbourne; 2050 - Camperdown	https://clinicaltrials.gov/ct2/show/NCT02584634
NCT02592707	2015-002867-41--D-FR-01072-001	Phase 1		VIC, WA	2015-10-30	2017-03-06		Satoreotide Tetraxetan	177Lu-DOTA-radioconjugate	Satoreotide Tetraxetan	177Lu-DOTA-radioconjugate	2015-002867-41  D-FR-01072-001	An International, Multicenter, Open-label Study to Evaluate Safety, Tolerability, Biodistribution, Dosimetry and Preliminary Efficacy of 177Lu-OPS201 for the Therapy of Somatostatin Receptor-positive Neuroendocrine Tumors (NETs)	Neuroendocrine Tumors	3002 - East Melbourne; 6009 - Perth	https://clinicaltrials.gov/ct2/show/NCT02592707
NCT02598960	2015-002505-11--CA009-002	Phase 1/Phase 2		NSW, QLD, WA	2015-11-06	2015-10-09		Nivolumab	anti-PD-1_monoclonal_antibody	Nivolumab	anti-PD-1_monoclonal_antibody	2015-002505-11  CA009-002	A Phase 1/2a Dose Escalation and Cohort Expansion Study for Safety, Tolerability, and Efficacy of BMS-986156 Administered Alone and in Combination With Nivolumab (BMS-936558, Anti PD-1 Monoclonal Antibody) in Advanced Solid Tumors	Solid Tumors	4102 - Brisbane; 2170 - Liverpool; 2145 - Westmead; 6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT02598960
NCT02601378	CLXS196X2101	Phase 1		NSW	2015-11-10	2016-02-01		Darovasertib; Darovasertib + Siremadlin; Siremadlin	HDM2_inhibitor + PKC_inhibitor; PKC_inhibitor; HDM2_inhibitor	Darovasertib; Darovasertib + Siremadlin	HDM2_inhibitor + PKC_inhibitor; PKC_inhibitor	CLXS196X2101	A Phase I, Multi-center, Open-label, Study of LXS196, an Oral Protein Kinase C Inhibitor, in Patients With Metastatic Uveal Melanoma	Uveal Melanoma	2145 - Westmead	https://clinicaltrials.gov/ct2/show/NCT02601378
NCT02603432	2015-003262-86--B9991001	Phase 3		NSW, NZ, QLD, SA, VIC, WA	2015-11-11	2016-04-25		Avelumab	anti-PD-L1_monoclonal_antibody	Avelumab	anti-PD-L1_monoclonal_antibody	2015-003262-86  B9991001	A PHASE 3, MULTICENTER, MULTINATIONAL, RANDOMIZED, OPEN-LABEL, PARALLEL-ARM STUDY OF AVELUMAB (MSB0010718C) PLUS BEST SUPPORTIVE CARE VERSUS BEST SUPPORTIVE CARE ALONE AS A MAINTENANCE TREATMENT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER WHOSE DISEASE DID NOT PROGRESS AFTER COMPLETION OF FIRST-LINE PLATINUM-CONTAINING CHEMOTHERAPY	Urothelial Cancer	3350 - Ballarat; 4032 - Chermside; 2485 - Tweed Heads; 2050 - Camperdown; 2830 - Dubbo; 3128 - Box Hill; 2139 - Concord; 5037 - Kurralta Park; 4575 - Birtinya; 5042 - Bedford Park; 2480 - Lismore; 5011 - Woodville South; 2109 - New South Wales; 3165 - East Bentleigh; 4215 - Southport; 2484 - Murwillubah; Auckland; Hamilton; 4034 - Geebung; 4066 - Auchenflower; 2217 - Kogarah; 6150 - Murdoch; 2109 - Macquarie University; 3355 - Ballarat; 4814 - Douglas; 5037 - Kurralta park; Christchurch; 4101 - South Brisbane; 3168 - Clayton; 3149 - Mount Waverley; 3355 - Wendouree	https://clinicaltrials.gov/ct2/show/NCT02603432
NCT02609776	CHRYSALIS	Phase 1		NSW, QLD, VIC, WA	2015-11-20	2016-05-24		Amivantamab; Amivantamab + Lazertinib; Carboplatin; Lazertinib; Pemetrexed	antimetabolite; platinum-based_antineoplastic_agent; bispecific_cMET/EGFR_antibody; EGFR_inhibitor,third_generation + bispecific_cMET/EGFR_antibody; EGFR_inhibitor,third_generation	Amivantamab + Lazertinib; Carboplatin; Pemetrexed	EGFR_inhibitor,third_generation + bispecific_cMET/EGFR_antibody; antimetabolite; platinum-based_antineoplastic_agent	61186372EDI1001  CR108064	A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Subjects With Advanced Non-Small Cell Lung Cancer	Non-Small-Cell Lung Cancer	- Kogarah; - Murdoch; - Woolloongabba; - Camperdown; - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT02609776
NCT02610140	2012-003650-88--15743	Phase 2		NSW, QLD, SA, VIC, WA	2015-11-20	2015-12-03		Anetumab Ravtansine; Pemetrexed; Vinorelbine	vinca_alkaloid; anti-mesothelin_antibody-drug_conjugate; antimetabolite	Anetumab Ravtansine; Vinorelbine; Pemetrexed	anti-mesothelin_antibody-drug_conjugate; vinca_alkaloid; antimetabolite	2012-003650-88  15743	A Randomized, Open-label, Active-controlled, Phase II Study of Intravenous Anetumab Ravtansine (BAY 94-9343) or Vinorelbine in Patients With Advanced or Metastatic Malignant Pleural Mesothelioma Overexpressing Mesothelin and Progressed on First Line Platinum/Pemetrexed-based Chemotherapy	Mesothelioma	6009 - Nedlands; 4102 - Woolloogabba; 2065 - St Leonards; 3122 - Richmond; 5043 - Adelaide	https://clinicaltrials.gov/ct2/show/NCT02610140
NCT02610361	ACTRN12614001176651--BGB-283-AU-001	Phase 1		NSW, NZ, QLD, SA, VIC, WA	2015-11-20	2013-11-20		Lifirafenib	EGFR/RAF_dimer_inhibitor	Lifirafenib	EGFR/RAF_dimer_inhibitor	ACTRN12614001176651  BGB-283-AU-001	A Phase 1A/1B, Open-Label, Multiple-Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Preliminary Antitumor Activities of the B RAF Inhibitor BGB 283 in Subjects With Solid Tumors	Solid Tumors	3144 - Malvern; 3168 - Clayton; Christchurch; 3004 - Melbourne; - Parkville; 4102 - Woolloongabba; Wellington; 6009 - Nedlands; Hamilton; 2145 - Westmead; Dunedin; 2444 - Port Macquarie; 3128 - Box Hill; 5011 - Woodville South; 4215 - Southport; - Heidelberg; 2031 - Randwick; 5000 - Adelaide; - Melbourne; 2050 - Camperdown	https://clinicaltrials.gov/ct2/show/NCT02610361
NCT02614794	HER2CLIMB	Phase 2		NSW, QLD, VIC, WA	2015-11-25	2016-01-28		Capecitabine; Capecitabine + Trastuzumab; Capecitabine + Trastuzumab + Tucatinib; Placebo; Trastuzumab; Tucatinib	placebo; anti-ERBB2_monoclonal_antibody; fluoropyrimidine; ERBB2_inhibitor,third_generation + anti-ERBB2_monoclonal_antibody + fluoropyrimidine; anti-ERBB2_monoclonal_antibody + fluoropyrimidine; ERBB2_inhibitor,third_generation	Capecitabine + Trastuzumab; Capecitabine + Trastuzumab + Tucatinib; Placebo	ERBB2_inhibitor,third_generation + anti-ERBB2_monoclonal_antibody + fluoropyrimidine; anti-ERBB2_monoclonal_antibody + fluoropyrimidine; placebo	2015-002801-12  ONT-380-206	Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma	HER2 Positive Breast Cancer	3000 - Melbourne; 3084 - Heidelberg; 3021 - St Albans; 2060 - North Sydney; 2145 - Westmead; 6009 - Nedlands; 4101 - South Brisbane; 3144 - Malvern	https://clinicaltrials.gov/ct2/show/NCT02614794
NCT02617589	CheckMate-498	Phase 3		NSW, VIC, WA	2015-12-01	2016-03-01		Nivolumab; Nivolumab + Radiotherapy; Radiotherapy; Radiotherapy + Temozolomide; Temozolomide	radiotherapy; alkylating_agent; anti-PD-1_monoclonal_antibody + radiotherapy; alkylating_agent + radiotherapy; anti-PD-1_monoclonal_antibody	Nivolumab + Radiotherapy; Radiotherapy + Temozolomide	alkylating_agent + radiotherapy; anti-PD-1_monoclonal_antibody + radiotherapy	2015-003739-37  CA209-498	A Randomized Phase 3 Open Label Study of Nivolumab vs Temozolomide Each in Combination With Radiation Therapy in Newly Diagnosed Adult Subjects With Unmethylated MGMT (Tumor O-6-methylguanine DNA Methyltransferase) Glioblastoma (CheckMate 498: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 498)	Brain Cancer	2170 - New South Wales; 2065 - St. Leonards; 3181 - Prahran; 3084 - Heidelberg; 6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT02617589
NCT02625610	2015-003300-23--EMR-100070-007	Phase 3		NSW, QLD, SA, TAS, VIC, WA	2015-12-09	2015-12-24		Avelumab; Capecitabine; Capecitabine + Fluorouracil + Oxaliplatin; Fluorouracil; Leucovorin; Oxaliplatin	Fluorouracil; fluoropyrimidine; anti-PD-L1_monoclonal_antibody; platinum-based_antineoplastic_agent; folinic_acid; fluoropyrimidine + platinum-based_antineoplastic_agent	Avelumab; Capecitabine + Fluorouracil + Oxaliplatin; Leucovorin	anti-PD-L1_monoclonal_antibody; fluoropyrimidine + platinum-based_antineoplastic_agent; Fluorouracil; folinic_acid	2015-003300-23  EMR 100070-007	A Phase III Open-label, Multicenter Trial of Maintenance Therapy With Avelumab (MSB0010718C) Versus Continuation of First-line Chemotherapy in Subjects With Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro-esophageal Junction	Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction	5042 - Bedford Park; 4006 - Herston; 3690 - Wodonga; 3128 - Box Hill; 5112 - Elizabeth Vale; 4120 - Greenslopes; 3350 - Ballarat; 2065 - St Leonards; 7000 - Hobart; 8120 - Bentleigh; 2217 - Kogarah; 6150 - Murdoch; 3050 - Parkville; 3550 - Bendigo	https://clinicaltrials.gov/ct2/show/NCT02625610
NCT02625623	2015-003301-42--EMR-100070-008	Phase 3		QLD, SA, TAS, VIC, WA	2015-12-09	2015-12-28		Avelumab; Irinotecan; Irinotecan + Paclitaxel; Paclitaxel	topoisomerase_inhibitor; taxane + topoisomerase_inhibitor; anti-PD-L1_monoclonal_antibody; taxane	Avelumab; Irinotecan + Paclitaxel	anti-PD-L1_monoclonal_antibody; taxane + topoisomerase_inhibitor	2015-003301-42  EMR 100070-008	A Phase III Open-label, Multicenter Trial of Avelumab (MSB0010718C) as a Third-line Treatment of Unresectable, Recurrent, or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma	Gastric Cancer Third Line; Unresectable, Recurrent, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma	3021 - St. Albans; 4102 - Woolloongabba; 6008 - Subiaco; 7000 - Hobart; 5042 - Bedford Park; 5011 - Woodville South; 3128 - Box Hill; 3690 - Wodonga	https://clinicaltrials.gov/ct2/show/NCT02625623
NCT02626000	MASTERKEY232	Phase 1		VIC	2015-12-10	2016-04-06		Pembrolizumab; Pembrolizumab + Talimogene Laherparepvec; Talimogene Laherparepvec	oncolytic_HSV_virus; anti-PD-1_monoclonal_antibody + oncolytic_HSV_virus; anti-PD-1_monoclonal_antibody	Pembrolizumab + Talimogene Laherparepvec	anti-PD-1_monoclonal_antibody + oncolytic_HSV_virus	20130232 / KEYNOTE-137  20130232	A Phase 1b/3 Multicenter, Randomized, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab for the Treatment of Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck	Carcinoma of the Head and Neck	3000 - Melbourne; 3220 - Geelong	https://clinicaltrials.gov/ct2/show/NCT02626000
NCT02628067	KEYNOTE-158	Phase 2			2015-12-11	2015-12-18		Pembrolizumab	anti-PD-1_monoclonal_antibody	Pembrolizumab	anti-PD-1_monoclonal_antibody	163196  3475-158	A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158)	Cervical Carcinoma; Carcinoid Tumor; Salivary Gland Carcinoma; Mesothelioma; Thyroid Cancer; Endometrial Carcinoma; Vulvar Cancer; Vulvar Carcinoma; Cholangiocarcinoma; Bile Duct Cancer; Advanced Cancer; Small Cell Lung Cancer (SCLC); Colorectal Carcinoma; Endometrial Cancer; Thyroid Carcinoma; Salivary Cancer; Salivary Gland Cancer; Neuroendocrine Tumor; Biliary Cancer; Cervical Cancer; Advanced Solid Tumors; Parotid Gland Cancer; Anal Cancer; Small Cell Lung Carcinoma; Anal Carcinoma		https://clinicaltrials.gov/ct2/show/NCT02628067
NCT02645149	MatchMel	Phase 2		NSW	2016-01-01	2021-11-22		Ribociclib; Ribociclib + Trametinib; Trametinib	CDK4/6_inhibitor; CDK4/6_inhibitor + MEK_inhibitor; MEK_inhibitor	Ribociclib + Trametinib; Trametinib	CDK4/6_inhibitor + MEK_inhibitor; MEK_inhibitor	MIA2015/174	Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma	Melanoma	2260 - Wollstonecraft; 2145 - Westmead	https://clinicaltrials.gov/ct2/show/NCT02645149
NCT02655822	CPI-444-001	Phase 1		QLD, VIC	2016-01-14	2016-01-01		Atezolizumab; Atezolizumab + Ciforadenant; Ciforadenant	adenosine_A2aR_and_A2bR_antagonist + anti-PD-L1_monoclonal_antibody; adenosine_A2aR_and_A2bR_antagonist; anti-PD-L1_monoclonal_antibody	Atezolizumab + Ciforadenant; Ciforadenant	adenosine_A2aR_and_A2bR_antagonist; adenosine_A2aR_and_A2bR_antagonist + anti-PD-L1_monoclonal_antibody	CPI-444-001	A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of Ciforadenant as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers	Renal Cell Cancer; Metastatic Castration Resistant Prostate Cancer	3168 - Clayton; 4029 - Brisbane	https://clinicaltrials.gov/ct2/show/NCT02655822
NCT02657330	CL-SBP-101-01	Phase 1		SA, VIC	2016-01-15	2016-01-01		Ivospemin	polyamine_analogue	Ivospemin	polyamine_analogue	CL-SBP-101-01	A Phase 1A/1B Study of SBP-101 in Previously Treated Subjects With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma	Ductal Adenocarcinoma of the Pancreas; Pancreatic Cancer	5037 - Kurralta Park; 3084 - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT02657330
NCT02657369	2015-001929-17--E7080-M000-213	Phase 2		NSW	2016-01-15	2016-07-07		Lenvatinib	VEGF_inhibitor	Lenvatinib	VEGF_inhibitor	2015-001929-17  E7080-M000-213	An Open-Label, Single-Arm, Multicenter, Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)	Thyroid Carcinoma, Anaplastic	2050 - Camperdown; - St Leonards	https://clinicaltrials.gov/ct2/show/NCT02657369
NCT02657434	2015-003605-42--GO29438	Phase 3		NSW, QLD, TAS, VIC	2016-01-15	2016-04-30		Atezolizumab; Atezolizumab + Carboplatin + Cisplatin + Pemetrexed; Carboplatin; Carboplatin + Cisplatin + Pemetrexed; Cisplatin; Pemetrexed	antimetabolite; platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody	Atezolizumab + Carboplatin + Cisplatin + Pemetrexed; Carboplatin + Cisplatin + Pemetrexed	anti-PD-L1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent	2015-003605-42  GO29438	A Phase III, Open-Label, Randomized Study of Atezolizumab (MPDL3280A, Anti-Pd-L1 Antibody) in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Patients Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer	Non-Small Cell Lung Cancer	2217 - Sydney; 3199 - Frankston; 7000 - Hobart; 2076 - Sydney; 3220 - Geelong; 4101 - South Brisbane; 2010 - Darlinghurst; 3350 - Ballarat; 4020 - Redcliffe	https://clinicaltrials.gov/ct2/show/NCT02657434
NCT02658890	2015-004914-79--CA017-003	Phase 1		NSW, QLD, VIC, WA	2016-01-20	2016-04-14		Ipilimumab; Ipilimumab + Linrodostat + Nivolumab; Linrodostat; Linrodostat + Nivolumab; Nivolumab	IDO1_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; IDO1_inhibitor; anti-PD-1_monoclonal_antibody; IDO1_inhibitor + anti-PD-1_monoclonal_antibody; anti-CTLA4_monoclonal_antibody	Ipilimumab + Linrodostat + Nivolumab; Linrodostat + Nivolumab	IDO1_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; IDO1_inhibitor + anti-PD-1_monoclonal_antibody	2015-004914-79  CA017-003	A Phase 1/2a Study of BMS-986205 Administered in Combination With Nivolumab (Anti-PD-1 Monoclonal Antibody) and in Combination With Both Nivolumab and Ipilimumab (Anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors	Advanced Cancer; Non-Small Cell Lung Cancer; Melanoma	2145 - Westmead; 6009 - Nedlands; 2146 - North Sydney; 3168 - Clayton; 3000 - Melbourne; 2010 - Sydney; 4102 - Brisbane	https://clinicaltrials.gov/ct2/show/NCT02658890
NCT02659020	ANNOUNCE-2	Phase 1/Phase 2		SA, VIC	2016-01-20	2016-03-01		Docetaxel; Docetaxel + Gemcitabine + Olaratumab; Gemcitabine; Olaratumab; Placebo	placebo; antimetabolite; taxane; gemcitabine; anti-PDGFRA_monoclonal_antibody + antimetabolite + taxane; anti-PDGFRA_monoclonal_antibody	Docetaxel + Gemcitabine + Olaratumab; Placebo	anti-PDGFRA_monoclonal_antibody + antimetabolite + taxane; gemcitabine; placebo	I5B-MC-JGDL  15839	A Phase 1b (Open-Label)/Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma	Soft Tissue Sarcoma	5000 - Adelaide; 3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT02659020
NCT02667587	CheckMate548	Phase 3		NSW, VIC, WA	2016-01-29	2016-05-09		Nivolumab; Nivolumab + Radiotherapy + Temozolomide; Placebo; Radiotherapy; Temozolomide	placebo; radiotherapy; alkylating_agent; alkylating_agent + anti-PD-1_monoclonal_antibody + radiotherapy; anti-PD-1_monoclonal_antibody	Nivolumab + Radiotherapy + Temozolomide; Placebo	alkylating_agent + anti-PD-1_monoclonal_antibody + radiotherapy; placebo	2015-004722-34  CA209-548	A Randomized Phase 3 Single Blind Study of Temozolomide Plus Radiation Therapy Combined With Nivolumab or Placebo in Newly Diagnosed Adult Subjects With MGMT-Methylated (Tumor O6-methylguanine DNA Methyltransferase) Glioblastoma	Brain Neoplasms	6009 - Nedlands; 3084 - Heidelberg; 3181 - Prahran; 2065 - St. Leonards; 2170 - Liverpool	https://clinicaltrials.gov/ct2/show/NCT02667587
NCT02675231	monarcHER	Phase 2		NSW, SA, WA	2016-02-05	2016-05-23		Abemaciclib; Abemaciclib + Fulvestrant + Trastuzumab; Abemaciclib + Trastuzumab; Fulvestrant; Trastuzumab	selective_estrogen_receptor_degrader; anti-ERBB2_monoclonal_antibody; CDK4/6_inhibitor; CDK4/6_inhibitor + anti-ERBB2_monoclonal_antibody + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + anti-ERBB2_monoclonal_antibody	Abemaciclib + Fulvestrant + Trastuzumab; Abemaciclib + Trastuzumab; Trastuzumab	CDK4/6_inhibitor + anti-ERBB2_monoclonal_antibody; CDK4/6_inhibitor + anti-ERBB2_monoclonal_antibody + selective_estrogen_receptor_degrader; anti-ERBB2_monoclonal_antibody	I3Y-MC-JPBZ  15804	monarcHER: A Phase 2, Randomized, Multicenter, 3-Arm, Open-Label Study to Compare the Efficacy of Abemaciclib Plus Trastuzumab With or Without Fulvestrant to Standard-of-Care Chemotherapy of Physician's Choice Plus Trastuzumab in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer	HER-2 Positive Breast Cancer; Hormone Receptor Positive Breast Cancer	6009 - Nedlands; 5037 - Kurralta Park; 2065 - St. Leonards	https://clinicaltrials.gov/ct2/show/NCT02675231
NCT02676869	TACTI-mel	Phase 1		QLD, SA, VIC, WA	2016-02-08	2016-04-01		Eftilagimod Alpha; Eftilagimod Alpha + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody; T-cell_immunostimulatory_factor + anti-PD-1_monoclonal_antibody; T-cell_immunostimulatory_factor	Eftilagimod Alpha + Pembrolizumab	T-cell_immunostimulatory_factor + anti-PD-1_monoclonal_antibody	IMP321-P012	A Multicentre, Open Label, Dose Escalation, Phase 1 Study in Patients With Unresectable or Metastatic Melanoma Receiving IMP321 (LAG-3Ig Fusion Protein-eftilagimod Alpha) as an Adjunctive Therapy to Anti-PD-1 Therapy With Pembrolizumab	Stage III Melanoma; Stage IV Melanoma	4029 - Brisbane; 5042 - Adelaide; 3353 - Ballarat; 6150 - Perth; 3181 - Melbourne; 4120 - Brisbane; 4102 - Brisbane	https://clinicaltrials.gov/ct2/show/NCT02676869
NCT02677896	ARCHES	Phase 3		NSW, NZ, QLD, SA, VIC	2016-02-09	2016-03-09		Enzalutamide; Enzalutamide + LHRH Agonist; LHRH Agonist; Placebo	placebo; LHRH_agonist; antiandrogen,nonsteroidal,second_generation; LHRH_agonist + antiandrogen,nonsteroidal,second_generation	Enzalutamide; Enzalutamide + LHRH Agonist; LHRH Agonist; Placebo	LHRH_agonist; LHRH_agonist + antiandrogen,nonsteroidal,second_generation; antiandrogen,nonsteroidal,second_generation; placebo	2015-003869-28  9785-CL-0335	A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)	Metastatic Hormone Sensitive Prostate Cancer	2065 - St Leonards; 2298 - Waratah; - Parkville; - Ballarat; - St. Albans; - Sydney; Hamilton; Northland; - Clayton; 5011 - Woodville South; 2485 - Tweed Heads; 2050 - Camperdown	https://clinicaltrials.gov/ct2/show/NCT02677896
NCT02684006	2015-002429-20--B9991003	Phase 3		NSW, NZ, QLD, VIC, WA	2016-02-17	2016-03-23		Avelumab; Avelumab + Axitinib; Axitinib; Sunitinib	VEGFR_inhibitor; VEGFR/PDGFR_inhibitor + anti-PD-L1_monoclonal_antibody; KIT_inhibitor,ATP-competitive; anti-PD-L1_monoclonal_antibody; KIT_inhibitor,first_generation; VEGFR/PDGFR_inhibitor; PDGFR_inhibitor; KIT_inhibitor,ATP-competitive + anti-PD-L1_monoclonal_antibody	Avelumab + Axitinib; Sunitinib	KIT_inhibitor,ATP-competitive + anti-PD-L1_monoclonal_antibody; KIT_inhibitor,first_generation; PDGFR_inhibitor; VEGFR/PDGFR_inhibitor + anti-PD-L1_monoclonal_antibody; VEGFR_inhibitor	2015-002429-20  B9991003	A PHASE 3, MULTINATIONAL, RANDOMIZED, OPEN-LABEL, PARALLEL-ARM STUDY OF AVELUMAB (MSB0010718C) IN COMBINATION WITH AXITINIB (INLYTA(REGISTERED)) VERSUS SUNITINIB (SUTENT(REGISTERED)) MONOTHERAPY IN THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA	Renal Cell Cancer	3165 - East Bentleigh; Tauranga; 6150 - Perth; Manawatu-wanganui; 3128 - Box Hill; 2031 - Randwick; 3350 - Ballarat; 4102 - Woolloongabba; 3355 - Wendouree; 6050 - Murdoch; Manawatu- Whanganui; 3149 - Mount Waverley; 3168 - Clayton; Christchurch; 6150 - Murdoch; 2109 - Macquarie University; Palmerston North; Auckland; Hamilton	https://clinicaltrials.gov/ct2/show/NCT02684006
NCT02688101	CMD-2015-001	Phase 1		NSW, VIC	2016-02-23	2016-04-11						CMD-2015-001	A Phase 1 Dose-finding and Pharmacokinetic Study of DpC, Administered Orally to Patients With Advanced Solid Tumors	Neoplasms	- Sydney; - Melbourne; - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT02688101
NCT02693067	PV-10-NET-01	Phase 1		SA	2016-02-26	2016-07-01		PV-10	rose_bengal_disodium	PV-10	rose_bengal_disodium	PV-10-NET-01	A Phase 1 Study to Assess the Safety, Tolerability and Effectiveness of PV-10 Chemoablation of Neuroendocrine Tumours (NET) Metastatic to the Liver in the Reduction of Biochemical Markers and Symptoms Caused by Secretory Products	Neuroendocrine Tumors Metastatic to the Liver	5011 - Woodville	https://clinicaltrials.gov/ct2/show/NCT02693067
NCT02702388	2014-005199-27--E7080-G000-211	Phase 2		NSW, QLD, VIC, WA	2016-03-08	2017-06-08		Lenvatinib; Placebo	placebo; VEGF_inhibitor	Lenvatinib; Placebo	VEGF_inhibitor; placebo	2014-005199-27  E7080-G000-211	A Multicenter, Randomized, Double-Blind Phase 2 Trial of Lenvatinib (E7080) in Subjects With 131I-Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 mg Daily Will Provide Comparable Efficacy to a 24-mg Starting Dose, But Have a Better Safety Profile	Thyroid Cancer	4006 - Brisbane; - Saint Leonards; - Chermside; - Nedlands; - Herston; - Darlinghurst; - Melbourne	https://clinicaltrials.gov/ct2/show/NCT02702388
NCT02703571	2015-005019-34--CTMT212X2106	Phase 1		VIC	2016-03-09	2016-06-29		Ribociclib; Trametinib	CDK4/6_inhibitor; MEK_inhibitor	Ribociclib; Trametinib	CDK4/6_inhibitor; MEK_inhibitor	2015-005019-34  CTMT212X2106	A Phase I/II Study of Safety and Efficacy of Ribociclib (LEE011) in Combination With Trametinib (TMT212) in Patients With Metastatic or Advanced Solid Tumors	Colorectal Cancer for Phase II; Pancreatic Cancer for Phase II; Solid Tumors for Phase Ib	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT02703571
NCT02709512	ATOMIC	Phase 2		NSW, QLD, SA, VIC, WA	2016-03-16	2017-08-01		Cisplatin; Pegargiminase; Pemetrexed; Placebo	placebo; antimetabolite; platinum-based_antineoplastic_agent; arginine_deiminase-polyethylene_glycol_conjugate	Pegargiminase; Cisplatin; Pemetrexed; Placebo	arginine_deiminase-polyethylene_glycol_conjugate; antimetabolite; placebo; platinum-based_antineoplastic_agent	POLARIS2015-003	Randomized, Double-Blind, Phase 2/3 Study in Subjects With Malignant Pleural Mesotheliomato Assess ADI-PEG 20 With Pemetrexed and Cisplatin (ATOMIC-Meso Phase 2/3 Study)	Mesothelioma	3084 - Heidelberg; 2050 - Camperdown; 5042 - Bedford Park; 2486 - Tweed Heads; 6009 - Perth; 4102 - Woolloongabba	https://clinicaltrials.gov/ct2/show/NCT02709512
NCT02713529	MASTERKEY--20150195	Phase 1/Phase 2		NSW, VIC	2016-03-18	2016-04-14		AMG 820; Pembrolizumab	anti-PD-1_monoclonal_antibody; anti-CSF1_monoclonal_antibody	Pembrolizumab; AMG 820	anti-PD-1_monoclonal_antibody; anti-CSF1_monoclonal_antibody	MASTERKEY  20150195	A Phase1b/2 Study Assessing Safety and Anti-tumor Activity of AMG 820 in Combination With Pembrolizumab in Select Advanced Solid Tumors	Pancreatic Cancer; Colorectal Cancer; Non-Small Cell Lung Cancer	3050 - Parkville; 2050 - Camperdown	https://clinicaltrials.gov/ct2/show/NCT02713529
NCT02713867	CheckMate-384	Phase 3		NSW, QLD, SA, TAS, VIC, WA	2016-03-21	2016-05-24		Nivolumab	anti-PD-1_monoclonal_antibody	Nivolumab	anti-PD-1_monoclonal_antibody	CA209-384	A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks	Lung Cancer	5112 - Elizabeth Vale; 3084 - Heidelberg; 5042 - Bedford Park; 5037 - Kurralta Park; 2065 - St. Leonards; 2145 - Westmead,; 6150 - Murdoch; 2298 - Waratah; 4102 - Woolloongabba; 7000 - Hobart	https://clinicaltrials.gov/ct2/show/NCT02713867
NCT02714218	CA209-511	Phase 3		NSW, QLD, VIC	2016-03-21	2016-04-04		Ipilimumab; Ipilimumab + Nivolumab; Nivolumab	anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-CTLA4_monoclonal_antibody	Ipilimumab + Nivolumab	anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	CA209-511	Phase IIIb/IV, Randomized, Double Blinded, Study of Nivolumab 3 mg/kg in Combination With Ipilimumab 1 mg/kg vs Nivolumab 1 mg/kg in Combination With Ipilimumab 3 mg/kg in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma	Melanoma	4120 - Greenslopes; 2060 - North Sydney; 2298 - Waratah; 3004 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT02714218
NCT02715531	GO30140	Phase 1		NZ, VIC	2016-03-22	2016-04-06		Atezolizumab; Atezolizumab + Bevacizumab; Atezolizumab + Bevacizumab + Capecitabine + Fluorouracil + Leucovorin + Oxaliplatin; Atezolizumab + Cisplatin + Fluorouracil + Oxaliplatin; Atezolizumab + Gemcitabine + Nab-paclitaxel; Bevacizumab; Capecitabine; Cisplatin; Fluorouracil; Gemcitabine; Leucovorin; Nab-paclitaxel; Oxaliplatin	antimetabolite; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; fluoropyrimidine; anti-PD-L1_monoclonal_antibody; gemcitabine; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; folinic_acid; anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; Fluorouracil; anti-PD-L1_monoclonal_antibody + antimetabolite + taxane; taxane; platinum-based_antineoplastic_agent	Atezolizumab + Bevacizumab; Atezolizumab + Bevacizumab + Capecitabine + Fluorouracil + Leucovorin + Oxaliplatin; Atezolizumab + Cisplatin + Fluorouracil + Oxaliplatin; Atezolizumab + Gemcitabine + Nab-paclitaxel	anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + antimetabolite + taxane; anti-PD-L1_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; Fluorouracil; gemcitabine	GO30140	An Open-Label, Multicenter Phase Ib Study of The Safety and Efficacy of Atezolizumab (Anti-PD-L1 Antibody) Administered in Combination With Bevacizumab and/or Other Treatments in Patients With Solid Tumors	Solid Tumor	3084 - Heidelberg; 3168 - Clayton; Auckland	https://clinicaltrials.gov/ct2/show/NCT02715531
NCT02715804	2015-004068-13--HALO-109-301	Phase 3		NSW, SA, VIC, WA	2016-03-22	2016-03-14		Gemcitabine; Gemcitabine + Nab-paclitaxel; Nab-paclitaxel; Placebo; rHuPH20	placebo; recombinant_human_hyaluronidase; antimetabolite; antimetabolite + taxane; taxane; gemcitabine	Gemcitabine + Nab-paclitaxel; Placebo; rHuPH20	antimetabolite + taxane; gemcitabine; placebo; recombinant_human_hyaluronidase	2015-004068-13  HALO-109-301	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Subjects With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma	Pancreatic Ductal Carcinoma	- Frankston; - Bankstown; - Bedford; - Bendigo; - Bentleigh East; - Darlinghurst; - St Leonards; - Camperdown	https://clinicaltrials.gov/ct2/show/NCT02715804
NCT02721641	2007-000348-28--BO15943	Phase 3		NSW, NZ, QLD, VIC	2016-03-29	1999-06-01		Trastuzumab	anti-ERBB2_monoclonal_antibody	Trastuzumab	anti-ERBB2_monoclonal_antibody	2007-000348-28  BO15943	A Single Arm, Multi-Center, International, Continuation Trial of Recombinant Humanized Antibody Herceptin (Trastuzumab) in Patients With HER2-Overexpressing Tumors	Neoplasms	3052 - Parkville; 2298 - Waratah; 3220 - Geelong; 3065 - Fitzroy; 4006 - Brisbane; 4066 - Brisbane; Auckland; 2170 - Liverpool	https://clinicaltrials.gov/ct2/show/NCT02721641
NCT02724579	NCI-2016-00150--ACNS1422	Phase 2		NSW, SA, WA	2016-03-31	2017-11-17		Cisplatin; Cyclophosphamide; Lomustine; Radiotherapy; Vincristine	radiotherapy; vinca_alkaloid; alkylating_agent; platinum-based_antineoplastic_agent	Radiotherapy; Cisplatin; Cyclophosphamide; Lomustine; Vincristine	radiotherapy; alkylating_agent; platinum-based_antineoplastic_agent; vinca_alkaloid	NCI-2016-00150  ACNS1422	A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients	Medulloblastoma	2310 - Hunter Regional Mail Centre; 5006 - North Adelaide; 6009 - Perth; 6008 - Perth	https://clinicaltrials.gov/ct2/show/NCT02724579
NCT02725268	U1111-1168-1824--C31004	Phase 2		NSW, QLD, VIC	2016-03-31	2016-04-01		MLN0128; Paclitaxel; Paclitaxel + Sapanisertib; Sapanisertib; Sapanisertib + Serabelisib; Serabelisib	taxane; mTORC1/mTORC2_inhibitor + taxane; PI3K_alpha_inhibitor; mTORC1/mTORC2_inhibitor; PI3K_alpha_inhibitor + mTORC1/mTORC2_inhibitor	Paclitaxel; Paclitaxel + Sapanisertib; Sapanisertib; Sapanisertib + Serabelisib; MLN0128	PI3K_alpha_inhibitor + mTORC1/mTORC2_inhibitor; mTORC1/mTORC2_inhibitor; mTORC1/mTORC2_inhibitor + taxane; taxane	U1111-1168-1824  C31004	A Phase 2, Randomized Study of MLN0128 (a Dual TORC1/2 Inhibitor), MLN0128+MLN1117 (a PI3Ka Inhibitor), Weekly Paclitaxel, or the Combination of Weekly Paclitaxel and MLN0128 in Women With Advanced, Recurrent, or Persistent Endometrial Cancer	Endometrial Neoplasms	3011 - Footscray; 3000 - Melbourne; 4029 - Herston; 2217 - Kogarah; 2145 - Westmead; 3144 - Malvern; 3168 - Clayton	https://clinicaltrials.gov/ct2/show/NCT02725268
NCT02726334	BNC101.-001	Phase 1		SA, VIC	2016-04-01	2016-03-01		BNC101	anti-LGR5_monoclonal_antibody	BNC101	anti-LGR5_monoclonal_antibody	BNC101. 001	A Phase I, Dose Escalation Study of BNC101 (Anti-LGR5 Humanized Monoclonal Antibody) in Patients With Metastatic Colorectal Cancer.	Colorectal Cancer	3050 - Melbourne; 5042 - Bedford Park; 3084 - Heidelberg; 3168 - Clayton	https://clinicaltrials.gov/ct2/show/NCT02726334
NCT02737501	ALTA-1L	Phase 3		NSW, VIC	2016-04-14	2016-05-26		Brigatinib; Brigatinib + Crizotinib + Radiotherapy; Crizotinib; Radiotherapy	radiotherapy; EGFR/FLT3/FER/ROS1/IGF1R_inhibitor + MET_inhibitor,type_1 + radiotherapy; EGFR/FLT3/FER/ROS1/IGF1R_inhibitor + ROS1_inhibitor + radiotherapy; ALK_inhibitor,second_generation + MET_inhibitor,type_1 + radiotherapy; ALK_inhibitor,first_generation + ROS1_inhibitor + radiotherapy; ROS1_inhibitor; EGFR/FLT3/FER/ROS1/IGF1R_inhibitor; MET_inhibitor,type_1 + ROS1_inhibitor + radiotherapy; ALK_inhibitor,first_generation + EGFR/FLT3/FER/ROS1/IGF1R_inhibitor + radiotherapy; ALK_inhibitor,second_generation + ROS1_inhibitor + radiotherapy; ALK_inhibitor,first_generation + ALK_inhibitor,second_generation + radiotherapy; ALK_inhibitor,first_generation; ROS1_inhibitor + radiotherapy; MET_inhibitor,type_1; ALK_inhibitor,second_generation	Brigatinib; Brigatinib + Crizotinib + Radiotherapy; Crizotinib	ALK_inhibitor,first_generation; ALK_inhibitor,first_generation + ALK_inhibitor,second_generation + radiotherapy; ALK_inhibitor,first_generation + EGFR/FLT3/FER/ROS1/IGF1R_inhibitor + radiotherapy; ALK_inhibitor,first_generation + ROS1_inhibitor + radiotherapy; ALK_inhibitor,second_generation; ALK_inhibitor,second_generation + MET_inhibitor,type_1 + radiotherapy; ALK_inhibitor,second_generation + ROS1_inhibitor + radiotherapy; EGFR/FLT3/FER/ROS1/IGF1R_inhibitor; EGFR/FLT3/FER/ROS1/IGF1R_inhibitor + MET_inhibitor,type_1 + radiotherapy; EGFR/FLT3/FER/ROS1/IGF1R_inhibitor + ROS1_inhibitor + radiotherapy; MET_inhibitor,type_1; MET_inhibitor,type_1 + ROS1_inhibitor + radiotherapy; ROS1_inhibitor; ROS1_inhibitor + radiotherapy	U1111-1210-4363  AP26113-13-301	A Phase 3 Multicenter Open-label Study of Brigatinib (AP26113) Versus Crizotinib in Patients With ALK-positive Advanced Lung Cancer	Non-small Cell Lung Cancer; Advanced Malignancies; Carcinoma; Lung Cancer	2065 - St Leonards; 3065 - Fitzroy; 2217 - Kogarah; 3165 - Bentleigh East	https://clinicaltrials.gov/ct2/show/NCT02737501
NCT02738970	BO30185	Phase 1		NZ	2016-04-14	2016-06-23		Pertuzumab; Pertuzumab + Trastuzumab; Pertuzumab + Trastuzumab + rHuPH20; Trastuzumab; rHuPH20	anti-ERBB2_monoclonal_antibody,dimerization_inhibitor; anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor + recombinant_human_hyaluronidase; recombinant_human_hyaluronidase; anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor; anti-ERBB2_monoclonal_antibody	Pertuzumab; Pertuzumab + Trastuzumab; Pertuzumab + Trastuzumab + rHuPH20; Trastuzumab	anti-ERBB2_monoclonal_antibody; anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor; anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor + recombinant_human_hyaluronidase; anti-ERBB2_monoclonal_antibody,dimerization_inhibitor	BO30185	A Phase I, Open-Label, Two-Part, Multicenter Perjeta® Subcutaneous Dose-Finding Study in Combination With Herceptin® in Healthy Male Volunteers and Female Patients With Early Breast Cancer	Early Breast Cancer	Auckland; Christchurch	https://clinicaltrials.gov/ct2/show/NCT02738970
NCT02741570	CheckMate-651	Phase 3		NSW, QLD, SA, VIC, WA	2016-04-18	2016-10-05		Carboplatin; Cetuximab; Cisplatin; Fluorouracil; Ipilimumab; Ipilimumab + Nivolumab; Nivolumab	fluoropyrimidine; anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-EGFR_monoclonal_antibody; anti-CTLA4_monoclonal_antibody	Ipilimumab + Nivolumab; Carboplatin; Cetuximab; Cisplatin; Fluorouracil	anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-EGFR_monoclonal_antibody; fluoropyrimidine; platinum-based_antineoplastic_agent	2016-000725-39  CA209-651	An Open Label, Randomized, Two Arm Phase III Study of Nivolumab in Combination With Ipilimumab Versus Extreme Study Regimen (Cetuximab + Cisplatin/Carboplatin + Fluorouracil) as First Line Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)	Head and Neck Cancer	2065 - St. Leonards; 2010 - Darlinghurst; 5112 - Elizabeth Vale; 3000 - Melbourne; 4102 - Brisbane; 2250 - Gosford; 3168 - Clayton; 4814 - Douglas; 6009 - Nedlands; 2148 - Blacktown	https://clinicaltrials.gov/ct2/show/NCT02741570
NCT02743221	TASCO1	Phase 2		NSW, SA, VIC	2016-04-19	2016-04-29		Bevacizumab; Bevacizumab + Capecitabine; Bevacizumab + Trifluridine/Tipiracil; Capecitabine; Trifluridine/Tipiracil	antimetabolite; fluoropyrimidine; anti-VEGF_monoclonal_antibody; anti-VEGF_monoclonal_antibody + thymidine_phosphorylase_inhibitor; Tipiracil Hydrochloride + anti-VEGF_monoclonal_antibody; Trifluridine + anti-VEGF_monoclonal_antibody; anti-VEGF_monoclonal_antibody + antimetabolite; anti-VEGF_monoclonal_antibody + fluoropyrimidine; Tipiracil Hydrochloride; Trifluridine; thymidine_phosphorylase_inhibitor	Bevacizumab + Capecitabine; Bevacizumab + Trifluridine/Tipiracil	Tipiracil Hydrochloride + anti-VEGF_monoclonal_antibody; Trifluridine + anti-VEGF_monoclonal_antibody; anti-VEGF_monoclonal_antibody + antimetabolite; anti-VEGF_monoclonal_antibody + fluoropyrimidine; anti-VEGF_monoclonal_antibody + thymidine_phosphorylase_inhibitor	2015-004544-18  CL2-95005-002	An Open-label, Randomised, Non-comparative Phase 2 Study Evaluating S 95005 (TAS-102) Plus Bevacizumab and Capecitabine Plus Bevacizumab in Patients With Previously Untreated Metastatic COlorectal Cancer Who Are Non-eligible for Intensive Therapy (TASCO1 Study).	Metastatic Colorectal Cancer	VIC 3084 - Heidelberg; NSW 2050 - Camperdown; VIC 3021 - Saint Albans; SA 5011 - Woodville	https://clinicaltrials.gov/ct2/show/NCT02743221
NCT02748213	MO16419	Phase 2		NSW, QLD, SA, VIC, WA	2016-04-22	2002-02-01		Capecitabine; Capecitabine + Docetaxel + Trastuzumab; Docetaxel; Docetaxel + Trastuzumab; Trastuzumab	anti-ERBB2_monoclonal_antibody + fluoropyrimidine + taxane; anti-ERBB2_monoclonal_antibody + taxane; anti-ERBB2_monoclonal_antibody; fluoropyrimidine; taxane	Capecitabine + Docetaxel + Trastuzumab; Docetaxel + Trastuzumab	anti-ERBB2_monoclonal_antibody + fluoropyrimidine + taxane; anti-ERBB2_monoclonal_antibody + taxane	MO16419	An Open-Label, Randomized Phase II Study of Herceptin (Trastuzumab), Taxotere (Docetaxel), and Xeloda (Capecitabine) in Combination, Versus Herceptin (Trastuzumab) Plus Taxotere (Docetaxel), in Patients With Advanced and/or Metastatic Breast Cancers That Overexpress HER2	Breast Cancer	3220 - Geelong; 5011 - Adelaide; 4066 - Brisbane; 6000 - Perth; 3002 - Melbourne; 4215 - Southport; 3181 - Melbourne; 2050 - Camperdown	https://clinicaltrials.gov/ct2/show/NCT02748213
NCT02750514	FRACTION-Lung	Phase 2		VIC	2016-04-25	2016-05-09		Dasatinib; Dasatinib + Nivolumab; Ipilimumab; Ipilimumab + Nivolumab; Linrodostat; Linrodostat + Nivolumab; Nivolumab; Nivolumab + Relatlimab; Relatlimab	YES1_inhibitor; IDO1_inhibitor; anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; PDGFRA_inhibitor; KIT_inhibitor; anti-CTLA4_monoclonal_antibody; anti-LAG3_monoclonal_antibody; KIT_inhibitor + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; SRC_inhibitor; IDO1_inhibitor + anti-PD-1_monoclonal_antibody; BCR-ABL1_inhibitor,second_generation; YES1_inhibitor + anti-PD-1_monoclonal_antibody; PDGFRA_inhibitor + anti-PD-1_monoclonal_antibody; BCR-ABL1_inhibitor,second_generation + anti-PD-1_monoclonal_antibody; SRC_inhibitor + anti-PD-1_monoclonal_antibody	Dasatinib + Nivolumab; Ipilimumab + Nivolumab; Linrodostat + Nivolumab; Nivolumab; Nivolumab + Relatlimab	BCR-ABL1_inhibitor,second_generation + anti-PD-1_monoclonal_antibody; IDO1_inhibitor + anti-PD-1_monoclonal_antibody; KIT_inhibitor + anti-PD-1_monoclonal_antibody; PDGFRA_inhibitor + anti-PD-1_monoclonal_antibody; SRC_inhibitor + anti-PD-1_monoclonal_antibody; YES1_inhibitor + anti-PD-1_monoclonal_antibody; anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody	CA018-001	A Phase 2, Fast Real Time Assessment of Combination Therapies in Immuno-Oncology Study in Subjects With Advanced Non-Small Cell Lung Cancer (FRACTION-Lung)	Advanced Cancer	- Clayton	https://clinicaltrials.gov/ct2/show/NCT02750514
NCT02752074	Keynote-252	Phase 3		NSW, NZ, QLD, SA, VIC	2016-04-26	2016-06-21		Epacadostat; Epacadostat + Pembrolizumab; Pembrolizumab; Placebo	placebo; IDO1_inhibitor; anti-PD-1_monoclonal_antibody; IDO1_inhibitor + anti-PD-1_monoclonal_antibody	Epacadostat + Pembrolizumab; Pembrolizumab; Placebo	IDO1_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; placebo	INCB 24360-301 (ECHO-301)	A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Pembrolizumab (MK-3475) in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)	Melanoma	- Cairns; Dunedin; - Westmead; - Melbourne; - Kurralta Park; - Greenslopes; Tauranga; - Wollstonecraft; - Camperdown	https://clinicaltrials.gov/ct2/show/NCT02752074
NCT02753127	CanStem303C	Phase 3		NSW, QLD, SA, VIC	2016-04-27	2016-06-01		Bevacizumab; Bevacizumab + Fluorouracil + Irinotecan + Leucovorin; Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Napabucasin; Fluorouracil; Irinotecan; Leucovorin; Napabucasin	topoisomerase_inhibitor; anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid + topoisomerase_inhibitor; Fluorouracil; fluoropyrimidine; anti-VEGF_monoclonal_antibody + cancer_stemness_inhibitor + fluoropyrimidine + folinic_acid + topoisomerase_inhibitor; cancer_stemness_inhibitor; folinic_acid; anti-VEGF_monoclonal_antibody	Bevacizumab + Fluorouracil + Irinotecan + Leucovorin; Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Napabucasin	anti-VEGF_monoclonal_antibody + cancer_stemness_inhibitor + fluoropyrimidine + folinic_acid + topoisomerase_inhibitor; anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid + topoisomerase_inhibitor; Fluorouracil	BB608-303CRC  CanStem303C	A Phase 3 Study of BBI-608 in Combination With 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients With Previously Treated Metastatic Colorectal Cancer (CRC).	Colorectal Cancer	2200 - Bankstown; 3550 - Bendigo; 3199 - Frankston; 3065 - Fitzroy; 2065 - St Leonards; 3630 - Shepparton; 5011 - Woodville; 2010 - Darlinghurst; 3084 - Heidelberg; 2031 - Randwick; 4560 - Nambour; 5042 - Bedford Park; 3021 - Melbourne; 4215 - Southport; 2444 - Port Macquarie	https://clinicaltrials.gov/ct2/show/NCT02753127
NCT02759640	HS-10241-001	Phase 1		NSW	2016-05-03	2016-09-01		HS-10241	MET_inhibitor	HS-10241	MET_inhibitor	HS-10241-001	First-in-Human, Dose-Escalation Trial of C-Met Kinase Inhibitor HS-10241 in Subjects With Advanced Solid Tumors	Neoplasm; Solid Tumors	2050 - Camperdown; 2170 - Liverpool	https://clinicaltrials.gov/ct2/show/NCT02759640
NCT02759666	SHR3162-002	Phase 1		NSW, VIC	2016-05-03	2016-06-01		Fuzuloparib	PARP_inhibitor	Fuzuloparib	PARP_inhibitor	SHR3162-002	A Multicenter, Open-Label, Phase 1 Trial of SHR3162 Given Orally to Subjects With Advanced Solid Tumors	Solid Tumors; Neoplasm	2640 - Albury; - Melbourne; 2170 - Liverpool	https://clinicaltrials.gov/ct2/show/NCT02759666
NCT02760498	2016-000105-36--R2810-ONC-1540	Phase 2		ACT, NSW, QLD, SA, VIC, WA	2016-05-03	2016-04-07		Cemiplimab	anti-PD-1_monoclonal_antibody	Cemiplimab	anti-PD-1_monoclonal_antibody	2016-000105-36  R2810-ONC-1540	A Phase 2 Study of REGN2810, a Fully Human Monoclonal Antibody to Programmed Death-1 (PD-1), in Patients With Advanced Cutaneous Squamous Cell Carcinoma	Advanced Cutaneous Squamous Cell Carcinoma	5037 - Kurralta Park; - Garran; - Waratah; 4029 - Herston; 3000 - Melbourne; - Woolloongabba; - Wodonga; 2065 - St Leonards; - Gosford; 6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT02760498
NCT02763579	IMpower133	Phase 3		NSW, QLD, VIC	2016-05-05	2016-06-07		Atezolizumab; Atezolizumab + Carboplatin + Etoposide; Carboplatin; Carboplatin + Etoposide; Etoposide; Placebo	platinum-based_antineoplastic_agent + topoisomerase_inhibitor; placebo; anti-PD-L1_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; topoisomerase_inhibitor; anti-PD-L1_monoclonal_antibody; platinum-based_antineoplastic_agent	Atezolizumab + Carboplatin + Etoposide; Carboplatin + Etoposide; Placebo	anti-PD-L1_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; platinum-based_antineoplastic_agent + topoisomerase_inhibitor; placebo	2015-004861-97  GO30081	A Phase I/III, Randomized, Double-Blind, Placebo-Controlled Study of Carboplatin Plus Etoposide With or Without Atezolizumab (Anti-PD-L1 Antibody) in Patients With Untreated Extensive-Stage Small Cell Lung Cancer	Small Cell Lung Carcinoma	4032 - Chermside; 2050 - Camperdown; 3052 - Parkville	https://clinicaltrials.gov/ct2/show/NCT02763579
NCT02767804	X396-CLI-301	Phase 3		NSW	2016-05-10	2016-06-01		Crizotinib; Ensartinib	ALK_inhibitor,third_generation; ROS1_inhibitor; ALK_inhibitor,first_generation; MET_inhibitor,type_1	Crizotinib; Ensartinib	ALK_inhibitor,first_generation; ALK_inhibitor,third_generation; MET_inhibitor,type_1; ROS1_inhibitor	X396-CLI-301	Phase 3 Randomized Study Comparing X-396 (Ensartinib) to Crizotinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients	Non-small Cell Lung Cancer	- Camperdown; 2640 - Albury	https://clinicaltrials.gov/ct2/show/NCT02767804
NCT02773524	INTEGRATEIIa	Phase 3		ACT, NSW, NT, NZ, QLD, SA, TAS, VIC, WA	2016-05-16	2016-11-01		Placebo; Regorafenib	placebo; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor	Regorafenib; Placebo	KIT/PDGFR/RET/VEGFR/FGFR_inhibitor; placebo	AG0315OG	A Randomised Phase III Double-Blind Placebo-Controlled Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer (AGOC)	Gastro-Oesophageal Cancer	2250 - Gosford; 6008 - Subiaco; 0810 - Tiwi; 3355 - Wendouree; 3168 - Clayton; 2217 - Kogarah; 2450 - Coffs Harbour; 4814 - Douglas; 2145 - Westmead; Auckland; 6009 - Nedlands; - Canberra; 5042 - Bedford Park; 5011 - Woodville South; - Saint Leonards; 2444 - Port Macquarie; 2139 - Concord; 4560 - Sunshine Coast; 5035 - Ashford; 2010 - Darlinghurst; 2035 - New Lambton Heights; 4029 - Herston; 3084 - Heidelberg; 700 - Hobart; 2640 - Albury; 2031 - Randwick; 2485 - Tweed Heads	https://clinicaltrials.gov/ct2/show/NCT02773524
NCT02788279	2016-000202-11--GO30182	Phase 3		NSW, VIC	2016-06-02	2016-07-05		Atezolizumab; Atezolizumab + Cobimetinib; Cobimetinib; Regorafenib	KIT/PDGFR/RET/VEGFR/FGFR_inhibitor; MEK_inhibitor + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; MEK_inhibitor	Atezolizumab; Atezolizumab + Cobimetinib; Regorafenib	KIT/PDGFR/RET/VEGFR/FGFR_inhibitor; MEK_inhibitor + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody	2016-000202-11  GO30182	A Phase III, Open-Label, Multicenter, Three-Arm, Randomized Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy vs. Regorafenib in Patients With Previously Treated Unresectable Locally Advanced or Metastatic Colorectal Adenocarcinoma	Colorectal Cancer	3084 - Heidelberg; 2444 - Port Macquarie; 3199 - Frankston; 3168 - Clayton; 2076 - Sydney; 2065 - St Leonards	https://clinicaltrials.gov/ct2/show/NCT02788279
NCT02794571	2016-000944-33--GO30103	Phase 1		NSW, VIC	2016-06-09	2016-05-23		Atezolizumab; Atezolizumab + Bevacizumab + Tiragolumab; Atezolizumab + Capecitabine + Tiragolumab; Atezolizumab + Carboplatin + Cisplatin + Etoposide + Tiragolumab; Atezolizumab + Carboplatin + Cisplatin + Pemetrexed + Tiragolumab; Atezolizumab + Carboplatin + Paclitaxel + Tiragolumab; Atezolizumab + Tiragolumab; Bevacizumab; Capecitabine; Carboplatin; Cisplatin; Etoposide; Paclitaxel; Pembrolizumab; Pembrolizumab + Tiragolumab; Pemetrexed; Tiragolumab	antimetabolite; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; fluoropyrimidine; anti-TIGIT_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-VEGF_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; topoisomerase_inhibitor; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + fluoropyrimidine; anti-PD-1_monoclonal_antibody; taxane; platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor	Atezolizumab + Bevacizumab + Tiragolumab; Atezolizumab + Capecitabine + Tiragolumab; Atezolizumab + Carboplatin + Cisplatin + Etoposide + Tiragolumab; Atezolizumab + Carboplatin + Cisplatin + Pemetrexed + Tiragolumab; Atezolizumab + Carboplatin + Paclitaxel + Tiragolumab; Atezolizumab + Tiragolumab; Pembrolizumab + Tiragolumab; Tiragolumab	anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + fluoropyrimidine; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; anti-TIGIT_monoclonal_antibody	2016-000944-33  GO30103	A Phase Ia/Ib Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Patients With Locally Advanced or Metastatic Tumors	Advanced/Metastatic Tumors	3051 - North Melbourne; 2010 - Darlinghurst	https://clinicaltrials.gov/ct2/show/NCT02794571
NCT02799095	ALK4230-A101	Phase 1		NSW	2016-06-14	2016-07-01		Nemvaleukin alfa; Nemvaleukin alfa + Pembrolizumab; Pembrolizumab	IL-2_fusion_protein; anti-PD-1_monoclonal_antibody; IL-2_fusion_protein + anti-PD-1_monoclonal_antibody	Nemvaleukin alfa; Nemvaleukin alfa + Pembrolizumab	IL-2_fusion_protein; IL-2_fusion_protein + anti-PD-1_monoclonal_antibody	ALK4230-A101	A Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors - ARTISTRY-1	Advanced Solid Tumors	2640 - Albury; 2298 - Waratah	https://clinicaltrials.gov/ct2/show/NCT02799095
NCT02799602	ARASENS	Phase 3		NSW, SA, VIC	2016-06-15	2016-11-30		Darolutamide; Darolutamide + Docetaxel; Docetaxel; Placebo	placebo; antiandrogen,nonsteroidal,second_generation + taxane; antiandrogen,nonsteroidal,second_generation; taxane	Darolutamide + Docetaxel; Placebo	antiandrogen,nonsteroidal,second_generation + taxane; placebo	2015-002590-38  17777	A Randomized, Double-blind, Placebo Controlled Phase III Study of Darolutamide (ODM-201) Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients With Metastatic Hormone Sensitive Prostate Cancer	Metastatic Hormone-sensitive Prostate Cancer	3065 - Fitzroy; 5037 - Kurralta Park; 2010 - Sydney; 5000 - Adelaide; 2031 - Randwick	https://clinicaltrials.gov/ct2/show/NCT02799602
NCT02807181	SIRCCA	Phase 2		NSW, VIC	2016-06-21	2017-01-01		Cisplatin; Cisplatin + Gemcitabine; Gemcitabine	antimetabolite; platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; gemcitabine	Cisplatin + Gemcitabine	antimetabolite + platinum-based_antineoplastic_agent; gemcitabine	STX0115	Prospective, Multicenter, Randomized, Controlled Study Evaluating SIR-Spheres Y-90 Resin Microspheres Preceding Cisplatin-gemcitabine (CIS-GEM) Chemotherapy Versus CIS-GEM Chemotherapy Alone as First-line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma	Intrahepatic Cholangiocarcinoma	3000 - Melbourne; 2109 - North Ryde	https://clinicaltrials.gov/ct2/show/NCT02807181
NCT02807636	IMvigor130	Phase 3		NSW, QLD, SA, VIC	2016-06-21	2016-06-30		Atezolizumab; Atezolizumab + Carboplatin + Cisplatin + Gemcitabine; Carboplatin; Cisplatin; Gemcitabine; Placebo	placebo; antimetabolite; platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody; gemcitabine	Atezolizumab; Atezolizumab + Carboplatin + Cisplatin + Gemcitabine; Placebo	anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; gemcitabine; placebo	2016-000250-35  WO30070	A Phase III, Multicenter, Randomized, Placebo-Controlled Study of Atezolizumab (Anti-PD-L1 Antibody) as Monotherapy and in Combination With Platinum-Based Chemotherapy in Patients With Untreated Locally Advanced or Metastatic Urothelial Carcinoma	Urothelial Carcinoma	- St Albans; 5112 - Adelaide; 3144 - Malvern; 2109 - Macquarie Park; 4029 - Herston; 3128 - Box Hill; 5037 - Kurralta Park	https://clinicaltrials.gov/ct2/show/NCT02807636
NCT02824965	ONJ2015-001	Phase 1		VIC	2016-07-07	2017-08-09		Coxsackievirus A21; Coxsackievirus A21 + Pembrolizumab; Pembrolizumab	oncolytic_Coxsackie_virus,ICAM_overexpressing; anti-PD-1_monoclonal_antibody + oncolytic_Coxsackie_virus,ICAM_overexpressing; anti-PD-1_monoclonal_antibody	Coxsackievirus A21 + Pembrolizumab	anti-PD-1_monoclonal_antibody + oncolytic_Coxsackie_virus,ICAM_overexpressing	ONJ2015-001	A Phase I/II Open-label Trial of Intravenous CAVATAK^TM in Combination With Pembrolizumab for the Treatment of Patients With Advanced NSCLC	Non-Small Cell Lung Cancer	3078 - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT02824965
NCT02829099	64457107CAN1001--CR108186	Phase 1			2016-07-12	2016-09-21		Mitazalimab	anti-CD40_agonistic_antibody	Mitazalimab	anti-CD40_agonistic_antibody	64457107CAN1001  CR108186	A Phase 1, Open-Label Study of the Safety, Pharmacokinetics and Pharmacodynamics of JNJ-64457107, an Agonistic Human Monoclonal Antibody Targeting CD40 in Patients With Advanced Stage Solid Tumors	Advanced Solid Neoplasms		https://clinicaltrials.gov/ct2/show/NCT02829099
NCT02861573	KEYNOTE-365	Phase 1		NSW, NZ	2016-08-10	2016-11-17		Abiraterone; Abiraterone + Pembrolizumab + Prednisone; Belzutifan; Belzutifan + Pembrolizumab; Carboplatin; Carboplatin + Etoposide; Carboplatin + Etoposide + Pembrolizumab; Dexamethasone; Docetaxel; Docetaxel + Pembrolizumab + Prednisone; Enzalutamide; Enzalutamide + Pembrolizumab; Etoposide; Lenvatinib; Lenvatinib + Pembrolizumab; Olaparib; Olaparib + Pembrolizumab; Pembrolizumab; Pembrolizumab + Vibostolimab; Prednisone; Vibostolimab	platinum-based_antineoplastic_agent + topoisomerase_inhibitor; HIF2a_inhibitor; CYP17A1_inhibitor; anti-TIGIT_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; PARP_inhibitor + anti-PD-1_monoclonal_antibody; CYP17A1_inhibitor + anti-PD-1_monoclonal_antibody + glucocorticoid; glucocorticoid; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; anti-PD-1_monoclonal_antibody + glucocorticoid + taxane; anti-PD-1_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation; topoisomerase_inhibitor; antiandrogen,nonsteroidal,second_generation; anti-PD-1_monoclonal_antibody; taxane; HIF2a_inhibitor + anti-PD-1_monoclonal_antibody; VEGF_inhibitor; platinum-based_antineoplastic_agent; PARP_inhibitor	Abiraterone + Pembrolizumab + Prednisone; Belzutifan + Pembrolizumab; Carboplatin + Etoposide; Carboplatin + Etoposide + Pembrolizumab; Docetaxel + Pembrolizumab + Prednisone; Enzalutamide + Pembrolizumab; Lenvatinib + Pembrolizumab; Olaparib + Pembrolizumab; Pembrolizumab + Vibostolimab; Dexamethasone	CYP17A1_inhibitor + anti-PD-1_monoclonal_antibody + glucocorticoid; HIF2a_inhibitor + anti-PD-1_monoclonal_antibody; PARP_inhibitor + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation; anti-PD-1_monoclonal_antibody + glucocorticoid + taxane; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; platinum-based_antineoplastic_agent + topoisomerase_inhibitor	KEYNOTE-365  3475-365	Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)	Metastatic Castration-Resistant Prostate Cancer	Auckland; - North Ryde	https://clinicaltrials.gov/ct2/show/NCT02861573
NCT02864381	2016-001402-41--GS-US-296-2013	Phase 2		NSW, QLD, TAS	2016-08-12	2016-09-01		Andecaliximab; Andecaliximab + Nivolumab; Nivolumab	anti-MMP9_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-MMP9_monoclonal_antibody + anti-PD-1_monoclonal_antibody	Andecaliximab + Nivolumab; Nivolumab	anti-MMP9_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody	2016-001402-41  GS-US-296-2013	A Phase 2, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of GS-5745 Combined With Nivolumab Versus Nivolumab Alone in Subjects With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma	Gastroesophageal Junction Adenocarcinoma; Gastric Adenocarcinoma	2640 - Albury; 4818 - Douglas; 2076 - Wahroonga; 7000 - Hobart	https://clinicaltrials.gov/ct2/show/NCT02864381
NCT02872116	CheckMate649	Phase 3		NSW, QLD, SA, VIC, WA	2016-08-19	2016-10-12		Capecitabine; Capecitabine + Oxaliplatin; Fluorouracil; Fluorouracil + Leucovorin + Oxaliplatin; Ipilimumab; Ipilimumab + Nivolumab; Leucovorin; Nivolumab; Oxaliplatin	Fluorouracil; fluoropyrimidine; anti-PD-1_monoclonal_antibody; fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent; folinic_acid; anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; fluoropyrimidine + platinum-based_antineoplastic_agent; anti-CTLA4_monoclonal_antibody	Capecitabine + Oxaliplatin; Fluorouracil + Leucovorin + Oxaliplatin; Ipilimumab + Nivolumab; Nivolumab	anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; fluoropyrimidine + platinum-based_antineoplastic_agent; Fluorouracil	2016-001018-76  CA209-649	A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab Plus Ipilimumab or Nivolumab in Combination With Oxaliplatin Plus Fluoropyrimidine Versus Oxaliplatin Plus Fluoropyrimidine in Subjects With Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer	Gastroesophageal Junction Cancer; Esophageal Adenocarcinoma; Gastric Cancer	2148 - Blacktown; 2250 - Gosford; 3630 - Shepparton; 3350 - Ballarat; 5000 - Adelaide; 4215 - Southport; 3021 - St Albans; 6150 - Perth	https://clinicaltrials.gov/ct2/show/NCT02872116
NCT02875548	TRuST	Phase 1		ACT, VIC	2016-08-23	2016-08-30		Tazemetostat	EZH2_inhibitor	Tazemetostat	EZH2_inhibitor	2015-004984-35  EZH-501	Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study	Synovial Sarcoma; Mesothelioma; Epitheliod Sarcoma (ES); Renal Medullary Carcinoma; Diffuse Large B-cell Lymphoma (DLBCL); Follicular Lymphoma (FL); Non-Hodgkin Lymphoma (NHL); Advanced Solid Tumors	3002 - Melbourne; - Geelong; - Monash; - Alexandra; 3168 - Clayton	https://clinicaltrials.gov/ct2/show/NCT02875548
NCT02877966	HF03-14-37	Not Applicable		QLD	2016-08-25			Placebo	placebo	Placebo	placebo	HF03-14-37	Evaluation of the Effects of a Stoichiometric Mixture of Amino Acids (Amixea) on Lean Body Mass and Muscle Strengh of Patients With Unresectable Advanced Non-small Cell Lung Cancer: a Randomized, Double Blind, Placebo-controlled, Multicenter Study	Cancer Patients With Cachexia	QLD 4215 - Southport; QLD 4226 - Robina; QLD 4226 - Woolloongabba	https://clinicaltrials.gov/ct2/show/NCT02877966
NCT02899299	CheckMate743	Phase 3		NSW, QLD, VIC, WA	2016-09-14	2016-11-29		Carboplatin; Carboplatin + Cisplatin + Pemetrexed; Cisplatin; Ipilimumab; Ipilimumab + Nivolumab; Nivolumab; Pemetrexed	antimetabolite; anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; antimetabolite + platinum-based_antineoplastic_agent; anti-CTLA4_monoclonal_antibody	Carboplatin + Cisplatin + Pemetrexed; Ipilimumab + Nivolumab	anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; antimetabolite + platinum-based_antineoplastic_agent	2016-001859-43  CA209-743	A Phase III, Randomized, Open Label Trial of Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma	Mesothelioma	3168 - Clayton; 3144 - Malvern; 6009 - Nedlands; 4575 - Birtinya; 2139 - Sydney	https://clinicaltrials.gov/ct2/show/NCT02899299
NCT02903771	NVGN-002-101	Phase 1		NSW, QLD, SA	2016-09-16	2016-11-01		Cantrixil	benzopyran	Cantrixil	benzopyran	NVGN-002-101	Phase I Study of Intra-peritoneal Cantrixil in Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer.	Ovarian Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms	- Adelaide; 2145 - Westmead; 4101 - South Brisbane	https://clinicaltrials.gov/ct2/show/NCT02903771
NCT02905266	2016-001941-26--CA209-742	Phase 3		NSW, QLD, VIC	2016-09-19	2016-10-27		Ipilimumab; Ipilimumab + Nivolumab; Nivolumab	anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-CTLA4_monoclonal_antibody	Ipilimumab + Nivolumab	anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	2016-001941-26  CA209-742	Phase IIIb, Randomized, Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Previously Untreated Unresectable or Metastatic Melanoma	Melanoma	- Greenslopes; - Malvern; - North Sydney	https://clinicaltrials.gov/ct2/show/NCT02905266
NCT02908672	2016-002482-54--CO39262	Phase 3		NZ, QLD, SA, VIC, WA	2016-09-21	2017-01-13		Atezolizumab; Atezolizumab + Cobimetinib + Vemurafenib; Cobimetinib; Placebo; Vemurafenib	placebo; BRAF_V600_inhibitor + MEK_inhibitor + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; BRAF_V600_inhibitor; MEK_inhibitor	Atezolizumab + Cobimetinib + Vemurafenib; Placebo	BRAF_V600_inhibitor + MEK_inhibitor + anti-PD-L1_monoclonal_antibody; placebo	2016-002482-54  CO39262	A Phase III, Double-Blinded, Randomized, Placebo-Controlled Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFV600 Mutation-Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma	Melanoma	4102 - Woolloongabba; Auckland; Palmerston North; 6150 - Murdoch; Tauranga; 5000 - Adelaide; 3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT02908672
NCT02915744	ATTAIN	Phase 3		NSW, VIC, WA	2016-09-27	2016-11-01		Capecitabine; Docetaxel; Docetaxel + Eribulin + Gemcitabine + Ixabepilone + Nab-paclitaxel + Paclitaxel + Vinorelbine; Eribulin; Etirinotecan Pegol; Gemcitabine; Ixabepilone; Nab-paclitaxel; Paclitaxel; Vinorelbine	antimetabolite; topoisomerase_inhibitor; macrocyclic_ketone_analogue; fluoropyrimidine; taxane; gemcitabine; vinca_alkaloid; microtubule_stabilizing_agent; antimetabolite + macrocyclic_ketone_analogue + microtubule_stabilizing_agent + taxane + vinca_alkaloid	Docetaxel + Eribulin + Gemcitabine + Ixabepilone + Nab-paclitaxel + Paclitaxel + Vinorelbine; Etirinotecan Pegol; Capecitabine	antimetabolite + macrocyclic_ketone_analogue + microtubule_stabilizing_agent + taxane + vinca_alkaloid; topoisomerase_inhibitor; fluoropyrimidine; gemcitabine	15-102-14	A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine	Breast Cancer; Metastasis	6008 - Subiaco; 6009 - Nedlands; 3128 - Box Hill; 2010 - Darlinghurst; 2640 - Albury; 2500 - Wollongong	https://clinicaltrials.gov/ct2/show/NCT02915744
NCT02923921	Sequoia	Phase 3		NSW, VIC, WA	2016-10-05	2017-03-01		Fluorouracil; Fluorouracil + Leucovorin + Oxaliplatin + Pegilodecakin; Fluorouracil + Oxaliplatin; Gemcitabine; Leucovorin; Oxaliplatin; Pegilodecakin	antimetabolite; Fluorouracil; pegylated_IL-10; platinum-based_antineoplastic_agent; folinic_acid; fluoropyrimidine + folinic_acid + pegylated_IL-10 + platinum-based_antineoplastic_agent; fluoropyrimidine + platinum-based_antineoplastic_agent	Fluorouracil + Leucovorin + Oxaliplatin + Pegilodecakin; Fluorouracil + Oxaliplatin; Gemcitabine	fluoropyrimidine + folinic_acid + pegylated_IL-10 + platinum-based_antineoplastic_agent; fluoropyrimidine + platinum-based_antineoplastic_agent; Fluorouracil; antimetabolite	J1L-AM-JZGB  17158	Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Metastatic Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen	Pancreatic Cancer	2010 - Sydney; 3084 - Heidelberg; 3144 - Malvern; 6150 - Murdoch	https://clinicaltrials.gov/ct2/show/NCT02923921
NCT02923934	ONJ2016-001	Phase 2		NSW, VIC	2016-10-05	2017-08-22		Ipilimumab; Ipilimumab + Nivolumab; Nivolumab	anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-CTLA4_monoclonal_antibody	Ipilimumab + Nivolumab	anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	ONJ2016-001	A Phase II Clinical Trial Evaluating Ipilimumab and Nivolumab in Combination for the Treatment of Rare Gastrointestinal, Neuro-Endocrine and Gynaecological Cancers	Malignant Female Reproductive System Neoplasm; Gastrointestinal Cancer; Neuroendocrine Tumours	3078 - Heidelberg; 2145 - Sydney; 3168 - Clayton; 3000 - Melbourne; 2640 - Albury	https://clinicaltrials.gov/ct2/show/NCT02923934
NCT02924272	U1111-1184-2041--C16027	Phase 2			2016-10-05	2016-12-16		Ixazomib	proteasome_inhibitor	Ixazomib	proteasome_inhibitor	U1111-1184-2041  C16027	An Open-Label, Rollover Protocol for Patients Previously Enrolled in Millennium-Sponsored Ixazomib Studies	Lymphoma; Multiple Myeloma; Carcinoma, Non-Small-Cell Lung		https://clinicaltrials.gov/ct2/show/NCT02924272
NCT02924883	KATE2	Phase 2		NSW, QLD, VIC, WA	2016-10-05	2016-09-26		Atezolizumab; Atezolizumab + Trastuzumab Emtansine; Placebo; Trastuzumab; Trastuzumab Emtansine	placebo; anti-ERBB2_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; anti-ERBB2_antibody-drug_conjugate; anti-ERBB2_antibody-drug_conjugate + anti-PD-L1_monoclonal_antibody	Atezolizumab + Trastuzumab Emtansine; Placebo	anti-ERBB2_antibody-drug_conjugate + anti-PD-L1_monoclonal_antibody; anti-ERBB2_monoclonal_antibody; placebo	2015-004189-27  WO30085	A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab and Taxane Based Therapy	Metastatic Breast Cancer	2217 - Kogarah; 3199 - Frankston; 6008 - Subiaco; 2298 - Waratah; 4102 - Woolloongabba; 3002 - East Melbourne; 3021 - St Albans	https://clinicaltrials.gov/ct2/show/NCT02924883
NCT02926768	CK-101-101	Phase 1		NZ, QLD	2016-10-06	2016-09-01		Olafertinib	EGFR_inhibitor,third_generation	Olafertinib	EGFR_inhibitor,third_generation	CK-101-101	A Phase I/II, Open-Label, Safety, Pharmacokinetic and Efficacy Study of Ascending Doses of Oral CK-101 in Patients With Advanced Solid Tumors	Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Lung Diseases	Christchurch; Auckland; Wellington; 4120 - Greenslopes	https://clinicaltrials.gov/ct2/show/NCT02926768
NCT02928224	BEACON-CRC	Phase 3		NEW South Wales (nsw)QLD, NSW, QLD, SA, VIC	2016-10-10	2016-10-13		Binimetinib; Binimetinib + Cetuximab + Encorafenib; Cetuximab; Cetuximab + Encorafenib; Cetuximab + Irinotecan; Encorafenib; Fluorouracil; Irinotecan; Leucovorin	topoisomerase_inhibitor; Fluorouracil; fluoropyrimidine; anti-EGFR_monoclonal_antibody + topoisomerase_inhibitor; BRAF_V600_inhibitor + anti-EGFR_monoclonal_antibody; MEK_inhibitor; folinic_acid; BRAF_V600_inhibitor + MEK_inhibitor + anti-EGFR_monoclonal_antibody; anti-EGFR_monoclonal_antibody; BRAF_V600_inhibitor	Binimetinib + Cetuximab + Encorafenib; Cetuximab + Encorafenib; Cetuximab + Irinotecan; Fluorouracil; Leucovorin	BRAF_V600_inhibitor + MEK_inhibitor + anti-EGFR_monoclonal_antibody; BRAF_V600_inhibitor + anti-EGFR_monoclonal_antibody; anti-EGFR_monoclonal_antibody + topoisomerase_inhibitor; Fluorouracil; fluoropyrimidine; folinic_acid	BEACON CRC  ARRAY-818-302	A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer	BRAF V600E-mutant Metastatic Colorectal Cancer	2300 - Sydney; 5042 - Bedford Park; 5011 - Woodville South; 3084 - Heidelberg; 5000 - Adelaide; 2010 - Darlinghurst; 3000 - Melbourne; 4101 - South Brisbane; 3168 - Clayton; 2150 - Parramatta	https://clinicaltrials.gov/ct2/show/NCT02928224
NCT02928406	2016-002625-11--MO29983	Phase 3		ACT, NSW, QLD, SA, TAS, VIC	2016-10-10	2016-11-30		Atezolizumab	anti-PD-L1_monoclonal_antibody	Atezolizumab	anti-PD-L1_monoclonal_antibody	2016-002625-11  MO29983	An Open Label, Single Arm, Multicenter, Safety Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract	Urinary Tract Cancer	2298 - Waratah; 7000 - Hobart; 4101 - South Brisbane; 2065 - St Leonards; 2606 - Canberra; 3128 - Box Hill; 5000 - Adelaide; 2031 - Randwick; 2109 - Macquarie Park; 3084 - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT02928406
NCT02933944	CT-TG02-01	Phase 1		NZ, QLD, VIC	2016-10-14	2016-09-01		Pembrolizumab	anti-PD-1_monoclonal_antibody	Pembrolizumab	anti-PD-1_monoclonal_antibody	CT TG02-01	A Non-Randomised Open-Label Phase Ib Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Advanced Primary and Recurrent Oncogenic RAS Exon 2 Mutant Colorectal Cancer	Rectal Cancer	- Brisbane; - Melbourne; Christchurch; Auckland	https://clinicaltrials.gov/ct2/show/NCT02933944
NCT02935634	FRACTION-GC	Phase 2		NSW, VIC	2016-10-17	2016-11-29		Ipilimumab; Ipilimumab + Nivolumab; Ipilimumab + Nivolumab + Rucaparib; Ipilimumab + Rucaparib; Linrodostat; Linrodostat + Nivolumab; Nivolumab; Nivolumab + Relatlimab; Nivolumab + Rucaparib; Relatlimab; Rucaparib	IDO1_inhibitor; PARP_inhibitor + anti-PD-1_monoclonal_antibody; anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA4_monoclonal_antibody; anti-LAG3_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; IDO1_inhibitor + anti-PD-1_monoclonal_antibody; PARP_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; PARP_inhibitor + anti-CTLA4_monoclonal_antibody; PARP_inhibitor	Ipilimumab + Nivolumab; Ipilimumab + Nivolumab + Rucaparib; Ipilimumab + Rucaparib; Linrodostat + Nivolumab; Nivolumab + Relatlimab; Nivolumab + Rucaparib	IDO1_inhibitor + anti-PD-1_monoclonal_antibody; PARP_inhibitor + anti-CTLA4_monoclonal_antibody; PARP_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; PARP_inhibitor + anti-PD-1_monoclonal_antibody; anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody	2016-002807-24  CA018-003	A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Participants With Advanced Gastric Cancer (FRACTION-Gastric Cancer)	Advanced Gastric Cancer	2031 - Randwick; 3084 - Heidelberg; 2145 - Westmead	https://clinicaltrials.gov/ct2/show/NCT02935634
NCT02947152	CHKT288X2101	Phase 1		VIC	2016-10-27	2016-12-01		HKT288	anti-CDH6_antibody-drug_conjugate	HKT288	anti-CDH6_antibody-drug_conjugate	CHKT288X2101	A Phase I, Multicenter, Open-label Dose Escalation and Expansion Study of HKT288, Administered Intravenously in Adult Patients With Advanced Solid Tumors, Including Epithelial Ovarian Cancer and Renal Cell Carcinoma	Renal Cell Carcinoma; Epithelial Ovarian Cancer	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT02947152
NCT02947685	PATINA	Phase 3		ACT, NSW, NZ, QLD, VIC, WA	2016-10-28	2017-06-21		Anastrozole; Anastrozole + Fulvestrant + Letrozole + Pertuzumab + Trastuzumab; Anastrozole + Letrozole + Palbociclib + Pertuzumab + Trastuzumab; Exemestane; Fulvestrant; Letrozole; Palbociclib; Pertuzumab; Trastuzumab	aromatase_inhibitor; CDK4/6_inhibitor + anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor + aromatase_inhibitor; anti-ERBB2_monoclonal_antibody; CDK4/6_inhibitor; anti-ERBB2_monoclonal_antibody,dimerization_inhibitor; selective_estrogen_receptor_degrader; anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor + aromatase_inhibitor + selective_estrogen_receptor_degrader	Anastrozole + Fulvestrant + Letrozole + Pertuzumab + Trastuzumab; Anastrozole + Letrozole + Palbociclib + Pertuzumab + Trastuzumab; Exemestane	CDK4/6_inhibitor + anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor + aromatase_inhibitor; anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor + aromatase_inhibitor + selective_estrogen_receptor_degrader	AFT-38	A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer	HER-2 Positive Breast Cancer; Estrogen Receptor Positive Breast Cancer	- Clayton; - Garran; - Darlinghurst; - Melbourne; - South Brisbane; - Nedlands; - Waratah; - Westmead; Auckland	https://clinicaltrials.gov/ct2/show/NCT02947685
NCT02952534	TRITON2	Phase 2		NSW, TAS, VIC, WA	2016-11-02	2017-02-15		Rucaparib	PARP_inhibitor	Rucaparib	PARP_inhibitor	CO-338-052	TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer Associated With Homologous Recombination Deficiency	Metastatic Castration Resistant Prostate Cancer	2065 - Saint Leonards; 2228 - Miranda; 2650 - Wagga Wagga; 2800 - Orange; 3220 - Geelong; 3144 - Malvern; 7000 - Hobart; 3199 - Frankston; 6008 - Subiaco	https://clinicaltrials.gov/ct2/show/NCT02952534
NCT02955069	2016-002522-36--CPDR001E2201	Phase 2		NSW	2016-11-04	2017-02-14		Spartalizumab	anti-PD-1_monoclonal_antibody	Spartalizumab	anti-PD-1_monoclonal_antibody	2016-002522-36  CPDR001E2201	An Open Label Phase II Study to Evaluate the Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC), That Have Progressed on Prior Treatment.	Well-differentiated Non-functional NET of Thoracic Origin; Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma; Well-differentiated Non-functional NET of Gastrointestinal Origin; Well-differentiated Non-functional NET of Pancreatic Origin	2065 - St Leonards	https://clinicaltrials.gov/ct2/show/NCT02955069
NCT02955251	2016-001461-88--M15-819	Phase 1		NSW	2016-11-04	2016-11-18		ABBV-428; ABBV-428 + Nivolumab; Nivolumab	anti-CD40_agonistic_antibody; anti-CD40_agonistic_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody	ABBV-428; ABBV-428 + Nivolumab	anti-CD40_agonistic_antibody; anti-CD40_agonistic_antibody + anti-PD-1_monoclonal_antibody	2016-001461-88  M15-819	A Multi-Center, Phase 1, Open-Label, Dose-Escalation Study of ABBV-428, an Immunotherapy in Subjects With Advanced Solid Tumors	Advanced Solid Tumors Cancer	2065 - St Leonards; 2050 - Camperdown	https://clinicaltrials.gov/ct2/show/NCT02955251
NCT02960022	2016-001694-32--9785-CL-0123	Phase 2		NSW, NZ, QLD, SA, VIC	2016-11-09	2016-12-22		Abiraterone; Abiraterone + Enzalutamide + Prednisone; Enzalutamide; Prednisone	CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + glucocorticoid; glucocorticoid; antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor	Abiraterone + Enzalutamide + Prednisone; Enzalutamide	CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + glucocorticoid; antiandrogen,nonsteroidal,second_generation	2016-001694-32  9785-CL-0123	A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study	Prostate Cancer	- Ashford; - Parkville; 2076 - Wahroonga; 2145 - Westmead; Dunedin; Auckland; Hamilton; 3165 - East Bentleigh; 3021 - St Albans; - Malvern; 2485 - Tweed Heads; - South Brisbane; 2640 - Albury; 3350 - Ballarat	https://clinicaltrials.gov/ct2/show/NCT02960022
NCT02966171	2015-453-00AU1	Phase 1		NSW, VIC	2016-11-17	2017-01-01		HMPL-453	FGFR1/2/3_inhibitor,reversible; FGFR_inhibitor	HMPL-453	FGFR1/2/3_inhibitor,reversible; FGFR_inhibitor	2015-453-00AU1	A Phase I, Open-label, Multi-center, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of HMPL-453 in Patients With Advanced Solid Malignancies	Solid Tumor	2010 - Sydney; 3199 - Frankston; 3168 - Melbourne; 2050 - Sydney	https://clinicaltrials.gov/ct2/show/NCT02966171
NCT02967692	COMBI-i	Phase 3		NSW, QLD, VIC, WA	2016-11-18	2017-02-17		Dabrafenib; Dabrafenib + Spartalizumab + Trametinib; Dabrafenib + Trametinib; Placebo; Spartalizumab; Trametinib	placebo; BRAF_V600_inhibitor + MEK_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; MEK_inhibitor; BRAF_V600_inhibitor + MEK_inhibitor; BRAF_V600_inhibitor	Dabrafenib + Spartalizumab + Trametinib; Dabrafenib + Trametinib; Placebo	BRAF_V600_inhibitor + MEK_inhibitor; BRAF_V600_inhibitor + MEK_inhibitor + anti-PD-1_monoclonal_antibody; placebo	2016-002794-35  CPDR001F2301	A Randomized, Double-blind, Placebo-controlled, Phase III Study Comparing the Combination of PDR001, Dabrafenib and Trametinib Versus Placebo, Dabrafenib and Trametinib in Previously Untreated Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma	Melanoma	2060 - North Sydney; 6009 - Nedlands; 3004 - Melbourne; 4120 - Greenslopes; 2290 - Gateshead	https://clinicaltrials.gov/ct2/show/NCT02967692
NCT02974725	2016-004293-18--CLXH254X2102	Phase 1		NSW, VIC	2016-11-28	2017-02-24		LTT462; LTT462 + Naporafenib; Naporafenib; Naporafenib + Ribociclib; Naporafenib + Trametinib; Ribociclib; Trametinib	ERK_inhibitor; ERK_inhibitor + RAF_dimer_inhibitor; MEK_inhibitor + RAF_dimer_inhibitor; CDK4/6_inhibitor; MEK_inhibitor; RAF_dimer_inhibitor; CDK4/6_inhibitor + RAF_dimer_inhibitor	LTT462 + Naporafenib; Naporafenib + Ribociclib; Naporafenib + Trametinib	CDK4/6_inhibitor + RAF_dimer_inhibitor; ERK_inhibitor + RAF_dimer_inhibitor; MEK_inhibitor + RAF_dimer_inhibitor	2016-004293-18  CLXH254X2102	A Phase Ib, Open-label, Multicenter Study of Oral LXH254-centric Combinations in Adult Patients With Advanced or Metastatic KRAS or BRAF Mutant Non-Small Cell Lung Cancer or NRAS Mutant Melanoma	Melanoma; Non-Small Cell Lung Cancer	2145 - Westmead; 3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT02974725
NCT02981342	I3Y-MC-JPCJ--16342	Phase 2		NSW	2016-12-05	2017-01-12		Abemaciclib; Abemaciclib + LY3023414; Capecitabine; Capecitabine + Gemcitabine; Gemcitabine; LY3023414	antimetabolite; CDK4/6_inhibitor + PI3K/mTOR_inhibitor; CDK4/6_inhibitor; fluoropyrimidine; gemcitabine; PI3K/mTOR_inhibitor; antimetabolite + fluoropyrimidine	Abemaciclib; Abemaciclib + LY3023414; Capecitabine + Gemcitabine	CDK4/6_inhibitor; CDK4/6_inhibitor + PI3K/mTOR_inhibitor; antimetabolite + fluoropyrimidine; gemcitabine	I3Y-MC-JPCJ  16342	An Adaptive, Open-Label, Randomized Phase 2 Study of Abemaciclib as a Monotherapy and in Combination With Other Agents Versus Choice of Standard of Care (Gemcitabine or Capecitabine) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma	Pancreatic Ductal Adenocarcinoma	2010 - Sydney; 2148 - Blacktown	https://clinicaltrials.gov/ct2/show/NCT02981342
NCT02987543	2016-000300-28--D081DC00007	Phase 3		NSW, QLD, SA, VIC, WA	2016-12-09	2017-02-06		Abiraterone; Abiraterone + Enzalutamide; Enzalutamide; Olaparib	antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation; PARP_inhibitor	Abiraterone + Enzalutamide; Olaparib	CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation; PARP_inhibitor	2016-000300-28  D081DC00007	A Phase III, Open Label, Randomized Study to Assess the Efficacy and Safety of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have Homologous Recombination Repair Gene Mutations (PROfound)	Metastatic Castration-resistant Prostate Cancer	4120 - Greenslopes; 5000 - Adelaide; 2031 - Randwick; 4029 - Herston; 3000 - Melbourne; 3128 - Box Hill; 6009 - Nedlands; 2109 - Macquarie University; 3168 - Clayton; 2298 - Waratah	https://clinicaltrials.gov/ct2/show/NCT02987543
NCT02988960	2016-002219-16--M15-862	Phase 1		VIC	2016-12-12	2017-02-22		ABBV-927; ABBV-927 + Budigalimab; Budigalimab	anti-CD40_agonistic_antibody; anti-CD40_agonistic_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody	ABBV-927; ABBV-927 + Budigalimab	anti-CD40_agonistic_antibody; anti-CD40_agonistic_antibody + anti-PD-1_monoclonal_antibody	2016-002219-16  M15-862	A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-927 and ABBV-181, an Immunotherapy, in Subjects With Advanced Solid Tumors	Advanced Solid Tumors Cancer	3199 - Frankston; 3084 - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT02988960
NCT02993731	CanStem111P	Phase 3		NSW, QLD, SA, VIC, WA	2016-12-15	2016-12-01		Gemcitabine; Gemcitabine + Nab-paclitaxel; Gemcitabine + Nab-paclitaxel + Napabucasin; Nab-paclitaxel; Napabucasin	antimetabolite; antimetabolite + taxane; taxane; gemcitabine; cancer_stemness_inhibitor; antimetabolite + cancer_stemness_inhibitor + taxane	Gemcitabine + Nab-paclitaxel; Gemcitabine + Nab-paclitaxel + Napabucasin	antimetabolite + cancer_stemness_inhibitor + taxane; antimetabolite + taxane; gemcitabine	CanStem111P	A Phase III Study of BBI-608 Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma	Carcinoma, Pancreatic Ductal	2148 - Blacktown; 6009 - Nedlands; 3144 - Malvern; 2109 - East Albury; 4101 - South Brisbane; 2076 - Wahroonga; 2031 - Randwick; 2485 - Tweed Heads; 3084 - Heidelberg; 2640 - East Albury; 2109 - Sydney	https://clinicaltrials.gov/ct2/show/NCT02993731
NCT02996110	FRACTION-RCC	Phase 2		NSW, VIC	2016-12-19	2017-02-02		BMS-813160; BMS-813160 + Nivolumab; Ipilimumab; Ipilimumab + Nivolumab; Linrodostat; Linrodostat + Nivolumab; Nivolumab; Nivolumab + Relatlimab; Relatlimab	anti-LAG3_monoclonal_antibody; CCR2/CCR5_antagonist; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; IDO1_inhibitor; anti-PD-1_monoclonal_antibody; IDO1_inhibitor + anti-PD-1_monoclonal_antibody; anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; CCR2/CCR5_antagonist + anti-PD-1_monoclonal_antibody; anti-CTLA4_monoclonal_antibody	BMS-813160 + Nivolumab; Ipilimumab + Nivolumab; Linrodostat + Nivolumab; Nivolumab + Relatlimab	CCR2/CCR5_antagonist + anti-PD-1_monoclonal_antibody; IDO1_inhibitor + anti-PD-1_monoclonal_antibody; anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody	2016-003082-26  CA018-005	A Phase 2, Real-time Assessment of Combination Therapies in Immuno-Oncology Study in Participants With Advanced Renal Cell Carcinoma (FRACTION-RCC)	Advanced Cancer	2145 - Westmead; 3165 - Bentleigh	https://clinicaltrials.gov/ct2/show/NCT02996110
NCT02999893	APROC	Phase 1/Phase 2		VIC	2016-12-21	2017-04-11		Cisplatin; Cisplatin + Eprenetapopt + Fluorouracil; Eprenetapopt; Fluorouracil	PRIMA-1_analog; Fluorouracil; mutant_p53_reactivator; fluoropyrimidine + mutant_p53_reactivator + platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent; PRIMA-1_analog + fluoropyrimidine + platinum-based_antineoplastic_agent	Cisplatin + Eprenetapopt + Fluorouracil	PRIMA-1_analog + fluoropyrimidine + platinum-based_antineoplastic_agent; fluoropyrimidine + mutant_p53_reactivator + platinum-based_antineoplastic_agent; Fluorouracil	16/012	A phase1b/2 Study Evaluating the Efficacy of APR-246, a First-in-class Agent Targeting Mutant p53 in the Treatment of Platinum Resistant Advanced and Metastatic Oesophageal or Gastro-oesophageal Junction Cancers	Oesophageal Carcinoma	3000 - Heidelberg; 3002 - Melbourne; 3000 - Sunshine; 3000 - Clayton; 3000 - Prahran	https://clinicaltrials.gov/ct2/show/NCT02999893
NCT03005782	2016-002789-30--R3767-ONC-1613	Phase 1		VIC, WA	2016-12-29	2016-11-07		Cemiplimab; Cemiplimab + Fianlimab; Fianlimab	anti-LAG3_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody	Cemiplimab + Fianlimab; Fianlimab	anti-LAG3_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody	2016-002789-30  R3767-ONC-1613	A Phase 1, Open-Label, Dose-Escalation and Cohort Expansion First-in-Human Study of the Safety, Tolerability, Activity and Pharmacokinetics of REGN3767 (Anti-LAG-3 mAb) Administered Alone or in Combination With REGN2810 (Anti-PD-1 mAb) in Patients With Advanced Malignancies	Malignancies	4029 - Brisbane; 3000 - Melbourne; 06009 - Perth	https://clinicaltrials.gov/ct2/show/NCT03005782
NCT03016312	IMbassador250	Phase 3		NSW, QLD, SA, VIC	2017-01-10	2017-01-10		Atezolizumab; Atezolizumab + Enzalutamide; Enzalutamide	anti-PD-L1_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation; antiandrogen,nonsteroidal,second_generation; anti-PD-L1_monoclonal_antibody	Atezolizumab + Enzalutamide; Enzalutamide	anti-PD-L1_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation; antiandrogen,nonsteroidal,second_generation	2016-003092-22  CO39385	A Phase III, Multicenter, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide Versus Enzalutamide Alone in Patients With Metastatic Castration-Resistant Prostate Cancer After Failure of an Androgen Synthesis Inhibitor and Failure of, Ineligibility for, or Refusal of a Taxane Regimen	Prostatic Neoplasms, Castration-Resistant	4029 - Herston; 5037 - Kurralta Park; 2139 - Concord; 3128 - Box Hill; 2113 - Macquarie Park; 3168 - Clayton	https://clinicaltrials.gov/ct2/show/NCT03016312
NCT03029780	CheckMate-800	Phase 2		NSW, QLD, SA, VIC	2017-01-24	2017-02-16		Ipilimumab; Ipilimumab + Nivolumab; Nivolumab	anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-CTLA4_monoclonal_antibody	Ipilimumab + Nivolumab	anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	CA209-800	Phase II, Randomized, Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma	Renal Cell Carcinoma	2298 - Waratah; 3144 - Malvern; 2145 - Westmead; 5112 - Elizabeth Vale; 4029 - Herston	https://clinicaltrials.gov/ct2/show/NCT03029780
NCT03030430	BAT-1706-001	Phase 1		NZ	2017-01-25	2016-03-15		Bevacizumab	anti-VEGF_monoclonal_antibody	Bevacizumab	anti-VEGF_monoclonal_antibody	BAT-1706-001	Randomized, Double-blind, Single-dose, 3-arm Parallel Design Comparative Pharmacokinetic(PK) and Safety Study of BAT1706 Versus European Union(EU)-Sourced Avastin® and United State (US)-Sourced Avastin® Administered in Healthy Subjects	NSCLC	Christchurch	https://clinicaltrials.gov/ct2/show/NCT03030430
NCT03033511	MERU	Phase 3		NSW, SA, VIC, WA	2017-01-26	2017-02-07		Dexamethasone; Dexamethasone + Rovalpituzumab Tesirine; Placebo; Rovalpituzumab Tesirine	placebo; glucocorticoid; anti-DLL3_antibody-drug_conjugate; anti-DLL3_antibody-drug_conjugate + glucocorticoid	Dexamethasone + Rovalpituzumab Tesirine; Placebo	anti-DLL3_antibody-drug_conjugate + glucocorticoid; placebo	2016-003503-64  M16-298	A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Subjects With Extensive Stage Small Cell Lung Cancer (MERU)	Small Cell Lung Cancer	2065 - Saint Leonards; 3021 - St Albans; 2305 - Lambton Heights; 6009 - Nedlands; 2450 - Coffs Harbour; 5006 - Adelaide; 2250 - Gosford	https://clinicaltrials.gov/ct2/show/NCT03033511
NCT03036098	CheckMate901	Phase 3		NSW, QLD, VIC, WA	2017-01-30	2017-03-24		Carboplatin; Cisplatin; Gemcitabine; Ipilimumab; Nivolumab	antimetabolite; platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody; gemcitabine; anti-CTLA4_monoclonal_antibody	Carboplatin; Cisplatin; Gemcitabine; Ipilimumab; Nivolumab	anti-CTLA4_monoclonal_antibody; anti-PD-1_monoclonal_antibody; antimetabolite; gemcitabine; platinum-based_antineoplastic_agent	2016-003881-14  CA209-901	A Phase 3, Open-label, Randomized Study of Nivolumab Combined With Ipilimumab, or With Standard of Care Chemotherapy, Versus Standard of Care Chemotherapy in Participants With Previously Untreated Unresectable or Metastatic Urothelial Cancer	Urothelial Cancer	6018 - Doubleview; 3084 - Heidelberg; 2298 - Waratah; 4101 - South Brisbane; 2145 - Westmead; 4224 - Tugun	https://clinicaltrials.gov/ct2/show/NCT03036098
NCT03040999	KEYNOTE-412	Phase 3		(Australia)NSW, NSW, NZ, QLD, SA, VIC	2017-02-02	2017-04-05		Cisplatin; Cisplatin + Pembrolizumab + Radiotherapy; Cisplatin + Radiotherapy; Pembrolizumab; Placebo; Radiotherapy	platinum-based_antineoplastic_agent + radiotherapy; placebo; radiotherapy; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + radiotherapy; anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent	Cisplatin + Pembrolizumab + Radiotherapy; Cisplatin + Radiotherapy; Placebo	anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + radiotherapy; platinum-based_antineoplastic_agent + radiotherapy; placebo	MK-3475-412  3475-412	A Randomized Phase III Study of Pembrolizumab Given Concomitantly With Chemoradiation and as Maintenance Therapy Versus Chemoradiation Alone in Subjects With Locally Advanced Head and Neck Squamous Cell Carcinoma (KEYNOTE-412)	Head and Neck Neoplasms	2148 - Blacktown; 2170 - Liverpool; 4029 - Herston; 3000 - Melbourne; 4102 - Brisbane; 5000 - Adelaide	https://clinicaltrials.gov/ct2/show/NCT03040999
NCT03041285	NOX66-version-1	Phase 1		NSW	2017-02-02	2017-08-31		Idronoxil; Idronoxil + Radiotherapy; Radiotherapy	radiotherapy; idronoxil_suppository + radiotherapy; idronoxil_suppository	Idronoxil + Radiotherapy	idronoxil_suppository + radiotherapy	NOX66 version 1	Phase I Study of Idronoxil Combined With Radiation Treatment in Men With Metastatic Prostate Cancer	Metastatic Castrate- Resistant Prostate Cancer	2065 - St Leonards	https://clinicaltrials.gov/ct2/show/NCT03041285
NCT03049189	COMPETE	Phase 3		NSW, VIC, WA	2017-02-09	2017-02-02		177Lu-edotreotide; Everolimus	177Lu-DOTA-radioconjugate; mTORC1_inhibitor	177Lu-edotreotide; Everolimus	177Lu-DOTA-radioconjugate; mTORC1_inhibitor	ITM-LET-01	A Prospective, Randomised, Controlled, Open-label, Multicentre Phase III Study to Evaluate Efficacy and Safety of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-Edotreotide Compared to Targeted Molecular Therapy With Everolimus in Patients With Inoperable, Progressive, Somatostatin Receptor-positive (SSTR+), Neuroendocrine Tumours of Gastroenteric or Pancreatic Origin (GEP-NET)	Neuroendocrine Tumors	3084 - Heidelberg; 2065 - Saint Leonards; 3000 - Melbourne; 6150 - Murdoch	https://clinicaltrials.gov/ct2/show/NCT03049189
NCT03053466	APL-501-01	Phase 1		NSW, VIC, WA	2017-02-15	2017-03-27		APL-501	anti-PD-1_monoclonal_antibody	APL-501	anti-PD-1_monoclonal_antibody	APL-501-01	A Phase 1 Multicenter, Dose Escalation, Cohort Extension and Dose and Disease Expansion Study of APL-501 in Subjects With Select Advanced or Relapsed/Recurrent Solid Tumors	Cancer of Unknown Primary Site; Mismatch Repair Deficiency; Microsatellite Instability; Solid Tumor	3144 - Malvern; 3004 - Melbourne; 6009 - Nedlands; 3000 - Melbourne; 2050 - Camperdown	https://clinicaltrials.gov/ct2/show/NCT03053466
NCT03059823	INCMGA-0012-101	Phase 1		NSW, NZ	2017-02-23	2016-11-15		Retifanlimab	anti-PD-1_monoclonal_antibody	Retifanlimab	anti-PD-1_monoclonal_antibody	INCMGA 0012-101	A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of INCMGA00012 in Patients With Advanced Solid Tumors	Metastatic Solid Tumors; Locally Advanced Solid Tumors	Auckland; 02010 - Darlinghurst; Wellington; 02050 - Camperdown	https://clinicaltrials.gov/ct2/show/NCT03059823
NCT03061812	TAHOE	Phase 3		NSW, QLD, VIC	2017-02-23	2017-04-11		Dexamethasone; Rovalpituzumab Tesirine; Topotecan	topoisomerase_inhibitor; glucocorticoid; anti-DLL3_antibody-drug_conjugate	Rovalpituzumab Tesirine; Topotecan; Dexamethasone	anti-DLL3_antibody-drug_conjugate; topoisomerase_inhibitor; glucocorticoid	2016-003726-17  M16-289	A Randomized, Open-Label, Multicenter, Phase 3 Study of Rovalpituzumab Tesirine Compared With Topotecan for Subjects With Advanced or Metastatic DLL3high Small Cell Lung Cancer (SCLC) Who Have First Disease Progression During or Following Front-Line Platinum-Based Chemotherapy (TAHOE)	Small Cell Lung Cancer	2500 - Wollongong; 3084 - Heidelberg; 3350 - Ballarat; 4032 - Chermside; 2217 - Kogarah; 2148 - Blacktown	https://clinicaltrials.gov/ct2/show/NCT03061812
NCT03066778	KEYNOTE-604	Phase 3		NSW, NZ, SA, VIC, WA	2017-02-28	2017-05-02		Carboplatin; Carboplatin + Cisplatin + Etoposide; Carboplatin + Cisplatin + Etoposide + Pembrolizumab; Cisplatin; Dexamethasone; Etoposide; Pembrolizumab; Placebo	platinum-based_antineoplastic_agent + topoisomerase_inhibitor; placebo; topoisomerase_inhibitor; anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; glucocorticoid; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor	Carboplatin + Cisplatin + Etoposide; Carboplatin + Cisplatin + Etoposide + Pembrolizumab; Dexamethasone; Placebo	anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; platinum-based_antineoplastic_agent + topoisomerase_inhibitor; glucocorticoid; placebo	2016-004309-15  3475-604	A Phase 3 Randomized, Double-Blind, Placebo-controlled Trial of Pembrolizumab (MK-3475/SCH900475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for the First-line Treatment of Subjects With Extensive Stage Small Cell Lung Cancer (KEYNOTE-604)	SCLC; Small Cell Lung Cancer	2500 - Wollongong; 5112 - Elizabeth Vale; 2148 - Blacktown; 6150 - Murdoch; 3065 - Fitzroy; Christchurch	https://clinicaltrials.gov/ct2/show/NCT03066778
NCT03069469	2024-514933-39-00--DCC-3014-01-001	Phase 1		VIC	2017-03-03	2017-02-16		Vimseltinib	CSF1R_inhibitor	Vimseltinib	CSF1R_inhibitor	2024-514933-39-00  DCC-3014-01-001	A Multicenter Phase 1/2, Open-Label Study of DCC-3014 to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor	Tenosynovial Giant Cell Tumor, Diffuse; Pigmented Villonodular Synovitis; Giant Cell Tumor of Tendon Sheath; Tenosynovial Giant Cell Tumor; Advanced Malignant Neoplasm	- Melbourne	https://clinicaltrials.gov/ct2/show/NCT03069469
NCT03072238	IPATential150	Phase 3		NSW, SA, VIC	2017-03-07	2017-06-30		Abiraterone; Abiraterone + Ipatasertib + Prednisolone + Prednisone; Abiraterone + Prednisolone + Prednisone; Ipatasertib; Placebo; Prednisolone; Prednisone	placebo; CYP17A1_inhibitor; glucocorticoid; pan-AKT_inhibitor; CYP17A1_inhibitor + glucocorticoid + pan-AKT_inhibitor; CYP17A1_inhibitor + glucocorticoid	Abiraterone + Ipatasertib + Prednisolone + Prednisone; Abiraterone + Prednisolone + Prednisone; Placebo	CYP17A1_inhibitor + glucocorticoid; CYP17A1_inhibitor + glucocorticoid + pan-AKT_inhibitor; placebo	2016-004429-17  CO39303	A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer	Metastatic Prostate Cancer	3168 - Clayton; 3128 - Melbourne; 2109 - Macquarie Park; 3000 - Melbourne; 5037 - Kurralta Park	https://clinicaltrials.gov/ct2/show/NCT03072238
NCT03081494	2017-000466-30--CPDR001I2102	Phase 1		NSW, WA	2017-03-16	2017-06-09		Regorafenib; Regorafenib + Spartalizumab; Spartalizumab	KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + anti-PD-1_monoclonal_antibody; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor; anti-PD-1_monoclonal_antibody	Regorafenib + Spartalizumab	KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + anti-PD-1_monoclonal_antibody	2017-000466-30  CPDR001I2102	Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Microsatellite Stable (MSS) Colorectal Cancer	Metastatic Colorectal Cancer	6150 - Murdoch; 2065 - St Leonards	https://clinicaltrials.gov/ct2/show/NCT03081494
NCT03089645	D6840C00001	Phase 1		NSW, VIC	2017-03-24	2017-03-21		Docetaxel; Docetaxel + Durvalumab + MEDI5083; Durvalumab; Durvalumab + MEDI5083; Durvalumab + MEDI5083 + Tremelimumab; MEDI5083; Tremelimumab	anti-PD-L1_monoclonal_antibody; CD40L-Fc_fusion_protein + anti-PD-L1_monoclonal_antibody + taxane; CD40L-Fc_fusion_protein + anti-CTLA4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; CD40L-Fc_fusion_protein; anti-CTLA4_monoclonal_antibody; anti-CD40_agonistic_antibody + anti-CTLA4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-CD40_agonistic_antibody + anti-PD-L1_monoclonal_antibody; taxane; anti-CD40_agonistic_antibody + anti-PD-L1_monoclonal_antibody + taxane; anti-CD40_agonistic_antibody; CD40L-Fc_fusion_protein + anti-PD-L1_monoclonal_antibody	Docetaxel + Durvalumab + MEDI5083; Durvalumab + MEDI5083; Durvalumab + MEDI5083 + Tremelimumab	CD40L-Fc_fusion_protein + anti-CTLA4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; CD40L-Fc_fusion_protein + anti-PD-L1_monoclonal_antibody; CD40L-Fc_fusion_protein + anti-PD-L1_monoclonal_antibody + taxane; anti-CD40_agonistic_antibody + anti-CTLA4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-CD40_agonistic_antibody + anti-PD-L1_monoclonal_antibody; anti-CD40_agonistic_antibody + anti-PD-L1_monoclonal_antibody + taxane	D6840C00001	A Phase 1 First Time in Human Study to Evaluate the Safety, Pharmacokinetics and Immunogenicity of MEDI5083 Alone or in Combination With Durvalumab, Tremelimumab, and/or Docetaxel in Advanced Solid Tumors	Advanced Solid Tumors	2031 - Randwick; 3000 - Melbourne; 3168 - Clayton; 3004 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT03089645
NCT03093116	TRIDENT-1	Phase 1		NSW, SA, VIC	2017-03-28	2017-03-07		Repotrectinib	ALK_inhibitor,third_generation; ROS1_inhibitor; TRK_inhibitor,second_generation	Repotrectinib	ALK_inhibitor,third_generation; ROS1_inhibitor; TRK_inhibitor,second_generation	CA127-1024  CA127-1024	A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)	Locally Advanced Solid Tumors; Metastatic Solid Tumors	5042 - Adelaide; 3002 - East Melbourne; 3000 - Melbourne; 2050 - Camperdown	https://clinicaltrials.gov/ct2/show/NCT03093116
NCT03093870	TreeTopp	Phase 2/Phase 3		NSW	2017-03-28	2017-07-04		Capecitabine; Capecitabine + Varlitinib; Placebo; Varlitinib	placebo; EGFR/ERBB2_inhibitor + fluoropyrimidine; EGFR/ERBB2_inhibitor; fluoropyrimidine	Capecitabine; Capecitabine + Varlitinib; Placebo	EGFR/ERBB2_inhibitor + fluoropyrimidine; fluoropyrimidine; placebo	ASLAN001-009	A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Varlitinib Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Advanced or Metastatic Biliary Tract Cancer as Second Line Systemic Therapy	Biliary Tract Cancer	- Camperdown	https://clinicaltrials.gov/ct2/show/NCT03093870
NCT03098030	DIV-SCLC-301	Phase 2/Phase 3		NSW, QLD, SA, VIC	2017-03-31	2017-06-01		Dinutuximab; Dinutuximab + Irinotecan; Irinotecan; Topotecan	anti-GD2_monoclonal_antibody + topoisomerase_inhibitor; anti-GD2_monoclonal_antibody; topoisomerase_inhibitor	Dinutuximab + Irinotecan; Irinotecan; Topotecan	anti-GD2_monoclonal_antibody + topoisomerase_inhibitor; topoisomerase_inhibitor	DIV-SCLC-301	A Two-part, Open-label, Randomized, Phase 2/3 Study of Dinutuximab and Irinotecan Versus Irinotecan for Second Line Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer	Small Cell Lung Cancer	QLD 4101 - South Brisbane; 3350 - Ballarat; NSW 2450 - Coffs Harbour; 5000 - Adelaide	https://clinicaltrials.gov/ct2/show/NCT03098030
NCT03098550	2017-000367-33--CA209-9GW	Phase 1/Phase 2		NSW	2017-03-31	2017-06-15		Daratumumab; Daratumumab + Nivolumab; Nivolumab	anti-CD38_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-CD38_monoclonal_antibody	Daratumumab + Nivolumab; Nivolumab	anti-CD38_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody	2017-000367-33  CA209-9GW	Phase 1/2 Study to Evaluate the Safety and Preliminary Efficacy of Nivolumab Combined With Daratumumab in Participants With Advanced or Metastatic Solid Tumors	Advanced Cancer	2065 - St Leonards	https://clinicaltrials.gov/ct2/show/NCT03098550
NCT03101280	2016-002610-47--WO39409	Phase 1		VIC	2017-04-05	2017-04-27		Atezolizumab; Atezolizumab + Rucaparib; Rucaparib	PARP_inhibitor + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; PARP_inhibitor	Atezolizumab + Rucaparib	PARP_inhibitor + anti-PD-L1_monoclonal_antibody	2016-002610-47  WO39409	A Phase IB Combination Study of Rucaparib (CO-338) and Atezolizumab (MPDL3280A) in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast Cancer	Gynecologic Neoplasms	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT03101280
NCT03102320	ARCS-Multi	Phase 1		NSW, SA, VIC, WA	2017-04-05	2017-05-26		Anetumab Ravtansine; Anetumab Ravtansine + Cisplatin; Anetumab Ravtansine + Gemcitabine; Cisplatin; Gemcitabine	anti-mesothelin_antibody-drug_conjugate; antimetabolite; platinum-based_antineoplastic_agent; gemcitabine; anti-mesothelin_antibody-drug_conjugate + antimetabolite; anti-mesothelin_antibody-drug_conjugate + platinum-based_antineoplastic_agent	Anetumab Ravtansine; Anetumab Ravtansine + Cisplatin; Anetumab Ravtansine + Gemcitabine	anti-mesothelin_antibody-drug_conjugate; anti-mesothelin_antibody-drug_conjugate + antimetabolite; anti-mesothelin_antibody-drug_conjugate + platinum-based_antineoplastic_agent; gemcitabine	2016-004002-33  15834	Phase 1b Multi-indication Study of Anetumab Ravtansine (BAY94-9343) in Patients With Mesothelin Expressing Advanced or Recurrent Malignancies	Neoplasms	2450 - Coffs Harbour; 2148 - Blacktown; 6009 - Nedlands; 5042 - Adelaide; 6008 - Subiaco; 2065 - St Leonards; 2010 - Darlinghurst; 3122 - Richmond	https://clinicaltrials.gov/ct2/show/NCT03102320
NCT03104699	C-700-01	Phase 1		QLD, SA	2017-04-07	2017-04-11		Balstilimab	anti-PD-1_monoclonal_antibody	Balstilimab	anti-PD-1_monoclonal_antibody	C-700-01	A Phase 1 / 2, Open-Label, Multiple Ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN2034 in Subjects With Metastatic or Locally Advanced Solid Tumors, With Expansion to Second Line Cervical Cancer	Cervical Cancer; Advanced Cancer	4217 - Benowa; 5006 - North Adelaide	https://clinicaltrials.gov/ct2/show/NCT03104699
NCT03110107	2017-000597-11--CA022-001	Phase 1		NSW, WA	2017-04-12	2017-05-04		BMS-986218; BMS-986218 + Ipilimumab; BMS-986218 + Nivolumab; Ipilimumab; Nivolumab	anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-CTLA4_monoclonal_antibody	BMS-986218; BMS-986218 + Ipilimumab; BMS-986218 + Nivolumab	anti-CTLA4_monoclonal_antibody; anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	2017-000597-11  CA022-001	Phase 1/2a First-In-Human Study of BMS-986218 Monoclonal Antibody Alone and in Combination With Nivolumab in Advanced Solid Tumors	Advanced Cancer	2065 - Wollstonecraft; 6150 - Murdoch; 2152 - Northmead	https://clinicaltrials.gov/ct2/show/NCT03110107
NCT03124615	EFFECT	Phase 2		NSW	2017-04-24			Enzalutamide	antiandrogen,nonsteroidal,second_generation	Enzalutamide	antiandrogen,nonsteroidal,second_generation	HGMQ201502	Effect of Enzalutamide Dose Reduction on Fatigue, Cognition, and Drug Trough Levels in Patients With Prostate Cancer	Prostate Cancer	2109 - North Ryde	https://clinicaltrials.gov/ct2/show/NCT03124615
NCT03133247	SHR1316-002	Phase 1		WA, West Australi	2017-04-28	2017-06-01		SHR-1316	anti-PD-L1_monoclonal_antibody	SHR-1316	anti-PD-L1_monoclonal_antibody	SHR1316-002	A Phase 1, Open-Label, Multicenter, Non-Randomized, Dose Escalation Study to Evaluate the Safety and Tolerability of SHR-1316 in Subjects With Advanced Solid Tumors	Advanced Solid Tumors	- Perth	https://clinicaltrials.gov/ct2/show/NCT03133247
NCT03138889	PROPEL	Phase 1		VIC	2017-05-03	2017-06-09		Atezolizumab; Atezolizumab + Bempegaldesleukin + Pembrolizumab; Bempegaldesleukin; Bempegaldesleukin + Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed; Bempegaldesleukin + Carboplatin + Nab-paclitaxel + Paclitaxel + Pembrolizumab; Bempegaldesleukin + Pembrolizumab; Carboplatin; Cisplatin; Nab-paclitaxel; Paclitaxel; Pembrolizumab; Pemetrexed	IL-2_variant + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite; IL-2_variant + anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; IL-2_variant + anti-PD-1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; IL-2_variant + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; IL-2_variant; anti-PD-1_monoclonal_antibody; taxane; platinum-based_antineoplastic_agent	Atezolizumab + Bempegaldesleukin + Pembrolizumab; Bempegaldesleukin + Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed; Bempegaldesleukin + Carboplatin + Nab-paclitaxel + Paclitaxel + Pembrolizumab; Bempegaldesleukin + Pembrolizumab	IL-2_variant + anti-PD-1_monoclonal_antibody; IL-2_variant + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; IL-2_variant + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; IL-2_variant + anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane	16-214-05	A Phase 1/2, Open-Label, Multicenter Study to Investigate the Safety and Preliminary Efficacy of Combined Bempegaldesleukin (NKTR-214) and Pembrolizumab With or Without Chemotherapy in Patients With Locally Advanced or Metastatic Solid Tumors	Non-Small Cell Lung Cancer	3121 - Richmond	https://clinicaltrials.gov/ct2/show/NCT03138889
NCT03145909	2016-004597-18--M15-916	Phase 1		NSW, QLD	2017-05-09	2017-07-03		Rolinsatamab Talirine	anti-PRLR_antibody-drug_conjugate	Rolinsatamab Talirine	anti-PRLR_antibody-drug_conjugate	2016-004597-18  M15-916	A Phase 1 Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR)	Advanced Solid Tumors Cancer	4101 - South Brisbane; 2031 - Randwick	https://clinicaltrials.gov/ct2/show/NCT03145909
NCT03146468	NIVALLO	Phase 2		VIC	2017-05-10	2017-05-08		Nivolumab	anti-PD-1_monoclonal_antibody	Nivolumab	anti-PD-1_monoclonal_antibody	RMH 2016.281	Pilot Study of the Tolerability of Nivolumab for Relapsed or Residual Haematological Malignancies After Allogeneic Haematopoietic Stem Cell Transplantation	Haematological Malignancy	3050 - Parkville	https://clinicaltrials.gov/ct2/show/NCT03146468
NCT03157128	LIBRETTO-001	Phase 1		NSW, VIC	2017-05-17	2017-05-02		Selpercatinib	RET-selective_inhibitor	Selpercatinib	RET-selective_inhibitor	J2G-OX-JZJA  17477	A Phase 1/2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)	Medullary Thyroid Cancer; Colon Cancer; Any Solid Tumor; Non-Small Cell Lung Cancer	3000 - Melbourne; 2065 - St Leonards	https://clinicaltrials.gov/ct2/show/NCT03157128
NCT03170960	XL184-021	Phase 1		NSW, VIC	2017-05-31	2017-09-05		Abiraterone; Abiraterone + Apalutamide + Enzalutamide; Abiraterone + Enzalutamide; Apalutamide; Atezolizumab; Atezolizumab + Cabozantinib; Cabozantinib; Cisplatin; Docetaxel; Enzalutamide; Irinotecan; Irinotecan + Oxaliplatin; Oxaliplatin	platinum-based_antineoplastic_agent + topoisomerase_inhibitor; anti-PD-L1_monoclonal_antibody; RET_inhibitor; AXL_inhibitor + anti-PD-L1_monoclonal_antibody; VEGFR2_inhibitor + anti-PD-L1_monoclonal_antibody; RET_inhibitor + anti-PD-L1_monoclonal_antibody; antiandrogen,nonsteroidal,second_generation; MET_inhibitor,type_2 + anti-PD-L1_monoclonal_antibody; KIT_inhibitor + anti-PD-L1_monoclonal_antibody; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation; platinum-based_antineoplastic_agent; ROS1_inhibitor + anti-PD-L1_monoclonal_antibody; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + anti-PD-L1_monoclonal_antibody; CYP17A1_inhibitor; ROS1_inhibitor; AXL_inhibitor; KIT_inhibitor; topoisomerase_inhibitor; VEGFR2_inhibitor; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor; taxane; MET_inhibitor,type_2	Abiraterone + Apalutamide + Enzalutamide; Abiraterone + Enzalutamide; Atezolizumab + Cabozantinib; Cisplatin; Docetaxel; Irinotecan + Oxaliplatin	AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + anti-PD-L1_monoclonal_antibody; AXL_inhibitor + anti-PD-L1_monoclonal_antibody; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation; KIT_inhibitor + anti-PD-L1_monoclonal_antibody; MET_inhibitor,type_2 + anti-PD-L1_monoclonal_antibody; RET_inhibitor + anti-PD-L1_monoclonal_antibody; ROS1_inhibitor + anti-PD-L1_monoclonal_antibody; VEGFR2_inhibitor + anti-PD-L1_monoclonal_antibody; platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent + topoisomerase_inhibitor; taxane	XL184-021	A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors	Hepatocellular Carcinoma; Gastric Cancer; Endometrial Cancer; Triple Negative Breast Cancer; Differentiated Thyroid Cancer; Colorectal Cancer; Non-Small Cell Lung Cancer; Ovarian Cancer; Lower Esophageal Cancer; Head and Neck Cancer; Gastroesophageal Junction Adenocarcinoma; Urothelial Carcinoma; Castration-resistant Prostate Cancer; Renal Cell Carcinoma	2250 - Gosford; 2050 - Camperdown; 2031 - Randwick; 2109 - North Ryde; 2640 - Albury; 3021 - St Albans	https://clinicaltrials.gov/ct2/show/NCT03170960
NCT03173560	2016-002778-11--E7080-G000-218	Phase 2		NSW, SA, VIC, WA	2017-06-02	2017-08-17		Everolimus; Everolimus + Lenvatinib; Lenvatinib	VEGF_inhibitor; VEGF_inhibitor + mTORC1_inhibitor; mTORC1_inhibitor	Everolimus + Lenvatinib	VEGF_inhibitor + mTORC1_inhibitor	2016-002778-11  E7080-G000-218	A Randomized, Open-Label (Formerly Double-Blind), Phase 2 Trial to Assess Safety and Efficacy of Lenvatinib at Two Different Starting Doses (18 mg vs. 14 mg QD) in Combination With Everolimus (5 mg QD) in Renal Cell Carcinoma Following One Prior VEGF-Targeted Treatment	Renal Cell Carcinoma	- Saint Leonards; - Kurralta Park; - Murdoch; - Macquarie Park; - Saint Albans	https://clinicaltrials.gov/ct2/show/NCT03173560
NCT03175224	SPARTA	Phase 2		VIC	2017-06-05	2017-09-27		Vebreltinib	MET_inhibitor,type_1	Vebreltinib	MET_inhibitor,type_1	APL-101-01	Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors	Brain Tumor; Colon Cancer; Thyroid Cancer; HGF; EGFR Gene Mutation; Lung Cancer; Gastroesophageal Junction Adenocarcinoma; Advanced Cancer; Solid Tumors; Exon 14 Skipping; Glioblastoma Multiforme; Renal Cancer; Gastric Cancer; MET Fusion; Pancreatic Cancer; NSCLC; MET Amplification; MET Alteration	- Melbourne	https://clinicaltrials.gov/ct2/show/NCT03175224
NCT03176238	EVEREXES	Phase 3		ACT, NSW, VIC	2017-06-05	2013-03-29		Everolimus; Everolimus + Exemestane; Exemestane	aromatase_inhibitor + mTORC1_inhibitor; aromatase_inhibitor; mTORC1_inhibitor	Everolimus + Exemestane	aromatase_inhibitor + mTORC1_inhibitor	CRAD001JIC06	A Phase IIIb, Multi-center, Open-label Study of RAD001 in Combination With EXemestane in Post-menopausal Women With EStrogen Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Locally Advanced or Metastatic Breast Cancer	Post Menopausal Breast Cancer	2605 - Garran; 3135 - Ringwood East; 2229 - Caringbah; 3084 - Heidelberg; 2170 - Liverpool; 3128 - Box Hill; 3021 - St Albans	https://clinicaltrials.gov/ct2/show/NCT03176238
NCT03176264	2017-000520-96--CPDR001I2101	Phase 1		NSW	2017-06-05	2017-09-25		Bevacizumab; Spartalizumab	anti-VEGF_monoclonal_antibody; anti-PD-1_monoclonal_antibody	Spartalizumab; Bevacizumab	anti-PD-1_monoclonal_antibody; anti-VEGF_monoclonal_antibody	2017-000520-96  CPDR001I2101	ElevatION: CRC-101: A Phase Ib Study of PDR001 in Combination With Bevacizumab and mFOLFOX6 as First Line Therapy in Patients With Metastatic MSS Colorectal Cancer	Metastatic Colorectal Cancer	2065 - St Leonards	https://clinicaltrials.gov/ct2/show/NCT03176264
NCT03177239	UNISoN	Phase 2	STATUS_UNKNOWN	NSW, QLD, SA, VIC, WA	2017-06-06	2017-10-19		Ipilimumab; Ipilimumab + Nivolumab; Nivolumab	anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-CTLA4_monoclonal_antibody	Ipilimumab + Nivolumab	anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	ANZUP 1602	A Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602).	Papillary Renal Cell Carcinoma Type 2; Papillary Renal Cell Carcinoma Type 1; Chromophobe Renal Cell Carcinoma; Sarcomatoid Renal Cell Carcinoma; Renal Cell Carcinoma; Xp11 Translocation Carcinoma	4575 - Birtinya; 5037 - Adelaide; 2298 - Newcastle; 2444 - Port Macquarie; 3128 - Box Hill; 2010 - Darlinghurst; 2050 - Camperdown; 2460 - Albury; 2340 - Tamworth; 5000 - Adelaide; 2031 - Randwick; 4000 - Brisbane; 2086 - Frenchs Forest; 3168 - Clayton; 3355 - Ballarat; 2145 - Westmead; 6150 - Murdoch; 2217 - Kogarah; 2560 - Campbelltown	https://clinicaltrials.gov/ct2/show/NCT03177239
NCT03178851	2016-004402-34--CO39721	Phase 1		NSW, QLD, SA, VIC	2017-06-07	2017-06-20		Atezolizumab; Atezolizumab + Cobimetinib; Cobimetinib	MEK_inhibitor + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; MEK_inhibitor	Atezolizumab + Cobimetinib	MEK_inhibitor + anti-PD-L1_monoclonal_antibody	2016-004402-34  CO39721	A Phase Ib Study Evaluating Cobimetinib Plus Atezolizumab in Patients With Advanced BRAF V600 Wild-Type Melanoma Who Have Progressed During or After Treatment With Anti-PD-1 Therapy and Atezolizumab Monotherapy in Patients With Previously Untreated Advanced BRAF V600 Wild-Type Melanoma	Malignant Melanoma	2060 - North Sydney; 2148 - Blacktown; 3004 - Melbourne; 3000 - Melbourne; 4120 - Greenslopes; 5042 - Bedford Park; 2444 - Port Macquarie	https://clinicaltrials.gov/ct2/show/NCT03178851
NCT03188159	GY01-05-16	Phase 2		VIC	2017-06-15	2017-07-01		Vinorelbine	vinca_alkaloid	Vinorelbine	vinca_alkaloid	GY01/05/16	Phase II Study of Intravenous Vinorelbine in Patients With Relapsed Platinum Resistant or Refractory C5 High Grade Serous, Endometrioid, or Undifferentiated Primary Peritoneum, Fallopian Tube or Ovarian Cancer (VIP)	Ovarian Cancer; Fallopian Tube Cancer	- Melbourne	https://clinicaltrials.gov/ct2/show/NCT03188159
NCT03189719	KEYNOTE-590	Phase 3		NSW, QLD, VIC	2017-06-16	2017-07-25		Cisplatin; Cisplatin + Fluorouracil + Pembrolizumab; Fluorouracil; Pembrolizumab; Placebo	placebo; platinum-based_antineoplastic_agent; Fluorouracil; fluoropyrimidine; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent	Cisplatin + Fluorouracil + Pembrolizumab; Placebo	anti-PD-1_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; Fluorouracil; placebo	173739  3475-590	A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial of Pembrolizumab (MK-3475) in Combination With Cisplatin and 5-Fluorouracil Versus Placebo in Combination With Cisplatin and 5-Fluorouracil as First-Line Treatment in Subjects With Advanced/Metastatic Esophageal Carcinoma (KEYNOTE-590)	Esophageal Neoplasms	3000 - Melbourne; 3128 - Box Hill; 2170 - Liverpool; 2148 - Blacktown; 4102 - Woolloongabba	https://clinicaltrials.gov/ct2/show/NCT03189719
NCT03208959	HTI-1090-101	Phase 1		NSW, QLD	2017-07-06	2017-08-30		HTI-1090	IDO/TDO_inhibitor	HTI-1090	IDO/TDO_inhibitor	HTI-1090-101	A Phase I, Open-Label, Multicenter, Non-Randomized, Dose-Escalation Study to Evaluate the Safety and Tolerability of HTI-1090 in Patients With Advanced Solid Tumors	Advanced Solid Tumors	4101 - South Brisbane	https://clinicaltrials.gov/ct2/show/NCT03208959
NCT03212404	CK-301-101	Phase 1		NSW, NZ, QLD, VIC	2017-07-11	2017-09-20		Cosibelimab	anti-PD-L1_monoclonal_antibody	Cosibelimab	anti-PD-L1_monoclonal_antibody	CK-301-101	A Phase 1, Open-label, Multicenter, Dose-escalation Study of CK-301 Administered Intravenously as a Single Agent to Subjects With Advanced Cancers	Malignant Mesothelioma, Advanced; Merkel Cell Carcinoma; Cutaneous Squamous Cell Carcinoma; Renal Cell Carcinoma; Lung Neoplasms; Non Hodgkin Lymphoma; Head and Neck Cancer; Carcinoma, Small Cell; Urothelial Carcinoma; Endometrial Cancer; Carcinoma, Non-Small-Cell Lung; Melanoma; Classical Hodgkin Lymphoma	3128 - Box Hill; 2500 - Wollongong; 4120 - Greenslopes; 3144 - Malvern; Christchurch; 4101 - South Brisbane; 4102 - Woolloongabba; 4556 - Buderim; 4217 - Benowa	https://clinicaltrials.gov/ct2/show/NCT03212404
NCT03255070	ARX788-1711	Phase 1		NSW, QLD, VIC, WA	2017-08-21	2018-03-20		ARX788	anti-ERBB2_antibody-drug_conjugate	ARX788	anti-ERBB2_antibody-drug_conjugate	ARX788-1711	A Phase 1, Multicenter, Open-label, Multiple Dose-escalation and Expansion Study of ARX788, as Monotherapy in Advanced Solid Tumors With HER2 Expression	Gastric Neoplasm; Solid Tumors; Breast Neoplasms; Solid Tumour	4102 - Woolloongabba; 3199 - Frankston; 2640 - North Sydney; 3168 - Clayton; 4101 - South Brisbane; 6009 - Nedlands; 2640 - East Albury	https://clinicaltrials.gov/ct2/show/NCT03255070
NCT03257267	2017-000350-19--R2810-ONC-1676	Phase 3		NSW, QLD, VIC, WA	2017-08-22	2017-09-05		Cemiplimab	anti-PD-1_monoclonal_antibody	Cemiplimab	anti-PD-1_monoclonal_antibody	2017-000350-19  R2810-ONC-1676	An Open-Label, Randomized, Phase 3 Clinical Trial of REGN2810 Versus Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Carcinoma	Recurrent or Metastatic, Platinum-refractory Cervical Cancer; Squamous Cell Carcinoma (SCC)	4011 - Herston; 2485 - Tweed Heads; 6008 - Subiaco; 6009 - Nedlands; 03000 - Melbourne; 2217 - Kogarah	https://clinicaltrials.gov/ct2/show/NCT03257267
NCT03261011	AK104-101	Phase 1	STATUS_UNKNOWN	VIC, WA	2017-08-24	2017-10-03		Cadonilimab	bispecific_PD-1/CTLA4_antibody	Cadonilimab	bispecific_PD-1/CTLA4_antibody	AK104-101	A Phase 1A/1B Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK104 in Subjects With Advanced Solid Tumors	Advanced Cancer	6009 - Nedlands; 3168 - Clayton; 3084 - Heidelberg; 3002 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT03261011
NCT03280667	KEYPAD	Phase 2		NSW, QLD, SA, VIC, WA	2017-09-12	2017-12-12		Denosumab; Denosumab + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody + anti-RANK_L_monoclonal_antibody; anti-RANK_L_monoclonal_antibody; anti-PD-1_monoclonal_antibody	Denosumab + Pembrolizumab	anti-PD-1_monoclonal_antibody + anti-RANK_L_monoclonal_antibody	20149171  ANZUP1601	Denosumab and Pembrolizumab in Clear Cell Renal Carcinoma: a Phase II Trial (ANZUP 1601)	Metastatic Kidney Cancer; Renal Cell Carcinoma, Clear Cell	- Sydney; 2229 - Sydney; 4814 - Townsville; 2086 - Frenchs Forest; 2640 - Albury; 2010 - Sydney; - Wendouree; 4029 - Herston; - Melbourne; 3128 - Box Hill; - Brisbane; 4575 - Birtinya; - Adelaide; 2298 - Newcastle; 6150 - Perth	https://clinicaltrials.gov/ct2/show/NCT03280667
NCT03281369	2016-004529-17--YO39609	Phase 1		NSW, VIC	2017-09-13	2017-10-13		Atezolizumab; Atezolizumab + Cisplatin + Fluorouracil; Atezolizumab + Cisplatin + Fluorouracil + Tiragolumab; Atezolizumab + Cobimetinib; Atezolizumab + Cobimetinib + Fluorouracil + Leucovorin + Oxaliplatin; Atezolizumab + Cobimetinib + Linagliptin; Atezolizumab + Cobimetinib + Motixafortide; Atezolizumab + Cobimetinib + Paclitaxel + Ramucirumab; Atezolizumab + Cobimetinib + rHuPH20; Cisplatin; Cisplatin + Fluorouracil; Cobimetinib; Fluorouracil; Leucovorin; Linagliptin; Motixafortide; Oxaliplatin; Paclitaxel; Ramucirumab; Tiragolumab; rHuPH20	anti-VEGFR2_monoclonal_antibody; fluoropyrimidine; anti-TIGIT_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; MEK_inhibitor; MEK_inhibitor + anti-PD-L1_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; MEK_inhibitor + anti-PD-L1_monoclonal_antibody + recombinant_human_hyaluronidase; MEK_inhibitor + anti-PD-L1_monoclonal_antibody + anti-VEGFR2_monoclonal_antibody + taxane; folinic_acid; MEK_inhibitor + anti-PD-L1_monoclonal_antibody; MEK_inhibitor + anti-PD-L1_monoclonal_antibody + dipeptidyl_peptidase-4_inhibitor; anti-PD-L1_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; recombinant_human_hyaluronidase; Fluorouracil; taxane; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent; dipeptidyl_peptidase-4_inhibitor; CXCR4_antagonist; fluoropyrimidine + platinum-based_antineoplastic_agent; CXCR4_antagonist + MEK_inhibitor + anti-PD-L1_monoclonal_antibody	Atezolizumab + Cisplatin + Fluorouracil; Atezolizumab + Cisplatin + Fluorouracil + Tiragolumab; Atezolizumab + Cobimetinib; Atezolizumab + Cobimetinib + Fluorouracil + Leucovorin + Oxaliplatin; Atezolizumab + Cobimetinib + Linagliptin; Atezolizumab + Cobimetinib + Motixafortide; Atezolizumab + Cobimetinib + Paclitaxel + Ramucirumab; Atezolizumab + Cobimetinib + rHuPH20; Cisplatin + Fluorouracil	CXCR4_antagonist + MEK_inhibitor + anti-PD-L1_monoclonal_antibody; MEK_inhibitor + anti-PD-L1_monoclonal_antibody; MEK_inhibitor + anti-PD-L1_monoclonal_antibody + anti-VEGFR2_monoclonal_antibody + taxane; MEK_inhibitor + anti-PD-L1_monoclonal_antibody + dipeptidyl_peptidase-4_inhibitor; MEK_inhibitor + anti-PD-L1_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; MEK_inhibitor + anti-PD-L1_monoclonal_antibody + recombinant_human_hyaluronidase; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; fluoropyrimidine + platinum-based_antineoplastic_agent; Fluorouracil	2016-004529-17  YO39609	A Phase Ib/II, Open-Label, Multicenter, Randomized, Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)	Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma	2148 - Blacktown; 3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT03281369
NCT03284424	MK-3475-629--3475-629	Phase 2		NSW, QLD	2017-09-15	2017-10-26		Pembrolizumab	anti-PD-1_monoclonal_antibody	Pembrolizumab	anti-PD-1_monoclonal_antibody	MK-3475-629  3475-629	A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)	Squamous Cell Carcinoma	4029 - Herston; 2500 - Wollongong; 2480 - Lismore; 2800 - Orange; 4814 - Douglas; 4102 - Woolloongabba	https://clinicaltrials.gov/ct2/show/NCT03284424
NCT03284723	2017-002538-22--C0541001	Phase 1		NSW	2017-09-15	2017-11-01		Letrozole; PF-06804103; Palbociclib	aromatase_inhibitor; CDK4/6_inhibitor; anti-ERBB2_antibody-drug_conjugate	PF-06804103; Letrozole; Palbociclib	anti-ERBB2_antibody-drug_conjugate; CDK4/6_inhibitor; aromatase_inhibitor	2017-002538-22  C0541001	A Phase 1 Dose Escalation Study Evaluating the Safety and Tolerability of PF-06804103 in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive and Negative Solid Tumors	Breast Neoplasms	2050 - Camperdown; 2109 - Macquarie University	https://clinicaltrials.gov/ct2/show/NCT03284723
NCT03292172	2017-001147-13--NP39487	Phase 1		NSW, VIC	2017-09-25	2017-11-08		Atezolizumab; Atezolizumab + RO6870810; RO6870810	anti-PD-L1_monoclonal_antibody; BET_inhibitor + anti-PD-L1_monoclonal_antibody; BET_inhibitor	Atezolizumab + RO6870810	BET_inhibitor + anti-PD-L1_monoclonal_antibody	2017-001147-13  NP39487	Open Label, Dose Finding and Expansion Phase IB Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (Pd L1 Antibody) in Pateints With Advanced Ovarian Cancer or Triple Negative Breast Cancer	Advanced Ovarian Cancer; Triple Negative Breast Cancer	2010 - Darlinghurst; 3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT03292172
NCT03294083	JX594-REN026	Phase 1		SA	2017-09-26	2018-06-07		Cemiplimab; Cemiplimab + Pexastimogene Devacirepvec; Pexastimogene Devacirepvec	thymidine_kinase-deleted_oncolytic_vaccinia_virus_expressing_human_GM-CSF; anti-PD-1_monoclonal_antibody + thymidine_kinase-deleted_oncolytic_vaccinia_virus_expressing_human_GM-CSF; anti-PD-1_monoclonal_antibody	Cemiplimab; Cemiplimab + Pexastimogene Devacirepvec; Pexastimogene Devacirepvec	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + thymidine_kinase-deleted_oncolytic_vaccinia_virus_expressing_human_GM-CSF; thymidine_kinase-deleted_oncolytic_vaccinia_virus_expressing_human_GM-CSF	JX594-REN026	A Phase 1b/2a Dose-escalation and Safety/Efficacy Evaluation Study of Pexa-Vec (Thymidine Kinase-Deactivated Vaccinia Virus Plus GM-CSF) in Combination With Cemiplimab (REGN2810; Anti-PD-1) in Patients With Metastatic or Unresectable Renal Cell Carcinoma (RCC)	Renal Cell Carcinoma	SA5042 - Bedford Park	https://clinicaltrials.gov/ct2/show/NCT03294083
NCT03302234	KEYNOTE-598	Phase 3		NSW, QLD, VIC, WA	2017-10-05	2017-12-14		Ipilimumab; Ipilimumab + Pembrolizumab; Pembrolizumab; Placebo	placebo; anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-CTLA4_monoclonal_antibody	Ipilimumab + Pembrolizumab; Pembrolizumab; Placebo	anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; placebo	MK-3475-598  3475-598	A Phase 3, Randomized, Double-Blind Study of Pembrolizumab Plus Ipilimumab vs Pembrolizumab Plus Placebo in Previously Untreated, Stage IV, Metastatic Non-small Cell Lung Cancer Subjects Whose Tumors Are PD-L1 Positive (TPS = 50%) (KEYNOTE-598)	Carcinoma, Non-Small-Cell Lung	6150 - Perth; 2050 - Camperdown; 4101 - South Brisbane; 3065 - Fitzroy; 4814 - Douglas	https://clinicaltrials.gov/ct2/show/NCT03302234
NCT03306394	PRECONNECT	Phase 3		ACT, NSW, SA, VIC, WA	2017-10-11	2016-10-18		Trifluridine/Tipiracil	antimetabolite; Trifluridine; thymidine_phosphorylase_inhibitor; Tipiracil Hydrochloride	Trifluridine/Tipiracil	Tipiracil Hydrochloride; Trifluridine; antimetabolite; thymidine_phosphorylase_inhibitor	2016-002311-18  CL3-95005-004	An Open-label Early Access Phase IIIb Study of Trifluridine / Tipiracil (S 95005/TAS-102) in Patients With a Pretreated Metastatic Colorectal Cancer (PRECONNECT)	Metastatic Colorectal Cancer	3144 - Malvern; 3065 - Fitzroy; 2605 - Garran; 6000 - Perth; SA 5011 - Woodville; NSW 2050 - Camperdown; 4029 - Herston; 2010 - Darlinghurst	https://clinicaltrials.gov/ct2/show/NCT03306394
NCT03319628	XMT-1536-1	Phase 1			2017-10-24	2017-12-12		Upifitamab Rilsodotin	anti-NaPi2b_antibody-drug_conjugate	Upifitamab Rilsodotin	anti-NaPi2b_antibody-drug_conjugate	XMT-1536-1	A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b	Platinum Resistant Ovarian Cancer; Non Small Cell Lung Cancer Metastatic		https://clinicaltrials.gov/ct2/show/NCT03319628
NCT03319940	NCT03319940	Phase 1		NSW	2017-10-24	2017-12-26		Pembrolizumab; Pembrolizumab + Tarlatamab; Tarlatamab	anti-PD-1_monoclonal_antibody + bispecific_T-cell_engager,DLL3-targeting; anti-PD-1_monoclonal_antibody; bispecific_T-cell_engager,DLL3-targeting	Pembrolizumab + Tarlatamab; Tarlatamab	anti-PD-1_monoclonal_antibody + bispecific_T-cell_engager,DLL3-targeting; bispecific_T-cell_engager,DLL3-targeting	20160323	A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of Tarlatamab in Subjects With Small Cell Lung Cancer (DeLLphi-300)	Small Cell Lung Carcinoma	2050 - Camperdown	https://clinicaltrials.gov/ct2/show/NCT03319940
NCT03322540	KEYNOTE-654-05-ECHO-305-05	Phase 2		VIC, WA	2017-10-26	2017-12-15		Epacadostat; Epacadostat + Pembrolizumab; Pembrolizumab; Placebo	placebo; IDO1_inhibitor; anti-PD-1_monoclonal_antibody; IDO1_inhibitor + anti-PD-1_monoclonal_antibody	Epacadostat + Pembrolizumab; Pembrolizumab; Placebo	IDO1_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; placebo	KEYNOTE-654-05/ECHO-305-05	A Phase 2, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) Plus Epacadostat (INCB024360) Versus Pembrolizumab Plus Placebo as First-Line Treatment in Patients With Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1	Lung Cancer	6150 - Murdoch; 3084 - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT03322540
NCT03322566	2017-001810-27--KEYNOTE-715-06-ECHO-306-06	Phase 2		(Australia)NSW, NSW, QLD	2017-10-26	2018-01-09		Carboplatin; Carboplatin + Cisplatin + Epacadostat + Paclitaxel + Pembrolizumab + Pemetrexed; Cisplatin; Epacadostat; Epacadostat + Pembrolizumab; Paclitaxel; Pembrolizumab; Pemetrexed; Placebo	placebo; antimetabolite; IDO1_inhibitor; anti-PD-1_monoclonal_antibody; taxane; IDO1_inhibitor + anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; IDO1_inhibitor + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane	Carboplatin + Cisplatin + Epacadostat + Paclitaxel + Pembrolizumab + Pemetrexed; Epacadostat + Pembrolizumab; Placebo	IDO1_inhibitor + anti-PD-1_monoclonal_antibody; IDO1_inhibitor + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; placebo	2017-001810-27  KEYNOTE-715-06/ECHO-306-06	A Randomized Phase 2 Study of the Combination of Pembrolizumab (MK-3475) Plus Epacadostat (INCB024360) With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo as First-Line Treatment in Patients With Metastatic Non-Small Cell Lung Cancer	Lung Cancer	2444 - Port Macquarie; 4870 - Cairns; 2050 - Camperdown; 2500 - Wollongong; 2145 - Westmead; 2148 - Blacktown	https://clinicaltrials.gov/ct2/show/NCT03322566
NCT03326674	CONTESSA	Phase 3		NSW, QLD, SA, VIC, WA	2017-10-31	2017-12-21		Capecitabine; Capecitabine + Tesetaxel; Tesetaxel	fluoropyrimidine + taxane; fluoropyrimidine; taxane	Capecitabine; Capecitabine + Tesetaxel	fluoropyrimidine; fluoropyrimidine + taxane	ODO-TE-B301	A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane	Breast Cancer	- Perth; - Clayton; 2640 - Albury; - Nedlands; - South Brisbane; - Bedford Park; - Woolloongabba; 2076 - Wahroonga; 3199 - Frankston	https://clinicaltrials.gov/ct2/show/NCT03326674
NCT03329846	2017-002499-14--CA017-055	Phase 3		NSW, NZ, QLD, VIC	2017-11-06	2017-11-30		Linrodostat; Linrodostat + Nivolumab; Nivolumab; Placebo	placebo; IDO1_inhibitor; anti-PD-1_monoclonal_antibody; IDO1_inhibitor + anti-PD-1_monoclonal_antibody	Linrodostat + Nivolumab; Nivolumab; Placebo	IDO1_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; placebo	2017-002499-14  CA017-055	A Phase 3, Randomized, Double-blind Study of BMS-986205 Combined With Nivolumab Versus Nivolumab in Participants With Metastatic or Unresectable Melanoma That is Previously Untreated	Skin Cancer; Melanoma	2148 - Blacktown; Wellington; Christchurch; 3004 - Melbourne; 4120 - Woolloongabba; 2146 - North Sydney; 4120 - Greenslopes; 3000 - Melbourne; 3128 - Box Hill	https://clinicaltrials.gov/ct2/show/NCT03329846
NCT03334487	2017-003173-33--M16-292	Phase 3		NSW, QLD, VIC, WA	2017-11-07	2018-03-15		Dexamethasone; Dexamethasone + Rovalpituzumab Tesirine; Rovalpituzumab Tesirine	glucocorticoid; anti-DLL3_antibody-drug_conjugate; anti-DLL3_antibody-drug_conjugate + glucocorticoid	Dexamethasone + Rovalpituzumab Tesirine	anti-DLL3_antibody-drug_conjugate + glucocorticoid	2017-003173-33  M16-292	Open-Label, Single Arm, Phase 3b Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory DLL3 Expressing Small Cell Lung Cancer	Small Cell Lung Cancer	6009 - Nedlands; 4814 - Douglas; 2450 - Coffs Harbour; 3690 - Wodonga; 2485 - Tweed Heads; 3084 - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT03334487
NCT03352531	AK105-101	Phase 1	_STATUS_UNKNOWN	NSW, QLD, SA	2017-11-24	2017-12-22		Penpulimab	anti-PD-1_monoclonal_antibody	Penpulimab	anti-PD-1_monoclonal_antibody	AK105-101	A Phase 1A/1B Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK105 in Subjects With Advanced Solid Tumors	Advanced Cancer	2170 - Liverpool; 5037 - Adelaide; 2010 - Darlinghurst; 2640 - East Albury; 4101 - South Brisbane	https://clinicaltrials.gov/ct2/show/NCT03352531
NCT03353753	INVICTUS	Phase 3		VIC	2017-11-27	2018-02-27		Placebo; Ripretinib	placebo; PDGFRA_inhibitor; KIT_inhibitor,switch_control_kinase_inhibitor	Ripretinib; Placebo	KIT_inhibitor,switch_control_kinase_inhibitor; PDGFRA_inhibitor; placebo	DCC-2618-03-001	A Phase 3, INterVentional, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of DCC-2618 In Patients With AdvanCed Gastrointestinal Stromal TUmorS Who Have Received Treatment With Prior Anticancer Therapies	Gastrointestinal Stromal Tumors	- Melbourne	https://clinicaltrials.gov/ct2/show/NCT03353753
NCT03361865	KEYNOTE-672	Phase 3		NSW, SA, VIC	2017-12-05	2017-12-04		Cisplatin; Epacadostat; Epacadostat + Pembrolizumab; Pembrolizumab; Placebo	placebo; platinum-based_antineoplastic_agent; IDO1_inhibitor; anti-PD-1_monoclonal_antibody; IDO1_inhibitor + anti-PD-1_monoclonal_antibody	Epacadostat + Pembrolizumab; Pembrolizumab; Cisplatin; Placebo	IDO1_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; placebo; platinum-based_antineoplastic_agent	KEYNOTE-672/ECHO-307	A Phase 3 Randomized, Double-Blind Trial of Pembrolizumab (MK-3475) in Combination With Epacadostat (INCB024360) or Placebo in Participants With Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307)	UC (Urothelial Cancer)	2298 - Waratah; 3084 - Heidelberg; 2109 - Macquarie Park; 2500 - Wollongong; 5037 - Kurralta Park	https://clinicaltrials.gov/ct2/show/NCT03361865
NCT03363867	BEACON	Phase 2		VIC	2017-12-06	2018-07-10		Atezolizumab; Atezolizumab + Bevacizumab + Cobimetinib; Bevacizumab; Cobimetinib	anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; MEK_inhibitor + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; MEK_inhibitor	Atezolizumab + Bevacizumab + Cobimetinib	MEK_inhibitor + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody	BEACON	BEACON - A Phase II Study of Bevacizumab, Atezolizumab and Cobimetinib in Patients With Recurrent Platinum Resistant High Grade Serous Ovarian Cancer	Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Carcinoma	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT03363867
NCT03369223	2018-000416-21--CA030-001	Phase 1		NSW, SA, VIC	2017-12-11	2017-12-06		BMS-986249; BMS-986249 + Nivolumab; Ipilimumab; Ipilimumab + Nivolumab; Nivolumab	anti-PD-1_monoclonal_antibody; CTLA4-directed_probody + anti-PD-1_monoclonal_antibody; anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; CTLA4-directed_probody; anti-CTLA4_monoclonal_antibody	BMS-986249; BMS-986249 + Nivolumab; Ipilimumab + Nivolumab; Nivolumab	CTLA4-directed_probody; CTLA4-directed_probody + anti-PD-1_monoclonal_antibody; anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody	2018-000416-21  CA030-001	A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors	Advanced Cancer	2060 - North Sydney; 3199 - Frankston; 3084 - Heidelberg; 5000 - Adelaide	https://clinicaltrials.gov/ct2/show/NCT03369223
NCT03374488	KEYNOTE-698	Phase 3		NSW, SA, VIC	2017-12-15	2017-12-22		Epacadostat; Epacadostat + Pembrolizumab; Pembrolizumab; Placebo	placebo; IDO1_inhibitor; anti-PD-1_monoclonal_antibody; IDO1_inhibitor + anti-PD-1_monoclonal_antibody	Epacadostat + Pembrolizumab; Pembrolizumab; Placebo	IDO1_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; placebo	KEYNOTE-698/ECHO-303	A Phase 3 Randomized, Double-Blind Clinical Study of Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo as a Treatment for Recurrent or Progressive Metastatic Urothelial Carcinoma in Patients Who Have Failed a First-Line Platinum-containing Chemotherapy Regimen for Advanced/Metastatic Disease (KEYNOTE-698/ECHO-303)	UC (Urothelial Cancer)	3084 - Heidelberg; 2500 - Wollongong; 2109 - Macquarie Park; 5037 - Kurralta Park	https://clinicaltrials.gov/ct2/show/NCT03374488
NCT03377491	EF-27	Phase 3		NSW, QLD, VIC, WA	2017-12-19	2018-02-10		Gemcitabine; Gemcitabine + Nab-paclitaxel; Nab-paclitaxel; Paclitaxel	antimetabolite; antimetabolite + taxane; taxane; gemcitabine	Gemcitabine + Nab-paclitaxel	antimetabolite + taxane; gemcitabine	EF-27	Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma	Pancreas Adenocarcinoma	NSW 2076 - Wahroonga; VIC 3168 - Clayton; 6150 - Murdoch; 4120 - Greenslopes; NSW 2145 - Westmead	https://clinicaltrials.gov/ct2/show/NCT03377491
NCT03379259	2018-000265-37--BGB-900-101	Phase 1/Phase 2		NZ, VIC, WA	2017-12-20	2017-11-27		BGB-A333; BGB-A333 + Tislelizumab; Tislelizumab	anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; anti-PD-1_monoclonal_antibody	BGB-A333; BGB-A333 + Tislelizumab	anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody	2018-000265-37  BGB-900-101	Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-PD-L1 Monoclonal Antibody BGB-A333 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors	Advanced Solid Tumors	6009 - Perth; 3004 - Melbourne; 3168 - Clayton	https://clinicaltrials.gov/ct2/show/NCT03379259
NCT03382340	IMX-110-001	Phase 1		NSW, QLD	2017-12-22	2018-02-15		IMX-110	nanoparticle_Stat3/NF-kB/poly-TKI; doxorubicin	IMX-110	doxorubicin; nanoparticle_Stat3/NF-kB/poly-TKI	IMX-110-001	A Phase 1/2a Open-Label, Dose-Escalation/Dose-Expansion Safety, Tolerability and Pharmacokinetic Study of IMX-110 in Patients With Advanced Solid Tumors	Solid Tumor, Adult; Breast Cancer; Ovarian Cancer; Advanced Solid Tumors; Pancreatic Cancer	QLD 4487 - Sydney	https://clinicaltrials.gov/ct2/show/NCT03382340
NCT03386721	2017-003182-94--BP40234	Phase 2		NZ	2017-12-29	2018-02-19		Atezolizumab; Atezolizumab + Docetaxel; Docetaxel; Docetaxel + Gemcitabine + Vinorelbine; Gemcitabine; RO-6874281; Vinorelbine	anti-PD-L1_monoclonal_antibody + taxane; antimetabolite; anti-PD-L1_monoclonal_antibody; taxane; gemcitabine; vinca_alkaloid; anti-FAP/IL-2_fusion_protein; antimetabolite + taxane + vinca_alkaloid	Atezolizumab; Atezolizumab + Docetaxel; Docetaxel; Docetaxel + Gemcitabine + Vinorelbine; RO-6874281	anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + taxane; antimetabolite + taxane + vinca_alkaloid; taxane; anti-FAP/IL-2_fusion_protein; gemcitabine	2017-003182-94  BP40234	An Open-Label, Multicenter, Phase II Study to Evaluate the Therapeutic Activity of Simlukafusp Alfa (RO6874281), an Immunocytokine, Consisting of Interleukin-2 Variant (IL-2v) Targeting Fibroblast Activation Protein-? (FAP), in Combination With Atezolizumab (Anti-PD-L1), Administered Intravenously, in Participants With Advanced and/or Metastatic Solid Tumors	Advanced/Metastatic Head and Neck, Oesophageal and Cervical Cancers	Auckland	https://clinicaltrials.gov/ct2/show/NCT03386721
NCT03390504	THOR	Phase 3		NSW, VIC, WA	2018-01-04	2018-03-23		Docetaxel; Docetaxel + Vinflunine; Erdafitinib; Pembrolizumab; Vinflunine	taxane + vinca_alkaloid; anti-PD-1_monoclonal_antibody; taxane; vinca_alkaloid; pan-FGFR_inhibitor,reversible; pan-FGFR_inhibitor	Docetaxel + Vinflunine; Erdafitinib; Pembrolizumab	anti-PD-1_monoclonal_antibody; pan-FGFR_inhibitor; pan-FGFR_inhibitor,reversible; taxane + vinca_alkaloid	42756493BLC3001  CR108401	A Phase 3 Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Subjects With Advanced Urothelial Cancer and Selected FGFR Gene Aberrations	Urothelial Cancer	3000 - Melbourne; 2050 - Camperdown; 6150 - Murdoch; 2217 - Kogarah; 3199 - Melbourne; 3199 - Frankston	https://clinicaltrials.gov/ct2/show/NCT03390504
NCT03392428	TheraP	Phase 2		NSW, QLD, SA, VIC, WA	2018-01-08	2018-01-29		Cabazitaxel; Lu-177 vipivotide tetraxetan	radioconjugate,PSMA-targeting; taxane	Cabazitaxel; Lu-177 vipivotide tetraxetan	radioconjugate,PSMA-targeting; taxane	ANZUP 1603	TheraP: A Randomised Phase 2 Trial of 177Lu-PSMA617 Theranostic Versus Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer (ANZUP Protocol 1603)	Metastatic Cancer; Cancer of the Prostate	2170 - Liverpool; 2065 - Sydney; 5000 - Adelaide; 2010 - Sydney; 3008 - Melbourne; 2298 - Waratah; 3084 - Melbourne; 4029 - Brisbane; 6009 - Nedlands; 6450 - Murdoch; 3165 - Moorabbin	https://clinicaltrials.gov/ct2/show/NCT03392428
NCT03400332	2023-509061-20--CA027-002	Phase 1		NSW, SA, VIC, WA	2018-01-17	2018-02-12		BMS-986253; BMS-986253 + Ipilimumab + Nivolumab; BMS-986253 + Nivolumab; Ipilimumab; Ipilimumab + Nivolumab; Nivolumab; Placebo	placebo; anti-IL8_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-CTLA4_monoclonal_antibody + anti-IL8_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-IL8_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA4_monoclonal_antibody	BMS-986253 + Ipilimumab + Nivolumab; BMS-986253 + Nivolumab; Ipilimumab + Nivolumab; Placebo	anti-CTLA4_monoclonal_antibody + anti-IL8_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-IL8_monoclonal_antibody + anti-PD-1_monoclonal_antibody; placebo	2023-509061-20  CA027-002	A Phase 1/2 Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers	Melanoma; Cancer	3000 - Melbourne; VIC 3350 - Ballarat Central; 5000 - Adelaide; 3004 - Melbourne; 6009 - Perth; 2065 - Wollstonecraft	https://clinicaltrials.gov/ct2/show/NCT03400332
NCT03410693	FORT-1	Phase 2/Phase 3		NSW, QLD, VIC	2018-01-25	2018-05-31		Rogaratinib	pan-FGFR_inhibitor; FGFR1/2/3_inhibitor,reversible	Rogaratinib	FGFR1/2/3_inhibitor,reversible; pan-FGFR_inhibitor	2016-004340-11  17403	A Randomized, Open Label, Multicenter Phase 2/3 Study to Evaluate the Efficacy and Safety of Rogaratinib (BAY1163877) Compared to Chemotherapy in Patients With FGFR-positive Locally Advanced or Metastatic Urothelial Carcinoma Who Have Received Prior Platinum-containing Chemotherapy	Carcinoma, Transitional Cell	2650 - Wagga Wagga; 2109 - Sydney; 2076 - Wahroonga; 3168 - Clayton; 2065 - St Leonards; 2450 - Coffs Harbour; 4217 - Benowa	https://clinicaltrials.gov/ct2/show/NCT03410693
NCT03411473	C-500-03	Phase 2		NSW, NZ, QLD	2018-01-26	2017-10-04		Pembrolizumab; Pembrolizumab + Zalifrelimab; Zalifrelimab	anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-CTLA4_monoclonal_antibody	Pembrolizumab + Zalifrelimab	anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	C-500-03	A Phase IIa Open-Label Trial of AGEN1884 in Combination With Pembrolizumab in Subjects With Chemotherapy Naïve, PD-L1 High, Metastatic Non-Small Cell Lung Cancer (NSCLC)	NSCLC Stage IV	- Wahroonga; - Brisbane; Auckland; - Sydney; - Tugun	https://clinicaltrials.gov/ct2/show/NCT03411473
NCT03412799	CL-SBP-101-03	Phase 1		NSW, QLD, SA, VIC	2018-01-26	2018-06-04		Gemcitabine; Ivospemin; Nab-paclitaxel	antimetabolite; polyamine_analogue; taxane; gemcitabine	Gemcitabine; Ivospemin; Nab-paclitaxel	antimetabolite; polyamine_analogue; taxane; gemcitabine	CL-SBP-101-03	Phase 1A/1B Dose Escalation and Expansion Study of SBP-101 in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma	Pancreatic Cancer Metastatic; Stage IV Pancreatic Cancer; Pancreatic Cancer Stage IV	5037 - Kurralta Park; 3084 - Heidelberg; 2148 - Blacktown; 4224 - Tugun	https://clinicaltrials.gov/ct2/show/NCT03412799
NCT03414047	I4D-MC-JTJN--16712	Phase 2		NSW, QLD, SA, VIC	2018-01-29	2018-04-10		Prexasertib	CHEK1_inhibitor	Prexasertib	CHEK1_inhibitor	I4D-MC-JTJN  16712	A Phase 2 Study of Prexasertib in Platinum-Resistant or Refractory Recurrent Ovarian Cancer	Ovarian Cancer	5065 - Toorak Gardens; 2145 - Wentworthville; 4101 - South Brisbane; 5042 - Bedford Park; 2139 - Concord; 3000 - Melbourne; 4029 - Herston; 2031 - Randwick	https://clinicaltrials.gov/ct2/show/NCT03414047
NCT03417037	2017-003058-18--CA017-062	Phase 3		NSW, QLD, VIC, WA	2018-01-31			Linrodostat; Linrodostat + Nivolumab; Nivolumab	IDO1_inhibitor; anti-PD-1_monoclonal_antibody; IDO1_inhibitor + anti-PD-1_monoclonal_antibody	Linrodostat + Nivolumab	IDO1_inhibitor + anti-PD-1_monoclonal_antibody	2017-003058-18  CA017-062	A Phase 3 Open Label, Randomized Study of BMS-986205 Combined With Nivolumab With or Without Chemotherapy Versus Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer	Non-Small Cell Lung Cancer; Lung Cancer	4102 - Brisbane; 2010 - Darlinghurst; 6150 - Murdoch; 2340 - North Tamworth; 3004 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT03417037
NCT03419403	2017-003171-64--M16-534	Phase 3		NSW, QLD, VIC	2018-02-05	2018-07-30		Depatuxizumab Mafodotin; Temozolomide	alkylating_agent; anti-EGFR/PBD_antibody-drug_conjugate	Depatuxizumab Mafodotin; Temozolomide	anti-EGFR/PBD_antibody-drug_conjugate; alkylating_agent	2017-003171-64  M16-534	Phase 3b Study for Management of Ocular Side Effects in Subjects With EGFR-amplified Glioblastoma Receiving Depatuxizumab Mafodotin (ABT-414)	Glioblastoma Multiforme	4029 - Herston; 2065 - Saint Leonards; 3084 - Heidelberg; 2298 - Waratah	https://clinicaltrials.gov/ct2/show/NCT03419403
NCT03424005	Morpheus-panBC	Phase 1		VIC, WA	2018-02-06	2018-03-30		Abemaciclib; Abemaciclib + Fulvestrant + Inavolisib; Abemaciclib + Inavolisib + Letrozole; Atezolizumab; Atezolizumab + Bevacizumab + Selicrelumab; Atezolizumab + Carboplatin + Eribulin + Gemcitabine; Atezolizumab + Ipatasertib; Atezolizumab + Ladiratuzumab Vedotin; Atezolizumab + Nab-paclitaxel; Atezolizumab + Nab-paclitaxel + Tocilizumab; Atezolizumab + Sacituzumab Govitecan; Bevacizumab; Capecitabine; Carboplatin; Eribulin; Fulvestrant; Fulvestrant + Inavolisib + Ribociclib; Gemcitabine; Inavolisib; Inavolisib + Letrozole + Ribociclib; Inavolisib + Trastuzumab Deruxtecan; Ipatasertib; Ladiratuzumab Vedotin; Letrozole; Nab-paclitaxel; Ribociclib; Sacituzumab Govitecan; Selicrelumab; Tocilizumab; Trastuzumab Deruxtecan	anti-Trop2_antibody-drug_conjugate; antimetabolite; anti-PD-L1_monoclonal_antibody; CDK4/6_inhibitor + PI3K_alpha_inhibitor + aromatase_inhibitor; selective_estrogen_receptor_degrader; anti-VEGF_monoclonal_antibody; anti-CD40_agonistic_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; macrocyclic_ketone_analogue; PI3K_alpha_inhibitor; platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + pan-AKT_inhibitor; CDK4/6_inhibitor + PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader; anti-LIV1_antibody-drug_conjugate + anti-PD-L1_monoclonal_antibody; CDK4/6_inhibitor; fluoropyrimidine; anti-IL-6_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + taxane; gemcitabine; PI3K_alpha_inhibitor + anti-ERBB2_antibody-drug_conjugate; pan-AKT_inhibitor; anti-ERBB2_antibody-drug_conjugate; anti-PD-L1_monoclonal_antibody + taxane; aromatase_inhibitor; taxane; anti-PD-L1_monoclonal_antibody + antimetabolite + macrocyclic_ketone_analogue + platinum-based_antineoplastic_agent; anti-IL-6_monoclonal_antibody; anti-LIV1_antibody-drug_conjugate; anti-CD40_agonistic_antibody; anti-PD-L1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate	Abemaciclib + Fulvestrant + Inavolisib; Abemaciclib + Inavolisib + Letrozole; Atezolizumab + Bevacizumab + Selicrelumab; Atezolizumab + Carboplatin + Eribulin + Gemcitabine; Atezolizumab + Ipatasertib; Atezolizumab + Ladiratuzumab Vedotin; Atezolizumab + Nab-paclitaxel; Atezolizumab + Nab-paclitaxel + Tocilizumab; Atezolizumab + Sacituzumab Govitecan; Capecitabine; Fulvestrant + Inavolisib + Ribociclib; Inavolisib + Letrozole + Ribociclib; Inavolisib + Trastuzumab Deruxtecan	CDK4/6_inhibitor + PI3K_alpha_inhibitor + aromatase_inhibitor; CDK4/6_inhibitor + PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader; PI3K_alpha_inhibitor + anti-ERBB2_antibody-drug_conjugate; anti-CD40_agonistic_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-IL-6_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + taxane; anti-LIV1_antibody-drug_conjugate + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; anti-PD-L1_monoclonal_antibody + antimetabolite + macrocyclic_ketone_analogue + platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + pan-AKT_inhibitor; anti-PD-L1_monoclonal_antibody + taxane; fluoropyrimidine; gemcitabine	2017-002038-21  CO40115	A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Treatment Combinations In Patients With Metastatic Breast Cancer (Morpheus-panBC)	Metastatic Breast Cancer	6150 - Murdoch; 3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT03424005
NCT03428217	CANTATA	Phase 2		NSW, NZ, QLD, VIC, WA	2018-02-09	2018-05-14		Cabozantinib; Cabozantinib + Telaglenastat; Placebo; Telaglenastat	glutaminase_inhibitor; ROS1_inhibitor + glutaminase_inhibitor; RET_inhibitor; ROS1_inhibitor; AXL_inhibitor; RET_inhibitor + glutaminase_inhibitor; MET_inhibitor,type_2 + glutaminase_inhibitor; KIT_inhibitor; placebo; VEGFR2_inhibitor; KIT_inhibitor + glutaminase_inhibitor; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor; VEGFR2_inhibitor + glutaminase_inhibitor; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + glutaminase_inhibitor; MET_inhibitor,type_2; AXL_inhibitor + glutaminase_inhibitor	Cabozantinib; Cabozantinib + Telaglenastat; Placebo	AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + glutaminase_inhibitor; AXL_inhibitor; AXL_inhibitor + glutaminase_inhibitor; KIT_inhibitor; KIT_inhibitor + glutaminase_inhibitor; MET_inhibitor,type_2; MET_inhibitor,type_2 + glutaminase_inhibitor; RET_inhibitor; RET_inhibitor + glutaminase_inhibitor; ROS1_inhibitor; ROS1_inhibitor + glutaminase_inhibitor; VEGFR2_inhibitor; VEGFR2_inhibitor + glutaminase_inhibitor; placebo	CX-839-008	A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)	Advanced Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma	3199 - Frankston; 4102 - Woolloongabba; 3630 - Shepparton; 4101 - South Brisbane; 3144 - Malvern; 4217 - Benowa; Hamilton; 6009 - Nedlands; Wellington; 2170 - Sydney; 4870 - Cairns; 2050 - Camperdown; 2109 - North Ryde; 3350 - Ballarat; 2576 - Bowral; 2485 - Tweed Heads	https://clinicaltrials.gov/ct2/show/NCT03428217
NCT03434379	IMbrave150	Phase 3		NSW, SA, VIC	2018-02-15	2018-03-15		Atezolizumab; Atezolizumab + Bevacizumab; Bevacizumab; Sorafenib	VEGFR_inhibitor; CRAF_inhibitor; anti-PD-L1_monoclonal_antibody; CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; FLT3_inhibitor; anti-VEGF_monoclonal_antibody; PDGFR_inhibitor; KIT_inhibitor	Atezolizumab + Bevacizumab; Sorafenib	CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor; CRAF_inhibitor; FLT3_inhibitor; KIT_inhibitor; PDGFR_inhibitor; VEGFR_inhibitor; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody	2017-003691-31  YO40245	A Phase III, Open-Label, Randomized Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma	Carcinoma, Hepatocellular	2217 - Kogarah; 2200 - Bankstown; 5011 - Woodville; 3021 - St Albans	https://clinicaltrials.gov/ct2/show/NCT03434379
NCT03441113	2017-004350-42--219627	Phase 2		QLD, SA, VIC, WA	2018-02-22	2018-05-03		Momelotinib	JAK1/JAK2_inhibitor; JAK2_inhibitor	Momelotinib	JAK1/JAK2_inhibitor	2017-004350-42  219627	Extended Access of Momelotinib for Subjects With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)	Post-polycythemia Vera Myelofibrosis (Post-PV MF); Neoplasms; Post-essential Thrombocythemia Myelofibrosis (Post-ET MF); Primary Myelofibrosis (PMF)	3050 - Parkville; 4812 - Hyde Park; 4101 - South Brisbane; 31 99 - Frankston; 3199 - Frankston; 3004 - Melbourne; 5000 - Adelaide; 6160 - Perth; 6000 - Perth	https://clinicaltrials.gov/ct2/show/NCT03441113
NCT03443674	CLO-SCB-313-001	Phase 1		NSW, QLD, SA	2018-02-23	2018-06-18		SCB-313	recombinant_human_TRAIL_trimer_fusion_protein	SCB-313	recombinant_human_TRAIL_trimer_fusion_protein	CLO-SCB-313-001	A Phase I Study Evaluating Safety, Tolerability, and Pharmacokinetics of SCB-313, a Fully-Human TRAIL-Trimer Fusion Protein, for the Treatment of Peritoneal Malignancies	Peritoneal Malignancies	2500 - Wollongong; 2170 - Liverpool; 5042 - Bedford Park; 4224 - Tugun; 2800 - Orange	https://clinicaltrials.gov/ct2/show/NCT03443674
NCT03445533	ILLUMINATE-301	Phase 3		QLD, SA, VIC, WA	2018-02-26	2018-05-30		Ipilimumab; Ipilimumab + Tilsotolimod Sodium; Tilsotolimod Sodium	TLR9_agonist; TLR9_agonist + anti-CTLA4_monoclonal_antibody; anti-CTLA4_monoclonal_antibody	Ipilimumab; Ipilimumab + Tilsotolimod Sodium	TLR9_agonist + anti-CTLA4_monoclonal_antibody; anti-CTLA4_monoclonal_antibody	2125-MEL-301	A Randomized Phase 3 Comparison of IMO-2125 With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301)	Metastatic Melanoma	4120 - Greenslopes; 5011 - Woodville South; 4215 - Southport; 6150 - Murdoch; 4101 - South Brisbane; 3220 - Geelong	https://clinicaltrials.gov/ct2/show/NCT03445533
NCT03450330	JACKPOT1	Phase 1/Phase 2		NSW, VIC	2018-03-01	2018-04-16		AZD4205; Osimertinib	JAK1-selective_inhibitor; EGFR_inhibitor,third_generation	AZD4205; Osimertinib	JAK1-selective_inhibitor; EGFR_inhibitor,third_generation	DZ2017J0001	A Phase I/II, Open-Label, Multicentre Study to Investigate the Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of AZD4205 as Monotherapy or in Combination With Osimertinib in Patients With EGFR Mutant Advanced Stage Non-Small Cell Lung Cancer (NSCLC)	Nonsmall Cell Lung Cancer	- Melbourne; 2066 - Sydney; 3084 - Heidelberg; - Sydney	https://clinicaltrials.gov/ct2/show/NCT03450330
NCT03452137	IMvoke010	Phase 3		NSW, SA, VIC, WA	2018-03-02	2018-04-03		Atezolizumab; Placebo	placebo; anti-PD-L1_monoclonal_antibody	Atezolizumab; Placebo	anti-PD-L1_monoclonal_antibody; placebo	2017-003302-40  WO40242	A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck	Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)	2217 - Kogarah; 6009 - Nedlands; 3051 - North Melbourne; 5037 - Kurralta Park	https://clinicaltrials.gov/ct2/show/NCT03452137
NCT03468426	2017-001378-41--1336-0011	Phase 1		NSW, VIC	2018-03-16	2018-07-05		BI836880; BI836880 + Ezabenlimab; Ezabenlimab	VEGF/Ang2-blocking_nanobody + anti-PD-1_monoclonal_antibody; VEGF/Ang2-blocking_nanobody; anti-PD-1_monoclonal_antibody	BI836880 + Ezabenlimab	VEGF/Ang2-blocking_nanobody + anti-PD-1_monoclonal_antibody	2017-001378-41  1336-0011	An Open Label Phase Ib Dose Finding Study of BI 836880 in Combination With Ezabenlimab to Characterize Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy in Patients With Locally Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer and in Other Solid Tumors	Neoplasms; Non-squamous, Non-Small-Cell Lung Cancer	2145 - Westmead; 3004 - Melbourne; 3199 - Frankston; 2065 - St Leonards	https://clinicaltrials.gov/ct2/show/NCT03468426
NCT03484520	2017-003213-26--M16-183	Phase 1		QLD, TAS, VIC	2018-03-30	2018-07-23		Dinaciclib; Dinaciclib + Venetoclax; Venetoclax	Bcl2_inhibitor + CDK12_inhibitor; Bcl2_inhibitor; Bcl2_inhibitor + CDK1/2/5/9_inhibitor; CDK12_inhibitor; CDK1/2/5/9_inhibitor	Dinaciclib + Venetoclax	Bcl2_inhibitor + CDK1/2/5/9_inhibitor; Bcl2_inhibitor + CDK12_inhibitor	2017-003213-26  M16-183	Phase 1b Study of Venetoclax and Dinaciclib (MK7965) in Patients With Relapsed/Refractory Acute Myeloid Leukemia	Cancer - Acute Myeloid Leukemia	4215 - SouthPort; 3168 - Melbourne; 7000 - Hobart	https://clinicaltrials.gov/ct2/show/NCT03484520
NCT03484923	PLATforM	Phase 2		NSW	2018-04-02	2018-09-10		Capmatinib; Capmatinib + Spartalizumab; Ieramilimab; Ieramilimab + Spartalizumab; Ribociclib; Ribociclib + Spartalizumab; Spartalizumab	anti-LAG3_monoclonal_antibody; CDK4/6_inhibitor + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; CDK4/6_inhibitor; anti-PD-1_monoclonal_antibody; MET_inhibitor,type_1 + anti-PD-1_monoclonal_antibody; MET_inhibitor,type_1	Capmatinib + Spartalizumab; Ieramilimab + Spartalizumab; Ribociclib + Spartalizumab; Spartalizumab	CDK4/6_inhibitor + anti-PD-1_monoclonal_antibody; MET_inhibitor,type_1 + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody	2018-000610-38  CPDR001J2201	A Randomized, Open-label, Phase II Open Platform Study Evaluating the Efficacy and Safety of Novel Spartalizumab (PDR001) Combinations in Previously Treated Unresectable or Metastatic Melanoma	Melanoma	2060 - North Sydney; 2145 - Westmead	https://clinicaltrials.gov/ct2/show/NCT03484923
NCT03486873	MK-3475-587--3475-587	Phase 3		NSW, NZ, QLD, SA, VIC, WA	2018-04-03	2018-08-21		Favezelimab; Favezelimab + Pembrolizumab; Lenvatinib; Lenvatinib + Pembrolizumab; Olaparib; Pembrolizumab	anti-LAG3_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; VEGF_inhibitor; PARP_inhibitor	Favezelimab + Pembrolizumab; Lenvatinib + Pembrolizumab; Olaparib; Pembrolizumab	PARP_inhibitor; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody	MK-3475-587  3475-587	A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants Who Are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab	Solid Tumors; Hematologic Malignancies	2444 - Port Macquarie; 3021 - St Albans; 4101 - Brisbane; 2170 - Liverpool; 4215 - Southport; 5000 - Adelaide; 3084 - Heidelberg; 4120 - Brisbane; 4029 - Herston; 3000 - Melbourne; 2050 - Camperdown; 3168 - Clayton; 4814 - Townsville; 2065 - St Leonards; 5011 - Woodville; 3355 - Wendouree; 4102 - Woolloongabba; 2298 - Waratah; 6008 - Subiaco; Wellington; 3065 - Melbourne; Canterbury; 2065 - Wollstonecraft; 6009 - Nedlands; Auckland; 2145 - Westmead; Waikato; 2060 - North Sydney; 2109 - Macquarie University; 2800 - Orange	https://clinicaltrials.gov/ct2/show/NCT03486873
NCT03495882	C-550-01	Phase 1		NSW, QLD, WA	2018-04-12	2017-12-18		Balstilimab; Balstilimab + Zalifrelimab; Zalifrelimab	anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-CTLA4_monoclonal_antibody	Balstilimab + Zalifrelimab	anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	C-550-01	A Phase 1 / 2, Open-Label, Multi-Arm Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN1884 in Combination With AGEN2034 in Subjects With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors	Cervical Cancer	- Sydney; 6009 - Perth; 4101 - South Brisbane; - South Brisbane	https://clinicaltrials.gov/ct2/show/NCT03495882
NCT03499899	CLAG525B2101	Phase 2		QLD, VIC, WA	2018-04-17	2018-07-02		Carboplatin; Carboplatin + Ieramilimab; Carboplatin + Ieramilimab + Spartalizumab; Ieramilimab; Ieramilimab + Spartalizumab; Spartalizumab	anti-LAG3_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + platinum-based_antineoplastic_agent; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent	Carboplatin + Ieramilimab; Carboplatin + Ieramilimab + Spartalizumab; Ieramilimab + Spartalizumab	anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent; anti-LAG3_monoclonal_antibody + platinum-based_antineoplastic_agent	CLAG525B2101	A Phase II Open-label, Randomized, Three-arm, Multicenter Study of LAG525 Given in Combination With Spartalizumab (PDR001), or With Spartalizumab and Carboplatin, or With Carboplatin, as First or Second Line Therapy in Patients With Advanced Triple-negative Breast Cancer	Triple-negative Breast Cancer	6009 - Nedlands; 4102 - Wooloongabba; 3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT03499899
NCT03504397	Spotlight	Phase 3		NSW, QLD, SA, VIC	2018-04-20	2018-06-21		Fluorouracil; Fluorouracil + Leucovorin + Oxaliplatin + Zolbetuximab; Leucovorin; Oxaliplatin; Placebo; Zolbetuximab	placebo; anti-CLDN18.2_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; Fluorouracil; fluoropyrimidine; platinum-based_antineoplastic_agent; folinic_acid; anti-CLDN18.2_monoclonal_antibody	Fluorouracil + Leucovorin + Oxaliplatin + Zolbetuximab; Placebo	anti-CLDN18.2_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; Fluorouracil; placebo	2017-002567-17  8951-CL-0301	A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus mFOLFOX6 Compared With Placebo Plus mFOLFOX6 as First-line Treatment of Subjects With Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma	Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer; Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer; Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma; Metastatic Gastric Adenocarcinoma or Cancer	4814 - Douglas; 4224 - Tugun; 2217 - Kogarah; 5011 - Adelaide; 3165 - East Bentleigh	https://clinicaltrials.gov/ct2/show/NCT03504397
NCT03505528	Epi-PRIMED	Phase 1		ACT, NSW	2018-04-23	2017-08-17		Nab-paclitaxel; Nab-paclitaxel + Phenelzine; Phenelzine	irreversible_monoamine_oxidase_inhibitor; irreversible_monoamine_oxidase_inhibitor + taxane; taxane	Nab-paclitaxel + Phenelzine	irreversible_monoamine_oxidase_inhibitor + taxane	EpiAxis 001-0716	A Phase Ib Safety and Pharmacokinetics (PK)/ Pharmacodynamics (PD) Study to Determine the Dosage of Abraxane in Combination With Phenelzine Sulfate in Metastatic or Inoperable Locally Advanced Breast Cancer	Metastatic Breast Cancer	2170 - Sydney; 2500 - Wollongong; 260 - Canberra	https://clinicaltrials.gov/ct2/show/NCT03505528
NCT03516981	KEYNOTE-495	Phase 2		NSW, QLD, WA	2018-05-07	2018-10-01		Favezelimab; Favezelimab + Pembrolizumab; Lenvatinib; Lenvatinib + Pembrolizumab; Pembrolizumab; Pembrolizumab + Quavonlimab; Quavonlimab	anti-LAG3_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; VEGF_inhibitor; anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA4_monoclonal_antibody	Favezelimab + Pembrolizumab; Lenvatinib + Pembrolizumab; Pembrolizumab + Quavonlimab	VEGF_inhibitor + anti-PD-1_monoclonal_antibody; anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody	MK-3475-495  3475-495	A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab-(MK-3475, SCH 900475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (KEYNOTE-495; KeyImPaCT)	Advanced Non-Small Cell Lung Cancer	4120 - Brisbane; 6150 - Murdoch; 2148 - Blacktown	https://clinicaltrials.gov/ct2/show/NCT03516981
NCT03517176	U1111-1213-3234--CEND1-001	Phase 1		SA, VIC, WA	2018-05-07	2018-07-31		Certepetide; Certepetide + Gemcitabine + Nab-paclitaxel; Gemcitabine; Nab-paclitaxel; Paclitaxel	antimetabolite; tumor-homing_peptide_iRGD; taxane; gemcitabine; antimetabolite + taxane + tumor-homing_peptide_iRGD	Certepetide + Gemcitabine + Nab-paclitaxel	antimetabolite + taxane + tumor-homing_peptide_iRGD; gemcitabine	U1111-1213-3234  CEND1-001	A Phase 1 Clinical Trial of CEND-1 in Combination With Nabpaclitaxel and Gemcitabine in Metastatic Exocrine Pancreatic Cancer	Pancreatic Ductal Adenocarcinoma; Pancreatic Cancer	5011 - Woodville South; 3004 - Melbourne; 6008 - Subiaco	https://clinicaltrials.gov/ct2/show/NCT03517176
NCT03522064	HiTeCH	Phase 2		NSW	2018-05-11	2018-07-30		Carboplatin; Testosterone Enanthate	testosterone; platinum-based_antineoplastic_agent	Carboplatin; Testosterone Enanthate	platinum-based_antineoplastic_agent; testosterone	HiTECH	High Dose Testosterone + Carboplatin in Men With Advanced Prostate Cancer	Castration-resistant Prostate Cancer; Homologous Recombination Deficiency	2010 - Sydney	https://clinicaltrials.gov/ct2/show/NCT03522064
NCT03523819	CS1002-101	Phase 1		NSW, SA, VIC	2018-05-14	2018-04-26		CS1002; CS1003	anti-PD-1_monoclonal_antibody; anti-CTLA4_monoclonal_antibody	CS1002; CS1003	anti-CTLA4_monoclonal_antibody; anti-PD-1_monoclonal_antibody	CS1002-101	A Phase Ia/Ib, Open-Label, Dose-Escalation, and Dose-Expansion Study of the Anti-CTLA-4 Monoclonal Antibody CS1002 As Monotherapy and in Combination with Anti-PD-1 Monoclonal Antibody CS1003 in Subjects with Advanced Solid Tumors	Solid Tumor, Adult	2010 - Sydney; 3186 - Malvern; 2640 - Albury; 2500 - Wollongong; 5037 - Adelaide; 2800 - Orange; 3128 - Melbourne; 3004 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT03523819
NCT03529526	KN046-AUS-001	Phase 1	STATUS_UNKNOWN	QLD	2018-05-18			KN046	bispecific_PD-L1/CTLA4_antibody	KN046	bispecific_PD-L1/CTLA4_antibody	KN046-AUS-001	An Open-Label, Multi-center, Dose-Escalation Phase I Study to Evaluate Safety, Tolerability, Pharmacokinetics and Immunogenicity of KN046 in Subjects With Advanced Solid Tumors	Advanced Solid Tumors	4125 - Southport	https://clinicaltrials.gov/ct2/show/NCT03529526
NCT03530397	2018-003075-35--D7980C00001	Phase 1		NSW, VIC	2018-05-21	2018-04-24		Carboplatin; Carboplatin + Paclitaxel + Pemetrexed + Volrustomig; Carboplatin + Pembrolizumab + Pemetrexed; Nab-paclitaxel; Paclitaxel; Pembrolizumab; Pemetrexed; Volrustomig	antimetabolite + bispecific_PD-L1/CTLA4_antibody + platinum-based_antineoplastic_agent + taxane; antimetabolite; bispecific_PD-L1/CTLA4_antibody; anti-PD-1_monoclonal_antibody; taxane; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent	Carboplatin + Paclitaxel + Pemetrexed + Volrustomig; Carboplatin + Pembrolizumab + Pemetrexed; Volrustomig; Nab-paclitaxel	anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite + bispecific_PD-L1/CTLA4_antibody + platinum-based_antineoplastic_agent + taxane; bispecific_PD-L1/CTLA4_antibody	2018-003075-35  D7980C00001	A Phase 1, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability Pharmacokinetics Immunogenicity, and Antitumor Activity of MEDI5752 in Subjects With Advanced Solid Tumors.	Selected Advanced Solid Tumors	3004 - Melbourne; 2031 - Randwick; 3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT03530397
NCT03535740	ALTA-2	Phase 2		VIC, WA	2018-05-24	2019-01-31		Alectinib; Brigatinib; Ceritinib	ROS1_inhibitor; ALK/RET_inhibitor; EGFR/FLT3/FER/ROS1/IGF1R_inhibitor; ALK_inhibitor,second_generation; ALK/ROS1/IGF1R_inhibitor	Brigatinib; Alectinib; Ceritinib	ALK_inhibitor,second_generation; EGFR/FLT3/FER/ROS1/IGF1R_inhibitor; ROS1_inhibitor; ALK/RET_inhibitor; ALK/ROS1/IGF1R_inhibitor	2018-000635-27  Brigatinib-2002	Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib	ALK-positive Advanced NSCLC	3065 - Fitzroy; 3199 - Frankston; 6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT03535740
NCT03537482	APG2575-001	Phase 0		VIC	2018-05-25	2018-08-07		Lisaftoclax	Bcl2_inhibitor	Lisaftoclax	Bcl2_inhibitor	APG2575-001	A Phase I Study of Safety, Tolerability, Pharmacokinetic and Pharmacodynamics Property of Orally Administered APG-2575 in Patients With Hematologic Malignancies	Hematologic Malignancies	3121 - Richmond; 3065 - Fitzroy	https://clinicaltrials.gov/ct2/show/NCT03537482
NCT03557619	M16-185	Phase 1		VIC	2018-06-15	2019-07-30		Venetoclax	Bcl2_inhibitor	Venetoclax	Bcl2_inhibitor	M16-185	A Study to Assess the Effect of Venetoclax on the Pharmacokinetics of Ethinyl Estradiol/Levonorgestrel in Female Subjects With Hematologic Malignancies	Hematologic Malignancies	3002 - East Melbourne	https://clinicaltrials.gov/ct2/show/NCT03557619
NCT03564340	2024--510783-23-00--R4018-ONC-1721	Phase 1		NSW, VIC	2018-06-20	2018-05-21		Cemiplimab; Cemiplimab + REGN4018; REGN4018	bispecific_T-cell_engager,MUC16-targeting; anti-PD-1_monoclonal_antibody + bispecific_T-cell_engager,MUC16-targeting; anti-PD-1_monoclonal_antibody	Cemiplimab + REGN4018; REGN4018	anti-PD-1_monoclonal_antibody + bispecific_T-cell_engager,MUC16-targeting; bispecific_T-cell_engager,MUC16-targeting	2024- 510783-23-00  R4018-ONC-1721	A Phase 1/2 Study of REGN4018 (A MUC16xCD3 Bispecific Antibody) Administered Alone or in Combination With Cemiplimab in Patients With Recurrent Ovarian Cancer or Other Recurrent MUC16+ Cancers	Recurrent Fallopian Tube Cancer; Recurrent Endometrial Cancer; Recurrent Primary Peritoneal Cancer; Recurrent Ovarian Cancer	NSW 2031 - Randwick; 3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT03564340
NCT03564691	MK-4830-001--4830-001	Phase 1		NSW, QLD	2018-06-21	2018-07-11		Carboplatin; Carboplatin + MK-4830 + Pembrolizumab + Pemetrexed; Cisplatin; Cisplatin + MK-4830 + Pembrolizumab + Pemetrexed; Lenvatinib; Lenvatinib + MK-4830 + Pembrolizumab; MK-4830; MK-4830 + Paclitaxel + Pembrolizumab; MK-4830 + Pembrolizumab; Paclitaxel; Pembrolizumab; Pemetrexed	antimetabolite; anti-ILT4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody; taxane; VEGF_inhibitor; platinum-based_antineoplastic_agent; anti-ILT4_monoclonal_antibody; anti-ILT4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + taxane; VEGF_inhibitor + anti-ILT4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-ILT4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	Carboplatin + MK-4830 + Pembrolizumab + Pemetrexed; Cisplatin + MK-4830 + Pembrolizumab + Pemetrexed; Lenvatinib + MK-4830 + Pembrolizumab; MK-4830; MK-4830 + Paclitaxel + Pembrolizumab; MK-4830 + Pembrolizumab	VEGF_inhibitor + anti-ILT4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-ILT4_monoclonal_antibody; anti-ILT4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-ILT4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-ILT4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + taxane	MK-4830-001  4830-001	A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab for Participants With Advanced Solid Tumors	Neoplasms	4102 - Brisbane; 2170 - Liverpool	https://clinicaltrials.gov/ct2/show/NCT03564691
NCT03588650	HLX20	Phase 1		NSW, QLD, SA, VIC	2018-07-17	2018-08-07		HLX20	anti-PD-1_monoclonal_antibody	HLX20	anti-PD-1_monoclonal_antibody	HLX20-001	A Phase 1 Study of HLX20, a Human Monoclonal Antibody Targeting Programmed Death Ligand 1 (PD-L1) Protein in Patients With Advanced Solid Tumors	Advanced Solid Tumors	4215 - Southport; 3144 - Melbourne; 2109 - Darlinghurst; 2010 - Darlinghurst; 5000 - Adelaide; 4000 - Brisbane	https://clinicaltrials.gov/ct2/show/NCT03588650
NCT03595059	2020-002495-12--M16-573	Phase 1		NSW, VIC	2018-07-23	2018-07-13		Docetaxel; Docetaxel + Mirzotamab clezutoclax + Paclitaxel; Mirzotamab clezutoclax; Mirzotamab clezutoclax + Paclitaxel; Paclitaxel	anti-B7H3_antibody-drug_conjugate + taxane; anti-B7H3_antibody-drug_conjugate; taxane	Docetaxel + Mirzotamab clezutoclax + Paclitaxel; Mirzotamab clezutoclax; Mirzotamab clezutoclax + Paclitaxel	anti-B7H3_antibody-drug_conjugate; anti-B7H3_antibody-drug_conjugate + taxane	2020-002495-12  M16-573	A Phase 1 First-in-Human Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors	Advanced Solid Tumors	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT03595059
NCT03599713	INCMGA-0012-201	Phase 2		NSW	2018-07-26	2019-02-25		Retifanlimab	anti-PD-1_monoclonal_antibody	Retifanlimab	anti-PD-1_monoclonal_antibody	INCMGA 0012-201	A Phase 2 Study of INCMGA00012 in Participants With Metastatic Merkel Cell Carcinoma (POD1UM-201)	Metastatic Merkel Cell Carcinoma	02010 - Darlinghurst	https://clinicaltrials.gov/ct2/show/NCT03599713
NCT03600883	NCT03600883	Phase 1		NSW, QLD, SA, VIC	2018-07-26	2018-08-27		Midazolam; Midazolam + Sotorasib; Sotorasib	KRAS_G12C_inhibitor + benzodiazepam; KRAS_G12C_inhibitor; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + benzodiazepam; benzodiazepam; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor	Midazolam + Sotorasib; Sotorasib	KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + benzodiazepam; KRAS_G12C_inhibitor; KRAS_G12C_inhibitor + benzodiazepam	20170543	A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Sotorasib (AMG 510) Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and Sotorasib (AMG 510) Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreaK 100)	KRAS p.G12C Mutant Advanced Solid Tumors	2031 - Randwick; 5011 - Woodville South; 3050 - Parkville; 4102 - Woolloongabba	https://clinicaltrials.gov/ct2/show/NCT03600883
NCT03603184	AtTEnd	Phase 3		NSW, NZ, QLD, SA, TAS, VIC	2018-07-27	2018-10-02		Atezolizumab; Atezolizumab + Carboplatin + Paclitaxel; Carboplatin; Carboplatin + Paclitaxel; Paclitaxel; Placebo	placebo; anti-PD-L1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; platinum-based_antineoplastic_agent + taxane; anti-PD-L1_monoclonal_antibody; taxane; platinum-based_antineoplastic_agent	Atezolizumab + Carboplatin + Paclitaxel; Carboplatin + Paclitaxel; Placebo	anti-PD-L1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; platinum-based_antineoplastic_agent + taxane; placebo	IRFMN-EN-7556	Phase III Double-blind Randomized Placebo Controlled Trial of Atezolizumab in Combination With Paclitaxel and Carboplatin in Women With Advanced/Recurrent Endometrial Cancer	Endometrial Cancer	Auckland; - Box Hill; - Hobart; - Frankston; - Liverpool; - Gosford; - Toowoomba; - Waratah; - Herston; - Wollongong; - Benowa; - Albury; - Auchenflower; - Saint Leonards; - Adelaide	https://clinicaltrials.gov/ct2/show/NCT03603184
NCT03611556	D6070C00005--D6070C00005	Phase 1		NSW, VIC	2018-08-02	2018-06-21		Durvalumab; Durvalumab + Fluorouracil + Leucovorin + Oleclumab + Oxaliplatin; Durvalumab + Gemcitabine + Nab-paclitaxel + Oleclumab; Fluorouracil; Gemcitabine; Gemcitabine + Nab-paclitaxel; Gemcitabine + Nab-paclitaxel + Oleclumab; Leucovorin; Nab-paclitaxel; Oleclumab; Oxaliplatin	antimetabolite; fluoropyrimidine; anti-PD-L1_monoclonal_antibody; anti-CD73_monoclonal_antibody + antimetabolite + taxane; gemcitabine; folinic_acid; anti-CD73_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; antimetabolite + taxane; anti-CD73_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + antimetabolite + taxane; Fluorouracil; taxane; anti-CD73_monoclonal_antibody; platinum-based_antineoplastic_agent	Durvalumab + Fluorouracil + Leucovorin + Oleclumab + Oxaliplatin; Durvalumab + Gemcitabine + Nab-paclitaxel + Oleclumab; Gemcitabine + Nab-paclitaxel; Gemcitabine + Nab-paclitaxel + Oleclumab	anti-CD73_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + antimetabolite + taxane; anti-CD73_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; anti-CD73_monoclonal_antibody + antimetabolite + taxane; antimetabolite + taxane; Fluorouracil; gemcitabine	D6070C00005  D6070C00005	A Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of Oleclumab (MEDI9447) With or Without Durvalumab in Combination With Chemotherapy in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma	Metastatic Pancreatic Adenocarcinoma; Carcinoma	3084 - Heidelberg; 2065 - St Leonards; 3168 - Clayton; 2148 - Blacktown	https://clinicaltrials.gov/ct2/show/NCT03611556
NCT03615326	KEYNOTE-811	Phase 3		NSW, NZ, VIC	2018-08-03	2018-10-05		Capecitabine; Cisplatin; Fluorouracil; Oxaliplatin; Oxaliplatin + Pembrolizumab + Tegafur-gimeracil-oteracil potassium + Trastuzumab; Pembrolizumab; Pembrolizumab + Trastuzumab; Placebo; Tegafur-gimeracil-oteracil potassium; Trastuzumab	antimetabolite; anti-ERBB2_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-ERBB2_monoclonal_antibody; fluoropyrimidine; placebo; Fluorouracil; DPD_inhibitor + anti-ERBB2_monoclonal_antibody + anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent; orotate_phosphoribosyltransferase_inhibitor; DPD_inhibitor; anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; anti-ERBB2_monoclonal_antibody + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-ERBB2_monoclonal_antibody + anti-PD-1_monoclonal_antibody + orotate_phosphoribosyltransferase_inhibitor + platinum-based_antineoplastic_agent	Oxaliplatin + Pembrolizumab + Tegafur-gimeracil-oteracil potassium + Trastuzumab; Pembrolizumab + Trastuzumab; Capecitabine; Cisplatin; Fluorouracil; Placebo	DPD_inhibitor + anti-ERBB2_monoclonal_antibody + anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent; anti-ERBB2_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-ERBB2_monoclonal_antibody + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-ERBB2_monoclonal_antibody + anti-PD-1_monoclonal_antibody + orotate_phosphoribosyltransferase_inhibitor + platinum-based_antineoplastic_agent; Fluorouracil; fluoropyrimidine; placebo	MK-3475-811  3475-811	A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab Plus Chemotherapy and Placebo as First-line Treatment in Participants With HER2 Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (KEYNOTE 811)	Gastric Neoplasms; Gastroesophageal Junction Adenocarcinoma	2170 - Liverpool; 2500 - Wollongong; 3168 - Clayton; Auckland; 2145 - Westmead	https://clinicaltrials.gov/ct2/show/NCT03615326
NCT03625323	TACTI-002	Phase 2			2018-08-10	2019-02-18		Eftilagimod Alpha; Pembrolizumab	anti-PD-1_monoclonal_antibody; T-cell_immunostimulatory_factor	Eftilagimod Alpha; Pembrolizumab	T-cell_immunostimulatory_factor; anti-PD-1_monoclonal_antibody	Keynote-MK-3475-798  TACTI-002	TACTI-002 (Two ACTive Immunotherapeutics): A Multicenter, Open Label, Phase II Study in Patients With Previously Untreated Unresectable or Metastatic Non-small Cell Lung Cancer (NSCLC), or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic Squamous Head and Neck Cancer (HNSCC) Receiving the Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) in Combination With Pembrolizumab (PD-1 Antagonist)	HNSCC; NSCLC		https://clinicaltrials.gov/ct2/show/NCT03625323
NCT03626545	CANOPY-2	Phase 3		QLD, VIC	2018-08-13	2019-01-23		Canakinumab; Canakinumab + Docetaxel; Docetaxel; Placebo	placebo; anti-IL-1beta_monoclonal_antibody; anti-IL-1beta_monoclonal_antibody + taxane; taxane	Canakinumab + Docetaxel; Docetaxel; Placebo	anti-IL-1beta_monoclonal_antibody + taxane; taxane; placebo	2018-002480-26  CACZ885V2301	A Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Canakinumab in Combination With Docetaxel Versus Placebo in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancer (NSCLC) Previously Treated With PD-(L)1 Inhibitors and Platinum-based Chemotherapy (CANOPY 2)	Non-Small-Cell Lung	3630 - Shepparton; 4120 - Greenslopes	https://clinicaltrials.gov/ct2/show/NCT03626545
NCT03628677	AB154CSP0001	Phase 1		NSW, QLD, VIC	2018-08-14	2018-09-12		Domvanalimab; Domvanalimab + Zimberelimab; Zimberelimab	anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody	Domvanalimab; Domvanalimab + Zimberelimab	anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-TIGIT_monoclonal_antibody	AB154CSP0001	A Phase 1 Study to Evaluate the Safety and Tolerability of AB154 Monotherapy and Combination Therapy in Participants With Advanced Malignancies	Solid Tumor, Unspecified, Adult	2486 - Tweed Heads; 2010 - Darlinghurst; 3084 - Heidelberg; 4101 - South Brisbane	https://clinicaltrials.gov/ct2/show/NCT03628677
NCT03635567	KEYNOTE-826	Phase 3		NSW, QLD, SA, VIC, WA	2018-08-17	2018-10-25		Bevacizumab; Bevacizumab + Carboplatin + Cisplatin + Paclitaxel; Bevacizumab + Carboplatin + Cisplatin + Paclitaxel + Pembrolizumab; Carboplatin; Cisplatin; Paclitaxel; Pembrolizumab; Placebo	placebo; anti-PD-1_monoclonal_antibody; taxane; platinum-based_antineoplastic_agent; anti-VEGF_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; anti-VEGF_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane	Bevacizumab + Carboplatin + Cisplatin + Paclitaxel; Bevacizumab + Carboplatin + Cisplatin + Paclitaxel + Pembrolizumab; Placebo	anti-PD-1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; anti-VEGF_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; placebo	MK-3475-826  3475-826	A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer (KEYNOTE-826)	Cervical Cancer	4101 - South Brisbane; 2065 - St Leonards; 3168 - Clayton; 6008 - Subiaco; 5042 - Bedford Park	https://clinicaltrials.gov/ct2/show/NCT03635567
NCT03635983	2018-001423-40--CA045-001	Phase 3		NSW, NZ, QLD, SA, VIC, WA	2018-08-17	2018-09-21		Bempegaldesleukin; Bempegaldesleukin + Nivolumab; Nivolumab	IL-2_variant; IL-2_variant + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody	Bempegaldesleukin + Nivolumab; Nivolumab	IL-2_variant + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody	2018-001423-40  CA045-001	A Phase 3, Randomized, Open-label Study of NKTR-214 Combined With Nivolumab Versus Nivolumab in Participants With Previously Untreated Unresectable or Metastatic Melanoma	Melanoma	4120 - Greenslopes; 5112 - Elizabeth Vale; 3000 - Melbourne; 4870 - Cairns; 6009 - Nedlands; Auckland; Wellington; 2450 - Coffs Harbour; 2060 - North Sydney; Christchurch; 4102 - Woolloongabba; 3004 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT03635983
NCT03642132	2017-004456-30--B9991030	Phase 3		VIC	2018-08-22	2018-07-19		Avelumab; Avelumab + Talazoparib; Bevacizumab; Talazoparib	anti-VEGF_monoclonal_antibody; PARP_inhibitor + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; PARP_inhibitor	Avelumab + Talazoparib; Bevacizumab; Talazoparib	PARP_inhibitor; PARP_inhibitor + anti-PD-L1_monoclonal_antibody; anti-VEGF_monoclonal_antibody	2017-004456-30  B9991030	A RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AVELUMAB IN COMBINATION WITH CHEMOTHERAPY FOLLOWED BY MAINTENANCE THERAPY OF AVELUMAB IN COMBINATION WITH THE POLY (ADENOSINE DIPHOSPHATE [ADP]-RIBOSE) POLYMERASE (PARP) INHIBITOR TALAZOPARIB IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED OVARIAN CANCER (JAVELIN OVARIAN PARP100)	Ovarian Cancer	3002 - East Melbourne; 3121 - Richmond	https://clinicaltrials.gov/ct2/show/NCT03642132
NCT03655613	APOLLO	Phase 1		NSW, NZ, New South WhalesSA, SA, VIC, WA	2018-08-31	2018-09-05		APL-501; APL-501 + Vebreltinib; Nivolumab; Nivolumab + Vebreltinib; Vebreltinib	MET_inhibitor,type_1 + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; MET_inhibitor,type_1	APL-501 + Vebreltinib; Nivolumab + Vebreltinib	MET_inhibitor,type_1 + anti-PD-1_monoclonal_antibody	APOLLO	A Phase 1/2 Dose Escalation and Expansion Study of Combination APL-501 or Nivolumab With APL-101 in Locally Advanced or Metastatic Hepatocellular and Renal Cell Carcinoma	Renal Cell Carcinoma; Hepatocellular Carcinoma	3021 - Saint Albans; Auckland; 2145 - Westmead; 6150 - Murdoch; 2640 - Albury; 5037 - Adelaide; 6018 - Perth; 3050 - Melbourne; 2109 - Sydney	https://clinicaltrials.gov/ct2/show/NCT03655613
NCT03662659	2018-001069-18--CA224-060	Phase 2		NSW, QLD, SA, VIC, WA	2018-09-07	2018-10-16		BMS-986213; Nivolumab; Relatlimab	anti-LAG3_monoclonal_antibody; anti-PD-1_monoclonal_antibody	BMS-986213; Nivolumab; Relatlimab	anti-LAG3_monoclonal_antibody; anti-PD-1_monoclonal_antibody	2018-001069-18  CA224-060	A Randomized, Open-label, Phase II Clinical Trial of Relatlimab (Anti-LAG-3) and Nivolumab in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy as First-Line Treatment in Patients With Gastric or Gastroesophageal Junction Adenocarcinoma	Gastric Cancer; Esophagogastric Junction; Cancer of the Stomach	3630 - Shepparton; 3144 - Malvern; 6150 - Murdoch; 2145 - Westmead; 5024 - Bedford Park; 3084 - Heidelberg; 4029 - Herston	https://clinicaltrials.gov/ct2/show/NCT03662659
NCT03665597	KEYNOTE-555	Phase 1		NSW, QLD, SA, VIC	2018-09-11	2018-11-19		Pembrolizumab	anti-PD-1_monoclonal_antibody	Pembrolizumab	anti-PD-1_monoclonal_antibody	MK-3475-555  3475-555	A Phase 1 Randomized Clinical Study of Pembrolizumab (MK-3475) to Evaluate the Relative Bioavailability of Subcutaneous Injection Versus Intravenous Infusion in Participants With Advanced Melanoma (KEYNOTE-555)	Melanoma	2298 - Waratah; 2800 - Orange; 2444 - Port Macquarie; 4870 - Cairns; 3350 - Ballarat; 5000 - Adelaide	https://clinicaltrials.gov/ct2/show/NCT03665597
NCT03668119	CheckMate-848	Phase 2		NSW, QLD	2018-09-12	2018-10-31		Ipilimumab; Ipilimumab + Nivolumab; Nivolumab	anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-CTLA4_monoclonal_antibody	Ipilimumab + Nivolumab; Nivolumab	anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody	2016-002898-35  CA209-848	A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination With Ipilimumab or Nivolumab Monotherapy in Participants With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)	Pan Tumor	2010 - Sydney; 4102 - Woolloongabba; 2065 - St Leonards	https://clinicaltrials.gov/ct2/show/NCT03668119
NCT03682068	NILE	Phase 3		NSW, QLD, SA, VIC, WA	2018-09-24	2018-09-27		Carboplatin; Cisplatin; Durvalumab; Durvalumab + Tremelimumab; Gemcitabine; Tremelimumab	antimetabolite; anti-PD-L1_monoclonal_antibody; platinum-based_antineoplastic_agent; anti-CTLA4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-CTLA4_monoclonal_antibody	Durvalumab; Durvalumab + Tremelimumab; Carboplatin; Cisplatin; Gemcitabine	anti-CTLA4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; antimetabolite; platinum-based_antineoplastic_agent	2018-001883-48  D933SC00001	A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination With Standard of Care Chemotherapy and Durvalumab in Combination With Tremelimumab and Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone in Patients With Unresectable Locally Advanced or Metastatic Urothelial Cancer.	Unresectable Locally Advanced Urothelial Cancer; Metastatic Urothelial Cancer	4101 - South Brisbane; 2217 - Kogarah; 2109 - Macquarie University; 2800 - Orange; 6150 - Murdoch; 3128 - Box Hill; 3021 - St Albans; 5112 - Elizabeth Vale	https://clinicaltrials.gov/ct2/show/NCT03682068
NCT03685448	UNICAB	Phase 2		NSW, QLD, SA, VIC	2018-09-26	2019-04-11		Cabozantinib	VEGFR2_inhibitor; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor; RET_inhibitor; ROS1_inhibitor; AXL_inhibitor; MET_inhibitor,type_2; KIT_inhibitor	Cabozantinib	AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor; AXL_inhibitor; KIT_inhibitor; MET_inhibitor,type_2; RET_inhibitor; ROS1_inhibitor; VEGFR2_inhibitor	ANZUP1802	A Phase II of Single Agent Cabozantinib in Patients With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma Post Immunotherapy or Who Are Unsuitable for Immunotherapy (ANZUP1802)	Renal Cell Carcinoma; Xp11.2 Translocation-Related Renal Cell Carcinoma; Sarcomatoid Renal Cell Carcinoma; Chromophobe Renal Cell Carcinoma; Papillary Renal Cell Carcinoma Type 1; Papillary Renal Cell Carcinoma Type 2	2560 - Campbelltown; 3630 - Shepparton; - Kogarah; - Herston; 2109 - Macquarie Park; 2460 - Albury; 3128 - Box Hill; 5037 - Kurralta Park; - Newcastle; 5042 - Bedford Park; - Clayton	https://clinicaltrials.gov/ct2/show/NCT03685448
NCT03693612	NCT03693612	Phase 1/Phase 2		VIC	2018-10-03	2018-11-26		Cetuximab; Cetuximab + Docetaxel + Paclitaxel; Docetaxel; Feladilimab; Feladilimab + Tremelimumab; GSK3359609; Paclitaxel; Tremelimumab	anti-ICOS_agonistic_antibody; taxane; anti-CTLA4_monoclonal_antibody + anti-ICOS_agonistic_antibody; anti-EGFR_monoclonal_antibody; anti-EGFR_monoclonal_antibody + taxane; anti-CTLA4_monoclonal_antibody	Cetuximab + Docetaxel + Paclitaxel; Feladilimab + Tremelimumab; GSK3359609	anti-CTLA4_monoclonal_antibody + anti-ICOS_agonistic_antibody; anti-EGFR_monoclonal_antibody + taxane	207871	A Phase I/II, Open-label, Two Part Study of GSK3359609 in Combination With Tremelimumab in Participants With Selected, Advanced Solid Tumors	Neoplasms	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT03693612
NCT03703466	I3Y-MC-JPCP--17041	Phase 2		NSW, SA, VIC	2018-10-12	2018-11-28		Abemaciclib	CDK4/6_inhibitor	Abemaciclib	CDK4/6_inhibitor	I3Y-MC-JPCP  17041	An Open-Label, Randomized Phase 2 Study of the Impact of Food on Tolerability When Receiving Abemaciclib for Patients With Previously Treated Hormone Receptor-Positive, HER2-Negative, Metastatic Breast Cancer	Metastatic Breast Cancer	3000 - Melbourne; 2010 - Sydney; 2291 - North Sydney; 5037 - Kurralta Park	https://clinicaltrials.gov/ct2/show/NCT03703466
NCT03704077	2018-001070-20--CA224-061	Phase 2		NSW, SA, VIC, WA	2018-10-12			BMS-986213; Nivolumab; Nivolumab + Paclitaxel; Nivolumab + Paclitaxel + Relatlimab; Nivolumab + Relatlimab; Paclitaxel; Paclitaxel + Ramucirumab; Ramucirumab; Relatlimab	anti-VEGFR2_monoclonal_antibody + taxane; anti-LAG3_monoclonal_antibody; anti-VEGFR2_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; taxane; anti-PD-1_monoclonal_antibody + taxane; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody + taxane	Nivolumab; Nivolumab + Paclitaxel; Nivolumab + Paclitaxel + Relatlimab; Nivolumab + Relatlimab; Paclitaxel + Ramucirumab; BMS-986213	anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody + taxane; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + taxane; anti-VEGFR2_monoclonal_antibody + taxane	2018-001070-20  CA224-061	A Randomized, Active-Controlled, Open-Label, Phase 2 Clinical Trial of BMS-986213, in Combination With Various Standard-of-Care Therapeutic Regimens, in Participants With Recurrent, Locally Advanced, or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction (GEJ) Adenocarcinoma	Gastroesophageal Junction; Stomach Cancer; Cancer of the Stomach; Gastric Cancer	3144 - Malvern; 6150 - Murdoch; 2145 - Westmead; 5024 - Bedford Park; 3000 - Melbourne; 3084 - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT03704077
NCT03706365	CYCLONE-2	Phase 2		NSW, VIC	2018-10-16	2018-11-26		Abemaciclib; Abemaciclib + Abiraterone + Prednisone; Abiraterone; Abiraterone + Prednisone; Placebo; Prednisone	placebo; CYP17A1_inhibitor; CDK4/6_inhibitor; glucocorticoid; CDK4/6_inhibitor + CYP17A1_inhibitor + glucocorticoid; CYP17A1_inhibitor + glucocorticoid	Abemaciclib + Abiraterone + Prednisone; Abiraterone + Prednisone; Placebo	CDK4/6_inhibitor + CYP17A1_inhibitor + glucocorticoid; CYP17A1_inhibitor + glucocorticoid; placebo	I3Y-MC-JPCM  16598	A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib in Patients With Metastatic Castration-Resistant Prostate Cancer	Prostate Cancer	2031 - Randwick; 3000 - Melbourne; 2050 - Camperdown; 2228 - Kogarah; 3065 - Melbourne; 2109 - Macquarie University	https://clinicaltrials.gov/ct2/show/NCT03706365
NCT03708328	2018-000982-35--NP40435	Phase 1		NZ	2018-10-17	2018-10-15		RO7121661	bispecific_PD-1/TIM3_antibody	RO7121661	bispecific_PD-1/TIM3_antibody	2018-000982-35  NP40435	An Open Label, Multicenter, Dose Escalation and Expansion, Phase 1 Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-Tumor Activity of RO7121661, a PD-1/TIM-3 Bispecific Antibody, in Patients With Advanced and/or Metastatic Solid Tumors	Small Cell Lung Cancer (SCLC); Esophageal Squamous Cell Carcinoma (ESCC); Metastatic Melanoma; Solid Tumors; Non-small Cell Lung Cancer (NSCLC)	Auckland	https://clinicaltrials.gov/ct2/show/NCT03708328
NCT03710876	INFINITE	Phase 3		NSW, VIC	2018-10-18	2019-01-21		Celecoxib; Celecoxib + Gemcitabine; Celecoxib + Gemcitabine + Nadofaragene Firadenovec; Gemcitabine; Nadofaragene Firadenovec	adenovirus-delivered_interferon_alpha-2b; COX2_inhibitor; antimetabolite; COX2_inhibitor + antimetabolite; gemcitabine; COX2_inhibitor + adenovirus-delivered_interferon_alpha-2b + antimetabolite	Celecoxib + Gemcitabine; Celecoxib + Gemcitabine + Nadofaragene Firadenovec	COX2_inhibitor + adenovirus-delivered_interferon_alpha-2b + antimetabolite; COX2_inhibitor + antimetabolite; gemcitabine	2017-003169-82  rAd-IFN-MM-301	A Phase 3, Open-Label, Randomized, Parallel Group Study to Evaluate the Efficacy and Safety of Intrapleural Administration of Adenovirus-Delivered Interferon Alpha-2b (rAd-IFN) in Combination With Celecoxib and Gemcitabine in Patients With Malignant Pleural Mesothelioma	Malignant Pleural Mesothelioma	2050 - Camperdown; 3168 - Clayton	https://clinicaltrials.gov/ct2/show/NCT03710876
NCT03713593	LEAP-002	Phase 3		NSW, NZ, QLD, VIC	2018-10-22	2018-12-31		Dexamethasone; Lenvatinib; Lenvatinib + Pembrolizumab; Pembrolizumab; Placebo	placebo; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; VEGF_inhibitor; glucocorticoid; anti-PD-1_monoclonal_antibody	Lenvatinib; Lenvatinib + Pembrolizumab; Dexamethasone; Placebo	VEGF_inhibitor; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; glucocorticoid; placebo	MK-7902-002  7902-002	A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib in First-line Therapy of Participants With Advanced Hepatocellular Carcinoma (LEAP-002)	Carcinoma, Hepatocellular	2170 - Liverpool; 2050 - Camperdown; 3168 - Clayton; 4102 - Wooloongabba; 3065 - Fitzroy; Christchurch; Auckland	https://clinicaltrials.gov/ct2/show/NCT03713593
NCT03719326	AB928CSP0002	Phase 1		NSW, QLD, VIC	2018-10-25	2018-10-15		Etrumadenant; IPI-549; Nab-paclitaxel; Pegylated liposomal doxorubicin	PI3K-gamma_inhibitor; anthracycline; adenosine_A2aR_and_A2bR_antagonist; taxane	Etrumadenant; IPI-549; Nab-paclitaxel; Pegylated liposomal doxorubicin	PI3K-gamma_inhibitor; adenosine_A2aR_and_A2bR_antagonist; anthracycline; taxane	AB928CSP0002	A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Breast or Gynecologic Malignancies	Ovarian Cancer; TNBC - Triple-Negative Breast Cancer	2217 - Kogarah; 4217 - Benowa; 3199 - Frankston; 3144 - Malvern; 2050 - Camperdown; 2010 - Darlinghurst; 2109 - Macquarie	https://clinicaltrials.gov/ct2/show/NCT03719326
NCT03719690	AIM-HN-SEQ-HN	Phase 2		NSW, VIC	2018-10-25	2019-03-15		Tipifarnib	farnesyltransferase_inhibitor	Tipifarnib	farnesyltransferase_inhibitor	KO-TIP-007	A 2 Cohort, Non-comparative, Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC) With HRAS Mutations (AIM-HN) and the Impact of HRAS Mutations on Response to First Line Systemic Therapies for HNSCC (SEQ-HN)	HRAS Gene Mutation; HNSCC	3000 - Melbourne; 2065 - Saint Leonards	https://clinicaltrials.gov/ct2/show/NCT03719690
NCT03722342	PMC-TTAC-0001-04	Phase 1		VIC, WA	2018-10-26	2019-01-16		Olinvacimab; Olinvacimab + Pembrolizumab; Pembrolizumab	anti-VEGFR2_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-VEGFR2_monoclonal_antibody; anti-PD-1_monoclonal_antibody	Olinvacimab + Pembrolizumab	anti-PD-1_monoclonal_antibody + anti-VEGFR2_monoclonal_antibody	PMC_TTAC-0001_04	A Phase 1b, Open-Label, Safety and Tolerability Study of TTAC-0001 in Combination With Pembrolizumab in Patients With Recurrent Glioblastoma	Recurrent Glioblastoma	3084 - Heidelberg; 6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT03722342
NCT03739710	2018-001316-29--205801	Phase 2			2018-11-14	2019-01-24		Docetaxel; Docetaxel + Feladilimab; Dostarlimab; Feladilimab; Feladilimab + Ipilimumab; Ipilimumab	anti-ICOS_agonistic_antibody + taxane; anti-ICOS_agonistic_antibody; anti-PD-1_monoclonal_antibody; taxane; anti-CTLA4_monoclonal_antibody + anti-ICOS_agonistic_antibody; anti-CTLA4_monoclonal_antibody	Docetaxel; Docetaxel + Feladilimab; Dostarlimab; Feladilimab + Ipilimumab	anti-CTLA4_monoclonal_antibody + anti-ICOS_agonistic_antibody; anti-ICOS_agonistic_antibody + taxane; anti-PD-1_monoclonal_antibody; taxane	2018-001316-29  205801	A Phase II, Randomized, Open-label Platform Trial Utilizing a Master Protocol to Study Novel Regimens Versus Standard of Care Treatment in NSCLC Participants	Neoplasms		https://clinicaltrials.gov/ct2/show/NCT03739710
NCT03740165	ENGOT-ov43--7339-001	Phase 3		NSW, QLD, VIC	2018-11-14	2018-12-18		Bevacizumab; Bevacizumab + Carboplatin + Docetaxel + Olaparib + Paclitaxel + Pembrolizumab; Carboplatin; Docetaxel; Olaparib; Paclitaxel; Pembrolizumab; Placebo	placebo; PARP_inhibitor + anti-PD-1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; anti-PD-1_monoclonal_antibody; taxane; platinum-based_antineoplastic_agent; anti-VEGF_monoclonal_antibody; PARP_inhibitor	Bevacizumab + Carboplatin + Docetaxel + Olaparib + Paclitaxel + Pembrolizumab; Placebo	PARP_inhibitor + anti-PD-1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; placebo	ENGOT-ov43  7339-001	A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (KEYLYNK-001 / ENGOT-ov43 / GOG-3036)	Peritoneal Neoplasms; Fallopian Tube Cancer; Ovarian Cancer	3350 - Ballarat; 3021 - St Albans; 4870 - Cairns; 2217 - Kogarah; 3168 - Clayton	https://clinicaltrials.gov/ct2/show/NCT03740165
NCT03742349	2018-002244-82--CADPT01A12101C	Phase 1		NSW	2018-11-15	2019-01-31		Canakinumab; Canakinumab + Ieramilimab + Spartalizumab; Capmatinib; Capmatinib + Ieramilimab + Spartalizumab; Ieramilimab; Ieramilimab + Lacnotuzumab + Spartalizumab; Ieramilimab + NIR178 + Spartalizumab; Lacnotuzumab; NIR178; Spartalizumab	anti-LAG3_monoclonal_antibody; MET_inhibitor,type_1 + anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; adenosine_A2A_receptor_antagonist + anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CSF1_monoclonal_antibody + anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; adenosine_A2A_receptor_antagonist; anti-IL-1beta_monoclonal_antibody; anti-IL-1beta_monoclonal_antibody + anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; MET_inhibitor,type_1; anti-CSF1_monoclonal_antibody	Canakinumab + Ieramilimab + Spartalizumab; Capmatinib + Ieramilimab + Spartalizumab; Ieramilimab + Lacnotuzumab + Spartalizumab; Ieramilimab + NIR178 + Spartalizumab	MET_inhibitor,type_1 + anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; adenosine_A2A_receptor_antagonist + anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CSF1_monoclonal_antibody + anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-IL-1beta_monoclonal_antibody + anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody	2018-002244-82  CADPT01A12101C	A Phase Ib, Multicenter, Open-label Dose Escalation and Expansion Platform Study of Select Immunotherapy Combinations in Adult Patients With Triple-negative Breast Cancer	Triple Negative Breast Cancer (TNBC)	2145 - Westmead	https://clinicaltrials.gov/ct2/show/NCT03742349
NCT03742895	MK-7339-002--7339-002	Phase 2		NSW, WA	2018-11-15	2018-12-12		Olaparib	PARP_inhibitor	Olaparib	PARP_inhibitor	MK-7339-002  7339-002	A Phase 2 Study of Olaparib Monotherapy in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer	Advanced Solid Neoplasms	2444 - Port Macquarie; 2010 - Darlinghurst; 6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT03742895
NCT03743064	2018-002927-40--ANAM-17-21	Phase 3		QLD, SA, VIC	2018-11-15	2019-05-06		Anamorelin; Placebo	placebo; GHSR_agonist	Anamorelin; Placebo	GHSR_agonist; placebo	2018-002927-40  ANAM-17-21	A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)	Cancer; Non Small Cell Lung Cancer; Cachexia	3065 - Fitzroy; 3050 - Parkville; 4215 - Southport; 5042 - Bedford Park; 3215 - North Geelong; 5112 - Elizabeth Vale	https://clinicaltrials.gov/ct2/show/NCT03743064
NCT03746431	FPX-01-01	Phase 1		SA, VIC	2018-11-19	2019-01-17		FPI-1175; FPI-1547	IGF1R-radionucleotide_conjugate	FPI-1175; FPI-1547	IGF1R-radionucleotide_conjugate	FPX-01-01	A Phase 1/2 Study of [225Ac]-FPI-1434 Injection in Patients With Locally Advanced or Metastatic Solid Tumours	HER2-negative Breast Cancer; Cervical Cancer; Endometrial Cancer; Head and Neck Squamous Cell Carcinoma (HNSCC); Uveal Melanoma; Advanced Solid Tumours; Ovarian Cancer; Triple Negative Breast Cancer (TNBC); Breast Cancer; Adrenocortical Carcinoma	5000 - Adelaide; 3084 - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT03746431
NCT03748134	2020-000533-40--CIBI308A301	Phase 3		NSW, SA, VIC, WA	2018-11-20	2018-12-24		Cisplatin; Cisplatin + Paclitaxel; Cisplatin + Paclitaxel + Sintilimab; Fluorouracil; Paclitaxel; Placebo; Sintilimab	placebo; Fluorouracil; platinum-based_antineoplastic_agent + taxane; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; fluoropyrimidine; anti-PD-1_monoclonal_antibody; taxane; platinum-based_antineoplastic_agent	Cisplatin + Paclitaxel; Cisplatin + Paclitaxel + Sintilimab; Sintilimab; Fluorouracil; Placebo	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; platinum-based_antineoplastic_agent + taxane; Fluorouracil; fluoropyrimidine; placebo	2020-000533-40  CIBI308A301	A Multicenter, Double-Blind, Randomized Phase 3 Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo, in Combination With Chemotherapy, for First-Line Treatment of Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)	Esophageal Squamous Cell Carcinoma	5011 - Woodville South; 2640 - East Albury; 6008 - Subiaco; 3079 - Heidelberg; 6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT03748134
NCT03750786	AGENT	Phase 3		NSW, VIC	2018-11-23	2018-12-18		Arfolitixorin; Arfolitixorin + Bevacizumab + Fluorouracil + Oxaliplatin; Bevacizumab; Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin; Fluorouracil; Leucovorin; Oxaliplatin	Fluorouracil; fluoropyrimidine; anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent; folinic_acid; anti-VEGF_monoclonal_antibody; anti-VEGF_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent + reduced_folate-based_biomodulator; reduced_folate-based_biomodulator	Arfolitixorin + Bevacizumab + Fluorouracil + Oxaliplatin; Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin	anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; anti-VEGF_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent + reduced_folate-based_biomodulator; Fluorouracil	ISO-CC-007	A Randomized, Multicenter, Parallel-group, Phase III Study to Compare the Efficacy of Arfolitixorin Versus Leucovorin in Combination With 5 Fluorouracil, Oxaliplatin, and Bevacizumab in Patients With Advanced Colorectal Cancer	Colo-rectal Cancer	3021 - Melbourne; 3076 - Melbourne; 2500 - Wollongong; 2640 - Albury; 2145 - Sydney; 3199 - Frankston; 2050 - Sydney; 3168 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT03750786
NCT03763422	IWOT	Phase 3		Brisbane, NSW, QLD, QLDNSW, SA, TAS, VIC, WA, West-Australi	2018-12-04	2020-03-16		Radiotherapy; Radiotherapy + Temozolomide; Temozolomide	radiotherapy; alkylating_agent; alkylating_agent + radiotherapy	Radiotherapy + Temozolomide	alkylating_agent + radiotherapy	EORTC-BTG-1635	IDH Mutated 1p/19q Intact Lower Grade Glioma Following Resection: Wait Or Treat? IWOT - a Phase III Study	Wait or Treat; Temozolomide; Low-grade Glioma; Phase III	2031 - Randwick - Sydney; 6009 - Nedlands; 2145 - Westmead; 3065 - Fitzroy (Melbourne); 7000 - Hobart; 3168 - Clayton; 4102 - Woolloongabba; 2500 - Wollongong; 5000 - Adelaide; 3084 - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT03763422
NCT03773302	2018-004004-19--QBGJ398-301	Phase 3		NSW, SA, VIC, WA	2018-12-12	2019-12-27		Cisplatin; Cisplatin + Gemcitabine + Infigratinib; Gemcitabine; Infigratinib	antimetabolite; platinum-based_antineoplastic_agent; FGFR1/2/3_inhibitor,reversible + antimetabolite + platinum-based_antineoplastic_agent; FGFR1/2/3_inhibitor,reversible; FGFR1/2/3_inhibitor + antimetabolite + platinum-based_antineoplastic_agent; gemcitabine; FGFR1/2/3_inhibitor	Cisplatin + Gemcitabine + Infigratinib; Infigratinib	FGFR1/2/3_inhibitor; FGFR1/2/3_inhibitor + antimetabolite + platinum-based_antineoplastic_agent; FGFR1/2/3_inhibitor,reversible; FGFR1/2/3_inhibitor,reversible + antimetabolite + platinum-based_antineoplastic_agent; gemcitabine	2018-004004-19  QBGJ398-301	A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib Versus Gemcitabine With Cisplatin in Subjects With Advanced/Metastatic or Inoperable Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations: The PROOF Trial	Advanced Cholangiocarcinoma; FGFR2 Gene Mutation	- Frankston; - Darlinghurst; - Bentleigh East; - Camperdown; - Adelaide; - Subiaco	https://clinicaltrials.gov/ct2/show/NCT03773302
NCT03776136	LEAP-004	Phase 2		NSW, QLD, VIC, WA	2018-12-14	2019-01-30		Lenvatinib; Lenvatinib + Pembrolizumab; Pembrolizumab	VEGF_inhibitor + anti-PD-1_monoclonal_antibody; VEGF_inhibitor; anti-PD-1_monoclonal_antibody	Lenvatinib + Pembrolizumab	VEGF_inhibitor + anti-PD-1_monoclonal_antibody	MK-7902-004  7902-004	A Multicenter, Open-label, Phase 2 Trial to Assess the Efficacy and Safety of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Melanoma Previously Exposed to an Anti-PD-1/L1 Agent (LEAP-004)	Advanced Melanoma	2480 - Lismore; 6150 - Perth; 3128 - Box Hill; 4102 - Woolloongabba; 2065 - Wollstonecraft	https://clinicaltrials.gov/ct2/show/NCT03776136
NCT03778957	EMERALD-1	Phase 3		NSW, QLD, VIC	2018-12-19	2018-11-30		Bevacizumab; Bevacizumab + Durvalumab; Durvalumab; Placebo	placebo; anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody	Bevacizumab + Durvalumab; Durvalumab; Placebo	anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; placebo	2023-509053-32-00  D933GC00001	A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination With Either Durvalumab Monotherapy or Durvalumab Plus Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma (EMERALD-1)	Hepatocellular Carcinoma	2170 - Liverpool; 3128 - Box Hill; 2050 - Camperdown; 4029 - Herston; 3004 - Melbourne; 3168 - Clayton; 4217 - Benowa	https://clinicaltrials.gov/ct2/show/NCT03778957
NCT03783078	KEYNOTE-913	Phase 3		NSW, NZ	2018-12-20	2019-02-25		Pembrolizumab	anti-PD-1_monoclonal_antibody	Pembrolizumab	anti-PD-1_monoclonal_antibody	MK-3475-913  3475-913	A Phase 3 Open-label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) as First Line Therapy in Participants With Advanced Merkel Cell Carcinoma (KEYNOTE-913)	Merkel Cell Carcinoma	2065 - North Sydney; 2298 - Waratah; Auckland	https://clinicaltrials.gov/ct2/show/NCT03783078
NCT03783403	U1111-1224-8251--CC-95251-ST-001	Phase 1		VIC	2018-12-21	2019-03-01		CC-95251; CC-95251 + Cetuximab; CC-95251 + Rituximab; Cetuximab; Rituximab	anti-EGFR_monoclonal_antibody; anti-CD20_monoclonal_antibody; anti-SIRPa_monoclonal_antibody; anti-EGFR_monoclonal_antibody + anti-SIRPa_monoclonal_antibody; anti-CD20_monoclonal_antibody + anti-SIRPa_monoclonal_antibody	CC-95251; CC-95251 + Cetuximab; CC-95251 + Rituximab	anti-CD20_monoclonal_antibody + anti-SIRPa_monoclonal_antibody; anti-EGFR_monoclonal_antibody + anti-SIRPa_monoclonal_antibody; anti-SIRPa_monoclonal_antibody	U1111-1224-8251  CC-95251-ST-001	A Phase 1, Open-label, Dose Finding Study of CC-95251, a Monoclonal Antibody Directed Against SIRPa, Alone and in Combination With Cetuximab or Rituximab in Subjects With Advanced Solid and Hematologic Cancers	Neoplasms	3000 - Melbourne; 3084 - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT03783403
NCT03783442	2018-000587-28--BGB-A317-306	Phase 3		NSW, VIC	2018-12-21	2018-12-11		Capecitabine; Cisplatin; Fluorouracil; Oxaliplatin; Paclitaxel; Placebo; Tislelizumab	placebo; Fluorouracil; fluoropyrimidine; anti-PD-1_monoclonal_antibody; taxane; platinum-based_antineoplastic_agent	Tislelizumab; Capecitabine; Cisplatin; Fluorouracil; Oxaliplatin; Paclitaxel; Placebo	anti-PD-1_monoclonal_antibody; Fluorouracil; fluoropyrimidine; placebo; platinum-based_antineoplastic_agent; taxane	2018-000587-28  BGB-A317-306	A Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Efficacy and Safety of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First-Line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma	Esophageal Squamous Cell Carcinoma (ESCC)	2450 - Coffs Harbour; 3065 - Fitzroy	https://clinicaltrials.gov/ct2/show/NCT03783442
NCT03787602	KRT-232-103	Phase 1		QLD	2018-12-26	2019-03-19		Avelumab; Avelumab + Navtemadlin; Navtemadlin	MDM2_inhibitor + anti-PD-L1_monoclonal_antibody; MDM2_inhibitor; anti-PD-L1_monoclonal_antibody	Avelumab + Navtemadlin; Navtemadlin	MDM2_inhibitor; MDM2_inhibitor + anti-PD-L1_monoclonal_antibody	KRT-232-103	A Phase 1b/2, Open-Label Study Evaluating the Safety and Efficacy of KRT-232 in Patients With p53 Wild-Type (p53WT) Merkel Cell Carcinoma (MCC) Who Have Failed Anti-PD-1 or Anti-PD-L1 Immunotherapy, or in Combination With Avelumab in MCC Patients Who Are Anti-PD-1 or Anti-PD-L1 Treatment Naïve	Merkel Cell Carcinoma	- Woolloongabba	https://clinicaltrials.gov/ct2/show/NCT03787602
NCT03798626	2018-003952-19--CVPM087A2101	Phase 1		VIC	2019-01-10	2019-05-22		Bevacizumab; Bevacizumab + Gevokizumab; Cabozantinib; Cabozantinib + Gevokizumab; Gevokizumab; Gevokizumab + Paclitaxel + Ramucirumab; Paclitaxel; Ramucirumab	anti-VEGFR2_monoclonal_antibody; ROS1_inhibitor + anti-IL-1beta_monoclonal_antibody; RET_inhibitor; anti-IL-1beta_monoclonal_antibody; ROS1_inhibitor; AXL_inhibitor + anti-IL-1beta_monoclonal_antibody; AXL_inhibitor; anti-VEGF_monoclonal_antibody; RET_inhibitor + anti-IL-1beta_monoclonal_antibody; anti-IL-1beta_monoclonal_antibody + anti-VEGFR2_monoclonal_antibody + taxane; KIT_inhibitor; VEGFR2_inhibitor + anti-IL-1beta_monoclonal_antibody; VEGFR2_inhibitor; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor; taxane; anti-IL-1beta_monoclonal_antibody + anti-VEGF_monoclonal_antibody; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + anti-IL-1beta_monoclonal_antibody; MET_inhibitor,type_2 + anti-IL-1beta_monoclonal_antibody; MET_inhibitor,type_2; KIT_inhibitor + anti-IL-1beta_monoclonal_antibody	Bevacizumab + Gevokizumab; Cabozantinib + Gevokizumab; Gevokizumab + Paclitaxel + Ramucirumab	AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + anti-IL-1beta_monoclonal_antibody; AXL_inhibitor + anti-IL-1beta_monoclonal_antibody; KIT_inhibitor + anti-IL-1beta_monoclonal_antibody; MET_inhibitor,type_2 + anti-IL-1beta_monoclonal_antibody; RET_inhibitor + anti-IL-1beta_monoclonal_antibody; ROS1_inhibitor + anti-IL-1beta_monoclonal_antibody; VEGFR2_inhibitor + anti-IL-1beta_monoclonal_antibody; anti-IL-1beta_monoclonal_antibody + anti-VEGFR2_monoclonal_antibody + taxane; anti-IL-1beta_monoclonal_antibody + anti-VEGF_monoclonal_antibody	2018-003952-19  CVPM087A2101	Phase Ib Study of Gevokizumab in Combination With Standard of Care Anti-cancer Therapies in Patients With Metastatic Colorectal Cancer, Gastroesophageal Cancer and Renal Cell Carcinoma	Colorectal Cancer; Renal Cell Carcinoma; Gastroesophageal Cancer	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT03798626
NCT03815058	IMCODE001	Phase 2		NSW, SA, VIC, WA	2019-01-24	2019-01-08		Autogene cevumeran; Autogene cevumeran + Pembrolizumab; Pembrolizumab	mRNA_personalised_cancer_vaccine; anti-PD-1_monoclonal_antibody + mRNA_personalised_cancer_vaccine; anti-PD-1_monoclonal_antibody	Autogene cevumeran + Pembrolizumab	anti-PD-1_monoclonal_antibody + mRNA_personalised_cancer_vaccine	2018-001773-24  GO40558	A Phase II, Open-Label, Multicenter, Randomized Study of the Efficacy and Safety of RO7198457 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Previously Untreated Advanced Melanoma	Advanced Melanoma	3000 - Melbourne; 2170 - Liverpool; 3181 - Melbourne; 5011 - Woodville South; 6008 - Subiaco	https://clinicaltrials.gov/ct2/show/NCT03815058
NCT03815643	2018-003711-21--MS100070-0176	Phase 3		VIC	2019-01-24	2019-03-22		Avelumab	anti-PD-L1_monoclonal_antibody	Avelumab	anti-PD-L1_monoclonal_antibody	2018-003711-21  MS100070_0176	An Open-Label, Multicenter Follow-up Study to Collect Long-term Data on Participants From Multiple Avelumab (MSB0010718C) Clinical Studies	Solid Tumors	- Clayton; - Ballarat	https://clinicaltrials.gov/ct2/show/NCT03815643
NCT03816163	2018-002551-15--8951-CL-5201	Phase 2		NSW, VIC	2019-01-25	2019-03-15		Gemcitabine; Gemcitabine + Nab-paclitaxel; Gemcitabine + Nab-paclitaxel + Zolbetuximab; Nab-paclitaxel; Zolbetuximab	antimetabolite; antimetabolite + taxane; anti-CLDN18.2_monoclonal_antibody + antimetabolite + taxane; taxane; gemcitabine; anti-CLDN18.2_monoclonal_antibody	Gemcitabine + Nab-paclitaxel; Gemcitabine + Nab-paclitaxel + Zolbetuximab	anti-CLDN18.2_monoclonal_antibody + antimetabolite + taxane; antimetabolite + taxane; gemcitabine	2018-002551-15  8951-CL-5201	A Phase 2, Open-Label, Randomized Study to Assess the Efficacy and Safety of Zolbetuximab (IMAB362) in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma	Pancreatic Cancer; Metastatic Pancreatic Cancer; Metastatic Pancreatic Adenocarcinoma	HVGM+3C - Wollongong; VIC 3280 - Warrnambool; NSW 2250 - Gosford; 5XRF+WX - Fitzroy	https://clinicaltrials.gov/ct2/show/NCT03816163
NCT03820986	LEAP-003	Phase 3		ACT, NSW, QLD, VIC, WA	2019-01-29	2019-03-12		Lenvatinib; Lenvatinib + Pembrolizumab; Pembrolizumab; Placebo	placebo; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; VEGF_inhibitor; anti-PD-1_monoclonal_antibody	Lenvatinib + Pembrolizumab; Placebo	VEGF_inhibitor + anti-PD-1_monoclonal_antibody; placebo	MK-7902-003  7902-003	A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) and Lenvatinib (E7080/MK-7902) Versus Pembrolizumab Alone as First-line Intervention in Participants With Advanced Melanoma (LEAP-003)	Malignant Melanoma	6150 - Murdoch; 2060 - North Sydney; 2145 - Westmead; 4102 - Wooloongabba; 2480 - Lismore; 3128 - Box Hill	https://clinicaltrials.gov/ct2/show/NCT03820986
NCT03821233	ZWI-ZW49-101	Phase 1		SA	2019-01-29	2019-04-15		ZW49	anti-ERBB2_antibody-drug_conjugate	ZW49	anti-ERBB2_antibody-drug_conjugate	ZWI-ZW49-101	A Phase 1 Study of ZW49 in Patients With Locally Advanced (Unresectable) or Metastatic HER2-Expressing Cancers	HER2-expressing Cancers	5042 - Adelaide	https://clinicaltrials.gov/ct2/show/NCT03821233
NCT03821935	2023-508281-15-00--M19-345	Phase 1		NSW, QLD	2019-01-30	2019-02-21		Budigalimab; Budigalimab + Livmoniplimab; Livmoniplimab	anti-GARP_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-GARP_monoclonal_antibody; anti-PD-1_monoclonal_antibody	Budigalimab; Budigalimab + Livmoniplimab; Livmoniplimab	anti-GARP_monoclonal_antibody; anti-GARP_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody	2023-508281-15-00  M19-345	A Phase 1 First-in Human, Multi-Center, Open Label Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Subjects With Locally Advanced or Metastatic Solid Tumors	Advanced Solid Tumors Cancer	4101 - South Brisbane; 2050 - Camperdown	https://clinicaltrials.gov/ct2/show/NCT03821935
NCT03833154	PACIFIC-4	Phase 3		VIC	2019-02-06	2019-03-06		Durvalumab; Osimertinib; Placebo; Radiotherapy	placebo; radiotherapy; anti-PD-L1_monoclonal_antibody; EGFR_inhibitor,third_generation	Durvalumab; Osimertinib; Placebo; Radiotherapy	EGFR_inhibitor,third_generation; anti-PD-L1_monoclonal_antibody; placebo; radiotherapy	2018-002572-41  D9103C00001	A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab With Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients With Unresected Stage I/II, Lymph-node Negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515) Osimertinib Following SBRT, a Single Arm Cohort for Patients With Unresected Stage I/II, Lymph Node Negative NSCLC Harboring a Sensitizing EGFR Mutation	Carcinoma, Non-Small-Cell Lung	3168 - Clayton	https://clinicaltrials.gov/ct2/show/NCT03833154
NCT03834220	2018-003584-53--Debio-1347-201	Phase 2		NSW, QLD, VIC, WA	2019-02-07	2019-03-22		Debio1347	FGFR1/2/3_inhibitor,reversible; FGFR1/2/3_inhibitor	Debio1347	FGFR1/2/3_inhibitor; FGFR1/2/3_inhibitor,reversible	2018-003584-53  Debio 1347-201	A Phase II Basket Study of the Oral Selective Pan-FGFR Inhibitor Debio 1347 in Subjects With Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3	Solid Tumor	6009 - Nedlands; 4224 - Tugun; NSW 2576 - Bowral; 3199 - Frankston	https://clinicaltrials.gov/ct2/show/NCT03834220
NCT03834506	KEYNOTE-921	Phase 3		NSW, QLD, WA	2019-02-08	2019-05-02		Dexamethasone; Dexamethasone + Docetaxel; Dexamethasone + Docetaxel + Pembrolizumab; Docetaxel; Pembrolizumab; Placebo; Prednisone	placebo; anti-PD-1_monoclonal_antibody; taxane; glucocorticoid + taxane; glucocorticoid; anti-PD-1_monoclonal_antibody + glucocorticoid + taxane	Dexamethasone + Docetaxel; Dexamethasone + Docetaxel + Pembrolizumab; Placebo; Prednisone	anti-PD-1_monoclonal_antibody + glucocorticoid + taxane; glucocorticoid + taxane; placebo	MK-3475-921  3475-921	A Phase 3, Randomized, Double-blind Study of Pembrolizumab (MK-3475) Plus Docetaxel Plus Prednisone Versus Placebo Plus Docetaxel Plus Prednisone in Participants With Chemotherapy-naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Have Progressed on a Next Generation Hormonal Agent (NHA) (KEYNOTE-921)	Prostatic Neoplasms	4020 - Redcliffe; 2444 - Port Macquarie; 6009 - Nedlands; 2217 - Kogarah; 4224 - Tugun; 2109 - Macquarie University; 2298 - Waratah	https://clinicaltrials.gov/ct2/show/NCT03834506
NCT03843359	NCT03843359	Phase 1		VIC	2019-02-18	2019-03-12		Dostarlimab; Dostarlimab + GSK3745417; GSK3745417	STING_agonist; STING_agonist + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody	Dostarlimab + GSK3745417; GSK3745417	STING_agonist; STING_agonist + anti-PD-1_monoclonal_antibody	208850	A Phase I First Time in Human Open Label Study of GSK3745417 Administered With and Without Anticancer Agents in Participants With Advanced Solid Tumors	Neoplasms	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT03843359
NCT03845166	STELLAR-001	Phase 1		NSW, QLD, SA, VIC	2019-02-19	2019-03-20		Atezolizumab; Atezolizumab + Zanzalintinib; Avelumab; Avelumab + Zanzalintinib; Zanzalintinib	MET/VEGFR2/AXL/MER_inhibitor + anti-PD-L1_monoclonal_antibody; MET/VEGFR2/AXL/MER_inhibitor; anti-PD-L1_monoclonal_antibody	Atezolizumab + Zanzalintinib; Avelumab + Zanzalintinib; Zanzalintinib	MET/VEGFR2/AXL/MER_inhibitor; MET/VEGFR2/AXL/MER_inhibitor + anti-PD-L1_monoclonal_antibody	2020-003569-21  XL092-001	A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects With Inoperable Locally Advanced or Metastatic Solid Tumors	Metastatic Castration-resistant Prostate Cancer; Neoplasm Malignant; Colorectal Cancer; Renal Cell Carcinoma; Hormone Receptor Positive Breast Carcinoma	3084 - Heidelberg; 2010 - Darlinghurst; 5037 - Kurralta Park; 2170 - Liverpool; 4101 - South Brisbane	https://clinicaltrials.gov/ct2/show/NCT03845166
NCT03850795	HC1119-CS-03	Phase 3		QLD, SA, WA	2019-02-22	2021-03-15		Enzalutamide	antiandrogen,nonsteroidal,second_generation	Enzalutamide	antiandrogen,nonsteroidal,second_generation	HC1119-CS-03	PROCADE: A Multinational Phase 3, Randomized, Double-Blind, Non-inferiority, Efficacy and Safety Study of Oral HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)	Castration-resistant Prostate Cancer; Prostate Cancer Metastatic	6009 - Nedlands; 4215 - Southport; 5037 - Kurralta Park	https://clinicaltrials.gov/ct2/show/NCT03850795
NCT03853109	2018-004268-80--20180143	Phase 1		NSW, SA	2019-02-25	2019-03-05		AMG 404	anti-PD-1_monoclonal_antibody	AMG 404	anti-PD-1_monoclonal_antibody	2018-004268-80  20180143	A Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 404, a Programmed Death-1 (PD-1) Antibody, in Patients With Advanced Solid Tumors	Advanced Solid Tumors	2050 - Camperdown; 5011 - Woodville South	https://clinicaltrials.gov/ct2/show/NCT03853109
NCT03856099	PMC-TTAC-0001-03	Phase 2		VIC	2019-02-27	2019-11-13		Bevacizumab; Olinvacimab	anti-VEGFR2_monoclonal_antibody; anti-VEGF_monoclonal_antibody	Olinvacimab; Bevacizumab	anti-VEGFR2_monoclonal_antibody; anti-VEGF_monoclonal_antibody	PMC_TTAC-0001_03	A Multicenter, Open-Label, Phase ? Clinical Trial to Evaluate the Safety and Efficacy of TTAC-0001, a Fully Human Monoclonal Antibody in Patients With Recurrent Glioblastoma Progressed on Bevacizumab Including Therapy	Recurrent Glioblastoma	3084 - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT03856099
NCT03873493	2018-002179-17--M18-803	Phase 2		VIC	2019-03-13	2020-01-14		Ibrutinib; Ibrutinib + Venetoclax; Venetoclax	BTK_inhibitor; BTK_inhibitor + Bcl2_inhibitor; Bcl2_inhibitor	Ibrutinib + Venetoclax	BTK_inhibitor + Bcl2_inhibitor	2018-002179-17  M18-803	A Prospective, Open-Label, Single-Arm, Phase 2, Multicenter Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Subjects With T-Cell Prolymphocytic Leukemia	T-cell Prolymphocytic Leukemia (T-PLL); Cancer; Leukemia	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT03873493
NCT03874884	LuPARP	Phase 1		NSW, VIC	2019-03-14	2019-07-09		Lu-177 vipivotide tetraxetan; Lu-177 vipivotide tetraxetan + Olaparib; Olaparib	PARP_inhibitor + radioconjugate,PSMA-targeting; radioconjugate,PSMA-targeting; PARP_inhibitor	Lu-177 vipivotide tetraxetan + Olaparib	PARP_inhibitor + radioconjugate,PSMA-targeting	Peter Mac project no.18/216	177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer	Metastatic Castration Resistant Prostate Cancer (mCRPC)	2010 - Sydney; 3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT03874884
NCT03893955	2019-000478-45--M19-037	Phase 1		QLD	2019-03-28	2019-05-21		ABBV-927; ABBV-927 + Budigalimab; ABBV-927 + Budigalimab + Carboplatin; ABBV-927 + Carboplatin; ABBV-927 + Nab-paclitaxel; Budigalimab; Carboplatin; Nab-paclitaxel	anti-PD-1_monoclonal_antibody; taxane; platinum-based_antineoplastic_agent; anti-CD40_agonistic_antibody + taxane; anti-CD40_agonistic_antibody; anti-CD40_agonistic_antibody + platinum-based_antineoplastic_agent; anti-CD40_agonistic_antibody + anti-PD-1_monoclonal_antibody; anti-CD40_agonistic_antibody + anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent	ABBV-927; ABBV-927 + Budigalimab; ABBV-927 + Budigalimab + Carboplatin; ABBV-927 + Carboplatin; ABBV-927 + Nab-paclitaxel	anti-CD40_agonistic_antibody; anti-CD40_agonistic_antibody + anti-PD-1_monoclonal_antibody; anti-CD40_agonistic_antibody + anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent; anti-CD40_agonistic_antibody + platinum-based_antineoplastic_agent; anti-CD40_agonistic_antibody + taxane	2019-000478-45  M19-037	A Phase 1, Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Combinations of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Subjects With Locally Advanced or Metastatic Solid Tumors	Non-small-cell-lung-cancer (NSCLC); Advanced Solid Tumors; Cancer; Triple-Negative Breast Cancer (TNBC); Metastatic Solid Tumors	4101 - South Brisbane	https://clinicaltrials.gov/ct2/show/NCT03893955
NCT03898180	LEAP-011	Phase 3		NSW, QLD, VIC	2019-04-01	2019-05-06		Cisplatin; Lenvatinib; Lenvatinib + Pembrolizumab; Pembrolizumab; Placebo	placebo; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; VEGF_inhibitor; platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody	Lenvatinib + Pembrolizumab; Cisplatin; Placebo	VEGF_inhibitor + anti-PD-1_monoclonal_antibody; placebo; platinum-based_antineoplastic_agent	MK-7902-011  7902-011	A Phase 3, Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Lenvatinib (E7080/MK-7902) Versus Pembrolizumab and Placebo as First Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma in Cisplatin-ineligible Participants Whose Tumors Express PD-L1, and in Participants Ineligible for Any Platinum-containing Chemotherapy Regardless of PD-L1 Expression (LEAP-011)	Urothelial Carcinoma	3199 - Frankston; 3168 - Clayton; 4101 - South Brisbane; 2109 - North Ryde; 3084 - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT03898180
NCT03900442	PTX-100-PD-012017	Phase 1	UNKNOWN_STATUS	VIC	2019-04-03	2019-09-01		PTX-100	geranylgeranyl_transferase_inhibitor	PTX-100	geranylgeranyl_transferase_inhibitor	PTX-100-PD-012017	Phase 1 Pharmacodynamic and Pharmacokinetic Study of the Geranylgeranyltransferase I Inhibitor PTX-100 (GGTI-2418) in Patients With Advanced Malignancies	Advanced Cancer; PTCL	3199 - Frankston; 3002 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT03900442
NCT03900884	PALVEN	Phase 1		VIC	2019-04-03	2019-09-25		Letrozole; Letrozole + Palbociclib + Venetoclax; Palbociclib; Venetoclax	Bcl2_inhibitor + CDK4/6_inhibitor + aromatase_inhibitor; aromatase_inhibitor; CDK4/6_inhibitor; Bcl2_inhibitor	Letrozole + Palbociclib + Venetoclax	Bcl2_inhibitor + CDK4/6_inhibitor + aromatase_inhibitor	18/028	A Phase 1b Study of Palbociclib, Letrozole and Venetoclax in ER and BCL-2 Positive Locally Advanced or Metastatic Breast Cancer	Breast Neoplasm Female	3000 - Melbourne; 3052 - Melbourne; 3084 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT03900884
NCT03901950	XNW7201-1-02	Phase 1		QLD	2019-04-03	2019-07-01		XNW7201	PORCN_inhibitor	XNW7201	PORCN_inhibitor	XNW7201-1-02	A Phrase I, Open-label, Multi-center, Non-randomized, Does Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of XNW7201 in Subjects With Advanced Solid Tumors	Advanced Solid Tumors	4101 - South Brisbane	https://clinicaltrials.gov/ct2/show/NCT03901950
NCT03906331	Selpercatinib-EAP--17494			NSW, NZ, QLD, VIC, WA	2019-04-08			Selpercatinib	RET-selective_inhibitor	Selpercatinib	RET-selective_inhibitor	Selpercatinib EAP  17494	Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation	Colon Cancer; Breast Cancer; Medullary Thyroid Cancer; Non Small Cell Lung Cancer; Papillary Thyroid Cancer; Pancreatic Cancer; Other Solid Tumors With Evidence of Activating RET Alteration	Auckland; 6009 - Nedlands; 2065 - St. Leonards; 4032 - Chermside; 2050 - Camperdown; 3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT03906331
NCT03918278	MK-0482-001--0482-001	Phase 1		NSW, VIC	2019-04-17	2019-06-19		Carboplatin; Carboplatin + MK-0482 + Pembrolizumab + Pemetrexed; Gemcitabine; Gemcitabine + MK-0482 + Nab-paclitaxel + Pembrolizumab; MK-0482; MK-0482 + Paclitaxel + Pembrolizumab; MK-0482 + Pembrolizumab; Nab-paclitaxel; Paclitaxel; Pembrolizumab; Pemetrexed	antimetabolite; gemcitabine; anti-ILT3_monoclonal_antibody + anti-PD-1_monoclonal_antibody + taxane; anti-ILT3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-ILT3_monoclonal_antibody + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody; taxane; platinum-based_antineoplastic_agent; anti-ILT3_monoclonal_antibody + anti-PD-1_monoclonal_antibody + antimetabolite + taxane; anti-ILT3_monoclonal_antibody	Carboplatin + MK-0482 + Pembrolizumab + Pemetrexed; Gemcitabine + MK-0482 + Nab-paclitaxel + Pembrolizumab; MK-0482; MK-0482 + Paclitaxel + Pembrolizumab; MK-0482 + Pembrolizumab	anti-ILT3_monoclonal_antibody; anti-ILT3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-ILT3_monoclonal_antibody + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-ILT3_monoclonal_antibody + anti-PD-1_monoclonal_antibody + antimetabolite + taxane; anti-ILT3_monoclonal_antibody + anti-PD-1_monoclonal_antibody + taxane; gemcitabine	MK-0482-001  0482-001	A Phase 1b, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-0482 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors.	Neoplasms	2109 - Macquarie University; 3004 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT03918278
NCT03937219	COSMIC-313	Phase 3		NSW, NZ, QLD, SA, VIC, WA	2019-05-03	2019-06-25		Cabozantinib; Cabozantinib + Ipilimumab + Nivolumab; Ipilimumab; Nivolumab; Placebo	RET_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; AXL_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; RET_inhibitor; ROS1_inhibitor; AXL_inhibitor; KIT_inhibitor; anti-CTLA4_monoclonal_antibody; placebo; VEGFR2_inhibitor; anti-PD-1_monoclonal_antibody; MET_inhibitor,type_2 + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; ROS1_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; KIT_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; MET_inhibitor,type_2; VEGFR2_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	Cabozantinib + Ipilimumab + Nivolumab; Placebo	AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; AXL_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; KIT_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; MET_inhibitor,type_2 + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; RET_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; ROS1_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; VEGFR2_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; placebo	XL184-313	A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination With Nivolumab and Ipilimumab Versus Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk	Renal Cell Carcinoma	4101 - South Brisbane; 4102 - Woolloongabba; 6008 - Subiaco; Wellington; 2217 - Kogarah; Waikato; 3128 - Box Hill; 2065 - Sydney; 2640 - Albury; 2109 - North Ryde; 3350 - Ballarat; 5000 - Adelaide; 5006 - North Adelaide	https://clinicaltrials.gov/ct2/show/NCT03937219
NCT03947385	IDE196-001	Phase 1		NSW	2019-05-13	2019-06-28		Binimetinib; Binimetinib + Darovasertib; Crizotinib; Crizotinib + Darovasertib; Crizotinib + Darovasertib + Lomustine; Darovasertib; Lomustine	ALK_inhibitor,first_generation + PKC_inhibitor; MET_inhibitor,type_1 + PKC_inhibitor; MEK_inhibitor; ROS1_inhibitor; MET_inhibitor,type_1 + PKC_inhibitor + alkylating_agent; PKC_inhibitor; ALK_inhibitor,first_generation + PKC_inhibitor + alkylating_agent; PKC_inhibitor + ROS1_inhibitor; MEK_inhibitor + PKC_inhibitor; alkylating_agent; PKC_inhibitor + ROS1_inhibitor + alkylating_agent; ALK_inhibitor,first_generation; MET_inhibitor,type_1	Binimetinib; Binimetinib + Darovasertib; Crizotinib; Crizotinib + Darovasertib; Crizotinib + Darovasertib + Lomustine; Darovasertib	ALK_inhibitor,first_generation; ALK_inhibitor,first_generation + PKC_inhibitor; ALK_inhibitor,first_generation + PKC_inhibitor + alkylating_agent; MEK_inhibitor; MEK_inhibitor + PKC_inhibitor; MET_inhibitor,type_1; MET_inhibitor,type_1 + PKC_inhibitor; MET_inhibitor,type_1 + PKC_inhibitor + alkylating_agent; PKC_inhibitor; PKC_inhibitor + ROS1_inhibitor; PKC_inhibitor + ROS1_inhibitor + alkylating_agent; ROS1_inhibitor	IDE196-001	A Phase 1/2 Study of IDE196 in Patients with Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions	Cutaneous Melanoma; Metastatic Uveal Melanoma; Colorectal Cancer; Other Solid Tumors	- Sydney	https://clinicaltrials.gov/ct2/show/NCT03947385
NCT03964233	2019-001173-84--1403-0002	Phase 1		WA	2019-05-28	2019-06-20		BI 754111; BI 754111 + Brigimadlin + Ezabenlimab; Brigimadlin; Brigimadlin + Ezabenlimab; Ezabenlimab	anti-LAG3_monoclonal_antibody; MDM2_inhibitor + anti-PD-1_monoclonal_antibody; MDM2_inhibitor + anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; MDM2_inhibitor; anti-PD-1_monoclonal_antibody	BI 754111 + Brigimadlin + Ezabenlimab; Brigimadlin + Ezabenlimab	MDM2_inhibitor + anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; MDM2_inhibitor + anti-PD-1_monoclonal_antibody	2019-001173-84  1403-0002	A Phase Ia/Ib, Open Label, Dose-escalation Study of the Combination of BI 907828 (Brigimadlin) With BI 754091 (Ezabenlimab) and BI 754111 and the Combination of BI 907828 (Brigimadlin) With BI 754091(Ezabenlimab) Followed by Expansion Cohorts, in Patients With Advanced Solid Tumors	Neoplasms	6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT03964233
NCT03969004	2019-000566-38--R2810-ONC-1788	Phase 3		NSW, NZ, North South WalesQLD, QLD, SA, TAS, VIC, WA	2019-05-31	2019-06-04		Cemiplimab; Placebo; Radiotherapy	placebo; radiotherapy; anti-PD-1_monoclonal_antibody	Cemiplimab; Placebo; Radiotherapy	anti-PD-1_monoclonal_antibody; placebo; radiotherapy	2019-000566-38  R2810-ONC-1788	A Randomized, Placebo-Controlled, Double-Blind Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma	Cutaneous Squamous Cell Carcinoma	4029 - Herston; 3000 - Melbourne; 2640 - Albury; 3084 - Heidelberg; 5000 - Adelaide; 2500 - Wollongong; 4215 - Southport; 2170 - Liverpool; 2650 - Wagga Wagga; 4870 - Cairns; 5037 - Kurralta Park; Palmerston North; 2450 - Coffs Harbour; 4224 - Tugun; 2217 - Kogarah; 2145 - Westmead; 6009 - Nedlands; Auckland; 4350 - Toowoomba; 4655 - Urraween; 3550 - Bendigo; 2250 - Gosford; 4670 - Bundaberg; 4102 - Woolloongabba; 2298 - Waratah; 2065 - St Leonards; 3065 - Fitzroy; 2060 - Sydney; 7000 - Hobart; 4814 - Townsville	https://clinicaltrials.gov/ct2/show/NCT03969004
NCT03970447	GBM-AGILE	Phase 2		NSW, QLD, SA, VIC	2019-05-31	2019-07-30		Lomustine; Paxalisib; Paxalisib + Radiotherapy + Temozolomide; Pegargiminase; Pegargiminase + Temozolomide; Radiotherapy; Radiotherapy + Regorafenib + Temozolomide; Radiotherapy + Temozolomide; Radiotherapy + Temozolomide + Troriluzole; Radiotherapy + Temozolomide + VAL-083; Regorafenib; Temozolomide; Temozolomide + Troriluzole; Troriluzole; VAL-083	radiotherapy; alkylating_agent + glutamate_modulator + radiotherapy; glutamate_modulator; arginine_deiminase-polyethylene_glycol_conjugate; alkylating_agent + glutamate_modulator; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor; alkylating_agent + dual_PI3K/mTOR_inhibitor + radiotherapy; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + alkylating_agent + radiotherapy; dual_PI3K/mTOR_inhibitor; alkylating_agent + arginine_deiminase-polyethylene_glycol_conjugate; alkylating_agent; alkylating_agent + radiotherapy	Paxalisib + Radiotherapy + Temozolomide; Pegargiminase; Pegargiminase + Temozolomide; Radiotherapy + Regorafenib + Temozolomide; Radiotherapy + Temozolomide; Radiotherapy + Temozolomide + Troriluzole; Radiotherapy + Temozolomide + VAL-083; Temozolomide + Troriluzole; Troriluzole; Lomustine	KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + alkylating_agent + radiotherapy; alkylating_agent + arginine_deiminase-polyethylene_glycol_conjugate; alkylating_agent + dual_PI3K/mTOR_inhibitor + radiotherapy; alkylating_agent + glutamate_modulator; alkylating_agent + glutamate_modulator + radiotherapy; alkylating_agent + radiotherapy; arginine_deiminase-polyethylene_glycol_conjugate; glutamate_modulator	GCAR-7213	GBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM	Glioblastoma	4029 - Herston; - Melbourne; 3084 - Heidelberg; 5042 - Bedford Park; 2298 - Waratah; 2065 - St Leonards	https://clinicaltrials.gov/ct2/show/NCT03970447
NCT03974022	DZ2019E0001	Phase 1		NSW, VIC, WA	2019-06-04	2019-07-09		Sunvozertinib	ERBB2_inhibitor,exon_20_selective; EGFR_inhibitor,exon_20_selective	Sunvozertinib	EGFR_inhibitor,exon_20_selective; ERBB2_inhibitor,exon_20_selective	DZ2019E0001	A Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Efficacy of DZD9008 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with EGFR or HER2 Mutation	Non-Small Cell Lung Cancer	- Heidelberg; - Camperdown; - Perth; - Wollongong; - North Melbourne; - Kogarah; - Blacktown	https://clinicaltrials.gov/ct2/show/NCT03974022
NCT03976375	LEAP-008	Phase 3		NSW, QLD, SA, VIC	2019-06-06	2019-06-26		Docetaxel; Lenvatinib; Lenvatinib + Pembrolizumab; Pembrolizumab	VEGF_inhibitor + anti-PD-1_monoclonal_antibody; VEGF_inhibitor; anti-PD-1_monoclonal_antibody; taxane	Docetaxel; Lenvatinib; Lenvatinib + Pembrolizumab	VEGF_inhibitor; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; taxane	MK-7902-008  7902-008	A Phase 3, Multicenter, Randomized, Open-label Trial to Compare the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Lenvatinib (E7080/MK-7902) Versus Docetaxel in Previously Treated Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (LEAP-008)	Metastatic Non-Small Cell Lung Cancer	2145 - Westmead; 2148 - Blacktown; 4102 - Woolloongabba; 3552 - Bendigo; 5112 - Elizabeth Vale; 2500 - Wollongong; 2444 - Port Macquarie	https://clinicaltrials.gov/ct2/show/NCT03976375
NCT03994393	ILLUMINATE	Phase 2		NSW, QLD, SA, TAS, VIC	2019-06-21	2018-10-23		Durvalumab; Tremelimumab	anti-PD-L1_monoclonal_antibody; anti-CTLA4_monoclonal_antibody	Durvalumab; Tremelimumab	anti-CTLA4_monoclonal_antibody; anti-PD-L1_monoclonal_antibody	ALTG 16/009  CTC 0209	A Phase 2 Trial of Durvalumab (MEDI4736) and Tremelimumab With Chemotherapy in Metastatic EGFR Mutant Non-squamous Non-small Cell Lung Cancer (NSCLC) Following Progression on EGFR Tyrosine Kinase Inhibitors (TKIs)	EGFR Mutant Advanced Non Small Cell Lung Cancer	- Chermside; - Clayton; - Melbourne; - Kogarah; - Liverpool; - Bedford Park; - Woolloongabba; - Hobart	https://clinicaltrials.gov/ct2/show/NCT03994393
NCT03995472	SHR-1501-I-101	Phase 1		NSW, QLD	2019-06-24	2020-02-14		SHR-1316; SHR-1316 + SHR-1501; SHR-1501	anti-IL-15_agonistic_antibody + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; anti-IL-15_agonistic_antibody	SHR-1316 + SHR-1501	anti-IL-15_agonistic_antibody + anti-PD-L1_monoclonal_antibody	SHR-1501-I-101	A Phase I Clinical Study to Evaluate the Tolerability, Safety, Pharmacokinetics and Efficacy of SHR-1501 in Combination With SHR-1316 in Patients With Advanced Malignancies	Advanced Malignancies	2031 - Randwick; 2170 - Liverpool; 4224 - Tugun; 4101 - South Brisbane	https://clinicaltrials.gov/ct2/show/NCT03995472
NCT04000529	CTNO155B12101	Phase 1		NSW	2019-06-27	2019-07-30		Ribociclib; Ribociclib + TNO155; Spartalizumab; Spartalizumab + TNO155; TNO155	SHP2_inhibitor + anti-PD-1_monoclonal_antibody; SHP2_inhibitor; CDK4/6_inhibitor + SHP2_inhibitor; CDK4/6_inhibitor; anti-PD-1_monoclonal_antibody	Ribociclib + TNO155; Spartalizumab + TNO155	CDK4/6_inhibitor + SHP2_inhibitor; SHP2_inhibitor + anti-PD-1_monoclonal_antibody	CTNO155B12101	A Phase Ib, Open-label, Multi-center Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies	Colorectal Cancer; Esophageal SCC; Gastrointestinal Stromal Tumors; Head and Neck Squamous Cell Carcinoma; Non-small Cell Lung Carcinoma	2145 - Westmead	https://clinicaltrials.gov/ct2/show/NCT04000529
NCT04025307	bacTRL-IL-12-001	Phase 1		VIC	2019-07-18	2019-08-05		bacTRL-IL-12	bifidobacterium-delivered_IL-12	bacTRL-IL-12	bifidobacterium-delivered_IL-12	bacTRL-IL-12-001	A Multi-centre, Open-label, Phase I Trial of bacTRL-IL-12 in Adult Subjects With Advanced, Treatment-refractory Solid Tumours	Cancer - Solid Tumours	- Melbourne	https://clinicaltrials.gov/ct2/show/NCT04025307
NCT04026412	CheckMate73L	Phase 3		NSW, QLD, SA, VIC, WA	2019-07-19	2019-10-08		Durvalumab; Ipilimumab; Ipilimumab + Nivolumab; Nivolumab; Radiotherapy	radiotherapy; anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-CTLA4_monoclonal_antibody	Durvalumab; Ipilimumab + Nivolumab; Nivolumab; Radiotherapy	anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; radiotherapy	2019-001222-98  CA209-73L	A Phase 3, Randomized, Open Label Study to Compare Nivolumab Plus Concurrent Chemoradiotherapy (CCRT) Followed by Nivolumab Plus Ipilimumab or Nivolumab Plus CCRT Followed by Nivolumab vs CCRT Followed by Durvalumab in Previously Untreated, Locally Advanced Non-small Cell Lung Cancer (LA NSCLC)	Non-Small Cell Lung Cancer (NSCLC)	5000 - Adelaide; 4120 - Greenslopes; 2747 - Kingswood; 2010 - Darlinghurst; 3350 - Ballarat Central; 6150 - Murdoch; 3004 - Melbourne; 3199 - Melbourne; 2250 - Gosford	https://clinicaltrials.gov/ct2/show/NCT04026412
NCT04029922	MT-5111	Phase 1		Melbourne, NSW, NZ, SA, VIC, VICNSW	2019-07-23	2019-11-12		MT-5111	anti-ERBB2_engineered_toxin_body	MT-5111	anti-ERBB2_engineered_toxin_body	MT-5111_001	A Phase 1 Open-label, Multicenter Dose Escalation and Expansion Study of MT-5111 in Subjects With Previously Treated Advanced HER2-positive Solid Tumors	HER2-positive Solid Cancers	3065 - Fitzroy; Christchurch; 3630 - Shepparton; 3021 - Saint Albans; 2109 - Macquarie; 2576 - Bowral; 5000 - Adelaide	https://clinicaltrials.gov/ct2/show/NCT04029922
NCT04032704	SGNLVA-005	Phase 2		NSW, Othe, QLD, SA, TAS, VIC	2019-07-25	2019-10-09		Ladiratuzumab Vedotin; Pembrolizumab	anti-LIV1_antibody-drug_conjugate; anti-PD-1_monoclonal_antibody	Ladiratuzumab Vedotin; Pembrolizumab	anti-LIV1_antibody-drug_conjugate; anti-PD-1_monoclonal_antibody	SGNLVA-005	Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors	Small Cell Lung Cancer; Non-small Cell Lung Cancer, Squamous; Head and Neck Squamous Cell Carcinoma; Esophageal Squamous Cell Carcinoma; Gastroesophageal Junction Adenocarcinoma; Prostate Cancer; Non-small Cell Lung Cancer, Non-squamous; Gastric Adenocarcinoma; Melanoma	2065 - Wollstonecraft; 4814 - Douglas; 3144 - Malvern; 7000 - Hobart; 2250 - Gosford; 3199 - Frankston; 2010 - Sydney; 5042 - Bedford Park	https://clinicaltrials.gov/ct2/show/NCT04032704
NCT04035434	CRSP-ONC-001	Phase 1		NSW, VIC, WA	2019-07-29	2019-07-22		CTX110	allogeneic_CAR-T-cell_therapy,CD19-targeting	CTX110	allogeneic_CAR-T-cell_therapy,CD19-targeting	CRSP-ONC-001	A Phase 1/2 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Allogeneic CRISPR-Cas9-Engineered T Cells (CTX110) in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)	Adult B Cell ALL; B-cell Malignancy; B-cell Lymphoma; Non-Hodgkin Lymphoma	6009 - Nedlands; 2050 - Sydney; 3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04035434
NCT04035473	KX-ORAX-002	Phase 1		NZ, VIC	2019-07-29	2015-08-01		Oraxol; Oraxol + Paclitaxel; Paclitaxel	taxane	Oraxol + Paclitaxel	taxane	KX-ORAX-002	A Randomized Crossover Study to Determine the Bioequivalence of Three Consecutive Daily Doses of Oraxol in Cancer Patients Treated With Intravenous Paclitaxel	Solid Tumor	- Melbourne; Dunedin; Wellington; Auckland	https://clinicaltrials.gov/ct2/show/NCT04035473
NCT04039607	CheckMate-9DW	Phase 3		NSW, NZ, QLD, SA, VIC	2019-07-31	2019-09-30		Ipilimumab; Ipilimumab + Nivolumab; Lenvatinib; Lenvatinib + Sorafenib; Nivolumab; Sorafenib	CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor + VEGF_inhibitor; CRAF_inhibitor + VEGF_inhibitor; anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; PDGFR_inhibitor; KIT_inhibitor; anti-CTLA4_monoclonal_antibody; VEGFR_inhibitor; KIT_inhibitor + VEGF_inhibitor; FLT3_inhibitor + VEGF_inhibitor; CRAF_inhibitor; anti-PD-1_monoclonal_antibody; CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor; FLT3_inhibitor; VEGFR_inhibitor + VEGF_inhibitor; VEGF_inhibitor; PDGFR_inhibitor + VEGF_inhibitor	Ipilimumab + Nivolumab; Lenvatinib + Sorafenib	CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor + VEGF_inhibitor; CRAF_inhibitor + VEGF_inhibitor; FLT3_inhibitor + VEGF_inhibitor; KIT_inhibitor + VEGF_inhibitor; PDGFR_inhibitor + VEGF_inhibitor; VEGFR_inhibitor + VEGF_inhibitor; anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	CA209-9DW	A Randomized, Multi-center, Phase 3 Study of Nivolumab in Combination With Ipilimumab Compared to Sorafenib or Lenvatinib as First-Line Treatment in Participants With Advanced Hepatocellular Carcinoma	Hepatocellular Carcinoma	5000 - Adelaide; 4560 - Birtinya; 1871 - Liverpool; 4029 - Herston; 3021 - St Albans; Auckland; Canterbury; 2217 - Kogarah; 2145 - Westmead; 3065 - Fitzroy; 3168 - Clayton; 3004 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04039607
NCT04045613	FIDES-02	Phase 1		NSW, NZ, QLD, VIC	2019-08-05	2019-08-02		Atezolizumab; Atezolizumab + Derazantinib; Derazantinib	anti-PD-L1_monoclonal_antibody; FGFR1/2/3_inhibitor,reversible; FGFR1/2/3_inhibitor + anti-PD-L1_monoclonal_antibody; FGFR1/2/3_inhibitor,reversible + anti-PD-L1_monoclonal_antibody; FGFR1/2/3_inhibitor	Atezolizumab + Derazantinib; Derazantinib	FGFR1/2/3_inhibitor; FGFR1/2/3_inhibitor + anti-PD-L1_monoclonal_antibody; FGFR1/2/3_inhibitor,reversible; FGFR1/2/3_inhibitor,reversible + anti-PD-L1_monoclonal_antibody	2019-000359-15  DZB-CS-201	An Open-label Multi-cohort Phase 1b/2 Study of Derazantinib and Atezolizumab in Patients With Urothelial Cancer Expressing Activating Molecular FGFR Aberrations	Urothelial Carcinoma	4575 - Birtinya; 3355 - Wendouree; Hamilton; 2145 - Westmead; 2065 - Canberra; 4224 - Tugun	https://clinicaltrials.gov/ct2/show/NCT04045613
NCT04047290	AK112-101	Phase 1		NSW, QLD, SA, VIC	2019-08-06	2019-09-20		Ivonescimab	bispecific_PD-1/VEGF_antibody	Ivonescimab	bispecific_PD-1/VEGF_antibody	AK112-101	A Phase 1a/1b, Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK112 in Subjects With Advanced Solid Tumors	Neoplasms Malignant	- Kurralta Park; - Randwick; - Clayton; - South Brisbane; - Albury; - Melbourne; - Sydney	https://clinicaltrials.gov/ct2/show/NCT04047290
NCT04047862	AdvanTIG-105--BGB-900-105	Phase 1		NSW, NZ, QLD, SA, TAS, VIC, WA	2019-08-07	2019-08-26		Capecitabine; Capecitabine + Cisplatin + Fluorouracil + Ociperlimab + Tislelizumab; Carboplatin; Cisplatin; Cisplatin + Fluorouracil + Ociperlimab + Paclitaxel + Tislelizumab; Etoposide; Etoposide + Ociperlimab + Tislelizumab; Fluorouracil; Nab-paclitaxel; Nab-paclitaxel + Ociperlimab + Paclitaxel + Tislelizumab; Ociperlimab; Ociperlimab + Pemetrexed + Tislelizumab; Ociperlimab + Tislelizumab; Oxaliplatin; Paclitaxel; Pemetrexed; Tislelizumab	antimetabolite; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent + taxane; fluoropyrimidine; anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + topoisomerase_inhibitor; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + antimetabolite; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; topoisomerase_inhibitor; Fluorouracil; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + taxane; anti-PD-1_monoclonal_antibody; taxane; platinum-based_antineoplastic_agent	Capecitabine + Cisplatin + Fluorouracil + Ociperlimab + Tislelizumab; Cisplatin + Fluorouracil + Ociperlimab + Paclitaxel + Tislelizumab; Etoposide + Ociperlimab + Tislelizumab; Nab-paclitaxel + Ociperlimab + Paclitaxel + Tislelizumab; Ociperlimab + Pemetrexed + Tislelizumab; Ociperlimab + Tislelizumab; Carboplatin; Oxaliplatin	anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + antimetabolite; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent + taxane; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + taxane; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + topoisomerase_inhibitor; Fluorouracil	AdvanTIG-105  BGB-900-105	Phase 1/1b Study Investigating Safety, Tolerability, PK and Antitumor Activity of Anti-TIGIT Monoclonal Antibody BGB-A1217 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors	Locally Advanced and Metastatic Solid Tumors	5087 - Windsor Gardens; 2050 - Camperdown; 4101 - South Brisbane; Christchurch; 3168 - Clayton; 7000 - Hobart; 4102 - Woolloongabba; 6008 - Subiaco; 6009 - Nedlands; Auckland; 2148 - Blacktown; 3550 - Bendigo	https://clinicaltrials.gov/ct2/show/NCT04047862
NCT04050436	CERPASS	Phase 2		NSW, QLD, VIC, WA	2019-08-08	2019-10-08		Cemiplimab	anti-PD-1_monoclonal_antibody	Cemiplimab	anti-PD-1_monoclonal_antibody	RPL-002-18	A Randomized, Controlled, Open-Label, Phase 2 Study of Cemiplimab as a Single Agent and in Combination With RP1 in Patients With Advanced Cutaneous Squamous Cell Carcinoma	Metastatic Cutaneous Squamous Cell Carcinoma; Advanced Cutaneous Squamous Cell Carcinoma; Cutaneous Squamous Cell Carcinoma	- Camperdown; - Clayton; - Wollongong; - Nedlands; - Melbourne; - Southport	https://clinicaltrials.gov/ct2/show/NCT04050436
NCT04052971	ABN401-001	Phase 1		NSW, WA	2019-08-12	2019-08-01		ABN401	MET_inhibitor,type_1	ABN401	MET_inhibitor,type_1	ABN401-001	A Phase 1 Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of ABN401 in Patients With Advanced Solid Tumors and Pilot Expansion in Patients With Non-Small Cell Lung Cancer Harboring c-MET Dysregulation	Advanced Solid Tumors	2031 - Randwick; 2170 - Liverpool; 6009 - Perth; 2217 - Kogarah	https://clinicaltrials.gov/ct2/show/NCT04052971
NCT04064060	U1111-1235-8123--ACE-536-LTFU-001	Phase 3		NSW, QLD, SA, VIC	2019-08-21	2019-08-12		Luspatercept	recombinant_human_ActRIIb_fusion_protein	Luspatercept	recombinant_human_ActRIIb_fusion_protein	U1111-1235-8123  ACE-536-LTFU-001	A Phase 3b, Open-label, Single-arm, Rollover Study to Evaluate Long-term Safety in Subjects Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials	Myelodysplastic Syndromes (MDS); Beta-thalassemia; Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis	4101 - South Brisbane; 3168 - Clayton; 2050 - Camperdown; 5000 - Adelaide	https://clinicaltrials.gov/ct2/show/NCT04064060
NCT04066491	2019-001992-35--MS200647-0055	Phase 2		NSW, QLD, VIC	2019-08-26	2019-09-20		Bintrafusp Alfa; Bintrafusp Alfa + Cisplatin + Gemcitabine; Cisplatin; Cisplatin + Gemcitabine; Gemcitabine; Placebo	placebo; antimetabolite; anti-PD-L1/TGF-beta_fusion_protein; gemcitabine; platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; anti-PD-L1/TGF-beta_fusion_protein + antimetabolite + platinum-based_antineoplastic_agent	Bintrafusp Alfa + Cisplatin + Gemcitabine; Cisplatin + Gemcitabine; Placebo	anti-PD-L1/TGF-beta_fusion_protein + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; gemcitabine; placebo	2019-001992-35  MS200647_0055	A Phase II/III, Multicenter, Randomized, Placebo-controlled Study of Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) as First-line Treatment of Biliary Tract Cancer	Cholangiocarcinoma; Biliary Tract Cancer; Gallbladder Cancer	- Blacktown; - Clayton; - South Brisbane; - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04066491
NCT04074759	FPT155-001	Phase 1		NSW, QLD, VIC, WA	2019-08-30	2018-11-14		FPT155; FPT155 + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody + soluble_CD80_fusion_protein; soluble_CD80_fusion_protein; anti-PD-1_monoclonal_antibody	FPT155; FPT155 + Pembrolizumab	anti-PD-1_monoclonal_antibody + soluble_CD80_fusion_protein; soluble_CD80_fusion_protein	FPT155-001	A Phase 1 Safety and Tolerability Study of FPT155 in Patients With Advanced Solid Tumors	Advanced Solid Tumors	3144 - Malvern; 4066 - Auchenflower; 6009 - Nedlands; 2031 - Randwick; 3084 - Heidelberg; 2010 - Darlinghurst; 2050 - Camperdown	https://clinicaltrials.gov/ct2/show/NCT04074759
NCT04083976	RAGNAR	Phase 2		NSW, QLD, SA, VIC, WA	2019-09-10	2019-11-20		Erdafitinib	pan-FGFR_inhibitor,reversible; pan-FGFR_inhibitor	Erdafitinib	pan-FGFR_inhibitor; pan-FGFR_inhibitor,reversible	42756493CAN2002  CR108661	A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations	Advanced Solid Tumor	6150 - Murdoch; 5042 - Adelaide; 3065 - Fitzroy; 4101 - South Brisbane; 2010 - Darlinghurst; 2050 - Camperdown	https://clinicaltrials.gov/ct2/show/NCT04083976
NCT04093362	FOENIX-CCA3	Phase 3		NSW, SA, VIC	2019-09-18	2020-03-01		Cisplatin; Cisplatin + Gemcitabine; Futibatinib; Gemcitabine	antimetabolite; platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; pan-FGFR_inhibitor,irreversible; gemcitabine	Cisplatin + Gemcitabine; Futibatinib	antimetabolite + platinum-based_antineoplastic_agent; pan-FGFR_inhibitor,irreversible; gemcitabine	2019-004630-42  TAS-120-301	A Phase 3, Open-Label, Randomized Study of Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements FOENIX-CCA3	FGFR2 Gene Rearrangements; Advanced Cholangiocarcinoma	3002 - Melbourne; 5042 - Bedford Park; 2305 - Newcastle	https://clinicaltrials.gov/ct2/show/NCT04093362
NCT04097769	HX009-I-01	Phase 1		NSW	2019-09-20	2019-06-12		HX009	bispecific_PD-1/CD47_antibody	HX009	bispecific_PD-1/CD47_antibody	HX009-I-01	A Phase I, First-in-Human Study Evaluating the Safety, Tolerability, and Initial Efficacy of HX009 in Patients With Advanced Malignancies	Advanced Solid Tumor	2217 - Kogarah	https://clinicaltrials.gov/ct2/show/NCT04097769
NCT04100018	CheckMate-7DX	Phase 3		NSW, NZ, QLD, SA, VIC	2019-09-23	2020-02-06		Docetaxel; Docetaxel + Nivolumab + Prednisone; Docetaxel + Prednisone; Nivolumab; Placebo; Prednisone	placebo; anti-PD-1_monoclonal_antibody; taxane; glucocorticoid + taxane; glucocorticoid; anti-PD-1_monoclonal_antibody + glucocorticoid + taxane	Docetaxel + Nivolumab + Prednisone; Docetaxel + Prednisone; Placebo	anti-PD-1_monoclonal_antibody + glucocorticoid + taxane; glucocorticoid + taxane; placebo	2019-002030-36  CA209-7DX	A Phase 3, Randomized, Double-Blind Study of Nivolumab or Placebo in Combination With Docetaxel, in Men With Metastatic Castration-resistant Prostate Cancer	Prostate Cancer	2145 - Westmead; Hamilton; 4102 - Woolloongabba; 2076 - Wahroonga; 2250 - Gosford; 3199 - Frankston; 3144 - Malvern; 4101 - South Brisbane; 5006 - North Adelaide; 3350 - Ballarat; 2480 - Lismore; Tauranga; Manawatu-Wanganui	https://clinicaltrials.gov/ct2/show/NCT04100018
NCT04106219	J1O-MC-JZHD--17295	Phase 1		WA	2019-09-26	2020-06-11		Cyclophosphamide; Cyclophosphamide + LY3295668 + Topotecan; LY3295668; Topotecan	alkylating_agent; topoisomerase_inhibitor; AURKA_inhibitor; AURKA_inhibitor + alkylating_agent + topoisomerase_inhibitor	Cyclophosphamide + LY3295668 + Topotecan; LY3295668	AURKA_inhibitor; AURKA_inhibitor + alkylating_agent + topoisomerase_inhibitor	J1O-MC-JZHD  17295	A Phase 1 Study of Aurora Kinase A Inhibitor LY3295668 Erbumine as a Single Agent and in Combination in Patients With Relapsed/Refractory Neuroblastoma	Neuroblastoma	6009 - Perth	https://clinicaltrials.gov/ct2/show/NCT04106219
NCT04106492	2020-0185--SQ3370-001	Phase 1		NSW, SA	2019-09-27	2020-08-01		SQ3370	anthracycline	SQ3370	anthracycline	2020-0185  SQ3370-001	A Multicenter Phase 1/2a, Open-Label Study of SQ3370 in Patients With Advanced Solid Tumors	Cancer	2065 - Sydney; 2050 - Camperdown; 5000 - Adelaide	https://clinicaltrials.gov/ct2/show/NCT04106492
NCT04109456	IN10018-004-01	Phase 1		NSW, VIC, WA	2019-09-30	2020-03-16		Atezolizumab; Atezolizumab + Cobimetinib; Cobimetinib	MEK_inhibitor + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; MEK_inhibitor	Atezolizumab + Cobimetinib; Cobimetinib	MEK_inhibitor; MEK_inhibitor + anti-PD-L1_monoclonal_antibody	IN10018-004-01	A Phase Ib, Open-label Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of IN10018 as Monotherapy and Combination Therapy in Subjects With Metastatic Melanoma	Metastatic Melanoma	- Melbourne; - Nedlands; - Sydney	https://clinicaltrials.gov/ct2/show/NCT04109456
NCT04122339	Maxinovel-10181-001	Phase 1		WA	2019-10-10	2020-02-11		MAX-10181	PD-L1_inhibitor,oral	MAX-10181	PD-L1_inhibitor,oral	Maxinovel-10181-001	A Phase I Study of MAX-10181 Given Orally to Patients With Advanced Solid Tumor	Solid Tumor	6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT04122339
NCT04123366	MK-7339-007--7339-007	Phase 2		NSW, QLD, VIC, WA	2019-10-10	2019-11-18		Olaparib; Olaparib + Pembrolizumab; Pembrolizumab	PARP_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; PARP_inhibitor	Olaparib + Pembrolizumab	PARP_inhibitor + anti-PD-1_monoclonal_antibody	MK-7339-007  7339-007	A Phase 2 Study of Olaparib in Combination With Pembrolizumab in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer	Solid Tumors	4215 - Southport; 2148 - Blacktown; 6009 - Nedlands; 3168 - Clayton	https://clinicaltrials.gov/ct2/show/NCT04123366
NCT04128696	INDUCE-3	Phase 3		NSW, QLD, VIC, WA	2019-10-16	2019-11-21		Feladilimab; Feladilimab + Pembrolizumab; GSK3359609; Pembrolizumab; Placebo	placebo; anti-ICOS_agonistic_antibody; anti-ICOS_agonistic_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody	Feladilimab + Pembrolizumab; Pembrolizumab; GSK3359609; Placebo	anti-ICOS_agonistic_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; placebo	2019-002263-99  209229	A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma	Neoplasms, Head and Neck	3084 - Heidelberg; 3000 - Melbourne; 4029 - Herston; 2010 - Darlinghurst; 2148 - Blacktown; 6009 - Nedlands; 2065 - St Leonards	https://clinicaltrials.gov/ct2/show/NCT04128696
NCT04129502	NL20191212--TAK-788-3001	Phase 3		NSW, QLD, SA	2019-10-16	2020-01-10		Carboplatin; Carboplatin + Cisplatin + Pemetrexed; Cisplatin; Mobocertinib; Pemetrexed	antimetabolite; platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; ERBB2_inhibitor,exon_20_selective; EGFR_inhibitor,exon_20_selective	Carboplatin + Cisplatin + Pemetrexed; Mobocertinib	EGFR_inhibitor,exon_20_selective; ERBB2_inhibitor,exon_20_selective; antimetabolite + platinum-based_antineoplastic_agent	NL20191212  TAK-788-3001	A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations	Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)	4102 - Woolloongabba; 2065 - St Leonards; 5042 - Bedford Park	https://clinicaltrials.gov/ct2/show/NCT04129502
NCT04135261	4003.1	Phase 1		NSW, VIC	2019-10-22	2019-09-24		HBM4003	anti-CTLA4_monoclonal_antibody	HBM4003	anti-CTLA4_monoclonal_antibody	4003.1	A Phase 1 Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of HBM4003 in Subjects With Advanced Solid Tumors	Advanced Solid Tumor	2109 - Macquarie; 2217 - Kogarah; 3168 - Clayton; 3004 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04135261
NCT04140526	PRESERVE-001	Phase 1		NSW, QLD, SA	2019-10-28	2020-09-16		Docetaxel; Docetaxel + ONC392; ONC392; ONC392 + Pembrolizumab; Pembrolizumab	anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-CTLA4_monoclonal_antibody + taxane; taxane; anti-CTLA4_monoclonal_antibody	Docetaxel + ONC392; ONC392; ONC392 + Pembrolizumab	anti-CTLA4_monoclonal_antibody; anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA4_monoclonal_antibody + taxane	4R44CA250824-02  ONC-392-001	Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study. Preserve CTLA4 Checkpoint Function (PRESERVE-001)	Metastatic Breast Cancer; Non Small Cell Lung Cancer; Adenoid Cystic Carcinoma; Metastatic Colorectal Cancer; Salivary Gland Cancer; Sarcomas; Esophageal Cancer; Pancreas Cancer; Metastatic Renal Cell Carcinoma; Cervical Cancer; Gastric Cancer; Metastatic Head and Neck Carcinoma; Small Cell Lung Cancer; Metastatic Melanoma; Urothelial Carcinoma; Advanced Solid Tumor; Gastroesophageal Junction Adenocarcinoma; Metastatic Prostate Cancer; Ovarian Cancer	5042 - Bedford Park; 5000 - Adelaide; 4120 - Southport; 2305 - New Lambton Heights	https://clinicaltrials.gov/ct2/show/NCT04140526
NCT04152018	2020-004009-29--C3891001	Phase 1		NSW	2019-11-05	2019-11-13		PF-06940434	alpha_V_beta_8_antagonist	PF-06940434	alpha_V_beta_8_antagonist	2020-004009-29  C3891001	A PHASE 1 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ESCALATING DOSES OF PF-06940434 IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS	Gastric Cancer; Pancreatic Cancer; Melanoma Cancer; Esophageal Cancer; Squamous Cell Carcinoma of the Head and Neck; Endometrial Cancer; Bile Duct Cancer; Ovarian Cancer; Lung Squamous Cell Carcinoma; Urothelial Cancer; Renal Cell Carcinoma	2500 - Wollongong	https://clinicaltrials.gov/ct2/show/NCT04152018
NCT04157517	U1111-1238-9163--TAK-573-1001	Phase 1		SA, VIC	2019-11-08	2019-12-12		Pembrolizumab; Pembrolizumab + modakafusp alfa; modakafusp alfa	IFN_alpha2b-CD38_fusion_protein + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; IFN_alpha2b-CD38_fusion_protein	Pembrolizumab + modakafusp alfa; modakafusp alfa	IFN_alpha2b-CD38_fusion_protein; IFN_alpha2b-CD38_fusion_protein + anti-PD-1_monoclonal_antibody	U1111-1238-9163  TAK-573-1001	An Open-Label, Dose-Escalation Phase 1b/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Modakafusp Alfa (TAK-573) as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors	Melanoma; Neoplasms	5011 - Woodville South; 3350 - Ballarat	https://clinicaltrials.gov/ct2/show/NCT04157517
NCT04158583	2019-002830-35--WP41188	Phase 1		VIC	2019-11-12	2019-12-09		RO7296682	anti-CD25_monoclonal_antibody	RO7296682	anti-CD25_monoclonal_antibody	2019-002830-35  WP41188	An Open-Label, Multicenter Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7296682, A CD25-Targeting, T-Regulatory Cell Depleting Antibody in Participants With Advanced and/or Metastatic Solid Tumor	Solid Tumors	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04158583
NCT04161885	VIALE-T	Phase 3		NSW, SA, VIC	2019-11-13	2020-02-26		Azacitidine; Azacitidine + Venetoclax; Venetoclax	DNA_methyltransferase_inhibitor; antimetabolite; Bcl2_inhibitor + antimetabolite; Bcl2_inhibitor + DNA_methyltransferase_inhibitor; Bcl2_inhibitor	Azacitidine + Venetoclax	Bcl2_inhibitor + DNA_methyltransferase_inhibitor; Bcl2_inhibitor + antimetabolite	2023-507222-17-00  M19-063	A Randomized, Open Label Phase 3 Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine After Allogeneic Stem Cell Transplantation in Subjects With Acute Myeloid Leukemia (AML) (VIALE-T)	Cancer; Acute Myeloid Leukemia (AML)	5000 - Adelaide; 2010 - Darlinghurst; 3000 - Melbourne; 3004 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04161885
NCT04163900	2019-001025-28--NuTide	Phase 3		NSW, QLD, VIC, WA	2019-11-15	2019-12-24		Cisplatin; Cisplatin + Fosgemcitabine Palabenamide; Cisplatin + Gemcitabine; Fosgemcitabine Palabenamide; Gemcitabine	antimetabolite; gemcitabine; gemcitabine-phosphoramidate; platinum-based_antineoplastic_agent; gemcitabine-phosphoramidate + platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent	Cisplatin + Fosgemcitabine Palabenamide; Cisplatin + Gemcitabine	antimetabolite + platinum-based_antineoplastic_agent; gemcitabine-phosphoramidate + platinum-based_antineoplastic_agent	2019-001025-28  NuTide:121	A Phase III Open-Label, Multi-Centre, Randomized Study Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Previously Untreated Locally Advanced or Metastatic Biliary Tract Cancer	Biliary Tract Cancer	6009 - Nedlands; 2145 - Westmead; 2217 - Kogarah; 6150 - Murdoch; 4814 - Townsville; 3004 - Melbourne; 3084 - Heidelberg; 2305 - Newcastle; 2050 - Camperdown	https://clinicaltrials.gov/ct2/show/NCT04163900
NCT04164199	2019-002554-23--BGB-A317-290-LTE1	Phase 3		NSW, NZ, QLD, SA, VIC	2019-11-15	2019-12-19		BGB-15025; BGB-15025 + Tislelizumab; BGB-A445; BGB-A445 + Tislelizumab; Fruquintinib; Fruquintinib + Tislelizumab; LBL-007; LBL-007 + Tislelizumab; Lenvatinib; Lenvatinib + Tislelizumab; Ociperlimab; Ociperlimab + Tislelizumab; Pamiparib; Pamiparib + Temozolomide; Pamiparib + Tislelizumab; Sitravatinib; Sitravatinib + Tislelizumab; Temozolomide; Tislelizumab; Tislelizumab + Zanidatamab; Zanidatamab	KIT/PDGFR/RET/VEGFR_inhibitor; PDGFR_inhibitor + anti-PD-1_monoclonal_antibody; VEGFR1/2/3_inhibitor + anti-PD-1_monoclonal_antibody; VEGFR_inhibitor + anti-PD-1_monoclonal_antibody; RET_inhibitor; PARP_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; PDGFR_inhibitor; HPK1_inhibitor + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody; HPK1_inhibitor; anti-OX40_agonistic_antibody + anti-PD-1_monoclonal_antibody; anti-OX40_agonistic_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; VEGF_inhibitor; KIT/PDGFR/RET/VEGFR_inhibitor + anti-PD-1_monoclonal_antibody; PARP_inhibitor + alkylating_agent; anti-TIGIT_monoclonal_antibody; VEGFR1/2/3_inhibitor; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; KIT_inhibitor; VEGFR_inhibitor; KIT_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; RET_inhibitor + anti-PD-1_monoclonal_antibody; alkylating_agent; anti-PD-1_monoclonal_antibody + bispecific_ERBB2/ERBB2_antibody; bispecific_ERBB2/ERBB2_antibody; PARP_inhibitor	BGB-15025; BGB-15025 + Tislelizumab; BGB-A445 + Tislelizumab; Fruquintinib + Tislelizumab; LBL-007 + Tislelizumab; Lenvatinib + Tislelizumab; Ociperlimab + Tislelizumab; Pamiparib; Pamiparib + Temozolomide; Pamiparib + Tislelizumab; Sitravatinib; Sitravatinib + Tislelizumab; Tislelizumab; Tislelizumab + Zanidatamab; Zanidatamab	HPK1_inhibitor; HPK1_inhibitor + anti-PD-1_monoclonal_antibody; KIT/PDGFR/RET/VEGFR_inhibitor; KIT/PDGFR/RET/VEGFR_inhibitor + anti-PD-1_monoclonal_antibody; KIT_inhibitor; KIT_inhibitor + anti-PD-1_monoclonal_antibody; PARP_inhibitor; PARP_inhibitor + alkylating_agent; PARP_inhibitor + anti-PD-1_monoclonal_antibody; PDGFR_inhibitor; PDGFR_inhibitor + anti-PD-1_monoclonal_antibody; RET_inhibitor; RET_inhibitor + anti-PD-1_monoclonal_antibody; VEGFR1/2/3_inhibitor + anti-PD-1_monoclonal_antibody; VEGFR_inhibitor; VEGFR_inhibitor + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-OX40_agonistic_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody + bispecific_ERBB2/ERBB2_antibody; bispecific_ERBB2/ERBB2_antibody	2019-002554-23  BGB-A317-290-LTE1	An Open-Label, Multicenter, Long-Term Extension Study of Treatment With Tislelizumab, Pamiparib, and Other Investigational Agents in Patients With Advanced Malignancies	Advanced Malignancies	2031 - Randwick; 3000 - Melbourne; 5011 - Woodville South; Auckland; 4101 - South Brisbane; 2065 - St Leonards; 3168 - Clayton; 2298 - Waratah	https://clinicaltrials.gov/ct2/show/NCT04164199
NCT04170283	BGB-3111-LTE1	Phase 3		ACT, NSW, NZ, QLD, SA, TAS, VIC, WA	2019-11-20	2020-01-21		Tislelizumab; Tislelizumab + Zanubrutinib; Zanubrutinib	BTK_inhibitor; BTK_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody	Tislelizumab + Zanubrutinib; Zanubrutinib	BTK_inhibitor; BTK_inhibitor + anti-PD-1_monoclonal_antibody	BGB-3111-LTE1	An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies	B-cell Malignancies	Canterbury; 4066 - Auchenflower; Wellington; 6009 - Nedlands; Auckland; 2145 - Westmead; 2217 - Kogarah; 4224 - Tugun; 7000 - Hobart; 3144 - Malvern; 3168 - Clayton; Christchurch; 3220 - Geelong; 2065 - St Leonards; 3065 - Fitzroy; 3004 - Melbourne; 2298 - Waratah; 3199 - Frankston; 4102 - Brisbane; 5000 - Adelaide; 3084 - Heidelberg; 4120 - Greenslopes; 3000 - Melbourne; Hamilton Waikato; 2640 - East Albury; 5042 - Bedford PK; 5037 - Kurralta Park; 2139 - Concord; Tauranga; 3128 - Box Hill; 2606 - Canberra; 6000 - Perth	https://clinicaltrials.gov/ct2/show/NCT04170283
NCT04171141	GUCY2C--C3861001	Phase 1		VIC	2019-11-20	2019-11-19		Bevacizumab; Bevacizumab + PF-07062119; PF-07062119	anti-VEGF_monoclonal_antibody + bispecific_T-cell_engager,GUCY2C-targeting; bispecific_T-cell_engager,GUCY2C-targeting; anti-VEGF_monoclonal_antibody	Bevacizumab + PF-07062119; PF-07062119	anti-VEGF_monoclonal_antibody + bispecific_T-cell_engager,GUCY2C-targeting; bispecific_T-cell_engager,GUCY2C-targeting	GUCY2C  C3861001	A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF-07062119 IN PATIENTS WITH ADVANCED GASTROINTESTINAL TUMORS	Colorectal Adenocarcinomas; Gastric Adenocarcinomas; Gastrointestinal Tumors; Esophageal Adenocarcinomas	3000 - Melbourne; 3050 - Parkville	https://clinicaltrials.gov/ct2/show/NCT04171141
NCT04175171	GB221-001	Phase 1		WA	2019-11-22	2011-11-07		Coprelotamab; Trastuzumab	anti-ERBB2_monoclonal_antibody	Coprelotamab; Trastuzumab	anti-ERBB2_monoclonal_antibody	GB221-001	A Randomized, Double-blind, Parallel-group, Comparative Phase I Study to Evaluate the Safety and Pharmacokinetics of Single Intravenous (IV) Administration of GB221 Versus Herceptin® (Trastuzumab)	Metastatic Breast Cancer	6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT04175171
NCT04176757	ZN-c5-002	Phase 1		NSW, QLD, VIC	2019-11-25	2020-01-03		ZN-C5	selective_estrogen_receptor_degrader	ZN-C5	selective_estrogen_receptor_degrader	ZN-c5-002	A Phase 1 Open-Label, Multicenter Study to Evaluate Biomarkers for ZN-c5 in Subjects With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer	Breast Cancer	4870 - Cairns; 3121 - Richmond; 2109 - Sydney; 2170 - Liverpool	https://clinicaltrials.gov/ct2/show/NCT04176757
NCT04178902	2018-003744-24--M19-025	Phase 1		SA, VIC, WA	2019-11-26	2020-05-19		ABBV-467	MCL1_inhibitor	ABBV-467	MCL1_inhibitor	2018-003744-24  M19-025	A First In Human Study of the MCL-1 Inhibitor, ABBV-467	Cancer; Multiple Myeloma (MM)	6000 - Perth; 5000 - Adelaide; 3065 - Fitzroy; 3004 - Melbourne; 6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT04178902
NCT04180384	KX-ORAX-003	Phase 2		NZ, VIC	2019-11-27	2015-09-23		Oraxol; Oraxol + Paclitaxel; Paclitaxel	taxane	Oraxol + Paclitaxel	taxane	KX-ORAX-003	A Safety Study of Oraxol (HM30181 + Oral Paclitaxel) in Cancer Patients	Solid Tumor	Auckland; Wellington; Dunedin; 3168 - Clayton	https://clinicaltrials.gov/ct2/show/NCT04180384
NCT04185883	2023-506794-35--20190135	Phase 1		NSW, QLD, SA, WA	2019-12-04	2019-12-17		AMG 404; AMG 404 + Sotorasib; Afatinib; Afatinib + Sotorasib; Atezolizumab; Atezolizumab + Sotorasib; BI 1701963; BI 1701963 + Sotorasib; Bevacizumab; Bevacizumab + Sotorasib; Carboplatin; Carboplatin + Docetaxel + Paclitaxel + Pembrolizumab + Pemetrexed + Sotorasib; Docetaxel; Everolimus; Everolimus + Sotorasib; Paclitaxel; Palbociclib; Palbociclib + Sotorasib; Panitumumab; Panitumumab + Sotorasib; Panitumumab + Sotorasib + Trametinib; Pembrolizumab; Pembrolizumab + Sotorasib; Pemetrexed; Sotorasib; Sotorasib + TNO155; Sotorasib + Vociprotafib; TNO155; Trametinib; Vociprotafib	antimetabolite; SHP2_inhibitor; anti-PD-L1_monoclonal_antibody; MEK_inhibitor; CDK4/6_inhibitor + KRAS_G12C_inhibitor; anti-VEGF_monoclonal_antibody; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; SOS1-KRAS_inhibitor; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; mTORC1_inhibitor; KRAS_G12C_inhibitor + mTORC1_inhibitor; platinum-based_antineoplastic_agent; ERBB2_inhibitor,second_generation + KRAS_G12C_inhibitor; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody; ERBB2_inhibitor,second_generation; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + SOS1-KRAS_inhibitor; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + SHP2_inhibitor; KRAS_G12C_inhibitor + anti-PD-L1_monoclonal_antibody; KRAS_G12C_inhibitor + MEK_inhibitor + anti-EGFR_monoclonal_antibody; CDK4/6_inhibitor; CDK4/6_inhibitor + KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor; ERBB2_inhibitor,second_generation + KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor; KRAS_G12C_inhibitor; KRAS_G12C_inhibitor + anti-VEGF_monoclonal_antibody; KRAS_G12C_inhibitor + SHP2_inhibitor; EGFR_inhibitor,second_generation + KRAS_G12C_inhibitor; EGFR_inhibitor,second_generation + KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor; KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + anti-VEGF_monoclonal_antibody; anti-PD-1_monoclonal_antibody; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + MEK_inhibitor + anti-EGFR_monoclonal_antibody; taxane; KRAS_G12C_inhibitor + SOS1-KRAS_inhibitor; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + mTORC1_inhibitor; anti-EGFR_monoclonal_antibody; EGFR_inhibitor,second_generation; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + anti-PD-L1_monoclonal_antibody	AMG 404 + Sotorasib; Afatinib + Sotorasib; Atezolizumab + Sotorasib; BI 1701963 + Sotorasib; Bevacizumab + Sotorasib; Carboplatin + Docetaxel + Paclitaxel + Pembrolizumab + Pemetrexed + Sotorasib; Everolimus + Sotorasib; Palbociclib + Sotorasib; Panitumumab + Sotorasib; Panitumumab + Sotorasib + Trametinib; Pembrolizumab + Sotorasib; Sotorasib; Sotorasib + TNO155; Sotorasib + Vociprotafib	CDK4/6_inhibitor + KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor; CDK4/6_inhibitor + KRAS_G12C_inhibitor; EGFR_inhibitor,second_generation + KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor; EGFR_inhibitor,second_generation + KRAS_G12C_inhibitor; ERBB2_inhibitor,second_generation + KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor; ERBB2_inhibitor,second_generation + KRAS_G12C_inhibitor; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + MEK_inhibitor + anti-EGFR_monoclonal_antibody; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + SHP2_inhibitor; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + SOS1-KRAS_inhibitor; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + anti-PD-L1_monoclonal_antibody; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + anti-VEGF_monoclonal_antibody; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + mTORC1_inhibitor; KRAS_G12C_inhibitor; KRAS_G12C_inhibitor + MEK_inhibitor + anti-EGFR_monoclonal_antibody; KRAS_G12C_inhibitor + SHP2_inhibitor; KRAS_G12C_inhibitor + SOS1-KRAS_inhibitor; KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; KRAS_G12C_inhibitor + anti-PD-L1_monoclonal_antibody; KRAS_G12C_inhibitor + anti-VEGF_monoclonal_antibody; KRAS_G12C_inhibitor + mTORC1_inhibitor	2023-506794-35  20190135	A Phase 1b, Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Sotorasib Monotherapy and in Combination With Other Anti-cancer Therapies in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)	Advanced Solid Tumors; Kirsten Rat Sarcoma (KRAS) pG12C Mutation	6008 - Subiaco; 4101 - South Brisbane; 2065 - St Leonards; 5011 - Woodville South; 2747 - Kingswood	https://clinicaltrials.gov/ct2/show/NCT04185883
NCT04186637	NEON-1	Phase 1		NedlandsVIC, VIC, WA	2019-12-05	2020-06-02		ALPN-202	dual_PD-L1/CTLA4_inhibitor; CD28_agonist	ALPN-202	CD28_agonist; dual_PD-L1/CTLA4_inhibitor	AIS-B01	An Open-label Study of ALPN-202 in Subjects With Advanced Malignancies (NEON-1)	Lymphoma; Advanced Solid Tumor	6009 - Perth; 3004 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04186637
NCT04188548	EMBER	Phase 1		NSW, SA, WA	2019-12-06	2019-12-10		Abemaciclib; Abemaciclib + Anastrozole + Exemestane + Imlunestrant + Letrozole; Abemaciclib + Imlunestrant + Trastuzumab; Alpelisib; Alpelisib + Imlunestrant; Anastrozole; Everolimus; Everolimus + Imlunestrant; Exemestane; Imlunestrant; Imlunestrant + Pertuzumab + Trastuzumab; Letrozole; Pertuzumab; Trastuzumab	PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader; anti-ERBB2_monoclonal_antibody; CDK4/6_inhibitor; anti-ERBB2_monoclonal_antibody,dimerization_inhibitor; selective_estrogen_receptor_degrader; anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + aromatase_inhibitor + selective_estrogen_receptor_degrader; aromatase_inhibitor; mTORC1_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + anti-ERBB2_monoclonal_antibody + selective_estrogen_receptor_degrader; mTORC1_inhibitor; PI3K_alpha_inhibitor	Abemaciclib + Anastrozole + Exemestane + Imlunestrant + Letrozole; Abemaciclib + Imlunestrant + Trastuzumab; Alpelisib + Imlunestrant; Everolimus + Imlunestrant; Imlunestrant; Imlunestrant + Pertuzumab + Trastuzumab	CDK4/6_inhibitor + anti-ERBB2_monoclonal_antibody + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + aromatase_inhibitor + selective_estrogen_receptor_degrader; PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader; anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor + selective_estrogen_receptor_degrader; mTORC1_inhibitor + selective_estrogen_receptor_degrader; selective_estrogen_receptor_degrader	J2J-MC-JZLA  17502	EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers	Breast Cancer; Advanced Breast Cancer; Endometrial Cancer; Metastatic Breast Cancer	2298 - Waratah; 6009 - Nedlands; 2010 - Darlinghurst; 5000 - Adelaide	https://clinicaltrials.gov/ct2/show/NCT04188548
NCT04195139	NUTMEG	Phase 2		NSW, QLD, SA, TAS, VIC, WA	2019-12-11	2018-02-22		Nivolumab; Nivolumab + Radiotherapy + Temozolomide; Radiotherapy; Radiotherapy + Temozolomide; Temozolomide	radiotherapy; alkylating_agent; alkylating_agent + radiotherapy; alkylating_agent + anti-PD-1_monoclonal_antibody + radiotherapy; anti-PD-1_monoclonal_antibody	Nivolumab + Radiotherapy + Temozolomide; Radiotherapy + Temozolomide	alkylating_agent + anti-PD-1_monoclonal_antibody + radiotherapy; alkylating_agent + radiotherapy	ACTRN12617000267358  COGNO 16/01, CTC 0156	A Randomised Phase II Study of NivolUmab and TeMozolomide vs Temozolomide Alone in Newly Diagnosed Elderly Patients With Glioblastoma (NUTMEG)	Glioblastoma Multiforme	5042 - Bedford Park; 2444 - Port Macquarie; 3121 - Richmond; 2050 - Camperdown; 3000 - Melbourne; 4029 - Herston; 2065 - Saint Leonards; 3084 - Heidelberg; 5000 - Adelaide; 2500 - Wollongong; 2031 - Randwick; 2250 - Gosford; 4102 - Woolloongabba; 2305 - New Lambton Heights; 4101 - South Brisbane; 3168 - Clayton; 7000 - Hobart; 2560 - Campbelltown; 6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT04195139
NCT04205227	MK3475-951	Phase 1		NSW	2019-12-19	2020-02-18		ENB003; ENB003 + Pembrolizumab; Pembrolizumab	ETBR_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; ETBR_inhibitor	ENB003 + Pembrolizumab	ETBR_inhibitor + anti-PD-1_monoclonal_antibody	ENB-003-101 (MK3475-951)	A Phase 1/2A Trial of ENB 003 in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors	Ovary Cancer; Cancer; Melanoma; Pancreatic Cancer; Solid Tumor	2148 - Blacktown; 2640 - Albury; 2010 - Darlinghurst	https://clinicaltrials.gov/ct2/show/NCT04205227
NCT04209855	MIRASOL	Phase 3		NSW, SA, VIC	2019-12-24	2019-12-31		Mirvetuximab Soravtansine; Paclitaxel; Paclitaxel + Pegylated liposomal doxorubicin + Topotecan; Pegylated liposomal doxorubicin; Topotecan	anthracycline + taxane + topoisomerase_inhibitor; topoisomerase_inhibitor; anthracycline; anti-FR-alpha_antibody-drug_conjugate; taxane	Mirvetuximab Soravtansine; Paclitaxel + Pegylated liposomal doxorubicin + Topotecan	anthracycline + taxane + topoisomerase_inhibitor; anti-FR-alpha_antibody-drug_conjugate	2019-003509-80  IMGN853-0416	MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression	Fallopian Tube Cancer; Peritoneal Cancer; Epithelial Ovarian Cancer	5065 - Toorak Gardens; 2305 - New Lambton Heights; 3168 - Clayton; 3144 - Malvern; 2065 - Saint Leonards; 2031 - Randwick	https://clinicaltrials.gov/ct2/show/NCT04209855
NCT04210037	APG1252SU101	Phase 1		NSW, SA	2019-12-24	2020-08-20		Paclitaxel; Pelcitoclax	Bcl2_inhibitor; taxane	Pelcitoclax; Paclitaxel	Bcl2_inhibitor; taxane	APG1252SU101	A Multi-Center, Phase Ib/II Study of Combination Treatment of APG-1252 With Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer	Small Cell Lung Cancer	5042 - Bedford Park; 2148 - Westmead	https://clinicaltrials.gov/ct2/show/NCT04210037
NCT04215978	2022-501177-39-00--BGB-A317-A445-101	Phase 2		NSW, NZ, QLD, VIC, WA	2020-01-02	2020-01-30		BGB-A445; BGB-A445 + Tislelizumab; Tislelizumab	anti-OX40_agonistic_antibody + anti-PD-1_monoclonal_antibody; anti-OX40_agonistic_antibody; anti-PD-1_monoclonal_antibody	BGB-A445; BGB-A445 + Tislelizumab	anti-OX40_agonistic_antibody; anti-OX40_agonistic_antibody + anti-PD-1_monoclonal_antibody	2022-501177-39-00  BGB-A317-A445-101	Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of the Anti OX40 Agonist Monoclonal Antibody BGB-A445 in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors	Non Small Cell Lung Cancer; Head and Neck Squamous Cell Carcinoma (HNSCC); Nasopharyngeal Carcinoma (NPC); Advanced Solid Tumor	Auckland; 4217 - Benowa; 6009 - Nedlands; 2148 - Blacktown; 3004 - Melbourne; 3168 - Clayton; 3000 - Melbourne; 4102 - Brisbane	https://clinicaltrials.gov/ct2/show/NCT04215978
NCT04221035	HR-NBL2	Phase 3		NSW, Randwic, VIC, WA	2020-01-09	2019-11-05		Busulfan; Carboplatin; Cisplatin; Cyclophosphamide; Dacarbazine; Dinutuximab; Doxorubicin; Etoposide; Ifosfamide; Irinotecan; Melphalan; Radiotherapy; Temozolomide; Thiotepa; Vincristine	anti-GD2_monoclonal_antibody; radiotherapy; doxorubicin; topoisomerase_inhibitor; anthracycline; vinca_alkaloid; alkylating_agent; platinum-based_antineoplastic_agent	Radiotherapy; Thiotepa; Busulfan; Carboplatin; Cisplatin; Cyclophosphamide; Dacarbazine; Dinutuximab; Doxorubicin; Etoposide; Ifosfamide; Irinotecan; Melphalan; Temozolomide; Vincristine	alkylating_agent; radiotherapy; anthracycline; anti-GD2_monoclonal_antibody; doxorubicin; platinum-based_antineoplastic_agent; topoisomerase_inhibitor; vinca_alkaloid	2019/2894  2019-001068-31	High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)	Patient With Insufficient Response Chemoimmunotherapy; High-Risk Neuroblastoma	WA, 6009 - Nedlands; NSW, 2031 - Sydney; NSW, 2305 - New Lambton Heights; VIC 3168 - Clayton; NSW, 2145, - Westmead	https://clinicaltrials.gov/ct2/show/NCT04221035
NCT04221542	2021-005052-11--20180146	Phase 1		NSW, VIC	2020-01-09	2020-03-04		Abiraterone; Enzalutamide; Xaluritamig	bispecific_T-cell_engager,STEAP1-targeting; antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor	Xaluritamig; Abiraterone; Enzalutamide	bispecific_T-cell_engager,STEAP1-targeting; CYP17A1_inhibitor; antiandrogen,nonsteroidal,second_generation	2021-005052-11  20180146	A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer	Prostate Cancer	2050 - Camperdown; 3168 - Clayton	https://clinicaltrials.gov/ct2/show/NCT04221542
NCT04233060	CS3005-101	Phase 1		NSW	2020-01-18	2020-01-10		CS3005	adenosine_A2A_receptor_antagonist	CS3005	adenosine_A2A_receptor_antagonist	CS3005-101	A Phase I, Multi-center, Open-label, Dose Escalation Study of CS3005 in Subjects With Advanced Solid Tumors	Advanced Solid Tumor	2031 - Sydney	https://clinicaltrials.gov/ct2/show/NCT04233060
NCT04242199	INCB-99280-112	Phase 1		NSW, VIC, WA	2020-01-27	2020-09-04		INCB099280	PD-L1_inhibitor,oral	INCB099280	PD-L1_inhibitor,oral	INCB 99280-112	A Phase 1 Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Select Advanced Solid Tumors	PD-L1 Amplified Tumor (9p24.1); Urothelial Carcinoma; Advanced Solid Tumor; Esophageal Squamous Cell Carcinoma; Cutaneous Squamous Cell Carcinoma; Merkel Cell Carcinoma; HepatoCellular Carcinoma; Mesothelioma; Nasopharyngeal Carcinoma; Cervical Cancer; Small-cell Lung Cancer; MSI-H/dMMR Tumors	02050 - Camperdown; 03084 - Heidelberg; 03004 - Melbourne; 06009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT04242199
NCT04243837	LYT-100-2020-US-02	Phase 2		NSW, QLD, SA, VIC	2020-01-28	2020-03-01		Placebo	placebo	Placebo	placebo	LYT-100-2020-US-02	A Phase 2a Double-Blind, Placebo-Controlled Study to Determine the Safety, Tolerability, Pharmacokinetics, and Efficacy of Deupirfenidone (LYT-100) in Patients With Breast Cancer-Related Upper Limb Secondary Lymphoedema	Lymphoedema; Breast Cancer Related Lymphoedema	- Sydney; - Ballarat; - Adelaide; - Sippy Downs	https://clinicaltrials.gov/ct2/show/NCT04243837
NCT04246177	LEAP-012	Phase 3		NSW, NZ, QLD, VIC, WA	2020-01-29	2020-05-22		Lenvatinib; Lenvatinib + Pembrolizumab; Pembrolizumab; Placebo	placebo; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; VEGF_inhibitor; anti-PD-1_monoclonal_antibody	Lenvatinib + Pembrolizumab; Placebo	VEGF_inhibitor + anti-PD-1_monoclonal_antibody; placebo	MK-7902-012  7902-012	A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (LEAP-012)	Carcinoma, Hepatocellular	2145 - Westmead; 2217 - Kogarah; Auckland; 3004 - Melbourne; 4102 - Brisbane; 3084 - Heidelberg; 6000 - Perth	https://clinicaltrials.gov/ct2/show/NCT04246177
NCT04249843	BGB-3245-AU-001	Phase 1		NSW, WA, WAVIC	2020-01-31	2020-02-17		Brimarafenib	RAF_dimer_inhibitor	Brimarafenib	RAF_dimer_inhibitor	BGB-3245-AU-001	A First-in-Human, Phase 1a/1b, Open Label, Dose-Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, and Antitumor Activity of the RAF Dimer Inhibitor BGB-3245 in Patients with Advanced or Refractory Tumors	Solid Tumor; B-Raf Mutation-Related Tumors	2010 - Sydney; 2010 - Melbourne; 6009 - Nedlands; 2148 - Blacktown	https://clinicaltrials.gov/ct2/show/NCT04249843
NCT04262466	IMC-F106C-101	Phase 1		NSW, NZ, VIC, WA	2020-02-10	2020-02-25		Bevacizumab; Bevacizumab + Pembrolizumab; IMC-F106C; Pembrolizumab; Tebentafusp	bispecific_T-cell_engager,PRAME-targeting; anti-PD-1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-VEGF_monoclonal_antibody; bispecfic_T-cell_engager,gp100-targeting	Bevacizumab + Pembrolizumab; Pembrolizumab; IMC-F106C; Tebentafusp	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; bispecfic_T-cell_engager,gp100-targeting; bispecific_T-cell_engager,PRAME-targeting	IMC-F106C-101	Phase 1/2 Study of IMC-F106C in Advance PRAME-Positive Cancers	Select Advanced Solid Tumors	2031 - Randwick; 2065 - Wollstonecraft; 6009 - Nedlands; Auckland; 3004 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04262466
NCT04262856	ARC-7	Phase 2		NSW, SA	2020-02-10	2020-05-28		Domvanalimab; Domvanalimab + Etrumadenant + Zimberelimab; Domvanalimab + Zimberelimab; Etrumadenant; Zimberelimab	adenosine_A2aR_and_A2bR_antagonist + anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; adenosine_A2aR_and_A2bR_antagonist; anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody	Domvanalimab + Etrumadenant + Zimberelimab; Domvanalimab + Zimberelimab; Zimberelimab	adenosine_A2aR_and_A2bR_antagonist + anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody	ARC-7 (AB154CSP0002)	A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination With AB122, and AB154 in Combination With AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer	Nonsquamous Non Small Cell Lung Cancer; Lung Cancer; Squamous Non Small Cell Lung Cancer; Non Small Cell Lung Cancer	- Elizabeth Vale; - Coffs Harbour; - Nowra; - Albury	https://clinicaltrials.gov/ct2/show/NCT04262856
NCT04269200	DUO-E	Phase 3		NSW, VIC, WA	2020-02-13	2020-05-05		Carboplatin; Durvalumab; Durvalumab + Olaparib; Olaparib; Paclitaxel; Placebo	placebo; PARP_inhibitor + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; taxane; platinum-based_antineoplastic_agent; PARP_inhibitor	Durvalumab + Olaparib; Carboplatin; Paclitaxel; Placebo	PARP_inhibitor + anti-PD-L1_monoclonal_antibody; placebo; platinum-based_antineoplastic_agent; taxane	GOG-3041  D9311C00001	A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination With Durvalumab, Followed by Maintenance Durvalumab With or Without Olaparib in Patients With Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E)	Endometrial Neoplasms	3000 - Melbourne; 6009 - Nedlands; NSW 2145 - Sydney; 3168 - Clayton; 3144 - Malvern	https://clinicaltrials.gov/ct2/show/NCT04269200
NCT04284761	Biolen-PC	Phase 1		NSW, NZ	2020-02-26	2020-10-11		Bicalutamide	antiandrogen,nonsteroidal,first_generation	Bicalutamide	antiandrogen,nonsteroidal,first_generation	CP-001	A Study to Establish the Feasibility of Biolen for the Local Delivery of Bicalutamide in Patients With Prostate Cancer	Lower Urinary Tract Symptoms; Prostate Adenocarcinoma	2500 - Wollongong; 2076 - Wahroonga	https://clinicaltrials.gov/ct2/show/NCT04284761
NCT04293094	NCT04293094	Phase 1		SA, VIC	2020-03-03	2020-03-11		AMG 650	KIF18A_inhibitor	AMG 650	KIF18A_inhibitor	20190131	A Phase 1, Multicenter, Open-label, Dose-Exploration and Dose-Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 650 in Subjects With Advanced Solid Tumors	Advanced Solid Tumors	3000 - Melbourne; 5011 - Woodville South	https://clinicaltrials.gov/ct2/show/NCT04293094
NCT04294160	CADPT01C12101	Phase 1		NSW	2020-03-03	2020-07-22		Dabrafenib; Dabrafenib + LTT462; Dabrafenib + LTT462 + Naporafenib; Dabrafenib + LTT462 + Spartalizumab; Dabrafenib + LTT462 + TNO155; Dabrafenib + LTT462 + Tislelizumab; Dabrafenib + LTT462 + Trametinib; Dabrafenib + TNO155 + Trametinib; LTT462; Naporafenib; Spartalizumab; TNO155; Tislelizumab; Trametinib	ERK_inhibitor; SHP2_inhibitor; MEK_inhibitor; BRAF_V600_inhibitor + MEK_inhibitor + SHP2_inhibitor; BRAF_V600_inhibitor + ERK_inhibitor + SHP2_inhibitor; anti-PD-1_monoclonal_antibody; BRAF_V600_inhibitor + ERK_inhibitor + anti-PD-1_monoclonal_antibody; RAF_dimer_inhibitor; BRAF_V600_inhibitor + ERK_inhibitor + MEK_inhibitor; BRAF_V600_inhibitor + ERK_inhibitor; BRAF_V600_inhibitor + ERK_inhibitor + RAF_dimer_inhibitor; BRAF_V600_inhibitor	Dabrafenib + LTT462; Dabrafenib + LTT462 + Naporafenib; Dabrafenib + LTT462 + Spartalizumab; Dabrafenib + LTT462 + TNO155; Dabrafenib + LTT462 + Tislelizumab; Dabrafenib + LTT462 + Trametinib; Dabrafenib + TNO155 + Trametinib	BRAF_V600_inhibitor + ERK_inhibitor; BRAF_V600_inhibitor + ERK_inhibitor + MEK_inhibitor; BRAF_V600_inhibitor + ERK_inhibitor + RAF_dimer_inhibitor; BRAF_V600_inhibitor + ERK_inhibitor + SHP2_inhibitor; BRAF_V600_inhibitor + ERK_inhibitor + anti-PD-1_monoclonal_antibody; BRAF_V600_inhibitor + MEK_inhibitor + SHP2_inhibitor	CADPT01C12101	A Phase Ib, Multicenter, Open-label Dose Escalation and Expansion Platform Study of Select Drug Combinations in Adult Patients With Advanced or Metastatic BRAF V600 Colorectal Cancer	BRAF V600 Colorectal Cancer	2145 - Westmead	https://clinicaltrials.gov/ct2/show/NCT04294160
NCT04296890	SORAYA	Phase 3		NSW, QLD, VIC, WA	2020-03-05	2020-07-23		Mirvetuximab Soravtansine	anti-FR-alpha_antibody-drug_conjugate	Mirvetuximab Soravtansine	anti-FR-alpha_antibody-drug_conjugate	2020-000179-19  IMGN853-0417	SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression	Fallopian Tube Cancer; Peritoneal Cancer; Epithelial Ovarian Cancer	4066 - Auchenflower; 3199 - Frankston; 6008 - Subiaco; 2065 - St. Leonards	https://clinicaltrials.gov/ct2/show/NCT04296890
NCT04298918	2019-004200-35--CO41863	Phase 1/Phase 2		VIC	2020-03-06	2020-09-23		Placebo; Trastuzumab Emtansine; Trastuzumab Emtansine + Venetoclax; Venetoclax	placebo; Bcl2_inhibitor; anti-ERBB2_antibody-drug_conjugate; Bcl2_inhibitor + anti-ERBB2_antibody-drug_conjugate	Trastuzumab Emtansine; Trastuzumab Emtansine + Venetoclax; Placebo	Bcl2_inhibitor + anti-ERBB2_antibody-drug_conjugate; anti-ERBB2_antibody-drug_conjugate; placebo	2019-004200-35  CO41863	A Phase lb/ll, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Venetoclax in Combination With Trastuzumab Emtansine in Patients With Previously Treated HER2-Positive Locally Advanced or Metastatic Breast Cancer	Breast Cancer	3002 - East Melbourne	https://clinicaltrials.gov/ct2/show/NCT04298918
NCT04300244	NIPU	Phase 2		WA	2020-03-09	2020-05-04		Ipilimumab; Ipilimumab + Nivolumab; Nivolumab; Sargramostim	anti-PD-1_monoclonal_antibody; anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA4_monoclonal_antibody; Granulocyte-Macrophage_Colony_Stimulating_Factor	Ipilimumab + Nivolumab; Sargramostim	anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; Granulocyte-Macrophage_Colony_Stimulating_Factor	CA209-7H4 NIPU	Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma (the NIPU-study)	Cancer; Mesotheliomas Pleural; Mesothelioma; Cancer, Lung; Pleura; Lung; Cancer of Lung	- Perth	https://clinicaltrials.gov/ct2/show/NCT04300244
NCT04300647	SKYSCRAPER-04	Phase 2		QLD	2020-03-09	2020-06-30		Atezolizumab; Atezolizumab + Tiragolumab; Tiragolumab	anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-TIGIT_monoclonal_antibody; anti-PD-L1_monoclonal_antibody	Atezolizumab; Atezolizumab + Tiragolumab	anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody	2019-004895-21  WO42017	A Phase II, Safety, and Efficacy Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Patients With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer	Cervical Cancer	4101 - South Brisbane	https://clinicaltrials.gov/ct2/show/NCT04300647
NCT04305041	MK-3475-02A--3475-02A	Phase 1		NSW, QLD, WA	2020-03-12	2020-06-26		Lenvatinib; Lenvatinib + Pembrolizumab + Quavonlimab; Pembrolizumab; Pembrolizumab + Quavonlimab + Vibostolimab; Quavonlimab; Vibostolimab	anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody; VEGF_inhibitor; VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA4_monoclonal_antibody	Lenvatinib + Pembrolizumab + Quavonlimab; Pembrolizumab; Pembrolizumab + Quavonlimab + Vibostolimab	VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody	MK-3475-02A  3475-02A	A Phase 1/2 Open-label Rolling-arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma (KEYMAKER-U02): Substudy 02A	Melanoma	2065 - Wollstonecraft; 6150 - Murdoch; 2298 - Waratah; 4215 - Southport	https://clinicaltrials.gov/ct2/show/NCT04305041
NCT04305054	MK-3475-02B--3475-02B	Phase 1		NSW, QLD, WA	2020-03-12	2020-07-01		Favezelimab; Favezelimab + Pembrolizumab; Favezelimab + Pembrolizumab + Vibostolimab; Lenvatinib; Lenvatinib + Pembrolizumab + Quavonlimab; Pembrolizumab; Pembrolizumab + Quavonlimab; Pembrolizumab + Vibostolimab; Quavonlimab; Vibostolimab	anti-LAG3_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody; VEGF_inhibitor; anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA4_monoclonal_antibody	Favezelimab + Pembrolizumab; Favezelimab + Pembrolizumab + Vibostolimab; Lenvatinib + Pembrolizumab + Quavonlimab; Pembrolizumab; Pembrolizumab + Quavonlimab; Pembrolizumab + Vibostolimab	VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody	MK-3475-02B  3475-02B	A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma (KEYMAKER-U02): Substudy 02B	Melanoma	2298 - Waratah; 4120 - Southport; 2065 - Wollstonecraft; 6150 - Murdoch	https://clinicaltrials.gov/ct2/show/NCT04305054
NCT04305249	ERASER	Phase 1		NSW, VIC	2020-03-12	2020-08-15		ATG-017; ATG-017 + Nivolumab; Nivolumab	ERK_inhibitor; anti-PD-1_monoclonal_antibody; ERK_inhibitor + anti-PD-1_monoclonal_antibody	ATG-017; ATG-017 + Nivolumab	ERK_inhibitor; ERK_inhibitor + anti-PD-1_monoclonal_antibody	ATG-017-001	A Phase I, Open-Label, Multi-Center Dose Finding Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG-017 Monotherapy or Combination Therapy With Nivolumab in Patients With Advanced Solid Tumors and Hematological Malignancies	Hematological Malignancy; Solid Tumor	3002 - East Melbourne; 3084 - Heidelberg; - Randwick; - Sydney; 3004 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04305249
NCT04305496	CAPItello-291	Phase 3		NSW, QLD, SA, VIC	2020-03-12	2020-04-16		Capivasertib; Capivasertib + Fulvestrant; Fulvestrant; Placebo	placebo; selective_estrogen_receptor_degrader; pan-AKT_inhibitor; pan-AKT_inhibitor + selective_estrogen_receptor_degrader	Capivasertib + Fulvestrant; Fulvestrant; Placebo	pan-AKT_inhibitor + selective_estrogen_receptor_degrader; selective_estrogen_receptor_degrader; placebo	2019-003629-78  D3615C00001	A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Fulvestrant Versus Placebo + Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Breast Cancer Following Recurrence or Progression On or After Treatment With an Aromatase Inhibitor	Locally Advanced (Inoperable) or Metastatic Breast Cancer	5037 - Kurralta Park; 2139 - Concord; 4575 - Birtinya; 3128 - Box Hill; 5000 - Adelaide; 3350 - Ballarat; 2298 - Waratah; 3355 - Wendouree; 4101 - South Brisbane; 2060 - North Sydney; 2800 - Orange; 3135 - Ringwood East	https://clinicaltrials.gov/ct2/show/NCT04305496
NCT04324814	SHR-1701-001AUS	Phase 1		NSW, QLD, WA	2020-03-27	2020-03-31		Retlirafusp alfa	PD-L1/TGF-beta_fusion_protein	Retlirafusp alfa	PD-L1/TGF-beta_fusion_protein	SHR-1701-001AUS	A Phase 1, Open-Label, Multi-Center, Non-Randomized, Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of SHR-1701 in Subjects With Advanced Solid Tumors.	Advanced Solid Tumor	- Perth; - Sydney; 4101 - South Brisbane	https://clinicaltrials.gov/ct2/show/NCT04324814
NCT04334759	DREAM3R	Phase 3		ACT, NSW, NZ, QLD, SA, TAS, VIC, WA	2020-04-06	2021-02-18		Durvalumab; Ipilimumab; Ipilimumab + Nivolumab; Nivolumab	anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-CTLA4_monoclonal_antibody	Durvalumab; Ipilimumab + Nivolumab	anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody	PrE0506  DREAM3R	DREAM3R: DuRvalumab (MEDI4736) With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma - A Phase 3 Randomised Trial	Pleural Mesothelioma; Malignant Pleural Mesothelioma; Mesothelioma	4814 - Douglas; 2145 - Westmead; 2605 - Garran; 2800 - Orange; 2450 - Coffs Harbour; 4066 - Auchenflower; 3021 - Saint Albans; 2148 - Blacktown; 6009 - Nedlands; 7250 - Launceston; Auckland; 2298 - Waratah; 4102 - Woolloongabba; 3199 - Frankston; 2250 - Gosford; 2259 - Hamlyn Terrace; 7000 - Hobart; 3168 - Clayton; 3630 - Shepparton; 4101 - South Brisbane; 2065 - Saint Leonards; 3000 - Melbourne; 2050 - Camperdown; 3084 - Heidelberg; 4032 - Chermside; 2747 - Kingswood; 5011 - Woodville South; 2170 - Liverpool; 5042 - Bedford Park; 4575 - Birtinya; 3121 - Richmond	https://clinicaltrials.gov/ct2/show/NCT04334759
NCT04338399	BURAN	Phase 3		QLD	2020-04-08	2020-12-12		Buparlisib; Buparlisib + Paclitaxel; Paclitaxel	PI3K_alpha_inhibitor; pan-PI3K_inhibitor; PI3K_alpha_inhibitor + taxane; taxane; pan-PI3K_inhibitor + taxane	Buparlisib + Paclitaxel; Paclitaxel	PI3K_alpha_inhibitor + taxane; pan-PI3K_inhibitor + taxane; taxane	AN2025H0301	The BURAN Study of Buparlisib (AN2025) In Combination With Paclitaxel Compared to Paclitaxel Alone, in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma	Head and Neck Cancer	4102 - Brisbane	https://clinicaltrials.gov/ct2/show/NCT04338399
NCT04340193	CheckMate-74W	Phase 3		NSW, QLD, SA, VIC, WA	2020-04-09	2020-09-14		Ipilimumab; Ipilimumab + Nivolumab; Nivolumab; Placebo	placebo; anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-CTLA4_monoclonal_antibody	Ipilimumab + Nivolumab; Nivolumab; Placebo	anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; placebo	CA209-74W	A Randomized, Multi-center, Double-blinded, Placebo-controlled Phase 3 Study of Nivolumab and Ipilimumab, Nivolumab Monotherapy, or Placebo in Combination With Trans-arterial ChemoEmbolization (TACE) in Patients With Intermediate-stage Hepatocellular Carcinoma (HCC)	Cancer, Hepatocellular	3065 - Melbourne; 6150 - Murdoch; 4575 - Birtinya; 5000 - Adelaide; 2500 - Wollongong	https://clinicaltrials.gov/ct2/show/NCT04340193
NCT04343885	UpFrontPSMA	Phase 2		NSW, QLD, SA, VIC, WA	2020-04-13	2020-04-21		Docetaxel; Docetaxel + Lu-177 vipivotide tetraxetan; Lu-177 vipivotide tetraxetan	radioconjugate,PSMA-targeting; taxane; radioconjugate,PSMA-targeting + taxane	Docetaxel + Lu-177 vipivotide tetraxetan	radioconjugate,PSMA-targeting + taxane	19/195	UpFrontPSMA : A Randomised Phase 2 Study of Sequential 177Lu-PSMA617 and Docetaxel Versus Docetaxel in Metastatic Hormone-Naive Prostate Cancer	Metastatic Hormone Naive Prostate Cancer	2065 - St Leonards; 3144 - Malvern; 3084 - Melbourne; 4029 - Brisbane; 6009 - Nedlands; 2050 - Sydney; 6150 - Murdoch; 3000 - Prahran; 2170 - Liverpool; 2010 - Sydney; 5000 - Adelaide; 3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04343885
NCT04349969	AK117-101	Phase 1		NSW, QLD, SA, VIC	2020-04-16	2020-04-23		AK117; Cadonilimab	bispecific_PD-1/CTLA4_antibody; anti-CD47_monoclonal_antibody	AK117; Cadonilimab	anti-CD47_monoclonal_antibody; bispecific_PD-1/CTLA4_antibody	AK117-101	A Phase 1 Multicenter, Open Label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK117 as Monotherapy or in Combination With AK104 in Subjects With Relapsed/Refractory Advanced or Metastatic Solid Tumors or Lymphomas	Neoplasms Malignant	- Sydney; - South Brisbane; - Heidelberg; - Kurralta Park	https://clinicaltrials.gov/ct2/show/NCT04349969
NCT04351165	IMP4297-107	Phase 1		NSW	2020-04-17	2020-10-29		Senaparib	PARP_inhibitor	Senaparib	PARP_inhibitor	IMP4297-107	An Open-Label, Randomized, Single-Dose, 2-Way Crossover Study to Compare the Bioavailability of Two IMP4297 Formulations (20 mg Capsules and 10 mg Capsules) After Single Oral Administration of 100 mg IMP4297 Under Fasted Condition in Healthy Male Subjects	Solid Tumor	- Sydney	https://clinicaltrials.gov/ct2/show/NCT04351165
NCT04353102	YH002002	Phase 1		NSW, VIC	2020-04-20	2020-04-22		YH002	anti-OX40_agonistic_antibody	YH002	anti-OX40_agonistic_antibody	YH002002	A First-in-Human (FIH), Multicenter, Open-Label, Phase 1 Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of YH002 in Subjects With Advanced Solid Malignancies	Advanced Solid Malignancies	2217 - Kogarah; 2162 - Macquarie; 3199 - Frankston	https://clinicaltrials.gov/ct2/show/NCT04353102
NCT04357756	YH001002	Phase 1		NSW, VIC	2020-04-22	2020-04-21		Toripalimab; Toripalimab + YH001; YH001	anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-CTLA4_monoclonal_antibody	Toripalimab + YH001	anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	YH001002	A First-in-human (FIH), Open-Label, Phase I Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of YH001 in Combination With Toripalimab Injection in Subjects With Advanced Solid Tumors	Advanced Solid Tumor	3199 - Frankston; 2148 - Blacktown; 2217 - Kogarah	https://clinicaltrials.gov/ct2/show/NCT04357756
NCT04362748	NCT04362748	Phase 1		NSW, VIC	2020-04-27	2020-09-15		Latikafusp	anti-PD-1_x_IL21_mutein	Latikafusp	anti-PD-1_x_IL21_mutein	20180144	A Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 256 in Patients With Advanced Solid Tumors	Advanced Solid Tumors	3168 - Clayton; 2050 - Camperdown; 2010 - Darlinghurst	https://clinicaltrials.gov/ct2/show/NCT04362748
NCT04370704	INCAGN-2385-201	Phase 1		NSW, QLD, SA, VIC, WA	2020-05-01	2020-07-27		Retifanlimab	anti-PD-1_monoclonal_antibody	Retifanlimab	anti-PD-1_monoclonal_antibody	INCAGN 2385-201	A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies	Melanoma	06009 - Nedlands; 02060 - Wollstonecraft; 05042 - Bedford Park; 03128 - Box Hill; - Brisbane	https://clinicaltrials.gov/ct2/show/NCT04370704
NCT04380805	AK104-201-AU	Phase 2		NSW, NZ, QLD, SA, VIC, WA	2020-05-08	2020-07-15		Cadonilimab	bispecific_PD-1/CTLA4_antibody	Cadonilimab	bispecific_PD-1/CTLA4_antibody	AK104-201-AU	A Phase 2, Multicenter, Single Arm, Open Label Study to Evaluate the Efficacy and Safety of AK104 in Subjects With Recurrent or Metastatic Cervical Cancer	Recurrent Cervical Cancer; Metastatic Cervical Cancer	Auckland; - Blacktown; - Nedlands; - Brisbane; - Adelaide; - Clayton	https://clinicaltrials.gov/ct2/show/NCT04380805
NCT04383210	ELVCAP-001-01	Phase 2		NSW, TAS, VIC, WA	2020-05-12	2024-02-28		Seribantumab	anti-ERBB3_monoclonal_antibody	Seribantumab	anti-ERBB3_monoclonal_antibody	ELVCAP-001-01	CRESTONE: a Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors	Ovarian Cancer; Bile Duct Cancer; Head and Neck Cancer; Cholangiocarcinoma; Breast Cancer; Prostate Cancer; Kidney Cancer; Locally Advanced Solid Tumor; Uterine Cancer; Lung Cancer; Sarcoma; Pancreatic Cancer; Metastatic Solid Tumor; Gallbladder Cancer; Esophageal Cancer; Colorectal Cancer; Bladder Cancer	2010 - Sydney; 3000 - Melbourne; 6009 - Nedlands; 7000 - Hobart	https://clinicaltrials.gov/ct2/show/NCT04383210
NCT04402073	PersoMed-I	Phase 2		NSW, QLD, SA, VIC, WA	2020-05-26	2022-11-11		Cisplatin; Lomustine; Radiotherapy; Sonidegib; Vincristine	radiotherapy; SMO_inhibitor,first_generation; vinca_alkaloid; alkylating_agent; platinum-based_antineoplastic_agent	Radiotherapy; Cisplatin; Lomustine; Sonidegib; Vincristine	radiotherapy; SMO_inhibitor,first_generation; alkylating_agent; platinum-based_antineoplastic_agent; vinca_alkaloid	1634	Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma (PersoMed-I)	Medulloblastoma	- Sydney; - Westmead; - Melbourne; - New Lambton Heights; - Nedlands; - Brisbane; - Adelaide	https://clinicaltrials.gov/ct2/show/NCT04402073
NCT04416516	ASN-002-003	Phase 2		QLD, VIC, WA	2020-06-04	2020-07-16		Gusacitinib; Gusacitinib + Vismodegib; Vismodegib	SMO_inhibitor,first_generation + SYK/JAK_inhibitor; SYK/JAK_inhibitor; SMO_inhibitor,first_generation	Gusacitinib; Gusacitinib + Vismodegib	SMO_inhibitor,first_generation + SYK/JAK_inhibitor; SYK/JAK_inhibitor	ASN-002-003	A Phase 2A Study to Assess the Safety and Efficacy of ASN-002 Combined With a Hedgehog Pathway Inhibitor in the Treatment of Multiple Low Risk Basal Cell Carcinomas in Sporadic or Basal Cell Nevus Syndrome Patients	Basal Cell Nevus Syndrome; Basal Cell Carcinoma	- Sunshine Coast; 4000 - Brisbane; 4102 - Brisbane; 6100 - Perth; 3000 - Melbourne; 3050 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04416516
NCT04417621	2020-000873-26--CLXH254C12201	Phase 2		NSW, QLD, WA	2020-06-04	2020-10-30		LTT462; LTT462 + Naporafenib; Naporafenib; Naporafenib + Ribociclib; Naporafenib + Trametinib; Ribociclib; Trametinib	ERK_inhibitor; ERK_inhibitor + RAF_dimer_inhibitor; MEK_inhibitor + RAF_dimer_inhibitor; CDK4/6_inhibitor; MEK_inhibitor; RAF_dimer_inhibitor; CDK4/6_inhibitor + RAF_dimer_inhibitor	LTT462 + Naporafenib; Naporafenib + Ribociclib; Naporafenib + Trametinib	CDK4/6_inhibitor + RAF_dimer_inhibitor; ERK_inhibitor + RAF_dimer_inhibitor; MEK_inhibitor + RAF_dimer_inhibitor	2020-000873-26  CLXH254C12201	A Randomized, Open-label, Multi-arm, Two-part, Phase II Study to Assess Efficacy and Safety of Multiple LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic BRAFV600 or NRAS Mutant Melanoma	Melanoma	4102 - Wooloongabba; 6008 - Subiaco; 2060 - North Sydney	https://clinicaltrials.gov/ct2/show/NCT04417621
NCT04419402	ENZA-p	Phase 2		NSW, QLD, SA, VIC, WA	2020-06-05	2020-08-17		Enzalutamide	antiandrogen,nonsteroidal,second_generation	Enzalutamide	antiandrogen,nonsteroidal,second_generation	ANZUP 1901	ENZA-p: A Randomised Phase II Trial Using PSMA as a Therapeutic Agent and Prognostic Indicator in Men With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide (ANZUP 1901)	Metastatic Castration-Resistant Prostate Cancer	4029 - Brisbane; 6009 - Nedlands; 2217 - Kogarah; 3168 - Clayton; 3004 - Melbourne; 2109 - Macquarie Park; 5000 - Adelaide; 3084 - Heidelberg; 2050 - Camperdown; 2010 - Darlinghurst; 6150 - Perth; 2298 - Newcastle; 3002 - Melbourne; 2170 - Liverpool; 2065 - Sydney	https://clinicaltrials.gov/ct2/show/NCT04419402
NCT04423029	2023-510511-19--DF6002	Phase 1		VIC	2020-06-09	2020-07-13		DF6002; DF6002 + Nivolumab; Nivolumab	IL-12_Fc-fusion_protein + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; IL-12_Fc-fusion_protein	DF6002; DF6002 + Nivolumab	IL-12_Fc-fusion_protein; IL-12_Fc-fusion_protein + anti-PD-1_monoclonal_antibody	2023-510511-19  DF6002 - 001	A Phase 1/1b, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF6002 as a Monotherapy and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications	Solid Tumors	3128 - Box Hill; 3084 - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT04423029
NCT04428151	LEAP-009	Phase 2		NSW, QLD, SA, VIC	2020-06-11	2020-08-06		Capecitabine; Capecitabine + Cetuximab + Docetaxel + Paclitaxel; Cetuximab; Docetaxel; Lenvatinib; Lenvatinib + Pembrolizumab; Paclitaxel; Pembrolizumab	anti-EGFR_monoclonal_antibody + fluoropyrimidine + taxane; fluoropyrimidine; anti-PD-1_monoclonal_antibody; taxane; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; VEGF_inhibitor; anti-EGFR_monoclonal_antibody	Capecitabine + Cetuximab + Docetaxel + Paclitaxel; Lenvatinib; Lenvatinib + Pembrolizumab	VEGF_inhibitor; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; anti-EGFR_monoclonal_antibody + fluoropyrimidine + taxane	LEAP-009  7902-009	A Phase 2, Randomized, Open-label Three-arm Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) That Have Progressed After Platinum Therapy and Immunotherapy (PD-1/PD-L1 Inhibitors) (LEAP-009)	Squamous Cell Carcinoma of Head and Neck	2148 - Sydney; 4814 - Douglas; 3168 - Clayton; 4120 - Greenslopes; 5000 - Adelaide; 2444 - Port Macquarie	https://clinicaltrials.gov/ct2/show/NCT04428151
NCT04428333	INDUCE-4	Phase 3		NSW, QLD, VIC	2020-06-11	2020-08-12		Feladilimab; Feladilimab + Fluorouracil + Pembrolizumab; Fluorouracil; Fluorouracil + Pembrolizumab; GSK3359609; Pembrolizumab; Placebo	placebo; anti-ICOS_agonistic_antibody; anti-PD-1_monoclonal_antibody + fluoropyrimidine; Fluorouracil; fluoropyrimidine; anti-PD-1_monoclonal_antibody; anti-ICOS_agonistic_antibody + anti-PD-1_monoclonal_antibody + fluoropyrimidine	Feladilimab + Fluorouracil + Pembrolizumab; Fluorouracil + Pembrolizumab; GSK3359609; Placebo	anti-ICOS_agonistic_antibody + anti-PD-1_monoclonal_antibody + fluoropyrimidine; anti-PD-1_monoclonal_antibody + fluoropyrimidine; Fluorouracil; placebo	2019-003981-42  209227	A Randomized, Double-Blind, Adaptive, Phase II/III Study of GSK3359609 in Combination With Pembrolizumab and 5FU-Platinum Chemotherapy Versus Placebo in Combination With Pembrolizumab Plus 5FU-Platinum Chemotherapy for First-Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma	Neoplasms, Head and Neck	4102 - Woolangabba; 3000 - Melbourne; 3084 - Heidelberg; 2148 - Blacktown	https://clinicaltrials.gov/ct2/show/NCT04428333
NCT04429542	KEYNOTE-E28--BCA101X1101	Phase 1		NSW, VIC	2020-06-12	2020-06-01		BCA101; BCA101 + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody + bifunctional_EGFR/TGF-beta_fusion_protein; anti-PD-1_monoclonal_antibody; bifunctional_EGFR/TGF-beta_fusion_protein	BCA101; BCA101 + Pembrolizumab	anti-PD-1_monoclonal_antibody + bifunctional_EGFR/TGF-beta_fusion_protein; bifunctional_EGFR/TGF-beta_fusion_protein	KEYNOTE-E28  BCA101X1101	First-in-Human, Phase 1/1b, Open-label, Multicenter Study of Bifunctional EGFR/TGFß Fusion Protein BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-Driven Advanced Solid Tumors	Epithelial Ovarian Cancer; Squamous Cell Carcinoma of Anal Canal; Pancreas Cancer; Colorectal Cancer; EGFR Amplification; Squamous Cell Carcinoma of the Lung; Squamous Cell Carcinoma of Head and Neck; Head and Neck Squamous Cell Carcinoma; Carcinoma, Squamous Cell; Head and Neck Neoplasms; Cutaneous Squamous Cell Carcinoma	2298 - Waratah; 3000 - Melbourne; 3084 - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT04429542
NCT04432207	IMU.201.101	Phase 1		NSW, VIC	2020-06-16	2020-11-30		Atezolizumab; Atezolizumab + IMU-201; IMU-201	B_cell_immunotherapy; anti-PD-L1_monoclonal_antibody; B_cell_immunotherapy + anti-PD-L1_monoclonal_antibody	Atezolizumab + IMU-201; IMU-201	B_cell_immunotherapy; B_cell_immunotherapy + anti-PD-L1_monoclonal_antibody	IMU.201.101	An Open Label, Multi-Center, Dose Escalation/Expansion, Phase 1/1b Study of IMU-201, a B-Cell Immunotherapy As Monotherapy or in Combination with Atezolizumab with or Without Chemotherapy, in Adults with Non- Small Cell Lung Cancer (IMPrinter)	Squamous Non-small-cell Lung Cancer; Non Small Cell Lung Cancer; Large Cell Carcinoma Lung; Non-small Cell Lung Cancer Stage IV; Adenocarcinoma Lung; Non Small Cell Lung Cancer Stage IIIB	3000 - Melbourne; 2050 - Camperdown; 2109 - Macquarie	https://clinicaltrials.gov/ct2/show/NCT04432207
NCT04434482	IMP4297-106	Phase 1		NSW, VIC	2020-06-17	2020-08-07		Senaparib; Senaparib + Temozolomide; Temozolomide	alkylating_agent; PARP_inhibitor + alkylating_agent; PARP_inhibitor	Senaparib + Temozolomide	PARP_inhibitor + alkylating_agent	IMP4297-106	A Phase Ib/II, Open-Label, Multi-Center, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer	Small Cell Lung Cancer; Advanced Solid Tumours	2640 - Albury; 3199 - Frankston; 2800 - Orange; 2148 - Blacktown	https://clinicaltrials.gov/ct2/show/NCT04434482
NCT04438083	CRSP-ONC-003	Phase 1		VIC	2020-06-18	2020-06-16		CTX130	allogeneic_CAR-T-cell_therapy,CD70-targeting	CTX130	allogeneic_CAR-T-cell_therapy,CD70-targeting	CRSP-ONC-003	A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Allogeneic CRISPR-Cas9-Engineered T Cells (CTX130) in Subjects With Advanced, Relapsed or Refractory Renal Cell Carcinoma With Clear Cell Differentiation	Renal Cell Carcinoma	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04438083
NCT04446117	CONTACT-02	Phase 3		ACT, NSW, QLD, SA, TAS, VIC	2020-06-24	2020-06-30		Abiraterone; Abiraterone + Enzalutamide + Prednisone; Atezolizumab; Atezolizumab + Cabozantinib; Cabozantinib; Enzalutamide; Prednisone	AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + anti-PD-L1_monoclonal_antibody; CYP17A1_inhibitor; anti-PD-L1_monoclonal_antibody; RET_inhibitor; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + glucocorticoid; ROS1_inhibitor; AXL_inhibitor + anti-PD-L1_monoclonal_antibody; AXL_inhibitor; VEGFR2_inhibitor + anti-PD-L1_monoclonal_antibody; glucocorticoid; RET_inhibitor + anti-PD-L1_monoclonal_antibody; KIT_inhibitor; antiandrogen,nonsteroidal,second_generation; VEGFR2_inhibitor; MET_inhibitor,type_2 + anti-PD-L1_monoclonal_antibody; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor; KIT_inhibitor + anti-PD-L1_monoclonal_antibody; ROS1_inhibitor + anti-PD-L1_monoclonal_antibody; MET_inhibitor,type_2	Abiraterone + Enzalutamide + Prednisone; Atezolizumab + Cabozantinib	AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + anti-PD-L1_monoclonal_antibody; AXL_inhibitor + anti-PD-L1_monoclonal_antibody; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + glucocorticoid; KIT_inhibitor + anti-PD-L1_monoclonal_antibody; MET_inhibitor,type_2 + anti-PD-L1_monoclonal_antibody; RET_inhibitor + anti-PD-L1_monoclonal_antibody; ROS1_inhibitor + anti-PD-L1_monoclonal_antibody; VEGFR2_inhibitor + anti-PD-L1_monoclonal_antibody	XL184-315	A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination With Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects With Metastatic Castration-Resistant Prostate Cancer	Metastatic Prostate Cancer; Prostate Adenocarcinoma	2605 - Garran; 7250 - Launceston; 3021 - Saint Albans; 3199 - Frankston; 3220 - Geelong; 2065 - Saint Leonards; 3000 - Melbourne; 3350 - Ballarat; 4032 - Chermside; 2500 - Wollongong; 5000 - Adelaide; 2444 - Port Macquarie; 3128 - Box Hill; 2109 - Sydney	https://clinicaltrials.gov/ct2/show/NCT04446117
NCT04446260	SHR-A1811-I-101	Phase 1		NSW, SA, VIC	2020-06-24	2020-09-07		SHR-A1811	anti-ERBB2_antibody-drug_conjugate	SHR-A1811	anti-ERBB2_antibody-drug_conjugate	SHR-A1811-I-101	A Phase 1 Multi-Country, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-A1811 in HER2 Expressing or Mutated Advanced Malignant Solid Tumor Subjects	Advanced Solid Tumors	3199 - Frankston; 3004 - Melbourne; 5042 - Bedford Park; 2109 - Macquarie	https://clinicaltrials.gov/ct2/show/NCT04446260
NCT04447118	PYRAMID-1	Phase 3		NSW, SA, Saint Leonard, WA	2020-06-25	2020-09-11		Docetaxel; Pyrotinib	ERBB2_inhibitor,second_generation; taxane; EGFR_inhibitor,exon_20_selective	Docetaxel; Pyrotinib	EGFR_inhibitor,exon_20_selective; ERBB2_inhibitor,second_generation; taxane	HR-BLTN-III-NSCLC	A Phase 3, Randomized, Open-label, Multicenter Study of the Efficacy and Safety of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC) Harboring a HER2 Exon 20 Mutation Who Progressed on or After Treatment With Platinum Based Chemotherapy	Non-squamous NSCLC; HER2 Exon 20 Mutation	- St Leonards; - North Adelaide; - Albury; - Nedlands; - Fitzroy	https://clinicaltrials.gov/ct2/show/NCT04447118
NCT04449874	2020-000084-22--GO42144	Phase 1		NSW, NZ, VIC, WA	2020-06-29	2020-07-29		Atezolizumab; Atezolizumab + Divarasib; Bevacizumab; Bevacizumab + Divarasib; Cetuximab; Cetuximab + Divarasib; Divarasib; Divarasib + Erlotinib; Divarasib + Inavolisib; Divarasib + RLY-1971; Erlotinib; Inavolisib; RLY-1971	KRAS_G12C_inhibitor + anti-PD-L1_monoclonal_antibody; SHP2_inhibitor; anti-PD-L1_monoclonal_antibody; KRAS_G12C_inhibitor; KRAS_G12C_inhibitor + anti-VEGF_monoclonal_antibody; anti-VEGF_monoclonal_antibody; KRAS_G12C_inhibitor + SHP2_inhibitor; KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody; EGFR_inhibitor,first_generation; KRAS_G12C_inhibitor + PI3K_alpha_inhibitor; PI3K_alpha_inhibitor; anti-EGFR_monoclonal_antibody; EGFR_inhibitor,first_generation + KRAS_G12C_inhibitor	Atezolizumab + Divarasib; Bevacizumab + Divarasib; Cetuximab + Divarasib; Divarasib; Divarasib + Erlotinib; Divarasib + Inavolisib; Divarasib + RLY-1971	EGFR_inhibitor,first_generation + KRAS_G12C_inhibitor; KRAS_G12C_inhibitor; KRAS_G12C_inhibitor + PI3K_alpha_inhibitor; KRAS_G12C_inhibitor + SHP2_inhibitor; KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody; KRAS_G12C_inhibitor + anti-PD-L1_monoclonal_antibody; KRAS_G12C_inhibitor + anti-VEGF_monoclonal_antibody	2020-000084-22  GO42144	A Phase Ia/Ib Dose-Escalation and Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-6036 as a Single Agent and in Combination With Other Anti-cancer Therapies in Patients With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation	Colorectal Cancer; Advanced Solid Tumors; Non-Small Cell Lung Cancer	3000 - Melbourne; 2080 - Mount Kuring-gai; 2010 - Darlinghurst; Auckland; 6009 - Nedlands; Christchurch; 3004 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04449874
NCT04450901	YBL006C101	Phase 1		NSW	2020-06-30	2020-07-01		YBL006	anti-PD-1_monoclonal_antibody	YBL006	anti-PD-1_monoclonal_antibody	YBL006C101	A Phase 1/2a, Open-Label, Multicenter, Single Arm, Dose Escalation/Dose Expansion Study of YBL-006 in Patients With Advanced Solid Tumors	Advanced Solid Tumors	2109 - Macquarie	https://clinicaltrials.gov/ct2/show/NCT04450901
NCT04456699	MK-7339-003--7339-003	Phase 3		NSW, QLD, SA, VIC	2020-07-02	2020-08-19		Bevacizumab; Bevacizumab + Capecitabine + Fluorouracil + Leucovorin; Bevacizumab + Olaparib; Capecitabine; Fluorouracil; Leucovorin; Olaparib	PARP_inhibitor + anti-VEGF_monoclonal_antibody; Fluorouracil; fluoropyrimidine; anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid; folinic_acid; anti-VEGF_monoclonal_antibody; PARP_inhibitor	Bevacizumab + Capecitabine + Fluorouracil + Leucovorin; Bevacizumab + Olaparib; Olaparib	PARP_inhibitor; PARP_inhibitor + anti-VEGF_monoclonal_antibody; anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid; Fluorouracil	MK-7339-003  7339-003	A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination With Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer Who Have Not Progressed Following First-line Induction (LYNK-003)	Metastatic Colorectal Cancer	4029 - Herston; 5011 - Woodville South; 2170 - Liverpool; 2217 - Kogarah; 3168 - Clayton; 3199 - Frankston	https://clinicaltrials.gov/ct2/show/NCT04456699
NCT04460456	SBT6050-101	Phase 1		NSW, VIC, WA	2020-07-07	2020-07-27		Cemiplimab; Cemiplimab + SBT6050; Pembrolizumab; Pembrolizumab + SBT6050; SBT6050	anti-ERBB2_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-ERBB2_antibody-drug_conjugate	Cemiplimab + SBT6050; Pembrolizumab + SBT6050; SBT6050	anti-ERBB2_antibody-drug_conjugate; anti-ERBB2_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody	SBT6050-101	A Phase 1/1B, Open-Label, Dose Escalation and Expansion Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced Solid Tumors Expressing HER2	HER2 Positive Solid Tumors	6009 - Nedlands; 2109 - Sydney; 3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04460456
NCT04464226	2019-003618-15--20321	Phase 3		SA	2020-07-09	2020-10-20		Darolutamide	antiandrogen,nonsteroidal,second_generation	Darolutamide	antiandrogen,nonsteroidal,second_generation	2019-003618-15  20321	An Open-label, Single Arm, Roll-over Study to Provide Continued Treatment With Darolutamide in Participants Who Were Enrolled in Previous Bayer Sponsored Studies	Cancer	5037 - Kurralta Park	https://clinicaltrials.gov/ct2/show/NCT04464226
NCT04472429	2020-000826-24--INCMGA-0012-303	Phase 3		QLD, SA, VIC	2020-07-15	2021-01-12		Carboplatin; Carboplatin + Paclitaxel; Carboplatin + Paclitaxel + Retifanlimab; Paclitaxel; Placebo; Retifanlimab	placebo; platinum-based_antineoplastic_agent + taxane; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; anti-PD-1_monoclonal_antibody; taxane; platinum-based_antineoplastic_agent	Carboplatin + Paclitaxel; Carboplatin + Paclitaxel + Retifanlimab; Placebo	anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; platinum-based_antineoplastic_agent + taxane; placebo	2020-000826-24  INCMGA 0012-303	A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2)	Squamous Cell Carcinoma of the Anal Canal	5042 - Bedford Park; 04102 - Woolloongabba; 03168 - Clayton	https://clinicaltrials.gov/ct2/show/NCT04472429
NCT04472650	BGB-Sitravatinib-101	Phase 1		WA	2020-07-15	2020-08-17		Sitravatinib	VEGFR_inhibitor; RET_inhibitor; KIT/PDGFR/RET/VEGFR_inhibitor; PDGFR_inhibitor; KIT_inhibitor	Sitravatinib	KIT/PDGFR/RET/VEGFR_inhibitor; KIT_inhibitor; PDGFR_inhibitor; RET_inhibitor; VEGFR_inhibitor	BGB-Sitravatinib-101	A Phase 1, Open-label, Single-dose, Randomized Crossover Study to Evaluate the Relative Bioavailability of Two Different Capsule Formulations of Sitravatinib in Healthy Subjects	Tumor	6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT04472650
NCT04475523	CI-8993-101	Phase 1		VIC	2020-07-17	2020-09-22		CI-8993	anti-VISTA_monoclonal_antibody	CI-8993	anti-VISTA_monoclonal_antibody	CI-8993-101	Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients With Advanced Solid Tumor Malignancies	Solid Tumor	3199 - Frankston	https://clinicaltrials.gov/ct2/show/NCT04475523
NCT04478266	AMEERA-5	Phase 3		NSW, VIC, WA	2020-07-20	2020-10-14		Amcenestrant; Amcenestrant + Goserelin + Letrozole + Palbociclib; Goserelin; Letrozole; Palbociclib; Placebo	placebo; aromatase_inhibitor; CDK4/6_inhibitor; GnRH_analogue; selective_estrogen_receptor_degrader; CDK4/6_inhibitor + GnRH_analogue + aromatase_inhibitor + selective_estrogen_receptor_degrader	Amcenestrant + Goserelin + Letrozole + Palbociclib; Placebo	CDK4/6_inhibitor + GnRH_analogue + aromatase_inhibitor + selective_estrogen_receptor_degrader; placebo	2020-001824-33  EFC15935	A Randomized, Multicenter, Double-blind Phase 3 Study of Amcenestrant (SAR439859) Plus Palbociclib Versus Letrozole Plus Palbociclib for the Treatment of Patients With ER (+), HER2 (-) Breast Cancer Who Have Not Received Prior Systemic Anti-cancer Treatment for Advanced Disease	Breast Cancer	3121 - Richmond; 2031 - Randwick; 2109 - Macquarie Park; 2076 - Wahroonga; 6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT04478266
NCT04481009	YH003002	Phase 1		WA	2020-07-22	2020-08-04		Gemcitabine; Gemcitabine + Nab-paclitaxel + Toripalimab + YH003; Nab-paclitaxel; Toripalimab; Toripalimab + YH003; YH003	antimetabolite; anti-OX40_agonistic_antibody + anti-PD-1_monoclonal_antibody; anti-OX40_agonistic_antibody; anti-PD-1_monoclonal_antibody; taxane; gemcitabine; anti-OX40_agonistic_antibody + anti-PD-1_monoclonal_antibody + antimetabolite + taxane	Gemcitabine + Nab-paclitaxel + Toripalimab + YH003; Toripalimab + YH003	anti-OX40_agonistic_antibody + anti-PD-1_monoclonal_antibody; anti-OX40_agonistic_antibody + anti-PD-1_monoclonal_antibody + antimetabolite + taxane; gemcitabine	YH003002	A Multicenter, Open-Label, Phase I/II Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of YH003 in Combination With Toripalimab (Anti-PD-1 mAb) in Subjects With Advanced Solid Tumors	Advanced Solid Tumors	6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT04481009
NCT04493853	CAPItello-281	Phase 3		NSW, QLD	2020-07-30	2020-07-13		Abiraterone; Abiraterone + Capivasertib + Prednisolone + Prednisone; Abiraterone + Prednisolone + Prednisone; Capivasertib; Placebo; Prednisolone; Prednisone	placebo; CYP17A1_inhibitor; glucocorticoid; pan-AKT_inhibitor; CYP17A1_inhibitor + glucocorticoid + pan-AKT_inhibitor; CYP17A1_inhibitor + glucocorticoid	Abiraterone + Capivasertib + Prednisolone + Prednisone; Abiraterone + Prednisolone + Prednisone; Placebo	CYP17A1_inhibitor + glucocorticoid; CYP17A1_inhibitor + glucocorticoid + pan-AKT_inhibitor; placebo	2023-504998-20-00  D361BC00001	A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib+Abiraterone Versus Placebo+Abiraterone as Treatment for Patients With DeNovo Metastatic Hormone-Sensitive Prostate Cancer Characterised by PTEN Deficiency.	Hormone-Sensitive Prostate Cancer	2747 - Kingswood; 2010 - Darlinghurst; 4575 - Birtinya; 2800 - Orange; 4101 - South Brisbane	https://clinicaltrials.gov/ct2/show/NCT04493853
NCT04497844	AMPLITUDE	Phase 3		NSW, NZ, QLD, SA, TAS, VIC, WA	2020-08-04	2020-09-23		Abiraterone; Abiraterone + Niraparib + Prednisone; Niraparib; Niraparib + Prednisone; Placebo; Prednisone	placebo; PARP_inhibitor + glucocorticoid; CYP17A1_inhibitor; CYP17A1_inhibitor + PARP_inhibitor + glucocorticoid; glucocorticoid; PARP_inhibitor	Abiraterone + Niraparib + Prednisone; Niraparib + Prednisone; Placebo	CYP17A1_inhibitor + PARP_inhibitor + glucocorticoid; PARP_inhibitor + glucocorticoid; placebo	67652000PCR3002  CR108852	A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)	Metastatic Castration-sensitive Prostate Cancer	6150 - Murdoch; Auckland; 6008 - Subiaco; Christchurch; 4101 - South Brisbane; 7000 - Hobart; 2010 - Darlinghurst; 4029 - Herston; 3000 - Melbourne; 2109 - North Ryde; Dunedin Central; 2170 - Liverpool; 5037 - Kurralta Park; 4575 - Birtinya; Tauranga	https://clinicaltrials.gov/ct2/show/NCT04497844
NCT04499924	MOUNTAINEER-02	Phase 2		NSW	2020-08-05	2021-03-22		Paclitaxel; Paclitaxel + Ramucirumab + Trastuzumab + Tucatinib; Placebo; Ramucirumab; Trastuzumab; Tucatinib	placebo; anti-VEGFR2_monoclonal_antibody; anti-ERBB2_monoclonal_antibody; taxane; ERBB2_inhibitor,third_generation + anti-ERBB2_monoclonal_antibody + anti-VEGFR2_monoclonal_antibody + taxane; ERBB2_inhibitor,third_generation	Paclitaxel + Ramucirumab + Trastuzumab + Tucatinib; Placebo	ERBB2_inhibitor,third_generation + anti-ERBB2_monoclonal_antibody + anti-VEGFR2_monoclonal_antibody + taxane; placebo	SGNTUC-022	A Randomized, Double-blind, Placebo-controlled, Active Comparator Phase 2/3 Study of Tucatinib in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Subjects With Previously Treated, Locally-advanced Unresectable or Metastatic HER2+ Gastric or Gastroesophageal Junction Adenocarcinoma (GEC)	Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma; Esophageal Adenocarcinoma	63V6 63 - Heidelberg; 2250 - Gosford	https://clinicaltrials.gov/ct2/show/NCT04499924
NCT04501276	ADG116-1003	Phase 1		NSW, SA, VIC	2020-08-06	2020-09-23		ADG106; ADG106 + ADG116; ADG116; Toripalimab	anti-4-1BB_agonistic_antibody; anti-PD-1_monoclonal_antibody; anti-4-1BB_agonistic_antibody + anti-CTLA4_monoclonal_antibody; anti-CTLA4_monoclonal_antibody	ADG106 + ADG116; ADG116; Toripalimab	anti-4-1BB_agonistic_antibody + anti-CTLA4_monoclonal_antibody; anti-CTLA4_monoclonal_antibody; anti-PD-1_monoclonal_antibody	ADG116-1003	A Phase 1b/2, Open-Label, Dose Escalation and Expansion Study of ADG116, ADG116 Combined With Toripalimab (Anti-PD-1 Antibody), ADG116 Combined With ADG106 (Anti-CD137 Antibody) in Patients With Advanced/Metastatic Solid Tumors	Advanced/Metastatic Solid Tumors	- Kurralta Park; - Malvern; - Sydney	https://clinicaltrials.gov/ct2/show/NCT04501276
NCT04503278	2019-004323-20--BNT211-01	Phase 1		VIC	2020-08-07	2020-09-16		CLDN6 CAR-T; CLDN6 RNA-LPX	mRNA_vaccine,CLDN6-targeting; autologous_CAR-T-cell_therapy,CLDN6-targeting	CLDN6 CAR-T; CLDN6 RNA-LPX	autologous_CAR-T-cell_therapy,CLDN6-targeting; mRNA_vaccine,CLDN6-targeting	2019-004323-20  BNT211-01	Phase I/IIa, First-in-human (FIH), Open-label, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety and Preliminary Efficacy of CLDN6 CAR-T With or Without CLDN6 RNA-LPX in Patients With CLDN6-positive Relapsed or Refractory Advanced Solid Tumors	Solid Tumor	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04503278
NCT04505826	OP-1250-001	Phase 1		NSW, QLD, SA	2020-08-10	2020-08-13		Palazestrant	complete_estrogen_receptor_antagonist	Palazestrant	complete_estrogen_receptor_antagonist	OP-1250-001	A Phase I Dose Escalation and Dose Expansion and Phase II Monotherapy Open-label, First-in-Human, Multicenter Study of OP-1250 in Adult Subjects With Advanced and/or Metastatic Hormone Receptor (HR)-Positive, HER2-negative Breast Cancer	HER2-negative Breast Cancer; Hormone Receptor Positive Breast Carcinoma	2145 - Westmead; 4066 - Auchenflower; 2109 - Sydney; 5000 - Adelaide	https://clinicaltrials.gov/ct2/show/NCT04505826
NCT04516447	ZN-c3-002	Phase 1		QLD, SA, VIC, WA	2020-08-18	2020-10-26		Azenosertib; Azenosertib + Bevacizumab; Azenosertib + Carboplatin; Azenosertib + Gemcitabine; Azenosertib + Paclitaxel; Bevacizumab; Carboplatin; Gemcitabine; Paclitaxel; Pegylated liposomal doxorubicin	antimetabolite; WEE1_inhibitor + anti-VEGF_monoclonal_antibody; WEE1_inhibitor; gemcitabine; anti-VEGF_monoclonal_antibody; WEE1_inhibitor + antimetabolite; WEE1_inhibitor + platinum-based_antineoplastic_agent; anthracycline; taxane; WEE1_inhibitor + taxane; platinum-based_antineoplastic_agent	Azenosertib; Azenosertib + Bevacizumab; Azenosertib + Carboplatin; Azenosertib + Gemcitabine; Azenosertib + Paclitaxel; Pegylated liposomal doxorubicin	WEE1_inhibitor; WEE1_inhibitor + anti-VEGF_monoclonal_antibody; WEE1_inhibitor + antimetabolite; WEE1_inhibitor + platinum-based_antineoplastic_agent; WEE1_inhibitor + taxane; anthracycline; gemcitabine	ZN-c3-002	A Phase 1b Study of ZN-c3 in Combination With Chemotherapy or Bevacizumab in Subjects With Ovarian, Peritoneal, or Fallopian Tube Cancer	Fallopian Tube Cancer; Solid Tumor; Peritoneal Cancer; Epithelial Ovarian Cancer	4101 - South Brisbane; 4556 - Sunshine Coast; 6009 - Nedlands; 3144 - Melbourne; 5000 - Adelaide; 3121 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04516447
NCT04521686	2020-002863-77--18077	Phase 1		NSW	2020-08-20	2020-10-01		Cisplatin; Cisplatin + Durvalumab + Gemcitabine + LY3410738; Durvalumab; Gemcitabine; LY3410738	antimetabolite; anti-PD-L1_monoclonal_antibody; gemcitabine; platinum-based_antineoplastic_agent; IDH1_R132_inhibitor,covalent + anti-PD-L1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; IDH1_R132_inhibitor,covalent	Cisplatin + Durvalumab + Gemcitabine + LY3410738; LY3410738	IDH1_R132_inhibitor,covalent; IDH1_R132_inhibitor,covalent + anti-PD-L1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; gemcitabine	2020-002863-77  18077	A Phase 1 Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations	Cholangiocarcinoma; Glioma; Any Solid Tumor; Chondrosarcoma	2010 - Darlinghurst	https://clinicaltrials.gov/ct2/show/NCT04521686
NCT04522323	2023-509604-15-00--D7980C00003	Phase 1		NSW, VIC	2020-08-21	2020-08-05		Axitinib; Axitinib + Lenvatinib + Volrustomig; Lenvatinib; Lenvatinib + Volrustomig; Volrustomig	bispecific_PD-L1/CTLA4_antibody; VEGF_inhibitor + bispecific_PD-L1/CTLA4_antibody; KIT_inhibitor,ATP-competitive; VEGF_inhibitor; VEGFR/PDGFR_inhibitor + VEGF_inhibitor + bispecific_PD-L1/CTLA4_antibody; KIT_inhibitor,ATP-competitive + VEGF_inhibitor + bispecific_PD-L1/CTLA4_antibody; VEGFR/PDGFR_inhibitor	Axitinib + Lenvatinib + Volrustomig; Lenvatinib + Volrustomig	KIT_inhibitor,ATP-competitive + VEGF_inhibitor + bispecific_PD-L1/CTLA4_antibody; VEGFR/PDGFR_inhibitor + VEGF_inhibitor + bispecific_PD-L1/CTLA4_antibody; VEGF_inhibitor + bispecific_PD-L1/CTLA4_antibody	2023-509604-15-00  D7980C00003	A Phase 1b, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI5752 in Combination With Axitinib in Subjects With Advanced Renal Cell Carcinoma	Advanced Renal Cell Carcinoma	2298 - Waratah; 3199 - Frankston	https://clinicaltrials.gov/ct2/show/NCT04522323
NCT04524689	CARMEN-LC05	Phase 2			2020-08-24	2020-10-26		Carboplatin; Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed + Tusamitamab ravtansine; Carboplatin + Cisplatin + Pembrolizumab + Tusamitamab ravtansine; Cisplatin; Pembrolizumab; Pemetrexed; Tusamitamab ravtansine	antimetabolite; anti-CEACAM5_antibody-drug_conjugate; anti-PD-1_monoclonal_antibody; anti-CEACAM5_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent; anti-CEACAM5_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent	Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed + Tusamitamab ravtansine; Carboplatin + Cisplatin + Pembrolizumab + Tusamitamab ravtansine; Pembrolizumab	anti-CEACAM5_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-CEACAM5_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody	U1111-1233-9798  ACT16146	Open-label, Phase 2 Study of Tusamitamab Ravtansine (SAR408701) Combined With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) Combined With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With CEACAM5 Positive Expression Advanced/Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)	Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)		https://clinicaltrials.gov/ct2/show/NCT04524689
NCT04524871	MORPHEUS-LIVER	Phase 1		NZ	2020-08-24	2020-11-01		ADG126; ADG126 + Atezolizumab + Bevacizumab; Atezolizumab; Atezolizumab + Bevacizumab; Atezolizumab + Bevacizumab + NKT2152; Atezolizumab + Bevacizumab + TPST-1120; Atezolizumab + Bevacizumab + Tiragolumab; Atezolizumab + Bevacizumab + Tocilizumab; Bevacizumab; Bevacizumab + Tobemstomig; NKT2152; TPST-1120; Tiragolumab; Tobemstomig; Tocilizumab	anti-VEGF_monoclonal_antibody + bispecific_PD-1/LAG3_antibody; PPAR-alpha_inhibitor + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; HIF2a_inhibitor; anti-TIGIT_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; bispecific_PD-1/LAG3_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-VEGF_monoclonal_antibody; anti-CTLA4_monoclonal_antibody; anti-IL-6_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; HIF2a_inhibitor + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-IL-6_monoclonal_antibody; PPAR-alpha_inhibitor; anti-CTLA4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody	ADG126 + Atezolizumab + Bevacizumab; Atezolizumab + Bevacizumab; Atezolizumab + Bevacizumab + NKT2152; Atezolizumab + Bevacizumab + TPST-1120; Atezolizumab + Bevacizumab + Tiragolumab; Atezolizumab + Bevacizumab + Tocilizumab; Bevacizumab + Tobemstomig	HIF2a_inhibitor + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; PPAR-alpha_inhibitor + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-CTLA4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-IL-6_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-VEGF_monoclonal_antibody + bispecific_PD-1/LAG3_antibody	GO42216	A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)	Advanced Liver Cancers	Auckland	https://clinicaltrials.gov/ct2/show/NCT04524871
NCT04526106	RLY-4008-101	Phase 1		NSW, QLD, WA	2020-08-25	2020-09-02		Lirafugratinib	FGFR2_inhibitor	Lirafugratinib	FGFR2_inhibitor	RLY-4008-101	A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With Intrahepatic Cholangiocarcinoma (ICC) and Other Advanced Solid Tumors	FGFR2 Gene Fusion/Rearrangement; Other Solid Tumors, Adult; FGFR2 Gene Mutation; FGFR2 Amplification; FGFR2 Gene Activation; Cholangiocarcinoma; FGFR2 Gene Translocation; Intrahepatic Cholangiocarcinoma	6009 - Nedlands; 4101 - South Brisbane,; 2010 - Darlinghurst	https://clinicaltrials.gov/ct2/show/NCT04526106
NCT04526509	2019-004446-14--209012	Phase 1		VIC	2020-08-25	2020-12-21		Cyclophosphamide; Fludarabine; GSK3845097; GSK3901961	autologous_CAR-T-cell_therapy,NY-ESO-1/CD8alpha-targeting; antimetabolite; alkylating_agent; autologous_CAR-T-cell_therapy,NY-ESO-1/dnTGFBR2-targeting	GSK3845097; GSK3901961; Cyclophosphamide; Fludarabine	autologous_CAR-T-cell_therapy,NY-ESO-1/CD8alpha-targeting; autologous_CAR-T-cell_therapy,NY-ESO-1/dnTGFBR2-targeting; alkylating_agent; antimetabolite	2019-004446-14  209012	Master Protocol to Assess the Safety and Recommended Phase 2 Dose of Next Generations of Autologous Enhanced NY-ESO-1/ LAGE-1a TCR Engineered T-cells, Alone or in Combination With Other Agents, in Participants With Advanced Tumors	Neoplasms	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04526509
NCT04527991	TROPiCS-04	Phase 3		NSW, NZ, QLD, SA, TAS, VIC, WA	2020-08-27	2021-01-13		Docetaxel; Docetaxel + Paclitaxel + Vinflunine; Paclitaxel; Sacituzumab Govitecan; Vinflunine	vinca_alkaloid; anti-Trop2_antibody-drug_conjugate; taxane + vinca_alkaloid; taxane	Docetaxel + Paclitaxel + Vinflunine; Sacituzumab Govitecan	anti-Trop2_antibody-drug_conjugate; taxane + vinca_alkaloid	2024-513870-23  IMMU-132-13	A Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Subjects With Metastatic or Locally Advanced Unresectable Urothelial Cancer	Locally Advanced or Metastatic Unresectable Urothelial Cancer	2298 - Waratah; 3168 - Clayton; 7001 - Hobart; 2145 - Westmead; 3021 - Saint Albans; 4066 - Auchenflower; Hamilton; 6009 - Nedlands; 5042 - Bedford Park; 5037 - Kurralta Park; 3000 - Melbourne; 2109 - North Ryde; 3084 - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT04527991
NCT04534205	AHEAD-MERIT	Phase 2		NSW, QLD, SA, VIC	2020-09-01	2021-01-07		BNT113; BNT113 + Pembrolizumab; Pembrolizumab	vaccine_therapy,HPV-E6/HPV-E7-targeting; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + vaccine_therapy,HPV-E6/HPV-E7-targeting	BNT113 + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + vaccine_therapy,HPV-E6/HPV-E7-targeting	2020-001400-41  BNT113-01	An Open-label Phase II/III Randomized Trial of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Monotherapy as a First Line Therapy in Patients With Unresectable Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Which is Positive for Human Papilloma Virus 16 (HPV16+) and Expresses PD-L1	Unresectable Head and Neck Squamous Cell Carcinoma; Metastatic Head and Neck Cancer; Recurrent Head and Neck Cancer	VIC 3065 - Fitzroy; 2200 - Bankstown; 2450 - Coffs Harbour; 4224 - Tugun; 5042 - Bedford Park; 2500 - Wollongong; 5000 - Adelaide; 2065 - Saint Leonards	https://clinicaltrials.gov/ct2/show/NCT04534205
NCT04538742	DB-07	Phase 1		VIC	2020-09-04	2020-12-28		Durvalumab; Durvalumab + Paclitaxel + Trastuzumab Deruxtecan; Durvalumab + Trastuzumab Deruxtecan; Paclitaxel; Paclitaxel + Trastuzumab Deruxtecan; Pertuzumab; Pertuzumab + Trastuzumab Deruxtecan; Trastuzumab Deruxtecan; Trastuzumab Deruxtecan + Tucatinib; Tucatinib	anti-PD-L1_monoclonal_antibody; taxane; anti-ERBB2_antibody-drug_conjugate + anti-PD-L1_monoclonal_antibody + taxane; anti-ERBB2_antibody-drug_conjugate + anti-PD-L1_monoclonal_antibody; anti-ERBB2_monoclonal_antibody,dimerization_inhibitor; anti-ERBB2_antibody-drug_conjugate + taxane; anti-ERBB2_antibody-drug_conjugate + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor; ERBB2_inhibitor,third_generation + anti-ERBB2_antibody-drug_conjugate; anti-ERBB2_antibody-drug_conjugate; ERBB2_inhibitor,third_generation	Durvalumab + Paclitaxel + Trastuzumab Deruxtecan; Durvalumab + Trastuzumab Deruxtecan; Paclitaxel + Trastuzumab Deruxtecan; Pertuzumab + Trastuzumab Deruxtecan; Trastuzumab Deruxtecan; Trastuzumab Deruxtecan + Tucatinib	ERBB2_inhibitor,third_generation + anti-ERBB2_antibody-drug_conjugate; anti-ERBB2_antibody-drug_conjugate; anti-ERBB2_antibody-drug_conjugate + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor; anti-ERBB2_antibody-drug_conjugate + anti-PD-L1_monoclonal_antibody; anti-ERBB2_antibody-drug_conjugate + anti-PD-L1_monoclonal_antibody + taxane; anti-ERBB2_antibody-drug_conjugate + taxane	2023-505309-18-00  D967JC00001	A Phase 1b/2 Multicentre, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore the Safety, Tolerability, and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination With Other Anti-cancer Agents in Patients With HER2-positive Metastatic Breast Cancer (DESTINY-Breast07)	Metastatic Breast Cancer	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04538742
NCT04543617	SKYSCRAPER-07	Phase 3		NZ, QLD, VIC, WA	2020-09-10	2020-09-28		Atezolizumab; Atezolizumab + Tiragolumab; Placebo; Radiotherapy; Tiragolumab	placebo; radiotherapy; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-TIGIT_monoclonal_antibody; anti-PD-L1_monoclonal_antibody	Atezolizumab + Tiragolumab; Placebo; Radiotherapy	anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; placebo; radiotherapy	2020-001178-31  YO42137	A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab With or Without Tiragolumab (Anti-TIGIT Antibody) in Patients With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy	Esophageal Squamous Cell Carcinoma	4102 - Woolloongabba; 6008 - Subiaco; Tauranga; 3084 - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT04543617
NCT04546009	2020-000119-66--BO41843	Phase 3		NSW, NZ, QLD, VIC, WA	2020-09-11	2020-10-09		Giredestrant; Giredestrant + Letrozole + Palbociclib; LHRH Agonist; Letrozole; Palbociclib; Placebo	placebo; LHRH_agonist; aromatase_inhibitor; CDK4/6_inhibitor; selective_estrogen_receptor_degrader; CDK4/6_inhibitor + aromatase_inhibitor + selective_estrogen_receptor_degrader	Giredestrant + Letrozole + Palbociclib; LHRH Agonist; Placebo	CDK4/6_inhibitor + aromatase_inhibitor + selective_estrogen_receptor_degrader; LHRH_agonist; placebo	2020-000119-66  BO41843	A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of GDC-9545 Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Patients With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer	Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer	Auckland; 6150 - Murdoch; 4101 - South Brisbane; 2298 - Waratah; 4102 - Woolloongabba; 3000 - Melbourne; 3021 - St Albans	https://clinicaltrials.gov/ct2/show/NCT04546009
NCT04551352	2020-000793-18--BP42169	Phase 1		VIC	2020-09-16	2020-10-28		Obinutuzumab; Tocilizumab	anti-CD20_monoclonal_antibody; anti-IL-6_monoclonal_antibody	Obinutuzumab; Tocilizumab	anti-CD20_monoclonal_antibody; anti-IL-6_monoclonal_antibody	2020-000793-18  BP42169	An Open-Label, Multicenter, Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7293583, A TYRP1-Targeting CD3 T-Cell Engager, in Participants With Metastatic Melanoma	Uveal Melanoma; Cutaneous Melanoma; Mucosal Melanoma	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04551352
NCT04551963	BGB-3111-113	Phase 1		NSW, QLD, SA, VIC, WA	2020-09-16	2020-11-15		Diltiazem; Diltiazem + Zanubrutinib; Zanubrutinib	calcium_channel_blockade; BTK_inhibitor; BTK_inhibitor + calcium_channel_blockade	Diltiazem + Zanubrutinib; Zanubrutinib	BTK_inhibitor; BTK_inhibitor + calcium_channel_blockade	BGB-3111-113	A Drug-Drug Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Patients With B-Cell Malignancies	B-cell Malignancies	3168 - Clayton; 3199 - Frankston; 6009 - Nedlands; 4224 - Tugun; 2139 - Concord; 5042 - Bedford PK; 5000 - Adelaide	https://clinicaltrials.gov/ct2/show/NCT04551963
NCT04556773	DB-08	Phase 1		NSW, VIC	2020-09-21	2020-12-17		Anastrozole; Anastrozole + Trastuzumab Deruxtecan; Capecitabine; Capecitabine + Trastuzumab Deruxtecan; Capivasertib; Capivasertib + Trastuzumab Deruxtecan; Durvalumab; Durvalumab + Paclitaxel + Trastuzumab Deruxtecan; Fulvestrant; Fulvestrant + Trastuzumab Deruxtecan; Paclitaxel; Trastuzumab Deruxtecan	fluoropyrimidine; anti-PD-L1_monoclonal_antibody; anti-ERBB2_antibody-drug_conjugate + anti-PD-L1_monoclonal_antibody + taxane; selective_estrogen_receptor_degrader; anti-ERBB2_antibody-drug_conjugate + aromatase_inhibitor; pan-AKT_inhibitor; anti-ERBB2_antibody-drug_conjugate; aromatase_inhibitor; anti-ERBB2_antibody-drug_conjugate + fluoropyrimidine; taxane; anti-ERBB2_antibody-drug_conjugate + pan-AKT_inhibitor; anti-ERBB2_antibody-drug_conjugate + selective_estrogen_receptor_degrader	Anastrozole + Trastuzumab Deruxtecan; Capecitabine + Trastuzumab Deruxtecan; Capivasertib + Trastuzumab Deruxtecan; Durvalumab + Paclitaxel + Trastuzumab Deruxtecan; Fulvestrant + Trastuzumab Deruxtecan	anti-ERBB2_antibody-drug_conjugate + anti-PD-L1_monoclonal_antibody + taxane; anti-ERBB2_antibody-drug_conjugate + aromatase_inhibitor; anti-ERBB2_antibody-drug_conjugate + fluoropyrimidine; anti-ERBB2_antibody-drug_conjugate + pan-AKT_inhibitor; anti-ERBB2_antibody-drug_conjugate + selective_estrogen_receptor_degrader	2023-505690-33-00  D967JC00002	A Phase 1b Multicentre, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore the Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination With Other Anti-cancer Agents in Patients With Metastatic HER2-low Breast Cancer (DESTINY-Breast08)	Metastatic Breast Cancer	3002 - East Melbourne; 2145 - Westmead	https://clinicaltrials.gov/ct2/show/NCT04556773
NCT04572152	AK119-102	Phase 1		NSW, QLD, SA, VIC	2020-10-01	2020-12-07		AK119; AK119 + Cadonilimab; Cadonilimab	anti-CD73_monoclonal_antibody + bispecific_PD-1/CTLA4_antibody; bispecific_PD-1/CTLA4_antibody; anti-CD73_monoclonal_antibody	AK119 + Cadonilimab	anti-CD73_monoclonal_antibody + bispecific_PD-1/CTLA4_antibody	AK119-102	A Phase 1a/1b, Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-tumor Activity of AK119 in Combination With AK104 in Subjects With Advanced or Metastatic Solid Tumors.	Advanced or Metastatic Solid Tumors	2148 - Blacktown; 4101 - South Brisbane; 3168 - Clayton; 3004 - Melbourne; 5037 - Adelaide	https://clinicaltrials.gov/ct2/show/NCT04572152
NCT04584112	2020-000531-47--CO42177	Phase 1		QLD, WA	2020-10-12	2020-09-28		Atezolizumab; Atezolizumab + Carboplatin + Cyclophosphamide + Doxorubicin + Filgrastim + Nab-paclitaxel + Pegfilgrastim + Tiragolumab; Atezolizumab + Cyclophosphamide + Doxorubicin + Filgrastim + Nab-paclitaxel + Pegfilgrastim + Tiragolumab; Atezolizumab + Nab-paclitaxel + Tiragolumab; Carboplatin; Cyclophosphamide; Doxorubicin; Filgrastim; Nab-paclitaxel; Pegfilgrastim; Tiragolumab	alkylating_agent + anthracycline + anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + granulocyte_colony_stimulating_factor + taxane; anti-TIGIT_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; granulocyte_colony_stimulating_factor; doxorubicin; anthracycline; alkylating_agent + anthracycline + anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + granulocyte_colony_stimulating_factor + platinum-based_antineoplastic_agent + taxane; taxane; alkylating_agent; platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + taxane	Atezolizumab + Carboplatin + Cyclophosphamide + Doxorubicin + Filgrastim + Nab-paclitaxel + Pegfilgrastim + Tiragolumab; Atezolizumab + Cyclophosphamide + Doxorubicin + Filgrastim + Nab-paclitaxel + Pegfilgrastim + Tiragolumab; Atezolizumab + Nab-paclitaxel + Tiragolumab	alkylating_agent + anthracycline + anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + granulocyte_colony_stimulating_factor + platinum-based_antineoplastic_agent + taxane; alkylating_agent + anthracycline + anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + granulocyte_colony_stimulating_factor + taxane; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + taxane; doxorubicin	2020-000531-47  CO42177	A Phase Ib, Open-Label, Multicohort Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Patients With Triple-Negative Breast Cancer	Triple-Negative Breast Cancer	6149 - Bull Creek; 4101 - South Brisbane	https://clinicaltrials.gov/ct2/show/NCT04584112
NCT04585035	KEYNOTE-C15-MK3475-C15--D1553-101	Phase 1		NSW, SA, VIC, WA	2020-10-14	2020-10-02		Cetuximab; Garsorasib; Pembrolizumab	KRAS_G12C_inhibitor; anti-EGFR_monoclonal_antibody; anti-PD-1_monoclonal_antibody	Garsorasib; Cetuximab; Pembrolizumab	KRAS_G12C_inhibitor; anti-EGFR_monoclonal_antibody; anti-PD-1_monoclonal_antibody	KEYNOTE-C15 MK3475-C15  D1553-101	A Phase 1/2, Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of D-1553 in Subjects With Advanced or Metastatic Solid Tumors With KRasG12C Mutation	NSCLC; Solid Tumor, Adult; CRC	3199 - Frankston; 2298 - Waratah; 3065 - Fitzroy; 3144 - Malvern; 2217 - Kogarah; 6009 - Nedlands; 2148 - Blacktown; 5011 - Woodville South; 2640 - East Albury	https://clinicaltrials.gov/ct2/show/NCT04585035
NCT04585750	KEYNOTE-D79--PMV-586-101	Phase 1		NSW, QLD, SA, VIC, WA	2020-10-14	2020-10-29		Pembrolizumab; Pembrolizumab + Rezatapopt; Rezatapopt	mutant_p53_reactivator,Y220C-selective; anti-PD-1_monoclonal_antibody + mutant_p53_reactivator,Y220C-selective; anti-PD-1_monoclonal_antibody	Pembrolizumab + Rezatapopt; Rezatapopt	anti-PD-1_monoclonal_antibody + mutant_p53_reactivator,Y220C-selective; mutant_p53_reactivator,Y220C-selective	KEYNOTE-D79  PMV-586-101	A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients With Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)	Non-Small Cell Lung Carcinoma; HER2-positive Breast Cancer; Colorectal Cancer; HER2+ Breast Cancer; Locally Advanced; Triple Negative Breast Cancer; Endometrial Cancer; NSCLC (Non-small Cell Lung Cancer); Metastatic Cancer; Small Cell Lung Carcinoma; Metastatic Solid Tumor; NSCLC; HER2-negative Breast Cancer; TNBC; ER/PR(+), Her2(-) Breast Cancer; Small Cell Lung Cancer; Small Cell Lung Cancer ( SCLC ); HER2- Breast Cancer; Lung Cancer; Breast Cancer; Advanced Solid Tumor; SCLC; Ovarian Cancer; Head and Neck Cancer; ER/PR Positive Breast Cancer; Advanced Malignant Neoplasm; Non-Small Cell Lung Cancer; Gall Bladder Cancer; Other Cancer; Prostate Cancer	- Bedford Park; - South Brisbane; - Nedlands; - Camperdown; - Clayton	https://clinicaltrials.gov/ct2/show/NCT04585750
NCT04586231	MK-6482-011--6482-011	Phase 3		NSW, SA, VIC	2020-10-14	2021-02-25		Belzutifan; Belzutifan + Lenvatinib; Cabozantinib; Lenvatinib	HIF2a_inhibitor + VEGF_inhibitor; HIF2a_inhibitor; VEGFR2_inhibitor; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor; RET_inhibitor; VEGF_inhibitor; ROS1_inhibitor; AXL_inhibitor; MET_inhibitor,type_2; KIT_inhibitor	Belzutifan + Lenvatinib; Cabozantinib	AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor; AXL_inhibitor; HIF2a_inhibitor + VEGF_inhibitor; KIT_inhibitor; MET_inhibitor,type_2; RET_inhibitor; ROS1_inhibitor; VEGFR2_inhibitor	MK-6482-011  6482-011	An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination With Lenvatinib (MK-7902) vs Cabozantinib in Participants With Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy	Carcinoma, Renal Cell	3000 - Melbourne; 5112 - Elizabeth Vale; 2065 - St Leonards; 3199 - Frankston	https://clinicaltrials.gov/ct2/show/NCT04586231
NCT04597411	CAAA817A12101--PSMA-617-100	Phase 1		NSW	2020-10-22	2021-04-01		225Ac-PSMA-617; 225Ac-PSMA-617 + Abiraterone + Enzalutamide + Lu-177 vipivotide tetraxetan; 225Ac-PSMA-617 + Lu-177 vipivotide tetraxetan; Abiraterone; Enzalutamide; Lu-177 vipivotide tetraxetan	CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + radioconjugate,PSMA-targeting + radioligand,PSMA-targeting; radioconjugate,PSMA-targeting + radioligand,PSMA-targeting; antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor; radioconjugate,PSMA-targeting; radioligand,PSMA-targeting	225Ac-PSMA-617 + Abiraterone + Enzalutamide + Lu-177 vipivotide tetraxetan; 225Ac-PSMA-617 + Lu-177 vipivotide tetraxetan	CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + radioconjugate,PSMA-targeting + radioligand,PSMA-targeting; radioconjugate,PSMA-targeting + radioligand,PSMA-targeting	CAAA817A12101  PSMA-617-100	AcTION: A Phase I Study of [225Ac]Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer With or Without Prior [177Lu]Lu-PSMA-617 Radioligand Therapy	Prostatic Neoplasms, Castration-Resistant	- Darlinghurst	https://clinicaltrials.gov/ct2/show/NCT04597411
NCT04604132	FIDES-03	Phase 1		VIC	2020-10-27	2020-10-06		Atezolizumab; Derazantinib; Derazantinib + Paclitaxel + Ramucirumab; Paclitaxel; Ramucirumab	anti-VEGFR2_monoclonal_antibody; FGFR1/2/3_inhibitor + anti-VEGFR2_monoclonal_antibody + taxane; anti-PD-L1_monoclonal_antibody; taxane; FGFR1/2/3_inhibitor,reversible; FGFR1/2/3_inhibitor,reversible + anti-VEGFR2_monoclonal_antibody + taxane; FGFR1/2/3_inhibitor	Derazantinib; Derazantinib + Paclitaxel + Ramucirumab; Atezolizumab	FGFR1/2/3_inhibitor; FGFR1/2/3_inhibitor + anti-VEGFR2_monoclonal_antibody + taxane; FGFR1/2/3_inhibitor,reversible; FGFR1/2/3_inhibitor,reversible + anti-VEGFR2_monoclonal_antibody + taxane; anti-PD-L1_monoclonal_antibody	DZB-CS-202	A Phase 1b/2 Study of Derazantinib as Monotherapy and Combination Therapy With Paclitaxel, Ramucirumab or Atezolizumab in Patients With HER2-negative Gastric Adenocarcinoma Expressing FGFR2 Genetic Aberrations	Gastric Adenocarcinoma	3168 - Clayton; 3000 - Melbourne; 3181 - Prahran	https://clinicaltrials.gov/ct2/show/NCT04604132
NCT04606446	KAT6	Phase 1		NSW, SA, VIC, WA	2020-10-28	2020-11-16		Fulvestrant; Fulvestrant + PF-07220060 + PF-07248144; Fulvestrant + PF-07248144; Letrozole; Letrozole + PF-07248144 + Palbociclib; PF-07220060; PF-07248144; PF-07248144 + Vepdegestrant; Palbociclib; Vepdegestrant	aromatase_inhibitor; CDK4/6_inhibitor; CDK4/6_inhibitor + KAT6_inhibitor + aromatase_inhibitor; CDK4_selective_inhibitor; selective_estrogen_receptor_degrader; KAT6_inhibitor + selective_estrogen_receptor_degrader; KAT6_inhibitor; ER_PROTAC_degrader + KAT6_inhibitor; CDK4_selective_inhibitor + KAT6_inhibitor + selective_estrogen_receptor_degrader; ER_PROTAC_degrader	Fulvestrant + PF-07220060 + PF-07248144; Fulvestrant + PF-07248144; Letrozole + PF-07248144 + Palbociclib; PF-07248144; PF-07248144 + Vepdegestrant	CDK4/6_inhibitor + KAT6_inhibitor + aromatase_inhibitor; CDK4_selective_inhibitor + KAT6_inhibitor + selective_estrogen_receptor_degrader; ER_PROTAC_degrader + KAT6_inhibitor; KAT6_inhibitor; KAT6_inhibitor + selective_estrogen_receptor_degrader	NCT04606446  C4551001	A PHASE 1/2A DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMIC, AND ANTI-TUMOR ACTIVITY OF PF-07248144 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS	Locally Advanced or Metastatic Castration-resistant Prostate Cancer; Locally Advanced or Metastatic Non-small Cell Lung Cancer; Locally Advanced or Metastatic ER+ HER2- Breast Cancer	3000 - Melbourne; 2050 - Camperdown; 5000 - Adelaide; 3021 - St Albans; 3050 - Parkville; 6008 - Subiaco	https://clinicaltrials.gov/ct2/show/NCT04606446
NCT04607421	2023-509405-77-00--C4221015	Phase 3		NSW, NZ, QLD, SA, VIC	2020-10-29	2020-12-21		Bevacizumab; Bevacizumab + Capecitabine + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin; Bevacizumab + Fluorouracil + Irinotecan + Leucovorin; Capecitabine; Cetuximab; Cetuximab + Encorafenib; Cetuximab + Encorafenib + Fluorouracil + Irinotecan + Leucovorin; Cetuximab + Encorafenib + Fluorouracil + Leucovorin + Oxaliplatin; Encorafenib; Fluorouracil; Irinotecan; Leucovorin; Oxaliplatin	fluoropyrimidine; folinic_acid; anti-VEGF_monoclonal_antibody; BRAF_V600_inhibitor + anti-EGFR_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; topoisomerase_inhibitor; anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid + topoisomerase_inhibitor; Fluorouracil; BRAF_V600_inhibitor + anti-EGFR_monoclonal_antibody + fluoropyrimidine + folinic_acid + topoisomerase_inhibitor; BRAF_V600_inhibitor + anti-EGFR_monoclonal_antibody; platinum-based_antineoplastic_agent; anti-EGFR_monoclonal_antibody; anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; BRAF_V600_inhibitor	Bevacizumab + Capecitabine + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin; Bevacizumab + Fluorouracil + Irinotecan + Leucovorin; Cetuximab + Encorafenib; Cetuximab + Encorafenib + Fluorouracil + Irinotecan + Leucovorin; Cetuximab + Encorafenib + Fluorouracil + Leucovorin + Oxaliplatin	BRAF_V600_inhibitor + anti-EGFR_monoclonal_antibody; BRAF_V600_inhibitor + anti-EGFR_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; BRAF_V600_inhibitor + anti-EGFR_monoclonal_antibody + fluoropyrimidine + folinic_acid + topoisomerase_inhibitor; anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid + topoisomerase_inhibitor; Fluorouracil	2023-509405-77-00  C4221015	AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE 3 STUDY OF FIRST-LINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEAD-IN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600E-MUTANT COLORECTAL CANCER	Neoplasms	Auckland; 3168 - Clayton; 5011 - Adelaide; 2065 - St Leonards; 3004 - Melbourne; 4102 - Woolloongabba; 3084 - Heidelberg; 3000 - Melbourne; 4029 - Herston; 2050 - Camperdown; 2170 - Liverpool	https://clinicaltrials.gov/ct2/show/NCT04607421
NCT04612751	TROPION-Lung04	Phase 1			2020-11-03	2021-02-02		AZD7789; AZD7789 + Datopotamab deruxtecan; Carboplatin; Carboplatin + Datopotamab deruxtecan + Durvalumab; Carboplatin + Datopotamab deruxtecan + Rilvegostomig; Carboplatin + Datopotamab deruxtecan + Volrustomig; Datopotamab deruxtecan; Datopotamab deruxtecan + Durvalumab; Datopotamab deruxtecan + Rilvegostomig; Datopotamab deruxtecan + Volrustomig; Durvalumab; Rilvegostomig; Volrustomig	anti-Trop2_antibody-drug_conjugate; bispecific_PD-L1/CTLA4_antibody; bispecific_PD-1/TIM3_antibody; anti-PD-L1_monoclonal_antibody; bispecific_PD-1/TIGIT_antibody; anti-Trop2_antibody-drug_conjugate + bispecific_PD-1/TIM3_antibody; anti-Trop2_antibody-drug_conjugate + bispecific_PD-1/TIGIT_antibody + platinum-based_antineoplastic_agent; anti-Trop2_antibody-drug_conjugate + bispecific_PD-1/TIGIT_antibody; anti-Trop2_antibody-drug_conjugate + bispecific_PD-L1/CTLA4_antibody; platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate + platinum-based_antineoplastic_agent; anti-Trop2_antibody-drug_conjugate + bispecific_PD-L1/CTLA4_antibody + platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate	AZD7789 + Datopotamab deruxtecan; Carboplatin + Datopotamab deruxtecan + Durvalumab; Carboplatin + Datopotamab deruxtecan + Rilvegostomig; Carboplatin + Datopotamab deruxtecan + Volrustomig; Datopotamab deruxtecan + Durvalumab; Datopotamab deruxtecan + Rilvegostomig; Datopotamab deruxtecan + Volrustomig	anti-PD-L1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; anti-PD-L1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate + platinum-based_antineoplastic_agent; anti-Trop2_antibody-drug_conjugate + bispecific_PD-1/TIGIT_antibody; anti-Trop2_antibody-drug_conjugate + bispecific_PD-1/TIGIT_antibody + platinum-based_antineoplastic_agent; anti-Trop2_antibody-drug_conjugate + bispecific_PD-1/TIM3_antibody; anti-Trop2_antibody-drug_conjugate + bispecific_PD-L1/CTLA4_antibody; anti-Trop2_antibody-drug_conjugate + bispecific_PD-L1/CTLA4_antibody + platinum-based_antineoplastic_agent	2023-505992-54-00  D926FC00001	A Phase 1b, Multicenter, 2-Part, Open-Label Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Immunotherapy With or Without Carboplatin in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (Tropion-Lung04)	Advanced or Metastatic NSCLC		https://clinicaltrials.gov/ct2/show/NCT04612751
NCT04613596	CA239-0009--CA239-0009	Phase 2		ACT, NSW, NZ, QLD, SA, VIC	2020-11-03	2020-12-02		Adagrasib; Adagrasib + Pembrolizumab; Pembrolizumab	KRAS_G12C_inhibitor; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody	Adagrasib; Adagrasib + Pembrolizumab; Pembrolizumab	KRAS_G12C_inhibitor; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody	CA239-0009  CA239-0009	A Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation	Metastatic Non-Small Cell Lung Cancer; Advanced Non-Small Cell Lung Cancer	3168 - Clayton; 4102 - Woolloongabba; Palmerston North; 2605 - Garran; 4812 - Hyde Park; 2444 - Port Macquarie; 5042 - Bedford Park; 2500 - Wollongong; 3350 - Ballarat	https://clinicaltrials.gov/ct2/show/NCT04613596
NCT04614103	2020-003629-45--IOV-LUN-202	Phase 2		NSW, WA	2020-11-03	2021-05-07		Cyclophosphamide; Fludarabine	antimetabolite; alkylating_agent	Cyclophosphamide; Fludarabine	alkylating_agent; antimetabolite	2020-003629-45  IOV-LUN-202	A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (TIL or LN-145) in Patients With Metastatic Non-Small-Cell Lung Cancer	Metastatic Non Small Cell Lung Cancer	2010 - Darlinghurst; 2145 - Westmead; 6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT04614103
NCT04618393	EMB02X101	Phase 1		NSW, VIC	2020-11-05	2021-03-11		EMB-02	bispecific_PD-1/LAG3_antibody	EMB-02	bispecific_PD-1/LAG3_antibody	EMB02X101	A Phase I/II Trial of EMB-02, a Bi-specific Antibody Against PD-1 and LAG-3, in Patients With Advanced Solid Tumors	Advanced Solid Tumors	3199 - Frankston; 3168 - Clayton; 2500 - Wollongong	https://clinicaltrials.gov/ct2/show/NCT04618393
NCT04619797	SKYSCRAPER-06	Phase 2		NZ	2020-11-06	2020-12-15		Atezolizumab; Atezolizumab + Carboplatin + Cisplatin + Pemetrexed + Tiragolumab; Carboplatin; Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed; Cisplatin; Pembrolizumab; Pemetrexed; Placebo; Tiragolumab	placebo; antimetabolite; anti-TIGIT_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent	Atezolizumab + Carboplatin + Cisplatin + Pemetrexed + Tiragolumab; Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed; Placebo	anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; placebo	2020-002851-39  BO42592	A Phase II/III, Randomized, Double-Blind, Placebo-Controlled Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Patients With Previously Untreated Advanced Non-Squamous Non-Small-Cell Lung Cancer	Non-small Cell Lung Cancer (NSCLC)	Auckland; Hamilton; Palmerston North; Tauranga	https://clinicaltrials.gov/ct2/show/NCT04619797
NCT04622007	KICKSTART	Phase 2		QLD, SA, VIC	2020-11-09	2021-06-02		Pembrolizumab; Pembrolizumab + Pemetrexed; Pembrolizumab + Tomivosertib; Pemetrexed; Placebo; Tomivosertib	placebo; antimetabolite; anti-PD-1_monoclonal_antibody + antimetabolite; anti-PD-1_monoclonal_antibody; MNK_inhibitor; MNK_inhibitor + anti-PD-1_monoclonal_antibody	Pembrolizumab; Pembrolizumab + Pemetrexed; Pembrolizumab + Tomivosertib; Placebo	MNK_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + antimetabolite; placebo	eFT508-0011	A Randomized, Double-Blind, Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With NSCLC as First Line Therapy or When Progressing on Single-Agent First-Line Anti PD (L)1 Therapy	Non-small Cell Lung Cancer	4217 - Benowa; 5042 - Bedford Park; 3350 - Ballarat	https://clinicaltrials.gov/ct2/show/NCT04622007
NCT04623775	2020-004026-31--CA224-104	Phase 2		NSW, QLD, VIC, WA	2020-11-10	2021-02-17		Carboplatin; Cisplatin; Nab-paclitaxel; Nivolumab; Nivolumab + Relatlimab; Paclitaxel; Pemetrexed; Relatlimab	anti-LAG3_monoclonal_antibody; antimetabolite; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; taxane; platinum-based_antineoplastic_agent	Nivolumab; Nivolumab + Relatlimab; Carboplatin; Cisplatin; Nab-paclitaxel; Pemetrexed	anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; antimetabolite; platinum-based_antineoplastic_agent; taxane	2020-004026-31  CA224-104	A Phase 2 Randomized Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)	Metastatic Non-small Cell Lung Cancer; Recurrent Non-small Cell Lung Cancer; Non-small Cell Lung Cancer	2250 - Gosford; 3199 - Frankston; 4101 - South Brisbane; 6150 - Murdoch; 3550 - Bendigo; 6009 - Nedlands; 3128 - Box Hill; 2050 - Camperdown; 2340 - Tamworth; 3350 - Ballarat	https://clinicaltrials.gov/ct2/show/NCT04623775
NCT04624204	MK-7339-013--7339-013	Phase 3		NSW, QLD, VIC	2020-11-10	2020-12-08		Dexamethasone; Etoposide; Etoposide + Olaparib + Pembrolizumab + Radiotherapy; Olaparib; Pembrolizumab; Placebo; Radiotherapy	placebo; radiotherapy; topoisomerase_inhibitor; anti-PD-1_monoclonal_antibody; PARP_inhibitor + anti-PD-1_monoclonal_antibody + radiotherapy + topoisomerase_inhibitor; glucocorticoid; PARP_inhibitor	Etoposide + Olaparib + Pembrolizumab + Radiotherapy; Dexamethasone; Placebo	PARP_inhibitor + anti-PD-1_monoclonal_antibody + radiotherapy + topoisomerase_inhibitor; glucocorticoid; placebo	MK-7339-013  7339-013	A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Pembrolizumab (MK-3475) in Combination With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib (MK-7339), Compared to Concurrent Chemoradiation Therapy Alone in Participants With Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC)	Small Cell Lung Cancer	2560 - Campbelltown; 2298 - Waratah; 3199 - Frankston; 3084 - Heidelberg; 2747 - Kingswood; 4215 - Southport; 3021 - St Albans	https://clinicaltrials.gov/ct2/show/NCT04624204
NCT04626479	MK-3475-03A--3475-03A	Phase 1		NSW, NZ, QLD, VIC	2020-11-12	2020-12-16		Belzutifan; Belzutifan + Lenvatinib + Pembrolizumab; Belzutifan + Pembrolizumab + Vibostolimab; Favezelimab; Favezelimab + Lenvatinib + Pembrolizumab; Lenvatinib; Lenvatinib + Pembrolizumab; Lenvatinib + Pembrolizumab + Quavonlimab; Pembrolizumab; Quavonlimab; Vibostolimab	VEGF_inhibitor + anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; HIF2a_inhibitor; anti-TIGIT_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; anti-CTLA4_monoclonal_antibody; anti-LAG3_monoclonal_antibody; anti-PD-1_monoclonal_antibody; VEGF_inhibitor; HIF2a_inhibitor + VEGF_inhibitor + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; HIF2a_inhibitor + anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody	Belzutifan + Lenvatinib + Pembrolizumab; Belzutifan + Pembrolizumab + Vibostolimab; Favezelimab + Lenvatinib + Pembrolizumab; Lenvatinib + Pembrolizumab; Lenvatinib + Pembrolizumab + Quavonlimab	HIF2a_inhibitor + VEGF_inhibitor + anti-PD-1_monoclonal_antibody; HIF2a_inhibitor + anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody	MK-3475-03A  3475-03A	A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants With RCC (U03): Substudy 03A in First Line Metastatic Participants	Carcinoma, Renal Cell	4029 - Herston; 3084 - Heidelberg; 2217 - Kogarah; 2148 - Blacktown; Auckland	https://clinicaltrials.gov/ct2/show/NCT04626479
NCT04626518	MK-3475-03B--3475-03B	Phase 1		NSW, NZ, QLD, VIC	2020-11-12	2020-12-17		Belzutifan; Belzutifan + Lenvatinib; Belzutifan + Pembrolizumab; Favezelimab; Favezelimab + Pembrolizumab; Lenvatinib; Lenvatinib + Pembrolizumab; MK-4830; MK-4830 + Pembrolizumab; Pembrolizumab; Pembrolizumab + Quavonlimab; Quavonlimab	HIF2a_inhibitor + VEGF_inhibitor; HIF2a_inhibitor; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA4_monoclonal_antibody; anti-LAG3_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; HIF2a_inhibitor + anti-PD-1_monoclonal_antibody; VEGF_inhibitor; anti-ILT4_monoclonal_antibody; anti-ILT4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	Belzutifan + Lenvatinib; Belzutifan + Pembrolizumab; Favezelimab + Pembrolizumab; Lenvatinib + Pembrolizumab; MK-4830 + Pembrolizumab; Pembrolizumab + Quavonlimab	HIF2a_inhibitor + VEGF_inhibitor; HIF2a_inhibitor + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-ILT4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody	MK-3475-03B  3475-03B	A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants With RCC (KEYMAKER-U03): Substudy 03B in Second-Line Metastatic Participants	Carcinoma, Renal Cell	4029 - Herston; Auckland; 2148 - Blacktown; 2217 - Kogarah; 3084 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04626518
NCT04630756	2020-001642-18--D8230C00002	Phase 1		VIC, WA	2020-11-16	2021-02-17		AZD4573; AZD4573 + Acalabrutinib; Acalabrutinib	BTK_inhibitor; CDK9_inhibitor; BTK_inhibitor + CDK9_inhibitor	AZD4573 + Acalabrutinib	BTK_inhibitor + CDK9_inhibitor	2020-001642-18  D8230C00002	A Modular Phase I/II, Open-label, Multicentre Study to Assess AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Haematological Malignancies	Advanced Haematological Malignancies	3168 - Clayton; 6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT04630756
NCT04631601	2020-001305-23--20190505	Phase 1		NSW	2020-11-17	2021-01-15		AMG 404; Abiraterone; Enzalutamide	antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor; anti-PD-1_monoclonal_antibody	AMG 404; Abiraterone; Enzalutamide	CYP17A1_inhibitor; anti-PD-1_monoclonal_antibody; antiandrogen,nonsteroidal,second_generation	2020-001305-23  20190505	A Master Protocol Evaluating the Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)	Metastatic Castration-resistant Prostate Cancer	2010 - Darlinghurst	https://clinicaltrials.gov/ct2/show/NCT04631601
NCT04634825	CP-MGA271-06	Phase 2		NSW, QLD, VIC, WA	2020-11-18	2021-03-17		Enoblituzumab; Enoblituzumab + Retifanlimab; Enoblituzumab + Tebotelimab; Retifanlimab; Tebotelimab	anti-CD276_monoclonal_antibody + humanized_PD-1xLAG-3_dual-affinity_re-targeting_protein; anti-PD-1_monoclonal_antibody; humanized_PD-1xLAG-3_dual-affinity_re-targeting_protein; anti-CD276_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CD276_monoclonal_antibody	Enoblituzumab + Retifanlimab; Enoblituzumab + Tebotelimab	anti-CD276_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CD276_monoclonal_antibody + humanized_PD-1xLAG-3_dual-affinity_re-targeting_protein	CP-MGA271-06	A Phase 2 Open-Label Trial to Evaluate Enoblituzumab in Combination With Retifanlimab or Tebotelimab in the First-Line Treatment of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck	Head and Neck Squamous Cell Carcinoma; Head and Neck Neoplasms; Head and Neck Cancer	3168 - Ruse; 2065 - Sydney; 4215 - Southport; 2170 - Liverpool; 6150 - Murdoch; 3220 - Geelong; 2298 - Waratah	https://clinicaltrials.gov/ct2/show/NCT04634825
NCT04642365	2020-003164-82--BP42595	Phase 1		VIC	2020-11-24	2021-01-04		Atezolizumab; Atezolizumab + RO7296682; RO7296682	anti-CD25_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; anti-CD25_monoclonal_antibody + anti-PD-L1_monoclonal_antibody	Atezolizumab + RO7296682	anti-CD25_monoclonal_antibody + anti-PD-L1_monoclonal_antibody	2020-003164-82  BP42595	An Open-Label, Multicenter, Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-Tumor Activity of RO7296682 in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors	Solid Tumors	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04642365
NCT04644237	DESTINY-LUNG02	Phase 2		QLD, WA	2020-11-25	2021-03-19		Trastuzumab Deruxtecan	anti-ERBB2_antibody-drug_conjugate	Trastuzumab Deruxtecan	anti-ERBB2_antibody-drug_conjugate	2020-003427-42  DS8201-A-U206	A Phase 2, Multicenter, Randomized Study of Trastuzumab Deruxtecan in Subjects With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC) (DESTINY-LUNG02)	Non-Small Cell Lung Cancer	6008 - Subiaco; 4102 - Woolloongabba	https://clinicaltrials.gov/ct2/show/NCT04644237
NCT04645069	ADG126-1001	Phase 1		NSW, QLD, VIC, WA	2020-11-27	2021-03-15		ADG106; ADG106 + ADG126; ADG126	anti-4-1BB_agonistic_antibody; anti-4-1BB_agonistic_antibody + anti-CTLA4_monoclonal_antibody; anti-CTLA4_monoclonal_antibody	ADG106 + ADG126; ADG126	anti-4-1BB_agonistic_antibody + anti-CTLA4_monoclonal_antibody; anti-CTLA4_monoclonal_antibody	ADG126-1001	A First-in-Human (FIH), Open-Label, Phase 1/2 Dose Escalation and Expansion Study of ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Patients With Advanced/Metastatic Solid Tumors	Advanced/Metastatic Solid Tumors	2228 - Miranda; 4575 - Birtinya; 6009 - Nedlands; - Sydney; 3144 - Malvern	https://clinicaltrials.gov/ct2/show/NCT04645069
NCT04649385	CTR20212721--BGB-A317-15025-101	Phase 1		NSW, NZ, SA, VIC, WA	2020-12-02	2021-03-04		BGB-15025; BGB-15025 + Tislelizumab; Tislelizumab	HPK1_inhibitor; anti-PD-1_monoclonal_antibody; HPK1_inhibitor + anti-PD-1_monoclonal_antibody	BGB-15025; BGB-15025 + Tislelizumab	HPK1_inhibitor; HPK1_inhibitor + anti-PD-1_monoclonal_antibody	CTR20212721  BGB-A317-15025-101	A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors	Advanced Solid Tumor	6009 - Nedlands; Auckland; 5087 - Windsor Gardens; 2031 - Randwick; 3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04649385
NCT04650581	FINER	Phase 3		ACT, NSW, NZ, QLD, VIC, WA	2020-12-02	2021-01-27		Fulvestrant; Fulvestrant + Ipatasertib; Ipatasertib; Placebo	placebo; selective_estrogen_receptor_degrader; pan-AKT_inhibitor; pan-AKT_inhibitor + selective_estrogen_receptor_degrader	Fulvestrant + Ipatasertib; Placebo	pan-AKT_inhibitor + selective_estrogen_receptor_degrader; placebo	2101  MA40	Double-Blind Placebo-Controlled Randomized Phase III Trial of Fulvestrant and Ipatasertib as Treatment for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor	Breast Cancer	2109 - Macquarie University; 3021 - St. Albans; 6150 - Murdoch; Wellington; ACT 2605 - Garran; 4350 - Toowoomba; Auckland; 3004 - Melbourne; 3199 - Frankston; 2250 - Gosford; 2324 - Gateshead; 4029 - Herston; 3076 - Epping; 3002 - East Melbourne; 2541 - Nowra; 2576 - Bowral; 4575 - Birtinya; 6230 - Bunbury	https://clinicaltrials.gov/ct2/show/NCT04650581
NCT04655976	COSTAR-Lung	Phase 3		QLD, SA, TAS, VIC	2020-12-07	2020-12-08		Cobolimab; Cobolimab + Docetaxel + Dostarlimab; Docetaxel; Docetaxel + Dostarlimab; Dostarlimab	anti-PD-1_monoclonal_antibody + anti-TIM3_monoclonal_antibody + taxane; anti-PD-1_monoclonal_antibody + taxane; anti-TIM3_monoclonal_antibody; anti-PD-1_monoclonal_antibody; taxane	Cobolimab + Docetaxel + Dostarlimab; Docetaxel; Docetaxel + Dostarlimab	anti-PD-1_monoclonal_antibody + anti-TIM3_monoclonal_antibody + taxane; anti-PD-1_monoclonal_antibody + taxane; taxane	2020-003433-37  213410	A Randomized, Open Label Phase 2/3 Study Comparing Cobolimab + Dostarlimab + Docetaxel To Dostarlimab + Docetaxel To Docetaxel Alone In Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed On Prior Anti-PD-(L)1 Therapy And Chemotherapy (COSTAR Lung)	Lung Cancer, Non-Small Cell	3350 - Ballarat; 3350 - Mount Waverley; 5037 - Ashford; 3004 - Melbourne; 7000 - Hobart; 4101 - South Brisbane	https://clinicaltrials.gov/ct2/show/NCT04655976
NCT04656652	2020-004643-80--DS1062-A-U301	Phase 3		NSW, SA, VIC	2020-12-07	2020-12-21		DS-1062a; Docetaxel	anti-Trop2_antibody-drug_conjugate; taxane	DS-1062a; Docetaxel	anti-Trop2_antibody-drug_conjugate; taxane	2020-004643-80  DS1062-A-U301	Phase 3 Randomized Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-LUNG01)	Non-small Cell Lung Cancer	02148 - Blacktown; 03084 - Heidelberg; 02109 - North Ryde; 2145 - Sydney; 02500 - Wollongong; 05042 - Bedford Park	https://clinicaltrials.gov/ct2/show/NCT04656652
NCT04657991	KEYNOTE-B80--C4221016	Phase 3		NZ	2020-12-08	2021-01-15		Binimetinib; Binimetinib + Encorafenib + Pembrolizumab; Encorafenib; Pembrolizumab; Placebo	placebo; BRAF_V600_inhibitor + MEK_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; BRAF_V600_inhibitor; MEK_inhibitor	Binimetinib + Encorafenib + Pembrolizumab; Pembrolizumab; Placebo	BRAF_V600_inhibitor + MEK_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; placebo	KEYNOTE-B80  C4221016	A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY OF ENCORAFENIB AND BINIMETINIB PLUS PEMBROLIZUMAB VERSUS PLACEBO PLUS PEMBROLIZUMAB IN PARTICIPANTS WITH BRAF V600E/K MUTATION-POSITIVE METASTATIC OR UNRESECTABLE LOCALLY ADVANCED MELANOMA	Melanoma	Manawatu	https://clinicaltrials.gov/ct2/show/NCT04657991
NCT04659629	NL201-101	Phase 1		NSW, VIC	2020-12-09	2021-04-26		NL-201; NL-201 + Pembrolizumab; Pembrolizumab	IL-2/IL-15_receptor_agonist + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; IL-2/IL-15_receptor_agonist	NL-201; NL-201 + Pembrolizumab	IL-2/IL-15_receptor_agonist; IL-2/IL-15_receptor_agonist + anti-PD-1_monoclonal_antibody	NL201-101	A First-in-Human Phase 1 Study of NL-201 Monotherapy and in Combination With Pembrolizumab in Patients With Relapsed or Refractory Cancer	Advanced Solid Tumor; Solid Tumor	- Sydney; - Heidelberg; 2065 - Sydney	https://clinicaltrials.gov/ct2/show/NCT04659629
NCT04662710	LEAP-015	Phase 3		NSW, QLD, WA	2020-12-10	2020-12-30		Capecitabine; Capecitabine + Fluorouracil + Lenvatinib + Leucovorin + Oxaliplatin + Pembrolizumab; Fluorouracil; Lenvatinib; Leucovorin; Oxaliplatin; Pembrolizumab	Fluorouracil; fluoropyrimidine; anti-PD-1_monoclonal_antibody; VEGF_inhibitor; platinum-based_antineoplastic_agent; folinic_acid; VEGF_inhibitor + anti-PD-1_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent	Capecitabine + Fluorouracil + Lenvatinib + Leucovorin + Oxaliplatin + Pembrolizumab	VEGF_inhibitor + anti-PD-1_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; Fluorouracil	MK-7902-015  7902-015	Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy Compared With Standard of Care Therapy as First-line Intervention in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (LEAP-015)	Advanced/Metastatic Gastroesophageal Adenocarcinoma	6009 - Nedlands; 2747 - Kingswood; 2500 - Wollongong; 4029 - Herston	https://clinicaltrials.gov/ct2/show/NCT04662710
NCT04665206	VT3989-001	Phase 1		VIC, WA	2020-12-11	2021-03-24		VT3989	TEAD_palmitoylation_inhibitor	VT3989	TEAD_palmitoylation_inhibitor	VT3989-001	Phase 1, Multi-Center, Open-Label Study of VT3989 in Patients With Refractory Locally Advanced or Metastatic Solid Tumors Enriched for Tumors Harboring Mutations of the Neurofibromatosis Type 2 Gene (Mutant NF2 or mNF2)	Solid Tumor, Adult; Mesothelioma	3000 - Melbourne; 6009 - Nedlands; 3168 - Clayton	https://clinicaltrials.gov/ct2/show/NCT04665206
NCT04665843	SKYSCRAPER-09	Phase 2		NZ	2020-12-14	2021-03-02		Atezolizumab; Atezolizumab + Tiragolumab; Placebo; Tiragolumab	placebo; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-TIGIT_monoclonal_antibody; anti-PD-L1_monoclonal_antibody	Atezolizumab; Atezolizumab + Tiragolumab; Placebo	anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; placebo	2020-002852-19  BO42533	A Phase II, Randomized, Double Blind Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Patients With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck	Squamous Cell Carcinoma of Head and Neck	Auckland	https://clinicaltrials.gov/ct2/show/NCT04665843
NCT04670679	FLAGSHP-1	Phase 1		VIC, WA	2020-12-17	2020-12-15		Cetuximab; Cetuximab + ERAS-601; ERAS-601; ERAS-601 + Pembrolizumab; Pembrolizumab	SHP2_inhibitor + anti-PD-1_monoclonal_antibody; anti-EGFR_monoclonal_antibody; SHP2_inhibitor; anti-PD-1_monoclonal_antibody; SHP2_inhibitor + anti-EGFR_monoclonal_antibody	Cetuximab + ERAS-601; ERAS-601; ERAS-601 + Pembrolizumab	SHP2_inhibitor; SHP2_inhibitor + anti-EGFR_monoclonal_antibody; SHP2_inhibitor + anti-PD-1_monoclonal_antibody	ERAS-601-01	An Open-Label, Multi-Center Phase 1/1b Dose Escalation and Expansion Study of ERAS-601 SHP2 Inhibitor as a Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced or Metastatic Solid Tumors	Advanced or Metastatic Solid Tumors	- Perth; - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04670679
NCT04674683	HBI-8000-303	Phase 3		NSW, NZ, QLD, VIC, WA	2020-12-19	2021-08-12		Nivolumab; Placebo	placebo; anti-PD-1_monoclonal_antibody	Nivolumab; Placebo	anti-PD-1_monoclonal_antibody; placebo	HBI-8000-303	A Multicenter, Randomized, Double-Blind Phase 3 Study of HBI-8000 Combined With Nivolumab Versus Placebo With Nivolumab in Patients With Unresectable or Metastatic Melanoma Not Previously Treated With PD-1 or PD-L1 Inhibitors	Progressive Brain Metastasis; Unresectable or Metastatic Melanoma	- Waratah; - Nedlands; - Wahroonga; - South Brisbane; - Brisbane; Tauranga; Auckland; Hamilton; - Ballarat; - Liverpool; - Shepparton; 4556 - Buderim; - Tweed Heads	https://clinicaltrials.gov/ct2/show/NCT04674683
NCT04675294	KEYNOTE-B87--AT148003	Phase 2		NSW, QLD, SA, VIC, WA	2020-12-19	2021-04-02		Evorpacept; Evorpacept + Pembrolizumab; Pembrolizumab	CD47-blocking_fusion_protein; anti-PD-1_monoclonal_antibody; CD47-blocking_fusion_protein + anti-PD-1_monoclonal_antibody	Evorpacept + Pembrolizumab; Pembrolizumab	CD47-blocking_fusion_protein + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody	KEYNOTE-B87  AT148003	A Phase 2 Study of ALX148 in Combination with Pembrolizumab in Patients with Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)	Head and Neck Squamous Cell Carcinoma; Head and Neck Cancer	6009 - Perth; 2146 - Sydney; 4029 - Brisbane; 5087 - Windsor Gardens; 3051 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04675294
NCT04675333	KEYNOTE-B88--AT148004	Phase 2		QLD, SA, VIC, WA	2020-12-19	2021-05-10		Carboplatin; Cisplatin; Evorpacept; Evorpacept + Pembrolizumab; Fluorouracil; Pembrolizumab	fluoropyrimidine; anti-PD-1_monoclonal_antibody; CD47-blocking_fusion_protein + anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; CD47-blocking_fusion_protein	Evorpacept + Pembrolizumab; Pembrolizumab; Carboplatin; Cisplatin; Fluorouracil	CD47-blocking_fusion_protein + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; fluoropyrimidine; platinum-based_antineoplastic_agent	KEYNOTE-B88  AT148004	A Phase 2 Study of ALX148 in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)	Head and Neck Squamous Cell Carcinoma; Head and Neck Cancer	6009 - Nedlands; 5037 - Adelaide; 4029 - Herston; 3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04675333
NCT04677855	PCUR101-003	Phase 1		NSW, SA	2020-12-21	2021-03-30		Abiraterone; Abiraterone + PCUR-101 + Prednisone; PCUR-101; Prednisone	CYP17A1_inhibitor + glucocorticoid + synthetic_plumbagin; glucocorticoid; CYP17A1_inhibitor; synthetic_plumbagin	Abiraterone + PCUR-101 + Prednisone; PCUR-101	CYP17A1_inhibitor + glucocorticoid + synthetic_plumbagin; synthetic_plumbagin	PCUR101-003	A Phase I Study of PCUR-101 in Combination With Androgen Directed Therapy in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer	Prostate Cancer	5042 - Bedford Park; 2217 - Kogarah	https://clinicaltrials.gov/ct2/show/NCT04677855
NCT04684108	CSG-301-101	Phase 1			2020-12-24	2021-11-04		SG301	anti-CD38_monoclonal_antibody	SG301	anti-CD38_monoclonal_antibody	CSG-301-101	A Phase 1 Study of SG301 in Subjects With Hematological Malignancies	Relapsed or Refractory Multiple Myeloma; Hematological Malignancy		https://clinicaltrials.gov/ct2/show/NCT04684108
NCT04686305	DL03	Phase 1		SA, VIC, WA	2020-12-28	2021-03-09		Carboplatin; Carboplatin + Durvalumab + Trastuzumab Deruxtecan; Carboplatin + Rilvegostomig + Trastuzumab Deruxtecan; Carboplatin + Trastuzumab Deruxtecan + Volrustomig; Cisplatin; Cisplatin + Durvalumab + Trastuzumab Deruxtecan; Durvalumab; Durvalumab + Pemetrexed + Trastuzumab Deruxtecan; Pemetrexed; Rilvegostomig; Rilvegostomig + Trastuzumab Deruxtecan; Trastuzumab Deruxtecan; Trastuzumab Deruxtecan + Volrustomig; Volrustomig	anti-ERBB2_antibody-drug_conjugate + anti-PD-L1_monoclonal_antibody + platinum-based_antineoplastic_agent; antimetabolite; anti-ERBB2_antibody-drug_conjugate + bispecific_PD-1/TIGIT_antibody + platinum-based_antineoplastic_agent; bispecific_PD-L1/CTLA4_antibody; anti-PD-L1_monoclonal_antibody; anti-ERBB2_antibody-drug_conjugate + bispecific_PD-L1/CTLA4_antibody + platinum-based_antineoplastic_agent; anti-ERBB2_antibody-drug_conjugate; bispecific_PD-1/TIGIT_antibody; anti-ERBB2_antibody-drug_conjugate + anti-PD-L1_monoclonal_antibody + antimetabolite; anti-ERBB2_antibody-drug_conjugate + bispecific_PD-L1/CTLA4_antibody; platinum-based_antineoplastic_agent; anti-ERBB2_antibody-drug_conjugate + bispecific_PD-1/TIGIT_antibody	Carboplatin + Durvalumab + Trastuzumab Deruxtecan; Carboplatin + Rilvegostomig + Trastuzumab Deruxtecan; Carboplatin + Trastuzumab Deruxtecan + Volrustomig; Cisplatin + Durvalumab + Trastuzumab Deruxtecan; Durvalumab + Pemetrexed + Trastuzumab Deruxtecan; Rilvegostomig + Trastuzumab Deruxtecan; Trastuzumab Deruxtecan; Trastuzumab Deruxtecan + Volrustomig	anti-ERBB2_antibody-drug_conjugate; anti-ERBB2_antibody-drug_conjugate + anti-PD-L1_monoclonal_antibody + antimetabolite; anti-ERBB2_antibody-drug_conjugate + anti-PD-L1_monoclonal_antibody + platinum-based_antineoplastic_agent; anti-ERBB2_antibody-drug_conjugate + bispecific_PD-1/TIGIT_antibody; anti-ERBB2_antibody-drug_conjugate + bispecific_PD-1/TIGIT_antibody + platinum-based_antineoplastic_agent; anti-ERBB2_antibody-drug_conjugate + bispecific_PD-L1/CTLA4_antibody; anti-ERBB2_antibody-drug_conjugate + bispecific_PD-L1/CTLA4_antibody + platinum-based_antineoplastic_agent	2023-504949-31-00  D967YC00001	A Phase Ib Multicenter, Open-label Study to Evaluate the Safety and Tolerability of Trastuzumab Deruxtecan (T-DXd) and Immunotherapy Agents With and Without Chemotherapy Agents in First-line Treatment of Patients With Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) and Human Epidermal Growth Factor Receptor 2 (HER2) Overexpression (OE) (DESTINY-Lung03)	Locally Advanced or Metastatic Non-Small Cell Lung Cancer	5000 - Adelaide; 3084 - Heidelberg; 6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT04686305
NCT04691804	SHR3162-III-305	Phase 3		NSW, SA, VIC	2020-12-31	2021-03-18		Abiraterone; Fuzuloparib; Placebo; Prednisone	placebo; glucocorticoid; CYP17A1_inhibitor; PARP_inhibitor	Fuzuloparib; Abiraterone; Placebo; Prednisone	PARP_inhibitor; CYP17A1_inhibitor; glucocorticoid; placebo	SHR3162-III-305	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer	Metastatic Castration-Resistant Prostate Cancer (mCRPC)	- Wahroonga; - Bendigo; - Fitzroy; - Melbourne; - Wagga Wagga; - Kurralta Park; - Concord; - Sydney; - St Albans; - Gosford	https://clinicaltrials.gov/ct2/show/NCT04691804
NCT04699188	KontRASt-01	Phase 1		VIC	2021-01-07	2021-02-24		JDQ443; JDQ443 + TNO155; JDQ443 + TNO155 + Tislelizumab; JDQ443 + Tislelizumab; TNO155; Tislelizumab	KRAS_G12C_inhibitor + SHP2_inhibitor + anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor; SHP2_inhibitor; KRAS_G12C_inhibitor + SHP2_inhibitor; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody	JDQ443; JDQ443 + TNO155; JDQ443 + TNO155 + Tislelizumab; JDQ443 + Tislelizumab	KRAS_G12C_inhibitor; KRAS_G12C_inhibitor + SHP2_inhibitor; KRAS_G12C_inhibitor + SHP2_inhibitor + anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody	2020-004129-22  CJDQ443A12101	A Phase Ib/II Open-label, Multi-center Dose Escalation Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation	KRAS G12C Mutant Solid Tumors; Neoplasms, Lung; Lung Cancer; Carcinoma, Colorectal; Cancer of the Lung; Pulmonary Neoplasms; Cancer of Lung; Pulmonary Cancer; Neoplasms, Pulmonary; Carcinoma, Non-Small-Cell Lung	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04699188
NCT04700072	MK-3475-02D--3475-02D	Phase 1		NSW	2021-01-07	2021-05-03		Lenvatinib; Lenvatinib + Pembrolizumab; Lenvatinib + Pembrolizumab + Quavonlimab; Pembrolizumab; Quavonlimab	VEGF_inhibitor + anti-PD-1_monoclonal_antibody; VEGF_inhibitor; anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA4_monoclonal_antibody	Lenvatinib + Pembrolizumab; Lenvatinib + Pembrolizumab + Quavonlimab	VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody	MK-3475-02D  3475-02D	A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma (KEYMAKER-U02): Substudy 02D	Melanoma	2298 - Waratah; 2065 - Wollstonecraft	https://clinicaltrials.gov/ct2/show/NCT04700072
NCT04702737	DeLLpro-300	Phase 1		NSW, VIC	2021-01-11	2021-06-10		Tarlatamab	bispecific_T-cell_engager,DLL3-targeting	Tarlatamab	bispecific_T-cell_engager,DLL3-targeting	20200040	A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of Delta-like Protein 3 Half-life Extended Bispecific T-cell Engager AMG 757 in Subjects With De Novo or Treatment Emergent Neuroendocrine Prostate Cancer	Neuroendocrine Prostate Cancer	3000 - Melbourne; 2050 - Camperdown	https://clinicaltrials.gov/ct2/show/NCT04702737
NCT04702880	2020-001863-10--CA001-050	Phase 2		NSW, QLD, VIC, WA	2021-01-11	2021-03-17		BMS-986012; BMS-986012 + Carboplatin + Etoposide + Nivolumab; Carboplatin; Carboplatin + Etoposide + Nivolumab; Etoposide; Nivolumab	topoisomerase_inhibitor; anti-PD-1_monoclonal_antibody + anti-fucosyl-GM1_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; anti-fucosyl-GM1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor	BMS-986012 + Carboplatin + Etoposide + Nivolumab; Carboplatin + Etoposide + Nivolumab	anti-PD-1_monoclonal_antibody + anti-fucosyl-GM1_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor	2020-001863-10  CA001-050	A Randomized, Open-label Phase 2 Clinical Trial of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer	Extensive-stage Small Cell Lung Cancer	2145 - Westmead; 6150 - Murdoch; 3144 - Malvern; 4120 - Greenslopes	https://clinicaltrials.gov/ct2/show/NCT04702880
NCT04704219	KEYNOTE-B61	Phase 2		NSW, QLD, SA, VIC, WA	2021-01-11	2021-02-23		Lenvatinib; Lenvatinib + Pembrolizumab; Pembrolizumab	VEGF_inhibitor + anti-PD-1_monoclonal_antibody; VEGF_inhibitor; anti-PD-1_monoclonal_antibody	Lenvatinib + Pembrolizumab	VEGF_inhibitor + anti-PD-1_monoclonal_antibody	MK-3475-B61  3475-B61	A Phase 2, Single-arm, Open-label Clinical Trial of Pembrolizumab Plus Lenvatinib in Participants With First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (nccRCC) (KEYNOTE-B61)	Renal Cell Carcinoma	2298 - Waratah; 3168 - Clayton; 6150 - Murdoch; 4029 - Brisbane; 5037 - Kurralta Park; 2109 - Macquarie Park	https://clinicaltrials.gov/ct2/show/NCT04704219
NCT04713891	KFCS001	Phase 1		NSW	2021-01-19	2021-03-09		Atezolizumab; Atezolizumab + KF-0210; KF-0210	anti-PD-L1_monoclonal_antibody; prostaglandin_EP4_receptor_inhibitor; anti-PD-L1_monoclonal_antibody + prostaglandin_EP4_receptor_inhibitor	Atezolizumab + KF-0210; KF-0210	anti-PD-L1_monoclonal_antibody + prostaglandin_EP4_receptor_inhibitor; prostaglandin_EP4_receptor_inhibitor	KFCS001	A Phase I, Multi-Center, Open-Label Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of KF-0210 in Patients With Advanced Solid Tumors	Squamous Cell Carcinoma of the Esophagus; Bladder Cancer; Colorectal Cancer; Gastric Cancer; Lung Cancer; Advanced Solid Tumor	2031 - Randwick	https://clinicaltrials.gov/ct2/show/NCT04713891
NCT04721015	2020-004953-57--M20-111	Phase 1		NSW, VIC	2021-01-22	2021-02-23		ABBV-637; ABBV-637 + Docetaxel; ABBV-637 + Osimertinib; Docetaxel; Osimertinib	anti-EGFR_antibody-drug_conjugate,Bcl-xL_payload + taxane; anti-EGFR_antibody-drug_conjugate,Bcl-xL_payload; EGFR_inhibitor,third_generation + anti-EGFR_antibody-drug_conjugate,Bcl-xL_payload; taxane; EGFR_inhibitor,third_generation	ABBV-637; ABBV-637 + Docetaxel; ABBV-637 + Osimertinib	EGFR_inhibitor,third_generation + anti-EGFR_antibody-drug_conjugate,Bcl-xL_payload; anti-EGFR_antibody-drug_conjugate,Bcl-xL_payload; anti-EGFR_antibody-drug_conjugate,Bcl-xL_payload + taxane	2020-004953-57  M20-111	A Phase 1 First In Human Study Evaluating Safety And Efficacy Of ABBV-637 As Either Monotherapy Or In Combination In Adult Subjects With Relapsed And Refractory Solid Tumors	Non Small Cell Lung Cancer (NSCLC); Advanced Solid Tumors Cancer	2500 - Wollongong; 3084 - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT04721015
NCT04725188	MK-7684A-002--7684A-002	Phase 2		ACT, QLD, WA	2021-01-26	2021-04-20		Docetaxel; Docetaxel + Pembrolizumab + Vibostolimab; Pembrolizumab; Pembrolizumab + Vibostolimab; Placebo; Vibostolimab	placebo; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + taxane; anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody; taxane; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody	Docetaxel; Docetaxel + Pembrolizumab + Vibostolimab; Pembrolizumab + Vibostolimab; Placebo	anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + taxane; taxane; placebo	MK-7684A-002  7684A-002	A Phase 2, Multicenter, Randomized Study to Compare the Efficacy and Safety of MK-7684A or MK-7684A Plus Docetaxel Versus Docetaxel Monotherapy in the Treatment of Participants With Metastatic Non-small Cell Lung Cancer With Progressive Disease After Treatment With a Platinum Doublet Chemotherapy and Immunotherapy	Metastatic Non Small Cell Lung Cancer	4215 - Southport; 2605 - Canberra; 6150 - Murdoch	https://clinicaltrials.gov/ct2/show/NCT04725188
NCT04726033	CUPID	Phase 0		WA	2021-01-27	2021-08-04		64Cu-TLX592	PSMA-targeting_antibody_radioimmunoconjugate	64Cu-TLX592	PSMA-targeting_antibody_radioimmunoconjugate	64Cu-TLX592-001	A Phase I, Single Centre, Open-label Study of TLX592 to Assess the Safety and Tolerability, Pharmacokinetics, Biodistribution and Radiation Dosimetry in Patients Diagnosed With Prostate Cancer	Metastatic Prostate Cancer	6014 - Perth	https://clinicaltrials.gov/ct2/show/NCT04726033
NCT04727554	NCT04727554	Phase 1		VIC, WA	2021-01-27	2021-04-29		AMG 404	anti-PD-1_monoclonal_antibody	AMG 404	anti-PD-1_monoclonal_antibody	20190136	A Phase 1, Multicenter, Open-label, Dose Exploration and Dose Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 994 Monotherapy and Combination of AMG 994 and AMG 404 in Subjects With Advanced Solid Tumors	Advanced Solid Tumors	3168 - Clayton; 6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT04727554
NCT04728893	MK-1026-003--1026-003	Phase 2		NSW, VIC, WA	2021-01-28	2021-04-05		Nemtabrutinib	BTK_inhibitor	Nemtabrutinib	BTK_inhibitor	MK-1026-003  1026-003	A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants With Hematologic Malignancies	Chronic Lymphocytic Leukaemia; Non-Hodgkins Lymphoma; Hematologic Malignancies; Waldenstroms Macroglobulinaemia	3128 - Box Hill; 6009 - Nedlands; 2747 - Sydney	https://clinicaltrials.gov/ct2/show/NCT04728893
NCT04736199	ARANOTE	Phase 3		NSW, NZ, SA, VIC	2021-02-03	2021-02-23		Darolutamide; Placebo	placebo; antiandrogen,nonsteroidal,second_generation	Darolutamide; Placebo	antiandrogen,nonsteroidal,second_generation; placebo	2022-502244-12-00  21140	A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Darolutamide in Addition to Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Men With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)	Prostatic Neoplasms	Hamilton; Canterbury; 2065 - St Leonards; 3199 - Frankston; 3084 - Heidelberg; 2747 - Kingswood; 5000 - Adelaide; 2109 - Sydney; Tauranga	https://clinicaltrials.gov/ct2/show/NCT04736199
NCT04736706	MK-6482-012--6482-012	Phase 3		NSW, SA, VIC, WA	2021-02-03	2021-04-14		Belzutifan; Belzutifan + Lenvatinib + Pembrolizumab; Lenvatinib; Lenvatinib + Pembrolizumab; Lenvatinib + Pembrolizumab + Quavonlimab; Pembrolizumab; Quavonlimab	HIF2a_inhibitor; anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; VEGF_inhibitor; HIF2a_inhibitor + VEGF_inhibitor + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA4_monoclonal_antibody	Belzutifan + Lenvatinib + Pembrolizumab; Lenvatinib + Pembrolizumab; Lenvatinib + Pembrolizumab + Quavonlimab	HIF2a_inhibitor + VEGF_inhibitor + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody	MK-6482-012  6482-012	An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or MK-1308A in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, as First-Line Treatment in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)	Carcinoma, Renal Cell	2170 - Liverpool; 6150 - Murdock; 5112 - Elizabeth Vale; 3168 - Clayton; 2109 - Macquarie University	https://clinicaltrials.gov/ct2/show/NCT04736706
NCT04737122	LM061-01-102	Phase 1		NSW	2021-02-03	2021-05-06		LM-061; LM-061 + Toripalimab; Toripalimab	MET/VEGFR2/FLT3_inhibitor; anti-PD-1_monoclonal_antibody; MET/VEGFR2/FLT3_inhibitor + anti-PD-1_monoclonal_antibody	LM-061; LM-061 + Toripalimab	MET/VEGFR2/FLT3_inhibitor; MET/VEGFR2/FLT3_inhibitor + anti-PD-1_monoclonal_antibody	LM061-01-102	A Phase I, First-in-Human, Open-Label, Dose Escalation Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LM-061 Tablet in Subjects With Advanced Tumors	Advanced Tumours	2217 - Kogarah	https://clinicaltrials.gov/ct2/show/NCT04737122
NCT04739670	BELLA	Phase 2		NSW, QLD, VIC	2021-02-05	2021-03-01		Atezolizumab; Atezolizumab + Bevacizumab + Carboplatin + Gemcitabine; Bevacizumab; Carboplatin; Gemcitabine	anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite; platinum-based_antineoplastic_agent; anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; gemcitabine	Atezolizumab + Bevacizumab + Carboplatin + Gemcitabine	anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; gemcitabine	19/002	A Single Arm Phase II Trial Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Early Relapsing Metastatic Triple Negative Breast Cancer	Metastatic Triple Negative Breast Cancer	2065 - St Leonards; 4101 - South Brisbane; - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04739670
NCT04739761	DESTINY-B12	Phase 3		NSW, QLD, SA, VIC, WA	2021-02-05	2021-06-22		Trastuzumab Deruxtecan	anti-ERBB2_antibody-drug_conjugate	Trastuzumab Deruxtecan	anti-ERBB2_antibody-drug_conjugate	2024-510588-53-00  D9673C00007	An Open-Label, Multinational, Multicenter, Phase 3b/4 Study of Trastuzumab Deruxtecan in Patients With or Without Baseline Brain Metastasis With Previously Treated Advanced/Metastatic HER2-Positive Breast Cancer (DESTINY-Breast12)	Breast Cancer	3084 - Heidelberg; 5000 - Adelaide; 6008 - Subiaco; 2065 - St Leonards; 3168 - Clayton; 4066 - Auchenflower	https://clinicaltrials.gov/ct2/show/NCT04739761
NCT04740424	FS222-19101	Phase 1		NSW, WA	2021-02-05	2020-12-14		FS222	bispecific_PD-L1/CD137_antibody	FS222	bispecific_PD-L1/CD137_antibody	FS222-19101	A Phase 1, Open-Label, First-in-Human Study to Evaluate the Safety and Anti-tumour Activity of FS222, a CD137/PD-L1 Bispecific Antibody, in Subjects With Advanced Malignancies	Metastatic Cancer; Advanced Cancer	2298 - Waratah; 6150 - Perth	https://clinicaltrials.gov/ct2/show/NCT04740424
NCT04740918	KATE3	Phase 3		NSW, QLD, VIC	2021-02-05	2021-06-07		Atezolizumab; Atezolizumab + Trastuzumab Emtansine; Pertuzumab; Placebo; Trastuzumab; Trastuzumab Emtansine	placebo; anti-ERBB2_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; anti-ERBB2_antibody-drug_conjugate + anti-PD-L1_monoclonal_antibody; anti-ERBB2_monoclonal_antibody,dimerization_inhibitor; anti-ERBB2_antibody-drug_conjugate	Atezolizumab + Trastuzumab Emtansine; Pertuzumab; Placebo	anti-ERBB2_antibody-drug_conjugate + anti-PD-L1_monoclonal_antibody; anti-ERBB2_monoclonal_antibody; anti-ERBB2_monoclonal_antibody,dimerization_inhibitor; placebo	2020-002818-41  MO42319	A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase III Study of the Efficacy and Safety of Trastuzumab Emtansine in Combination with Atezolizumab or Placebo in Patients with HER2-Positive and PD-L1-Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab- (+/- Pertuzumab) and Taxane-Based Therapy (KATE3)	Metastatic Breast Cancer	4102 - Woolloongabba; 2290 - Gateshead; 2065 - St. Leonards; 3051 - North Melbourne; 3021 - St Albans	https://clinicaltrials.gov/ct2/show/NCT04740918
NCT04744831	DESTINY-CRC02	Phase 2		NSW, QLD, SA, VIC	2021-02-09	2021-03-05		Trastuzumab Deruxtecan	anti-ERBB2_antibody-drug_conjugate	Trastuzumab Deruxtecan	anti-ERBB2_antibody-drug_conjugate	2020-004782-39  DS8201-A-U207	A Phase 2, Multicenter, Randomized, Study of Trastuzumab Deruxtecan in Participants With HER2-overexpressing Locally Advanced, Unresectable or Metastatic Colorectal Cancer (DESTINY-CRC02)	Advanced Colorectal Cancer	- Blacktown; - Bedford Park; - Melbourne; - Clayton; - Brisbane	https://clinicaltrials.gov/ct2/show/NCT04744831
NCT04745689	TAZMAN	Phase 2			2021-02-09	2021-02-23		Barasertib; Barasertib + Durvalumab; Carboplatin; Cisplatin; Durvalumab; Etoposide	topoisomerase_inhibitor; platinum-based_antineoplastic_agent; AURKB_inhibitor + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; AURKB_inhibitor	Barasertib + Durvalumab; Carboplatin; Cisplatin; Etoposide	AURKB_inhibitor + anti-PD-L1_monoclonal_antibody; platinum-based_antineoplastic_agent; topoisomerase_inhibitor	2024-511887-10-00  D6132C00001	A Phase II Multicenter, Open-Label, Single Arm Study to Determine the Efficacy, Safety and Tolerability of AZD2811 and Durvalumab Combination as Maintenance Therapy After Induction With Platinum-Based Chemotherapy Combined With Durvalumab, for the First-Line Treatment of Patients With Extensive Stage Small-Cell Lung Cancer	Small-Cell Lung Cancer		https://clinicaltrials.gov/ct2/show/NCT04745689
NCT04746612	HH30134-G101	Phase 1		NSW	2021-02-10	2021-04-08		HH30134	AXL/FLT3/NTRK_inhibitor	HH30134	AXL/FLT3/NTRK_inhibitor	HH30134-G101	A Phase I, Multi-centre, Open-Label, First in Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HH30134 in Patients With Advanced Solid Tumours	Advanced Solid Tumors	- Randwick; - Blacktown	https://clinicaltrials.gov/ct2/show/NCT04746612
NCT04746924	BGB-A317-A1217-302--AdvanTIG-302	Phase 3		NSW, QLD, SA, VIC, WA	2021-02-10	2021-06-08		Ociperlimab; Ociperlimab + Tislelizumab; Pembrolizumab; Placebo; Tislelizumab	placebo; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody	Ociperlimab + Tislelizumab; Pembrolizumab; Tislelizumab; Placebo	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; placebo	BGB-A317-A1217-302  AdvanTIG-302	A Phase 3, Randomized, Double-Blind Study of Ociperlimab, an Anti-TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab in Patients With Previously Untreated, PD-L1-Selected, and Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer	NSCLC; Non-small Cell Lung Cancer	2139 - Concord; 3021 - St Albans; 4032 - Chermside; 3350 - Ballarat; 5112 - Elizabeth Vale; 3168 - Clayton; 4101 - South Brisbane; 2065 - St Leonards; 2298 - Waratah; 4217 - Benowa; 6150 - Murdoch; 4224 - Tugun	https://clinicaltrials.gov/ct2/show/NCT04746924
NCT04771130	2021-003285-12--BGB-11417-103	Phase 1		NSW, NZ, QLD, VIC, WA	2021-02-25	2021-05-24		Azacitidine; Azacitidine + Posaconazole + Sonrotoclax; Azacitidine + Sonrotoclax; Posaconazole; Sonrotoclax	DNA_methyltransferase_inhibitor; antimetabolite; Bcl2_inhibitor + DNA_methyltransferase_inhibitor; Bcl2_inhibitor + antimetabolite + azole_antifungal; Bcl2_inhibitor + antimetabolite; Bcl2_inhibitor + DNA_methyltransferase_inhibitor + azole_antifungal; Bcl2_inhibitor; azole_antifungal	Azacitidine + Posaconazole + Sonrotoclax; Azacitidine + Sonrotoclax; Sonrotoclax	Bcl2_inhibitor; Bcl2_inhibitor + DNA_methyltransferase_inhibitor; Bcl2_inhibitor + DNA_methyltransferase_inhibitor + azole_antifungal; Bcl2_inhibitor + antimetabolite; Bcl2_inhibitor + antimetabolite + azole_antifungal	2021-003285-12  BGB-11417-103	A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients With Myeloid Malignancies	Myelodysplastic Syndromes; Acute Myeloid Leukemia; Myelodysplastic/Myeloproliferative Neoplasm	3084 - Heidelberg; 2139 - Concord; 4215 - Southport; 6009 - Nedlands; Auckland; Wellington; 2217 - Kogarah; 6150 - Murdoch; 2800 - Orange; 3065 - Fitzroy; 3168 - Clayton; 3004 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04771130
NCT04776148	MK-7902-017--7902-017	Phase 3		QLD, SA, VIC, WA	2021-03-01	2021-03-29		Lenvatinib; Lenvatinib + Pembrolizumab; Pembrolizumab; Regorafenib; Regorafenib + Trifluridine/Tipiracil; Trifluridine/Tipiracil	antimetabolite; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + thymidine_phosphorylase_inhibitor; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + antimetabolite; anti-PD-1_monoclonal_antibody; Tipiracil Hydrochloride; VEGF_inhibitor; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + Trifluridine; Trifluridine; thymidine_phosphorylase_inhibitor; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + Tipiracil Hydrochloride	Lenvatinib + Pembrolizumab; Regorafenib + Trifluridine/Tipiracil	KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + Tipiracil Hydrochloride; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + Trifluridine; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + antimetabolite; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + thymidine_phosphorylase_inhibitor; VEGF_inhibitor + anti-PD-1_monoclonal_antibody	MK-7902-017  7902-017	A Phase 3 Randomized Study of Lenvatinib in Combination With Pembrolizumab Versus Standard of Care in Participants With Metastatic Colorectal Cancer Who Have Received and Progressed On or After or Became Intolerant to Prior Treatment	Colorectal Neoplasms	3021 - St Albans; 3002 - Melbourne; 4120 - Greenslopes; 5011 - Woodville; 4029 - Brisbane; 6009 - Perth	https://clinicaltrials.gov/ct2/show/NCT04776148
NCT04778410	2021-003833-13--GS-US-546-5920	Phase 2		VIC, WA	2021-03-03	2021-06-28		Azacitidine; Azacitidine + Magrolimab; Azacitidine + Magrolimab + Venetoclax; Cytarabine; Etoposide; Magrolimab; Mitoxantrone; Venetoclax	DNA_methyltransferase_inhibitor; antimetabolite; topoisomerase_inhibitor; antineoplastic_antibiotic; anti-CD47_monoclonal_antibody + antimetabolite; DNA_methyltransferase_inhibitor + anti-CD47_monoclonal_antibody; Bcl2_inhibitor + DNA_methyltransferase_inhibitor + anti-CD47_monoclonal_antibody; Bcl2_inhibitor + anti-CD47_monoclonal_antibody + antimetabolite; Bcl2_inhibitor; anti-CD47_monoclonal_antibody	Azacitidine + Magrolimab; Azacitidine + Magrolimab + Venetoclax; Magrolimab; Cytarabine; Etoposide; Mitoxantrone	Bcl2_inhibitor + DNA_methyltransferase_inhibitor + anti-CD47_monoclonal_antibody; Bcl2_inhibitor + anti-CD47_monoclonal_antibody + antimetabolite; DNA_methyltransferase_inhibitor + anti-CD47_monoclonal_antibody; anti-CD47_monoclonal_antibody; anti-CD47_monoclonal_antibody + antimetabolite; antineoplastic_antibiotic; topoisomerase_inhibitor	2021-003833-13  GS-US-546-5920	A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients With Myeloid Malignancies	Myeloid Malignancies	6000 - Perth; 3084 - Heidelberg; 3004 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04778410
NCT04786847	ProstACTSelect	Phase 1		GatesheadWA, NSW, WA	2021-03-08	2022-01-30		177Lu-DOTA-rosopatamab	radioligand,PSMA-targeting	177Lu-DOTA-rosopatamab	radioligand,PSMA-targeting	177Lu-TLX591-001	A Phase 1 Safety, Tolerability, Biodistribution, Dosimetry and Efficacy Study of 177Lu-DOTA-TLX591 With Best Standard of Care in Patients With PSMA Expressing Metastatic Castration-resistant Prostate Cancer	Metastatic Prostate Cancer	6150 - Perth; 6009 - Perth; 2290 - Newcastle	https://clinicaltrials.gov/ct2/show/NCT04786847
NCT04786964	CONTERNO	Phase 3		NZ	2021-03-08	2021-12-08		Carboplatin; Carboplatin + Cisplatin + Cosibelimab + Pemetrexed; Carboplatin + Cisplatin + Pemetrexed; Cisplatin; Cosibelimab; Dexamethasone; Pemetrexed	antimetabolite; anti-PD-L1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody; platinum-based_antineoplastic_agent; glucocorticoid; antimetabolite + platinum-based_antineoplastic_agent	Carboplatin + Cisplatin + Cosibelimab + Pemetrexed; Carboplatin + Cisplatin + Pemetrexed; Dexamethasone	anti-PD-L1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; glucocorticoid	CK-301-301	A Randomized, Open-Label, Phase 3 Study of Cosibelimab (CK-301) in Combination With Platinum+Pemetrexed Chemotherapy in Subjects With First-Line Metastatic Non-squamous Non-Small Cell Lung Cancer	Metastatic Non-squamous Non Small Cell Lung Cancer	Wellington	https://clinicaltrials.gov/ct2/show/NCT04786964
NCT04789096	TUGETHER	Phase 2		NSW, QLD, SA, TAS, VIC	2021-03-09	2023-03-07		Capecitabine; Pembrolizumab; Trastuzumab; Tucatinib	anti-ERBB2_monoclonal_antibody; fluoropyrimidine; anti-PD-1_monoclonal_antibody; ERBB2_inhibitor,third_generation	Capecitabine; Pembrolizumab; Trastuzumab; Tucatinib	ERBB2_inhibitor,third_generation; anti-ERBB2_monoclonal_antibody; anti-PD-1_monoclonal_antibody; fluoropyrimidine	BCT 2102	A Phase II, Two-arm, Non-comparative, Multicentre Study of Tucatinib (ONT-380), Pembrolizumab and Trastuzumab in Patients With Pre-treated Advanced HER2-positive Breast Cancer	Breast Cancer; HER2-positive Breast Cancer	7000 - Hobart; 2310 - Waratah; 2250 - Gosford; 3002 - Parkville; 2450 - Coffs Harbour; 2145 - Westmead; 3121 - Richmond; 3021 - St Albans; 4575 - Birtinya; 3084 - Heidelberg; 2747 - Kingswood; 2109 - Macquarie Park; 2500 - Wollongong; 2031 - Randwick; 5000 - Adelaide	https://clinicaltrials.gov/ct2/show/NCT04789096
NCT04793958	KRYSTAL-10--CA239-0006	Phase 3		NSW, SA, VIC	2021-03-11	2021-06-24		Adagrasib; Adagrasib + Cetuximab; Cetuximab	KRAS_G12C_inhibitor; anti-EGFR_monoclonal_antibody; KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody	Adagrasib + Cetuximab	KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody	KRYSTAL-10  CA239-0006	A Randomized Phase 3 Study of MRTX849 in Combination With Cetuximab Versus Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation With Disease Progression On or After Standard First-Line Therapy	Advanced Colorectal Cancer; Metastatic Colorectal Cancer	5042 - Bedford Park; 2065 - Garran; 3084 - Heidelberg; 2298 - Waratah; 3004 - Melbourne; 3168 - Clayton	https://clinicaltrials.gov/ct2/show/NCT04793958
NCT04794699	IDE397-001	Phase 1		NSW, SA	2021-03-12	2021-04-14		Docetaxel; Docetaxel + Paclitaxel; IDE397; Paclitaxel; Sacituzumab Govitecan	anti-Trop2_antibody-drug_conjugate; MAT2A_inhibitor; taxane	Docetaxel + Paclitaxel; Sacituzumab Govitecan; IDE397	anti-Trop2_antibody-drug_conjugate; taxane; MAT2A_inhibitor	IDE397-001	An Open Label, Phase 1, Treatment Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of IDE397 (MAT2A Inhibitor) In Adult Participants With Advanced Solid Tumors	Solid Tumor	02010 - Darlinghurst; 05042 - Bedford Park	https://clinicaltrials.gov/ct2/show/NCT04794699
NCT04799054	transcendIT-101--TCTLR-101	Phase 1		NSW, SA, VIC	2021-03-16	2021-03-18		Pembrolizumab; Pembrolizumab + TransCon TLR7/8 agonist; TransCon TLR7/8 agonist	TLR7/TLR8_agonist; TLR7/TLR8_agonist + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody	Pembrolizumab + TransCon TLR7/8 agonist; TransCon TLR7/8 agonist	TLR7/TLR8_agonist; TLR7/TLR8_agonist + anti-PD-1_monoclonal_antibody	transcendIT-101  TCTLR-101	Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study of TransCon TLR7/8 Agonist Alone or in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies	Neoadjuvant Melanoma; Locally Advanced Solid Tumor; Neoadjuvant Cutaneous Squamous Cell Carcinoma (cSCC); Advanced Solid Tumor; HPV-associated Cancers; Head and Neck Squamous Cell Carcinoma HNSCC; Metastatic Solid Tumor	2500 - Wollongong; 5042 - Bedford Park; 3199 - Frankston	https://clinicaltrials.gov/ct2/show/NCT04799054
NCT04799249	PRESERVE-2	Phase 3		NSW, QLD, VIC	2021-03-16	2021-05-14		Carboplatin; Carboplatin + Gemcitabine + Trilaciclib; Gemcitabine; Placebo; Trilaciclib	placebo; antimetabolite; CDK4/6_inhibitor + antimetabolite + platinum-based_antineoplastic_agent; CDK4/6_inhibitor; gemcitabine; platinum-based_antineoplastic_agent	Carboplatin + Gemcitabine + Trilaciclib; Placebo	CDK4/6_inhibitor + antimetabolite + platinum-based_antineoplastic_agent; gemcitabine; placebo	2020-004930-39  G1T28-208	A Phase 3, Randomized, Double-Blind Study of Trilaciclib or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (PRESERVE 2)	Breast Cancer; TNBC - Triple-Negative Breast Cancer	08006 - East Melbourne; 3144 - Malvern; 2060 - North Sydney; 4575 - Birtinya; 2050 - Camperdown	https://clinicaltrials.gov/ct2/show/NCT04799249
NCT04801966	TAILOR	Not applicable		VIC	2021-03-17	2021-09-23		Abemaciclib; Alpelisib; Atezolizumab; Binimetinib; Cobimetinib; Dabrafenib; Encorafenib; Nivolumab; Olaparib; Palbociclib; Pembrolizumab; Ribociclib; Talazoparib; Trametinib; Vemurafenib	CDK4/6_inhibitor; anti-PD-L1_monoclonal_antibody; MEK_inhibitor; anti-PD-1_monoclonal_antibody; PI3K_alpha_inhibitor; BRAF_V600_inhibitor; PARP_inhibitor	Abemaciclib; Alpelisib; Atezolizumab; Binimetinib; Cobimetinib; Dabrafenib; Encorafenib; Nivolumab; Olaparib; Palbociclib; Pembrolizumab; Ribociclib; Talazoparib; Trametinib; Vemurafenib	BRAF_V600_inhibitor; CDK4/6_inhibitor; MEK_inhibitor; PARP_inhibitor; PI3K_alpha_inhibitor; anti-PD-1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody	20/029	Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study	Cancer	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04801966
NCT04802759	2020-004889-19--CO42867	Phase 1		SA, VIC, WA	2021-03-17	2021-06-22		Abemaciclib; Abemaciclib + Atezolizumab + Giredestrant; Abemaciclib + Giredestrant; Abemaciclib + Giredestrant + Inavolisib; Atezolizumab; Atezolizumab + Giredestrant; Everolimus; Everolimus + Giredestrant; Giredestrant; Giredestrant + Inavolisib; Giredestrant + Inavolisib + Palbociclib; Giredestrant + Inavolisib + Ribociclib; Giredestrant + Ipatasertib; Giredestrant + Palbociclib; Giredestrant + Ribociclib; Giredestrant + Samuraciclib; Inavolisib; Ipatasertib; Palbociclib; Ribociclib; Samuraciclib	PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor; anti-PD-L1_monoclonal_antibody; selective_estrogen_receptor_degrader; pan-AKT_inhibitor; CDK7_inhibitor; CDK7_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + anti-PD-L1_monoclonal_antibody + selective_estrogen_receptor_degrader; mTORC1_inhibitor + selective_estrogen_receptor_degrader; pan-AKT_inhibitor + selective_estrogen_receptor_degrader; mTORC1_inhibitor; anti-PD-L1_monoclonal_antibody + selective_estrogen_receptor_degrader; PI3K_alpha_inhibitor; CDK4/6_inhibitor + selective_estrogen_receptor_degrader	Abemaciclib + Atezolizumab + Giredestrant; Abemaciclib + Giredestrant; Abemaciclib + Giredestrant + Inavolisib; Atezolizumab + Giredestrant; Everolimus + Giredestrant; Giredestrant; Giredestrant + Inavolisib; Giredestrant + Inavolisib + Palbociclib; Giredestrant + Inavolisib + Ribociclib; Giredestrant + Ipatasertib; Giredestrant + Palbociclib; Giredestrant + Ribociclib; Giredestrant + Samuraciclib	CDK4/6_inhibitor + PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + anti-PD-L1_monoclonal_antibody + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + selective_estrogen_receptor_degrader; CDK7_inhibitor + selective_estrogen_receptor_degrader; PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader; anti-PD-L1_monoclonal_antibody + selective_estrogen_receptor_degrader; mTORC1_inhibitor + selective_estrogen_receptor_degrader; pan-AKT_inhibitor + selective_estrogen_receptor_degrader; selective_estrogen_receptor_degrader	2020-004889-19  CO42867	A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Breast Cancer (MORPHEUS-BREAST CANCER)	Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer	3000 - Melbourne; 5042 - Bedford Park; 6009 - Nedlands; 3199 - Frankston	https://clinicaltrials.gov/ct2/show/NCT04802759
NCT04807972	2020-005767-31--M20-732	Phase 1		VIC	2021-03-19	2021-05-28		ABBV-927; ABBV-927 + Budigalimab; Budigalimab	anti-CD40_agonistic_antibody; anti-CD40_agonistic_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody	ABBV-927; ABBV-927 + Budigalimab; Budigalimab	anti-CD40_agonistic_antibody; anti-CD40_agonistic_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody	2020-005767-31  M20-732	A Phase 1b/2, Randomized, Controlled, Open-Label Study Evaluating the Safety and Efficacy of ABBV-927 Administered in Combination With Modified FOLFIRINOX (mFFX) With or Without Budigalimab Compared to mFFX in Subjects With Untreated Metastatic Pancreatic Adenocarcinoma	Pancreatic Cancer	3168 - Clayton; 3084 - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT04807972
NCT04810078	CheckMate-67T	Phase 3		NZ	2021-03-22	2021-05-21		Nivolumab; rHuPH20	recombinant_human_hyaluronidase; anti-PD-1_monoclonal_antibody	Nivolumab; rHuPH20	anti-PD-1_monoclonal_antibody; recombinant_human_hyaluronidase	2020-003655-15  CA209-67T	A Phase 3, Open-label, Randomized, Noninferiority Trial of Subcutaneous Formulation of Nivolumab Versus Intravenous Nivolumab in Participants With Advanced or Metastatic Clear Cell Renal Cell Carcinoma Who Have Received Prior Systemic Therapy	Clear Cell Renal Cell Carcinoma	Auckland; Hamilton; Palmerston North	https://clinicaltrials.gov/ct2/show/NCT04810078
NCT04811027	TACTI-003	Phase 2		NSW	2021-03-23	2021-08-27		Eftilagimod Alpha; Eftilagimod Alpha + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody; T-cell_immunostimulatory_factor + anti-PD-1_monoclonal_antibody; T-cell_immunostimulatory_factor	Eftilagimod Alpha + Pembrolizumab; Pembrolizumab	T-cell_immunostimulatory_factor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody	2021-000055-39  TACTI-003	TACTI-003 (Two ACTive Immunotherapeutics): A Multicenter, Open Label, Randomized, Phase II Trial to Investigate a Soluble LAG-3 Fusion Protein, Eftilagimod Alpha (Efti; IMP321) in Combination With Pembrolizumab (PD-1 Antagonist) for First Line Treatment of Subjects With Unresectable Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)	HNSCC	2109 - Macquarie Park	https://clinicaltrials.gov/ct2/show/NCT04811027
NCT04814875	AM-ATX101-03	Phase 1		NSW, QLD, VIC, WA	2021-03-24	2021-09-01		ATX-101; ATX-101 + Carboplatin + Pegylated liposomal doxorubicin; Carboplatin; Pegylated liposomal doxorubicin	anthracycline + cell_penetrating_peptide,PCNA-targeting + platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent; cell_penetrating_peptide,PCNA-targeting; anthracycline	ATX-101 + Carboplatin + Pegylated liposomal doxorubicin	anthracycline + cell_penetrating_peptide,PCNA-targeting + platinum-based_antineoplastic_agent	AM ATX101-03	Phase 1b/2a Study Investigating ATX-101 in Combination With Platinum-based Chemotherapy in Platinum-sensitive, Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancer	Ovarian Cancer; High Grade Serious or Endometrioid Carcinoma of the Ovary, Fallopian Tube, or Primary Peritoneal Cancer; Primary Peritoneal Carcinoma; Fallopian Tube Cancer	3199 - Frankston; 6008 - Subiaco; 4101 - South Brisbane; 3144 - Malvern; 6009 - Nedlands; 2148 - Blacktown	https://clinicaltrials.gov/ct2/show/NCT04814875
NCT04821622	TALAPRO-3--C3441052	Phase 3		NSW, QLD, SA, VIC	2021-03-29	2021-05-12		Enzalutamide; Enzalutamide + Talazoparib; Placebo; Talazoparib	placebo; antiandrogen,nonsteroidal,second_generation; PARP_inhibitor + antiandrogen,nonsteroidal,second_generation; PARP_inhibitor	Enzalutamide; Enzalutamide + Talazoparib; Placebo	PARP_inhibitor + antiandrogen,nonsteroidal,second_generation; antiandrogen,nonsteroidal,second_generation; placebo	TALAPRO-3  C3441052	TALAPRO-3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER	Prostate Cancer	4215 - Southport; 5011 - Woodville South; 3021 - St Albans; 2050 - Camperdown; 3002 - East Melbourne; 2500 - Wollongong; 4120 - Brisbane; 3144 - Malvern	https://clinicaltrials.gov/ct2/show/NCT04821622
NCT04822298	NCT04822298	Phase 1		NSW	2021-03-30	2021-08-31		AMG 160	bispecific_T-cell_engager,PSMA-targeting	AMG 160	bispecific_T-cell_engager,PSMA-targeting	20180273	A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 160 in Subjects With Non-Small Cell Lung Cancer	Non-small Cell Lung Cancer; NSCLC	2050 - Camperdown	https://clinicaltrials.gov/ct2/show/NCT04822298
NCT04822961	IMP4297-202	Phase 2		NSW, QLD, VIC	2021-03-30			Docetaxel; Placebo; Senaparib	placebo; taxane; PARP_inhibitor	Senaparib; Docetaxel; Placebo	PARP_inhibitor; placebo; taxane	IMP4297-202	A Randomized, Double-Blinded, Placebo-Controlled, Multicenter, Phase II Study to Evaluate Senaparib in mCRPC Patients With Homologous Recombination Repair Gene Alterations After Docetaxel Treatment	mCRPC 0 0	- Sydney; - Tugun; - Melbourne; - Brisbane	https://clinicaltrials.gov/ct2/show/NCT04822961
NCT04830124	ARTISTRY-6	Phase 2		NSW, QLD, SA	2021-04-02	2021-09-27		Nemvaleukin alfa; Pembrolizumab	IL-2_fusion_protein; anti-PD-1_monoclonal_antibody	Pembrolizumab; Nemvaleukin alfa	anti-PD-1_monoclonal_antibody; IL-2_fusion_protein	ALKS 4230-006	A Phase 2, Open-Label, Multicenter, Cohort Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous Melanoma or Advanced Mucosal Melanoma - ARTISTRY-6	Cutaneous Melanoma; Mucosal Melanoma	5011 - Woodville; 2298 - Waratah; 4224 - Tugun	https://clinicaltrials.gov/ct2/show/NCT04830124
NCT04830202	C20-503			WA	2021-04-05			Telisotuzumab Vedotin	anti-cMET_antibody-drug_conjugate	Telisotuzumab Vedotin	anti-cMET_antibody-drug_conjugate	C20-503	Expanded Access to Telisotuzumab Vedotin	Non-Small Cell Lung Cancer (NSCLC)	6005 - West Perth	https://clinicaltrials.gov/ct2/show/NCT04830202
NCT04835805	2020-003674-41--GO42273	Phase 1		NSW, VIC, WA	2021-04-08	2021-05-13		Belvarafenib; Belvarafenib + Cobimetinib; Belvarafenib + Cobimetinib + Nivolumab; Cobimetinib; Nivolumab	MEK_inhibitor + anti-PD-1_monoclonal_antibody + pan-RAF_inhibitor; pan-RAF_inhibitor; anti-PD-1_monoclonal_antibody; MEK_inhibitor + pan-RAF_inhibitor; MEK_inhibitor	Belvarafenib; Belvarafenib + Cobimetinib; Belvarafenib + Cobimetinib + Nivolumab	MEK_inhibitor + anti-PD-1_monoclonal_antibody + pan-RAF_inhibitor; MEK_inhibitor + pan-RAF_inhibitor; pan-RAF_inhibitor	2020-003674-41  GO42273	A Phase Ib, Open-Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-Mutant Advanced Melanoma Who Have Received Anti-PD-1/PD-L1 Therapy	Melanoma	3000 - Melbourne; 2298 - Waratah; 6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT04835805
NCT04844073	CP-MVC-101-01	Phase 1		NSW, SA, VIC	2021-04-14	2021-03-08		MVC-101	bispecific_T-cell_engager,EGFR-targeting	MVC-101	bispecific_T-cell_engager,EGFR-targeting	CP-MVC-101-01	A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-186 (Also Known as MVC-101), An EGFR x CD3 COnditional Bispecific Redirected Activation (COBRA) Protein in Patients With Unresectable Locally Advanced or Metastatic Cancer	Colorectal Cancer; Non-small Cell Lung Cancer (NSCLC); Squamous Cell Cancer of Head and Neck (SCCHN)	5042 - Bedford Park; 2031 - Randwick; 3004 - Heidelberg; 3004 - Melbourne; 3168 - Clayton; 2050 - Sydney	https://clinicaltrials.gov/ct2/show/NCT04844073
NCT04849273	CA226-1036--CA226-1036	Phase 1		NSW, VIC, WA	2021-04-19	2021-07-28		Zotizalkib	ALK_inhibitor,fourth_generation	Zotizalkib	ALK_inhibitor,fourth_generation	CA226-1036  CA226-1036	A Phase 1/2 Study of TPX-0131, A Novel Oral ALK Tyrosine Kinase Inhibitor in Subjects With ALK+ Advanced or Metastatic NSCLC	NSCLC; Metastatic Solid Tumor; Non Small Cell Lung Cancer; Non-Small Cell Lung Cancer; Advanced Solid Tumor; ALK Gene Mutation	2148 - Blacktown; 6009 - Nedlands; 3084 - Heidelberg; 3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04849273
NCT04851834	XNTR-20-02	Phase 1		NSW	2021-04-20	2021-08-25		NTX-301; NTX-301 + Temozolomide; Temozolomide	DNMT1_inhibitor; alkylating_agent; DNMT1_inhibitor + alkylating_agent	NTX-301; NTX-301 + Temozolomide	DNMT1_inhibitor; DNMT1_inhibitor + alkylating_agent	XNTR-20-02	A Phase 1/2, Open-label, Dose-exploration and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NTX-301 Monotherapy in Advanced Solid Tumours, and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer, and in Combination With Temozolomide as Adjuvant (Maintenance) Therapy in High-grade Glioma (Optional Arm)	Platinum-Resistant Urothelial Carcinoma; Advanced Solid Tumor; Platinum-Resistant Ovarian Cancer; High-grade Glioma	2217 - Kogarah; 2010 - Darlinghurst	https://clinicaltrials.gov/ct2/show/NCT04851834
NCT04854499	ELEVATE-HNSCC	Phase 2		NSW, QLD, VIC	2021-04-22	2021-09-07		Carboplatin; Carboplatin + Cisplatin + Fluorouracil + Magrolimab + Pembrolizumab; Carboplatin + Cisplatin + Fluorouracil + Magrolimab + Zimberelimab; Carboplatin + Cisplatin + Fluorouracil + Pembrolizumab; Cisplatin; Docetaxel; Docetaxel + Magrolimab; Fluorouracil; Fluorouracil + Magrolimab + Pembrolizumab; Magrolimab; Magrolimab + Pembrolizumab; Pembrolizumab; Zimberelimab	fluoropyrimidine; anti-CD47_monoclonal_antibody + anti-PD-1_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; anti-CD47_monoclonal_antibody + taxane; Fluorouracil; anti-PD-1_monoclonal_antibody; taxane; anti-PD-1_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent; anti-CD47_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CD47_monoclonal_antibody; anti-CD47_monoclonal_antibody + anti-PD-1_monoclonal_antibody + fluoropyrimidine	Carboplatin + Cisplatin + Fluorouracil + Magrolimab + Pembrolizumab; Carboplatin + Cisplatin + Fluorouracil + Magrolimab + Zimberelimab; Carboplatin + Cisplatin + Fluorouracil + Pembrolizumab; Docetaxel + Magrolimab; Fluorouracil + Magrolimab + Pembrolizumab; Magrolimab + Pembrolizumab	anti-CD47_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CD47_monoclonal_antibody + anti-PD-1_monoclonal_antibody + fluoropyrimidine; anti-CD47_monoclonal_antibody + anti-PD-1_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; anti-CD47_monoclonal_antibody + taxane; anti-PD-1_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; Fluorouracil	2020-005708-20  GS-US-548-5916	A Phase 2 Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma	Head and Neck Squamous Cell Carcinoma	2145 - Westmead; 3004 - Melbourne; 4102 - Woolloongabba; 2109 - Macquarie Park; 3084 - Heidelberg; 2010 - Darlinghurst; 4870 - Cairns; 4556 - Sippy Downs	https://clinicaltrials.gov/ct2/show/NCT04854499
NCT04857372	CIAG933A12101	Phase 1		VIC	2021-04-23	2021-10-21		IAG933	YAP-TEAD_inhibitor	IAG933	YAP-TEAD_inhibitor	CIAG933A12101	An Open-label, Multi-center, Phase I Study of Oral IAG933 in Adult Patients With Advanced Mesothelioma and Other Solid Tumors	Mesothelioma	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04857372
NCT04861779	HSK29116-101	Phase 1		WA	2021-04-27	2021-08-24		HSK29116	BTK_PROTAC_degrader	HSK29116	BTK_PROTAC_degrader	HSK29116-101	A Phase Ia/b Clinical Study on Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of BTK Protein Degradation Agent HSK29116 in Subjects With Relapsed or Refractory B-Cell Malignancy	Relapsed/Refractory B-Cell Malignancies	- Perth	https://clinicaltrials.gov/ct2/show/NCT04861779
NCT04862663	CAPItello-292	Phase 3		NSW, WA	2021-04-28	2021-05-10		Abemaciclib; Abemaciclib + Capivasertib + Fulvestrant; Capivasertib; Capivasertib + Fulvestrant + Palbociclib; Capivasertib + Fulvestrant + Palbociclib + Ribociclib; Capivasertib + Fulvestrant + Ribociclib; Fulvestrant; Fulvestrant + Palbociclib + Ribociclib; Palbociclib; Ribociclib	CDK4/6_inhibitor + pan-AKT_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor; selective_estrogen_receptor_degrader; CDK4/6_inhibitor + selective_estrogen_receptor_degrader; pan-AKT_inhibitor	Abemaciclib + Capivasertib + Fulvestrant; Capivasertib + Fulvestrant + Palbociclib; Capivasertib + Fulvestrant + Palbociclib + Ribociclib; Capivasertib + Fulvestrant + Ribociclib; Fulvestrant + Palbociclib + Ribociclib	CDK4/6_inhibitor + pan-AKT_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + selective_estrogen_receptor_degrader	2020-004637-20  D361DC00001	A Phase Ib/III, Open-label, Randomised Study of Capivasertib Plus CDK4/6 Inhibitors and Fulvestrant Versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292)	Locally Advanced (Inoperable) or Metastatic Breast Cancer	2228 - Miranda; 2010 - Darlinghurst; 2076 - Wahroonga; 2298 - Waratah; 6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT04862663
NCT04865419	2020-005106-25--D8241C00001	Phase 1		VIC	2021-04-29	2021-06-11		AZD0466	dual_Bcl2/BclxL_inhibitor	AZD0466	dual_Bcl2/BclxL_inhibitor	2020-005106-25  D8241C00001	A Modular Phase I/II, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD0466 Monotherapy or in Combination in Patients With Advanced Haematological Malignancies	Haematological Malignancies	3050 - Parkville; 3004 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04865419
NCT04868604	SECuRE	Phase 1		NSW	2021-05-03	2021-08-11						CLP05	A Phase I/IIa Theranostic Study of 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer	Prostatic Neoplasms, Castration-Resistant	2010 - Darlinghurst	https://clinicaltrials.gov/ct2/show/NCT04868604
NCT04870112	SCope-D1	Phase 1/Phase 2		NZ	2021-05-03	2021-06-28		Carboplatin; Cisplatin; Durvalumab; Etoposide	topoisomerase_inhibitor; platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody	Carboplatin; Cisplatin; Durvalumab; Etoposide	anti-PD-L1_monoclonal_antibody; platinum-based_antineoplastic_agent; topoisomerase_inhibitor	2020-006041-18  D9072C00001	A Phase 1/2a, Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of Subcutaneous Durvalumab in Patients With Non-Small Cell and Small Cell Lung Cancer - SCope-D1	Non-Small Cell Lung Cancer; Small Cell Lung Cancer	Christchurch	https://clinicaltrials.gov/ct2/show/NCT04870112
NCT04870944	NCI-2021-03150--PEPN2111	Phase 1		NSW	2021-05-04	2022-01-28		CBL0137	curaxin,FACT_complex-targeting	CBL0137	curaxin,FACT_complex-targeting	NCI-2021-03150  PEPN2111	A Phase 1/2 Trial of CBL0137 (NSC# 825802) in Patients With Relapsed or Refractory Solid Tumors Including CNS Tumors and Lymphoma	Refractory Primary Malignant Central Nervous System Neoplasm; Diffuse Midline Glioma, H3 K27M-Mutant; Refractory Lymphoma; Refractory Malignant Solid Neoplasm; Recurrent Malignant Solid Neoplasm; Refractory Osteosarcoma; Metastatic Malignant Neoplasm in the Central Nervous System; Recurrent Primary Malignant Central Nervous System Neoplasm; Recurrent Diffuse Intrinsic Pontine Glioma; Recurrent Lymphoma; Recurrent Osteosarcoma	2031 - Randwick	https://clinicaltrials.gov/ct2/show/NCT04870944
NCT04871282	RINGSIDE	Phase 2		NSW, QLD, SA, VIC	2021-05-04	2021-03-30		Placebo; Varegacestat	placebo; gamma_secretase_inhibitor	Varegacestat; Placebo	gamma_secretase_inhibitor; placebo	AL-DES-01	RINGSIDE: A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients With Progressing Desmoid Tumors	Desmoid Tumor; Desmoid	4102 - Woolloongabba; 3000 - Melbourne; 2050 - Camperdown; 5037 - Kurralta Park	https://clinicaltrials.gov/ct2/show/NCT04871282
NCT04876651	177Lu-TLX591-002	Phase 3		NSW, NZ, QLD, VIC, WA	2021-05-06	2023-08-29		177Lu-DOTA-rosopatamab; Abiraterone; Docetaxel; Enzalutamide; Prednisolone; Prednisone	glucocorticoid; antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor; taxane; radioligand,PSMA-targeting	177Lu-DOTA-rosopatamab; Abiraterone; Docetaxel; Enzalutamide; Prednisolone; Prednisone	CYP17A1_inhibitor; antiandrogen,nonsteroidal,second_generation; glucocorticoid; radioligand,PSMA-targeting; taxane	177Lu-TLX591-002	A Multinational, Multicenter, Prospective, Randomized, Controlled, Open Label Phase 3 Study With Best Standard of Care With and Without 177Lu-DOTA-rosopatamab for Patients With PSMA Expressing Metastatic Castration-resistant Prostate Cancer Progressing Despite Prior Treatment With a Novel Androgen Axis Drug	Metastatic Prostate Cancer	3083 - Melbourne; Auckland; 2145 - Westmead; 6150 - Murdoch; 3168 - Clayton; 4102 - Woolloongabba	https://clinicaltrials.gov/ct2/show/NCT04876651
NCT04879329	C5731002--RC48G001	Phase 2		NSW, QLD, SA, VIC	2021-05-10	2022-05-03		Disitamab vedotin; Disitamab vedotin + Pembrolizumab; Pembrolizumab	anti-ERBB2_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-ERBB2_antibody-drug_conjugate	Disitamab vedotin; Disitamab vedotin + Pembrolizumab	anti-ERBB2_antibody-drug_conjugate; anti-ERBB2_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody	C5731002  RC48G001	A Phase 2 Multi-Cohort, Open-Label, Multi-Center Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin (RC48-ADC) Alone or in Combination With Pembrolizumab in Subjects With Locally-Advanced Unresectable or Metastatic Urothelial Carcinoma That Expresses HER2	Urothelial Carcinoma	2109 - Sydney; 5112 - Elizabeth Vale; 3199 - Frankston; 4102 - Woolloongabba; 2065 - St Leonards; QLD 4101 - South Brisbane	https://clinicaltrials.gov/ct2/show/NCT04879329
NCT04879368	INTEGRATEIIb	Phase 3		NSW, NT, QLD, SA, TAS, VIC, WA	2021-05-10	2021-06-01		Docetaxel; Irinotecan; Nivolumab; Paclitaxel; Regorafenib	topoisomerase_inhibitor; anti-PD-1_monoclonal_antibody; taxane; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor	Docetaxel; Irinotecan; Nivolumab; Paclitaxel; Regorafenib	KIT/PDGFR/RET/VEGFR/FGFR_inhibitor; anti-PD-1_monoclonal_antibody; taxane; topoisomerase_inhibitor	2020-004617-12  AG0315OG/CTC0140	A Randomised Phase III Open Label Study of Regorafenib + Nivolumab vs Standard Chemotherapy in Refractory Advanced Gastro-Oesophageal Cancer (AGOC)	Gastro-Oesophageal Cancer	6009 - Nedlands; 4814 - Douglas; 2145 - Westmead; 2217 - Kogarah; 2450 - Coffs Harbour; 3168 - Clayton; 5011 - Adelaide; 6008 - Subiaco; 0810 - Tiwi; 3084 - Melbourne; 3355 - Wendouree; 2250 - Gosford; 2031 - Randwick; 2485 - Tweed Heads; 700 - Hobart; 2035 - New Lambton Heights; 4029 - Herston; 2640 - East Albury; 2010 - Darlinghurst; 2139 - Concord; 4560 - Sunshine Coast; 2444 - Port Macquarie; 2065 - Sydney; 5042 - Bedford Park	https://clinicaltrials.gov/ct2/show/NCT04879368
NCT04880564	CN1-201	Phase 1		VIC	2021-05-10	2021-07-28		CN1; CN1 + Tenalisib; Tenalisib	PI3K-delta/gamma_inhibitor + anti-OX40_agonistic_antibody; PI3K_delta_inhibitor; anti-OX40_agonistic_antibody; PI3K-delta/gamma/SIK3_inhibitor; PI3K-delta/gamma/SIK3_inhibitor + anti-OX40_agonistic_antibody; PI3K-delta/gamma_inhibitor; PI3K_delta_inhibitor + anti-OX40_agonistic_antibody	CN1 + Tenalisib	PI3K-delta/gamma/SIK3_inhibitor + anti-OX40_agonistic_antibody; PI3K-delta/gamma_inhibitor + anti-OX40_agonistic_antibody; PI3K_delta_inhibitor + anti-OX40_agonistic_antibody	CN1-201	An Open-label, Multi-centre, Phase I/II Study to Investigate the Safety, Tolerability, and Preliminary Efficacy of CN1 in Combination With CN401 in Adult Patients With Relapsed/Refractory Lymphoid Malignancies	Refractory Lymphoid Malignancies; Relapsed Lymphoid Malignancies	3168 - Bentleigh	https://clinicaltrials.gov/ct2/show/NCT04880564
NCT04891718	PBI-MST-02	Phase 0		NSW, SA	2021-05-18	2021-09-15		MVC-101; MVC-101 + Nivolumab; Nivolumab	anti-PD-1_monoclonal_antibody + bispecific_T-cell_engager,EGFR-targeting; bispecific_T-cell_engager,EGFR-targeting; anti-PD-1_monoclonal_antibody	MVC-101 + Nivolumab	anti-PD-1_monoclonal_antibody + bispecific_T-cell_engager,EGFR-targeting	PBI-MST-02	A Phase 0 Master Protocol Using the CIVO® Platform to Evaluate Intratumoural Microdoses of Anti-Cancer Therapies in Patients With Solid Tumours	Solid Tumour	5042 - Bedford Park; 2500 - Wollongong; 2050 - Camperdown	https://clinicaltrials.gov/ct2/show/NCT04891718
NCT04895358	MK-3475-B49--3475-B49	Phase 3		NSW, VIC, WA	2021-05-20	2021-06-18		Capecitabine; Capecitabine + Nab-paclitaxel + Paclitaxel + Pegylated liposomal doxorubicin; Capecitabine + Nab-paclitaxel + Paclitaxel + Pegylated liposomal doxorubicin + Pembrolizumab; Dexamethasone; Nab-paclitaxel; Paclitaxel; Pegylated liposomal doxorubicin; Pembrolizumab; Placebo	placebo; anthracycline; fluoropyrimidine; anti-PD-1_monoclonal_antibody; taxane; glucocorticoid; anthracycline + anti-PD-1_monoclonal_antibody + fluoropyrimidine + taxane; anthracycline + fluoropyrimidine + taxane	Capecitabine + Nab-paclitaxel + Paclitaxel + Pegylated liposomal doxorubicin; Capecitabine + Nab-paclitaxel + Paclitaxel + Pegylated liposomal doxorubicin + Pembrolizumab; Dexamethasone; Placebo	anthracycline + anti-PD-1_monoclonal_antibody + fluoropyrimidine + taxane; anthracycline + fluoropyrimidine + taxane; glucocorticoid; placebo	MK-3475-B49  3475-B49	A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the Treatment of Chemotherapy-Candidate Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Locally Recurrent Inoperable or Metastatic Breast Cancer (KEYNOTE-B49)	Breast Neoplasms	2145 - Westmead; 6009 - Nedlands; 3199 - Frankston; 2109 - Macquarie Park	https://clinicaltrials.gov/ct2/show/NCT04895358
NCT04895709	2023-503651-10--CA052-002	Phase 1		NSW, QLD, VIC, WA	2021-05-20	2021-05-27		BMS-986340; BMS-986340 + Docetaxel; BMS-986340 + Nivolumab; Docetaxel; Nivolumab	anti-CCR8_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-CCR8_monoclonal_antibody; taxane; anti-CCR8_monoclonal_antibody + taxane	BMS-986340; BMS-986340 + Docetaxel; BMS-986340 + Nivolumab	anti-CCR8_monoclonal_antibody; anti-CCR8_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CCR8_monoclonal_antibody + taxane	2023-503651-10  CA052-002	A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors	Triple Negative Breast Neoplasms; Melanoma; Cervical Cancer; Pancreatic Adenocarcinoma; Carcinoma, Renal Cell; Urothelial Carcinoma; Gastric/Gastroesophageal Junction Adenocarcinoma; Non-Small-Cell Lung Cancer; Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Microsatellite Stable Colorectal Cancer	3144 - Malvern; 6009 - Nedlands; 2148 - Blacktown; 3065 - Melbourne; 2170 - Liverpool; 4102 - Brisbane	https://clinicaltrials.gov/ct2/show/NCT04895709
NCT04901806	PBI-200-101	Phase 1		VIC	2021-05-26	2021-07-20		PBI-200	TRK_inhibitor,second_generation	PBI-200	TRK_inhibitor,second_generation	PBI-200-101	A Phase 1/2 Study of PBI-200 in Subjects With NTRK-Fusion-Positive Advanced or Metastatic Solid Tumors	Desmoplastic Small Round Cell Tumor; Brain Tumor, Primary; Solid Tumor, Adult	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04901806
NCT04913220	U1111-1254-0189--ACT16845	Phase 1		NSW	2021-06-04	2021-07-15		Cemiplimab; THOR-707	IL-2_variant; anti-PD-1_monoclonal_antibody	Cemiplimab; THOR-707	anti-PD-1_monoclonal_antibody; IL-2_variant	U1111-1254-0189  ACT16845	A Phase 1/2 Non-randomized, Open-label, Multi-cohort, Multi-center Study Assessing the Clinical Benefit of SAR444245 (THOR- 707) Combined With Cemiplimab for the Treatment of Participants With Advanced Unresectable or Metastatic Skin Cancers	Malignant Melanoma; Squamous Cell Carcinoma of Skin	2109 - Macquarie University	https://clinicaltrials.gov/ct2/show/NCT04913220
NCT04914117	RC118G001	Phase 1		NSW, SA, VIC	2021-06-04	2021-11-29		RC118	anti-CLDN18.2_antibody-drug_conjugate	RC118	anti-CLDN18.2_antibody-drug_conjugate	RC118G001	Phase 1, First-in-Human, Multicentre, Open-label Study of RC118 for Injection in Patients With Locally Advanced Unresectable/Metastatic Solid Tumours	Metastatic Solid Tumor; Unresectable Solid Tumor; Locally Advanced Solid Tumor	5042 - Bedford Park; 2109 - Macquarie Park; 3144 - Malvern; 3199 - Frankston	https://clinicaltrials.gov/ct2/show/NCT04914117
NCT04914286	GFH018X0201	Phase 1		WA	2021-06-04	2021-10-20		GFH018; GFH018 + Toripalimab; Toripalimab	anti-PD-1_monoclonal_antibody; TGFBR1_inhibitor + anti-PD-1_monoclonal_antibody; TGFBR1_inhibitor	GFH018 + Toripalimab	TGFBR1_inhibitor + anti-PD-1_monoclonal_antibody	GFH018X0201	A Multi-center, Single-arm, and Open-label Phase Ib/II Study Exploring the Safety/tolerability, Pharmacokinetics, and Efficacy of GFH018 in Combination with Toripalimab in the Treatment of Patients with Advanced Solid Tumors	Advanced Solid Tumor	- Perth	https://clinicaltrials.gov/ct2/show/NCT04914286
NCT04914897	U1111-1254-0107--ACT16849	Phase 2		VIC	2021-06-07	2021-09-23		Pembrolizumab; THOR-707	IL-2_variant; anti-PD-1_monoclonal_antibody	Pembrolizumab; THOR-707	anti-PD-1_monoclonal_antibody; IL-2_variant	U1111-1254-0107  ACT16849	A Phase 2 Non-randomized, Open-label, Multi-cohort, Multi-center Study Assessing the Clinical Benefit of SAR444245 (THOR-707) Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Pleural Mesothelioma	Non-small Cell Lung Cancer; Pleural Mesothelioma	3121 - Richmond	https://clinicaltrials.gov/ct2/show/NCT04914897
NCT04915755	ZEST	Phase 3		NSW	2021-06-07	2021-06-28		Niraparib; Placebo	placebo; PARP_inhibitor	Niraparib; Placebo	PARP_inhibitor; placebo	2020-003973-23  213831	A Randomized Phase 3 Double-Blinded Study Comparing the Efficacy and Safety of Niraparib to Placebo in Participants With Either HER2-Negative BRCA-Mutated or Triple-Negative Breast Cancer With Molecular Disease Based on Presence of Circulating Tumor DNA After Definitive Therapy (ZEST)	Neoplasms, Breast	2060 - North Sydney; 2050 - Camperdown; 2109 - Macquarie Park	https://clinicaltrials.gov/ct2/show/NCT04915755
NCT04918810	GUIDE	Phase 2		NSW, VIC	2021-06-09	2022-07-29		Docetaxel	taxane	Docetaxel	taxane	ANZUP 1903	A Phase II Trial of Biomarker-driven Intermittent Docetaxel in Metastatic Castration-resistant Prostate Cancer (mCRPC)	Castration Resistant Prostatic Cancer	2830 - Dubbo; 2460 - Albury; 2050 - Camperdown; 3630 - Shepparton; 3199 - Frankston; - Sydney; 2021 - Darlinghurst; 3844 - Traralgon	https://clinicaltrials.gov/ct2/show/NCT04918810
NCT04921358	2022-001779-15--BGB-A317-Sitravatinib-301	Phase 3		NSW, QLD, SA, VIC	2021-06-10	2021-07-27		Docetaxel; Sitravatinib; Sitravatinib + Tislelizumab; Tislelizumab	KIT/PDGFR/RET/VEGFR_inhibitor; PDGFR_inhibitor + anti-PD-1_monoclonal_antibody; VEGFR_inhibitor + anti-PD-1_monoclonal_antibody; RET_inhibitor; PDGFR_inhibitor; KIT_inhibitor; VEGFR_inhibitor; KIT_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; taxane; RET_inhibitor + anti-PD-1_monoclonal_antibody; KIT/PDGFR/RET/VEGFR_inhibitor + anti-PD-1_monoclonal_antibody	Docetaxel; Sitravatinib + Tislelizumab	KIT/PDGFR/RET/VEGFR_inhibitor + anti-PD-1_monoclonal_antibody; KIT_inhibitor + anti-PD-1_monoclonal_antibody; PDGFR_inhibitor + anti-PD-1_monoclonal_antibody; RET_inhibitor + anti-PD-1_monoclonal_antibody; VEGFR_inhibitor + anti-PD-1_monoclonal_antibody; taxane	2022-001779-15  BGB-A317-Sitravatinib-301	SAFFRON-301: A Randomized Phase 3 Study of Tislelizumab in Combination With Sitravatinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer That Progressed on or After Platinum-Based Chemotherapy and Anti-PD-(L)1 Antibody	Non-Small Cell Lung Cancer (NSCLC)	3021 - St Albans; 4870 - Cairns; 2485 - Tweed Heads; 5000 - Adelaide; 3076 - Epping; 3065 - Fitzroy; 3168 - Clayton; 4217 - Benowa; 2560 - Campbelltown; 2148 - Blacktown; 2217 - Kogarah	https://clinicaltrials.gov/ct2/show/NCT04921358
NCT04924075	MK-6482-015--6482-015	Phase 2		NSW, VIC	2021-06-11	2021-08-12		Belzutifan	HIF2a_inhibitor	Belzutifan	HIF2a_inhibitor	MK-6482-015  6482-015	A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, Formerly PT2977) Monotherapy in Participants With Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Advanced Solid Tumors With HIF-2a Related Genetic Alterations	Pancreatic Neuroendocrine Tumor; HIF-2a Mutated Cancers; Pheochromocytoma/Paraganglioma; Von Hippel-Lindau Disease; Advanced Gastrointestinal Stromal Tumor	2031 - Randwick; 3050 - Parkville	https://clinicaltrials.gov/ct2/show/NCT04924075
NCT04925284	XB002-101	Phase 1		NSW, WA	2021-06-14	2021-06-07		Bevacizumab; Bevacizumab + XB002; Nivolumab; Nivolumab + XB002; XB002	anti-TF_antibody-drug_conjugate + anti-VEGF_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TF_antibody-drug_conjugate; anti-TF_antibody-drug_conjugate; anti-VEGF_monoclonal_antibody; anti-PD-1_monoclonal_antibody	Bevacizumab + XB002; Nivolumab + XB002; XB002	anti-PD-1_monoclonal_antibody + anti-TF_antibody-drug_conjugate; anti-TF_antibody-drug_conjugate; anti-TF_antibody-drug_conjugate + anti-VEGF_monoclonal_antibody	XB002-101	A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 as Single-Agent and Combination Therapy in Subjects With Inoperable Locally Advanced or Metastatic Solid Tumors	Epithelial Ovarian Cancer; Cervical Cancer; Esophageal SCC; Metastatic Castration-resistant Prostate Cancer; Pancreatic Cancer; Tissue Factor-Expressing Solid Tumors; SCCHN; Triple Negative Breast Cancer; Endometrial Cancer; Non Small Cell Lung Cancer; Hormone Receptor-positive Breast Cancer	6009 - Nedlands; 2170 - Liverpool; 2228 - Miranda; 2065 - Saint Leonards; 2010 - Darlinghurst	https://clinicaltrials.gov/ct2/show/NCT04925284
NCT04925648	PICASSO	Phase 2		NSW, VIC	2021-06-14	2021-10-18		Darolutamide; Dasatinib	YES1_inhibitor; antiandrogen,nonsteroidal,second_generation; SRC_inhibitor; BCR-ABL1_inhibitor,second_generation; PDGFRA_inhibitor; KIT_inhibitor	Dasatinib; Darolutamide	BCR-ABL1_inhibitor,second_generation; KIT_inhibitor; PDGFRA_inhibitor; SRC_inhibitor; YES1_inhibitor; antiandrogen,nonsteroidal,second_generation	PICASSO	PICAASO / CA180-722: Psma Intensity Can be Altered by Androgen and Phospho-SrC Obstruction	Metastatic Prostate Cancer	3000 - Melbourne; 2010 - Sydney	https://clinicaltrials.gov/ct2/show/NCT04925648
NCT04928846	2023-505749-14-00--M18-868	Phase 3		VIC	2021-06-16	2022-03-25		Docetaxel; Telisotuzumab Vedotin	anti-cMET_antibody-drug_conjugate; taxane	Docetaxel; Telisotuzumab Vedotin	anti-cMET_antibody-drug_conjugate; taxane	2023-505749-14-00  M18-868	A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer	Non Small Cell Lung Cancer	3220 - Geelong; 3084 - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT04928846
NCT04929223	2021-001207-33--WO42758	Phase 1		VIC	2021-06-18	2021-10-22		Atezolizumab; Atezolizumab + Bevacizumab + Tiragolumab; Atezolizumab + SY-5609; Atezolizumab + Tiragolumab; Bevacizumab; Bevacizumab + Divarasib; Bevacizumab + Inavolisib; Cetuximab; Cetuximab + Divarasib; Cetuximab + Inavolisib; Divarasib; Inavolisib; SY-5609; Tiragolumab	PI3K_alpha_inhibitor + anti-EGFR_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; PI3K_alpha_inhibitor + anti-VEGF_monoclonal_antibody; anti-TIGIT_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + anti-VEGF_monoclonal_antibody; KRAS_G12C_inhibitor; KRAS_G12C_inhibitor + anti-VEGF_monoclonal_antibody; anti-VEGF_monoclonal_antibody; CDK7_inhibitor; KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody; CDK7_inhibitor + anti-PD-L1_monoclonal_antibody; PI3K_alpha_inhibitor; anti-EGFR_monoclonal_antibody	Atezolizumab + Bevacizumab + Tiragolumab; Atezolizumab + SY-5609; Atezolizumab + Tiragolumab; Bevacizumab + Divarasib; Bevacizumab + Inavolisib; Cetuximab + Divarasib; Cetuximab + Inavolisib	CDK7_inhibitor + anti-PD-L1_monoclonal_antibody; KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody; KRAS_G12C_inhibitor + anti-VEGF_monoclonal_antibody; PI3K_alpha_inhibitor + anti-EGFR_monoclonal_antibody; PI3K_alpha_inhibitor + anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + anti-VEGF_monoclonal_antibody	2021-001207-33  WO42758	A Phase I/Ib Global, Multicenter, Open-label Umbrella Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)	Metastatic Colorectal Cancer	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04929223
NCT04935359	2021-000591-10--CNIS793B12301	Phase 3		SA, WA	2021-06-23	2021-09-30		Gemcitabine; Gemcitabine + NIS793 + Nab-paclitaxel; Gemcitabine + Nab-paclitaxel; NIS793; Nab-paclitaxel; Placebo	placebo; antimetabolite; antimetabolite + taxane; taxane; gemcitabine; anti-TGF-beta_monoclonal_antibody + antimetabolite + taxane; anti-TGF-beta_monoclonal_antibody	Gemcitabine + NIS793 + Nab-paclitaxel; Gemcitabine + Nab-paclitaxel; Placebo	anti-TGF-beta_monoclonal_antibody + antimetabolite + taxane; antimetabolite + taxane; gemcitabine; placebo	2021-000591-10  CNIS793B12301	A Randomized, Double-blind, Phase III Study, Comparing NIS793 in Combination With Gemcitabine and Nab-paclitaxel Versus (vs.) Placebo Combined With Gemcitabine and Nab-paclitaxel for First Line Treatment of Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2	Metastatic Pancreatic Ductal Adenocarcinoma	6009 - Perth; 5000 - Adelaide	https://clinicaltrials.gov/ct2/show/NCT04935359
NCT04938817	MK-3475-B98--3475-B98	Phase 1		NSW, QLD, VIC, WA	2021-06-24	2021-08-19		Favezelimab; Favezelimab + Pembrolizumab; Lenvatinib; Lenvatinib + Pembrolizumab + Quavonlimab; MK-4830; MK-4830 + Pembrolizumab + Quavonlimab; Pembrolizumab; Pembrolizumab + Quavonlimab; Quavonlimab	anti-LAG3_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-CTLA4_monoclonal_antibody + anti-ILT4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; VEGF_inhibitor; anti-ILT4_monoclonal_antibody; anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA4_monoclonal_antibody	Favezelimab + Pembrolizumab; Lenvatinib + Pembrolizumab + Quavonlimab; MK-4830 + Pembrolizumab + Quavonlimab; Pembrolizumab + Quavonlimab	VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA4_monoclonal_antibody + anti-ILT4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody	MK-3475-B98  3475-B98	A Phase 1b/2 Study to Evaluate the Efficacy and Safety of Investigational Agents as Monotherapy or in Combination With Pembrolizumab for the Treatment of Participants With PD-1/L1-refractory Extensive-Stage Small Cell Lung Cancer in Need of Second-Line Therapy (KEYNOTE-B98)	Small Cell Lung Carcinoma	4032 - Brisbane; 3168 - Clayton; 6009 - Perth; 2145 - Westmead	https://clinicaltrials.gov/ct2/show/NCT04938817
NCT04939610	LuMIERE	Phase 1		SA, VIC	2021-06-25	2021-07-30		177Lu-FAP-2286	radioligand,FAP-targeting	177Lu-FAP-2286	radioligand,FAP-targeting	CAAA614A12101  CO-2286-114	LuMIERE: A Phase 1/2, Multicenter, Open-label, Non-randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of 177Lu-FAP-2286 in Patients With an Advanced Solid Tumor	Solid Tumor	5000 - Adelaide; 3004 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04939610
NCT04947189	4CAST	Phase 1		NSW	2021-07-01	2022-11-01		Dexamethasone; Dexamethasone + Docetaxel + Seviteronel; Docetaxel; Seviteronel	glucocorticoid; CYP17A1_inhibitor; taxane; CYP17A1_inhibitor + glucocorticoid + taxane	Dexamethasone + Docetaxel + Seviteronel	CYP17A1_inhibitor + glucocorticoid + taxane	4CAST	4CAST: A Phase 1b Dose Exploration and Dose Expansion, Open-label, Single-centre Study Evaluating the Safety and Efficacy of INO-464 in Combination With Chemotherapy in Patients With metASTatic Breast Cancer	Triple Negative Breast Cancer	2010 - Darlinghurst	https://clinicaltrials.gov/ct2/show/NCT04947189
NCT04950075	ChonDRAgon	Phase 2		NSW, QLD, SA	2021-07-06	2021-09-23		INBRX-109; Placebo	placebo; anti-DR5_agonistic_antibody	INBRX-109; Placebo	anti-DR5_agonistic_antibody; placebo	Ph2 INBRX-109 SA CS	A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma	Conventional Chondrosarcoma	5000 - Adelaide; 2050 - Camperdown; - Woolloongabba	https://clinicaltrials.gov/ct2/show/NCT04950075
NCT04952753	daNIS-3	Phase 2		SA, VIC, WA	2021-07-07	2021-11-15		Bevacizumab; Bevacizumab + NIS793; Bevacizumab + NIS793 + Tislelizumab; NIS793; Tislelizumab	anti-VEGF_monoclonal_antibody; anti-TGF-beta_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-TGF-beta_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TGF-beta_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-1_monoclonal_antibody	Bevacizumab; Bevacizumab + NIS793; Bevacizumab + NIS793 + Tislelizumab	anti-PD-1_monoclonal_antibody + anti-TGF-beta_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-TGF-beta_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-VEGF_monoclonal_antibody	2021-000553-40  CNIS793E12201	An Open-label, Multi-center, ph II Platform Study Evaluating the Efficacy and Safety of NIS793 and Other New Investigational Drug Combinations With SOC Anti-cancer Therapy for the 2L Treatment of Metastatic Colorectal Cancer (mCRC)	Metastatic Colorectal Cancer	6009 - Perth; 3550 - Bendigo; 5000 - Adelaide	https://clinicaltrials.gov/ct2/show/NCT04952753
NCT04956640	2021-000595-12--LOXO-RAS-20001	Phase 1		NSW, SA, VIC, WA	2021-07-09	2021-07-19		Carboplatin; Cetuximab; Cisplatin; Olomorasib; Pembrolizumab; Pemetrexed	antimetabolite; anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor; platinum-based_antineoplastic_agent; anti-EGFR_monoclonal_antibody	Olomorasib; Carboplatin; Cetuximab; Cisplatin; Pembrolizumab; Pemetrexed	KRAS_G12C_inhibitor; anti-EGFR_monoclonal_antibody; anti-PD-1_monoclonal_antibody; antimetabolite; platinum-based_antineoplastic_agent	2021-000595-12  LOXO-RAS-20001	A Phase 1/2 Study of LY3537982 in Patients With KRAS G12C-Mutant Advanced Solid Tumors	Pancreatic Neoplasms; Biliary Tract Neoplasms; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Colorectal Neoplasms; Ovarian Neoplasms	6009 - Nedlands; 2065 - St Leonards; 3199 - Frankston; 5000 - Adelaide; 2010 - Sydney	https://clinicaltrials.gov/ct2/show/NCT04956640
NCT04958239	2021-000234-34--1463-0001	Phase 1		NSW, QLD, VIC	2021-07-12	2021-10-18		Ezabenlimab; Pembrolizumab	anti-PD-1_monoclonal_antibody	Ezabenlimab; Pembrolizumab	anti-PD-1_monoclonal_antibody	2021-000234-34  1463-0001	An Open Label, Phase I Dose-finding and Expansion Study of BI 765179 as Monotherapy and in Combination With Ezabenlimab (BI 754091) in Patients With Advanced Solid Cancers, and BI 765179 in Combination With Pembrolizumab in First-line PD-L1-positive Metastatic or Incurable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)	Neoplasms	4814 - Douglas; 2640 - Albury; 3084 - Heidelberg; 2010 - Darlinghurst	https://clinicaltrials.gov/ct2/show/NCT04958239
NCT04958785	ELEVATE-TNBC	Phase 2		QLD, SA, VIC	2021-07-12	2021-12-14		Magrolimab; Magrolimab + Nab-paclitaxel + Paclitaxel; Magrolimab + Sacituzumab Govitecan; Nab-paclitaxel; Nab-paclitaxel + Paclitaxel; Paclitaxel; Sacituzumab Govitecan	anti-Trop2_antibody-drug_conjugate; anti-CD47_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; anti-CD47_monoclonal_antibody + taxane; taxane; anti-CD47_monoclonal_antibody	Magrolimab + Nab-paclitaxel + Paclitaxel; Magrolimab + Sacituzumab Govitecan; Nab-paclitaxel + Paclitaxel	anti-CD47_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; anti-CD47_monoclonal_antibody + taxane; taxane	2021-001074-27  GS-US-586-6144	A Phase 2 Study of Magrolimab Combination Therapy in Patients With Unresectable, Locally Advanced or Metastatic Triple-Negative Breast Cancer	Triple-Negative Breast Cancer	5042 - Bedford Park; 4556 - Sippy Downs; 3128 - Box Hill; 4870 - Cairns; 5000 - Adelaide; '03220 - Geelong; 3199 - Frankston; 4102 - Woolloongabba; 3355 - Wendouree; 3065 - Fitzroy	https://clinicaltrials.gov/ct2/show/NCT04958785
NCT04964375	ABSK043-101	Phase 1		NSW, QLD, VIC	2021-07-16	2021-08-31		ABSK-043	PD-L1_inhibitor,oral	ABSK-043	PD-L1_inhibitor,oral	ABSK043-101	A Phase 1, Open-Label Study of ABSK043 to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced Solid Tumor	Neoplasms	- Frankston; - Liverpool; 4101 - Brisbane	https://clinicaltrials.gov/ct2/show/NCT04964375
NCT04964934	SERENA-6	Phase 3		NSW, QLD	2021-07-16	2021-06-30		Abemaciclib; Abemaciclib + Anastrozole + Camizestrant + Letrozole + Palbociclib + Ribociclib; Anastrozole; Camizestrant; Letrozole; Palbociclib; Placebo; Ribociclib	placebo; aromatase_inhibitor; CDK4/6_inhibitor; selective_estrogen_receptor_degrader; CDK4/6_inhibitor + aromatase_inhibitor + selective_estrogen_receptor_degrader	Abemaciclib + Anastrozole + Camizestrant + Letrozole + Palbociclib + Ribociclib; Placebo	CDK4/6_inhibitor + aromatase_inhibitor + selective_estrogen_receptor_degrader; placebo	2023-503990-39-00  D8534C00001	A Phase III, Double-blind, Randomised Study to Assess Switching to AZD9833 (a Next Generation, Oral SERD) + CDK4/6 Inhibitor vs Continuing Aromatase Inhibitor (Letrozole or Anastrozole)+ CDK4/6 Inhibitor in HR+/HER2-MBC Patients With Detectable ESR1Mutation Without Disease Progression During 1L Treatment With Aromatase Inhibitor+ CDK4/6 Inhibitor- A ctDNA Guided Early Switch Study	ER-Positive HER2-Negative Breast Cancer	4575 - Birtinya; 2010 - Darlinghurst	https://clinicaltrials.gov/ct2/show/NCT04964934
NCT04974398	AK105-304	Phase 3		NSW, VIC, WA	2021-07-23	2021-08-16		Carboplatin; Carboplatin + Cisplatin + Gemcitabine; Carboplatin + Cisplatin + Gemcitabine + Penpulimab; Cisplatin; Gemcitabine; Penpulimab; Placebo	placebo; anti-PD-1_monoclonal_antibody; gemcitabine; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent	Carboplatin + Cisplatin + Gemcitabine; Carboplatin + Cisplatin + Gemcitabine + Penpulimab; Placebo	anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; gemcitabine; placebo	AK105-304	A Randomized, Double-blind, Multi-center Phase III Study of Penpulimab (AK105) Combined With Chemotherapy Versus Placebo Combined With Chemotherapy in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma	Nasopharyngeal Carcinoma	2010 - Darlinghurst; 3084 - Heidelberg; - Camperdown; 6009 - Nedlands; 2065 - St Leonards	https://clinicaltrials.gov/ct2/show/NCT04974398
NCT04975308	EMBER-3	Phase 3		NSW, QLD, SA, VIC	2021-07-23	2021-10-04		Abemaciclib; Abemaciclib + Imlunestrant; Exemestane; Exemestane + Fulvestrant; Fulvestrant; Imlunestrant	aromatase_inhibitor; aromatase_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor; selective_estrogen_receptor_degrader; CDK4/6_inhibitor + selective_estrogen_receptor_degrader	Abemaciclib + Imlunestrant; Exemestane + Fulvestrant; Imlunestrant	CDK4/6_inhibitor + selective_estrogen_receptor_degrader; aromatase_inhibitor + selective_estrogen_receptor_degrader; selective_estrogen_receptor_degrader	J2J-OX-JZLC  18175	EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With Endocrine Therapy	Neoplasm Metastasis; Breast Neoplasms	2010 - Darlinghurst; 5037 - Kurralta Park; 3128 - Box Hill; 3135 - Melbourne; 4102 - Woolloongabba	https://clinicaltrials.gov/ct2/show/NCT04975308
NCT04976634	MK-6482-016--6482-016	Phase 2		NSW, NZ, VIC	2021-07-26	2021-08-18		Belzutifan; Belzutifan + Lenvatinib + Pembrolizumab; Lenvatinib; Lenvatinib + Pembrolizumab; Pembrolizumab	VEGF_inhibitor + anti-PD-1_monoclonal_antibody; VEGF_inhibitor; HIF2a_inhibitor + VEGF_inhibitor + anti-PD-1_monoclonal_antibody; HIF2a_inhibitor; anti-PD-1_monoclonal_antibody	Belzutifan + Lenvatinib + Pembrolizumab; Lenvatinib + Pembrolizumab	HIF2a_inhibitor + VEGF_inhibitor + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody	MK-6482-016  6482-016	An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Multiple Solid Tumors	Neoplasm Malignant	3144 - Malvern; 2250 - Gosford; Auckland; 2145 - Westmead; 3076 - Epping	https://clinicaltrials.gov/ct2/show/NCT04976634
NCT04985604	DAY101-102	Phase 1		VIC	2021-08-02	2021-07-15		Pimasertib; Pimasertib + Tovorafenib; Tovorafenib	RAF_inhibitor,type_2; MEK_inhibitor + RAF_inhibitor,type_2; MEK_inhibitor	Pimasertib + Tovorafenib; Tovorafenib	MEK_inhibitor + RAF_inhibitor,type_2; RAF_inhibitor,type_2	DAY101-102	A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination With Other Therapies for Patients With Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations	CRAF Gene Amplification; Colorectal Cancer; Bladder Cancer; RAF1 Gene Fusion; Non Small Cell Lung Cancer; RAF1 Fusion; MEK Mutation; Solid Tumor; Melanoma; Spitzoid Melanoma; Pilocytic Astrocytoma, Adult; MAP Kinase Family Gene Mutation; RAF Mutation; Thyroid Cancer, Papillary; Pilocytic Astrocytoma; Non-Small Cell Adenocarcinoma; Bladder Urothelial Carcinoma; CRAF Gene Fusion; CRAF Fusion; Pancreatic Acinar Carcinoma; Spitzoid Malignant Melanoma; BRAF Fusion; BRAF Gene Fusion; RAS Mutation; RAF1 Gene Amplification	- Clayton	https://clinicaltrials.gov/ct2/show/NCT04985604
NCT04986852	KEYNOTE-C14	Phase 2		WA	2021-08-03	2021-09-30		Olinvacimab; Olinvacimab + Pembrolizumab; Pembrolizumab	anti-VEGFR2_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-VEGFR2_monoclonal_antibody; anti-PD-1_monoclonal_antibody	Olinvacimab + Pembrolizumab	anti-PD-1_monoclonal_antibody + anti-VEGFR2_monoclonal_antibody	PMC_TTAC-0001_06 / KEYNOTE-C14	A Phase II, Open-Label, Multicenter Study of Olinvacimab in Combination With Pembrolizumab in Patients With Metastatic Triple-Negative Breast Cancer	Metastatic Triple-Negative Breast Cancer	6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT04986852
NCT04986865	PROBE	Phase 1		NSW, SA, VIC	2021-08-03	2021-12-15		ATG-101	bispecific_PD-L1/4-1BB_antibody	ATG-101	bispecific_PD-L1/4-1BB_antibody	ATG-101-001	A First-in-Human Phase I Trial of ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas	Metastatic Solid Tumor; Advanced Solid Tumor; Mature B-cell Non-Hodgkin Lymphoma	3004 - Melbourne; 8006 - East Melbourne; 3084 - Heidelberg; 2031 - Randwick; 5000 - Adelaide	https://clinicaltrials.gov/ct2/show/NCT04986865
NCT04987203	AV-951-20-304	Phase 3		NSW, QLD, VIC	2021-08-03	2021-09-09		Nivolumab; Nivolumab + Tivozanib; Tivozanib	VEGF_inhibitor + anti-PD-1_monoclonal_antibody; VEGF_inhibitor; anti-PD-1_monoclonal_antibody	Nivolumab + Tivozanib; Tivozanib	VEGF_inhibitor; VEGF_inhibitor + anti-PD-1_monoclonal_antibody	AV-951-20-304	TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor	Renal Cell Carcinoma	4101 - Brisbane; 2170 - Liverpool; 3220 - Geelong; 4102 - Woolloongabba	https://clinicaltrials.gov/ct2/show/NCT04987203
NCT04994132	NCI-2021-06711--ARST2031	Phase 3		NSW, VIC, WA	2021-08-06	2021-09-14		Cyclophosphamide; Cyclophosphamide + Dactinomycin + Radiotherapy + Vincristine; Cyclophosphamide + Dactinomycin + Radiotherapy + Vincristine + Vinorelbine; Dactinomycin; Radiotherapy; Vincristine; Vinorelbine	radiotherapy; alkylating_agent + antineoplastic_antibiotic + radiotherapy + vinca_alkaloid; vinca_alkaloid; antineoplastic_antibiotic; alkylating_agent	Cyclophosphamide + Dactinomycin + Radiotherapy + Vincristine; Cyclophosphamide + Dactinomycin + Radiotherapy + Vincristine + Vinorelbine	alkylating_agent + antineoplastic_antibiotic + radiotherapy + vinca_alkaloid	NCI-2021-06711  ARST2031	A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy With Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) Plus VINO-CPO Maintenance in Patients With High Risk Rhabdomyosarcoma (HR-RMS)	Spindle Cell Rhabdomyosarcoma; Spindle Cell/Sclerosing Rhabdomyosarcoma; Botryoid-Type Embryonal Rhabdomyosarcoma; Solid Alveolar Rhabdomyosarcoma; Metastatic Rhabdomyosarcoma; Embryonal Rhabdomyosarcoma; Alveolar Rhabdomyosarcoma; Metastatic Embryonal Rhabdomyosarcoma	2031 - Randwick; 2310 - Hunter Regional Mail Centre; 3052 - Parkville; 2145 - Westmead; 6009 - Perth	https://clinicaltrials.gov/ct2/show/NCT04994132
NCT04995523	ARTEMIDE-01	Phase 1		VIC	2021-08-09	2021-09-14		Rilvegostomig	bispecific_PD-1/TIGIT_antibody	Rilvegostomig	bispecific_PD-1/TIGIT_antibody	2023-508262-15-00  D7020C00001	Phase I/II, Open-label, Dose Escalation and Dose Expansion Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC	Non-Small-Cell Lung Carcinoma	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04995523
NCT04996875	2024-511407-42-00--CGT9486-20-201	Phase 2		NSW, QLD, VIC	2021-08-09	2021-11-09		Bezuclastinib	KIT_inhibitor,type_1; KIT_D816V_inhibitor	Bezuclastinib	KIT_D816V_inhibitor; KIT_inhibitor,type_1	2024-511407-42-00  CGT9486-20-201	A Phase 2 Open-Label, Multicenter Clinical Study of the Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Profiles of CGT9486 as a Single Agent in Patients With Advanced Systemic Mastocytosis	Mast Cell Leukemia (MCL); SM With an Associated Hematologic Neoplasm (SM-AHN); Aggressive Systemic Mastocytosis (ASM); Advanced Systemic Mastocytosis (AdvSM)	2747 - Kingswood; 3051 - Melbourne N.; 4215 - Southport	https://clinicaltrials.gov/ct2/show/NCT04996875
NCT05002127	AT148006	Phase 2		QLD, VIC	2021-08-12	2022-01-15		Evorpacept; Evorpacept + Paclitaxel + Ramucirumab + Trastuzumab; Paclitaxel; Paclitaxel + Ramucirumab; Paclitaxel + Ramucirumab + Trastuzumab; Ramucirumab; Trastuzumab	anti-VEGFR2_monoclonal_antibody + taxane; anti-VEGFR2_monoclonal_antibody; anti-ERBB2_monoclonal_antibody; CD47-blocking_fusion_protein + anti-ERBB2_monoclonal_antibody + anti-VEGFR2_monoclonal_antibody + taxane; taxane; CD47-blocking_fusion_protein; anti-ERBB2_monoclonal_antibody + anti-VEGFR2_monoclonal_antibody + taxane	Evorpacept + Paclitaxel + Ramucirumab + Trastuzumab; Paclitaxel + Ramucirumab; Paclitaxel + Ramucirumab + Trastuzumab	CD47-blocking_fusion_protein + anti-ERBB2_monoclonal_antibody + anti-VEGFR2_monoclonal_antibody + taxane; anti-ERBB2_monoclonal_antibody + anti-VEGFR2_monoclonal_antibody + taxane; anti-VEGFR2_monoclonal_antibody + taxane	AT148006	A Phase 2/3 Study of Evorpacept (ALX148) in Patients With Advanced HER2-Overexpressing Gastric/Gastroesophageal Junction Adenocarcinoma (ASPEN-06)	Gastric Adenocarcinoma; Gastric Cancer; Gastroesophageal Junction Adenocarcinoma	4215 - Southport; 3168 - Clayton	https://clinicaltrials.gov/ct2/show/NCT05002127
NCT05005273	2021-000039-29--CA020-016	Phase 2		NSW, VIC	2021-08-13	2022-10-03		BMS-986207; Ipilimumab; Nivolumab; Placebo	placebo; anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-CTLA4_monoclonal_antibody	BMS-986207; Ipilimumab; Nivolumab; Placebo	anti-CTLA4_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-TIGIT_monoclonal_antibody; placebo	2021-000039-29  CA020-016	A Phase 2 Randomized Study of BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer	Non-Small Cell Lung Cancer	2800 - Orange; 3280 - Warrnambool; 0 - Wahroonga	https://clinicaltrials.gov/ct2/show/NCT05005273
NCT05007782	2022-501684-40--GS-US-570-6015	Phase 1		NSW, VIC	2021-08-16	2021-08-18		GS-1811; Zimberelimab	anti-PD-1_monoclonal_antibody; anti-CCR8_monoclonal_antibody	Zimberelimab; GS-1811	anti-PD-1_monoclonal_antibody; anti-CCR8_monoclonal_antibody	2022-501684-40  GS-US-570-6015	A Phase 1 Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of GS-1811, an Afucosylated Anti-CCR8 Monoclonal Antibody, as Monotherapy and in Combination With an Anti-PD-1 Monoclonal Antibody in Adults With Advanced Solid Tumors	Advanced Solid Tumor	3168 - Clayton; 3000 - Melbourne; 2050 - Camperdown	https://clinicaltrials.gov/ct2/show/NCT05007782
NCT05014815	2021-001075-17--AdvanTIG-205	Phase 2		NSW, QLD, TAS, VIC	2021-08-20	2021-11-16		Ociperlimab; Ociperlimab + Tislelizumab; Placebo; Tislelizumab	placebo; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody	Ociperlimab + Tislelizumab; Tislelizumab; Placebo	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; placebo	2021-001075-17  AdvanTIG-205	AdvanTIG-205: A Phase 2, Randomized Study of Ociperlimab (BGB-A1217) and Tislelizumab With Chemotherapy in Patients With Previously Untreated Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer (NSCLC)	Locally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC); Nonsmall Cell Lung Cancer, Stage IV	4350 - Toowoomba; 7250 - Launceston; 4814 - Douglas; 2086 - Frenchs Forest; 3199 - Frankston; 3084 - Heidelberg; 2640 - East Albury; 2444 - Port Macquarie	https://clinicaltrials.gov/ct2/show/NCT05014815
NCT05021120	AK127-101	Phase 0		NSW, SA, VIC	2021-08-25	2021-10-12		AK127; Cadonilimab	bispecific_PD-1/CTLA4_antibody; anti-TIGIT_monoclonal_antibody	AK127; Cadonilimab	anti-TIGIT_monoclonal_antibody; bispecific_PD-1/CTLA4_antibody	AK127-101	A Phase 1a/1b, Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-tumour Activity of AK127 in Combination With AK104 in Subjects With Advanced or Metastatic Solid Tumours	Advanced or Metastatic Solid Tumours	- Melbourne; - Adelaide; - Sydney	https://clinicaltrials.gov/ct2/show/NCT05021120
NCT05027867	KRT-232-112	Phase 2		SA	2021-08-30	2021-12-06		Navtemadlin	MDM2_inhibitor	Navtemadlin	MDM2_inhibitor	KRT-232-112	An Open-Label, Multicenter, Phase 2 Study of the Safety and Efficacy of KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer (SCLC)	Small Cell Lung Cancer Extensive Stage; Small Cell Lung Carcinoma; Small-cell Lung Cancer; Small Cell Lung Cancer Recurrent	5042 - Bedford Park	https://clinicaltrials.gov/ct2/show/NCT05027867
NCT05029882	2023-509335-60-00--M21-404	Phase 1		QLD, VIC	2021-09-01	2021-10-13		ABBV-400; ABBV-400 + Bevacizumab; Bevacizumab; Bevacizumab + Trifluridine/Tipiracil; Trifluridine/Tipiracil	antimetabolite; anti-VEGF_monoclonal_antibody; anti-VEGF_monoclonal_antibody + anti-cMET_antibody-drug_conjugate; anti-VEGF_monoclonal_antibody + thymidine_phosphorylase_inhibitor; Tipiracil Hydrochloride + anti-VEGF_monoclonal_antibody; Trifluridine + anti-VEGF_monoclonal_antibody; anti-VEGF_monoclonal_antibody + antimetabolite; anti-cMET_antibody-drug_conjugate; Tipiracil Hydrochloride; Trifluridine; thymidine_phosphorylase_inhibitor	ABBV-400; ABBV-400 + Bevacizumab; Bevacizumab + Trifluridine/Tipiracil	Tipiracil Hydrochloride + anti-VEGF_monoclonal_antibody; Trifluridine + anti-VEGF_monoclonal_antibody; anti-VEGF_monoclonal_antibody + anti-cMET_antibody-drug_conjugate; anti-VEGF_monoclonal_antibody + antimetabolite; anti-VEGF_monoclonal_antibody + thymidine_phosphorylase_inhibitor; anti-cMET_antibody-drug_conjugate	2023-509335-60-00  M21-404	A Phase 1 First in Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-400 as Monotherapy and in Combination With Bevacizumab in Adult Subjects With Advanced Solid Tumors	Non-Small Cell Lung Cancer; Gastroesophageal Adenocarcinoma; Advanced Solid Tumors; Colorectal Cancer	3084 - Heidelberg; 4101 - South Brisbane	https://clinicaltrials.gov/ct2/show/NCT05029882
NCT05031494	YH003004	Phase 2		VIC	2021-09-02	2021-12-08		Gemcitabine; Gemcitabine + Nab-paclitaxel + Toripalimab + YH003; Nab-paclitaxel; Toripalimab; Toripalimab + YH003; YH003	antimetabolite; anti-OX40_agonistic_antibody + anti-PD-1_monoclonal_antibody; anti-OX40_agonistic_antibody; anti-PD-1_monoclonal_antibody; taxane; gemcitabine; anti-OX40_agonistic_antibody + anti-PD-1_monoclonal_antibody + antimetabolite + taxane	Gemcitabine + Nab-paclitaxel + Toripalimab + YH003; Toripalimab + YH003	anti-OX40_agonistic_antibody + anti-PD-1_monoclonal_antibody; anti-OX40_agonistic_antibody + anti-PD-1_monoclonal_antibody + antimetabolite + taxane; gemcitabine	YH003004	A Multi-center, Open-label Phase II Study to Evaluate the Safety and Efficacy of YH003 in Combination with Toripalimab (anti-PD-1 MAb) in Patients with Unresectable/metastatic Melanoma and Pancreatic Ductal Adenocarcinoma (PDAC)	Melanoma; Pancreatic Ductal Adenocarcinoma	3121 - Richmond	https://clinicaltrials.gov/ct2/show/NCT05031494
NCT05040932	YH004002	Phase 1		NSW, VIC	2021-09-10	2021-12-07		Toripalimab; YH004	anti-4-1BB_agonistic_antibody; anti-PD-1_monoclonal_antibody	YH004; Toripalimab	anti-4-1BB_agonistic_antibody; anti-PD-1_monoclonal_antibody	YH004002	A First-In-Human, Multicenter, Open-Label, Phase I Dose Escalation Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of YH004 As A Single Agent And Combination With Toripalimab In Subjects With Advanced Solid Tumors And Relapsed Or Refractory Non-Hodgkin Lymphoma	Cancer	2217 - Wollongong; 3144 - Malvern East; 2145 - Sydney	https://clinicaltrials.gov/ct2/show/NCT05040932
NCT05041257	IMGN853-0419	Phase 2		NSW, SA, VIC, WA	2021-09-13	2021-08-31		Mirvetuximab Soravtansine	anti-FR-alpha_antibody-drug_conjugate	Mirvetuximab Soravtansine	anti-FR-alpha_antibody-drug_conjugate	IMGN853-0419	A Phase 2, Single Arm Study of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression (PICCOLO)	Peritoneal Cancer; Fallopian Tube Cancer; Ovarian Cancer	3165 - Clayton; 3144 - Malvern; 5065 - Toorak Gardens; 2305 - New Lambton Heights; 6008 - Subiaco; 2065 - St. Leonards	https://clinicaltrials.gov/ct2/show/NCT05041257
NCT05042128	ASCEND	Phase 2		NSW, NZ, QLD, SA, TAS, VIC, WA	2021-09-13	2022-04-13		Certepetide; Certepetide + Gemcitabine + Nab-paclitaxel; Gemcitabine; Gemcitabine + Nab-paclitaxel; Nab-paclitaxel; Paclitaxel; Placebo	placebo; antimetabolite; antimetabolite + taxane; taxane; gemcitabine; antimetabolite + taxane + tumor-homing_peptide_iRGD; tumor-homing_peptide_iRGD	Certepetide + Gemcitabine + Nab-paclitaxel; Gemcitabine + Nab-paclitaxel; Placebo	antimetabolite + taxane; antimetabolite + taxane + tumor-homing_peptide_iRGD; gemcitabine; placebo	CTC0304	A Randomised, Double-blinded Phase II Study of Gemcitabine and Nab-Paclitaxel With LSTA1 (Certepetide) or Placebo in Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma	Pancreatic Ductal Adenocarcinoma; Metastatic Pancreatic Cancer	6008 - Subiaco; 3004 - Melbourne; 3168 - Clayton; 2217 - Kogarah; Dunedin; 6150 - Murdoch; - Launceston; Hamilton; - Sydney; 4066 - Auchenflower; 2290 - Gateshead; - Newcastle; 5011 - Woodville South; 4215 - Southport; 3121 - Richmond; - Adelaide; 2050 - Camperdown; 3076 - Epping; - Melbourne; 4029 - Herston; 3084 - Heidelberg; 575 - Birtinya; 2640 - Albury	https://clinicaltrials.gov/ct2/show/NCT05042128
NCT05043090	SAMETA	Phase 3		NSW, VIC	2021-09-13	2021-10-28		Durvalumab; Durvalumab + Savolitinib; Savolitinib; Sunitinib	VEGFR_inhibitor; anti-PD-L1_monoclonal_antibody; KIT_inhibitor,first_generation; MET_inhibitor,type_1 + anti-PD-L1_monoclonal_antibody; MET_inhibitor,type_1; PDGFR_inhibitor	Durvalumab; Durvalumab + Savolitinib; Sunitinib	KIT_inhibitor,first_generation; MET_inhibitor,type_1 + anti-PD-L1_monoclonal_antibody; PDGFR_inhibitor; VEGFR_inhibitor; anti-PD-L1_monoclonal_antibody	2022-503105-38-00  D5086C00001	A Phase III, Open Label, Randomised, 3-Arm, Multi-Centre Study of Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic Papillary Renal Cell Carcinoma (SAMETA)	Papillary Renal Cell Carcinoma	2065 - St Leonards; 2109 - Macquarie University; 3128 - Box Hill	https://clinicaltrials.gov/ct2/show/NCT05043090
NCT05050942	SORENTO	Phase 3		NSW, SA, VIC, WA	2021-09-21	2021-10-22		Lanreotide; Lanreotide + Octreotide; Octreotide	somatostatin_analog	Lanreotide + Octreotide	somatostatin_analog	2023-508723-12-00  HS-19-657	A Randomized, Multi-center, Open-label, Active-controlled Phase 3 Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot (CAM2029) Versus Octreotide LAR or Lanreotide ATG in Patients with GEP-NET	Gastro-enteropancreatic Neuroendocrine Tumor	- Alexandria; - Adelaide; - Melbourne; - Murdoch; - Blacktown	https://clinicaltrials.gov/ct2/show/NCT05050942
NCT05052801	FORTITUDE-101	Phase 3		NSW, WA	2021-09-22	2022-03-07		Bemarituzumab; Placebo	placebo; anti-FGFR2b_monoclonal_antibody	Bemarituzumab; Placebo	anti-FGFR2b_monoclonal_antibody; placebo	2023-505457-40  20210096	A Randomized, Multi-center, Double-blind, Placebo-controlled Phase 3 Study of Bemarituzumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer With FGFR2b Overexpression	Gastroesophageal Junction Adenocarcinoma; Gastric Cancer	6150 - Murdoch; 2170 - Liverpool	https://clinicaltrials.gov/ct2/show/NCT05052801
NCT05053854	PARLuNET	Phase 1			2021-09-23	2021-12-08						PMC67199	Phase 1 Trial of PARP Inhibitor Combined With 177Lu-DOTA-Octreotate Peptide Receptor Radionuclide Therapy (PRRT) in Patients With Metastatic NeuroEndocrine Tumor	Neuroendocrine Tumors		https://clinicaltrials.gov/ct2/show/NCT05053854
NCT05054725	RMC-4630-03	Phase 2		NSW, VIC	2021-09-23	2021-12-30		Sotorasib; Sotorasib + Vociprotafib; Vociprotafib	KRAS_G12C_inhibitor; SHP2_inhibitor; KRAS_G12C_inhibitor + SHP2_inhibitor; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + SHP2_inhibitor	Sotorasib + Vociprotafib	KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + SHP2_inhibitor; KRAS_G12C_inhibitor + SHP2_inhibitor	RMC-4630-03	A Phase 2, Open-Label, Multicenter Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung Cancer Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies	Non-Small Cell Lung Cancer	2148 - Blacktown; 3630 - Shepparton; 3280 - Warrnambool	https://clinicaltrials.gov/ct2/show/NCT05054725
NCT05059262	MOTION	Phase 3		NSW	2021-09-28	2021-10-14		Placebo; Vimseltinib	placebo; CSF1R_inhibitor	Vimseltinib; Placebo	CSF1R_inhibitor; placebo	2024-513624-42-00  DCC-3014-03-001	A Phase 3, Randomized, Placebo-controlled, Double-blind Study of Vimseltinib to Assess the Efficacy and Safety in Patients With Tenosynovial Giant Cell Tumor (MOTION)	Tenosynovial Giant Cell Tumor, Localized; Pigmented Villonodular Synovitis; Tenosynovial Giant Cell Tumor, Diffuse; Giant Cell Tumor of Tendon Sheath; Tenosynovial Giant Cell Tumor	- Camperdown	https://clinicaltrials.gov/ct2/show/NCT05059262
NCT05059522	2023-509466-38-00--B9991046	Phase 3		NSW, NZ, QLD	2021-09-28	2021-09-29		Avelumab; Avelumab + Axitinib; Avelumab + PF-04518600 + Utomilumab; Avelumab + Pemetrexed; Avelumab + Talazoparib; Axitinib; PF-04518600; Pemetrexed; Talazoparib; Utomilumab	antimetabolite; VEGFR/PDGFR_inhibitor + anti-PD-L1_monoclonal_antibody; PARP_inhibitor + anti-PD-L1_monoclonal_antibody; KIT_inhibitor,ATP-competitive; anti-PD-L1_monoclonal_antibody; anti-4-1BB_agonistic_antibody + anti-OX40_agonistic_antibody + anti-PD-L1_monoclonal_antibody; KIT_inhibitor,ATP-competitive + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + antimetabolite; anti-4-1BB_agonistic_antibody; anti-OX40_agonistic_antibody; VEGFR/PDGFR_inhibitor; PARP_inhibitor	Avelumab; Avelumab + Axitinib; Avelumab + PF-04518600 + Utomilumab; Avelumab + Pemetrexed; Avelumab + Talazoparib	KIT_inhibitor,ATP-competitive + anti-PD-L1_monoclonal_antibody; PARP_inhibitor + anti-PD-L1_monoclonal_antibody; VEGFR/PDGFR_inhibitor + anti-PD-L1_monoclonal_antibody; anti-4-1BB_agonistic_antibody + anti-OX40_agonistic_antibody + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + antimetabolite	2023-509466-38-00  B9991046	Avelumab Master Protocol: An Open-label Continuation Study for Participants Continuing From Pfizer-sponsored Avelumab Clinical Studies.	Advanced Malignancies; NSCLC; Solid Tumors; Urothelial Cancer; Ovarian Cancer	4032 - Chermside; 2109 - North Ryde; 2060 - Wollstonecraft; 2065 - Wollstonecraft; Auckland	https://clinicaltrials.gov/ct2/show/NCT05059522
NCT05061134	MONETTE	Phase 2		NSW, QLD, VIC	2021-09-29	2022-08-31		Ceralasertib; Ceralasertib + Durvalumab; Durvalumab	ATR_inhibitor + anti-PD-L1_monoclonal_antibody; ATR_inhibitor; anti-PD-L1_monoclonal_antibody	Ceralasertib; Ceralasertib + Durvalumab	ATR_inhibitor; ATR_inhibitor + anti-PD-L1_monoclonal_antibody	2024-512378-91-00  D533AC00001	A Randomised, Open-Label, Phase 2 Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Unresectable or Advanced Melanoma and Primary or Secondary Resistance to PD-(L)1 Inhibition	Melanoma	3002 - East Melbourne; 4029 - Herston; 2010 - Darlinghurst; 4102 - Woolloongabba	https://clinicaltrials.gov/ct2/show/NCT05061134
NCT05064059	MK-4280A-007--4280A-007	Phase 3		NSW, QLD, SA, VIC, WA	2021-10-01	2021-11-10		Favezelimab; Favezelimab + Pembrolizumab; Pembrolizumab; Regorafenib; Regorafenib + Trifluridine/Tipiracil; Trifluridine/Tipiracil	antimetabolite; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + thymidine_phosphorylase_inhibitor; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + antimetabolite; anti-LAG3_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; Tipiracil Hydrochloride; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + Trifluridine; Trifluridine; thymidine_phosphorylase_inhibitor; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + Tipiracil Hydrochloride	Favezelimab + Pembrolizumab; Regorafenib + Trifluridine/Tipiracil	KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + Tipiracil Hydrochloride; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + Trifluridine; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + antimetabolite; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + thymidine_phosphorylase_inhibitor; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody	MK-4280A-007  4280A-007	A Phase 3 Study of MK-4280A (Coformulated Favezelimab [MK-4280] Plus Pembrolizumab [MK-3475]) Versus Standard of Care in Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (KEYFORM-007)	Colorectal Cancer	4029 - Herston; 3021 - St Albans; 5011 - Woodville South; 6008 - Perth; 2145 - Westmead; 3199 - Frankston	https://clinicaltrials.gov/ct2/show/NCT05064059
NCT05067283	KANDLELIT-001	Phase 1		NSW, NZ, VIC	2021-10-05	2021-12-17		Carboplatin; Carboplatin + MK-1084 + Pembrolizumab + Pemetrexed; Cetuximab; Cetuximab + Fluorouracil + Leucovorin + MK-1084 + Oxaliplatin; Cetuximab + MK-1084; Fluorouracil; Leucovorin; MK-1084; MK-1084 + Pembrolizumab; Oxaliplatin; Pembrolizumab; Pemetrexed	antimetabolite; fluoropyrimidine; KRAS_G12C_inhibitor; folinic_acid; KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody; Fluorouracil; anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent; anti-EGFR_monoclonal_antibody; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent	Carboplatin + MK-1084 + Pembrolizumab + Pemetrexed; Cetuximab + Fluorouracil + Leucovorin + MK-1084 + Oxaliplatin; Cetuximab + MK-1084; MK-1084; MK-1084 + Pembrolizumab	KRAS_G12C_inhibitor; KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody; KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; Fluorouracil	MK-1084-001  1084-001	A Phase 1, Open-label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and as Part of Various Combination Therapies in Participants With KRAS G12C Mutant Advanced Solid Tumors	Advanced Solid Tumors	Canterbury; 2145 - Westmead; 3168 - Clayton; 2050 - Camperdown; 2170 - Liverpool	https://clinicaltrials.gov/ct2/show/NCT05067283
NCT05073484	BAT-6021-002-CR	Phase 1		NSW, VIC	2021-10-11	2021-10-29		BAT6021	anti-TIGIT_monoclonal_antibody	BAT6021	anti-TIGIT_monoclonal_antibody	BAT-6021-002-CR	A Phase 1, Multi-Center, Open-Label Study to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BAT6021 as Mono Therapy or in Combination With BAT1308 in Patients With Advanced Solid Tumors	Advanced Solid Tumor	- Sydney; - Liverpool; - Melbourne	https://clinicaltrials.gov/ct2/show/NCT05073484
NCT05075577	EPI-7386-CS-010	Phase 1		ACT, NSW, VIC	2021-10-13	2021-12-21		EPI-7386; EPI-7386 + Enzalutamide; Enzalutamide	antiandrogen,AR_NTD_inhibitor + antiandrogen,nonsteroidal,second_generation; antiandrogen,nonsteroidal,second_generation; antiandrogen,AR_NTD_inhibitor	EPI-7386 + Enzalutamide; Enzalutamide	antiandrogen,AR_NTD_inhibitor + antiandrogen,nonsteroidal,second_generation; antiandrogen,nonsteroidal,second_generation	EPI-7386-CS-010	A Phase 1/2 Study of EPI-7386 in Combination with Enzalutamide Compared with Enzalutamide Alone in Subjects with Metastatic Castration-Resistant Prostate Cancer	Prostate Cancer	2605 - Garran; 2050 - Camperdown; 2010 - Darlinghurst; 3128 - Box Hill	https://clinicaltrials.gov/ct2/show/NCT05075577
NCT05081609	IL-Believe	Phase 1		NSW, QLD, SA, VIC	2021-10-18	2022-01-11		Pembrolizumab; TransCon TLR7/8 agonist; Trastuzumab; Trastuzumab Emtansine	anti-ERBB2_monoclonal_antibody; anti-PD-1_monoclonal_antibody; TLR7/TLR8_agonist; anti-ERBB2_antibody-drug_conjugate	Pembrolizumab; TransCon TLR7/8 agonist; Trastuzumab; Trastuzumab Emtansine	TLR7/TLR8_agonist; anti-ERBB2_antibody-drug_conjugate; anti-ERBB2_monoclonal_antibody; anti-PD-1_monoclonal_antibody	ASND0029	IL Believe: A Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study to Investigate the Safety and Tolerability of TransCon IL-2 ß/? Alone or in Combination With Pembrolizumab, TransCon TLR7/8 Agonist, or Other Anticancer Therapies, in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies	Third Line or Later (3L+) HER2+ Breast Cancer; Advanced Solid Tumor; Neoadjuvant Melanoma; Post Anti-PD-1 Melanoma; Second or Third Line (2L/3L) Cervical Cancer; Locally Advanced Solid Tumor; 2L+ Cervical Cancer 0 0; Post Anti-PD-(L)1 Small Cell Lung Cancer; Post Anti-PD-(L)1 Non-Small Cell Lung Cancer; Metastatic Solid Tumor; Platinum-resistant Ovarian Cancer; Third-line or Later (3L+) Platinum-resistant Ovarian Cancer (PROC); Neoadjuvant Non-Small Cell Lung Cancer	5000 - Adelaide; 4215 - Southport; 5042 - Adelaide; 04120 - Brisbane; 05065 - Toorak Gardens; 3199 - Frankston; 2298 - Waratah	https://clinicaltrials.gov/ct2/show/NCT05081609
NCT05082545	SHR-2002-I-102--SHR-2002-102	Phase 1			2021-10-19	2021-11-23		SHR-1316; SHR-2002	bispecific_CD112R/TIGIT_antibody; anti-PD-L1_monoclonal_antibody	SHR-1316; SHR-2002	anti-PD-L1_monoclonal_antibody; bispecific_CD112R/TIGIT_antibody	SHR-2002-I-102  SHR-2002-102	A Phase I Clinical Study on the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SHR-2002 Injection in Combination With SHR-1316 in Patients With Advanced Malignant Tumors	Advanced Malignant Tumors		https://clinicaltrials.gov/ct2/show/NCT05082545
NCT05084859	SM08502-ONC-03	Phase 1		NSW, QLD, SA	2021-10-20	2021-11-03		Abiraterone; Abiraterone + Prednisone + SM08502; Docetaxel; Docetaxel + SM08502; Panitumumab; Panitumumab + SM08502; Prednisone; SM08502	CLK_inhibitor + CYP17A1_inhibitor + glucocorticoid; CYP17A1_inhibitor; CLK_inhibitor + anti-EGFR_monoclonal_antibody; taxane; CLK_inhibitor; glucocorticoid; anti-EGFR_monoclonal_antibody; CLK_inhibitor + taxane	Abiraterone + Prednisone + SM08502; Docetaxel + SM08502; Panitumumab + SM08502	CLK_inhibitor + CYP17A1_inhibitor + glucocorticoid; CLK_inhibitor + anti-EGFR_monoclonal_antibody; CLK_inhibitor + taxane	SM08502-ONC-03	A Phase 1b, Open-Label, Dose-Escalation, Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors	Castration-resistant Prostate Cancer; Colorectal Cancer; Non-small Cell Lung Cancer	5011 - Woodville South; 2050 - Camperdown; 2010 - Darlinghurst; 4215 - South Brisbane	https://clinicaltrials.gov/ct2/show/NCT05084859
NCT05086692	ABILITY-1	Phase 1		NSW, QLD	2021-10-21	2021-08-27		MDNA11; Pembrolizumab	anti-PD-1_monoclonal_antibody; IL-2_superkine	MDNA11; Pembrolizumab	IL-2_superkine; anti-PD-1_monoclonal_antibody	KEYNOTE-E53  MDNA11-01	A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination With Immune Checkpoint Inhibitor in Patients With Advanced Solid Tumors	Cutaneous Squamous Cell Carcinoma; MSI-H Solid Malignant Tumor; Cancer With A High Tumor Mutational Burden; MSI-H Cancer; Fallopian Tube Cancer; Gastroesophageal Junction (GEJ) Cancer; Merkel Cell Carcinoma; Epithelial Ovarian Carcinoma; Solid Tumor, Adult; Mucosal Melanoma; Endometrial Carcinoma; Cervical Cancers; Squamous Cell Carcinoma of Head and Neck; Basal Cell Carcinoma; Non-Small Cell Lung Cancer Squamous; Advanced Solid Tumor; Viral Cancer; Unresectable Solid Tumor; Skin Cancer; Ovarian Cancer; Acral Melanoma; DMMR Cancer; Pancreas Adenocarcinoma (MSI-H); Solid Tumor; Clear Cell Renal Cell Carcinoma; Endometrial Cancer; Triple Negative Breast Cancer; Pleural Mesothelioma; DMMR Solid Malignant Tumor; Colorectal Cancer (MSI-H); Bladder Cancer; Non-Small Cell Lung Cancer Non-squamous; Esophageal Cancer; Primary Peritoneal Cancer; Gastric Cancer; Cervical Cancer; Cutaneous Melanoma	2109 - Sydney; 2031 - Randwick; 4120 - Greenslopes; 4556 - Buderim	https://clinicaltrials.gov/ct2/show/NCT05086692
NCT05092360	ARTISTRY-7	Phase 3		ACT, NSW, QLD, SA, VIC	2021-10-25	2022-01-10		Gemcitabine; Gemcitabine + Paclitaxel + Pegylated liposomal doxorubicin + Topotecan; Nemvaleukin alfa; Paclitaxel; Pegylated liposomal doxorubicin; Pembrolizumab; Topotecan	antimetabolite; topoisomerase_inhibitor; anthracycline; IL-2_fusion_protein; anti-PD-1_monoclonal_antibody; taxane; gemcitabine; anthracycline + antimetabolite + taxane + topoisomerase_inhibitor	Gemcitabine + Paclitaxel + Pegylated liposomal doxorubicin + Topotecan; Pembrolizumab; Nemvaleukin alfa	anthracycline + antimetabolite + taxane + topoisomerase_inhibitor; anti-PD-1_monoclonal_antibody; IL-2_fusion_protein; gemcitabine	GOG-3063  ALKS 4230-007	A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARTISTRY-7)	Primary Peritoneal Cancer; Platinum-resistant Ovarian Cancer; Fallopian Tube Cancer	4066 - South Brisbane; 2500 - Wollongong; 5000 - Adelaide; 3184 - East Melbourne; 2605 - Garran; 4029 - Brisbane; 2148 - Blacktown	https://clinicaltrials.gov/ct2/show/NCT05092360
NCT05093231	PemOla	Phase 2			2021-10-26			Olaparib; Olaparib + Pembrolizumab; Pembrolizumab	PARP_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; PARP_inhibitor	Olaparib + Pembrolizumab	PARP_inhibitor + anti-PD-1_monoclonal_antibody	PemOla	A Phase II Study Combining Pembrolizumab With Olaparib in Metastatic Pancreatic Adenocarcinoma (PDA) Patients With Mismatch Repair Deficiency or Tumour Mutation Burden > 4 Mutations/Mb	Pancreatic Cancer		https://clinicaltrials.gov/ct2/show/NCT05093231
NCT05094336	MTAPESTRY-101	Phase 1		NSW, VIC	2021-10-26	2022-02-01		AMG 193; AMG 193 + Docetaxel; Docetaxel	PRMT5_inhibitor + taxane; taxane; PRMT5_inhibitor	AMG 193; AMG 193 + Docetaxel	PRMT5_inhibitor; PRMT5_inhibitor + taxane	2023-504363-17  20210023	A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 Alone and in Combination With Docetaxel in Subjects With Advanced MTAP-null Solid Tumors	Advanced MTAP-null Solid Tumors	2050 - Camperdown; 3002 - East Melbourne; 3050 - Parkville	https://clinicaltrials.gov/ct2/show/NCT05094336
NCT05102214	HLX301-001	Phase 1		NSW, QLD, SA, TAS, VIC	2021-11-01	2022-05-03		HLX301	bispecific_PD-L1/TIGIT_antibody	HLX301	bispecific_PD-L1/TIGIT_antibody	HLX301-001	A Phase 1/2 Study of HLX301, A Recombinant Humanized Anti-PDL1 and Anti-TIGIT Bispecific Antibody, in Patients With Locally Advanced or Metastatic Solid Tumors	Non-small Cell Lung Cancer; Locally Advanced or Metastatic Solid Tumors	4575 - Birtinya; - Adelaide; - Camperdown; - Blacktown; - Brighton	https://clinicaltrials.gov/ct2/show/NCT05102214
NCT05109650	BAT-6026-002-CR	Phase 1		NSW	2021-11-05	2021-11-15		BAT6026	anti-OX40_agonistic_antibody	BAT6026	anti-OX40_agonistic_antibody	BAT-6026-002-CR	A Phase 1, Multi-Center, Open-Label Study to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BAT6026 as Monotherapy and in Combination With BAT1308 in Patients With Advanced Solid Tumours	Advanced Solid Tumour	- Kogarah; - Sydney	https://clinicaltrials.gov/ct2/show/NCT05109650
NCT05111626	FORTITUDE-102	Phase 3		NSW, SA, VIC	2021-11-08	2022-03-14		Bemarituzumab; Bemarituzumab + Nivolumab; Nivolumab; Placebo	placebo; anti-FGFR2b_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-FGFR2b_monoclonal_antibody; anti-PD-1_monoclonal_antibody	Bemarituzumab + Nivolumab; Nivolumab; Placebo	anti-FGFR2b_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; placebo	2023-505458-16  20210098	A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression	Gastric Cancer; Gastroesophageal Junction Adenocarcinoma	3084 - Heidelberg; 3350 - Ballarat; 5011 - Woodville South; 2298 - Waratah; 2065 - St Leonards	https://clinicaltrials.gov/ct2/show/NCT05111626
NCT05116189	MK-3475-B96--3475-B96	Phase 3		NSW, NZ, QLD, VIC, WA	2021-11-10	2021-12-13		Bevacizumab; Bevacizumab + Docetaxel + Paclitaxel; Bevacizumab + Docetaxel + Paclitaxel + Pembrolizumab; Docetaxel; Paclitaxel; Pembrolizumab; Placebo	placebo; anti-VEGF_monoclonal_antibody + taxane; anti-PD-1_monoclonal_antibody; taxane; anti-PD-1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + taxane; anti-VEGF_monoclonal_antibody	Bevacizumab + Docetaxel + Paclitaxel; Bevacizumab + Docetaxel + Paclitaxel + Pembrolizumab; Placebo	anti-PD-1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + taxane; anti-VEGF_monoclonal_antibody + taxane; placebo	MK-3475-B96  3475-B96	A Phase 3, Randomized, Double-Blind Study of Pembrolizumab Versus Placebo in Combination With Paclitaxel With or Without Bevacizumab for the Treatment of Platinum-resistant Recurrent Ovarian Cancer (KEYNOTE-B96/ENGOT-ov65)	Fallopian Tube Neoplasms; Carcinoma, Ovarian Epithelial; Ovarian Cancer	Auckland; 2145 - Westmead; 6008 - Subiaco; 4120 - Brisbane; 3002 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT05116189
NCT05116202	BO43328	Phase 1	_PAUSED	NSW, WA	2021-11-10	2022-02-02		Atezolizumab; Atezolizumab + Tiragolumab; Ipilimumab; Ipilimumab + Nivolumab; Nivolumab; RO7247669; RO7247669 + Tiragolumab; Tiragolumab	anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-TIGIT_monoclonal_antibody + bispecific_PD-1/LAG3_antibody; anti-TIGIT_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; bispecific_PD-1/LAG3_antibody; anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA4_monoclonal_antibody	Atezolizumab + Tiragolumab; Ipilimumab + Nivolumab; RO7247669; RO7247669 + Tiragolumab	anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-TIGIT_monoclonal_antibody + bispecific_PD-1/LAG3_antibody; bispecific_PD-1/LAG3_antibody	BO43328	A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)	Melanoma	2060 - North Sydney; 6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT05116202
NCT05117476	CLN-619-001	Phase 1		VIC, WA	2021-11-11	2021-10-29		CLN-619; CLN-619 + Pembrolizumab; Pembrolizumab	anti-MICA/MICB_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-MICA/MICB_monoclonal_antibody; anti-PD-1_monoclonal_antibody	CLN-619; CLN-619 + Pembrolizumab	anti-MICA/MICB_monoclonal_antibody; anti-MICA/MICB_monoclonal_antibody + anti-PD-1_monoclonal_antibody	CLN-619-001	A Phase 1 Dose-Escalation Study to Investigate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamic Activity of CLN-619 (Anti-MICA/MICB Antibody) Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors	Advanced Solid Tumor	3168 - Clayton; 3004 - Melbourne; 6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT05117476
NCT05118789	NVL-520-01	Phase 1		NSW, VIC	2021-11-12	2022-01-04		Tegafur-gimeracil-oteracil potassium; Zidesamtinib	antimetabolite; ROS1_inhibitor; orotate_phosphoribosyltransferase_inhibitor; DPD_inhibitor	Zidesamtinib; Tegafur-gimeracil-oteracil potassium	ROS1_inhibitor; DPD_inhibitor; antimetabolite; orotate_phosphoribosyltransferase_inhibitor	NVL-520-01	A Phase 1/2 Study of the Highly Selective ROS1 Inhibitor NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors (ARROS-1)	Locally Advanced Solid Tumor; Metastatic Solid Tumor	3000 - Melbourne; 2050 - Camperdown	https://clinicaltrials.gov/ct2/show/NCT05118789
NCT05123482	2022-502759-70-01--D6900C00001	Phase 1		QLD, VIC, WA	2021-11-17	2021-10-18		Puxitatug samrotecan; Puxitatug samrotecan + Rilvegostomig; Puxitatug samrotecan + Rilvegostomig + Saruparib; Rilvegostomig; Saruparib	anti-B7H4_antibody-drug_conjugate + bispecific_PD-1/TIGIT_antibody; PARP1-selective_inhibitor; anti-B7H4_antibody-drug_conjugate; bispecific_PD-1/TIGIT_antibody; PARP1-selective_inhibitor + anti-B7H4_antibody-drug_conjugate + bispecific_PD-1/TIGIT_antibody	Puxitatug samrotecan; Puxitatug samrotecan + Rilvegostomig; Puxitatug samrotecan + Rilvegostomig + Saruparib	PARP1-selective_inhibitor + anti-B7H4_antibody-drug_conjugate + bispecific_PD-1/TIGIT_antibody; anti-B7H4_antibody-drug_conjugate; anti-B7H4_antibody-drug_conjugate + bispecific_PD-1/TIGIT_antibody	2022-502759-70-01  D6900C00001	A Phase I/IIa Multi-center, Open-label Master Protocol Dose Escalation and Expansion Study of AZD8205 as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors (BLUESTAR)	Ovarian Cancer; Breast Cancer; Squamous Non-Small Cell Lung Cancer; Biliary Tract Carcinoma; Endometrial Cancer	3168 - Clayton; 4101 - South Brisbane; VIC 3000 - Melbourne; 6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT05123482
NCT05128825	DENALI	Phase 2		QLD, SA, VIC, WA	2021-11-22	2022-02-17		Azenosertib	WEE1_inhibitor	Azenosertib	WEE1_inhibitor	ZN-c3-005	A Phase 2 Open-Label, Multicenter Study To Evaluate Efficacy And Safety Of ZN-c3 In Subjects With High-Grade Serous Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer (DENALI / ZN-c3-005 / GOG-3066)	High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer; Fallopian tube carcinoma	5037 - Adelaide; 4032 - Brisbane; 6008 - Subiaco; 5065 - Toorak Gardens; 4101 - South Brisbane; 3021 - Footscray; 6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT05128825
NCT05129280	2021-000624-35--BE43244	Phase 1		VIC	2021-11-22	2022-01-25		RO7444973; Tocilizumab	bispecific_T-cell_engager,MAGE-A4-targeting; anti-IL-6_monoclonal_antibody	RO7444973; Tocilizumab	bispecific_T-cell_engager,MAGE-A4-targeting; anti-IL-6_monoclonal_antibody	2021-000624-35  BE43244	An Open-label, Multicenter, Phase I Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-tumor Activity of RO7444973 in Participants With Unresectable and/or Metastatic MAGE-A4-positive Solid Tumors	Solid Tumors	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT05129280
NCT05132075	KontRASt-02	Phase 3		QLD	2021-11-24	2022-06-15		Docetaxel; JDQ443	KRAS_G12C_inhibitor; taxane	Docetaxel; JDQ443	KRAS_G12C_inhibitor; taxane	2021-002605-10  CJDQ443B12301	A Randomized, Controlled, Open Label, Phase III Study Evaluating the Efficacy and Safety of JDQ443 Versus Docetaxel in Previously Treated Subjects With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer	Non-Small Cell Lung Cancer	4066 - Auchenflower; 4101 - South Brisbane	https://clinicaltrials.gov/ct2/show/NCT05132075
NCT05132582	HER2CLIMB-05	Phase 3		NSW, SA, VIC, WA, WashingtonWA	2021-11-24	2022-03-07		Pertuzumab; Pertuzumab + Trastuzumab; Pertuzumab + Trastuzumab + Tucatinib; Placebo; Trastuzumab; Tucatinib	placebo; anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor; anti-ERBB2_monoclonal_antibody; anti-ERBB2_monoclonal_antibody,dimerization_inhibitor; ERBB2_inhibitor,third_generation + anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor; ERBB2_inhibitor,third_generation	Pertuzumab + Trastuzumab; Pertuzumab + Trastuzumab + Tucatinib; Placebo	ERBB2_inhibitor,third_generation + anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor; anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor; placebo	C4251007  SGNTUC-028	A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05)	HER2 Positive Breast Cancer	3084 - Heidelberg; 5000 - Adelaide; 2050 - Camperdown; 2109 - Sydney; 3128 - Box Hill; 5042 - Bedford Park; 2146 - Old Tonggabbie; 2109 - Macquarie University; 2145 - Westmead; 2145 - Sydney; 6008 - Subiaco	https://clinicaltrials.gov/ct2/show/NCT05132582
NCT05141149	2024-514379-16-00--PAUF-I	Phase 1		VIC	2021-12-02	2023-06-05		Gemcitabine	antimetabolite; gemcitabine	Gemcitabine	antimetabolite; gemcitabine	2024-514379-16-00  PAUF-I	A First in Human, Phase 1/2a, Multicentre, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of PBP1510 in Patients With Advanced/Metastatic Pancreatic Cancer	Pancreatic Cancer	- Melbourne	https://clinicaltrials.gov/ct2/show/NCT05141149
NCT05142189	LuCa-MERIT-1	Phase 1		NSW, SA, VIC	2021-12-02	2022-06-17		Carboplatin; Carboplatin + Cemiplimab + Paclitaxel; Cemiplimab; Docetaxel; Paclitaxel	anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; anti-PD-1_monoclonal_antibody; taxane; platinum-based_antineoplastic_agent	Carboplatin + Cemiplimab + Paclitaxel; Cemiplimab; Docetaxel	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; taxane	2021-004739-94  BNT116-01	LuCa-MERIT-1: First-in-human, Open Label, Phase I Dose Confirmation Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer	Non-Small Cell Lung Cancer	5000 - Adelaide; 2031 - Randwick; 3168 - Clayton	https://clinicaltrials.gov/ct2/show/NCT05142189
NCT05150236	ANZUP2001	Phase 2		NSW, QLD, SA, VIC, WA	2021-12-09	2022-04-29		Ipilimumab; Ipilimumab + Lu-177 vipivotide tetraxetan + Nivolumab; Lu-177 vipivotide tetraxetan; Nivolumab	radioconjugate,PSMA-targeting; anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + radioconjugate,PSMA-targeting; anti-PD-1_monoclonal_antibody; anti-CTLA4_monoclonal_antibody	Ipilimumab + Lu-177 vipivotide tetraxetan + Nivolumab; Lu-177 vipivotide tetraxetan	anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + radioconjugate,PSMA-targeting; radioconjugate,PSMA-targeting	ANZUP 2001	Phase II Study of Radionuclide 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With MetastaticCastration Resistant Prostate Cancer (mCRPC)	Prostatic Disease; Prostate Cancer; Neoplasms; Urogenital Neoplasms; Genital Neoplasms, Male; Neoplasms by Site; Prostatic Neoplasms	6009 - Nedlands; 3004 - Melbourne; 2010 - Darlinghurst; 3000 - Melbourne; 4029 - Herston; 3084 - Heidelberg; 5000 - Adelaide; 2298 - Newcastle	https://clinicaltrials.gov/ct2/show/NCT05150236
NCT05150457	BNA035-101	Phase 1		NSW, QLD, VIC	2021-12-09	2022-02-08		BNA35	bispecific_EGFR/4-1BB_antibody	BNA35	bispecific_EGFR/4-1BB_antibody	BNA035-101	A Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BNA035 in Patients With Advanced Solid Tumors	Refractory Solid Tumors	2217 - Kogarah; 4217 - Benowa; 3065 - Fitzroy	https://clinicaltrials.gov/ct2/show/NCT05150457
NCT05150691	DB-1303-O-1001	Phase 1		NSW, QLD, VIC	2021-12-09	2022-01-31		DB-1303; DB-1303 + Itraconazole; DB-1303 + Pertuzumab; DB-1303 + Trastuzumab; Itraconazole; Pertuzumab; Trastuzumab	SMO_inhibitor + anti-ERBB2_antibody-drug_conjugate; SMO_inhibitor; anti-ERBB2_monoclonal_antibody; anti-ERBB2_monoclonal_antibody,dimerization_inhibitor; anti-ERBB2_antibody-drug_conjugate + anti-ERBB2_monoclonal_antibody; anti-ERBB2_antibody-drug_conjugate + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor; anti-ERBB2_antibody-drug_conjugate	DB-1303; DB-1303 + Itraconazole; DB-1303 + Pertuzumab; DB-1303 + Trastuzumab	SMO_inhibitor + anti-ERBB2_antibody-drug_conjugate; anti-ERBB2_antibody-drug_conjugate; anti-ERBB2_antibody-drug_conjugate + anti-ERBB2_monoclonal_antibody; anti-ERBB2_antibody-drug_conjugate + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor	DB-1303-O-1001	A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1303/BNT323 in Patients With Advanced/Metastatic Solid Tumors	HER2-positive Advanced Solid Tumor	3168 - Melbourne; 4101 - South Brisbane; 2031 - Randwick; 2109 - Sydney	https://clinicaltrials.gov/ct2/show/NCT05150691
NCT05152147	HERIZON-GEA-01	Phase 3		NSW, SA, VIC, WA	2021-12-09	2021-12-02		Capecitabine; Capecitabine + Cisplatin + Fluorouracil + Oxaliplatin + Trastuzumab; Cisplatin; Fluorouracil; Oxaliplatin; Tislelizumab; Tislelizumab + Zanidatamab; Trastuzumab; Zanidatamab	Fluorouracil; anti-ERBB2_monoclonal_antibody; fluoropyrimidine; anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + bispecific_ERBB2/ERBB2_antibody; anti-ERBB2_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; bispecific_ERBB2/ERBB2_antibody	Capecitabine + Cisplatin + Fluorouracil + Oxaliplatin + Trastuzumab; Tislelizumab + Zanidatamab; Zanidatamab	anti-ERBB2_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + bispecific_ERBB2/ERBB2_antibody; bispecific_ERBB2/ERBB2_antibody; Fluorouracil	2021-000296-36  ZWI-ZW25-301	A Randomized, Multicenter, Phase 3 Study of Zanidatamab in Combination With Chemotherapy With or Without Tislelizumab in Subjects With HER2-positive Unresectable Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma (GEA)	Gastric Neoplasms; Gastroesophageal Adenocarcinoma; Esophageal Adenocarcinoma	3084 - Heidelberg; 5042 - Bedford Park; 2170 - Liverpool; 6150 - Murdoch	https://clinicaltrials.gov/ct2/show/NCT05152147
NCT05153239	PM1183-C-008-21	Phase 3		NSW, VIC, WA	2021-12-10	2022-07-22		Irinotecan; Irinotecan + Lurbinectedin; Lurbinectedin; Topotecan	topoisomerase_inhibitor; DNA_minor_groove-binding_agent; DNA_minor_groove-binding_agent + topoisomerase_inhibitor	Irinotecan + Lurbinectedin; Lurbinectedin; Topotecan	DNA_minor_groove-binding_agent; DNA_minor_groove-binding_agent + topoisomerase_inhibitor	PM1183-C-008-21	A Randomized, Multicenter, Open-label, Phase III Study of Lurbinectedin Single-Agent or Lurbinectedin in Combination With Irinotecan Versus Investigator's Choice (Topotecan or Irinotecan) in Relapsed Small Cell Lung Cancer Patients (LAGOON Trial)	Relapsed Small Cell Lung Cancer	2250 - Gosford; NSW 2500 - Wollongong; VIC 3084 - Heidelberg; NSW 2086 - Frenchs Forest; 3350 - Ballarat Central; 3128 - Box Hill; 2050 - Camperdown; WA 6150 - Murdoch	https://clinicaltrials.gov/ct2/show/NCT05153239
NCT05155332	2020-003902-30--1456-0001	Phase 1		SA, VIC	2021-12-13	2022-03-28		VSV-GP	oncolytic_virus	VSV-GP	oncolytic_virus	2020-003902-30  1456-0001	Phase I Open-label, Dose Escalation Trial of BI 1831169 Monotherapy and in Combination With an Anti-PD-1 mAb in Patients With Advanced or Metastatic Solid Tumors	Solid Tumors	5062 - Bedford Park; 3199 - Frankston	https://clinicaltrials.gov/ct2/show/NCT05155332
NCT05156892	TICTOC	Phase 1		NSW	2021-12-14	2022-09-04		Itraconazole; Itraconazole + Tamoxifen; Tamoxifen	selective_estrogen_receptor_modulator; SMO_inhibitor; SMO_inhibitor + selective_estrogen_receptor_modulator	Itraconazole + Tamoxifen	SMO_inhibitor + selective_estrogen_receptor_modulator	TICTOC	A Phase I/II Trial Investigating the Tolerability, Toxicity and Efficacy of Tamoxifen and SUBA-Itraconazole in Patients With Platinum Resistant Recurrent Epithelial Ovarian Cancer	Ovarian Cancer	2010 - Sydney	https://clinicaltrials.gov/ct2/show/NCT05156892
NCT05159388	2019-003456-36--CL1-95012-001	Phase 1		NSW, SA, VIC	2021-12-16	2021-09-08		Dexamethasone; PRS-344	glucocorticoid; bispecific_PD-L1/4-1BB_antibody	PRS-344; Dexamethasone	bispecific_PD-L1/4-1BB_antibody; glucocorticoid	2019-003456-36  CL1-95012-001	A First in Human Phase 1-2 Open-Label, Multicenter, Dose Escalation and Expansion Study of PRS-344/S095012 in Patients With Solid Tumors	Solid Tumor	- Malvern; - Camperdown; - Woodville South	https://clinicaltrials.gov/ct2/show/NCT05159388
NCT05163223	Cornerstone001	Phase 2			2021-12-20	2022-02-28		AST-301	vaccine_therapy,pNGVL3-based,ERBB2-targeting	AST-301	vaccine_therapy,pNGVL3-based,ERBB2-targeting	PN-301-21	A Phase 2 Study to Evaluate the Efficacy and Safety of an Adjuvant Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With HER2 Low Breast Cancer (Cornerstone-001)	Breast Cancer		https://clinicaltrials.gov/ct2/show/NCT05163223
NCT05166577	VT3996-301	Phase 1		NSW	2021-12-22	2021-10-08		Nanatinostat; Nanatinostat + Pembrolizumab; Pembrolizumab	HDAC_inhibitor,class_1_selective + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; HDAC_inhibitor,class_1_selective	Nanatinostat; Nanatinostat + Pembrolizumab	HDAC_inhibitor,class_1_selective; HDAC_inhibitor,class_1_selective + anti-PD-1_monoclonal_antibody	VT3996-301	An Open-Label, Multicenter Phase 1b/2 Study of Nanatinostat and Valganciclovir in Patients With Advanced Epstein-Barr Virus-Positive (EBV+) Solid Tumors and in Combination With Pembrolizumab in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma	EBV-Related Leiomyosarcoma; Nasopharyngeal Carcinoma; EBV Related Carcinoma; EBV-Related Sarcoma; EBV-Related Gastric Carcinoma	- Blacktown	https://clinicaltrials.gov/ct2/show/NCT05166577
NCT05169697	YH002004	Phase 1		NSW, VIC	2021-12-27	2022-02-21		YH001; YH001 + YH002; YH002	anti-CTLA4_monoclonal_antibody + anti-OX40_agonistic_antibody; anti-OX40_agonistic_antibody; anti-CTLA4_monoclonal_antibody	YH001 + YH002	anti-CTLA4_monoclonal_antibody + anti-OX40_agonistic_antibody	YH002004	A Multicenter, Open-label, Phase I Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of YH002 in Combination with YH001 in Subjects with Advanced Solid Tumors	Advanced Solid Tumor	2800 - Orange; 3144 - Malvern; 3199 - Frankston; 2109 - Sydney	https://clinicaltrials.gov/ct2/show/NCT05169697
NCT05173987	MK-3475-C93--3475-C93	Phase 3		NSW, NZ, QLD, VIC, WA	2021-12-30	2022-02-03		Carboplatin; Carboplatin + Cisplatin + Docetaxel + Paclitaxel; Cisplatin; Docetaxel; Paclitaxel; Pembrolizumab	platinum-based_antineoplastic_agent + taxane; anti-PD-1_monoclonal_antibody; taxane; platinum-based_antineoplastic_agent	Carboplatin + Cisplatin + Docetaxel + Paclitaxel; Pembrolizumab	anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent + taxane	MK-3475-C93  3475-C93	A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab Versus Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma in the First-line Setting (KEYNOTE-C93/GOG-3064/ENGOT-en15)	Endometrial Neoplasms	2145 - Westmead; 4029 - Brisbane; Auckland; 6008 - Subiaco; 2065 - St Leonards; 3168 - Clayton; 3000 - Melbourne; 3002 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT05173987
NCT05176483	STELLAR-002	Phase 1		NSW, NZ, QLD	2022-01-04	2021-12-14		Ipilimumab; Ipilimumab + Nivolumab + Zanzalintinib; Nivolumab; Nivolumab + Relatlimab + Zanzalintinib; Nivolumab + Zanzalintinib; Relatlimab; Zanzalintinib	anti-LAG3_monoclonal_antibody; MET/VEGFR2/AXL/MER_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; MET/VEGFR2/AXL/MER_inhibitor + anti-PD-1_monoclonal_antibody; MET/VEGFR2/AXL/MER_inhibitor + anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; MET/VEGFR2/AXL/MER_inhibitor; anti-CTLA4_monoclonal_antibody	Ipilimumab + Nivolumab + Zanzalintinib; Nivolumab + Relatlimab + Zanzalintinib; Nivolumab + Zanzalintinib; Zanzalintinib	MET/VEGFR2/AXL/MER_inhibitor; MET/VEGFR2/AXL/MER_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; MET/VEGFR2/AXL/MER_inhibitor + anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; MET/VEGFR2/AXL/MER_inhibitor + anti-PD-1_monoclonal_antibody	2023-510061-10-00  XL092-002	A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination With Immuno-Oncology Agents in Subjects With Unresectable Advanced or Metastatic Solid Tumors	Renal Cell Carcinoma; Head and Neck Squamous Cell Carcinoma; Urothelial Carcinoma; Solid Tumor; Colorectal Cancer; Hepatocellular Carcinoma; Non-small Cell Lung Cancer; Metastatic Castration-resistant Prostate Cancer	Hamilton; 4102 - Brisbane; 2640 - Albury; 2065 - Saint Leonards; 4575 - Birtinya; 2109 - Sydney	https://clinicaltrials.gov/ct2/show/NCT05176483
NCT05180799	BA3071-001	Phase 1		NSW, SA	2022-01-06	2022-08-03		BA3071; Nivolumab; Pembrolizumab; Pemetrexed	antimetabolite; anti-PD-1_monoclonal_antibody; anti-CTLA4_monoclonal_antibody	BA3071; Nivolumab; Pembrolizumab; Pemetrexed	anti-CTLA4_monoclonal_antibody; anti-PD-1_monoclonal_antibody; antimetabolite	BA3071-001	A Phase 1/2 Study of BA3071 in Patients With Solid Tumors	Melanoma; NSCLC	2228 - Miranda; 5000 - Adelaide; 2640 - Albury	https://clinicaltrials.gov/ct2/show/NCT05180799
NCT05182931	I-FIRST	Phase 2		NSW, QLD, SA, VIC, WA	2022-01-10	2022-07-14		Dabrafenib; Trametinib	BRAF_V600_inhibitor; MEK_inhibitor	Dabrafenib; Trametinib	BRAF_V600_inhibitor; MEK_inhibitor	ONJ2021-006	A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (I-FIRST Study)	Thyroid Cancer	3128 - Box Hill; - Adelaide; - Perth; 3084 - Heidelberg; - Prahran; - Melbourne; 3168 - Clayton; 4029 - Brisbane; - Sydney	https://clinicaltrials.gov/ct2/show/NCT05182931
NCT05186974	EVOKE-02	Phase 2		NSW, QLD, SA, VIC, WA	2022-01-11	2022-05-30		Carboplatin; Carboplatin + Cisplatin + Pembrolizumab; Carboplatin + Pembrolizumab; Cisplatin; Cisplatin + Pembrolizumab; Pembrolizumab; Pembrolizumab + Sacituzumab Govitecan; Sacituzumab Govitecan	anti-Trop2_antibody-drug_conjugate; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent	Carboplatin + Cisplatin + Pembrolizumab; Carboplatin + Pembrolizumab; Cisplatin + Pembrolizumab; Pembrolizumab; Pembrolizumab + Sacituzumab Govitecan	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent	2021-004280-27  GS-US-576-6220	An Open-label, Multicenter, Phase 2 Study of Sacituzumab Govitecan Combinations in First-line Treatment of Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) Without Actionable Genomic Alterations	Non-small Cell Lung Cancer	3021 - Melbourne; 5042 - Bedford Park; 4575 - Birtinya; 2010 - Darlinghurst; 5087 - Windsor Gardens; 2576 - Bowral; 3199 - Frankston; 2217 - Kogarah; 6027 - Joondalup; 4217 - Benowa	https://clinicaltrials.gov/ct2/show/NCT05186974
NCT05188664	LM302-01-201	Phase 1		VIC	2022-01-12	2022-05-10		LM-302; LM-302 + Toripalimab; Toripalimab	anti-CDLN18.2_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-CDLN18.2_antibody-drug_conjugate	LM-302; LM-302 + Toripalimab	anti-CDLN18.2_antibody-drug_conjugate; anti-CDLN18.2_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody	LM302-01-201	A Phase I/II, Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of LM- 302 in Combination With Toripalimab in Patients With Advanced Solid Tumors	Advanced Solid Tumor	- Melbourne	https://clinicaltrials.gov/ct2/show/NCT05188664
NCT05198752	SWP1001-06	Phase 1		QLD, VIC	2022-01-20	2022-03-18		SW1115C3	mRNA_personalised_cancer_vaccine	SW1115C3	mRNA_personalised_cancer_vaccine	SWP1001-06	A Phase 1 Clinical Study to Evaluate the Tolerability, Safety,Immunogenicity and Efficacy of the Neoantigen mRNA Personalised Cancer Vaccine SW1115C3 in Patients With Advanced Malignant Solid Tumours	Solid Tumor	- Frankston; - Benowa	https://clinicaltrials.gov/ct2/show/NCT05198752
NCT05198934	CodeBreak300	Phase 3		NSW, SA	2022-01-20	2022-04-19		Panitumumab; Panitumumab + Sotorasib; Regorafenib; Sotorasib	KIT/PDGFR/RET/VEGFR/FGFR_inhibitor; KRAS_G12C_inhibitor; anti-EGFR_monoclonal_antibody; KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody	Panitumumab + Sotorasib; Regorafenib	KIT/PDGFR/RET/VEGFR/FGFR_inhibitor; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody; KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody	2024-511187-81-00  20190172	A Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib and Panitumumab Versus Investigator's Choice (Trifluridine and Tipiracil, or Regorafenib) for the Treatment of Previously Treated Metastatic Colorectal Cancer Subjects With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation	Colorectal Cancer (CRC)	2145 - Westmead; 2065 - St Leonards; 2050 - Camperdown; 5011 - Woodville South	https://clinicaltrials.gov/ct2/show/NCT05198934
NCT05199753	LM108-01-101	Phase 1		NSW, QLD, VIC, WA	2022-01-20	2022-03-16		Cafelkibart	anti-CCR8_monoclonal_antibody	Cafelkibart	anti-CCR8_monoclonal_antibody	LM108-01-101	A Phase I/II, First-in-Human (FIH), Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LM-108 as a Single Agent or in Combination With Anti-PD-1 Antibody in Subjects With Advanced Solid Tumours	Advanced Solid Tumor	VIC 3144 - Malvern; QLD 4575 - Birtinya; QLD 4101 - South Brisbane; WA 6009 - Nedlands; VIC 3004 - Melbourne; NSW 2148 - Sydney	https://clinicaltrials.gov/ct2/show/NCT05199753
NCT05200013	BAT-7104-002-CR	Phase 1		NSW, WA	2022-01-20	2022-04-29		BAT7104	bispecific_PD-L1/CD47_antibody	BAT7104	bispecific_PD-L1/CD47_antibody	BAT-7104-002-CR	A Phase 1, Multi-Center, Open-Label Study to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BAT7104 in Patients With Advanced Solid Tumours	Patients With Advanced Solid Tumors	- Nedlands; 2109 - Sydney	https://clinicaltrials.gov/ct2/show/NCT05200013
NCT05200273	AK114-102	Phase 1		SA	2022-01-20			AK114	anti-IL-1beta_monoclonal_antibody	AK114	anti-IL-1beta_monoclonal_antibody	AK114-102	A Phase 1a, Multicenter, Open-label, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK114 in Subjects With Advanced or Metastatic Solid Tumors	Metastasis; Malignancy; Advanced or Metastatic Solid Tumors	- Kurralta Park	https://clinicaltrials.gov/ct2/show/NCT05200273
NCT05201547	DOMENICA	Phase 3		ACT, NSW, NZ	2022-01-21	2022-04-15		Carboplatin; Carboplatin + Paclitaxel; Dostarlimab; Paclitaxel	platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent + taxane; anti-PD-1_monoclonal_antibody; taxane	Carboplatin + Paclitaxel; Dostarlimab	anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent + taxane	GINECO-EN105b	Randomized Phase III Trial in MMR Deficient Endometrial Cancer Patients Comparing Chemotherapy Alone Versus Dostarlimab in First Line Advanced/Metastatic Setting	Endometrial Cancer	2605 - Garran; Auckland; 2298 - Waratah	https://clinicaltrials.gov/ct2/show/NCT05201547
NCT05205109	KEYNOTE-E73--ATG-037-001	Phase 1		NSW, QLD, SA, VIC, WA	2022-01-24	2022-06-07		ATG 037; ATG 037 + Pembrolizumab; Pembrolizumab	CD73_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; CD73_inhibitor	ATG 037 + Pembrolizumab	CD73_inhibitor + anti-PD-1_monoclonal_antibody	KEYNOTE-E73  ATG-037-001	A Phase I/Ib, Multi-center, Open-label, and Dose-finding Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ATG-037 Monotherapy and Combination Therapy With Pembrolizumab in Patients With Locally Advanced or Metastatic Solid Tumors	Locally Advanced or Metastatic Solid Tumors	5042 - Bedford Park; WA6153 - Mount Pleasant; 3199 - Frankston; 4217 - Benowa; 2298 - Sydney	https://clinicaltrials.gov/ct2/show/NCT05205109
NCT05208047	CGT9486-21-301	Phase 3		NSW, WA	2022-01-26	2022-04-14		Bezuclastinib; Bezuclastinib + Midazolam + Sunitinib; Bezuclastinib + Sunitinib; Midazolam; Sunitinib	KIT_D816V_inhibitor + PDGFR_inhibitor; KIT_inhibitor,type_1 + VEGFR_inhibitor; KIT_D816V_inhibitor + KIT_inhibitor,first_generation; KIT_D816V_inhibitor; KIT_inhibitor,type_1 + PDGFR_inhibitor; KIT_inhibitor,first_generation; benzodiazepam; PDGFR_inhibitor; KIT_D816V_inhibitor + KIT_inhibitor,first_generation + benzodiazepam; VEGFR_inhibitor; KIT_inhibitor,type_1; KIT_inhibitor,first_generation + KIT_inhibitor,type_1; KIT_D816V_inhibitor + VEGFR_inhibitor; KIT_inhibitor,first_generation + KIT_inhibitor,type_1 + benzodiazepam; KIT_inhibitor,type_1 + VEGFR_inhibitor + benzodiazepam; KIT_D816V_inhibitor + VEGFR_inhibitor + benzodiazepam; KIT_D816V_inhibitor + PDGFR_inhibitor + benzodiazepam; KIT_inhibitor,type_1 + PDGFR_inhibitor + benzodiazepam	Bezuclastinib + Midazolam + Sunitinib; Bezuclastinib + Sunitinib; Sunitinib	KIT_D816V_inhibitor + KIT_inhibitor,first_generation; KIT_D816V_inhibitor + KIT_inhibitor,first_generation + benzodiazepam; KIT_D816V_inhibitor + PDGFR_inhibitor; KIT_D816V_inhibitor + PDGFR_inhibitor + benzodiazepam; KIT_D816V_inhibitor + VEGFR_inhibitor; KIT_D816V_inhibitor + VEGFR_inhibitor + benzodiazepam; KIT_inhibitor,first_generation; KIT_inhibitor,first_generation + KIT_inhibitor,type_1; KIT_inhibitor,first_generation + KIT_inhibitor,type_1 + benzodiazepam; KIT_inhibitor,type_1 + PDGFR_inhibitor; KIT_inhibitor,type_1 + PDGFR_inhibitor + benzodiazepam; KIT_inhibitor,type_1 + VEGFR_inhibitor; KIT_inhibitor,type_1 + VEGFR_inhibitor + benzodiazepam; PDGFR_inhibitor; VEGFR_inhibitor	CGT9486-21-301	A Phase 3 Randomized, Open-Label, Multicenter Clinical Study of CGT9486+Sunitinib vs. Sunitinib in Subjects With Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumors	Metastatic Cancer; Advanced Gastrointestinal Stromal Tumors	2200 - Bankstown; 6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT05208047
NCT05208944	2023-504595-26-00--THIO-101	Phase 2		QLD, SA, VIC	2022-01-26	2022-06-08		Cemiplimab	anti-PD-1_monoclonal_antibody	Cemiplimab	anti-PD-1_monoclonal_antibody	2023-504595-26-00  THIO-101	A Multicenter, Open-Label, Dose-Finding, Phase 2 Study Evaluating THIO Sequenced With Cemiplimab (LIBTAYO®) in Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC)	Carcinoma, Non-Small-Cell Lung	4556 - Buderim; 3065 - Fitzroy; 5000 - Adelaide	https://clinicaltrials.gov/ct2/show/NCT05208944
NCT05212922	YH001	Phase 2		NSW, VIC	2022-01-28			Toripalimab; Toripalimab + YH001; YH001	anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-CTLA4_monoclonal_antibody	Toripalimab + YH001	anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	YH001004	An Open-Label, Non-Randomized, Multi-center Phase 2 Study of YH001 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC) and Hepatocellular Carcinoma (HCC)	NSCLC Stage IIIB; HCC; NSCLC Stage IV	3220 - Geelong; 2170 - Liverpool	https://clinicaltrials.gov/ct2/show/NCT05212922
NCT05215340	TROPION-Lung08	Phase 3		NSW, SA, VIC	2022-01-31	2022-03-04		Datopotamab deruxtecan; Datopotamab deruxtecan + Pembrolizumab; Pembrolizumab	anti-Trop2_antibody-drug_conjugate; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate	Datopotamab deruxtecan + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate	2021-002555-10  DS1062-A-U304	A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naïve Subjects With Advanced or Metastatic PD-L1 High (TPS =50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)	Metastatic Non Small Cell Lung Cancer	3084 - Heidelberg; 2050 - Camperdown; 5011 - Woodville South; 3149 - Mount Waverley	https://clinicaltrials.gov/ct2/show/NCT05215340
NCT05216432	RLY-2608-101	Phase 1		NSW, VIC	2022-01-31	2021-12-08		Fulvestrant; Fulvestrant + PF-07220060 + RLY-2608; Fulvestrant + Palbociclib + RLY-2608; Fulvestrant + RLY-2608; Fulvestrant + RLY-2608 + Ribociclib; PF-07220060; Palbociclib; RLY-2608; Ribociclib	PI3K_alpha_inhibitor,allosteric,mutant-selective + selective_estrogen_receptor_degrader; PI3K_alpha_inhibitor,allosteric,mutant-selective; CDK4/6_inhibitor; CDK4/6_inhibitor + PI3K_alpha_inhibitor,allosteric,mutant-selective + selective_estrogen_receptor_degrader; CDK4_selective_inhibitor; selective_estrogen_receptor_degrader; CDK4_selective_inhibitor + PI3K_alpha_inhibitor,allosteric,mutant-selective + selective_estrogen_receptor_degrader	Fulvestrant + PF-07220060 + RLY-2608; Fulvestrant + Palbociclib + RLY-2608; Fulvestrant + RLY-2608; Fulvestrant + RLY-2608 + Ribociclib; RLY-2608	CDK4/6_inhibitor + PI3K_alpha_inhibitor,allosteric,mutant-selective + selective_estrogen_receptor_degrader; CDK4_selective_inhibitor + PI3K_alpha_inhibitor,allosteric,mutant-selective + selective_estrogen_receptor_degrader; PI3K_alpha_inhibitor,allosteric,mutant-selective; PI3K_alpha_inhibitor,allosteric,mutant-selective + selective_estrogen_receptor_degrader	RLY-2608-101	A First-in-Human Study of Mutant-selective PI3Ka Inhibitor, RLY-2608, As a Single Agent in Advanced Solid Tumor Patients and in Combination with Fulvestrant in Patients with Advanced Breast Cancer	Metastatic Breast Cancer; Endometrial Cancer; HER2-negative Breast Cancer; PIK3CA Mutation; Solid Tumor, Adult; Breast Cancer; Unresectable Solid Tumor; Advanced Breast Cancer	3000 - Melbourne; 2019 - Sydney; 3004 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT05216432
NCT05217446	SEAMARK	Phase 2		VIC	2022-02-01	2022-07-11		Cetuximab; Cetuximab + Encorafenib + Pembrolizumab; Encorafenib; Pembrolizumab	anti-EGFR_monoclonal_antibody; anti-PD-1_monoclonal_antibody; BRAF_V600_inhibitor + anti-EGFR_monoclonal_antibody + anti-PD-1_monoclonal_antibody; BRAF_V600_inhibitor	Cetuximab + Encorafenib + Pembrolizumab; Pembrolizumab	BRAF_V600_inhibitor + anti-EGFR_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody	SEAMARK  C4221022	A PHASE 2, RANDOMIZED, OPEN-LABEL STUDY OF ENCORAFENIB AND CETUXIMAB PLUS PEMBROLIZUMAB VERSUS PEMBROLIZUMAB ALONE IN PARTICIPANTS WITH PREVIOUSLY UNTREATED BRAF V600E-MUTANT, MSI H/DMMR METASTATIC COLORECTAL CANCER	Metastatic Colorectal Cancer	3052 - Parkville; 3084 - Heidelberg; 3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT05217446
NCT05218499	2021-002392-20--1403-0008	Phase 2		NSW, QLD, SA, VIC	2022-02-01	2022-03-31		Brigimadlin; Doxorubicin	anthracycline; MDM2_inhibitor; doxorubicin	Brigimadlin; Doxorubicin	MDM2_inhibitor; anthracycline; doxorubicin	2021-002392-20  1403-0008	Brightline-1: A Phase II/III, Randomized, Open-label, Multi-center Study of Brigimadlin (BI 907828) Compared to Doxorubicin as First Line Treatment of Patients With Advanced Dedifferentiated Liposarcoma	Liposarcoma, Dedifferentiated	4102 - Woolloongabba; 3000 - Melbourne; 2031 - Randwick; 5037 - Kurralta Park	https://clinicaltrials.gov/ct2/show/NCT05218499
NCT05220098	2023-504012-16-00--TAK-280-1501	Phase 1		NSW, SA, VIC	2022-02-02	2022-04-22		TAK-280	bispecific_T-cell_engager,B7H3-targeting	TAK-280	bispecific_T-cell_engager,B7H3-targeting	2023-504012-16-00  TAK-280-1501	A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-280 in Patients With Unresectable Locally Advanced or Metastatic Cancer	Unresectable Locally Advanced or Metastatic Cancer	3144 - Malvern; 3168 - Clayton; 2050 - Camperdown; 5042 - Bedford Park	https://clinicaltrials.gov/ct2/show/NCT05220098
NCT05224141	MK-7684A-008--7684A-008	Phase 3		NSW, VIC	2022-02-04	2022-03-24		Atezolizumab; Atezolizumab + Carboplatin + Cisplatin + Etoposide; Carboplatin; Carboplatin + Cisplatin + Etoposide + Pembrolizumab + Vibostolimab; Cisplatin; Dexamethasone; Etoposide; Pembrolizumab; Placebo; Vibostolimab	placebo; anti-PD-L1_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; topoisomerase_inhibitor; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; anti-TIGIT_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; glucocorticoid	Atezolizumab + Carboplatin + Cisplatin + Etoposide; Carboplatin + Cisplatin + Etoposide + Pembrolizumab + Vibostolimab; Dexamethasone; Placebo	anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; anti-PD-L1_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; glucocorticoid; placebo	MK-7684A-008  7684A-008	A Phase 3, Randomized, Double-Blind Study of MK-7684A in Combination With Etoposide and Platinum Followed by MK-7684A vs Atezolizumab in Combination With Etoposide and Platinum Followed by Atezolizumab for the First-Line Treatment of Participants With Extensive-Stage Small Cell Lung Cancer (KEYVIBE-008)	Small Cell Lung Carcinoma	2747 - Kingswood; 3021 - Melbourne; 3199 - Frankston; 2298 - Waratah	https://clinicaltrials.gov/ct2/show/NCT05224141
NCT05228015	IK930-001	Phase 1		VIC	2022-02-08	2022-01-07		IK-930; IK-930 + Osimertinib; Osimertinib	YAP-TEAD_inhibitor; EGFR_inhibitor,third_generation + YAP-TEAD_inhibitor; EGFR_inhibitor,third_generation	IK-930; IK-930 + Osimertinib	EGFR_inhibitor,third_generation + YAP-TEAD_inhibitor; YAP-TEAD_inhibitor	IK930-001	A Phase 1, First-in-Human Study of IK-930, an Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors	NF2 Deficiency; Epithelioid Hemangioendothelioma (EHE); NF2 Deficient Mesothelioma; Other NF2 Deficient Solid Tumors and Solid Tumors with YAP1/TAZ Fusion Genes; Solid Tumors, Adult; Malignant Pleural Mesothelioma (MPM); Solid Tumor; YAP1 or TAZ Gene Fusions	3199 - Frankston	https://clinicaltrials.gov/ct2/show/NCT05228015
NCT05245968	NCT05245968	Phase 1		SA, VIC	2022-02-18	2021-12-01		Imatinib; Imatinib + Pimitespib; Pimitespib; Sunitinib	VEGFR_inhibitor; BCR-ABL1_inhibitor,first_generation + HSP90_inhibitor; HSP90_inhibitor + PDGFRA_inhibitor; KIT_inhibitor,first_generation; HSP90_inhibitor + KIT_inhibitor; BCR-ABL1_inhibitor,first_generation; PDGFR_inhibitor; PDGFRA_inhibitor; HSP90_inhibitor; KIT_inhibitor	Imatinib + Pimitespib; Sunitinib	BCR-ABL1_inhibitor,first_generation + HSP90_inhibitor; HSP90_inhibitor + KIT_inhibitor; HSP90_inhibitor + PDGFRA_inhibitor; KIT_inhibitor,first_generation; PDGFR_inhibitor; VEGFR_inhibitor	10058060	A Phase 1 Study of TAS-116 (pimitespib) in Combination with Imatinib in Patients with Advanced Gastrointestinal Stromal Tumor	Gastrointestinal Stromal Tumors	- Melbourne; - Adelaide	https://clinicaltrials.gov/ct2/show/NCT05245968
NCT05252364	HP518-CS-001	Phase 1		NSW, VIC	2022-02-23	2021-12-14		HP518	AR_PROTAC_degrader	HP518	AR_PROTAC_degrader	HP518-CS-001	A Phase 1 Open-Label Study to Assess the Safety, Pharmacokinetics, and Anti-tumor Activity of Oral HP518 in Patients With Metastatic Castration-Resistant Prostate Cancer	Metastatic Castration-resistant Prostate Cancer	2113 - Macquarie Park; 3181 - Melbourne; 2640 - Albury; 2050 - Camperdown; 3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT05252364
NCT05253651	MOUNTAINEER-03	Phase 3		NSW, QLD, VIC	2022-02-24	2022-10-24		Bevacizumab; Bevacizumab + Cetuximab; Cetuximab; Fluorouracil; Leucovorin; Oxaliplatin; Trastuzumab; Trastuzumab + Tucatinib; Tucatinib	Fluorouracil; anti-ERBB2_monoclonal_antibody; anti-EGFR_monoclonal_antibody + anti-VEGF_monoclonal_antibody; fluoropyrimidine; ERBB2_inhibitor,third_generation + anti-ERBB2_monoclonal_antibody; platinum-based_antineoplastic_agent; folinic_acid; anti-VEGF_monoclonal_antibody; anti-EGFR_monoclonal_antibody; ERBB2_inhibitor,third_generation	Bevacizumab + Cetuximab; Trastuzumab + Tucatinib; Fluorouracil; Leucovorin; Oxaliplatin	ERBB2_inhibitor,third_generation + anti-ERBB2_monoclonal_antibody; anti-EGFR_monoclonal_antibody + anti-VEGF_monoclonal_antibody; Fluorouracil; fluoropyrimidine; folinic_acid; platinum-based_antineoplastic_agent	C4251008  SGNTUC-029	An Open-label Randomized Phase 3 Study of Tucatinib in Combination With Trastuzumab and mFOLFOX6 Versus mFOLFOX6 Given With or Without Either Cetuximab or Bevacizumab as First-line Treatment for Subjects With HER2+ Metastatic Colorectal Cancer	Colorectal Neoplasms	2050 - Camperdown; 4102 - Woolloongabba; 3004 - Melbourne; 4814 - Townsville; 3065 - Fitzroy	https://clinicaltrials.gov/ct2/show/NCT05253651
NCT05254171	ASPIRE	Phase 2		ACT, ACTtoryNSW, NSW, SA, VIC, WA	2022-02-24	2022-08-08		Gemcitabine; Gemcitabine + Ivospemin + Nab-paclitaxel; Gemcitabine + Nab-paclitaxel; Ivospemin; Nab-paclitaxel; Placebo	placebo; antimetabolite; polyamine_analogue; antimetabolite + taxane; taxane; gemcitabine; antimetabolite + polyamine_analogue + taxane	Gemcitabine + Ivospemin + Nab-paclitaxel; Gemcitabine + Nab-paclitaxel; Placebo	antimetabolite + polyamine_analogue + taxane; antimetabolite + taxane; gemcitabine; placebo	CL-SBP-101-04	A Randomized, Double-Blind, Placebo-Controlled Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Subjects Previously Untreated for Metastatic Pancreatic Ductal Adenocarcinoma	Pancreatic Ductal Adenocarcinoma; Pancreatic Cancer Metastatic; Pancreatic Cancer Stage IV	6150 - Murdoch; 2605 - Garran; 5307 - Kurralta Park; 2485 - Tweed Heads; 3084 - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT05254171
NCT05257408	ROSELLA-Study-556--CORT125134-556	Phase 3		NSW, QLD, VIC	2022-02-25	2022-06-29		Nab-paclitaxel	taxane	Nab-paclitaxel	taxane	ROSELLA Study 556  CORT125134-556	A Phase 3 Study of Relacorilant in Combination With Nab-Paclitaxel Versus Nab-Paclitaxel Monotherapy in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (ROSELLA)	Ovarian Neoplasm; Fallopian Tube Neoplasms; Peritoneal Neoplasms	4217 - Benowa; 3128 - Melbourne; 3000 - Melbourne; 2065 - St. Leonards	https://clinicaltrials.gov/ct2/show/NCT05257408
NCT05261399	SAFFRON	Phase 3		NSW, QLD, VIC, WA	2022-03-02	2022-08-03		Carboplatin; Carboplatin + Cisplatin + Pemetrexed; Cisplatin; Osimertinib; Osimertinib + Savolitinib; Pemetrexed; Savolitinib	antimetabolite; platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; MET_inhibitor,type_1; EGFR_inhibitor,third_generation; EGFR_inhibitor,third_generation + MET_inhibitor,type_1	Carboplatin + Cisplatin + Pemetrexed; Osimertinib + Savolitinib	EGFR_inhibitor,third_generation + MET_inhibitor,type_1; antimetabolite + platinum-based_antineoplastic_agent	2024-511169-12-00  D5087C00001	A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated, MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed on Treatment With Osimertinib (SAFFRON).	Carcinoma; Non-Small-Cell Lung	2170 - Liverpool; 4215 - Southport; 2298 - Waratah NSW; 2145 - Westmead; 6160 - Fremantle; 3168 - Clayton; 3220 - Geelong	https://clinicaltrials.gov/ct2/show/NCT05261399
NCT05263180	EMB09X101	Phase 1		NSW, VIC	2022-03-02	2022-07-25		EMB-09	bispecific_PD-L1/OX40_antibody	EMB-09	bispecific_PD-L1/OX40_antibody	EMB09X101	A First-in-human, Phase I Trial of EMB-09, a Bispecific Antibody Targeting PD-L1 and OX-40 in Patients With Advanced or Metastatic Solid Tumors	Advanced Solid Tumor	- Leonards Hill; - Frankston; - Sydney	https://clinicaltrials.gov/ct2/show/NCT05263180
NCT05264038	OC514-001	Phase 1		VIC	2022-03-03	2022-03-03		Placebo	placebo	Placebo	placebo	OC514-001	A Phase 1, Randomized, Double-Blind, Dose-Ranging, Placebo-controlled Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics Effects of OC514 in Healthy Adult Volunteers	Cancer Cachexia	- Melbourne	https://clinicaltrials.gov/ct2/show/NCT05264038
NCT05266105	OP-1250-002	Phase 1		NSW, QLD, VIC, WA	2022-03-04	2021-12-10		Palazestrant; Palazestrant + Palbociclib; Palbociclib	complete_estrogen_receptor_antagonist; CDK4/6_inhibitor; CDK4/6_inhibitor + complete_estrogen_receptor_antagonist	Palazestrant + Palbociclib	CDK4/6_inhibitor + complete_estrogen_receptor_antagonist	OP-1250-002	A Phase 1 Dose Escalation and Expansion Open-label, Multicenter, Study of OP-1250 in Combination With the CDK4/6 Inhibitor Palbociclib in Adult Subjects With Advanced or Metastatic HR-positive, HER2-negative Breast Cancer	Breast Cancer	4215 - Southport; 4101 - South Brisbane; 3220 - Geelong; 3168 - Clayton; 3199 - Frankston; 2298 - Waratah; 6009 - Nedlands; 2145 - Westmead	https://clinicaltrials.gov/ct2/show/NCT05266105
NCT05267626	CP-AU-007-01	Phase 1		NSW, SA, VIC	2022-03-04	2022-04-04		AU-007; AU-007 + Aldesleukin; AU-007 + Aldesleukin + Avelumab; AU-007 + Aldesleukin + Nivolumab; Aldesleukin; Avelumab; Nivolumab	IL-2_variant; IL-2_variant + anti-IL-2_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; IL-2_variant + anti-IL-2_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-IL-2_monoclonal_antibody; IL-2_variant + anti-IL-2_monoclonal_antibody + anti-PD-1_monoclonal_antibody	AU-007; AU-007 + Aldesleukin; AU-007 + Aldesleukin + Avelumab; AU-007 + Aldesleukin + Nivolumab	IL-2_variant + anti-IL-2_monoclonal_antibody; IL-2_variant + anti-IL-2_monoclonal_antibody + anti-PD-1_monoclonal_antibody; IL-2_variant + anti-IL-2_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-IL-2_monoclonal_antibody	CP-AU-007-01	A Phase 1/2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Ra Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer	Advanced Solid Tumor; Non-Small Cell Lung Cancer; Metastatic Cancer; Cutaneous Melanoma	3199 - Frankston; 3004 - Melbourne; 3168 - Clayton; 3021 - Saint Albans; 5042 - Bedford Park; 2228 - Miranda; 3084 - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT05267626
NCT05269316	IMP9064-101	Phase 1		NSW, WA	2022-03-07	2022-02-11		IMP9064; Senaparib	ATR_inhibitor; PARP_inhibitor	IMP9064; Senaparib	ATR_inhibitor; PARP_inhibitor	IMP9064-101	A First-in-human, Phase 1/2, Open-label, Multi-center, Dose-escalation and Dose-expansion Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of the ATR Inhibitor IMP9064 Monotherapy and in Combination With PARP Inhibitor Senaparib in Patients With Advanced Solid Tumors	Solid Tumor; Advanced Solid Tumor	2148 - Blacktown; 6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT05269316
NCT05269355	SUNRISELMS	Phase 2		NSW, VIC	2022-03-08	2022-05-23		Dacarbazine; Dacarbazine + Unesbulin; Placebo; Unesbulin	placebo; BMI-1_inhibitor + alkylating_agent; alkylating_agent; BMI-1_inhibitor	Dacarbazine + Unesbulin; Placebo	BMI-1_inhibitor + alkylating_agent; placebo	2022-000073-12  PTC596-ONC-008-LMS	A Phase 2/3 Study to Evaluate the Efficacy and Safety of Unesbulin in Unresectable or Metastatic, Relapsed or Refractory Leiomyosarcoma	Leiomyosarcoma	2050 - Camperdown; 2031 - Randwick; 3000 - East Melbourne	https://clinicaltrials.gov/ct2/show/NCT05269355
NCT05277051	2023-509414-11--217228	Phase 1		WA	2022-03-14	2022-03-22		Dostarlimab; Dostarlimab + GSK4381562; GSK4381562	anti-PVRIG_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-PVRIG_monoclonal_antibody	Dostarlimab; Dostarlimab + GSK4381562; GSK4381562	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-PVRIG_monoclonal_antibody; anti-PVRIG_monoclonal_antibody	2023-509414-11  217228	A Phase 1 First-Time-in-Human, Open-Label Study of GSK4381562 Administered as Monotherapy and in Combination With Anticancer Agents in Participants With Selected Advanced Solid Tumors	Neoplasms	6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT05277051
NCT05279300	CS5001-101	Phase 1		NSW, SA, VIC	2022-03-15	2022-03-28		CS5001	anti-ROR1_antibody-drug_conjugate	CS5001	anti-ROR1_antibody-drug_conjugate	CS5001-101	A Phase I, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of CS5001, an Anti-ROR1 Antibody Drug Conjugate, in Patients With Advanced Solid Tumors and Lymphomas	Advanced Lymphoma; Advanced Solid Tumor	- Adelaide; - Melbourne; 2031 - Randwick	https://clinicaltrials.gov/ct2/show/NCT05279300
NCT05286801	NCI-2022-01992--NCI-2022-01992	Phase 1		NSW, QLD, VIC	2022-03-18	2022-11-17		Atezolizumab; Atezolizumab + Tiragolumab; Tiragolumab	anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-TIGIT_monoclonal_antibody; anti-PD-L1_monoclonal_antibody	Atezolizumab + Tiragolumab	anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody	NCI-2022-01992  NCI-2022-01992	A Phase 1/2 Study of Tiragolumab (NSC# 827799) and Atezolizumab (NSC# 783608) in Patients With Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors	Atypical Teratoid/Rhabdoid Tumor; Refractory Chordoma; Epithelioid Sarcoma; Recurrent Chordoma; Kidney Medullary Carcinoma; Recurrent Atypical Teratoid/Rhabdoid Tumor; Malignant Solid Neoplasm; Refractory Atypical Teratoid/Rhabdoid Tumor; Refractory Kidney Medullary Carcinoma; Poorly Differentiated Chordoma; Recurrent Epithelioid Sarcoma; Rhabdoid Tumor; Refractory Rhabdoid Tumor; Recurrent Malignant Solid Neoplasm; Refractory Malignant Solid Neoplasm; Recurrent Rhabdoid Tumor; Recurrent Kidney Medullary Carcinoma; Refractory Epithelioid Sarcoma	2031 - Randwick; 4101 - South Brisbane; 3052 - Parkville	https://clinicaltrials.gov/ct2/show/NCT05286801
NCT05288166	CYCLONE-3	Phase 3		NSW, QLD, SA, TAS, VIC, WA	2022-03-21	2022-04-14		Abemaciclib; Abemaciclib + Abiraterone + Prednisone; Abiraterone; Abiraterone + Prednisone; Placebo; Prednisolone; Prednisone	placebo; CYP17A1_inhibitor; CDK4/6_inhibitor; glucocorticoid; CDK4/6_inhibitor + CYP17A1_inhibitor + glucocorticoid; CYP17A1_inhibitor + glucocorticoid	Abemaciclib + Abiraterone + Prednisone; Abiraterone + Prednisone; Placebo; Prednisolone	CDK4/6_inhibitor + CYP17A1_inhibitor + glucocorticoid; CYP17A1_inhibitor + glucocorticoid; placebo	I3Y-MC-JPEG  18448	CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer	Hormones; Enzyme Inhibitors; Prednisone; Urogenital Neoplasms; Androgens; Steroid Synthesis Inhibitors; Cyclin-Dependent Kinase 6; Prostatic Neoplasms; Prednisolone; Cytochrome P-450; Antineoplastic Agents; Physiological Effects of Drugs; Antineoplastic Agents, Hormonal; Hormones, Hormone Substitutes, and Hormone Antagonists; Neoplasm Metastasis; Abiraterone Acetate; Cyclin-Dependent Kinase 4	4215 - Southport; 2170 - Liverpool; 3128 - Box Hill; 3121 - Richmond; 5037 - Kurralta Park; 2050 - Camperdown; 2010 - Darlinghurst; 5112 - Elizabeth Vale; 3084 - Heidelberg; 4102 - Woolloongabba; 4101 - South Brisbane; 3220 - Geelong; 3168 - Clayton; 7000 - Hobart; 2109 - Macquarie University; 6150 - Murdoch; 2450 - Coffs Harbour; 3065 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT05288166
NCT05290597	CIBI363A101	Phase 1		NSW	2022-03-22	2022-08-22		IBI363	anti-PD-1/IL-2-immunocytokine_conjugate	IBI363	anti-PD-1/IL-2-immunocytokine_conjugate	CIBI363A101	A Phase 1, Open-label, Multicenter, Dose Escalation Study of IBI363 (PD1-IL2m) in Subjects with Advanced Solid Malignancies or Lymphomas	Solid Malignancies or Lymphomas	2500 - Sydney; 2145 - Sydney; 2170 - Sydney; 2109 - Sydney	https://clinicaltrials.gov/ct2/show/NCT05290597
NCT05303532	ROSY-D	Phase 3		VIC	2022-03-31	2022-04-19		Durvalumab	anti-PD-L1_monoclonal_antibody	Durvalumab	anti-PD-L1_monoclonal_antibody	2021-003031-29  D4191C00137	ROSY-D: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab and Are Judged by the Investigator to Clinically Benefit From Continued Treatment	Cancer	3128 - Box Hill; 3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT05303532
NCT05304585	NCI-2022-01012--ARST2032	Phase 3		NSW, NZ, WA	2022-03-31	2022-08-04		Cyclophosphamide; Cyclophosphamide + Dactinomycin + Radiotherapy + Vincristine; Dactinomycin; Dactinomycin + Vincristine; Radiotherapy; Vincristine	radiotherapy; antineoplastic_antibiotic; antineoplastic_antibiotic + vinca_alkaloid; alkylating_agent + antineoplastic_antibiotic + radiotherapy + vinca_alkaloid; vinca_alkaloid; alkylating_agent	Cyclophosphamide + Dactinomycin + Radiotherapy + Vincristine; Dactinomycin + Vincristine	alkylating_agent + antineoplastic_antibiotic + radiotherapy + vinca_alkaloid; antineoplastic_antibiotic + vinca_alkaloid	NCI-2022-01012  ARST2032	A Prospective Phase 3 Study of Patients With Newly Diagnosed Very Low-Risk and Low-Risk Fusion Negative Rhabdomyosarcoma	Spindle Cell/Sclerosing Rhabdomyosarcoma; Fusion-Negative Alveolar Rhabdomyosarcoma; Embryonal Rhabdomyosarcoma	Christchurch; 2145 - Westmead; 6009 - Perth; Auckland; 2031 - Randwick	https://clinicaltrials.gov/ct2/show/NCT05304585
NCT05306444	CLN-418-001	Phase 1		NSW	2022-04-01	2022-05-12		CLN-418	bispecific_B7H4/4-1BB_antibody	CLN-418	bispecific_B7H4/4-1BB_antibody	CLN-418-001	A Phase 1 Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CLN-418 in Subjects With Advanced Solid Tumors	Advanced Solid Tumor	2217 - Kogarah; 2500 - Wollongong	https://clinicaltrials.gov/ct2/show/NCT05306444
NCT05307705	PIKASSO-01	Phase 1		NSW, SA, VIC	2022-04-01	2022-05-11		Abemaciclib; Abemaciclib + Fulvestrant + Imlunestrant + LOXO-783; Anastrozole; Exemestane; Fulvestrant; Fulvestrant + Imlunestrant + LOXO-783; Fulvestrant + LOXO-783; Imlunestrant; LOXO-783; LOXO-783 + Paclitaxel; Letrozole; Paclitaxel	PI3Kalpha_H1047R_inhibitor + selective_estrogen_receptor_degrader; PI3Kalpha_H1047R_inhibitor; aromatase_inhibitor; CDK4/6_inhibitor; taxane; PI3Kalpha_H1047R_inhibitor + taxane; CDK4/6_inhibitor + PI3Kalpha_H1047R_inhibitor + selective_estrogen_receptor_degrader; selective_estrogen_receptor_degrader	Abemaciclib + Fulvestrant + Imlunestrant + LOXO-783; Fulvestrant + Imlunestrant + LOXO-783; Fulvestrant + LOXO-783; LOXO-783; LOXO-783 + Paclitaxel; Anastrozole; Exemestane; Letrozole	CDK4/6_inhibitor + PI3Kalpha_H1047R_inhibitor + selective_estrogen_receptor_degrader; PI3Kalpha_H1047R_inhibitor; PI3Kalpha_H1047R_inhibitor + selective_estrogen_receptor_degrader; PI3Kalpha_H1047R_inhibitor + taxane; aromatase_inhibitor	2022-000175-40  18394	A Study of LOXO-783 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With Advanced Breast Cancer and Other Solid Tumors With a PIK3CA H1047R Mutation	Breast Cancer; Solid Tumour	2010 - Sydney; 3002 - East Melbourne; 5000 - Adelaide	https://clinicaltrials.gov/ct2/show/NCT05307705
NCT05309421	KEYNOTE-D36--EVX-01-001	Phase 2		NSW, VIC, WA	2022-04-04	2022-08-30		EVX-01; EVX-01 + Pembrolizumab; Pembrolizumab	autologous_anticancer_vaccine; anti-PD-1_monoclonal_antibody + autologous_anticancer_vaccine; anti-PD-1_monoclonal_antibody	EVX-01 + Pembrolizumab	anti-PD-1_monoclonal_antibody + autologous_anticancer_vaccine	KEYNOTE-D36  EVX-01-001	An Open Label, Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Checkpoint Inhibitor Treatment naïve Adults With Unresectable or Metastatic Melanoma	Melanoma Stage IV; Melanoma Stage III	3350 - Ballarat Central; 2065 - Wollstonecraft; 6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT05309421
NCT05311176	nextHERIZON	Phase 2		NSW, SA	2022-04-05	2022-08-17		IMU-131; IMU-131 + Paclitaxel + Ramucirumab; IMU-131 + Pembrolizumab + Trastuzumab; Paclitaxel; Pembrolizumab; Ramucirumab; Trastuzumab	anti-VEGFR2_monoclonal_antibody; anti-ERBB2_monoclonal_antibody; anti-PD-1_monoclonal_antibody; taxane; ERBB2_B-cell_antigen + anti-ERBB2_monoclonal_antibody + anti-PD-1_monoclonal_antibody; ERBB2_B-cell_antigen; ERBB2_B-cell_antigen + anti-VEGFR2_monoclonal_antibody + taxane	IMU-131 + Paclitaxel + Ramucirumab; IMU-131 + Pembrolizumab + Trastuzumab	ERBB2_B-cell_antigen + anti-ERBB2_monoclonal_antibody + anti-PD-1_monoclonal_antibody; ERBB2_B-cell_antigen + anti-VEGFR2_monoclonal_antibody + taxane	IMU.131.203	NextHERIZON: an Open-Label, Signal Generating, Phase 2 Study of HER-Vaxx in Combination with Chemotherapy or Pembrolizumab in Patients with Metastatic HER2/Neu Over-Expressing Gastric or Gastroesophageal Junction (GEJ) Adenocarcinomas Who Have Previously Received Trastuzumab and Progressed on This Treatment	Gastroesophageal Junction Adenocarcinoma; Stomach Adenocarcinoma; Cancer of Stomach; Stomach Cancer; Gastric Adenocarcinoma; Gastric Cancer	5011 - Woodville South; - Wollongong	https://clinicaltrials.gov/ct2/show/NCT05311176
NCT05315700	ORIC-114-01	Phase 1		NSW, VIC, WA	2022-04-07	2022-03-10		ORIC-114	ERBB2_inhibitor,exon_20_selective; EGFR_inhibitor,exon_20_selective	ORIC-114	EGFR_inhibitor,exon_20_selective; ERBB2_inhibitor,exon_20_selective	ORIC-114-01	An Open-Label, Phase 1/2 Study of ORIC-114 As a Single Agent or in Combination with Chemotherapy, in Patients with Advanced Solid Tumors Harboring an EGFR or HER2 Alteration	Solid Tumors	- Camperdown; - Nedlands; - Melbourne; - Sydney	https://clinicaltrials.gov/ct2/show/NCT05315700
NCT05317078	NCT05317078	Phase 1		SA, VIC	2022-04-07	2023-02-28		AMG-794	bispecific_T-cell_engager,CLDN6-targeting	AMG-794	bispecific_T-cell_engager,CLDN6-targeting	20210007	Phase 1 First-In-Human Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 794 in Participants With Claudin 6-positive Advanced/Metastatic Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications	Non-squamous Non-small Cell Lung Cancer; Claudin 6-positive Advanced/Metastatic Malignant Solid Tumors; Epithelial Ovarian Cancer	5042 - Bedford Park; 3144 - Malvern; 3168 - Clayton	https://clinicaltrials.gov/ct2/show/NCT05317078
NCT05325866	FORTITUDE-301	Phase 1		NSW, QLD, VIC, WA	2022-04-13	2022-09-23		Bemarituzumab	anti-FGFR2b_monoclonal_antibody	Bemarituzumab	anti-FGFR2b_monoclonal_antibody	2023-505455-44  20210104	A Phase 1b/2, Multicenter, Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors With FGFR2b Overexpression (FORTITUDE-301)	Solid Tumors	3144 - Malvern; 6150 - Murdoch; 4350 - Toowoomba; 2170 - Liverpool; 2031 - Randwick; 2500 - Wollongong	https://clinicaltrials.gov/ct2/show/NCT05325866
NCT05327530	2021-003669-36--MS100070-0119	Phase 2		NSW, QLD, SA, VIC	2022-04-14	2022-08-17		Avelumab; Avelumab + Sacituzumab Govitecan; Sacituzumab Govitecan	anti-Trop2_antibody-drug_conjugate; anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate	Avelumab; Avelumab + Sacituzumab Govitecan	anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate	2021-003669-36  MS100070_0119	A Phase II, Multicenter, Randomized, Open Label, Parallel-Arm, Umbrella Study of Avelumab (MSB0010718C) in Combination With Other AntiTumor Agents as a Maintenance Treatment in Participants With Locally Advanced or Metastatic Urothelial Carcinoma Whose Disease Did Not Progress With First Line Platinum-Containing Chemotherapy (JAVELIN Bladder Medley)	Locally Advanced or Metastatic Urothelial Carcinoma	- Westmead; - Liverpool; - Southport; - Bedford Park; - Sydney; - Newcastle; - Kurralta Park; - Footscray	https://clinicaltrials.gov/ct2/show/NCT05327530
NCT05327686	SAMURAI	Phase 2		VIC	2022-04-14	2023-02-01		Avelumab; Avelumab + Axitinib + Cabozantinib + Ipilimumab + Lenvatinib + Nivolumab + Pembrolizumab; Axitinib; Cabozantinib; Ipilimumab; Lenvatinib; Nivolumab; Pembrolizumab; Radiotherapy	radiotherapy; anti-PD-L1_monoclonal_antibody; ROS1_inhibitor + VEGFR/PDGFR_inhibitor + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; RET_inhibitor; KIT_inhibitor + VEGFR/PDGFR_inhibitor + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-CTLA4_monoclonal_antibody; MET_inhibitor,type_2 + VEGFR/PDGFR_inhibitor + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; KIT_inhibitor,ATP-competitive + VEGFR2_inhibitor + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; KIT_inhibitor,ATP-competitive + ROS1_inhibitor + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; VEGF_inhibitor; VEGFR/PDGFR_inhibitor; KIT_inhibitor + KIT_inhibitor,ATP-competitive + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; AXL_inhibitor + VEGFR/PDGFR_inhibitor + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; KIT_inhibitor,ATP-competitive + MET_inhibitor,type_2 + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; KIT_inhibitor,ATP-competitive + RET_inhibitor + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; KIT_inhibitor,ATP-competitive; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + KIT_inhibitor,ATP-competitive + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + VEGFR/PDGFR_inhibitor + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; ROS1_inhibitor; AXL_inhibitor; KIT_inhibitor; AXL_inhibitor + KIT_inhibitor,ATP-competitive + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; VEGFR/PDGFR_inhibitor + VEGFR2_inhibitor + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; VEGFR2_inhibitor; anti-PD-1_monoclonal_antibody; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor; RET_inhibitor + VEGFR/PDGFR_inhibitor + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; MET_inhibitor,type_2	Avelumab + Axitinib + Cabozantinib + Ipilimumab + Lenvatinib + Nivolumab + Pembrolizumab; Radiotherapy	AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + KIT_inhibitor,ATP-competitive + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + VEGFR/PDGFR_inhibitor + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; AXL_inhibitor + KIT_inhibitor,ATP-competitive + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; AXL_inhibitor + VEGFR/PDGFR_inhibitor + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; KIT_inhibitor + KIT_inhibitor,ATP-competitive + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; KIT_inhibitor + VEGFR/PDGFR_inhibitor + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; KIT_inhibitor,ATP-competitive + MET_inhibitor,type_2 + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; KIT_inhibitor,ATP-competitive + RET_inhibitor + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; KIT_inhibitor,ATP-competitive + ROS1_inhibitor + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; KIT_inhibitor,ATP-competitive + VEGFR2_inhibitor + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; MET_inhibitor,type_2 + VEGFR/PDGFR_inhibitor + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; RET_inhibitor + VEGFR/PDGFR_inhibitor + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; ROS1_inhibitor + VEGFR/PDGFR_inhibitor + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; VEGFR/PDGFR_inhibitor + VEGFR2_inhibitor + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; radiotherapy	NCI-2022-02189  NRG-GU012	Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI)	Stage III Renal Cell Cancer AJCC v8; Unresectable Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma; Stage IV Renal Cell Cancer AJCC v8	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT05327686
NCT05328908	RELATIVITY-123	Phase 3		NSW, QLD, VIC, WA	2022-04-14	2022-04-28		Nivolumab; Nivolumab + Relatlimab; Regorafenib; Regorafenib + Trifluridine/Tipiracil; Relatlimab; Trifluridine/Tipiracil	antimetabolite; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + thymidine_phosphorylase_inhibitor; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + antimetabolite; anti-LAG3_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; Tipiracil Hydrochloride; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + Trifluridine; Trifluridine; thymidine_phosphorylase_inhibitor; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + Tipiracil Hydrochloride	Nivolumab + Relatlimab; Regorafenib + Trifluridine/Tipiracil	KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + Tipiracil Hydrochloride; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + Trifluridine; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + antimetabolite; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + thymidine_phosphorylase_inhibitor; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody	2021-004285-35  CA224-123	A Phase 3, Randomized, Open-label Study of Relatlimab-nivolumab Fixed-dose Combination Versus Regorafenib or Trifluridine + Tipiracil (TAS-102) for Participants With Later-lines of Metastatic Colorectal Cancer	Colorectal Neoplasms	4120 - Greenslopes; 2650 - Wagga Wagga; 2145 - Westmead; 6150 - Murdoch; 3084 - Melbourne; 3168 - Clayton	https://clinicaltrials.gov/ct2/show/NCT05328908
NCT05330429	ELEVATE-CRC	Phase 2		NSW, QLD, SA, VIC	2022-04-15	2022-07-08		Bevacizumab; Bevacizumab + Fluorouracil + Irinotecan + Leucovorin; Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Magrolimab; Fluorouracil; Irinotecan; Leucovorin; Magrolimab	topoisomerase_inhibitor; anti-CD47_monoclonal_antibody + anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid + topoisomerase_inhibitor; anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid + topoisomerase_inhibitor; Fluorouracil; fluoropyrimidine; folinic_acid; anti-VEGF_monoclonal_antibody; anti-CD47_monoclonal_antibody	Bevacizumab + Fluorouracil + Irinotecan + Leucovorin; Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Magrolimab	anti-CD47_monoclonal_antibody + anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid + topoisomerase_inhibitor; anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid + topoisomerase_inhibitor; Fluorouracil	2022-500177-13  GS-US-587-6156	A Phase 2, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Bevacizumab and FOLFIRI Versus Bevacizumab and FOLFIRI in Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC)	Metastatic Colorectal Cancer	2148 - Blacktown; 2065 - St Leonards; 4102 - Woolloongabba; 3004 - Melbourne; 3084 - Heidelberg; 2010 - Darlinghurst; 2228 - Miranda; 5042 - Bedford Park	https://clinicaltrials.gov/ct2/show/NCT05330429
NCT05337137	RELATIVITY-106	Phase 1		NSW, SA, VIC, WA	2022-04-20	2022-05-05		Bevacizumab; Bevacizumab + Nivolumab; Bevacizumab + Nivolumab + Relatlimab; Nivolumab; Placebo; Relatlimab	placebo; anti-LAG3_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-VEGF_monoclonal_antibody	Bevacizumab + Nivolumab; Bevacizumab + Nivolumab + Relatlimab; Placebo	anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; placebo	2021-003606-53  CA224-106	A Phase 1/2, Safety Confirmation, Placebo-controlled, Randomized Study of Nivolumab in Combination With Relatlimab and Bevacizumab in Treatment-naive Advanced/Metastatic Hepatocellular Carcinoma	Carcinoma, Hepatocellular	5000 - Adelaide; 3084 - Heidelberg; 2050 - Camperdown; 3065 - Melbourne; 6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT05337137
NCT05338970	2021-005879-40--U31402-A-U301	Phase 3		NSW, QLD, VIC, WA	2022-04-21	2022-07-08		Carboplatin; Carboplatin + Cisplatin + Pemetrexed; Cisplatin; Patritumab Deruxtecan; Pemetrexed	antimetabolite; platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; anti-ERBB3_antibody-drug_conjugate	Carboplatin + Cisplatin + Pemetrexed; Patritumab Deruxtecan	anti-ERBB3_antibody-drug_conjugate; antimetabolite + platinum-based_antineoplastic_agent	2021-005879-40  U31402-A-U301	A Phase 3, Randomized, Open-label Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced Epidermal Growth Factor Receptor-mutated (EGFRm) Non-small Cell Lung Cancer (NSCLC) After Failure of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy (HERTHENA-Lung02)	EGFR L858R; Nonsquamous Non-small Cell Lung Cancer; EGFR Exon 19 Deletion	2050 - Camperdown; 2170 - Liverpool; 2217 - Kogarah; 6008 - Subiaco; 3084 - Melbourne; 4102 - Woolloongabba	https://clinicaltrials.gov/ct2/show/NCT05338970
NCT05340374	LuCAB	Phase 1		NSW, VIC	2022-04-22	2022-07-14		Cabazitaxel; Cabazitaxel + Lu-177 vipivotide tetraxetan; Lu-177 vipivotide tetraxetan	radioconjugate,PSMA-targeting; taxane; radioconjugate,PSMA-targeting + taxane	Cabazitaxel + Lu-177 vipivotide tetraxetan	radioconjugate,PSMA-targeting + taxane	21/018	Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer	Metastatic Castration-resistant Prostate Cancer; mCRPC 0 0	3000 - Melbourne; 2000 - Sydney	https://clinicaltrials.gov/ct2/show/NCT05340374
NCT05348577	CAPItello280	Phase 3		NSW, QLD, SA	2022-04-27	2022-03-25		Capivasertib; Capivasertib + Docetaxel; Docetaxel; Placebo	placebo; pan-AKT_inhibitor; pan-AKT_inhibitor + taxane; taxane	Capivasertib + Docetaxel; Docetaxel; Placebo	pan-AKT_inhibitor + taxane; taxane; placebo	2023-504996-26-00  D361EC00001	A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)	Prostate Cancer	5000 - North Adelaide; 2076 - Wahroonga; 2800 - Orange; 2217 - Kogarah; 4575 - Birtinya; 4020 - Redcliffe; 4120 - Greenslopes	https://clinicaltrials.gov/ct2/show/NCT05348577
NCT05349643	AMB-051-07	Phase 2		NSW, QLD	2022-04-27	2023-01-26		AMB-05X	anti-CSF1R_monoclonal_antibody	AMB-05X	anti-CSF1R_monoclonal_antibody	AMB-051-07	A Phase 2, Open-Label, Adaptive, Dose-Ranging Study With Long-Term Extension to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Intra Articular AMB-05X Injections in Subjects With Tenosynovial Giant Cell Tumor	TGCT; Tenosynovial Giant Cell Tumor; Pigmented Villonodular Synovitis	- Camperdown; - Woolloongabba	https://clinicaltrials.gov/ct2/show/NCT05349643
NCT05352672	2021-004453-23--R3767-ONC-2011	Phase 3		QLD, SA, TAS, VIC	2022-04-29	2022-07-14		Cemiplimab; Cemiplimab + Fianlimab; Fianlimab; Pembrolizumab; Placebo	placebo; anti-LAG3_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody	Cemiplimab; Cemiplimab + Fianlimab; Pembrolizumab; Placebo	anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; placebo	2021-004453-23  R3767-ONC-2011	A Phase 3 Trial of Fianlimab (REGN3767, Anti-LAG-3) + Cemiplimab Versus Pembrolizumab in Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma	Melanoma	03004 - Melbourne; 03355 - Wendouree; 7000 - Hobart; 05006 - Adelaide; 04814 - Townsville; 4215 - Southport; 03220 - Geelong	https://clinicaltrials.gov/ct2/show/NCT05352672
NCT05355298	AMP945-PC-201	Phase 1		NSW, QLD, VIC	2022-05-02	2022-05-31		AMP945; Gemcitabine; Nab-paclitaxel	antimetabolite; FAK_inhibitor; taxane	AMP945; Gemcitabine; Nab-paclitaxel	FAK_inhibitor; antimetabolite; taxane	AMP945-PC-201	A Phase 1b/2a, Multicentre, Open Label Study of the Pharmacokinetics, Safety and Efficacy of AMP945 in Combination with Nab-paclitaxel and Gemcitabine in Pancreatic Cancer Patients	Pancreatic Ductal Adenocarcinoma; Pancreatic Cancer; PDAC	2298 - Waratah; 2065 - St Leonards; 3168 - Clayton; 2145 - Westmead; 3128 - Box Hill; 3021 - St Albans; 3121 - Richmond; 4120 - Greenslopes	https://clinicaltrials.gov/ct2/show/NCT05355298
NCT05356741	TCD17730--AMX-818-001	Phase 1		NSW, VIC	2022-05-02	2022-04-13		AMX-818; AMX-818 + Pembrolizumab; Pembrolizumab	bispecific_T-cell_engager,ERBB2-targeting; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + bispecific_T-cell_engager,ERBB2-targeting	AMX-818; AMX-818 + Pembrolizumab	anti-PD-1_monoclonal_antibody + bispecific_T-cell_engager,ERBB2-targeting; bispecific_T-cell_engager,ERBB2-targeting	TCD17730  AMX-818-001	A Phase 1, Multicenter, Open-Label, First-in-Human Study of the Safety and Pharmacokinetics of AMX-818 Alone and in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers	Locally Advanced or Metastatic HER2-Expressing Cancers	2031 - Randwick; 3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT05356741
NCT05359861	SRF388-201	Phase 2		VIC	2022-05-04	2022-04-12		Atezolizumab; Atezolizumab + Bevacizumab; Atezolizumab + Bevacizumab + Casdozokitug; Bevacizumab; Casdozokitug; Placebo	placebo; anti-IL27_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-VEGF_monoclonal_antibody; anti-IL27_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody	Atezolizumab + Bevacizumab; Atezolizumab + Bevacizumab + Casdozokitug; Placebo	anti-IL27_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; placebo	SRF388-201	A Randomized Phase 2 Trial of Atezolizumab and Bevacizumab in Combination With SRF388 or Placebo in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma	Hepatocellular Carcinoma	- Melbourne; 3004 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT05359861
NCT05361395	2024-511021-58--20200469	Phase 1		NSW	2022-05-04	2022-08-24		Atezolizumab; Atezolizumab + Carboplatin + Etoposide + Tarlatamab; Atezolizumab + Tarlatamab; Carboplatin; Durvalumab; Durvalumab + Tarlatamab; Etoposide; Tarlatamab	topoisomerase_inhibitor; anti-PD-L1_monoclonal_antibody + bispecific_T-cell_engager,DLL3-targeting; anti-PD-L1_monoclonal_antibody; platinum-based_antineoplastic_agent; bispecific_T-cell_engager,DLL3-targeting; anti-PD-L1_monoclonal_antibody + bispecific_T-cell_engager,DLL3-targeting + platinum-based_antineoplastic_agent + topoisomerase_inhibitor	Atezolizumab; Atezolizumab + Carboplatin + Etoposide + Tarlatamab; Atezolizumab + Tarlatamab; Durvalumab; Durvalumab + Tarlatamab	anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + bispecific_T-cell_engager,DLL3-targeting; anti-PD-L1_monoclonal_antibody + bispecific_T-cell_engager,DLL3-targeting + platinum-based_antineoplastic_agent + topoisomerase_inhibitor	2024-511021-58  20200469	A Phase 1b Study Evaluating the Safety and Efficacy of First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung (DeLLphi-303)	Extensive Stage Small Cell Lung Cancer	2050 - Camperdown	https://clinicaltrials.gov/ct2/show/NCT05361395
NCT05363605	FPI-1966-101	Phase 1			2022-05-06	2022-04-20		111In-FPI-1967; 225Ac-FPI-1966	radioconjugate,FGFR3-targeting	111In-FPI-1967; 225Ac-FPI-1966	radioconjugate,FGFR3-targeting	FPI-1966-101	A Phase 1/2 Study of [225Ac]-FPI-1966, [111In]-FPI-1967, and Vofatamab in Participants With FGFR3-expressing Advanced, Inoperable, Metastatic and/or Recurrent Solid Tumours	Advanced Solid Tumor		https://clinicaltrials.gov/ct2/show/NCT05363605
NCT05364073	FURMO-002	Phase 1		NSW, VIC	2022-05-06	2022-06-30		Furmonertinib	ERBB2_inhibitor,exon_20_selective; EGFR_inhibitor,third_generation; EGFR_inhibitor,exon_20_selective	Furmonertinib	EGFR_inhibitor,exon_20_selective; EGFR_inhibitor,third_generation; ERBB2_inhibitor,exon_20_selective	FURMO-002	A Phase 1b Dose Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, and Antitumor Activity of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations	EGFR Uncommon Mutations, Including G719X and S768I; HER2 Exon 20 Mutations; Metastatic Non-Small Cell Lung Cancer; EGFR Exon 20 Mutations; Non-Small Cell Lung Cancer (NSCLC); Advanced Non-Small Cell Lung Cancer	3084 - Heidelberg; 2065 - St Leonards; 2148 - Blacktown	https://clinicaltrials.gov/ct2/show/NCT05364073
NCT05367440	PETRANHA	Phase 1		NSW, VIC	2022-05-10	2022-06-02		Abiraterone; Abiraterone + Saruparib; Apalutamide; Apalutamide + Saruparib; Darolutamide; Darolutamide + Saruparib; Enzalutamide; Enzalutamide + Saruparib; Saruparib	PARP1-selective_inhibitor; CYP17A1_inhibitor + PARP1-selective_inhibitor; antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor; PARP1-selective_inhibitor + antiandrogen,nonsteroidal,second_generation	Abiraterone + Saruparib; Apalutamide + Saruparib; Darolutamide + Saruparib; Enzalutamide + Saruparib	CYP17A1_inhibitor + PARP1-selective_inhibitor; PARP1-selective_inhibitor + antiandrogen,nonsteroidal,second_generation	2023-508536-64-00  D9720C00003	A Multi-arm, Open-label Phase I/IIa Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD5305 in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer (PETRANHA)	Metastatic Prostate Cancer	3004 - Melbourne; 2010 - Darlinghurst; 2050 - Camperdown; 3002 - East Melbourne; 3084 - Heidelberg; 2065 - St. Leonards	https://clinicaltrials.gov/ct2/show/NCT05367440
NCT05381909	CTR20232532--BGB-24714-101	Phase 1		NSW, NZ, QLD, VIC	2022-05-19	2022-07-06		BGB-24714; BGB-24714 + Paclitaxel; Carboplatin; Docetaxel; Docetaxel + Paclitaxel; Paclitaxel	SMAC_mimetic + taxane; SMAC_mimetic; taxane; platinum-based_antineoplastic_agent; IAP_inhibitor + taxane; IAP_inhibitor	BGB-24714; BGB-24714 + Paclitaxel; Docetaxel + Paclitaxel; Carboplatin	IAP_inhibitor; IAP_inhibitor + taxane; SMAC_mimetic; SMAC_mimetic + taxane; taxane; platinum-based_antineoplastic_agent	CTR20232532  BGB-24714-101	A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of Second Mitochondrial-derived Activator of Caspases Mimetic BGB-24714 as Monotherapy and With Combination Therapies in Patients With Solid Tumors	Solid Tumor, Adult	4102 - Woolloongabba; 2086 - Frenchs Forest; 4101 - South Brisbane; Auckland; 3021 - St Albans; 3000 - Melbourne; 3084 - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT05381909
NCT05382286	ASCENT-04	Phase 3		NSW, QLD, SA, TAS, VIC, WA	2022-05-19	2022-07-25		Carboplatin; Gemcitabine; Nab-paclitaxel; Paclitaxel; Pembrolizumab; Pembrolizumab + Sacituzumab Govitecan; Sacituzumab Govitecan	anti-Trop2_antibody-drug_conjugate; antimetabolite; anti-PD-1_monoclonal_antibody; taxane; gemcitabine; anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; platinum-based_antineoplastic_agent	Pembrolizumab; Pembrolizumab + Sacituzumab Govitecan; Carboplatin; Gemcitabine; Nab-paclitaxel	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; antimetabolite; gemcitabine; platinum-based_antineoplastic_agent; taxane	2021-005742-14  GS-US-592-6173	A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1	PD-L1 Positive; Triple Negative Breast Cancer	2640 - Albury; 5000 - Adelaide; 6009 - Nedlands; 3050 - Parkville; 2217 - Kogarah; 2060 - North Sydney; 2065 - St Leonards; 4101 - South Brisbane; 3168 - Clayton; 7000 - Hobart; 4102 - Woolloongabba; 3084 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT05382286
NCT05382299	ASCENT-03	Phase 3		NSW, QLD, SA, TAS, VIC, WA	2022-05-19	2022-07-20		Carboplatin; Gemcitabine; Nab-paclitaxel; Paclitaxel; Sacituzumab Govitecan	anti-Trop2_antibody-drug_conjugate; antimetabolite; platinum-based_antineoplastic_agent; taxane; gemcitabine	Sacituzumab Govitecan; Carboplatin; Gemcitabine; Nab-paclitaxel	anti-Trop2_antibody-drug_conjugate; antimetabolite; gemcitabine; platinum-based_antineoplastic_agent; taxane	2021-005743-79  GS-US-592-6238	A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose Tumors Do Express PD-L1	PD-L1 Negative; Triple Negative Breast Cancer	2217 - Kogarah; 2060 - North Sydney; 6009 - Nedlands; 3084 - Melbourne; 4102 - Woolloongabba; 4101 - South Brisbane; 2065 - St Leonards; 7000 - Hobart; 3168 - Clayton; 2640 - Albury; 5000 - Adelaide	https://clinicaltrials.gov/ct2/show/NCT05382299
NCT05383079	AlphaBet	Phase 1		VIC	2022-05-19	2022-09-13		Lu-177 vipivotide tetraxetan; Lu-177 vipivotide tetraxetan + Radium-223; Radium-223	radioconjugate,PSMA-targeting + radium_223_radionuclide; radium_223_radionuclide; radioconjugate,PSMA-targeting	Lu-177 vipivotide tetraxetan + Radium-223	radioconjugate,PSMA-targeting + radium_223_radionuclide	21/029	Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men with Metastatic Castration-Resistant Prostate Cancer	Prostate Cancer; Metastatic Castration-resistant Prostate Cancer; MCRPC	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT05383079
NCT05383352	SIRACUSA	Phase 1		SA, VIC	2022-05-20	2022-05-30		Fluorouracil; Fluorouracil + Liposomal Irinotecan; Irinotecan; Leucovorin; Liposomal Irinotecan	topoisomerase_inhibitor; folinic_acid; Fluorouracil; fluoropyrimidine; fluoropyrimidine + topoisomerase_inhibitor	Fluorouracil + Liposomal Irinotecan; Leucovorin	fluoropyrimidine + topoisomerase_inhibitor; Fluorouracil; folinic_acid	2021-003264-26  D-FR-60010-015	A Phase I, Randomised, Open-Label, Single-Dose, Two-Treatment, Two-Way Crossover, Two-Stage Study to Evaluate the Bioequivalence of Onivyde (Irinotecan Liposome Injection) Manufactured at Two Different Sites Administered in Combination With Anti-Cancer Agents in Adult Participants With Metastatic Pancreatic Adenocarcinoma	Metastatic Pancreatic Adenocarcinoma	- Bedford Park; - Frankston	https://clinicaltrials.gov/ct2/show/NCT05383352
NCT05384626	NVL-655-01	Phase 1		NSW, QLD, VIC	2022-05-20	2022-06-09		Lorlatinib; NVL-655	ALK_inhibitor,third_generation; ALK_inhibitor,fourth_generation; ROS1_inhibitor	Lorlatinib; NVL-655	ALK_inhibitor,fourth_generation; ALK_inhibitor,third_generation; ROS1_inhibitor	NVL-655-01	A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors (ALKOVE-1)	Locally Advanced Solid Tumor; Metastatic Solid Tumor	2065 - Saint Leonards; 3000 - Melbourne; 4102 - Woolloongabba	https://clinicaltrials.gov/ct2/show/NCT05384626
NCT05388669	PALOMA-3	Phase 3		NSW, QLD, SA, VIC, WA	2022-05-24	2022-08-05		Amivantamab; Amivantamab + Lazertinib; Amivantamab + Lazertinib + rHuPH20; Lazertinib; Osimertinib; rHuPH20	recombinant_human_hyaluronidase; EGFR_inhibitor,third_generation + bispecific_cMET/EGFR_antibody + recombinant_human_hyaluronidase; bispecific_cMET/EGFR_antibody; EGFR_inhibitor,third_generation + bispecific_cMET/EGFR_antibody; EGFR_inhibitor,third_generation	Amivantamab + Lazertinib; Amivantamab + Lazertinib + rHuPH20; Osimertinib	EGFR_inhibitor,third_generation + bispecific_cMET/EGFR_antibody; EGFR_inhibitor,third_generation + bispecific_cMET/EGFR_antibody + recombinant_human_hyaluronidase	61186372NSC3004  CR109211	A Phase 3, Open-label, Randomized Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Patients With EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer After Progression on Osimertinib and Chemotherapy	Advanced or Metastatic Non-small Cell Lung Cancer	3000 - Melbourne; 2050 - Camperdown; 5000 - Adelaide; 4102 - Woolloongabba; 2145 - Westmead; 6150 - Murdoch	https://clinicaltrials.gov/ct2/show/NCT05388669
NCT05393791	ANZadapt	Phase 2		NSW, QLD, SA, VIC, WA	2022-05-26	2022-11-10		Abiraterone; Abiraterone + Enzalutamide; Enzalutamide	antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation	Abiraterone + Enzalutamide	CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation	ANZUP 2101  79835	ANZadapt: Phase II Randomised Controlled Trial of Patient-specific Adaptive Versus Continuous Abiraterone or eNZalutamide in Metastatic Castration-resistant Prostate Cancer	Prostatic Neoplasms, Castration-Resistant	2298 - Newcastle; - Adelaide; 5000 - Adelaide; 2050 - Camperdown; 2460 - Albury; 4101 - South Brisbane; 2065 - St Leonards; - Kogarah; 2076 - Wahroonga; - Birtinya; 6150 - Murdoch; - Box Hill	https://clinicaltrials.gov/ct2/show/NCT05393791
NCT05399654	INCLINE-101	Phase 1		WA	2022-06-01	2022-06-28		TAC-001	TLR9_agonistic_antibody_conjugate	TAC-001	TLR9_agonistic_antibody_conjugate	INCLINE-101	A Phase 1/2, Open Label, Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors	Advanced or Metastatic Solid Tumors	6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT05399654
NCT05410145	2023-508517-16--D3S-001-100	Phase 1		NSW, SA, VIC, WA	2022-06-08	2022-08-03		Carboplatin; Carboplatin + Cisplatin + D3S-001 + Pemetrexed; Cetuximab; Cetuximab + D3S-001; Cisplatin; D3S-001; D3S-001 + Pembrolizumab; Pembrolizumab; Pemetrexed	antimetabolite; anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor + antimetabolite + platinum-based_antineoplastic_agent; KRAS_G12C_inhibitor; platinum-based_antineoplastic_agent; anti-EGFR_monoclonal_antibody; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody	Carboplatin + Cisplatin + D3S-001 + Pemetrexed; Cetuximab + D3S-001; D3S-001; D3S-001 + Pembrolizumab	KRAS_G12C_inhibitor; KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor + antimetabolite + platinum-based_antineoplastic_agent	2023-508517-16  D3S-001-100	A Phase 1/2, Open Label, Dose-escalation, and Dose-expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of D3S 001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation	KRAS P.G12C	5042 - Bedford Park; 2109 - Sydney; 3000 - Melbourne; 3144 - Malvern; 6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT05410145
NCT05411133	A001	Phase 1		NSW, SA	2022-06-09	2022-05-30		Cabotamig	bispecific_T-cell_engager,CDH17-targeting	Cabotamig	bispecific_T-cell_engager,CDH17-targeting	A001	A Phase 1, First-in-human Study of Cabotamig (ARB202), Bispecific Antibody to CDH17 and CD3 in Advanced Gastrointestinal Malignancies	Gastrointestinal Cancer; Cholangiocarcinoma; Colorectal Adenocarcinoma; Esophageal Adenocarcinoma; Gastroesophageal Junction; Gastric Cancer; Liver Cancer; Pancreatic Cancer	- Sydney; - Adelaide	https://clinicaltrials.gov/ct2/show/NCT05411133
NCT05413421	ORIC-944-01	Phase 1		NSW, VIC	2022-06-10	2022-06-01		Abiraterone; Abiraterone + Apalutamide + Darolutamide + Enzalutamide + ORIC-944; Apalutamide; Apalutamide + ORIC-944; Darolutamide; Enzalutamide; ORIC-944	PRC2_complex_inhibitor; PRC2_complex_inhibitor + antiandrogen,nonsteroidal,second_generation; antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor; CYP17A1_inhibitor + PRC2_complex_inhibitor + antiandrogen,nonsteroidal,second_generation	Abiraterone + Apalutamide + Darolutamide + Enzalutamide + ORIC-944; Apalutamide + ORIC-944; ORIC-944	CYP17A1_inhibitor + PRC2_complex_inhibitor + antiandrogen,nonsteroidal,second_generation; PRC2_complex_inhibitor; PRC2_complex_inhibitor + antiandrogen,nonsteroidal,second_generation	ORIC-944-01	An Open-Label, Phase 1/1b Study of ORIC-944 As a Single Agent or in Combination with an Androgen Receptor Pathway Inhibitor in Patients with Metastatic Prostate Cancer	Metastatic Prostate Cancer	- Wahroonga; - Bendigo	https://clinicaltrials.gov/ct2/show/NCT05413421
NCT05415072	2021-003380-95--CDYP688A12101	Phase 1		NSW, VIC	2022-06-10	2022-07-04		DYP688; Tebentafusp	GNAQ/GNA11_inhibitor; bispecfic_T-cell_engager,gp100-targeting	Tebentafusp; DYP688	bispecfic_T-cell_engager,gp100-targeting; GNAQ/GNA11_inhibitor	2021-003380-95  CDYP688A12101	A Phase I/II, Multi-center, Open Label Study of DYP688 in Patients With Metastatic Uveal Melanoma (MUM) and Other GNAQ/11 Mutant Melanomas	Metastatic Uveal Melanoma	3000 - Melbourne; 2145 - Westmead	https://clinicaltrials.gov/ct2/show/NCT05415072
NCT05417594	CERTIS1	Phase 1		NSW, VIC	2022-06-14	2022-06-24		Datopotamab deruxtecan; Datopotamab deruxtecan + Palacaparib; Palacaparib; Palacaparib + Temozolomide; Palacaparib + Trastuzumab Deruxtecan; Temozolomide; Trastuzumab Deruxtecan	anti-Trop2_antibody-drug_conjugate; PARP1-selective_inhibitor + anti-Trop2_antibody-drug_conjugate; PARP1-selective_inhibitor; PARP1-selective_inhibitor + alkylating_agent; alkylating_agent; PARP1-selective_inhibitor + anti-ERBB2_antibody-drug_conjugate; anti-ERBB2_antibody-drug_conjugate	Datopotamab deruxtecan + Palacaparib; Palacaparib; Palacaparib + Temozolomide; Palacaparib + Trastuzumab Deruxtecan	PARP1-selective_inhibitor; PARP1-selective_inhibitor + alkylating_agent; PARP1-selective_inhibitor + anti-ERBB2_antibody-drug_conjugate; PARP1-selective_inhibitor + anti-Trop2_antibody-drug_conjugate	2023-504984-17-00  D8410C00001	A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (CERTIS1)	Advanced Solid Malignancies	2031 - Randwick; 3000 - Melbourne; 2010 - Darlinghurst; 2050 - Camperdown	https://clinicaltrials.gov/ct2/show/NCT05417594
NCT05425862	REPAIR	Phase 1		NSW, VIC	2022-06-21	2022-10-21		Pidnarulex; Pidnarulex + Talazoparib; Talazoparib	RNA_polymerase_I_transcription_inhibitor; PARP_inhibitor + RNA_polymerase_I_transcription_inhibitor; PARP_inhibitor	Pidnarulex + Talazoparib	PARP_inhibitor + RNA_polymerase_I_transcription_inhibitor	20/019	Phase 1 Trial of Pidnarulex and Talazoparib in Patients With Metastatic Castration Resistant Prostate Cancer	Metastatic Castration Resistant Prostate Cancer (mCRPC)	3128 - Box Hill; 3000 - Prahran; 2010 - Sydney; 3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT05425862
NCT05425940	STELLAR-303	Phase 3		NSW, NZ, SA, VIC	2022-06-21	2022-09-07		Atezolizumab; Atezolizumab + Zanzalintinib; Regorafenib; Zanzalintinib	KIT/PDGFR/RET/VEGFR/FGFR_inhibitor; MET/VEGFR2/AXL/MER_inhibitor + anti-PD-L1_monoclonal_antibody; MET/VEGFR2/AXL/MER_inhibitor; anti-PD-L1_monoclonal_antibody	Atezolizumab + Zanzalintinib; Regorafenib	KIT/PDGFR/RET/VEGFR/FGFR_inhibitor; MET/VEGFR2/AXL/MER_inhibitor + anti-PD-L1_monoclonal_antibody	2021-003243-21  XL092-303	A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer	Colorectal Cancer	5011 - Woodville South; 3021 - Melbourne; 3002 - Melbourne; 5042 - Bedford Park; 2444 - Port Macquarie; 3084 - Heidelberg; 2640 - Albury; Dunedin; Wellington; 2200 - Bankstown; Hamilton; Auckland	https://clinicaltrials.gov/ct2/show/NCT05425940
NCT05440786	J1S-MC-JP04--18434	Phase 2		NSW, VIC	2022-07-01	2022-09-20		Abemaciclib; Abemaciclib + Irinotecan + Temozolomide; Irinotecan; Irinotecan + Temozolomide; Temozolomide	alkylating_agent; topoisomerase_inhibitor; CDK4/6_inhibitor + alkylating_agent + topoisomerase_inhibitor; CDK4/6_inhibitor; alkylating_agent + topoisomerase_inhibitor	Abemaciclib + Irinotecan + Temozolomide; Irinotecan + Temozolomide	CDK4/6_inhibitor + alkylating_agent + topoisomerase_inhibitor; alkylating_agent + topoisomerase_inhibitor	J1S-MC-JP04  18434	A Randomized, Open-Label, Phase 2 Study Evaluating Abemaciclib in Combination With Irinotecan and Temozolomide in Participants With Relapsed or Refractory Ewing's Sarcoma	Sarcoma, Ewing; Neoplasm Metastasis	3052 - Melbourne; 3000 - Melbourne; 2145 - Westmead	https://clinicaltrials.gov/ct2/show/NCT05440786
NCT05450692	LATIFY	Phase 3		NSW, QLD, SA, WA	2022-07-11	2022-09-15		Ceralasertib; Ceralasertib + Durvalumab; Docetaxel; Durvalumab	ATR_inhibitor + anti-PD-L1_monoclonal_antibody; ATR_inhibitor; anti-PD-L1_monoclonal_antibody; taxane	Ceralasertib + Durvalumab; Docetaxel	ATR_inhibitor + anti-PD-L1_monoclonal_antibody; taxane	2022-000493-26  D533BC00001	A Phase III, Open-label, Randomised, Multicentre Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations, and Whose Disease Has Progressed On or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy: LATIFY	Advanced or Metastatic Non-Small Cell Lung Cancer	2480 - Lismore; 5112 - Elizabeth Vale; 2500 - Wollongong; 4101 - South Brisbane; 6150 - Murdoch	https://clinicaltrials.gov/ct2/show/NCT05450692
NCT05450744	IPAX-2	Phase 1		NZ, QLD, SA, VIC	2022-07-11	2023-04-01		131I-IPA; 131I-TLX-101	radioiodine_conjugate; radioligand,LAT1/LAT2-targeting	131I-IPA; 131I-TLX-101	radioiodine_conjugate; radioligand,LAT1/LAT2-targeting	131I-TLX-101-002 (IPAX-2)	A Phase 1 Safety and Dose Finding Study of 131I -TLX101 Plus Standard of Care in Patients With Newly Diagnosed Glioblastoma	Neoplastic Disease; Glioblastoma; Glioblastoma Multiforme	- Gold Coast; Auckland; - Adelaide; - Melbourne	https://clinicaltrials.gov/ct2/show/NCT05450744
NCT05458219	CIBI343A101	Phase 1		NSW, QLD	2022-07-14	2022-10-26		IBI343	anti-CLDN18.2_antibody-drug_conjugate	IBI343	anti-CLDN18.2_antibody-drug_conjugate	CIBI343A101	A Phase 1a/b, Multicenter, Open-label, First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors	Locally Advanced Unresectable or Metastatic Solid Tumors	2500 - Wollongong; 2010 - Darlinghurst; 4575 - Birtinya; 4217 - Benowa	https://clinicaltrials.gov/ct2/show/NCT05458219
NCT05459129	CO43613	Phase 1		SA, WA	2022-07-14	2023-04-13		Atezolizumab; Atezolizumab + Carboplatin + Paclitaxel + Tiragolumab; Atezolizumab + Tiragolumab; Carboplatin; Paclitaxel; Tiragolumab	anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-TIGIT_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; taxane; platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane	Atezolizumab + Carboplatin + Paclitaxel + Tiragolumab; Atezolizumab + Tiragolumab	anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane	CO43613	A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)	Squamous Cell Carcinoma of the Head and Neck	6009 - Perth; 5000 - Adelaide	https://clinicaltrials.gov/ct2/show/NCT05459129
NCT05462236	KEYNOTE-D65--AUM001-2001-MK3475-D65	Phase 2		NSW, QLD, VIC	2022-07-18	2023-04-14		Irinotecan; Irinotecan + Pembrolizumab + Tinodasertib; Pembrolizumab; Tinodasertib	MNK1/2_inhibitor + anti-PD-1_monoclonal_antibody + topoisomerase_inhibitor; topoisomerase_inhibitor; anti-PD-1_monoclonal_antibody; MNK1/2_inhibitor	Irinotecan + Pembrolizumab + Tinodasertib; Tinodasertib	MNK1/2_inhibitor; MNK1/2_inhibitor + anti-PD-1_monoclonal_antibody + topoisomerase_inhibitor	KEYNOTE-D65  AUM001-2001-MK3475-D65	A Phase II Open Label, Dose-finding run-in and Cohort Expansion Study to Evaluate the Safety, Tolerability and Effectiveness of Tinodasertib in Combination With Pembrolizumab or Irinotecan in Metastatic Colorectal Cancer	Metastatic Colorectal Cancer	3355 - Wendouree; 3144 - Malvern; 4217 - Benowa; 2050 - Camperdown; 2500 - Wollongong	https://clinicaltrials.gov/ct2/show/NCT05462236
NCT05462717	RMC-6291-001	Phase 1		NSW, VIC	2022-07-18	2022-09-19		RMC-6291	KRAS_G12C_inhibitor	RMC-6291	KRAS_G12C_inhibitor	RMC-6291-001	Phase 1/1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors	Non-Small Cell Lung Cancer (NSCLC); Pancreatic Ductal Adenocarcinoma; Colorectal Cancer (CRC); Advanced Solid Tumor	3084 - Heidelberg; 2228 - Sydney; 3199 - Frankston; 3280 - Warrnambool	https://clinicaltrials.gov/ct2/show/NCT05462717
NCT05466799	TRIPP-FFX	Phase 2		SA, TAS, VIC	2022-07-20	2023-04-26		OncoSil	brachytherapy	OncoSil	brachytherapy	ONCO01P04	An Open-label, Multi-centre, Randomized Study of TaRgeted Intratumoural Placement of P-32 (OncoSil™) in Addition to FOLFIRINOX Chemotherapy vs FOLFIRINOX Alone in Patients With Unresectable Locally Advanced Pancreatic Adenocarcinoma.	Locally Advanced Pancreatic Cancer	- Richmond; - Adelaide	https://clinicaltrials.gov/ct2/show/NCT05466799
NCT05468697	MK-6482-024--6482-024	Phase 1		NSW, VIC, WA	2022-07-21	2022-08-10		Belzutifan; Palbociclib; Thiotepa	alkylating_agent; HIF2a_inhibitor; CDK4/6_inhibitor	Palbociclib; Belzutifan; Thiotepa	CDK4/6_inhibitor; HIF2a_inhibitor; alkylating_agent	MK-6482-024  6482-024	A Multicenter, Open-label, Randomized, Phase 1/2 Study of Belzutifan in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma	Renal Cell Carcinoma	2145 - Westmead; 2109 - Macquarie University; 6009 - Nedlands; 3199 - Frankston	https://clinicaltrials.gov/ct2/show/NCT05468697
NCT05480865	Argonaut	Phase 1		NSW, SA, VIC, WA	2022-07-29	2022-07-06		BBP-398; BBP-398 + Sotorasib; Sotorasib	KRAS_G12C_inhibitor; SHP2_inhibitor; KRAS_G12C_inhibitor + SHP2_inhibitor; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + SHP2_inhibitor	BBP-398 + Sotorasib	KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + SHP2_inhibitor; KRAS_G12C_inhibitor + SHP2_inhibitor	NAV-1003	A Phase 1 Study of the SHP2 Inhibitor BBP-398 (Formerly Known as IACS-15509) in Combination With the KRAS-G12C Inhibitor Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation	Solid Tumor, Adult; Non Small Cell Lung Cancer; Metastatic Solid Tumor; Metastatic NSCLC	6008 - Subiaco; 3199 - Frankston; NSW 2800 - Orange; 6009 - Perth; 5042 - Adelaide; 5000 - Adelaide	https://clinicaltrials.gov/ct2/show/NCT05480865
NCT05483530	HLX60HLX10-FIH101	Phase 1		NSW	2022-08-02	2022-12-14		HLX10; HLX10 + HLX60; HLX60	anti-GARP_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-GARP_monoclonal_antibody; anti-PD-1_monoclonal_antibody	HLX10 + HLX60	anti-GARP_monoclonal_antibody + anti-PD-1_monoclonal_antibody	HLX60HLX10-FIH101	A Phase 1 Clinical Study to Investigate the Safety, Tolerability and Efficacy of HLX60 (Anti-GARP Monoclonal Antibody) Combination With HLX10 (Anti-PD-1 Monoclonal Antibody) in Subjects With Advanced or Metastatic Solid Tumors	Advanced or Metastatic Solid Tumors	- Sydney	https://clinicaltrials.gov/ct2/show/NCT05483530
NCT05494762	BGB-A317-B167-101	Phase 1		NSW, SA, VIC	2022-08-10	2022-08-25		BGB-B167; BGB-B167 + Tislelizumab; Tislelizumab	bispecific_CEACAM5/4-1BB_antibody; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + bispecific_CEACAM5/4-1BB_antibody	BGB-B167 + Tislelizumab	anti-PD-1_monoclonal_antibody + bispecific_CEACAM5/4-1BB_antibody	BGB-A317-B167-101	A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B167, Alone and in Combination With Tislelizumab in Patients With Selected Advanced or Metastatic Solid Tumors	Solid Tumor	5037 - Kurralta Park; 3000 - Melbourne; 3004 - Melbourne; 3168 - Clayton; 2148 - Blacktown	https://clinicaltrials.gov/ct2/show/NCT05494762
NCT05494918	JSKN003-101	Phase 1		WA	2022-08-10	2022-09-02		JSKN003	biparatopic_ERBB2_antibody-drug_conjugate; UNDEF + anti-PD-L1_monoclonal_antibody	JSKN003	biparatopic_ERBB2_antibody-drug_conjugate; UNDEF + anti-PD-L1_monoclonal_antibody	JSKN003-101	A Phase I, Multi-center, Open-label, Dose Escalation, First-In-Human Study to Assess the Safety, Tolerability and Pharmacokinetics of JSKN003 in Subjects With Advanced or Metastatic Solid Malignant Tumors	Advanced Solid Tumors; Metastatic Solid Tumors	6009 - Perth	https://clinicaltrials.gov/ct2/show/NCT05494918
NCT05498428	PALOMA-2	Phase 2			2022-08-12	2022-11-11		Amivantamab; Amivantamab + Carboplatin + Lazertinib + Osimertinib + Pemetrexed; Amivantamab + Carboplatin + Lazertinib + Pemetrexed; Amivantamab + Carboplatin + Osimertinib + Pemetrexed; Amivantamab + Carboplatin + Pemetrexed; Amivantamab + Lazertinib; Amivantamab + Lazertinib + rHuPH20; Carboplatin; Lazertinib; Osimertinib; Pemetrexed; rHuPH20	antimetabolite; bispecific_cMET/EGFR_antibody; EGFR_inhibitor,third_generation; recombinant_human_hyaluronidase; EGFR_inhibitor,third_generation + bispecific_cMET/EGFR_antibody + recombinant_human_hyaluronidase; platinum-based_antineoplastic_agent; antimetabolite + bispecific_cMET/EGFR_antibody + platinum-based_antineoplastic_agent; EGFR_inhibitor,third_generation + bispecific_cMET/EGFR_antibody; EGFR_inhibitor,third_generation + antimetabolite + bispecific_cMET/EGFR_antibody + platinum-based_antineoplastic_agent	Amivantamab + Carboplatin + Lazertinib + Osimertinib + Pemetrexed; Amivantamab + Carboplatin + Lazertinib + Pemetrexed; Amivantamab + Carboplatin + Osimertinib + Pemetrexed; Amivantamab + Carboplatin + Pemetrexed; Amivantamab + Lazertinib; Amivantamab + Lazertinib + rHuPH20	EGFR_inhibitor,third_generation + antimetabolite + bispecific_cMET/EGFR_antibody + platinum-based_antineoplastic_agent; EGFR_inhibitor,third_generation + bispecific_cMET/EGFR_antibody; EGFR_inhibitor,third_generation + bispecific_cMET/EGFR_antibody + recombinant_human_hyaluronidase; antimetabolite + bispecific_cMET/EGFR_antibody + platinum-based_antineoplastic_agent	61186372NSC2002  CR109264	A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients With Advanced or Metastatic Solid Tumors Including EGFR-mutated Non-Small Cell Lung Cancer	Carcinoma, Non-small-Cell Lung		https://clinicaltrials.gov/ct2/show/NCT05498428
NCT05500508	AMXT1501-102	Phase 1		NSW	2022-08-15	2022-11-29		AMXT-1501	polyamine_transport_inhibitor	AMXT-1501	polyamine_transport_inhibitor	AMXT1501-102	A Phase 1B/2A Study of the Safety, Tolerability and Initial Efficacy of Oral AMXT 1501 Dicaprate and Intravenous Difluoromethylornithine (DFMO) in Patients With Cancer	Ovary Cancer; Cancer; Head and Neck Cancer; Mesotheliomas Pleural; Advanced Cancer; Nsclc; Breast Cancer; Solid Carcinoma; Melanoma; Diffuse Midline Glioma, H3 K27M-Mutant; Mesothelioma Peritoneum; Cervical Cancer; Gastric Cancer; Endometrial Cancer; Solid Tumor; Papillary Thyroid Cancer; Glioma, Malignant; Esophageal Cancer; Colorectal Cancer; DIPG Brain Tumor	- Sydney	https://clinicaltrials.gov/ct2/show/NCT05500508
NCT05501886	VIKTORIA-1	Phase 3		NSW, QLD, SA, VIC, WA	2022-08-16	2022-12-08		Alpelisib; Alpelisib + Fulvestrant; Fulvestrant; Fulvestrant + Gedatolisib; Fulvestrant + Gedatolisib + Palbociclib; Gedatolisib; Palbociclib	CDK4/6_inhibitor + pan-PI3K/mTORC1/mTORC2_inhibitor + selective_estrogen_receptor_degrader; pan-PI3K/mTORC1/mTORC2_inhibitor + selective_estrogen_receptor_degrader; pan-PI3K/mTORC1/mTORC2_inhibitor; PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor; PI3K_alpha_inhibitor; selective_estrogen_receptor_degrader	Alpelisib + Fulvestrant; Fulvestrant; Fulvestrant + Gedatolisib; Fulvestrant + Gedatolisib + Palbociclib	CDK4/6_inhibitor + pan-PI3K/mTORC1/mTORC2_inhibitor + selective_estrogen_receptor_degrader; PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader; pan-PI3K/mTORC1/mTORC2_inhibitor + selective_estrogen_receptor_degrader; selective_estrogen_receptor_degrader	2021-005235-24  CELC-G-301	Phase 3, Open-Label, Randomized, Study Comparing Gedatolisib Combined With Fulvestrant & With or Without Palbociclib to Standard-of-Care Therapies in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination w/Non-Steroidal Aromatase Inhibitor Therapy	Breast Cancer	- Adelaide; - Woodville; - Wahroonga; - Nedlands; - South Brisbane; - Fitzroy; - Frankston; - Southport	https://clinicaltrials.gov/ct2/show/NCT05501886
NCT05503797	2022-000627-20--F8394-201	Phase 2		NSW, VIC	2022-08-17	2023-02-21		Plixorafenib	RAF_dimer_inhibitor	Plixorafenib	RAF_dimer_inhibitor	2022-000627-20  F8394-201	A Phase 2 Master Protocol to Assess the Efficacy and Safety of FORE8394, an Inhibitor of BRAF Class 1 and Class 2 Alterations, in Participants With Cancer Harboring BRAF Alterations	HGG; LGG; Melanoma BRAF V600E/K Mutated; Thyroid Cancer; Cancer Harboring BRAF Alterations; Solid Tumors	3004 - Melbourne; 2305 - New Lambton Heights; 2031 - Randwick	https://clinicaltrials.gov/ct2/show/NCT05503797
NCT05504291	NCI-2022-06082--ARET2121	Phase 2		WA	2022-08-17	2022-11-04		Carboplatin; Etoposide; Melphalan; Vincristine	topoisomerase_inhibitor; vinca_alkaloid; alkylating_agent; platinum-based_antineoplastic_agent	Melphalan; Carboplatin; Etoposide; Vincristine	alkylating_agent; platinum-based_antineoplastic_agent; topoisomerase_inhibitor; vinca_alkaloid	NCI-2022-06082  ARET2121	Intravitreal Melphalan for Intraocular Retinoblastoma	Stage I Retinoblastoma; Group D Retinoblastoma; Childhood Intraocular Retinoblastoma; Unilateral Retinoblastoma; Bilateral Retinoblastoma	6009 - Perth	https://clinicaltrials.gov/ct2/show/NCT05504291
NCT05505825	AK104-212	Phase 1		NSW, QLD, SA, VIC	2022-08-18	2022-08-26		Cadonilimab	bispecific_PD-1/CTLA4_antibody	Cadonilimab	bispecific_PD-1/CTLA4_antibody	AK104-212	A Phase Ib/II Clinical Study of Anti-PD-1 and CTLA-4 Bispecific Antibody, Cadonilimab(AK104), in Combination With Chiauranib in the Treatment of Patients With Extensive Stage Small Cell Lung Cancer Who Failed First-line Platinum-based Chemotherapy in Combination With Programmed Cell Death-1(PD1)/Programmed Cell Death Protein Ligand-1(PDL1) Inhibitors	SCLC,Extensive Stage	- South Brisbane; - Woolloongabba; - Bedford Park; - Frankston; - Westmead; - St Albans	https://clinicaltrials.gov/ct2/show/NCT05505825
NCT05508906	OP-1250-003	Phase 1		NSW, WA	2022-08-19	2022-08-31		Alpelisib; Alpelisib + Palazestrant; Everolimus; Everolimus + Palazestrant; Palazestrant; Palazestrant + Ribociclib; Ribociclib	PI3K_alpha_inhibitor + complete_estrogen_receptor_antagonist; complete_estrogen_receptor_antagonist; CDK4/6_inhibitor; mTORC1_inhibitor; CDK4/6_inhibitor + complete_estrogen_receptor_antagonist; PI3K_alpha_inhibitor; complete_estrogen_receptor_antagonist + mTORC1_inhibitor	Alpelisib + Palazestrant; Everolimus + Palazestrant; Palazestrant + Ribociclib	CDK4/6_inhibitor + complete_estrogen_receptor_antagonist; PI3K_alpha_inhibitor + complete_estrogen_receptor_antagonist; complete_estrogen_receptor_antagonist + mTORC1_inhibitor	OP-1250-003	A Phase 1b Open-Label Multicenter Study of OP-1250 (Palazestrant) in Combination With the CDK4/6 Inhibitor Ribociclib, With the PI3K Inhibitor Alpelisib, or With the mTOR Inhibitor Everolimus in Adult Subjects With Advanced and/or Metastatic ER Positive, HER2 Negative Breast Cancer	Metastatic Breast Cancer; HER2-negative Breast Cancer; Breast Cancer; Advanced Breast Cancer; ER-positive Breast Cancer	6009 - Nedlands; 2109 - Sydney	https://clinicaltrials.gov/ct2/show/NCT05508906
NCT05509985	ASKG315-101	Phase 1		NSW, VIC	2022-08-22			ASKG315; Pembrolizumab	IL-15_prodrug; anti-PD-1_monoclonal_antibody	ASKG315; Pembrolizumab	IL-15_prodrug; anti-PD-1_monoclonal_antibody	ASKG315-101	A Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ASKG315 as a Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors	Advanced Solid Tumors	- Sydney; - Melbourne	https://clinicaltrials.gov/ct2/show/NCT05509985
NCT05512377	2023-506369-79-00--1403-0011	Phase 2		NSW, QLD, SA, VIC	2022-08-23	2022-12-13		Brigimadlin	MDM2_inhibitor	Brigimadlin	MDM2_inhibitor	2023-506369-79-00  1403-0011	Brightline-2: A Phase IIa/IIb, Open-label, Single-arm, Multi-centre Trial of BI 907828 (Brigimadlin) for Treatment of Patients With Locally Advanced / Metastatic, MDM2 Amplified, TP53 Wild-type Biliary Tract Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, or Other Selected Solid Tumours	Solid Tumors; Lung Neoplasms; Pancreatic Neoplasms; Bladder Cancer; Biliary Tract Cancer	4101 - South Brisbane; 3084 - Heidelberg; 2031 - Randwick; 5042 - Bedford Park	https://clinicaltrials.gov/ct2/show/NCT05512377
NCT05513703	2022-500608-23-00--M22-137	Phase 2		VIC	2022-08-24	2022-11-21		Telisotuzumab Vedotin	anti-cMET_antibody-drug_conjugate	Telisotuzumab Vedotin	anti-cMET_antibody-drug_conjugate	2022-500608-23-00  M22-137	Phase 2, Open-Label Study in Subjects With Previously Untreated MET Amplified Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)	Non Small Cell Lung Cancer	3168 - Clayton	https://clinicaltrials.gov/ct2/show/NCT05513703
NCT05519449	ENGAGER-PSMA-01--PSMA-007-001	Phase 1		NSW, SA, WA	2022-08-29	2022-09-15		Darolutamide; JANX007	PSMA-tumor-activated_T-cell_engager; antiandrogen,nonsteroidal,second_generation	Darolutamide; JANX007	PSMA-tumor-activated_T-cell_engager; antiandrogen,nonsteroidal,second_generation	ENGAGER-PSMA-01  PSMA-007-001	A Phase 1, Open-Label, Multicenter Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer	Prostate Cancer; Castration Resistant Prostatic Cancer; Metastatic Castration-resistant Prostate Cancer	6009 - Nedlands; 5042 - Bedford Park; 2050 - Camperdown	https://clinicaltrials.gov/ct2/show/NCT05519449
NCT05521412	VIOLET	Phase 1		VIC	2022-08-30	2022-09-29						21/028	EValuation of radIOLigand Treatment in mEn With Metastatic Castration-resistant Prostate Cancer With [161Tb]Tb-PSMA-I&T: Phase I/II Study	Prostate Cancer; Metastatic Castration-resistant Prostate Cancer	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT05521412
NCT05523947	YH32367-101	Phase 1		NSW, SA, VIC, WA	2022-09-01	2022-08-26		YH32367	bispecific_ERBB2/4-1BB_antibody	YH32367	bispecific_ERBB2/4-1BB_antibody	YH32367-101	A Phase 1/2, Open-label, Multicenter, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of YH32367 in Patients With HER2-Positive Locally Advanced or Metastatic Solid Tumors	HER2-Positive Solid Tumor	- Sydney; - Melbourne; - Perth; - Adelaide	https://clinicaltrials.gov/ct2/show/NCT05523947
NCT05533697	2023-504506-11-00--mRNA-4359-P101	Phase 1		NSW, VIC, WA	2022-09-09	2022-08-18		Pembrolizumab; Pembrolizumab + mRNA-4359; mRNA-4359	mRNA_personalised_cancer_vaccine,IDO/PD-L1-targeting; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + mRNA_personalised_cancer_vaccine,IDO/PD-L1-targeting	Pembrolizumab + mRNA-4359; mRNA-4359	anti-PD-1_monoclonal_antibody + mRNA_personalised_cancer_vaccine,IDO/PD-L1-targeting; mRNA_personalised_cancer_vaccine,IDO/PD-L1-targeting	2023-504506-11-00  mRNA-4359-P101	Phase 1/2 Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors	Advanced Solid Tumors	2228 - Miranda; 3084 - Melbourne; 6009 - Nedlands; 2065 - Wollstonecraft	https://clinicaltrials.gov/ct2/show/NCT05533697
NCT05536141	ARC-20	Phase 1		NSW, VIC	2022-09-10	2022-10-26		AB-521; Cabozantinib; Zimberelimab	HIF2a_inhibitor; VEGFR2_inhibitor; anti-PD-1_monoclonal_antibody; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor; RET_inhibitor; ROS1_inhibitor; AXL_inhibitor; MET_inhibitor,type_2; KIT_inhibitor	Cabozantinib; Zimberelimab; AB-521	AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor; AXL_inhibitor; KIT_inhibitor; MET_inhibitor,type_2; RET_inhibitor; ROS1_inhibitor; VEGFR2_inhibitor; anti-PD-1_monoclonal_antibody; HIF2a_inhibitor	2024-519142-70-00  ARC-20	A Phase 1, Open-label, Dose Escalation and Dose Expansion Study, to Investigate the Safety, Tolerability, and Pharmacokinetic Profile of AB521 Monotherapy and Combination Therapies in Participants With Clear Cell Renal Cell Carcinoma and Other Solid Tumors	Solid Tumors; Clear Cell Renal Cell Carcinoma	- Sydney; - Melbourne; - Camperdown	https://clinicaltrials.gov/ct2/show/NCT05536141
NCT05543629	2022-501676-26--CA115-001	Phase 1		NSW, QLD, VIC, WA	2022-09-16	2022-10-04		BMS-986442; BMS-986442 + Carboplatin + Nivolumab + Paclitaxel; BMS-986442 + Carboplatin + Nivolumab + Pemetrexed; BMS-986442 + Docetaxel + Nivolumab; BMS-986442 + Nivolumab; Carboplatin; Docetaxel; Nivolumab; Paclitaxel; Pemetrexed	antimetabolite; anti-PD-1_monoclonal_antibody + bispecific_TIGIT/CD96_antibody + platinum-based_antineoplastic_agent + taxane; anti-PD-1_monoclonal_antibody + bispecific_TIGIT/CD96_antibody; anti-PD-1_monoclonal_antibody; taxane; anti-PD-1_monoclonal_antibody + bispecific_TIGIT/CD96_antibody + taxane; platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + antimetabolite + bispecific_TIGIT/CD96_antibody + platinum-based_antineoplastic_agent; bispecific_TIGIT/CD96_antibody	BMS-986442 + Carboplatin + Nivolumab + Paclitaxel; BMS-986442 + Carboplatin + Nivolumab + Pemetrexed; BMS-986442 + Docetaxel + Nivolumab; BMS-986442 + Nivolumab	anti-PD-1_monoclonal_antibody + antimetabolite + bispecific_TIGIT/CD96_antibody + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + bispecific_TIGIT/CD96_antibody; anti-PD-1_monoclonal_antibody + bispecific_TIGIT/CD96_antibody + platinum-based_antineoplastic_agent + taxane; anti-PD-1_monoclonal_antibody + bispecific_TIGIT/CD96_antibody + taxane	2022-501676-26  CA115-001	A Phase 1b/2 Study of BMS-986442 in Combination With Nivolumab or Nivolumab and Chemotherapies in Participants With Advanced Solid Tumors and Non-small Cell Lung Cancer	Non-small Cell Lung Cancer; Advanced Solid Tumors	4215 - Southport; 2010 - Darlinghurst; 3168 - Clayton; 6150 - Murdoch; 2145 - Westmead	https://clinicaltrials.gov/ct2/show/NCT05543629
NCT05544552	SURF301	Phase 1		NSW, QLD, VIC, WA	2022-09-16	2022-11-22		TYRA-300	FGFR3_inhibitor	TYRA-300	FGFR3_inhibitor	TYR300-101	A Multicenter, Open-label Phase 1/2 Study of TYRA300 in Advanced Urothelial Carcinoma and Other Solid Tumors With Activating FGFR3 Gene Alterations (SURF301)	Advanced Solid Tumor; Urothelial Carcinoma; Solid Tumor, Adult; Locally Advanced Urothelial Carcinoma; Advanced Urothelial Carcinoma; Non-muscle-invasive Bladder Cancer; FGFR3 Gene Mutation; Urinary Tract Cancer; Metastatic Urothelial Carcinoma; FGFR3 Gene Alteration; Bladder Cancer; Urinary Tract Carcinoma; Solid Tumor; Urinary Tract Tumor	4215 - Southport; 3000 - Melbourne; 2109 - Macquarie Park; 3084 - Heidelberg; 4102 - Woolloongabba; 6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT05544552
NCT05546476	PROACC-1	Phase 2		NSW, VIC	2022-09-19	2022-11-21		Placebo; Ponsegromab	placebo; anti-GDF15_monoclonal_antibody	Ponsegromab; Placebo	anti-GDF15_monoclonal_antibody; placebo	2023-510446-24-00  C3651003	A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF PONSEGROMAB IN PATIENTS WITH CANCER, CACHEXIA, AND ELEVATED CONCENTRATIONS OF GDF-15, FOLLOWED BY AN OPTIONAL OPEN-LABEL TREATMENT PERIOD (PROACC -1)	Fatigue; Non-small Cell Lung Cancer; Pancreatic Cancer; Loss of Appetite; Cachexia; Colorectal Cancer	2800 - Orange; 3021 - St Albans; 2010 - Darlinghurst; 3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT05546476
NCT05549297	IMCgp100-203	Phase 3		NSW, QLD, VIC	2022-09-22	2022-12-19		Pembrolizumab; Pembrolizumab + Tebentafusp; Tebentafusp	anti-PD-1_monoclonal_antibody; bispecfic_T-cell_engager,gp100-targeting; anti-PD-1_monoclonal_antibody + bispecfic_T-cell_engager,gp100-targeting	Pembrolizumab + Tebentafusp; Tebentafusp	anti-PD-1_monoclonal_antibody + bispecfic_T-cell_engager,gp100-targeting; bispecfic_T-cell_engager,gp100-targeting	IMCgp100-203	Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination With Pembrolizumab Versus Investigator's Choice in HLA-A*02:01-positive Participants With Previously Treated Advanced Melanoma (TEBE-AM)	Advanced Melanoma	4102 - Woolloongabba; 3004 - Melbourne; 2065 - Wollstonecraft; 4120 - Greenslopes	https://clinicaltrials.gov/ct2/show/NCT05549297
NCT05551117	Tamarack	Phase 2		NSW, QLD, VIC	2022-09-22	2023-06-13		Abiraterone; Abiraterone + Enzalutamide; Enzalutamide; Vobramitamab duocarmazine	anti-B7H3_antibody-drug_conjugate; antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation	Abiraterone + Enzalutamide; Vobramitamab duocarmazine	CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation; anti-B7H3_antibody-drug_conjugate	CP-MGC018-03	A Phase 2, Open-label, Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors	Hormone Refractory Prostatic Cancer; Malignant Melanoma; Head and Neck Squamous Cell Carcinoma; Androgen-Insensitive Prostatic Cancer; Small Cell Carcinoma; Non-small Cell Carcinoma; Anal Cancer; Androgen-Resistant Prostatic Cancer; Small-cell Lung Cancer; Oral Squamous Cell Carcinoma; Melanoma; Non-small Cell Lung Cancer; Castration-Resistant Prostatic Cancer; Androgen-Independent Prostatic Cancer; Carcinoma, Squamous Cell of Head and Neck; Anal Neoplasm; Laryngeal Squamous Cell Carcinoma	3000 - Melbourne; 4102 - Woolloongabba; 3144 - Malvern; 2145 - Westmead	https://clinicaltrials.gov/ct2/show/NCT05551117
NCT05555732	2022-500802-16-00--DS1062-A-U303	Phase 3		NSW, QLD, SA, VIC	2022-09-27	2023-01-11		Carboplatin; Carboplatin + Cisplatin + Datopotamab deruxtecan + Pembrolizumab; Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed; Cisplatin; Datopotamab deruxtecan; Datopotamab deruxtecan + Pembrolizumab; Pembrolizumab; Pemetrexed	anti-Trop2_antibody-drug_conjugate; antimetabolite; anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent	Carboplatin + Cisplatin + Datopotamab deruxtecan + Pembrolizumab; Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed; Datopotamab deruxtecan + Pembrolizumab	anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent	2022-500802-16-00  DS1062-A-U303	A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in Subjects With No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07)	Metastatic Non Small Cell Lung Cancer	2217 - Kogarah; 3199 - Frankston; 5000 - Adelaide; 2500 - Wollongong; 5042 - Bedford Park; QLD 4102 - Woolloongabba	https://clinicaltrials.gov/ct2/show/NCT05555732
NCT05562830	MK-3475-04A--3475-04A	Phase 1		QLD	2022-10-03	2022-11-16		Pembrolizumab; Zilovertamab vedotin	anti-ROR1_antibody-drug_conjugate; anti-PD-1_monoclonal_antibody	Pembrolizumab; Zilovertamab vedotin	anti-PD-1_monoclonal_antibody; anti-ROR1_antibody-drug_conjugate	MK-3475-04A  3475-04A	A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Study of Investigational Agents With or Without Pembrolizumab in Participants With PD-1/L1 Refractory Locally Advanced or Metastatic Urothelial Carcinoma (KEYMAKER-U04): Substudy 04A	Urothelial Carcinoma	4029 - Brisbane	https://clinicaltrials.gov/ct2/show/NCT05562830
NCT05563220	ELEVATE	Phase 1		NSW	2022-10-03	2023-01-24		Abemaciclib; Abemaciclib + Elacestrant + Palbociclib + Ribociclib; Abemaciclib + Elacestrant + Ribociclib; Alpelisib; Alpelisib + Elacestrant; Capivasertib; Capivasertib + Elacestrant; Elacestrant; Elacestrant + Everolimus; Everolimus; Palbociclib; Ribociclib	PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor; selective_estrogen_receptor_degrader; pan-AKT_inhibitor; mTORC1_inhibitor + selective_estrogen_receptor_degrader; pan-AKT_inhibitor + selective_estrogen_receptor_degrader; mTORC1_inhibitor; PI3K_alpha_inhibitor; CDK4/6_inhibitor + selective_estrogen_receptor_degrader	Abemaciclib + Elacestrant + Palbociclib + Ribociclib; Abemaciclib + Elacestrant + Ribociclib; Alpelisib + Elacestrant; Capivasertib + Elacestrant; Elacestrant + Everolimus	CDK4/6_inhibitor + selective_estrogen_receptor_degrader; PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader; mTORC1_inhibitor + selective_estrogen_receptor_degrader; pan-AKT_inhibitor + selective_estrogen_receptor_degrader	STML-ELA-0222	A Phase 1b/2, Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer	Breast Cancer; Metastatic Breast Cancer	2113 - Sydney	https://clinicaltrials.gov/ct2/show/NCT05563220
NCT05568095	STAR-221	Phase 3		NSW, VIC, WA	2022-10-05	2022-11-21		Capecitabine; Capecitabine + Domvanalimab + Fluorouracil + Leucovorin + Oxaliplatin + Zimberelimab; Domvanalimab; Fluorouracil; Leucovorin; Nivolumab; Oxaliplatin; Zimberelimab	anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; Fluorouracil; fluoropyrimidine; anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; folinic_acid	Capecitabine + Domvanalimab + Fluorouracil + Leucovorin + Oxaliplatin + Zimberelimab; Nivolumab	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; Fluorouracil	jRCT2051220179  STAR-221	A Randomized, Open-Label, Multicenter Phase 3 Trial of Domvanalimab, Zimberelimab, and Chemotherapy Versus Nivolumab and Chemotherapy in Participants With Previously Untreated Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma	Advanced Upper Gastrointestinal Tract Adenocarcinoma	- Clayton; - Murdoch; - Gosford; - Liverpool	https://clinicaltrials.gov/ct2/show/NCT05568095
NCT05572463	PLATFORM201	Phase 1		QLD	2022-10-07			IBI110; IBI110 + Sintilimab; Sintilimab	anti-LAG3_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody	IBI110 + Sintilimab	anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody	PLATFORM201	A Randomized, Open-label, Multicenter, Multi-arm, Phase 1b/2 Platform Study to Evaluate Safety and Efficacy of Investigational Immunotherapies in Participants With Previously Treated Unresectable or Metastatic Melanoma	Unresectable Cutaneous Melanoma; Metastatic Cutaneous Melanoma	4102 - Woolloongabba	https://clinicaltrials.gov/ct2/show/NCT05572463
NCT05577416	AB-218-IIT-201	Phase 0		VIC	2022-10-13	2022-10-11		Safusidenib	IDH1_R132_inhibitor	Safusidenib	IDH1_R132_inhibitor	2022.003	A Phase 0/2 Study of AB-218 in Patients With IDH1 Mutated Low Grade Glioma	Glioma	- Melbourne	https://clinicaltrials.gov/ct2/show/NCT05577416
NCT05577715	2022-000131-23--CA116-003	Phase 2		NSW, VIC, WA	2022-10-13	2022-11-14		Farletuzumab Ecteribulin	anti-FR-alpha_antibody-drug_conjugate	Farletuzumab Ecteribulin	anti-FR-alpha_antibody-drug_conjugate	2022-000131-23  CA116-003	A Phase 2, Open-label, Randomized Study of MORAb-202 (Farletuzumab Ecteribulin), a Folate Receptor Alpha-targeting Antibody-Drug Conjugate, in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC) After Progression on Prior Therapies	Carcinoma, Non-Small-Cell Lung	3350 - Ballarat Central; 1871 - Liverpool; 2500 - Wollongong; 6150 - Murdoch	https://clinicaltrials.gov/ct2/show/NCT05577715
NCT05580770	MEKRAF-AST-101	Phase 1		NSW, VIC	2022-10-14	2023-02-03		Brimarafenib; Mirdametinib	RAF_dimer_inhibitor; MEK_inhibitor	Brimarafenib; Mirdametinib	MEK_inhibitor; RAF_dimer_inhibitor	MEKRAF-AST-101	A Phase 1/2a Open-Label, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Mirdametinib in Combination With BGB-3245 in Patients With Advanced Solid Tumors	Advanced Solid Tumor	2298 - Waratah; 3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT05580770
NCT05581004	2021-006708-34--GO43860	Phase 1		NSW, VIC, WA	2022-10-14	2022-10-20		Atezolizumab; Atezolizumab + Pembrolizumab + RO7502175; Atezolizumab + RO7502175; Pembrolizumab; RO7502175	anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + unknown_drug_class; anti-PD-L1_monoclonal_antibody + unknown_drug_class; unknown_drug_class; anti-PD-L1_monoclonal_antibody; anti-PD-1_monoclonal_antibody	Atezolizumab + Pembrolizumab + RO7502175; Atezolizumab + RO7502175; RO7502175	anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + unknown_drug_class; anti-PD-L1_monoclonal_antibody + unknown_drug_class; unknown_drug_class	2021-006708-34  GO43860	A Phase Ia/Ib, Open Label, Multicenter, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Patients With Locally Advanced or Metastatic Solid Tumors	NSCLC; HNSCC; Melanoma; Gastric Cancer; Cervical Cancer; Colorectal Cancer; Esophageal Cancer; Clear Cell RCC; HCC; Urothelial Carcinoma; TNBC; Locally Advanced or Metastatic Solid Tumors	3168 - Clayton; 6009 - Nedlands; 2010 - Darlinghurst	https://clinicaltrials.gov/ct2/show/NCT05581004
NCT05594875	SHR-A1921-I-102-AUS	Phase 1		NSW, QLD	2022-10-26	2022-12-01		SHR-A1921	antibody-drug_conjugate,unknown_target	SHR-A1921	antibody-drug_conjugate,unknown_target	SHR-A1921-I-102-AUS	An Open-Label, Multi-Center Phase I Clinical Study on the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of SHR-A1921 for Injection in Subjects With Advanced Solid Tumors	Advanced Solid Tumor	2170 - Sydney; 4101 - Brisbane; 2109 - Sydney; 2031 - Sydney	https://clinicaltrials.gov/ct2/show/NCT05594875
NCT05598151	HM-EZHI-101	Phase 1		SA, VIC	2022-10-28	2023-01-11		HM97662	EZH1/2_inhibitor	HM97662	EZH1/2_inhibitor	HM-EZHI-101	A Phase I, Open-Label, Multicenter, Dose Escalation and Expansion Study of HM97662 as a Single Agent in Patients With Advanced or Metastatic Solid Tumors	Advanced or Metastatic Solid Tumors	- Ballarat; - Frankston; - Clayton; - Adelaide	https://clinicaltrials.gov/ct2/show/NCT05598151
NCT05599984	M23-385	Phase 1		NSW, VIC	2022-10-31	2022-12-05		ABBV-706; ABBV-706 + Budigalimab; ABBV-706 + Carboplatin + Cisplatin; Budigalimab; Carboplatin; Cisplatin	antibody-drug_conjugate,SEZ6-targeting + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + antibody-drug_conjugate,SEZ6-targeting; antibody-drug_conjugate,SEZ6-targeting; platinum-based_antineoplastic_agent	ABBV-706; ABBV-706 + Budigalimab; ABBV-706 + Carboplatin + Cisplatin	anti-PD-1_monoclonal_antibody + antibody-drug_conjugate,SEZ6-targeting; antibody-drug_conjugate,SEZ6-targeting; antibody-drug_conjugate,SEZ6-targeting + platinum-based_antineoplastic_agent	M23-385	A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-706 as Monotherapy and in Combination With Budigalimab (ABBV-181), Carboplatin, or Cisplatin in Adult Subjects With Advanced Solid Tumors	Advanced Solid Tumors	3084 - Heidelberg; 2050 - Camperdown; 2010 - Darlinghurst; 3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT05599984
NCT05605522	FPI-2059-101	Phase 1		NSW	2022-11-04	2023-02-07		225Ac-FPI-2059	radioconjugate,NTSR1-targeting	225Ac-FPI-2059	radioconjugate,NTSR1-targeting	FPI-2059-101	A Phase 1 Study of [225Ac]-FPI-2059 in Adult Participants With NTSR1-Expressing Advanced, Metastatic and/or Recurrent Solid Tumours	Pancreatic Ductal Adenocarcinoma (PDAC); Gastric Cancer; Neuroendocrine Differentiated (NED) Prostate Cancer; Colorectal Cancer; Ewing Sarcoma; NTSR1 Expressing Solid Tumours; Squamous Cell Carcinoma of Head and Neck	2145 - Sydney	https://clinicaltrials.gov/ct2/show/NCT05605522
NCT05607498	EMB07X101	Phase 1		VIC, WA	2022-11-07	2023-03-01		EMB-07	bispecific_T-cell_engager,ROR1-targeting	EMB-07	bispecific_T-cell_engager,ROR1-targeting	EMB07X101	A First-in-human, Phase I, Open-Label Study of EMB-07, a Bi-specific Antibody Anti-CD3 and Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) in Patients With Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma	Advanced/Metastatic Solid Tumors; Relapse/Refractory Lymphoma	- Frankston; - Nedlands	https://clinicaltrials.gov/ct2/show/NCT05607498
NCT05607550	2022-502977-41-00--FURMO-004	Phase 3		NSW, QLD, VIC	2022-11-07	2023-06-01		Carboplatin; Carboplatin + Cisplatin + Pemetrexed; Cisplatin; Furmonertinib; Pemetrexed	antimetabolite; ERBB2_inhibitor,exon_20_selective; platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; EGFR_inhibitor,third_generation; EGFR_inhibitor,exon_20_selective	Carboplatin + Cisplatin + Pemetrexed; Furmonertinib	EGFR_inhibitor,exon_20_selective; EGFR_inhibitor,third_generation; ERBB2_inhibitor,exon_20_selective; antimetabolite + platinum-based_antineoplastic_agent	2022-502977-41-00  FURMO-004	A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)	Metastatic Non-Small Cell Lung Cancer; EGFR Exon 20 Mutations; Advanced Non-Small Cell Lung Cancer	2148 - Blacktown; NSW 2065 - St Leonards; 4102 - Woolloongabba; 3084 - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT05607550
NCT05609370	CTR20223077--BGB-A317-LBL-007-201	Phase 1		NSW, QLD, SA, VIC, WA	2022-11-08	2023-01-29		Bevacizumab; Bevacizumab + Capecitabine + Fluorouracil; Bevacizumab + Capecitabine + Fluorouracil + LBL-007; Bevacizumab + Capecitabine + Fluorouracil + LBL-007 + Tislelizumab; Bevacizumab + Capecitabine + LBL-007 + Tislelizumab; Bevacizumab + Fluorouracil + LBL-007 + Tislelizumab; Capecitabine; Fluorouracil; LBL-007; Tislelizumab	anti-LAG3_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + fluoropyrimidine; Fluorouracil; anti-VEGF_monoclonal_antibody + fluoropyrimidine; fluoropyrimidine; anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-VEGF_monoclonal_antibody + fluoropyrimidine; anti-VEGF_monoclonal_antibody	Bevacizumab + Capecitabine + Fluorouracil; Bevacizumab + Capecitabine + Fluorouracil + LBL-007; Bevacizumab + Capecitabine + Fluorouracil + LBL-007 + Tislelizumab; Bevacizumab + Capecitabine + LBL-007 + Tislelizumab; Bevacizumab + Fluorouracil + LBL-007 + Tislelizumab	anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + fluoropyrimidine; anti-LAG3_monoclonal_antibody + anti-VEGF_monoclonal_antibody + fluoropyrimidine; anti-VEGF_monoclonal_antibody + fluoropyrimidine; Fluorouracil	CTR20223077  BGB-A317-LBL-007-201	A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer	Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer	5112 - Elizabeth Vale; 3084 - Heidelberg; 2650 - Wagga Wagga; 5042 - Bedford Park; 2800 - Orange; 6150 - Murdoch; 2148 - Blacktown; 6009 - Nedlands; 4217 - Benowa; 3004 - Melbourne; 2298 - Waratah; 3168 - Clayton; 4101 - South Brisbane	https://clinicaltrials.gov/ct2/show/NCT05609370
NCT05609968	MK-3475-D46--3475-D46	Phase 3		NSW, SA, VIC	2022-11-08	2023-02-06		Pembrolizumab; Pembrolizumab + Sacituzumab Govitecan; Sacituzumab Govitecan	anti-Trop2_antibody-drug_conjugate; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate	Pembrolizumab; Pembrolizumab + Sacituzumab Govitecan	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate	MK-3475-D46  3475-D46	An Open-label, Multicenter, Phase 3 Randomized, Active-Comparator-Controlled Clinical Study of Pembrolizumab (MK-3475) in Combination With Sacituzumab Govitecan Versus MK-3475 Monotherapy as First-line Treatment in Participants With PD L1 TPS Greater Than or Equal to 50% Metastatic Non-small Cell Lung Cancer (KEYNOTE D46/EVOKE-03)	Carcinoma, Non-Small-Cell Lung	3199 - Frankston; 2800 - Orange; 5000 - Adelaide	https://clinicaltrials.gov/ct2/show/NCT05609968
NCT05611931	XPORT-EC-042	Phase 3		NSW, QLD, SA, TAS, VIC	2022-11-10	2023-04-18		Placebo; Selinexor	placebo; XPO1_inhibitor	Selinexor; Placebo	XPO1_inhibitor; placebo	GOG-3083  XPORT-EC-042	A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma	Endometrial Cancer	2640 - Albury East; - Saint Leonards; 3128 - Box Hill; 4215 - Southport; 3000 - Melbourne; 2050 - Camperdown; 7000 - Hobart; 3144 - Malvern; 3168 - Clayton; 2145 - Wentworthville; 5000 - Southport; 2305 - New Lambton Heights; 3199 - Frankston; 2250 - Gosford; 2560 - Campbell Town; 4350 - Toowoomba	https://clinicaltrials.gov/ct2/show/NCT05611931
NCT05613088	2021-004807-42--CA116-001	Phase 2		NSW, QLD, VIC, WA	2022-11-14	2023-02-01		Farletuzumab Ecteribulin; Paclitaxel; Pegylated liposomal doxorubicin; Topotecan	topoisomerase_inhibitor; anthracycline; anti-FR-alpha_antibody-drug_conjugate; taxane	Farletuzumab Ecteribulin; Paclitaxel; Pegylated liposomal doxorubicin; Topotecan	anti-FR-alpha_antibody-drug_conjugate; anthracycline; taxane; topoisomerase_inhibitor	2021-004807-42  CA116-001	A Phase 2 Open-label Randomized Study of Farletuzumab Ecteribulin (MORAb-202), a Folate Receptor Alpha-targeting Antibody-drug Conjugate, Versus Investigator's Choice Chemotherapy in Women With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	Neoplasms, Ovarian	2298 - Waratah; 3168 - Clayton; 3144 - Malvern; 6009 - Nedlands; 2065 - Sydney; 4032 - Chermside	https://clinicaltrials.gov/ct2/show/NCT05613088
NCT05613842	BOP	Phase 2		NSW	2022-11-14	2022-08-09		Lu-177 vipivotide tetraxetan	radioconjugate,PSMA-targeting	Lu-177 vipivotide tetraxetan	radioconjugate,PSMA-targeting	062022-01	Assessment of the Diagnostic Value of 64Cu-SAR-BBN PET Imaging for Men With Negative PSMA PET in Prostate Cancer	Prostate Cancer	2010 - Sydney	https://clinicaltrials.gov/ct2/show/NCT05613842
NCT05614258	ADG206-1001	Phase 1		SA, VIC	2022-11-14	2023-02-13		ADG206	anti-4-1BB_agonistic_antibody	ADG206	anti-4-1BB_agonistic_antibody	ADG206-1001	A First-in-Human (FIH), Open-Label, Phase 1 Study of ADG206, a CD137 Agonist Antibody, in Subjects With Advanced/Metastatic Solid Tumors	Advanced/Metastatic Solid Tumors	5037 - Kurralta Park; 3168 - Clayton	https://clinicaltrials.gov/ct2/show/NCT05614258
NCT05614739	FORAGER-1	Phase 1		NSW	2022-11-14	2023-01-12		Enfortumab Vedotin; Enfortumab Vedotin + LOXO-435 + Pembrolizumab; LOXO-435; LOXO-435 + Pembrolizumab; Pembrolizumab	FGFR3_inhibitor; anti-NECTIN4_antibody-drug_conjugate; anti-PD-1_monoclonal_antibody; FGFR3_inhibitor + anti-NECTIN4_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody; FGFR3_inhibitor + anti-PD-1_monoclonal_antibody	Enfortumab Vedotin + LOXO-435 + Pembrolizumab; LOXO-435; LOXO-435 + Pembrolizumab	FGFR3_inhibitor; FGFR3_inhibitor + anti-NECTIN4_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody; FGFR3_inhibitor + anti-PD-1_monoclonal_antibody	J4G-OX-JZVA  18594	FORAGER-1: A Phase 1, Open-Label, Multicenter Study of LOXO-435 (LY3866288) in Locally Advanced or Metastatic Solid Tumors Including Urothelial Cancer With FGFR3 Alterations	Ureteral Neoplasms; Neoplasm Metastasis; Urinary Bladder Neoplasms	2298 - Waratah; 2065 - St. Leonards; 2010 - Darlinghurst	https://clinicaltrials.gov/ct2/show/NCT05614739
NCT05619913	EPOCH	Phase 2		NSW, QLD, VIC	2022-11-17	2023-05-22		Eribulin; Eribulin + Pembrolizumab; Pembrolizumab	macrocyclic_ketone_analogue; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + macrocyclic_ketone_analogue	Eribulin; Eribulin + Pembrolizumab	anti-PD-1_monoclonal_antibody + macrocyclic_ketone_analogue; macrocyclic_ketone_analogue	ANZGOG 1828/2021	The EPOCH Study: Phase II Open Labelled Study Investigating the Use of Single Agent Eribulin and Eribulin in Combination With Pembrolizumab in Relapsed Tubo-ovarian or Uterine Carcinosarcoma	Uterine Carcinosarcoma; Ovarian Carcinosarcoma	8006 - Melbourne; - Randwick; - Clayton; - Herston	https://clinicaltrials.gov/ct2/show/NCT05619913
NCT05625412	2022-500930-27--IM043-004	Phase 1		NSW, QLD, VIC	2022-11-22	2022-12-09		BMS-986360; BMS-986360 + Capecitabine; BMS-986360 + Docetaxel; BMS-986360 + Nivolumab; Capecitabine; Docetaxel; Nivolumab	fluoropyrimidine; anti-PD-1_monoclonal_antibody; taxane; JNK_inhibitor + anti-PD-1_monoclonal_antibody; JNK_inhibitor + taxane; JNK_inhibitor + fluoropyrimidine; JNK_inhibitor	BMS-986360; BMS-986360 + Capecitabine; BMS-986360 + Docetaxel; BMS-986360 + Nivolumab	JNK_inhibitor; JNK_inhibitor + anti-PD-1_monoclonal_antibody; JNK_inhibitor + fluoropyrimidine; JNK_inhibitor + taxane	2022-500930-27  IM043-004	A Phase 1, Open-label, Multicenter Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors	Advanced Solid Tumors	4120 - Brisbane; 2010 - Darlinghurst; 2065 - St Leonards; 3199 - Frankston	https://clinicaltrials.gov/ct2/show/NCT05625412
NCT05635708	CTR20230892--BGB-LC-201	Phase 2		NSW, WA	2022-12-02	2023-03-07		BGB-15025; BGB-15025 + Tislelizumab; BGB-A445; BGB-A445 + Tislelizumab; Carboplatin; Cisplatin; LBL-007; LBL-007 + Tislelizumab; Paclitaxel; Pemetrexed; Tislelizumab	anti-LAG3_monoclonal_antibody; antimetabolite; HPK1_inhibitor; anti-OX40_agonistic_antibody + anti-PD-1_monoclonal_antibody; anti-OX40_agonistic_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; taxane; platinum-based_antineoplastic_agent; HPK1_inhibitor + anti-PD-1_monoclonal_antibody	BGB-15025 + Tislelizumab; BGB-A445 + Tislelizumab; LBL-007 + Tislelizumab; Tislelizumab; Carboplatin; Cisplatin; Paclitaxel; Pemetrexed	HPK1_inhibitor + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-OX40_agonistic_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; antimetabolite; platinum-based_antineoplastic_agent; taxane	CTR20230892  BGB-LC-201	Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer	Metastatic Non-small Cell Lung Cancer; Non-small Cell Lung Cancer	2050 - Camperdown; 2444 - Port Macquarie; 6009 - Nedlands; 2148 - Blacktown; 6008 - Subiaco; 2086 - Frenchs Forest	https://clinicaltrials.gov/ct2/show/NCT05635708
NCT05642780	SKB264-II-06	Phase 2		NSW, QLD, SA	2022-12-08	2023-01-17		Pembrolizumab; Pembrolizumab + Sacituzumab tirumotecan; Sacituzumab tirumotecan	anti-Trop2_antibody-drug_conjugate; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate	Pembrolizumab + Sacituzumab tirumotecan	anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate	SKB264-II-06	A Multicenter, Open-label, Phase 2, Basket Study to Evaluate the Efficacy and Safety of SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors	Solid Tumor	- Kogarah; - Bedford Park; 4066 - Auchenflower	https://clinicaltrials.gov/ct2/show/NCT05642780
NCT05642949	MHB036C-CP001EN	Phase 1		QLD, SA, VIC	2022-12-08			MHB036C	anti-Trop2_antibody-drug_conjugate	MHB036C	anti-Trop2_antibody-drug_conjugate	MHB036C-CP001EN	Phase 1/2, Multi-center, Open-label, Dose Escalation and Cohort Expansion Study to Evaluate the Safety/Tolerability, Pharmacokinetics and Efficacy of MHB036C in Participants With Advanced or Metastatic Solid Tumors	Advanced Solid Tumor	5042 - Adelaide; 4217 - Gold Coast; 3144 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT05642949
NCT05647122	EGRET	Phase 1		NSW, VIC	2022-12-12	2022-12-22		AZD9592; AZD9592 + Bevacizumab + Fluorouracil + Leucovorin; AZD9592 + Osimertinib; Bevacizumab; Fluorouracil; Leucovorin; Osimertinib	anti_EGFR/cMET_antibody-drug_conjugate; Fluorouracil; fluoropyrimidine; anti-VEGF_monoclonal_antibody + anti_EGFR/cMET_antibody-drug_conjugate + fluoropyrimidine + folinic_acid; folinic_acid; anti-VEGF_monoclonal_antibody; EGFR_inhibitor,third_generation + anti_EGFR/cMET_antibody-drug_conjugate; EGFR_inhibitor,third_generation	AZD9592; AZD9592 + Bevacizumab + Fluorouracil + Leucovorin; AZD9592 + Osimertinib	EGFR_inhibitor,third_generation + anti_EGFR/cMET_antibody-drug_conjugate; anti-VEGF_monoclonal_antibody + anti_EGFR/cMET_antibody-drug_conjugate + fluoropyrimidine + folinic_acid; anti_EGFR/cMET_antibody-drug_conjugate; Fluorouracil	2022-501570-18-00  D9350C00001	A Phase I, Multicenter, Open-label, First-in-Human, Dose Escalation and Expansion Study of AZD9592 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumors	Colorectal Neoplasms; Advanced Solid Tumours; Head and Neck Neoplasms; Carcinoma Non-small Cell Lung	2217 - Kogarah; 3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT05647122
NCT05650203	JS009-002-I	Phase 1			2022-12-14			JS-006; JS-006 + JS-009 + Toripalimab; JS-009; MHB088C; Toripalimab	anti-CD112R_monoclonal_antibody; anti-B7H3_antibody-drug_conjugate; anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-CD112R_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody	JS-006 + JS-009 + Toripalimab; MHB088C	anti-B7H3_antibody-drug_conjugate; anti-CD112R_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody	JS009-002-I	A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of JS009 Monotherapy and JS009 as a Triple Combination Therapy in Combination With Toripalimab and JS006 in Patients With Advanced Malignancies	Primary Condition: Advanced Tumors		https://clinicaltrials.gov/ct2/show/NCT05650203
NCT05650879	HER2	Phase 1		NSW, WA	2022-12-14	2023-03-20		ELVN-002; ELVN-002 + Trastuzumab Deruxtecan; ELVN-002 + Trastuzumab Emtansine; Trastuzumab Deruxtecan; Trastuzumab Emtansine	ERBB2_inhibitor,exon_20_selective; anti-ERBB2_antibody-drug_conjugate; ERBB2_inhibitor,exon_20_selective + anti-ERBB2_antibody-drug_conjugate	ELVN-002; ELVN-002 + Trastuzumab Deruxtecan; ELVN-002 + Trastuzumab Emtansine	ERBB2_inhibitor,exon_20_selective; ERBB2_inhibitor,exon_20_selective + anti-ERBB2_antibody-drug_conjugate	ELVN-002-001	A Phase 1a/1b Study of ELVN-002 for the Treatment of Patients With HER2 Mutant Non-Small Cell Lung Cancer	HER2-positive Metastatic Breast Cancer; HER2 Mutant Non-small Cell Lung Cancer; HER2 Amplification; HER2 Gene Mutation	2010 - Darlinghurst; 6009 - Nedlands; 2145 - Westmead	https://clinicaltrials.gov/ct2/show/NCT05650879
NCT05652855	MHB088C-CP001EN	Phase 1		QLD, SA, VIC	2022-12-15			MHB088C	anti-B7H3_antibody-drug_conjugate	MHB088C	anti-B7H3_antibody-drug_conjugate	MHB088C-CP001EN	Phase 1/2, Two-Part, Multi-center, Open-label, Dose Escalation and Dose Expansion First-In-Human Study to Evaluate the Safety/Tolerability, Pharmacokinetics and Efficacy of MHB088C in Participants With Advanced or Metastatic Solid Tumors	Advanced or Metastatic Solid Tumors	5042 - Adelaide; 3144 - Melbourne; 4217 - Gold Coast	https://clinicaltrials.gov/ct2/show/NCT05652855
NCT05652868	KisMET-01--MYTX-011-01	Phase 1		NSW, SA	2022-12-15	2023-03-23		MYTX-011	anti-cMET_antibody-drug_conjugate	MYTX-011	anti-cMET_antibody-drug_conjugate	KisMET-01  MYTX-011-01	A Phase 1 Multicenter Dose Escalation and Dose Expansion Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer - KisMET-01	NSCLC Stage IV; NSCLC Stage IIIB; Non-Small Cell Lung Cancer; Advanced Non-Small Cell Squamous Lung Cancer; Advanced Non-Small Cell Lung Cancer; Advanced Non-Small Cell Non-Squamous Lung Cancer; NSCLC	2050 - Camperdown; 5000 - Adelaide; 5011 - Adelaide; 2148 - Blacktown	https://clinicaltrials.gov/ct2/show/NCT05652868
NCT05654623	VERITAC-2	Phase 3		NSW, QLD, SA, TAS, VIC	2022-12-16	2023-03-03		Fulvestrant; Vepdegestrant	selective_estrogen_receptor_degrader; ER_PROTAC_degrader	Fulvestrant; Vepdegestrant	ER_PROTAC_degrader; selective_estrogen_receptor_degrader	2022-500544-38-00  C4891001	A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER TRIAL OF ARV-471 (PF-07850327) VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE (VERITAC-2)	Advanced Breast Cancer	4575 - Birtinya; 5037 - Kurralta Park; 2450 - Coffs Harbour; 3186 - Brighton; 4102 - Woolloongabba; 3220 - Geelong; 7000 - Hobart; 3144 - Malvern	https://clinicaltrials.gov/ct2/show/NCT05654623
NCT05668988	DZ2022E0005	Phase 3		NSW, VIC, WA	2022-12-30	2022-12-13		Carboplatin; Pemetrexed; Sunvozertinib	antimetabolite; platinum-based_antineoplastic_agent; ERBB2_inhibitor,exon_20_selective; EGFR_inhibitor,exon_20_selective	Sunvozertinib; Carboplatin; Pemetrexed	EGFR_inhibitor,exon_20_selective; ERBB2_inhibitor,exon_20_selective; antimetabolite; platinum-based_antineoplastic_agent	DZ2022E0005	A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation	Non-small Cell Lung Cancer	- Randwick; - Concord; - Nedlands; - Melbourne	https://clinicaltrials.gov/ct2/show/NCT05668988
NCT05671510	PRESERVE-003	Phase 3		NSW, QLD, SA	2023-01-04	2023-06-28		Docetaxel; ONC392	taxane; anti-CTLA4_monoclonal_antibody	Docetaxel; ONC392	taxane; anti-CTLA4_monoclonal_antibody	PRESERVE-003	Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers That Progressed on PD-1/PD-L1 Inhibitors	Non Small Cell Lung Cancer	5000 - Adelaide; - New Lambton Heights; 4006 - Newstead; 2200 - Bankstown	https://clinicaltrials.gov/ct2/show/NCT05671510
NCT05676931	EDGE-Lung	Phase 2		NSW, QLD, SA, WA	2023-01-09	2023-02-21		Docetaxel; Docetaxel + Domvanalimab + Zimberelimab; Docetaxel + Quemliclustat + Zimberelimab; Domvanalimab; Domvanalimab + Quemliclustat + Zimberelimab; Domvanalimab + Zimberelimab; Quemliclustat; Quemliclustat + Zimberelimab; Zimberelimab	CD73_inhibitor + anti-PD-1_monoclonal_antibody; CD73_inhibitor + anti-PD-1_monoclonal_antibody + taxane; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + taxane; anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody; taxane; CD73_inhibitor + anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; CD73_inhibitor	Docetaxel + Domvanalimab + Zimberelimab; Docetaxel + Quemliclustat + Zimberelimab; Domvanalimab + Quemliclustat + Zimberelimab; Domvanalimab + Zimberelimab; Quemliclustat + Zimberelimab	CD73_inhibitor + anti-PD-1_monoclonal_antibody; CD73_inhibitor + anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; CD73_inhibitor + anti-PD-1_monoclonal_antibody + taxane; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + taxane	2022-502916-35-01  EDGE-Lung	A Phase II, Open-label, Platform Study, to Evaluate Immunotherapy-based Combinations in Participants With Advanced Non-Small Cell Lung Cancer	Advanced Non-Small Cell Lung Cancer	6009 - Nedlands; 4217 - Benowa; 2450 - Coffs Harbour; 5000 - Adelaide; - Albury	https://clinicaltrials.gov/ct2/show/NCT05676931
NCT05678673	STELLAR-304	Phase 3		NSW, QLD, SA, VIC	2023-01-10	2023-01-01		Nivolumab; Nivolumab + Zanzalintinib; Sunitinib; Zanzalintinib	VEGFR_inhibitor; anti-PD-1_monoclonal_antibody; MET/VEGFR2/AXL/MER_inhibitor + anti-PD-1_monoclonal_antibody; KIT_inhibitor,first_generation; MET/VEGFR2/AXL/MER_inhibitor; PDGFR_inhibitor	Nivolumab + Zanzalintinib; Sunitinib	KIT_inhibitor,first_generation; MET/VEGFR2/AXL/MER_inhibitor + anti-PD-1_monoclonal_antibody; PDGFR_inhibitor; VEGFR_inhibitor	EU CTR: 2022-501703-27-0  XL092-304	A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma	Non-Clear Cell Renal Cell Carcinoma	3021 - Camperdown; 4814 - Douglas; 4101 - South Brisbane; 2298 - Waratah; 2145 - Sydney; 2640 - Albury; 2109 - Macquarie; 4032 - Chermside; 5112 - Elizabeth Vale; 3128 - Box Hill; 3021 - St Albans; 2170 - Liverpool	https://clinicaltrials.gov/ct2/show/NCT05678673
NCT05694936	VADER	Phase 2		NSW, SA, VIC	2023-01-23	2023-01-23		Cetuximab; Cetuximab + Panitumumab; Cetuximab + Panitumumab + Sodium Valproate; Panitumumab; Sodium Valproate	anti-EGFR_monoclonal_antibody; HDAC_inhibitor + anti-EGFR_monoclonal_antibody; HDAC_inhibitor	Cetuximab + Panitumumab; Cetuximab + Panitumumab + Sodium Valproate	HDAC_inhibitor + anti-EGFR_monoclonal_antibody; anti-EGFR_monoclonal_antibody	VADER	A Phase II Randomised Controlled Trial to Determine the Efficacy of Combining the HDAC Inhibitor Sodium Valproate With EGFR Monoclonal Antibody (Panitumumab or Cetuximab) Maintenance in the First-line Treatment of Patients With RAS Wild Type Metastatic Colorectal Cancer (CRC)	Metastatic Colorectal Cancer	2065 - Saint Leonards; 3000 - Melbourne; 5000 - Adelaide; 3350 - Ballarat Central; 5042 - Bedford Park; 3128 - Box Hill; 3084 - Melbourne; 3199 - Frankston; 3280 - Warrnambool	https://clinicaltrials.gov/ct2/show/NCT05694936
NCT05696626	ELAINEIII	Phase 3		NSW, QLD	2023-01-25	2023-10-31		Abemaciclib; Fulvestrant; Lasofoxifene; Palbociclib; Palbociclib + Ribociclib; Ribociclib	CDK4/6_inhibitor; selective_estrogen_receptor_modulator; selective_estrogen_receptor_degrader	Palbociclib + Ribociclib; Abemaciclib; Fulvestrant; Lasofoxifene	CDK4/6_inhibitor; selective_estrogen_receptor_degrader; selective_estrogen_receptor_modulator	SMX 22-002	An Open Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of the Combination of Lasofoxifene and Abemaciclib to the Combination of Fulvestrant and Abemaciclib for the Treatment of Pre- and Postmenopausal Women and Men With Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation	Metastatic Breast Cancer	- South Brisbane; - Concord; - Blacktown	https://clinicaltrials.gov/ct2/show/NCT05696626
NCT05712356	BOLSTER	Phase 2			2023-02-03	2023-08-24		Certepetide; Cisplatin; Durvalumab; Gemcitabine; Placebo	placebo; antimetabolite; platinum-based_antineoplastic_agent; tumor-homing_peptide_iRGD; anti-PD-L1_monoclonal_antibody; gemcitabine	Certepetide; Cisplatin; Durvalumab; Gemcitabine; Placebo	tumor-homing_peptide_iRGD; anti-PD-L1_monoclonal_antibody; antimetabolite; gemcitabine; placebo; platinum-based_antineoplastic_agent	2023-503740-14  LSTA1-P02	A Phase 2a, Double-blind, Placebo-controlled, Multi-center, Randomized Study Evaluating LSTA1 When Added to Standard of Care (SoC) Versus Standard of Care Alone in Subjects With Advanced Solid Tumors (BOLSTER)	Intrahepatic Cholangiocarcinoma; Bile Duct Cancer; Cholangiocarcinoma; Gallbladder Carcinoma; Gall Bladder Cancer; Extrahepatic Cholangiocarcinoma; Gall Bladder Carcinoma; Gallbladder Cancer		https://clinicaltrials.gov/ct2/show/NCT05712356
NCT05712889	VNC-236-101	Phase 1		NSW, QLD, SA	2023-02-06	2023-01-24		VIP236	small-molecule-drug-conjugate,alpha-V-beta-3-targeting	VIP236	small-molecule-drug-conjugate,alpha-V-beta-3-targeting	VNC-236-101	An Open-label, Multicenter Phase 1 Study to Characterize Safety, Tolerability, Preliminary Antitumor Activity and Pharmacokinetics of VIP236 Monotherapy in Subjects With Advanced Cancer	Neoplasms	2109 - Macquarie Park; 4101 - Brisbane; 5037 - Adelaide	https://clinicaltrials.gov/ct2/show/NCT05712889
NCT05718895	CLINCH	Phase 1		QLD, SA, VIC	2023-02-08	2023-03-27		ATG 022	anti-CLDN18.2_antibody-drug_conjugate	ATG 022	anti-CLDN18.2_antibody-drug_conjugate	ATG-022-ST-001	An Open, Multi-center, Phase I Clinical Study of ATG 022 in Patients With Advanced/Metastatic Solid Tumors	Advanced/Metastatic Solid Tumors	- Malvern; - South Brisbane; - Adelaide	https://clinicaltrials.gov/ct2/show/NCT05718895
NCT05720130	TheraPb-ADVC001	Phase 1		QLD	2023-02-09	2023-03-15		212Pb-ADVC001	radioligand,PSMA-targeting	212Pb-ADVC001	radioligand,PSMA-targeting	TheraPb-ADVC001	Phase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Castration Resistant Prostate Cancer (TheraPb - Phase I/II Study).	Prostate Cancer; Metastatic Castration-resistant Prostate Cancer	4029 - Brisbane; 4102 - Brisbane	https://clinicaltrials.gov/ct2/show/NCT05720130
NCT05725291	AMT-116-01	Phase 1		NSW, QLD, SA, VIC	2023-02-13	2023-07-25		AMT-116	anti-CD44v9_antibody-drug_conjugate	AMT-116	anti-CD44v9_antibody-drug_conjugate	AMT-116-01	First-in-Human, Phase 1 Study of AMT-116 in Patients With Advanced Solid Tumors	Advanced Solid Tumor	2109 - Syd; 5042 - Adelaide; 3144 - Victoria Park; - Brisbane; 3084 - Victoria Park; 3004 - Victoria Park	https://clinicaltrials.gov/ct2/show/NCT05725291
NCT05727176	FOENIX-CCA4	Phase 2		NSW, VIC, WA	2023-02-14	2023-07-05		Futibatinib	pan-FGFR_inhibitor,irreversible	Futibatinib	pan-FGFR_inhibitor,irreversible	2023-503665-39  TAS-120-205	Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusions or Rearrangements	FGFR2 Fusions; Gene Rearrangement; Advanced Cholangiocarcinoma	3004 - Melbourne; 6008 - Subiaco; 2010 - Sydney	https://clinicaltrials.gov/ct2/show/NCT05727176
NCT05727904	TILVANCE-301--IOV-MEL-301	Phase 3		NSW, QLD, SA, VIC, WA	2023-02-14	2023-03-30		Lifileucel; Lifileucel + Pembrolizumab; Pembrolizumab	autologous_tumor-infiltrating_lymphocytes_therapy; anti-PD-1_monoclonal_antibody + autologous_tumor-infiltrating_lymphocytes_therapy; anti-PD-1_monoclonal_antibody	Lifileucel + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + autologous_tumor-infiltrating_lymphocytes_therapy	TILVANCE-301  IOV-MEL-301	A Phase 3, Multicenter, Randomized, Open-label, Parallel Group, Treatment Study to Assess the Efficacy and Safety of the Lifileucel (LN-144, Autologous Tumor Infiltrating Lymphocytes [TIL]) Regimen in Combination With Pembrolizumab Compared With Pembrolizumab Monotherapy in Participants With Untreated, Unresectable or Metastatic Melanoma	Melanoma; Unresectable Melanoma; Metastatic Melanoma	6150 - Murdoch; 4120 - Greenslopes; 3000 - Melbourne; NSW 2145 - Westmead; 5042 - Bedford Park	https://clinicaltrials.gov/ct2/show/NCT05727904
NCT05735080	INX-315-01	Phase 1		QLD, VIC	2023-02-21	2023-03-28		Abemaciclib; Abemaciclib + Fulvestrant + INX-315; Fulvestrant; Fulvestrant + INX-315; INX-315	CDK2_inhibitor + CDK4/6_inhibitor + selective_estrogen_receptor_degrader; selective_estrogen_receptor_degrader; CDK2_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor; CDK2_inhibitor	Abemaciclib + Fulvestrant + INX-315; Fulvestrant + INX-315; INX-315	CDK2_inhibitor; CDK2_inhibitor + CDK4/6_inhibitor + selective_estrogen_receptor_degrader; CDK2_inhibitor + selective_estrogen_receptor_degrader	INX-315-01	A Phase 1/2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of INX-315 in Patients With Advanced Cancer	Human Epidermal Growth Factor 2 Negative Carcinoma of Breast; CCNE1 Amplification; Breast Cancer; Advanced Cancer; Ovarian Cancer; Solid Tumor; Hormone Receptor Positive Tumor; Breast Cancer Metastatic; Metastatic Cancer	4101 - South Brisbane; 3052 - Parkville	https://clinicaltrials.gov/ct2/show/NCT05735080
NCT05740566	DeLLphi-304	Phase 3		NSW, VIC	2023-02-23	2023-05-31		Amrubicin; Lurbinectedin; Tarlatamab; Topotecan	topoisomerase_inhibitor; DNA_minor_groove-binding_agent; anthracycline; bispecific_T-cell_engager,DLL3-targeting	Tarlatamab; Amrubicin; Lurbinectedin; Topotecan	bispecific_T-cell_engager,DLL3-targeting; DNA_minor_groove-binding_agent; anthracycline; topoisomerase_inhibitor	20210004	A Randomized, Open-label, Phase 3 Study of Tarlatamab Compared With Standard of Care in Subjects With Relapsed Small Cell Lung Cancer After Platinum-based First-line Chemotherapy	Small Cell Lung Cancer (SCLC)	2170 - Liverpool; 2298 - Waratah; 3004 - Melbourne; 3168 - Clayton	https://clinicaltrials.gov/ct2/show/NCT05740566
NCT05743036	Z0011001--ZN-c3-016	Phase 1		SA, VIC	2023-02-24	2023-02-27		Azenosertib; Azenosertib + Cetuximab + Encorafenib; Cetuximab; Encorafenib	BRAF_V600_inhibitor + WEE1_inhibitor + anti-EGFR_monoclonal_antibody; anti-EGFR_monoclonal_antibody; WEE1_inhibitor; BRAF_V600_inhibitor	Azenosertib + Cetuximab + Encorafenib	BRAF_V600_inhibitor + WEE1_inhibitor + anti-EGFR_monoclonal_antibody	Z0011001  ZN-c3-016	A Phase 1/2, Open-Label, Multi-Center Study of ZN-c3 Administered in Combination With Encorafenib and Cetuximab in Adults With Metastatic Colorectal Cancer	Metastatic Colorectal Cancer	3000 - Melbourne; 5011 - Woodville South	https://clinicaltrials.gov/ct2/show/NCT05743036
NCT05756907	SB221	Phase 1		NSW, SA	2023-03-07	2023-09-15		Atezolizumab; Atezolizumab + SON-1010; SON-1010	IL-12_variant + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; IL-12_variant	Atezolizumab + SON-1010; SON-1010	IL-12_variant; IL-12_variant + anti-PD-L1_monoclonal_antibody	SB221	A Proof-of-Concept Study to Assess the Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer	Platinum-resistant Ovarian Cancer; Advanced Solid Tumor	2148 - Blacktown; 5037 - Kurralta Park; 2640 - Albury	https://clinicaltrials.gov/ct2/show/NCT05756907
NCT05759728	CNA3103-001	Phase 1		SA	2023-03-08	2023-10-24		CNA3103	autologous_CAR-T-cell_therapy,LGR5-targeting	CNA3103	autologous_CAR-T-cell_therapy,LGR5-targeting	CNA3103-001	A Phase 1/2a, Multicenter, Open-Label, Dose Escalation and Expansion Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Adult Subjects With Metastatic Colorectal Cancer	Colorectal Cancer Metastatic	5000 - Adelaide	https://clinicaltrials.gov/ct2/show/NCT05759728
NCT05763004	KEYNOTE-F49	Phase 1		VIC, WA	2023-03-10	2023-03-15		IOS1002; IOS1002 + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody + fusion_protein,LILRB2/LILRB2/KIR3DL1-targeting; fusion_protein,LILRB2/LILRB2/KIR3DL1-targeting; anti-PD-1_monoclonal_antibody	IOS1002; IOS1002 + Pembrolizumab	anti-PD-1_monoclonal_antibody + fusion_protein,LILRB2/LILRB2/KIR3DL1-targeting; fusion_protein,LILRB2/LILRB2/KIR3DL1-targeting	KEYNOTE-F49 / MK-3475-F49  IOS-1002-201	A Phase 1a/1b, First-in-human, Open-label, Non-randomized, Multicenter, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Efficacy, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of IOS 1002 Administered Alone and in Combination with Pembrolizumab, a PD-1 Monoclonal Antibody in Advanced Solid Tumors	Solid Tumor, Adult	- Melbourne; - Perth; - Clayton; - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT05763004
NCT05774873	CIBI334A101	Phase 1		NSW	2023-03-20	2023-08-09		IBI334	bispecific_EGFR/B7H3_antibody	IBI334	bispecific_EGFR/B7H3_antibody	CIBI334A101	A Phase I/II Study of IBI334 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors	Solid Tumors	2145 - Waratah	https://clinicaltrials.gov/ct2/show/NCT05774873
NCT05775289	BO44178	Phase 2		NSW, SA, VIC	2023-03-20	2023-03-15		Carboplatin; Carboplatin + Pembrolizumab + Pemetrexed; Carboplatin + Pemetrexed + Tobemstomig; Paclitaxel; Pembrolizumab; Pemetrexed; Tobemstomig	antimetabolite; anti-PD-1_monoclonal_antibody; taxane; antimetabolite + bispecific_PD-1/LAG3_antibody + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; bispecific_PD-1/LAG3_antibody; platinum-based_antineoplastic_agent	Carboplatin + Pembrolizumab + Pemetrexed; Carboplatin + Pemetrexed + Tobemstomig; Paclitaxel	anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite + bispecific_PD-1/LAG3_antibody + platinum-based_antineoplastic_agent; taxane	BO44178	A Phase II, Randomized, Multicenter, Double-Blind, Controlled Study of Tobemstomig Plus Platinum-Based Chemotherapy Versus Pembrolizumab Plus Platinum-Based Chemotherapy in Patients With Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer	Non-small Cell Lung Cancer	3168 - Melbourne; 2145 - Westmead; 3220 - Geelong; 5112 - Adelaide	https://clinicaltrials.gov/ct2/show/NCT05775289
NCT05785754	DCSZ11-101	Phase 1		NSW, QLD, SA, VIC, WA	2023-03-27	2023-06-28		DCSZ11; DCSZ11 + Pembrolizumab; Doxorubicin; Pembrolizumab; Tebentafusp	anthracycline; anti-PD-1_monoclonal_antibody; anti-CD93_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CD93_monoclonal_antibody; doxorubicin; bispecfic_T-cell_engager,gp100-targeting	DCSZ11; DCSZ11 + Pembrolizumab; Pembrolizumab; Doxorubicin; Tebentafusp	anti-CD93_monoclonal_antibody; anti-CD93_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anthracycline; bispecfic_T-cell_engager,gp100-targeting; doxorubicin	DCSZ11-101	A Phase 1, Multicenter, Open-Label, Dose Escalation and Expansion Study to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors	Advanced or Metastatic Solid Tumors	6009 - Nedlands; NSW2170 - Liverpool; 4556 - Buderim; 3144 - Malvern; 3168 - Clayton; 2031 - Randwick; - Wahroonga; 2010 - Sydney; QLD4810 - Douglas; QLD4101 - South Brisbane; 5011 - Woodville South; 5042 - Bedford Park	https://clinicaltrials.gov/ct2/show/NCT05785754
NCT05785767	2022-501483-18-00--R3767-ONC-2235	Phase 2		NSW, VIC	2023-03-27	2023-06-30		Cemiplimab; Cemiplimab + Fianlimab; Fianlimab; Placebo	placebo; anti-LAG3_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody	Cemiplimab; Cemiplimab + Fianlimab; Placebo	anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; placebo	2022-501483-18-00  R3767-ONC-2235	A Randomized, Double-Blind Phase 2/3 Study of Fianlimab (Anti-LAG-3 Antibody) in Combination With Cemiplimab (Anti-PD-1 Antibody) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 =50%	Advanced Non-Small Cell Lung Cancer	2650 - Wagga Wagga; 3350 - Ballarat; 2109 - Macquarie Park; 2500 - Wollongong; 3550 - Bendigo	https://clinicaltrials.gov/ct2/show/NCT05785767
NCT05789082	Krascendo-170	Phase 1		NSW, VIC	2023-03-29	2023-06-20		Carboplatin; Carboplatin + Cisplatin + Divarasib + Pembrolizumab + Pemetrexed; Cisplatin; Divarasib; Divarasib + Pembrolizumab; Pembrolizumab; Pemetrexed	antimetabolite; anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; KRAS_G12C_inhibitor; platinum-based_antineoplastic_agent; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody	Carboplatin + Cisplatin + Divarasib + Pembrolizumab + Pemetrexed; Divarasib + Pembrolizumab	KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent	2022-003048-28  BO44426	A Phase Ib/II, Open-Label, Multicenter Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib in Combination With Other Anti-Cancer Therapies in Patients With Previously Untreated Advanced Or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation	Non-Small Cell Lung Cancer	2139 - Concord; 3000 - Melbourne; 3004 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT05789082
NCT05797168	FONTANA	Phase 1		NSW, VIC	2023-04-04	2023-06-05		AZD5335; AZD5335 + Bevacizumab; AZD5335 + Bevacizumab + Carboplatin; AZD5335 + Saruparib; Bevacizumab; Carboplatin; Saruparib	PARP1-selective_inhibitor; anti-FR-alpha_antibody-drug_conjugate; PARP1-selective_inhibitor + anti-FR-alpha_antibody-drug_conjugate; anti-FR-alpha_antibody-drug_conjugate + anti-VEGF_monoclonal_antibody + platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent; anti-VEGF_monoclonal_antibody; anti-FR-alpha_antibody-drug_conjugate + anti-VEGF_monoclonal_antibody	AZD5335; AZD5335 + Bevacizumab; AZD5335 + Bevacizumab + Carboplatin; AZD5335 + Saruparib	PARP1-selective_inhibitor + anti-FR-alpha_antibody-drug_conjugate; anti-FR-alpha_antibody-drug_conjugate; anti-FR-alpha_antibody-drug_conjugate + anti-VEGF_monoclonal_antibody; anti-FR-alpha_antibody-drug_conjugate + anti-VEGF_monoclonal_antibody + platinum-based_antineoplastic_agent	2022-502576-23-00  D8990C00001	A Modular Phase I/IIa, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Ascending Doses of AZD5335 Monotherapy and in Combination With Anti-cancer Agents in Participants With Solid Tumors	Ovarian Cancer; Lung Adenocarcinoma	2170 - Liverpool; 3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT05797168
NCT05800015	2022-501577-40-00--R3767-ONC-2236	Phase 2		NSW, VIC, WA	2023-04-05	2023-08-08		Carboplatin; Cemiplimab; Cemiplimab + Fianlimab; Cisplatin; Fianlimab; Paclitaxel; Pemetrexed; Placebo	placebo; anti-LAG3_monoclonal_antibody; antimetabolite; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; taxane; platinum-based_antineoplastic_agent	Cemiplimab; Cemiplimab + Fianlimab; Carboplatin; Cisplatin; Paclitaxel; Pemetrexed; Placebo	anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; antimetabolite; placebo; platinum-based_antineoplastic_agent; taxane	2022-501577-40-00  R3767-ONC-2236	A Randomized, Double-Blind Phase 2/3 Study of Fianlimab (Anti-LAG-3 Antibody), Cemiplimab (Anti-PD-1 Antibody), and Chemotherapy Versus Cemiplimab and Chemotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Irrespective of PD-L1 Expression Levels	Non-small Cell Lung Cancer	3065 - Fitzroy; 6150 - Murdoch; 3550 - Bendigo; 3350 - Ballarat; 2109 - Macquarie Park; 2500 - Wollongong	https://clinicaltrials.gov/ct2/show/NCT05800015
NCT05800665	2023-504013-68-00--GO44537	Phase 1	_COHORTS_FULL	NSW, VIC	2023-04-05	2023-05-02		RO-7656594	unknown_drug_class; AR_PROTAC_degrader	RO-7656594	AR_PROTAC_degrader; unknown_drug_class	2023-504013-68-00  GO44537	A Phase 1, Open-Label, Multicenter, Dose-Escalation and Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 in Patients With Advanced or Metastatic Prostate Cancer	Advanced Prostate Cancer; Metastatic Prostate Cancer	2010 - Darlinghurst; 3084 - Heidelberg; 2162 - New South Wales; 3168 - Clayton	https://clinicaltrials.gov/ct2/show/NCT05800665
NCT05800964	2022-502867-39--20220073	Phase 1		NSW, VIC	2023-04-06	2023-06-13		AMG 305	bispecific_T-cell_engager,MSLN-targeting	AMG 305	bispecific_T-cell_engager,MSLN-targeting	2022-502867-39  20220073	Phase 1 First-In-Human Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors	Advanced Solid Tumors	3000 - Melbourne; 2050 - Camperdown	https://clinicaltrials.gov/ct2/show/NCT05800964
NCT05805501	BO43936	Phase 2	_PAUSED	QLD	2023-04-10	2023-04-21		Axitinib; Axitinib + Pembrolizumab; Axitinib + Tiragolumab + Tobemstomig; Axitinib + Tobemstomig; Pembrolizumab; Tiragolumab; Tobemstomig	VEGFR/PDGFR_inhibitor + anti-PD-1_monoclonal_antibody; KIT_inhibitor,ATP-competitive; anti-TIGIT_monoclonal_antibody; bispecific_PD-1/LAG3_antibody; KIT_inhibitor,ATP-competitive + bispecific_PD-1/LAG3_antibody; KIT_inhibitor,ATP-competitive + anti-TIGIT_monoclonal_antibody + bispecific_PD-1/LAG3_antibody; VEGFR/PDGFR_inhibitor + anti-TIGIT_monoclonal_antibody + bispecific_PD-1/LAG3_antibody; anti-PD-1_monoclonal_antibody; VEGFR/PDGFR_inhibitor + bispecific_PD-1/LAG3_antibody; VEGFR/PDGFR_inhibitor; KIT_inhibitor,ATP-competitive + anti-PD-1_monoclonal_antibody	Axitinib + Pembrolizumab; Axitinib + Tiragolumab + Tobemstomig; Axitinib + Tobemstomig	KIT_inhibitor,ATP-competitive + anti-PD-1_monoclonal_antibody; KIT_inhibitor,ATP-competitive + anti-TIGIT_monoclonal_antibody + bispecific_PD-1/LAG3_antibody; KIT_inhibitor,ATP-competitive + bispecific_PD-1/LAG3_antibody; VEGFR/PDGFR_inhibitor + anti-PD-1_monoclonal_antibody; VEGFR/PDGFR_inhibitor + anti-TIGIT_monoclonal_antibody + bispecific_PD-1/LAG3_antibody; VEGFR/PDGFR_inhibitor + bispecific_PD-1/LAG3_antibody	BO43936	A Randomized Open Label Phase II Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma	Renal Cell Carcinoma	4575 - Birtinya	https://clinicaltrials.gov/ct2/show/NCT05805501
NCT05807035	CAN001	Phase 1		SA	2023-04-10	2023-02-10		Radvax	autologous_anticancer_vaccine	Radvax	autologous_anticancer_vaccine	CAN001	A Phase I Trial of Autologous Tumour Vaccine for Advanced Solid Cancers	Solid Tumor	5046 - Adelaide	https://clinicaltrials.gov/ct2/show/NCT05807035
NCT05816252	MK-2870-003--SKB264-II-04	Phase 2			2023-04-18	2023-04-19		Carboplatin; Carboplatin + Pembrolizumab + Sacituzumab tirumotecan; Carboplatin + Sacituzumab tirumotecan; Osimertinib; Osimertinib + Sacituzumab tirumotecan; Pembrolizumab; Pembrolizumab + Sacituzumab tirumotecan; Sacituzumab tirumotecan	anti-Trop2_antibody-drug_conjugate; anti-Trop2_antibody-drug_conjugate + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody; EGFR_inhibitor,third_generation + anti-Trop2_antibody-drug_conjugate; anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; platinum-based_antineoplastic_agent; EGFR_inhibitor,third_generation	Carboplatin + Pembrolizumab + Sacituzumab tirumotecan; Carboplatin + Sacituzumab tirumotecan; Osimertinib + Sacituzumab tirumotecan; Pembrolizumab + Sacituzumab tirumotecan; Sacituzumab tirumotecan	EGFR_inhibitor,third_generation + anti-Trop2_antibody-drug_conjugate; anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate + platinum-based_antineoplastic_agent; anti-Trop2_antibody-drug_conjugate; anti-Trop2_antibody-drug_conjugate + platinum-based_antineoplastic_agent	MK-2870-003  SKB264-II-04	A Phase II Study of SKB264 as Monotherapy or as Combination Therapy in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer	Non-small Cell Lung Cancer		https://clinicaltrials.gov/ct2/show/NCT05816252
NCT05818683	78278343PCR1003--CR109321	Phase 1		NSW, QLD, SA, VIC	2023-04-19	2023-04-26		Abiraterone; Abiraterone + Apalutamide + Cabazitaxel + Cetrelimab + Darolutamide + Docetaxel + Enzalutamide + JNJ-78278343 + Prednisone; Apalutamide; Cabazitaxel; Cetrelimab; Darolutamide; Docetaxel; Enzalutamide; JNJ-78278343; Prednisone	bispecific_T-cell_engager,KLK2-targeting; CYP17A1_inhibitor + anti-PD-1_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation + bispecific_T-cell_engager,KLK2-targeting + glucocorticoid + taxane; antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor; anti-PD-1_monoclonal_antibody; taxane; glucocorticoid	Abiraterone + Apalutamide + Cabazitaxel + Cetrelimab + Darolutamide + Docetaxel + Enzalutamide + JNJ-78278343 + Prednisone	CYP17A1_inhibitor + anti-PD-1_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation + bispecific_T-cell_engager,KLK2-targeting + glucocorticoid + taxane	78278343PCR1003  CR109321	A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer	Metastatic Castration-resistant Prostate Neoplasms	3000 - Melbourne; 5037 - Kurralta Park; 2109 - Macquarie University; 4102 - Woolloongabba	https://clinicaltrials.gov/ct2/show/NCT05818683
NCT05828303	CA127-1027	Phase 1		NSW	2023-04-25			Metformin; Metformin + Repotrectinib; Repotrectinib	biguanide_antihyperglycaemic_agent; TRK_inhibitor,second_generation + biguanide_antihyperglycaemic_agent; TRK_inhibitor,second_generation; ALK_inhibitor,third_generation; ROS1_inhibitor; ALK_inhibitor,third_generation + biguanide_antihyperglycaemic_agent; ROS1_inhibitor + biguanide_antihyperglycaemic_agent	Metformin + Repotrectinib	ALK_inhibitor,third_generation + biguanide_antihyperglycaemic_agent; ROS1_inhibitor + biguanide_antihyperglycaemic_agent; TRK_inhibitor,second_generation + biguanide_antihyperglycaemic_agent	CA127-1027	A Phase 1, Open-Label, Fixed-Sequence Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid Tumors Harboring ROS1 or NTRK1-3 Rearrangements	Advanced Solid Tumor; Metastatic Solid Tumor	2145 - Westmead	https://clinicaltrials.gov/ct2/show/NCT05828303
NCT05840211	ASCENT-07	Phase 3		MENSW, NSW, QLD, SA, TAS, VIC, WA	2023-05-03	2023-05-08		Capecitabine; Nab-paclitaxel; Paclitaxel; Sacituzumab Govitecan	anti-Trop2_antibody-drug_conjugate; fluoropyrimidine; taxane	Sacituzumab Govitecan; Capecitabine; Nab-paclitaxel	anti-Trop2_antibody-drug_conjugate; fluoropyrimidine; taxane	2022-502593-17-00  GS-US-598-6168	A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) (HER2 IHC0 or HER2-low [IHC 1+, IHC 2+/ISH-]) Inoperable, Locally Advanced, or Metastatic Breast Cancer and Have Received Endocrine Therapy	Locally Advanced or Unresectable Metastatic Breast Cancer; Stage IV Breast Cancer	5042 - Bedford Park; 2170 - Liverpool; 3021 - St Albans; 2010 - Darlinghurst; 4029 - Queensland; 3084 - Melbourne; 2065 - St Leonards; 7000 - Hobart; 6009 - Nedlands; 4066 - Auchenflower	https://clinicaltrials.gov/ct2/show/NCT05840211
NCT05845814	MK-3475-04B--3475-04B	Phase 1		QLD, VIC	2023-05-06	2023-06-23		Enfortumab Vedotin; Favezelimab; Favezelimab + Pembrolizumab; Pembrolizumab; Pembrolizumab + Vibostolimab; Vibostolimab	anti-LAG3_monoclonal_antibody; anti-NECTIN4_antibody-drug_conjugate; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody	Favezelimab + Pembrolizumab; Pembrolizumab; Pembrolizumab + Vibostolimab; Enfortumab Vedotin	anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-NECTIN4_antibody-drug_conjugate	MK-3475-04B  3475-04B	A Phase 1/2 Randomized, Umbrella Study to Evaluate the Safety and Efficacy of Pembrolizumab Plus Enfortumab Vedotin (EV) in Combination With Investigational Agents Versus Pembrolizumab Plus EV, as First-Line Treatment for Participants With Advanced Urothelial Carcinoma (KEYMAKER-U04): Substudy 04B	Metastatic Urothelial Carcinoma; Urothelial Neoplasms	4029 - Brisbane; 3084 - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT05845814
NCT05848011	CP-MGD019-02	Phase 2		NSW, VIC	2023-05-08	2023-09-28		Docetaxel; Docetaxel + Lorigerlimab + Prednisone; Lorigerlimab; Prednisone	bispecific_PD-1×CTLA4_dual-affinity_responsive_target_molecule + glucocorticoid + taxane; glucocorticoid; bispecific_PD-1×CTLA4_dual-affinity_responsive_target_molecule; taxane	Docetaxel + Lorigerlimab + Prednisone	bispecific_PD-1×CTLA4_dual-affinity_responsive_target_molecule + glucocorticoid + taxane	CP-MGD019-02	A Phase 2, Randomized, Open-Label, Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer	Immunotherapy; Hormone Refractory Prostatic Cancer; Androgen-Independent Prostatic Cancer; Androgen-Resistant Prostatic Cancer; Androgen-Independent Prostatic Neoplasms; Inhibitory Checkpoint Molecule; Androgen-Insensitive Prostatic Cance; Prostate Cancer Recurrent; Immune Checkpoint Inhibitor	- Concord; - St Leonards; - Westmead; - North Melbourne	https://clinicaltrials.gov/ct2/show/NCT05848011
NCT05852691	CO44194	Phase 2	_PAUSED	NSW, VIC	2023-05-10	2023-07-18		Nab-paclitaxel; Nab-paclitaxel + Pembrolizumab; Nab-paclitaxel + Tobemstomig; Pembrolizumab; RO7247669; Tobemstomig	bispecific_PD-1/LAG3_antibody + taxane; bispecific_PD-1/LAG3_antibody; anti-PD-1_monoclonal_antibody + taxane; anti-PD-1_monoclonal_antibody; taxane	Nab-paclitaxel + Pembrolizumab; Nab-paclitaxel + Tobemstomig; RO7247669	anti-PD-1_monoclonal_antibody + taxane; bispecific_PD-1/LAG3_antibody + taxane	CO44194	A Phase II, Multicenter, Randomized, Double-Blind Study of Tobemstomig/RO7247669 Combined With Nab-Paclitaxel Compared With Pembrolizumab Combined With Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer	Breast Cancer	- St Albans	https://clinicaltrials.gov/ct2/show/NCT05852691
NCT05858164	2024-510998-26-00--22231	Phase 1		NSW, QLD	2023-05-15	2023-08-07		BAY2862789	DGK-alpha_inhibitor	BAY2862789	DGK-alpha_inhibitor	2024-510998-26-00  22231	An Open-label, Phase 1, First-in-human, Dose Escalation Study to Evaluate the Safety, Tolerability, Maximum Tolerated or Administered Dose, Pharmacokinetics, Pharmacodynamics, and Tumor Response Profile of the Diacylglycerol Kinase Alpha Inhibitor (DGKai) BAY 2862789 in Participants With Advanced Solid Tumors	Non-small Cell Lung Cancer; Advanced Solid Tumors	4102 - QLD; 2010 - Darlinghurst	https://clinicaltrials.gov/ct2/show/NCT05858164
NCT05858736	PRESERVE-009	Phase 1		NSW, QLD, SA	2023-05-15	2023-07-11		AI-025; ONC392	anti-PD-1_monoclonal_antibody; anti-CTLA4_monoclonal_antibody	AI-025; ONC392	anti-CTLA4_monoclonal_antibody; anti-PD-1_monoclonal_antibody	AI-061-AU-01	Safety, Pharmacokinetics (PK) and Efficacy of AI-061, A 1:1 Co-formulation of AI-025 (Anti-PD-1) and ONC-392 (Anti-CTLA-4) Antibodies in Advanced Solid Tumors: An Open-Label Phase 1 Study	Primary Peritoneal Carcinoma; Fallopian Tube Cancer; Head and Neck Squamous Cell Carcinoma; Renal Cell Carcinoma; High Grade Serous Adenocarcinoma of Ovary; Bile Duct Cancer; Endometrial Cancer; Non Small Cell Lung Cancer; Colorectal Cancer; Bladder Cancer; Gastroesophageal-junction Cancer; Esophageal Cancer; Hepatocellular Carcinoma; Melanoma; Gastric Cancer; Cervical Cancer; Anal Cancer	4120 - Southport; 4006 - Brisbane; 5042 - Bedford Park; 2010 - Darlinghurst; 5000 - Adelaide	https://clinicaltrials.gov/ct2/show/NCT05858736
NCT05867121	2022-502615-11-00--GO44010	Phase 1		NSW, NZ, SA	2023-05-19	2023-10-02		Atezolizumab; Atezolizumab + Gemcitabine + Nab-paclitaxel + RO7496353; Atezolizumab + RO7496353; Capecitabine; Capecitabine + Nivolumab + Oxaliplatin + RO7496353 + Tegafur-gimeracil-oteracil potassium; Gemcitabine; Nab-paclitaxel; Nivolumab; Oxaliplatin; RO7496353; Tegafur-gimeracil-oteracil potassium	antimetabolite; anti-PD-L1_monoclonal_antibody + anti-TGF-beta_monoclonal_antibody + antimetabolite + taxane; fluoropyrimidine; anti-PD-L1_monoclonal_antibody; gemcitabine; anti-PD-1_monoclonal_antibody + anti-TGF-beta_monoclonal_antibody + antimetabolite + fluoropyrimidine + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + anti-TGF-beta_monoclonal_antibody + fluoropyrimidine + orotate_phosphoribosyltransferase_inhibitor + platinum-based_antineoplastic_agent; DPD_inhibitor + anti-PD-1_monoclonal_antibody + anti-TGF-beta_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; orotate_phosphoribosyltransferase_inhibitor; DPD_inhibitor; anti-PD-1_monoclonal_antibody; taxane; anti-PD-L1_monoclonal_antibody + anti-TGF-beta_monoclonal_antibody; platinum-based_antineoplastic_agent; anti-TGF-beta_monoclonal_antibody	Atezolizumab + Gemcitabine + Nab-paclitaxel + RO7496353; Atezolizumab + RO7496353; Capecitabine + Nivolumab + Oxaliplatin + RO7496353 + Tegafur-gimeracil-oteracil potassium	DPD_inhibitor + anti-PD-1_monoclonal_antibody + anti-TGF-beta_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + anti-TGF-beta_monoclonal_antibody + antimetabolite + fluoropyrimidine + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + anti-TGF-beta_monoclonal_antibody + fluoropyrimidine + orotate_phosphoribosyltransferase_inhibitor + platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + anti-TGF-beta_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TGF-beta_monoclonal_antibody + antimetabolite + taxane; gemcitabine	2022-502615-11-00  GO44010	A Phase Ib, Open-label, Multicenter Dose-expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Patients With Locally Advanced or Metastatic Solid Tumors	Pancreatic Ductal Adenocarcinoma; Non-small Cell Lung Cancer; Gastric Cancer	Auckland; 2010 - Darlinghurst; 5042 - Bedford Park	https://clinicaltrials.gov/ct2/show/NCT05867121
NCT05867251	AVZO-021-1001	Phase 1		NSW	2023-05-19	2023-08-30		AVZO-021; Abemaciclib; Carboplatin; Fulvestrant; Letrozole; Palbociclib; Ribociclib; Sacituzumab Govitecan	anti-Trop2_antibody-drug_conjugate; aromatase_inhibitor; CDK4/6_inhibitor; selective_estrogen_receptor_degrader; platinum-based_antineoplastic_agent; CDK2_inhibitor	AVZO-021; Abemaciclib; Carboplatin; Fulvestrant; Letrozole; Palbociclib; Ribociclib; Sacituzumab Govitecan	CDK2_inhibitor; CDK4/6_inhibitor; anti-Trop2_antibody-drug_conjugate; aromatase_inhibitor; platinum-based_antineoplastic_agent; selective_estrogen_receptor_degrader	AVZO-021-1001	A Phase 1/2, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AVZO-021 as a Single Agent and in Combination Therapy in Patients With Advanced Solid Tumors	Fallopian Tube Cancer; Advanced Solid Tumor; CCNE1 Amplification; Endometrial Cancer; HR+, HER2-, Advanced Breast Cancer; HR+/HER2- Breast Cancer; TNBC - Triple-Negative Breast Cancer; Epithelial Ovarian Cancer; Primary Peritoneal Cancer	- Wollongong; - Macquarie University	https://clinicaltrials.gov/ct2/show/NCT05867251
NCT05867303	RC198-G001	Phase 1		QLD, SA, VIC	2023-05-19	2023-06-05		RC198	undisclosed_fusion_protein	RC198	undisclosed_fusion_protein	RC198-G001	A Phase 1, First-in-Human, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Immunogenetic and Efficacy of RC198 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors	Colorectal Carcinoma; Melanoma; Non-small Cell Lung Cancer; Renal Cell Carcinoma; Head and Neck Squamous Cell Carcinoma; Urothelial Carcinoma	4066 - Auchenflower; 3144 - Malvern; 5042 - Bedford Park	https://clinicaltrials.gov/ct2/show/NCT05867303
NCT05868174	177Lu-TLX250-001	Phase 1		NSW, QLD, SA, VIC, WA	2023-05-22	2023-05-23		177Lu-TLX250; 177Lu-TLX250 + Peposertib; Peposertib	DNA-dependent_protein_kinase_inhibitor; 177Lu-anti-CA9-radioconjugate; 177Lu-anti-CA9-radioconjugate + DNA-dependent_protein_kinase_inhibitor	177Lu-TLX250 + Peposertib	177Lu-anti-CA9-radioconjugate + DNA-dependent_protein_kinase_inhibitor	177Lu-TLX250-001	A Phase 1b Dose Escalation/Expansion Study of the Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX (CAIX)-Expressing Solid Tumors	Advanced Solid Tumor; Solid Tumor, Adult; Advanced Renal Cell Carcinoma	- North Ryde; - Melbourne; - Perth; - Brisbane; - Adelaide	https://clinicaltrials.gov/ct2/show/NCT05868174
NCT05870748	GOG-3086--STRO-002-GM3	Phase 2		NSW, NZ	2023-05-23	2023-07-12		Gemcitabine; Luveltamab tazevibulin; Luveltamab tazevibulin + Pegfilgrastim; Paclitaxel; Pegfilgrastim; Pegylated liposomal doxorubicin; Topotecan	antimetabolite; topoisomerase_inhibitor; anthracycline; anti-FR-alpha_antibody-drug_conjugate + granulocyte_colony_stimulating_factor; anti-FR-alpha_antibody-drug_conjugate; taxane; gemcitabine; granulocyte_colony_stimulating_factor	Gemcitabine; Luveltamab tazevibulin; Luveltamab tazevibulin + Pegfilgrastim; Paclitaxel; Pegylated liposomal doxorubicin; Topotecan	anti-FR-alpha_antibody-drug_conjugate; anti-FR-alpha_antibody-drug_conjugate + granulocyte_colony_stimulating_factor; antimetabolite; anthracycline; gemcitabine; taxane; topoisomerase_inhibitor	GOG-3086  STRO-002-GM3	REFRaME-O1: A Phase 2/3 Open-label Study Evaluating the Efficacy and Safety of Luveltamab Tazevibulin (STRO-002) Versus Investigator's Choice (IC) Chemotherapy in Women With Relapsed Platinum-resistant Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing Folate Receptor Alpha (FOLR1)	Platinum-resistant Ovarian Cancer; Primary Peritoneal Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Ovarian Cancer	Wellington; 2145 - Westmead; 2031 - Randwick; 2050 - Camperdown	https://clinicaltrials.gov/ct2/show/NCT05870748
NCT05872295	IKS014-01	Phase 1		NSW, VIC, WA	2023-05-24	2023-09-14		IKS014	anti-ERBB2_antibody-drug_conjugate	IKS014	anti-ERBB2_antibody-drug_conjugate	IKS014-01	A Phase 1 Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of IKS014, a HER2-Targeting Antibody Drug Conjugate (ADC), in Participants With Advanced HER2+ Solid Tumors	Breast Cancer; Gastric Cancer; Gastroesophageal-junction Cancer	3004 - Melbourne; 3199 - Frankston; 6009 - Nedlands; 2145 - Westmead; 2139 - Concord; 2109 - Sydney	https://clinicaltrials.gov/ct2/show/NCT05872295
NCT05878288	DISCERN	Phase 2		VIC	2023-05-26	2023-05-26		Cemiplimab	anti-PD-1_monoclonal_antibody	Cemiplimab	anti-PD-1_monoclonal_antibody	HREC/88736/PMCC-2022-326880	Comprehensive and Deep Profiling in Cutaneous Squamous Cell Carcinomas to Unravel Treatment Efficacy in Immunotherapy Treated Patients	Cutaneous Squamous Cell Carcinoma; Non-melanoma Skin Cancer; Cutaneous Squamous Cell Carcinoma of the Head and Neck; Neoplasms	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT05878288
NCT05879822	2022-502716-37-00--INCB-99280-211	Phase 2		NZ	2023-05-30	2023-10-30		INCB099280	PD-L1_inhibitor,oral	INCB099280	PD-L1_inhibitor,oral	2022-502716-37-00  INCB 99280-211	A Phase 2 Study Evaluating INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive	Advanced Solid Tumor	Dunedin	https://clinicaltrials.gov/ct2/show/NCT05879822
NCT05884398	LIBERTAS	Phase 3		NSW, QLD, VIC	2023-06-01	2023-08-31		Apalutamide	antiandrogen,nonsteroidal,second_generation	Apalutamide	antiandrogen,nonsteroidal,second_generation	56021927PCR3020  CR109327	A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide With Continued Versus Intermittent Androgen-Deprivation Therapy (ADT) Following PSA Response in Participants With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)	Metastatic Castrate-sensitive Prostate Cancer	3000 - Melbourne; 2109 - Macquarie University; 4101 - South Brisbane	https://clinicaltrials.gov/ct2/show/NCT05884398
NCT05886868	BL0020-101	Phase 1		NSW, QLD	2023-06-02	2023-10-24		BL0020	unknown_drug_class	BL0020	unknown_drug_class	BL0020-101	A Phase I, International, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of BL0020 as A Single Agent in Patients With Advanced Solid Tumors	Advanced Solid Tumor	- Sydney; - Birtinya	https://clinicaltrials.gov/ct2/show/NCT05886868
NCT05886920	D3S-002-100	Phase 1		NSW, SA, WA	2023-06-02	2023-07-10		D3S-002	ERK_inhibitor	D3S-002	ERK_inhibitor	D3S-002-100	A Phase 1, Open-label, Dose-escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose of D3S-002 Monotherapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations	Advanced Solid Tumors With MAPK Pathway Mutations	5042 - Bedford Park; 6009 - Nedlands; 2148 - Blacktown	https://clinicaltrials.gov/ct2/show/NCT05886920
NCT05888844	2022-502476-23-00--INCB-99280-212	Phase 2		NSW, NZ, QLD, VIC	2023-06-05	2023-10-09		INCB099280	PD-L1_inhibitor,oral	INCB099280	PD-L1_inhibitor,oral	2022-502476-23-00  INCB 99280-212	A Phase 2 Study Evaluating INCB099280 in Participants With Advanced Squamous Cell Carcinoma	Cutaneous Squamous Cell Carcinoma	03168 - Clayton; Hamilton; 03128 - Box Hill; 02640 - Albury; 04814 - Townsville; 04102 - Woolloongabba	https://clinicaltrials.gov/ct2/show/NCT05888844
NCT05891171	ARC-25	Phase 1		SA	2023-06-06	2023-10-13		AB598; AB598 + Fluorouracil + Leucovorin + Oxaliplatin + Zimberelimab; Fluorouracil; Leucovorin; Oxaliplatin; Zimberelimab	anti-CD39_monoclonal_antibody; Fluorouracil; fluoropyrimidine; anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; folinic_acid; anti-CD39_monoclonal_antibody + anti-PD-1_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent	AB598; AB598 + Fluorouracil + Leucovorin + Oxaliplatin + Zimberelimab	anti-CD39_monoclonal_antibody; anti-CD39_monoclonal_antibody + anti-PD-1_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; Fluorouracil	ARC-25	A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB598 Monotherapy and Combination Therapy in Participants With Advanced Malignancies	Advanced Cancer; Ovarian Cancer; Triple Negative Breast Cancer (TNBC); Renal Cell Carcinoma (RCC); Non-Small Cell Lung Cancer (NSCLC); Gastroesophageal-junction Cancer (GEJ); Gastric Cancer; Cervical Cancer; Advanced Malignancies; Head and Neck Squamous Cell Carcinoma (HNSCC); Esophageal Cancer; Bladder Cancer	- Adelaide	https://clinicaltrials.gov/ct2/show/NCT05891171
NCT05894239	INAVO122	Phase 3		NSW, QLD, VIC, WA	2023-06-08	2023-09-08		Inavolisib; Placebo	placebo; PI3K_alpha_inhibitor	Inavolisib; Placebo	PI3K_alpha_inhibitor; placebo	2022-502046-28-00  WO44263	A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo As Maintenance Therapy After First Line Induction Therapy in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer	Metastatic Breast Cancer	2148 - Blacktown; 6009 - Perth; 3168 - Clayton; 2250 - Gosford; 2010 - Darlinghurst; 4556 - Sippy Downs	https://clinicaltrials.gov/ct2/show/NCT05894239
NCT05904496	U1111-1290-6118--BGB-A317-30813-101	Phase 1		VIC, WA	2023-06-15	2023-07-19		BGB-30813; BGB-30813 + Tislelizumab; Tislelizumab	anti-PD-1_monoclonal_antibody; DGK-zeta_inhibitor + anti-PD-1_monoclonal_antibody; DGK-zeta_inhibitor	BGB-30813; BGB-30813 + Tislelizumab	DGK-zeta_inhibitor; DGK-zeta_inhibitor + anti-PD-1_monoclonal_antibody	U1111-1290-6118  BGB-A317-30813-101	A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DGK? Inhibitor BGB-30813, Alone or in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced or Metastatic Solid Tumors	Advanced Solid Tumors	3168 - Clayton; 6009 - Nedlands; 3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT05904496
NCT05904886	SKYSCRAPER-14	Phase 3		NZ	2023-06-15	2023-09-14		Atezolizumab; Atezolizumab + Bevacizumab; Atezolizumab + Bevacizumab + Tiragolumab; Bevacizumab; Placebo; Tiragolumab	placebo; anti-TIGIT_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-VEGF_monoclonal_antibody	Atezolizumab + Bevacizumab; Atezolizumab + Bevacizumab + Tiragolumab; Placebo	anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; placebo	2023-503422-39-00  CO44668	A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma	Carcinoma, Hepatocellular	Christchurch; Wellington; Auckland	https://clinicaltrials.gov/ct2/show/NCT05904886
NCT05906862	AMT-253-01	Phase 1		NSW, QLD, SA, VIC	2023-06-18	2023-11-06		AMT-253	anti-MUC18_antibody-drug_conjugate	AMT-253	anti-MUC18_antibody-drug_conjugate	AMT-253-01	First-in-Human, Phase 1 Study of AMT-253, in Patients With Advanced Solid Tumors	Advanced Solid Tumor	- Sydney; VIC 3004 - Melbourne; - Malvern; - Adelaide; - Brisbane	https://clinicaltrials.gov/ct2/show/NCT05906862
NCT05907304	SEACRAFT-1	Phase 1		NSW, VIC, WA	2023-06-18	2023-08-17		Naporafenib; Naporafenib + Trametinib; Trametinib	RAF_dimer_inhibitor; MEK_inhibitor + RAF_dimer_inhibitor; MEK_inhibitor	Naporafenib + Trametinib	MEK_inhibitor + RAF_dimer_inhibitor	ERAS-254-01	An Open-label Study to Assess the Safety and Efficacy of Naporafenib (ERAS-254) Administered With Trametinib in Previously Treated Patients With Locally Advanced Unresectable or Metastatic Solid Tumor Malignancies With RAS Q61X Mutations	Advanced or Metastatic Solid Tumors	- Perth; - Melbourne; - Macquarie Park	https://clinicaltrials.gov/ct2/show/NCT05907304
NCT05907954	IDE196-009	Phase 2		NSW, VIC	2023-06-18	2023-07-03		Darovasertib	PKC_inhibitor	Darovasertib	PKC_inhibitor	IDE196-009	(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma	Uveal Melanoma	2010 - Sydney; 3004 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT05907954
NCT05909397	VERITAC-3	Phase 3		SA, VIC	2023-06-18	2023-08-09		Letrozole; Palbociclib; Vepdegestrant	aromatase_inhibitor; CDK4/6_inhibitor; ER_PROTAC_degrader	Letrozole; Palbociclib; Vepdegestrant	CDK4/6_inhibitor; ER_PROTAC_degrader; aromatase_inhibitor	2022-500545-24-00  C4891002	A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY OF ARV-471(PF-07850327) PLUS PALBOCICLIB VERSUS LETROZOLE PLUS PALBOCICLIB FOR THE TREATMENT OF PARTICIPANTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI-CANCER TREATMENT FOR ADVANCED DISEASE (VERITAC-3)	Breast Cancer	3220 - Geelong; 5000 - Adelaide	https://clinicaltrials.gov/ct2/show/NCT05909397
NCT05909904	CTR20232123--BGB-HNSCC-201	Phase 2		NSW, QLD, SA, VIC, WA	2023-06-18	2023-07-21		BGB-A425; BGB-A425 + LBL-007 + Tislelizumab; BGB-A425 + Tislelizumab; LBL-007; LBL-007 + Tislelizumab; Tislelizumab	anti-LAG3_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIM3_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-TIM3_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-TIM3_monoclonal_antibody	BGB-A425 + LBL-007 + Tislelizumab; BGB-A425 + Tislelizumab; LBL-007 + Tislelizumab; Tislelizumab	anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-TIM3_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIM3_monoclonal_antibody	CTR20232123  BGB-HNSCC-201	A Randomized, Phase 2, Open-Label, Multi-Arm Study of Tislelizumab in Combination With Investigational Agents as First-Line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma	Head and Neck Squamous Cell Carcinoma; Head and Neck Cancer	4120 - Greenslopes; 2747 - Kingswood; 5000 - Adelaide; 6150 - Murdoch; 3677 - Wangaratta; 2065 - St Leonards; 4215 - Gold Coast	https://clinicaltrials.gov/ct2/show/NCT05909904
NCT05909995	2023-503243-34-00--INCB-99280-205	Phase 1			2023-06-18	2023-08-29		INCB099280; INCB099280 + Ipilimumab; Ipilimumab	PD-L1_inhibitor,oral + anti-CTLA4_monoclonal_antibody; PD-L1_inhibitor,oral; anti-CTLA4_monoclonal_antibody	INCB099280 + Ipilimumab	PD-L1_inhibitor,oral + anti-CTLA4_monoclonal_antibody	2023-503243-34-00  INCB 99280-205	A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors	Colorectal Carcinoma (CRC); Melanoma; Hepatocellular Carcinoma (HCC); Mismatch Repair Deficient (dMMR); Microsatellite Instability - High (MSI-H); Renal Cell Carcinoma (RCC)		https://clinicaltrials.gov/ct2/show/NCT05909995
NCT05910827	HMBD-001-103	Phase 1	_COHORTS_FULL	NSW, QLD, SA, VIC, WA	2023-06-20	2024-02-05		Cetuximab; Cetuximab + Docetaxel + HMBD-001; Cetuximab + HMBD-001; Docetaxel; Docetaxel + HMBD-001; HMBD-001	anti-ERBB3_monoclonal_antibody,third_generation; anti-EGFR_monoclonal_antibody + anti-ERBB3_monoclonal_antibody,third_generation; anti-EGFR_monoclonal_antibody; anti-EGFR_monoclonal_antibody + anti-ERBB3_monoclonal_antibody,third_generation + taxane; anti-ERBB3_monoclonal_antibody,third_generation + taxane; taxane	Cetuximab + Docetaxel + HMBD-001; Cetuximab + HMBD-001; Docetaxel + HMBD-001	anti-EGFR_monoclonal_antibody + anti-ERBB3_monoclonal_antibody,third_generation; anti-EGFR_monoclonal_antibody + anti-ERBB3_monoclonal_antibody,third_generation + taxane; anti-ERBB3_monoclonal_antibody,third_generation + taxane	HMBD-001-103	A Phase 1b Study to Evaluate HMBD-001 in Combination With Docetaxel With or Without Cetuximab in Participants With Advanced Squamous Non-Small Cell Lung Cancers, and HMBD-001 in Combination With Cetuximab in Participants With Advanced Squamous Cell Cancers	Cervical Squamous Cell Carcinoma; Advanced Esophageal Squamous Cell Carcinoma; Advanced Cutaneous Squamous Cell Carcinoma; Advanced Head and Neck Squamous Cell Carcinoma; Advanced or Metastatic Squamous Non-Small Cell Lung Cancer	2065 - Sydney; 4101 - Brisbane; 4120 - Greenslopes; - Frankston; 3144 - Malvern; 2145 - Westmead; 6009 - Perth; 5042 - Adelaide	https://clinicaltrials.gov/ct2/show/NCT05910827
NCT05911295	C5731001--SGNDV-001	Phase 3		NSW, QLD, SA, VIC	2023-06-22	2023-09-22		Carboplatin; Carboplatin + Cisplatin + Gemcitabine; Cisplatin; Disitamab vedotin; Disitamab vedotin + Pembrolizumab; Gemcitabine; Pembrolizumab	antimetabolite; anti-ERBB2_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; gemcitabine; platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; anti-ERBB2_antibody-drug_conjugate	Carboplatin + Cisplatin + Gemcitabine; Disitamab vedotin + Pembrolizumab	anti-ERBB2_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody; antimetabolite + platinum-based_antineoplastic_agent; gemcitabine	C5731001  SGNDV-001	An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination With Pembrolizumab Versus Chemotherapy in Subjects With Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma That Expresses HER2 (IHC 1+ and Greater)	Urothelial Carcinoma	2031 - Randwick; 2109 - North Ryde; 4029 - Herston; 5112 - Elizabeth Vale; 2010 - Darlinghurst; 2139 - Concord; 4101 - Brisbane; 2444 - Port Macquarie; 4101 - South Bribane; 2109 - Macquarie University; 3144 - Malvern; 2229 - Caringbah; NSW 2450 - NSW; 2065 - St Leonards; 4101 - South Brisbane; 3199 - Frankston	https://clinicaltrials.gov/ct2/show/NCT05911295
NCT05914116	DB-1311-O-1001	Phase 1		NSW, QLD, WA	2023-06-22	2023-08-17		DB-1311	anti-B7H3_antibody-drug_conjugate	DB-1311	anti-B7H3_antibody-drug_conjugate	DB-1311-O-1001	A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1311 in Subjects With Advanced/Metastatic Solid Tumors	Advanced Solid Tumors	4224 - Gold Coast; 2050 - Camperdown; 4102 - Brisbane; 4575 - Birtinya; 2139 - Concord; 2109 - Sydney; 2228 - Sydney; 2148 - Blacktown; 2031 - Sydney; 6009 - Nedlands; 2298 - Waratah; 2305 - New Lambton Heights	https://clinicaltrials.gov/ct2/show/NCT05914116
NCT05923008	CIBI130A101	Phase 1		QLD	2023-06-28	2023-11-14		IBI130	anti-Trop2_antibody-drug_conjugate; anti-Trop2_monoclonal_antibody	IBI130	anti-Trop2_antibody-drug_conjugate; anti-Trop2_monoclonal_antibody	CIBI130A101	A Phase 1/2, Multicenter, Open-label Study of IBI130 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors	Solid Tumor	4575 - Birtinya	https://clinicaltrials.gov/ct2/show/NCT05923008
NCT05935098	2023-505322-34-00--BGB-A317-A3055-101	Phase 1		NSW, QLD, WA	2023-07-07	2023-08-21		BGB-A3055; BGB-A3055 + Tislelizumab; Tislelizumab	anti-CCR8_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-CCR8_monoclonal_antibody	BGB-A3055; BGB-A3055 + Tislelizumab	anti-CCR8_monoclonal_antibody; anti-CCR8_monoclonal_antibody + anti-PD-1_monoclonal_antibody	2023-505322-34-00  BGB-A317-A3055-101	A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-A3055, Alone and in Combination With Tislelizumab in Patients With Selected Advanced or Metastatic Solid Tumors	Solid Tumor; Metastatic Solid Tumor; Advanced Solid Tumor	2050 - Camperdown; 6009 - Nedlands; 4101 - South Brisbane	https://clinicaltrials.gov/ct2/show/NCT05935098
NCT05943990	2019-004446-14--209012-Substudy-2	Phase 1		VIC	2023-07-13	2020-12-21		Cyclophosphamide; Fludarabine; GSK3845097	antimetabolite; alkylating_agent; autologous_CAR-T-cell_therapy,NY-ESO-1/dnTGFBR2-targeting	GSK3845097; Cyclophosphamide; Fludarabine	autologous_CAR-T-cell_therapy,NY-ESO-1/dnTGFBR2-targeting; alkylating_agent; antimetabolite	2019-004446-14  209012 Substudy 2	Assessment of Safety and Recommended Phase 2 Dose of Autologous T Cells Engineered With an Affinity-enhanced TCR Targeting NY ESO 1 and LAGE 1a, and Co-expressing the dnTGF-ßRII (GSK3845097) in Participants With NY ESO 1 and/or LAGE 1a Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma	Neoplasms	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT05943990
NCT05947851	MK-1026-010--1026-010	Phase 3		SA, VIC	2023-07-17	2023-08-08		Nemtabrutinib; Nemtabrutinib + Venetoclax; Rituximab; Rituximab + Venetoclax; Venetoclax	BTK_inhibitor; BTK_inhibitor + Bcl2_inhibitor; anti-CD20_monoclonal_antibody; Bcl2_inhibitor; Bcl2_inhibitor + anti-CD20_monoclonal_antibody	Nemtabrutinib + Venetoclax; Rituximab + Venetoclax	BTK_inhibitor + Bcl2_inhibitor; Bcl2_inhibitor + anti-CD20_monoclonal_antibody	MK-1026-010  1026-010	A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib (MK-1026) Plus Venetoclax Versus Venetoclax Plus Rituximab in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Following at Least 1 Prior Therapy (BELLWAVE-010)	CLL; Leukemia, Chronic Lymphocytic; SLL; Lymphoma, Small Lymphocytic; Leukemia, Lymphocytic, Chronic, B-Cell; Small-Cell Lymphoma	3021 - Melbourne; 5000 - Adelaide	https://clinicaltrials.gov/ct2/show/NCT05947851
NCT05950945	2023-505616-38-00--DS8201-0001-CIS-MA	Phase 3		NSW, VIC	2023-07-18	2023-12-30		Trastuzumab Deruxtecan	anti-ERBB2_antibody-drug_conjugate	Trastuzumab Deruxtecan	anti-ERBB2_antibody-drug_conjugate	2023-505616-38-00  DS8201-0001-CIS-MA	A Phase 3b, Multicenter, Global, Interventional, Open-label Study of Trastuzumab Deruxtecan (T-DXd), an Anti-HER2-Antibody Drug Conjugate (ADC), in Subjects Who Have Unresectable and/or Metastatic HER2-low or HER2 Immunohistochemistry (IHC) 0 Breast Cancer (DESTINY-Breast15)	Breast Cancer	3165 - East Bentleigh; 2065 - North Sydney	https://clinicaltrials.gov/ct2/show/NCT05950945
NCT05954871	2022-502530-10-00--GO44272	Phase 1		NSW, VIC	2023-07-20	2024-01-08		Cetuximab; Cetuximab + RLY-1971; Osimertinib; Osimertinib + RLY-1971; RLY-1971	anti-EGFR_monoclonal_antibody; SHP2_inhibitor; EGFR_inhibitor,third_generation + SHP2_inhibitor; SHP2_inhibitor + anti-EGFR_monoclonal_antibody; EGFR_inhibitor,third_generation	Cetuximab + RLY-1971; Osimertinib + RLY-1971	EGFR_inhibitor,third_generation + SHP2_inhibitor; SHP2_inhibitor + anti-EGFR_monoclonal_antibody	2022-502530-10-00  GO44272	A Phase Ib Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Patients With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Patients With Metastatic Colorectal Cancer	Non-Small Cell Lung Cancer; Colorectal Cancer	3065 - Fitzroy; 3690 - Wodonga	https://clinicaltrials.gov/ct2/show/NCT05954871
NCT05957081	MarkV-01	Phase 1		QLD, VIC	2023-07-24			PMC-309; PMC-309 + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody + anti-VISTA_monoclonal_antibody; anti-VISTA_monoclonal_antibody; anti-PD-1_monoclonal_antibody	PMC-309; PMC-309 + Pembrolizumab	anti-PD-1_monoclonal_antibody + anti-VISTA_monoclonal_antibody; anti-VISTA_monoclonal_antibody	KEYNOTE-E80  MarkV-01	A Phase 1a/1b, First-in-Human, Open Label Study to Assess the Safety, Tolerability, and Pharmacokinetics of PMC-309 (Anti-VISTA), as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced or Metastatic Solid Tumors	Advanced or Metastatic Solid Tumors	3350 - Ballarat; 4217 - Benowa; 3004 - Melbourne; 3144 - Malvern	https://clinicaltrials.gov/ct2/show/NCT05957081
NCT05957536	D3L-001-100	Phase 1		NSW, VIC	2023-07-24	2023-09-19		D3L-001	bispecific_ERBB2/CD47_antibody	D3L-001	bispecific_ERBB2/CD47_antibody	D3L-001-100	A Phase 1, Open-label Dose Escalation and Dose-Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of D3L-001 Monotherapy in Subjects With HER2-Positive Advanced Solid Tumors.	HER-2 Positive Advanced Solid Tumors	3144 - Malvern; 2109 - Sydney	https://clinicaltrials.gov/ct2/show/NCT05957536
NCT05967689	REZILIENT2	Phase 2		NSW, WA	2023-08-01	2023-07-31		Zipalertinib	EGFR_inhibitor,exon_20_selective	Zipalertinib	EGFR_inhibitor,exon_20_selective	2023-503865-48  TAS6417-201	An Open-Label, Phase 2b, Global Multicenter Cohort Trial to Assess the Safety and Efficacy of Zipalertinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Exon 20 Insertion and Uncommon/Single or Compound Epidermal Growth Factor Receptor Mutations.	Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations	2065 - Saint Leonards; 2200 - Bankstown; 6027 - Joondalup	https://clinicaltrials.gov/ct2/show/NCT05967689
NCT05969041	MYE-Symphony	Phase 1		NSW, SA, VIC, WA	2023-08-01	2023-08-02		MT-302	Trop2-targeting_lipid-nanoparticles	MT-302	Trop2-targeting_lipid-nanoparticles	MTX-TROP2-302	MYE Symphony: A Phase 1, Open-Label, First-in-Human, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors	Epithelial Tumors, Malignant	6009 - Nedlands; 2145 - Westmead; 3144 - Malvern; 2031 - Randwick; 2010 - Darlinghurst; 5042 - Bedford Park	https://clinicaltrials.gov/ct2/show/NCT05969041
NCT05975073	NCT05975073	Phase 1	_COHORTS_FULL	SA, VIC	2023-08-03	2023-08-01		AMG 193; AMG 193 + IDE397; IDE397	MAT2A_inhibitor + PRMT5_inhibitor; MAT2A_inhibitor; PRMT5_inhibitor	AMG 193 + IDE397	MAT2A_inhibitor + PRMT5_inhibitor	20220127	A Phase 1/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 in Combination With IDE397 in Subjects With Advanced MTAP-null Solid Tumors	MTAP-null Solid Tumors; MTAP-null Non-Small-Cell Lung Cancer	3168 - Clayton; 5011 - Woodville South	https://clinicaltrials.gov/ct2/show/NCT05975073
NCT05981703	CTR20240210--BGB-A317-26808-101	Phase 1		NSW, NZ, SA, WA	2023-08-08	2023-09-07		BGB-26808; BGB-26808 + Tislelizumab; Tislelizumab	HPK1_inhibitor; anti-PD-1_monoclonal_antibody; HPK1_inhibitor + anti-PD-1_monoclonal_antibody	BGB-26808 + Tislelizumab	HPK1_inhibitor + anti-PD-1_monoclonal_antibody	CTR20240210  BGB-A317-26808-101	A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor BGB-26808 Alone or in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors	Advanced Solid Tumor; Solid Tumor	2109 - North Ryde; 2228 - Miranda; 5037 - Kurralta Park; Auckland; 6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT05981703
NCT05983198	SatisfACtion	Phase 1		NSW, VIC	2023-08-09	2023-11-07		225Ac-PSMA-R2; 225Ac-PSMA-R2 + Bicalutamide + Flutamide; Bicalutamide; Flutamide; Lu-177 vipivotide tetraxetan	radioconjugate,PSMA-targeting; antiandrogen,nonsteroidal,first_generation + radioligand,PSMA-targeting; antiandrogen,nonsteroidal,first_generation; radioligand,PSMA-targeting	225Ac-PSMA-R2 + Bicalutamide + Flutamide; Lu-177 vipivotide tetraxetan	antiandrogen,nonsteroidal,first_generation + radioligand,PSMA-targeting; radioconjugate,PSMA-targeting	2021-003478-30  CAAA802A12101	SatisfACtion: Phase I/II, Open-label, Multi-center Study of [225Ac]Ac-PSMA-R2 in Men With mHSPC and Heavily Pre-treated PSMA-positive mCRPC, With/Without Prior 177Lu-labelled PSMA-targeted Radioligand Therapy	Prostate Cancer	3004 - Melbourne; 2010 - Darlinghurst	https://clinicaltrials.gov/ct2/show/NCT05983198
NCT05984277	eVOLVE-Lung02	Phase 3		NSW, QLD, VIC	2023-08-09	2023-10-24		Carboplatin; Carboplatin + Paclitaxel + Pembrolizumab + Pemetrexed; Carboplatin + Paclitaxel + Pemetrexed + Volrustomig; Paclitaxel; Pembrolizumab; Pemetrexed; Volrustomig	antimetabolite + bispecific_PD-L1/CTLA4_antibody + platinum-based_antineoplastic_agent + taxane; antimetabolite; platinum-based_antineoplastic_agent; bispecific_PD-L1/CTLA4_antibody; anti-PD-1_monoclonal_antibody; taxane; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane	Carboplatin + Paclitaxel + Pembrolizumab + Pemetrexed; Carboplatin + Paclitaxel + Pemetrexed + Volrustomig	anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; antimetabolite + bispecific_PD-L1/CTLA4_antibody + platinum-based_antineoplastic_agent + taxane	2023-000056-38  D798AC00001	A Phase III, Two-Arm, Parallel, Randomized, Multi-Center, Open-Label, Global Study to Determine the Efficacy of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer (mNSCLC).	Metastatic Non-small Cell Lung Cancer	3084 - Heidelberg; 3168 - Clayton; 3065 - Fitzroy; 4101 - South Brisbane; NSW 2145 - Sydney	https://clinicaltrials.gov/ct2/show/NCT05984277
NCT05985083	IMM47-201	Phase 1			2023-08-14	2023-08-18		IMM47	anti-CD24_monoclonal_antibody	IMM47	anti-CD24_monoclonal_antibody	IMM47-201	A Phase I, Open-Label, Multicenter, Dose-Escalation And Cohort-Expansion Study Of IMM47 In Subjects With Advanced Solid Tumors	Oncology; Advanced or Metastatic Solid Tumors		https://clinicaltrials.gov/ct2/show/NCT05985083
NCT05987332	IDE196-002	Phase 2		NSW, QLD, SA, VIC, WA, Washingto	2023-08-14	2023-10-31		Crizotinib; Crizotinib + Darovasertib; Dacarbazine; Dacarbazine + Ipilimumab + Nivolumab + Pembrolizumab; Darovasertib; Ipilimumab; Nivolumab; Pembrolizumab	PKC_inhibitor + ROS1_inhibitor; ALK_inhibitor,first_generation + PKC_inhibitor; alkylating_agent + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; MET_inhibitor,type_1 + PKC_inhibitor; anti-PD-1_monoclonal_antibody; alkylating_agent; ROS1_inhibitor; ALK_inhibitor,first_generation; PKC_inhibitor; MET_inhibitor,type_1; anti-CTLA4_monoclonal_antibody	Crizotinib + Darovasertib; Dacarbazine + Ipilimumab + Nivolumab + Pembrolizumab	ALK_inhibitor,first_generation + PKC_inhibitor; MET_inhibitor,type_1 + PKC_inhibitor; PKC_inhibitor + ROS1_inhibitor; alkylating_agent + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	IDE196-002	IDE196 (Darovasertib) in Combination With Crizotinib Versus Investigator's Choice of Treatment as First-line Therapy in HLA-A2 Negative Metastatic Uveal Melanoma (DAR-UM-2)	Metastatic Uveal Melanoma	3168 - Melbourne; 6009 - Perth; 2145 - Sydney; 4102 - Brisbane; 3000 - Melbourne; - Adelaide	https://clinicaltrials.gov/ct2/show/NCT05987332
NCT05991349	CIBI129A101	Phase 1		NSW	2023-08-14	2024-03-12		IBI129	anti-B7H3_antibody-drug_conjugate	IBI129	anti-B7H3_antibody-drug_conjugate	CIBI129A101	A Phase 1/2 Study of IBI129 in Subjects with Unresectable, Locally Advanced or Metastatic Solid Tumors	Solid Tumor	2050 - Camperdown; 2500 - Wollongong; 2217 - Kogarah	https://clinicaltrials.gov/ct2/show/NCT05991349
NCT05997615	U1111-1287-6968--TCD17896	Phase 1		NSW, VIC	2023-08-18	2023-08-10		AMX-500	unknown_drug_class	AMX-500	unknown_drug_class	U1111-1287-6968  TCD17896	A Phase 1, First-in-human Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of AMX-500 in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC)	Hormone-refractory Prostate Cancer	3000 - Victoria; 2010 - New South Wales	https://clinicaltrials.gov/ct2/show/NCT05997615
NCT06003231	C5731005--SGNDV-005	Phase 2		NSW, VIC	2023-08-21	2023-11-14		Disitamab vedotin	anti-ERBB2_antibody-drug_conjugate	Disitamab vedotin	anti-ERBB2_antibody-drug_conjugate	C5731005  SGNDV-005	A Phase 2 Basket Study of Disitamab Vedotin in Adult Subjects With Previously Treated, Locally-Advanced Unresectable or Metastatic Solid Tumors That Express HER2	Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung; Head and Neck Neoplasms; Ovarian Neoplasms	2148 - Blacktown; 2109 - Macquarie University; 3199 - Frankston; 2050 - Camperdown; 2146 - Old Toongabie	https://clinicaltrials.gov/ct2/show/NCT06003231
NCT06007482	ES009-1001	Phase 1		NSW, VIC	2023-08-23	2023-09-26		ES009	anti-LILRB2_monoclonal_antibody	ES009	anti-LILRB2_monoclonal_antibody	ES009-1001	An Open-Label, Multicenter, First-in-Human, Phase 1 Study of ES009 in Subjects With Locally Advanced or Metastatic Solid Tumors	Advanced Solid Tumor	- Randwick; - Sunshine Coast; - Frankston; - Kogarah	https://clinicaltrials.gov/ct2/show/NCT06007482
NCT06007690	CoMpass	Phase 3		QLD, VIC	2023-08-23	2023-12-06		Belzupacap Sarotalocan	viral_nanoparticle_drug_conjugates	Belzupacap Sarotalocan	viral_nanoparticle_drug_conjugates	AU-011-301	A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma	Ocular Melanoma; Choroidal Melanoma; Uveal Melanoma; Indeterminate Lesions	3002 - East Melbourne; 4000 - Brisbane	https://clinicaltrials.gov/ct2/show/NCT06007690
NCT06012435	C5751002--SGNB6A-002	Phase 3		NSW, QLD, VIC, WA	2023-08-25	2024-02-21		Docetaxel; Sigvotatug vedotin	anti-ITGB6_antibody-drug_conjugate; taxane	Docetaxel; Sigvotatug vedotin	anti-ITGB6_antibody-drug_conjugate; taxane	C5751002  SGNB6A-002	A Randomized, Phase 3, Open-label Study to Evaluate Sigvotatug Vedotin Compared With Docetaxel in Adult Participants With Previously Treated Non-small Cell Lung Cancer (Be6A Lung-01)	Carcinoma, Non-Small-Cell Lung	6150 - Murdoch; 3199 - Frankston; 2298 - Waratah; 3004 - Melbourne; 4102 - Woolloongabba; 2747 - Kingswood; 2640 - Albury	https://clinicaltrials.gov/ct2/show/NCT06012435
NCT06016738	OPERA-01	Phase 3		NSW, SA, VIC, WA	2023-08-30	2023-11-16		Anastrozole; Anastrozole + Exemestane + Fulvestrant + Letrozole; Exemestane; Fulvestrant; Letrozole; Palazestrant	complete_estrogen_receptor_antagonist; selective_estrogen_receptor_degrader; aromatase_inhibitor; aromatase_inhibitor + selective_estrogen_receptor_degrader	Anastrozole + Exemestane + Fulvestrant + Letrozole; Palazestrant	aromatase_inhibitor + selective_estrogen_receptor_degrader; complete_estrogen_receptor_antagonist	OPERA-01  OP-1250-301	A Phase 3 Randomized, Open-Label Study of OP-1250 Monotherapy vs Standard of Care for the Treatment of ER+, HER2- Advanced or Metastatic Breast Cancer Following Endocrine and CDK 4/6 Inhibitor Therapy (OPERA-01)	Breast Cancer; Advanced Breast Cancer; ER Positive Breast Cancer; Metastatic Breast Cancer; HER2 Negative Breast Carcinoma	5000 - Adelaide; 3168 - Clayton; 3630 - Shepparton; 3355 - Ballarat Central; 2250 - Gosford; 6009 - Nedlands; 2145 - Westmead	https://clinicaltrials.gov/ct2/show/NCT06016738
NCT06018337	CTR20233708--DB-1303-O-3002	Phase 3		NSW, QLD, SA, VIC	2023-08-30	2024-01-18		Capecitabine; Capecitabine + Nab-paclitaxel + Paclitaxel; DB-1303; Nab-paclitaxel; Paclitaxel	fluoropyrimidine + taxane; fluoropyrimidine; taxane; anti-ERBB2_antibody-drug_conjugate	Capecitabine + Nab-paclitaxel + Paclitaxel; DB-1303	anti-ERBB2_antibody-drug_conjugate; fluoropyrimidine + taxane	CTR20233708  DB-1303-O-3002	A Phase 3, Randomized, Multi-center, Open-Label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-Low, Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients Whose Disease Has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02)	Metastatic Breast Cancer	3550 - Bendigo; 3021 - St. Albans; 4101 - South Brisbane; 4814 - Townsville; 2050 - Camperdown; 2109 - Sydney; 2155 - Adelaide; 4575 - Birtinya; 4215 - Southport; 2170 - Liverpool	https://clinicaltrials.gov/ct2/show/NCT06018337
NCT06024174	2023-505070-15--CA126-0015	Phase 1		NSW	2023-09-06	2023-11-09		Adagrasib; BMS-986466; Cetuximab	KRAS_G12C_inhibitor; anti-EGFR_monoclonal_antibody; SHP2_inhibitor	Adagrasib; BMS-986466; Cetuximab	KRAS_G12C_inhibitor; SHP2_inhibitor; anti-EGFR_monoclonal_antibody	2023-505070-15  CA126-0015	Phase 1/2 Open-label Study of BMS-986466 in Combination With Adagrasib With or Without Cetuximab in Participants With KRAS G12C-mutant Advanced Solid Tumors	Advanced Solid Tumors	2145 - Westmead	https://clinicaltrials.gov/ct2/show/NCT06024174
NCT06031441	2023-509266-38-00--GO44431	Phase 1		NSW, VIC	2023-09-11	2023-11-27		Atezolizumab; Atezolizumab + RO7566802; RO7566802	anti-PD-L1_monoclonal_antibody + unknown_drug_class; unknown_drug_class; anti-PD-L1_monoclonal_antibody	Atezolizumab + RO7566802	anti-PD-L1_monoclonal_antibody + unknown_drug_class	2023-509266-38-00  GO44431	A Phase I, Open-Label, Multicenter, Dose-Escalation Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors	Recurrent Solid Tumors; Locally Advanced Solid Tumors; Metastatic Solid Tumors	3000 - Melbourne; 2010 - Darlinghurst	https://clinicaltrials.gov/ct2/show/NCT06031441
NCT06036836	MK-4280A-010--4280A-010	Phase 2		NSW, QLD, VIC, WA	2023-09-14	2023-09-29		Favezelimab; Favezelimab + Lenvatinib + Pembrolizumab; Favezelimab + Pembrolizumab; Lenvatinib; Lenvatinib + Pembrolizumab; Pembrolizumab	anti-LAG3_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; VEGF_inhibitor; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody	Favezelimab + Lenvatinib + Pembrolizumab; Favezelimab + Pembrolizumab; Lenvatinib + Pembrolizumab; Pembrolizumab	VEGF_inhibitor + anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody	MK-4280A-010  4280A-010	A Multicenter, Randomized, Double-Blind, Phase 2, Basket Study of MK-4280A, a Coformulation of Favezelimab (MK-4280) With Pembrolizumab (MK-3475) in Selected Solid Tumors (KeyForm-010)	Endometrial Cancer; Solid Tumor; Cutaneous Squamous Cell Carcinoma	4029 - Brisbane; 2148 - Sydney; 2065 - St Leonards; 3004 - Melbourne; 6150 - Murdock; 2010 - Darlinghurst	https://clinicaltrials.gov/ct2/show/NCT06036836
NCT06048705	209012-Substudy-1	Phase 1		VIC	2023-09-21	2021-03-09		Cyclophosphamide; Fludarabine; GSK3901961	autologous_CAR-T-cell_therapy,NY-ESO-1/CD8alpha-targeting; antimetabolite; alkylating_agent	GSK3901961; Cyclophosphamide; Fludarabine	autologous_CAR-T-cell_therapy,NY-ESO-1/CD8alpha-targeting; alkylating_agent; antimetabolite	209012 Substudy 1	Assessment of Safety and Recommended Phase 2 Dose of Autologous T Cells Engineered With an Affinity-enhanced TCR Targeting NYESO1 and LAGE1a, and Co-expressing CD8a (GSK3901961) in Participants With NYESO1 and/or LAGE1a Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma / Myxoid/Round Cell Liposarcoma; or NYESO1 and/or LAGE1a Positive Previously Treated Metastatic Non-Small Cell Lung Cancer	Neoplasms	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT06048705
NCT06063681	StingrayTx	Phase 1		NSW, VIC	2023-10-02	2023-10-12		SR-8541A	ENPP1_inhibitor	SR-8541A	ENPP1_inhibitor	StingrayTx	Phase 1, Dose Escalation, Safety, Tolerability, and Pharmacokinetic Study of SR-8541A (ENPP1 Inhibitor) Administered Orally As Monotherapy or in Combination with Checkpoint Inhibitors in Subjects with Advanced/Metastatic Solid Tumors	Advanced / Metastatic Solid Tumor	3168 - Clayton; 3199 - Frankston; 2031 - Randwick	https://clinicaltrials.gov/ct2/show/NCT06063681
NCT06064877	FIERCE-HN	Phase 3		NSW, QLD, WA	2023-10-03	2024-01-11		Cetuximab; Cetuximab + Ficlatuzumab; Ficlatuzumab; Placebo	placebo; anti-HGF_monoclonal_antibody; anti-EGFR_monoclonal_antibody; anti-EGFR_monoclonal_antibody + anti-HGF_monoclonal_antibody	Cetuximab + Ficlatuzumab; Placebo	anti-EGFR_monoclonal_antibody + anti-HGF_monoclonal_antibody; placebo	AV-299-23-301	A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN)	Recurrent Head and Neck Squamous Cell Carcinoma; Metastatic Head-and-neck Squamous-cell Carcinoma	6150 - Murdoch; 2217 - Kogarah; 2010 - Sydney; 4102 - Brisbane	https://clinicaltrials.gov/ct2/show/NCT06064877
NCT06065748	2022-502980-39-00--CO44657	Phase 3		NSW, NZ, QLD, SA, VIC	2023-10-04	2023-12-11		Abemaciclib; Abemaciclib + Fulvestrant + Palbociclib + Ribociclib; Abemaciclib + Giredestrant + Palbociclib + Ribociclib; Fulvestrant; Giredestrant; LHRH Agonist; Palbociclib; Ribociclib	LHRH_agonist; CDK4/6_inhibitor; selective_estrogen_receptor_degrader; CDK4/6_inhibitor + selective_estrogen_receptor_degrader	Abemaciclib + Fulvestrant + Palbociclib + Ribociclib; Abemaciclib + Giredestrant + Palbociclib + Ribociclib; LHRH Agonist	CDK4/6_inhibitor + selective_estrogen_receptor_degrader; LHRH_agonist	2022-502980-39-00  CO44657	A Phase III Randomized, Open-Label Study Evaluating Efficacy and Safety of Giredestrant Compared With Fulvestrant, Both Combined With a CDK4/6 Inhibitor, in Patients With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer With Resistance to Prior Adjuvant Endocrine Therapy	Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer	Palmerston North; 2060 - North Sydney; 3220 - Geelong; 4101 - South Brisbane; 3280 - Warrnambool; Christchurch; 2086 - Frenchs Forest; 2747 - Kingswood; 3021 - St Albans; - Adelaide; 4556 - Sippy Downs	https://clinicaltrials.gov/ct2/show/NCT06065748
NCT06072781	RAMP-301	Phase 3		NSW, NZ, QLD, SA, VIC, WA	2023-10-10	2024-03-18		Anastrozole; Avutometinib; Avutometinib + Defactinib; Defactinib; Letrozole; Paclitaxel; Pegylated liposomal doxorubicin	aromatase_inhibitor; FAK_inhibitor + RAF/MEK_clamp; anthracycline; taxane; RAF/MEK_clamp; FAK_inhibitor	Avutometinib + Defactinib; Anastrozole; Letrozole; Paclitaxel; Pegylated liposomal doxorubicin	FAK_inhibitor + RAF/MEK_clamp; anthracycline; aromatase_inhibitor; taxane	GOG-3097  VS-6766-301	A Phase 3, Randomized, Open-Label Study of Combination Therapy With Avutometinib Plus Defactinib Versus Investigator's Choice of Treatment in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (RAMP 301)	Low Grade Serous Ovarian Cancer	Auckland; 6009 - Nedlands; 4066 - Auchenflower; 3000 - Melbourne; 5000 - Adelaide; 2031 - Randwick	https://clinicaltrials.gov/ct2/show/NCT06072781
NCT06074497	KGX101ST101	Phase 1		QLD, VIC	2023-10-10	2023-12-13		Envafolimab; Envafolimab + KGX101; KGX101	anti-PD-L1_monoclonal_antibody; IL-12_Fc-fusion_protein + anti-PD-L1_monoclonal_antibody; IL-12_Fc-fusion_protein	Envafolimab + KGX101; KGX101	IL-12_Fc-fusion_protein; IL-12_Fc-fusion_protein + anti-PD-L1_monoclonal_antibody	KGX101ST101	A Phase 1, First-in-Human, Multicenter, Open-Label, Dose Escalation Trial of KGX101 Monotherapy and in Combination with Envafolimab in Patients with Advanced or Metastatic Solid Tumors.	Advanced or Metastatic Solid Tumors	4217 - Benowa; 3199 - Frankston; 4575 - Birtinya	https://clinicaltrials.gov/ct2/show/NCT06074497
NCT06074588	2023-503539-16-00--2870-004	Phase 3		NSW, VIC	2023-10-10	2023-11-12		Dexamethasone; Dexamethasone + Sacituzumab tirumotecan; Docetaxel; Docetaxel + Pemetrexed; Pemetrexed; Sacituzumab tirumotecan	anti-Trop2_antibody-drug_conjugate; antimetabolite; antimetabolite + taxane; anti-Trop2_antibody-drug_conjugate + glucocorticoid; taxane; glucocorticoid	Dexamethasone + Sacituzumab tirumotecan; Docetaxel + Pemetrexed	anti-Trop2_antibody-drug_conjugate + glucocorticoid; antimetabolite + taxane	2023-503539-16-00  2870-004	A Randomized, Open-label, Phase 3 Study of MK-2870 vs Chemotherapy (Docetaxel or Pemetrexed) in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations	Non-small Cell Lung Cancer (NSCLC)	3021 - Melbourne; 2145 - Westmead; 2217 - Kogarah; 3168 - Clayton	https://clinicaltrials.gov/ct2/show/NCT06074588
NCT06082167	STELLAR-305	Phase 2		NSW, SA, WA	2023-10-13	2024-06-07		Pembrolizumab; Pembrolizumab + Zanzalintinib; Placebo; Zanzalintinib	placebo; MET/VEGFR2/AXL/MER_inhibitor; anti-PD-1_monoclonal_antibody; MET/VEGFR2/AXL/MER_inhibitor + anti-PD-1_monoclonal_antibody	Pembrolizumab + Zanzalintinib; Placebo	MET/VEGFR2/AXL/MER_inhibitor + anti-PD-1_monoclonal_antibody; placebo	EU CTR: 2023-506308-24-00  XL092-305; KEYNOTE-G06	A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma	Head and Neck Squamous Cell Carcinoma	6150 - Murdoch; 2444 - Port Macquarie; NSW 2050 - Camperdown; 5042 - Bedford Park; 5000 - Adelaide	https://clinicaltrials.gov/ct2/show/NCT06082167
NCT06082960	GS-US-521-6317	Phase 1		VIC	2023-10-13	2023-10-09		GS-9911; GS-9911 + Zimberelimab; Zimberelimab	DGK-alpha_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; DGK-alpha_inhibitor	GS-9911; GS-9911 + Zimberelimab	DGK-alpha_inhibitor; DGK-alpha_inhibitor + anti-PD-1_monoclonal_antibody	GS-US-521-6317	A Phase 1 Study to Evaluate the Safety and Tolerability of GS-9911 as Monotherapy and in Combination With an Anti-PD-1 Monoclonal Antibody in Adults With Advanced Solid Tumors	Solid Tumors	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT06082960
NCT06084481	2023-506227-29-00--M24-427	Phase 1		NSW, VIC	2023-10-16	2023-11-09		ABBV-400	anti-cMET_antibody-drug_conjugate	ABBV-400	anti-cMET_antibody-drug_conjugate	2023-506227-29-00  M24-427	A Phase 1 Open-Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor Indications	Triple Negative Breast Cancer; Hepatocellular Carcinoma; Pancreatic Ductal Adenocarcinoma; Biliary Tract Cancers; Head and Neck Squamous-Cell Carcinoma; Hormone Receptor+/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer; Esophageal Squamous Cell Carcinoma; Platinum Resistant High Grade Epithelial Ovarian Cancer	2050 - Camperdown; 3084 - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT06084481
NCT06092580	AWT020-001	Phase 1		QLD, SA, VIC	2023-10-23	2023-09-15		AWT020	anti-PD1-IL2_fusion_protein	AWT020	anti-PD1-IL2_fusion_protein	AWT020-001	A Phase 1/2, First-in-human, Open-label Study of Single-agent AWT020 in Patients With Progressive Locally Advanced or Metastatic Cancer	Advanced Cancer	4101 - South Brisbane; - Melbourne; 5042 - Bedford Park	https://clinicaltrials.gov/ct2/show/NCT06092580
NCT06094296	2022-503007-22--CA047-1009	Phase 2		NSW, WA	2023-10-23	2023-11-27		BMS-986315; BMS-986315 + Nivolumab; Carboplatin; Cisplatin; Nivolumab; Paclitaxel; Pemetrexed	antimetabolite; platinum-based_antineoplastic_agent; anti-NKG2A_monoclonal_antibody; anti-PD-1_monoclonal_antibody; taxane; anti-NKG2A_monoclonal_antibody + anti-PD-1_monoclonal_antibody	BMS-986315 + Nivolumab; Nivolumab; Carboplatin; Cisplatin; Paclitaxel; Pemetrexed	anti-NKG2A_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; antimetabolite; platinum-based_antineoplastic_agent; taxane	2022-503007-22  CA047-1009	A Randomized, Double-blind, Phase 2 Study of BMS-986315 and Nivolumab in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy as First-line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)	NSCLC	2485 - Tweed Heads; 6027 - Joondalup; 2065 - St Leonards	https://clinicaltrials.gov/ct2/show/NCT06094296
NCT06097728	eVOLVE-Meso	Phase 3		NSW, QLD, VIC, WA	2023-10-24	2023-11-09		Carboplatin; Carboplatin + Pemetrexed + Volrustomig; Cisplatin; Ipilimumab; Ipilimumab + Nivolumab + Pemetrexed; Nivolumab; Pemetrexed; Volrustomig	antimetabolite; bispecific_PD-L1/CTLA4_antibody; anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + antimetabolite; antimetabolite + bispecific_PD-L1/CTLA4_antibody + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; anti-CTLA4_monoclonal_antibody	Carboplatin + Pemetrexed + Volrustomig; Ipilimumab + Nivolumab + Pemetrexed; Cisplatin	anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + antimetabolite; antimetabolite + bispecific_PD-L1/CTLA4_antibody + platinum-based_antineoplastic_agent	2023-503231-17-00  D7988C00001	A Phase III, Randomized, Open-Label, Multicenter, Global Study of Volrustomig (MEDI5752) in Combination With Carboplatin Plus Pemetrexed Versus Platinum Plus Pemetrexed or Nivolumab Plus Ipilimumab in Participants With Unresectable Pleural Mesothelioma (eVOLVE-Meso)	Unresectable Pleural Mesothelioma	3168 - Clayton; 2145 - Westmead; 6009 - Nedlands; 3000 - Melbourne; 4032 - Chermside	https://clinicaltrials.gov/ct2/show/NCT06097728
NCT06099782	2023-506017-22--3475A-F11	Phase 2		NSW, NZ, VIC	2023-10-25	2023-12-26		Pembrolizumab	anti-PD-1_monoclonal_antibody	Pembrolizumab	anti-PD-1_monoclonal_antibody	2023-506017-22  3475A-F11	A Phase 2 Study to Evaluate Patient Reported Preference for Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Over Intravenous Pembrolizumab Formulation in Participants With Multiple Tumor Types (MK-3475A-F11)	Melanoma; Non-Small Cell Lung Cancer; Renal Cell Carcinoma	3199 - Frankston; Wellington; Auckland; 2444 - Port Macquarie	https://clinicaltrials.gov/ct2/show/NCT06099782
NCT06103864	D7630C00001	Phase 3		NSW, VIC, WA	2023-10-27	2023-11-23		Carboplatin; Carboplatin + Gemcitabine + Nab-paclitaxel + Paclitaxel + Pembrolizumab; Datopotamab deruxtecan; Datopotamab deruxtecan + Durvalumab; Durvalumab; Gemcitabine; Nab-paclitaxel; Paclitaxel; Pembrolizumab	anti-Trop2_antibody-drug_conjugate; antimetabolite; anti-PD-L1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; taxane; gemcitabine; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate	Carboplatin + Gemcitabine + Nab-paclitaxel + Paclitaxel + Pembrolizumab; Datopotamab deruxtecan; Datopotamab deruxtecan + Durvalumab	anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; anti-PD-L1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; anti-Trop2_antibody-drug_conjugate; gemcitabine	D7630C00001	A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)	Breast Cancer	3000 - Melbourne; 2050 - Camperdown; 2010 - Darlinghurst; 3084 - Heidelberg; 2298 - Waratah; 6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT06103864
NCT06105632	2023-506487-13-00--C4391022	Phase 3		NSW, QLD	2023-10-27	2023-06-30		Everolimus; Exemestane; Fulvestrant; Fulvestrant + PF-07220060; PF-07220060	CDK4_selective_inhibitor; CDK4_selective_inhibitor + selective_estrogen_receptor_degrader; selective_estrogen_receptor_degrader; aromatase_inhibitor; mTORC1_inhibitor	Fulvestrant + PF-07220060; Everolimus; Exemestane	CDK4_selective_inhibitor + selective_estrogen_receptor_degrader; aromatase_inhibitor; mTORC1_inhibitor	2023-506487-13-00  C4391022	AN INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER PHASE 3 STUDY OF PF-07220060 PLUS FULVESTRANT COMPARED TO INVESTIGATOR'S CHOICE OF THERAPY IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED/METASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR CDK 4/6 INHIBITOR-BASED THERAPY	Advanced or Metastatic Breast Cancer	4812 - Townsville; 2109 - North Ryde; 4812 - Rosslea	https://clinicaltrials.gov/ct2/show/NCT06105632
NCT06108479	DF6215-001	Phase 1		VIC	2023-10-31	2023-11-28		DF6215	IL-2_variant	DF6215	IL-2_variant	DF6215-001	A Phase 1/1b, First-In-Human, Multi-Part, Open-Label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of DF6215 in Patients With Advanced (Unresectable, Recurrent, or Metastatic) Solid Tumors	Solid Tumor, Adult	3199 - Frankston	https://clinicaltrials.gov/ct2/show/NCT06108479
NCT06112314	PRISM-MEL-301	Phase 3		NSW, QLD, VIC, WA	2023-11-01	2024-06-05		IMC-F106C; Nivolumab; Nivolumab + Relatlimab; Relatlimab	anti-LAG3_monoclonal_antibody; bispecific_T-cell_engager,PRAME-targeting; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody	Nivolumab; Nivolumab + Relatlimab; IMC-F106C	anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; bispecific_T-cell_engager,PRAME-targeting	2023-505306-42  IMC-F106C-301	A Phase 3 Randomized, Controlled Study of IMC-F106C Plus Nivolumab Versus Nivolumab Regimens in HLA-A*02:01-Positive Participants With Previously Untreated Advanced Melanoma (PRISM-MEL-301	Advanced Melanoma	- Woolloongabba; 06009 - Nedlands; - Wollstonecraft; 3051 - North Melbourne; 4120 - Greenslopes; 3084 - Heidelberg; 02298 - Waratah	https://clinicaltrials.gov/ct2/show/NCT06112314
NCT06116136	Keynote-E70--CL1-95029-002	Phase 1		SA	2023-11-03	2024-08-31		Pembrolizumab; Pembrolizumab + S095029; S095029	anti-NKG2A_monoclona_antibody; anti-NKG2A_monoclona_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody	Pembrolizumab + S095029	anti-NKG2A_monoclona_antibody + anti-PD-1_monoclonal_antibody	Keynote E70  CL1-95029-002	Open Label, Non-randomized, Phase 1b/2 Trial Investigating the Safety, Tolerability, and Antitumor Activity of S095029 (Anti-NKG2A Antibody) as a Part of Combination Therapy in Participants With Locally Advanced and Unresectable or Metastatic MSI-H/dMMR Gastro-esophageal Junction /Gastric Cancer	MSI-H/dMMR Gastroesophageal-junction Cancer; MSI-H/dMMR Gastric Cancer	5011 - Woodville South	https://clinicaltrials.gov/ct2/show/NCT06116136
NCT06117774	DeLLphi-306	Phase 3		NSW, SA, VIC, WA	2023-11-07	2024-02-20		Placebo; Radiotherapy; Tarlatamab	placebo; radiotherapy; bispecific_T-cell_engager,DLL3-targeting	Tarlatamab; Placebo; Radiotherapy	bispecific_T-cell_engager,DLL3-targeting; placebo; radiotherapy	2023-506235-15  20230016	A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Tarlatamab Therapy in Subjects With Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Who Have Not Progressed Following Concurrent Chemoradiation Therapy	Small Cell Lung Cancer; Limited Stage Small Cell Lung Cancer	5042 - Bedford Park; 2444 - Port Macquarie; 3168 - Clayton; 2145 - Westmead; 6150 - Murdoch	https://clinicaltrials.gov/ct2/show/NCT06117774
NCT06119217	TTX-030-003	Phase 2		NSW, QLD	2023-11-07	2024-03-25		Budigalimab; Budigalimab + Gemcitabine + Nab-paclitaxel + TTX-030; Gemcitabine; Gemcitabine + Nab-paclitaxel; Gemcitabine + Nab-paclitaxel + TTX-030; Nab-paclitaxel; TTX-030	antimetabolite; antimetabolite + taxane; anti-CD39_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-CD39_monoclonal_antibody + anti-PD-1_monoclonal_antibody + antimetabolite + taxane; taxane; gemcitabine; anti-CD39_monoclonal_antibody + antimetabolite + taxane	Budigalimab + Gemcitabine + Nab-paclitaxel + TTX-030; Gemcitabine + Nab-paclitaxel; Gemcitabine + Nab-paclitaxel + TTX-030	anti-CD39_monoclonal_antibody + anti-PD-1_monoclonal_antibody + antimetabolite + taxane; anti-CD39_monoclonal_antibody + antimetabolite + taxane; antimetabolite + taxane; gemcitabine	TTX-030-003	An Open-Label Multicenter 3-Arm Randomized Phase 2 Study to Assess the Efficacy and Safety of TTX-030 and Chemotherapy With or Without Budigalimab, Compared to Chemotherapy Alone, for the Treatment of Patients Not Previously Treated for Metastatic Pancreatic Adenocarcinoma	Pancreatic Cancer	2145 - Westmead; 2640 - Albury; 4029 - Herston	https://clinicaltrials.gov/ct2/show/NCT06119217
NCT06119581	SUNRAY-01	Phase 3		NSW, QLD, SA, VIC, WA	2023-11-07	2023-12-21		Carboplatin; Carboplatin + Cisplatin + Olomorasib + Pembrolizumab + Pemetrexed; Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed; Cisplatin; Olomorasib; Olomorasib + Pembrolizumab; Pembrolizumab; Pemetrexed; Placebo	placebo; antimetabolite; anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; KRAS_G12C_inhibitor; platinum-based_antineoplastic_agent; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody	Carboplatin + Cisplatin + Olomorasib + Pembrolizumab + Pemetrexed; Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed; Olomorasib + Pembrolizumab; Pembrolizumab; Placebo	KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; placebo	J3M-MC-JZQB  18612	SUNRAY-01, A Global Pivotal Study in Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in Those With PD-L1 Expression =50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum Regardless of PD-L1 Expression	Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung	3065 - Melbourne; 4066 - Auchenflower; 4740 - Mackay; 6009 - Perth; 4814 - Townsville; 3630 - Shepparton; 2250 - Gosford; 5000 - Adelaide; 4575 - Birtinya; 3350 - Ballarat Central; 4215 - Southport	https://clinicaltrials.gov/ct2/show/NCT06119581
NCT06120075	ARC-27	Phase 1			2023-11-07	2024-01-19		AB-801; AB-801 + Docetaxel; Docetaxel	AXL_inhibitor; AXL_inhibitor + taxane; taxane	AB-801; AB-801 + Docetaxel	AXL_inhibitor; AXL_inhibitor + taxane	ARC-27	A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies	Advanced Cancer		https://clinicaltrials.gov/ct2/show/NCT06120075
NCT06120283	2023-506888-34-00--BGB-43395-101	Phase 1		NSW, NZ, QLD, SA, VIC	2023-11-07	2023-12-01		BGB-43395; BGB-43395 + Elacestrant + Fulvestrant + Letrozole; BGB-43395 + Fulvestrant + Letrozole; Elacestrant; Fulvestrant; Letrozole	aromatase_inhibitor; CDK4_selective_inhibitor + aromatase_inhibitor + selective_estrogen_receptor_degrader; CDK4_selective_inhibitor; selective_estrogen_receptor_degrader	BGB-43395 + Elacestrant + Fulvestrant + Letrozole; BGB-43395 + Fulvestrant + Letrozole	CDK4_selective_inhibitor + aromatase_inhibitor + selective_estrogen_receptor_degrader	2023-506888-34-00  BGB-43395-101	A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the CDK4 Inhibitor BGB-43395, Alone or as Part of Combination Therapies in Patients With Metastatic HR+/HER2- Breast Cancer and Other Advanced Solid Tumors	Advanced Breast Cancer; Advanced Solid Tumor; Hormone Receptor Positive Breast Carcinoma; Non-small Cell Lung Cancer; Hormone Receptor Positive HER-2 Negative Breast Cancer; HER2-negative Breast Cancer; Hormone-receptor-positive Breast Cancer; Metastatic Breast Cancer; Hormone Receptor Positive Malignant Neoplasm of Breast	3000 - Melbourne; 5000 - Adelaide; 2576 - Bowral; 3084 - Heidelberg; 2109 - North Ryde; 2139 - Concord; 4814 - Douglas; 2148 - Blacktown; Auckland; Christchurch	https://clinicaltrials.gov/ct2/show/NCT06120283
NCT06120491	EvoPAR-PR01	Phase 3		NSW, QLD, SA, VIC	2023-11-07	2023-11-21		Abiraterone; Abiraterone + Darolutamide + Enzalutamide; Abiraterone + Darolutamide + Enzalutamide + Saruparib; Darolutamide; Enzalutamide; Placebo; Saruparib	placebo; PARP1-selective_inhibitor; antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor + PARP1-selective_inhibitor + antiandrogen,nonsteroidal,second_generation	Abiraterone + Darolutamide + Enzalutamide; Abiraterone + Darolutamide + Enzalutamide + Saruparib; Placebo	CYP17A1_inhibitor + PARP1-selective_inhibitor + antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation; placebo	2023-504214-30-00  D9723C00001	A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of Saruparib (AZD5305) in Combination With Physician's Choice New Hormonal Agents in Patients With HRRm and Non-HRRm Metastatic Castration-Sensitive Prostate Cancer (EvoPAR-Prostate01)	Metastatic Castration-Sensitive Prostate Cancer	5037 - Kurralta Park; 2010 - Darlinghurst; 3000 - Melbourne; 4032 - Chermside; 2031 - Randwick; 4101 - South Brisbane; 4812 - Hyde Park	https://clinicaltrials.gov/ct2/show/NCT06120491
NCT06127407	CHONQUER	Phase 3		NSW, QLD, SA, VIC, WA	2023-11-13	2024-07-09		Ivosidenib; Placebo	placebo; IDH1_R132_inhibitor	Ivosidenib; Placebo	IDH1_R132_inhibitor; placebo	CL3-95031-007	A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled Study of Ivosidenib in Participants =18 Years of Age With Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen	Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen	4102 - Woolloongabba; 3065 - Fitzroy; 6009 - Nedlands; 5042 - Bedford Park; 2050 - Camperdown	https://clinicaltrials.gov/ct2/show/NCT06127407
NCT06130553	PRIMROSE	Phase 1		VIC	2023-11-14	2024-01-18		AZD3470	PRMT5_inhibitor	AZD3470	PRMT5_inhibitor	165618  D9970C00001	PRIMROSE: A Modular Phase I/IIa, Multi-centre, Dose Escalation, and Expansion Study of AZD3470, a MTA Cooperative PRMT5 Inhibitor, as Monotherapy and in Combination With Anticancer Agents in Patients With Advanced/Metastatic Solid Tumors That Are MTAP Deficient	Advanced Solid Tumors That Are MTAP Deficient	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT06130553
NCT06131398	NCT06131398	Phase 1		NSW, SA	2023-11-14	2024-03-07		AMG-355; AMG-355 + Pembrolizumab; Pembrolizumab	anti-CCR8_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-CCR8_monoclonal_antibody	AMG-355; AMG-355 + Pembrolizumab	anti-CCR8_monoclonal_antibody; anti-CCR8_monoclonal_antibody + anti-PD-1_monoclonal_antibody	20220028	A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 355 as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors	Advanced Solid Tumors	2010 - Darlinghurst; 5011 - Woodville South	https://clinicaltrials.gov/ct2/show/NCT06131398
NCT06132958	TroFuse-005	Phase 3		NSW, QLD, VIC	2023-11-15	2023-12-06		Dexamethasone; Dexamethasone + Sacituzumab tirumotecan; Doxorubicin; Doxorubicin + Nab-paclitaxel + Paclitaxel; Nab-paclitaxel; Paclitaxel; Sacituzumab tirumotecan	anti-Trop2_antibody-drug_conjugate; anti-Trop2_antibody-drug_conjugate + glucocorticoid; anthracycline; taxane; anthracycline + taxane; glucocorticoid; doxorubicin	Dexamethasone + Sacituzumab tirumotecan; Doxorubicin + Nab-paclitaxel + Paclitaxel	anthracycline + taxane; anti-Trop2_antibody-drug_conjugate + glucocorticoid; doxorubicin	2023-504816-14-00  2870-005	A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Immunotherapy (MK-2870-005/ENGOT-en23/GOG-3095)	Endometrial Cancer	3199 - Frankston; 2065 - St Leonards; 2148 - Sydney; 4029 - Brisbane; 3002 - East Melbourne	https://clinicaltrials.gov/ct2/show/NCT06132958
NCT06136624	2023-504899-25-00--5684-003	Phase 3		NSW, NZ, QLD, VIC	2023-11-18	2023-12-31		Abiraterone; Abiraterone + Enzalutamide + Prednisone; Dexamethasone; Dexamethasone + Opevesostat; Enzalutamide; Opevesostat; Prednisone	antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor; CYP11A1_inhibitor; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + glucocorticoid; glucocorticoid; CYP11A1_inhibitor + glucocorticoid	Abiraterone + Enzalutamide + Prednisone; Dexamethasone + Opevesostat	CYP11A1_inhibitor + glucocorticoid; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + glucocorticoid	2023-504899-25-00  5684-003	A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy (OMAHA-003)	Prostate Cancer Metastatic	Otago; 4102 - Brisbane; 3000 - Melbourne; 2830 - Dubbo; 2109 - Macquarie University; 2145 - Westmead	https://clinicaltrials.gov/ct2/show/NCT06136624
NCT06136650	MK-5684-004--5684-004	Phase 3		NSW, NZ, QLD, VIC	2023-11-18	2023-12-18		Abiraterone; Abiraterone + Enzalutamide + Prednisone; Dexamethasone; Dexamethasone + Opevesostat; Enzalutamide; Opevesostat; Prednisone	antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor; CYP11A1_inhibitor; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + glucocorticoid; glucocorticoid; CYP11A1_inhibitor + glucocorticoid	Abiraterone + Enzalutamide + Prednisone; Dexamethasone + Opevesostat	CYP11A1_inhibitor + glucocorticoid; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + glucocorticoid	MK-5684-004  5684-004	MK-5684-004: A Phase 3, Randomized, Open-label Study of Opevesostat Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment With One Next-generation Hormonal Agent (NHA) (OMAHA-004)	Prostatic Neoplasms; Metastatic Castration-resistant Prostate Cancer (mCRPC)	3168 - Clayton; Auckland; 4029 - Brisbane; 2145 - Westmead; 2109 - Macquarie University; Otago; 3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT06136650
NCT06151574	2023-504308-27-00--1479-0008	Phase 3		NSW, QLD, VIC, WA	2023-11-30	2024-02-09		Carboplatin; Cisplatin; Pembrolizumab; Pembrolizumab + Pemetrexed; Pemetrexed; Zongertinib	antimetabolite; platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + antimetabolite; ERBB2_inhibitor,second_generation; anti-PD-1_monoclonal_antibody	Pembrolizumab + Pemetrexed; Zongertinib; Carboplatin; Cisplatin	ERBB2_inhibitor,second_generation; anti-PD-1_monoclonal_antibody + antimetabolite; platinum-based_antineoplastic_agent	2023-504308-27-00  1479-0008	Beamion LUNG 2: A Phase III, Open-label, Randomized, Active-controlled, Multi-centre Trial Evaluating Orally Administered Zongertinib (BI 1810631) Compared With Standard of Care as First-line Treatment in Patients With Unresectable, Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Harbouring HER2 Tyrosine Kinase Domain Mutations	Lung Cancer, Non-squamous, Non-small Cell	3084 - Heidelberg; 2031 - Randwick; 2065 - St Leonards; 6008 - Subiaco; 4102 - Woolloongabba	https://clinicaltrials.gov/ct2/show/NCT06151574
NCT06157541	TCaP	Phase 1		QLD, VIC	2023-12-06	2024-02-08		Ifosfamide; Pembrolizumab	alkylating_agent; anti-PD-1_monoclonal_antibody	Ifosfamide; Pembrolizumab	alkylating_agent; anti-PD-1_monoclonal_antibody	P3894 / MSD-MK3475-E78	Phase I/II Clinical Trial of Allogeneic Cytomegalovirus-specific T Cells in Combination With Pembrolizumab for Recurrent and Newly Diagnosed Glioblastoma Multiforme	Glioblastoma Multiforme; Astrocytoma, Grade IV	4006 - Herston; 4006 - Bowen Hills; 3084 - Heidelberg; 4102 - Woolloongabba	https://clinicaltrials.gov/ct2/show/NCT06157541
NCT06157892	C5731004--SGNDV-004	Phase 2		SA, VIC	2023-12-06	2024-05-20		Disitamab vedotin; Disitamab vedotin + Tucatinib; Tucatinib	ERBB2_inhibitor,third_generation + anti-ERBB2_antibody-drug_conjugate; anti-ERBB2_antibody-drug_conjugate; ERBB2_inhibitor,third_generation	Disitamab vedotin + Tucatinib	ERBB2_inhibitor,third_generation + anti-ERBB2_antibody-drug_conjugate	C5731004  SGNDV-004	A Phase 1b/2 Open-Label Study of Disitamab Vedotin in Combination With Other Anticancer Therapies in Solid Tumors	HER2 Positive Breast Neoplasms; Gastroesophageal Junction Adenocarcinoma; Stomach Neoplasms; Advanced Breast Cancer; HER2 Low Breast Neoplasms; Metastatic Breast Cancer; Breast Neoplasms; Triple Negative Breast Neoplasms; Metastatic Gastric Cancer; Advanced Gastric Cancer	3199 - Frankston; 3149 - Mount Waverley; 5033 - Richmond	https://clinicaltrials.gov/ct2/show/NCT06157892
NCT06161025	REJOICE-Ovarian01--DS6000-109	Phase 2		NSW	2023-12-07	2024-02-27		Gemcitabine; Gemcitabine + Paclitaxel + Pegylated liposomal doxorubicin + Topotecan; Paclitaxel; Pegylated liposomal doxorubicin; Raludotatug deruxtecan; Topotecan	antimetabolite; topoisomerase_inhibitor; anthracycline; taxane; gemcitabine; anti-CDH6_antibody-drug_conjugate; anthracycline + antimetabolite + taxane + topoisomerase_inhibitor	Gemcitabine + Paclitaxel + Pegylated liposomal doxorubicin + Topotecan; Raludotatug deruxtecan	anthracycline + antimetabolite + taxane + topoisomerase_inhibitor; anti-CDH6_antibody-drug_conjugate; gemcitabine	REJOICE-Ovarian01  DS6000-109	A Phase 2/3, Multicenter, Randomized Study of Raludotatug Deruxtecan (R-DXd), a CDH6-directed Antibody-drug Conjugate, in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	Solid Cancer	- South Australia; - St Leonards	https://clinicaltrials.gov/ct2/show/NCT06161025
NCT06161441	2023-505172-29-00--R3767-ONC-2266	Phase 2		VIC, WA	2023-12-07	2024-07-16		Carboplatin; Cemiplimab; Cisplatin; Fianlimab; Paclitaxel; Pemetrexed; Placebo	placebo; anti-LAG3_monoclonal_antibody; antimetabolite; anti-PD-1_monoclonal_antibody; taxane; platinum-based_antineoplastic_agent	Carboplatin; Cemiplimab; Cisplatin; Fianlimab; Paclitaxel; Pemetrexed; Placebo	anti-LAG3_monoclonal_antibody; anti-PD-1_monoclonal_antibody; antimetabolite; placebo; platinum-based_antineoplastic_agent; taxane	2023-505172-29-00  R3767-ONC-2266	A Phase 2 Peri-Operative Trial of Fianlimab and Cemiplimab in Combination With Chemotherapy Versus Cemiplimab in Combination With Chemotherapy in Patients With Resectable Early Stage (Stage II to IIIB [N2]) NSCLC	Resectable Non-small Cell Lung Cancer	3065 - Fitzroy; 6150 - Murdoch; 3128 - Box Hill	https://clinicaltrials.gov/ct2/show/NCT06161441
NCT06162572	SPLFIO-174	Phase 1		NSW, SA, VIC	2023-12-08	2024-08-07		Cemiplimab; Cemiplimab + S095018; Cemiplimab + S095024; Cemiplimab + S095029; S095018; S095024; S095029	anti-NKG2A_monoclona_antibody; anti-PD-1_monoclonal_antibody; anti-CD73_monoclona_antibody; anti-PD-1_monoclonal_antibody + anti-TIM3_monoclona_antibody; anti-NKG2A_monoclona_antibody + anti-PD-1_monoclonal_antibody; anti-CD73_monoclona_antibody + anti-PD-1_monoclonal_antibody; anti-TIM3_monoclona_antibody	Cemiplimab; Cemiplimab + S095018; Cemiplimab + S095024; Cemiplimab + S095029	anti-CD73_monoclona_antibody + anti-PD-1_monoclonal_antibody; anti-NKG2A_monoclona_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIM3_monoclona_antibody	SPLFIO-174	A Phase 1b/2, Multicenter, Open-label Platform Study of Select Immunotherapy Combinations in Adult Participants With Previously Untreated Advanced Non-small Cell Lung Cancer (NSCLC) With High PD-L1 Expression	Non-small Cell Lung Cancer (NSCLC)	3844 - Traralgon; 2640 - Albury; 5042 - Bedford Park; 3021 - St Albans	https://clinicaltrials.gov/ct2/show/NCT06162572
NCT06170190	CIBI133A101	Phase 1		NSW	2023-12-14	2024-01-16		IBI133	anti-ERBB3_monoclonal_antibody	IBI133	anti-ERBB3_monoclonal_antibody	CIBI133A101	A Multicentre, Open-label, Phase 1/2 Study of IBI133 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumours	Locally Advanced Unresectable or Metastatic Solid Tumors	2170 - Liverpool	https://clinicaltrials.gov/ct2/show/NCT06170190
NCT06170788	TroFuse-007	Phase 3		NSW, VIC	2023-12-14	2023-12-15		Dexamethasone; Dexamethasone + Pembrolizumab + Sacituzumab tirumotecan; Pembrolizumab; Sacituzumab tirumotecan	anti-Trop2_antibody-drug_conjugate; anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate + glucocorticoid; glucocorticoid; anti-PD-1_monoclonal_antibody	Dexamethasone + Pembrolizumab + Sacituzumab tirumotecan; Pembrolizumab	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate + glucocorticoid	MK-2870-007  2870-007	A Randomized, Open-label, Phase 3 Study of MK-2870 in Combination With Pembrolizumab Compared to Pembrolizumab Monotherapy in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer With PD-L1 TPS Greater Than or Equal to 50% (TroFuse-007)	Non-small Cell Lung Cancer (NSCLC)	2145 - Westmead; 3350 - Ballarat Central; 2444 - Port Macquarie; 3076 - Epping	https://clinicaltrials.gov/ct2/show/NCT06170788
NCT06172478	2023-507641-29-00--U31402-277	Phase 2		NSW, QLD, TAS, VIC	2023-12-15	2024-02-26		Patritumab Deruxtecan	anti-ERBB3_antibody-drug_conjugate	Patritumab Deruxtecan	anti-ERBB3_antibody-drug_conjugate	2023-507641-29-00  U31402-277	HERTHENA-PanTumor01 (U31402-277): A Phase 2, Multicenter, Multicohort, Open-Label, Proof of Concept Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Subjects With Locally Advanced or Metastatic Solid Tumors	Head and Neck Cancer; Advanced Solid Tumor; Prostate Cancer; Gastric Cancer; Cervical Cancer; Melanoma; Pancreatic Carcinoma; Ovarian Carcinoma; Esophageal Cancer; Bladder Cancer; Endometrial Cancer	2050 - Camperdown; 4032 - Chermside; 7000 - Hobart; 3168 - Clayton; 4812 - Hyde Park	https://clinicaltrials.gov/ct2/show/NCT06172478
NCT06174987	2023-506330-73-00--ROMast-001	Phase 3		SA, VIC	2023-12-18	2024-01-05		Trastuzumab Deruxtecan	anti-ERBB2_antibody-drug_conjugate	Trastuzumab Deruxtecan	anti-ERBB2_antibody-drug_conjugate	2023-506330-73-00  ROMast-001	A Master Rollover Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)	Metastatic Cancer; Advanced Cancer	5042 - Bedford Park; 3168 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT06174987
NCT06179160	2023-507091-47-00--INCB161734-101	Phase 1		NSW, VIC, WA	2023-12-21	2024-01-04		Cetuximab; INCB161734; Retifanlimab	anti-EGFR_monoclonal_antibody; anti-PD-1_monoclonal_antibody; KRAS_G12D_inhibitor	INCB161734; Cetuximab; Retifanlimab	KRAS_G12D_inhibitor; anti-EGFR_monoclonal_antibody; anti-PD-1_monoclonal_antibody	2023-507091-47-00  INCB161734-101	A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation	Solid Tumors	03004 - Melbourne; 06009 - Nedlands; 02010 - Darlinghurst; 3051 - North Melbourne; 02050 - Camperdown	https://clinicaltrials.gov/ct2/show/NCT06179160
NCT06179511	D9470C00001	Phase 1		VIC	2023-12-22	2024-01-31		AZD9829	anti-CD123_antibody-drug_conjugate	AZD9829	anti-CD123_antibody-drug_conjugate	D9470C00001	A Modular Phase I/II, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of AZD9829 as Monotherapy or in Combination in Patients With CD123-Positive Hematological Malignancies	Hematological Malignancies	VIC 3000 - Melbourne; 3084 - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT06179511
NCT06184035	Tumorad	Phase 1		SA, VIC	2023-12-28	2023-11-30		177Lu-SN201	nanoparticle_radiopharmaceutics	177Lu-SN201	nanoparticle_radiopharmaceutics	2023-505224-64  Tumorad-01	A Phase I/IIa, Dose Escalation and Dose Expansion, First-in-human, Open-label, Multicenter, Single-arm Study Evaluating the Safety, Tolerability, Dosimetry, and Early Efficacy of [177Lu]Lu-SN201 in Participants With Progressive or Treatment-refractory Locally Advanced Unresectable, Metastatic or Recurrent Solid Tumors	Unresectable Solid Tumor; Recurrent Solid Tumor; Locally Advanced Solid Tumor; Refractory Cancer; Metastatic Cancer; Solid Tumor	3065 - Melbourne; 5000 - Adelaide	https://clinicaltrials.gov/ct2/show/NCT06184035
NCT06188208	2023-508386-32-00--VVD-130850-01	Phase 1		NSW, QLD, SA	2024-01-03	2024-01-05		Pembrolizumab; Pembrolizumab + VVD-130850; VVD-130850	STAT3_inhibitor; STAT3_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody	Pembrolizumab + VVD-130850; VVD-130850	STAT3_inhibitor; STAT3_inhibitor + anti-PD-1_monoclonal_antibody	2023-508386-32-00  VVD-130850-01	A Phase 1, Open-Label, 2-Part, Multicenter, First-in-Human Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-Tumor Activity of the STAT3 Inhibitor VVD-130850 as Single Agent and in Combination With Checkpoint Inhibition in Participants With Advanced Solid and Hematologic Tumors	Advanced Solid Tumors; Advanced Hematologic Tumors	- South Brisbane; - Adelaide; - Orange; - Blacktown; - Southport	https://clinicaltrials.gov/ct2/show/NCT06188208
NCT06188520	CYCAD-1	Phase 1		VIC	2024-01-03	2023-12-05		AZD8421; AZD8421 + Abemaciclib + Camizestrant; AZD8421 + Camizestrant + Palbociclib; AZD8421 + Camizestrant + Ribociclib; Abemaciclib; Camizestrant; Palbociclib; Ribociclib	CDK4/6_inhibitor; CDK2_inhibitor + CDK4/6_inhibitor + selective_estrogen_receptor_degrader; selective_estrogen_receptor_degrader; CDK2_inhibitor	AZD8421; AZD8421 + Abemaciclib + Camizestrant; AZD8421 + Camizestrant + Palbociclib; AZD8421 + Camizestrant + Ribociclib	CDK2_inhibitor; CDK2_inhibitor + CDK4/6_inhibitor + selective_estrogen_receptor_degrader	D8470C00001	A Phase I/IIa, First-in-human, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors	ER+ HER2- Advanced Breast Cancer; High-grade Serous Ovarian Cancer (HGSOC)	3002 - East Melbourne	https://clinicaltrials.gov/ct2/show/NCT06188520
NCT06188702	2025-521249-25-00--CL1-95035-001	Phase 1		NSW, QLD, TAS, VIC	2024-01-03	2024-04-29		S095035	MAT2A_inhibitor	S095035	MAT2A_inhibitor	2025-521249-25-00  CL1-95035-001	A Phase 1/2, Open-label, Multicenter Clinical Trial Investigating the Safety, Tolerability, Pharmacokinetics, and Antineoplastic Activity of S095035 (MAT2A Inhibitor) as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Homozygous Deletion of MTAP	MTAP-deleted Solid Tumors	2031 - Randwick; 4812 - Douglas; 7000 - Hobart; 3004 - Prahran	https://clinicaltrials.gov/ct2/show/NCT06188702
NCT06194877	BGB-3245-EGFR-001	Phase 1		NSW, VIC	2024-01-08	2024-04-18		Brimarafenib; Brimarafenib + Panitumumab; Panitumumab	RAF_dimer_inhibitor; anti-EGFR_monoclonal_antibody; RAF_dimer_inhibitor + anti-EGFR_monoclonal_antibody	Brimarafenib + Panitumumab	RAF_dimer_inhibitor + anti-EGFR_monoclonal_antibody	BGB-3245-EGFR-001	A Phase 1b, Open-Label, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 With Panitumumab in Patients With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers	Pancreatic Ductal Cancer; Colorectal Cancer; Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers	2145 - Westmead; 3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT06194877
NCT06198426	CIBI3004A101	Phase 1		NSW	2024-01-10	2024-08-19		IBI3004	unknown_drug_class	IBI3004	unknown_drug_class	CIBI3004A101	A Phase 1/2, Multicenter, Open-label Study of IBI3004 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors	Solid Tumor	2170 - Sydney; 2770 - Randwick	https://clinicaltrials.gov/ct2/show/NCT06198426
NCT06199908	AMT-562-01	Phase 1		NSW, VIC	2024-01-10	2024-05-20		AMT-562	anti-ERBB3_antibody-drug_conjugate	AMT-562	anti-ERBB3_antibody-drug_conjugate	AMT-562-01	First-in-Human, Phase 1 Study of AMT-562 in Patients With Advanced Solid Tumors	Advanced Solid Tumors	- Malvern; - North Ryde	https://clinicaltrials.gov/ct2/show/NCT06199908
NCT06203210	IDeate-Lung02	Phase 3		NSW, QLD, SA, VIC, WA	2024-01-12	2024-05-21		Amrubicin; Amrubicin + Lurbinectedin + Topotecan; Ifinatamab Deruxtecan; Lurbinectedin; Topotecan	DNA_minor_groove-binding_agent + anthracycline + topoisomerase_inhibitor; topoisomerase_inhibitor; DNA_minor_groove-binding_agent; anti-B7H3_antibody-drug_conjugate; anthracycline	Amrubicin + Lurbinectedin + Topotecan; Ifinatamab Deruxtecan	DNA_minor_groove-binding_agent + anthracycline + topoisomerase_inhibitor; anti-B7H3_antibody-drug_conjugate	2023-509628-16-00  DS7300-188	A Phase 3, Multicenter, Randomized, Open-label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody Drug Conjugate (ADC), Versus Treatment of Physician's Choice (TPC) in Subjects With Relapsed Small Cell Lung Cancer (SCLC) (IDeate-Lung02)	Small Cell Lung Cancer	5042 - Bedford Park; 3021 - St Albans; 2050 - Camperdown; 3350 - Ballarat; 4102 - Woolloongabba; 6008 - Subiaco; 4814 - Townsville	https://clinicaltrials.gov/ct2/show/NCT06203210
NCT06208657	OPTIMISE	Phase 1		NSW, QLD, SA, VIC, WA, Washingto	2024-01-17	2024-07-10		Irinotecan; Irinotecan + Paxalisib + Temozolomide; Paxalisib; Temozolomide	dual_PI3K/mTOR_inhibitor; alkylating_agent; topoisomerase_inhibitor; alkylating_agent + dual_PI3K/mTOR_inhibitor + topoisomerase_inhibitor	Irinotecan + Paxalisib + Temozolomide	alkylating_agent + dual_PI3K/mTOR_inhibitor + topoisomerase_inhibitor	OPTIMISE	Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer	Childhood Brain Tumor; Childhood Solid Tumor; Childhood Cancer; Recurrent Cancer; Refractory Cancer	- Sydney; - Melbourne; - Adelaide; - Brisbane; - Perth; - Newcastle	https://clinicaltrials.gov/ct2/show/NCT06208657
NCT06211036	DeLLphi-305	Phase 3		NSW, QLD, SA, VIC, WA	2024-01-18	2024-06-05		Durvalumab; Durvalumab + Tarlatamab; Etoposide; Tarlatamab	topoisomerase_inhibitor; anti-PD-L1_monoclonal_antibody + bispecific_T-cell_engager,DLL3-targeting; anti-PD-L1_monoclonal_antibody; bispecific_T-cell_engager,DLL3-targeting	Durvalumab; Durvalumab + Tarlatamab; Etoposide	anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + bispecific_T-cell_engager,DLL3-targeting; topoisomerase_inhibitor	2023-505989-29  20200041	A Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects With Extensive-Stage Small-Cell Lung Cancer Following Platinum, Etoposide and Durvalumab (DeLLphi-305)	Small-Cell Lung Cancer; Extensive-Stage Small-Cell Lung Cancer	3168 - Clayton; 6009 - Nedlands; 2050 - Camperdown; 4120 - Greenslopes; 2500 - Wollongong; 5000 - Adelaide	https://clinicaltrials.gov/ct2/show/NCT06211036
NCT06219941	D9800C00001	Phase 2		NSW, VIC, WA	2024-01-23	2023-12-13		AZD0901; Fluorouracil; Gemcitabine; Irinotecan; Leucovorin; Liposomal Irinotecan	antimetabolite; topoisomerase_inhibitor; Fluorouracil; fluoropyrimidine; gemcitabine; folinic_acid; anti-CLDN18.2_antibody-drug_conjugate	AZD0901; Fluorouracil; Gemcitabine; Irinotecan; Leucovorin; Liposomal Irinotecan	anti-CLDN18.2_antibody-drug_conjugate; Fluorouracil; antimetabolite; fluoropyrimidine; folinic_acid; gemcitabine; topoisomerase_inhibitor	D9800C00001	A Phase II, Open-label, Multi-centre Study to Evaluate Safety, Tolerability, Efficacy, PK, and Immunogenicity of AZD0901 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Tumours Expressing Claudin 18.2 (CLARITY-PanTumour01)	Gastroesophageal Junction Cancer; Biliary Tract Cancer; Pancreatic Ductal Adenocarcinoma; Gastric Cancer	2031 - Randwick; 3000 - Melbourne; WA6150 - Murdoch	https://clinicaltrials.gov/ct2/show/NCT06219941
NCT06220864	SNV1521-101	Phase 1		NSW, WA	2024-01-24	2024-02-23		SNV1521	PARP1-selective_inhibitor	SNV1521	PARP1-selective_inhibitor	SNV1521-101	A Phase 1, Open-Label Dose Escalation and Expansion Study of SNV1521 in Participants With Advanced Solid Tumors	Advanced Solid Tumor	2031 - Randwick; 6009 - Crawley	https://clinicaltrials.gov/ct2/show/NCT06220864
NCT06225596	2023-504231-41--BT8009-230	Phase 2		NSW, QLD, SA, VIC, WA	2024-01-26	2024-01-24		Avelumab; BT8009; BT8009 + Pembrolizumab; Carboplatin; Cisplatin; Gemcitabine; Pembrolizumab	antimetabolite; bicycle_toxin_conjugate,NECTIN4-targeting; anti-PD-L1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; gemcitabine; platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + bicycle_toxin_conjugate,NECTIN4-targeting	Avelumab; BT8009; BT8009 + Pembrolizumab; Carboplatin; Cisplatin; Gemcitabine	anti-PD-1_monoclonal_antibody + bicycle_toxin_conjugate,NECTIN4-targeting; anti-PD-L1_monoclonal_antibody; bicycle_toxin_conjugate,NECTIN4-targeting; antimetabolite; gemcitabine; platinum-based_antineoplastic_agent	2023-504231-41  BT8009-230	A Randomized Open-Label Phase 2/3 Study of BT8009 as Monotherapy or in Combination in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)	Metastatic Urothelial Cancer	5000 - Adelaide; 2031 - Randwick; 4215 - Southport; 2310 - Hunter; 4066 - South Brisbane; 4101 - Brisbane; 4814 - Douglas; 2148 - New South Wales; 6009 - Nedlands; 4102 - Woolloongabba; 3220 - Geelong	https://clinicaltrials.gov/ct2/show/NCT06225596
NCT06226766	JSKN033-101	Phase 1		NSW	2024-01-26	2024-01-18		Envafolimab; JSKN003	anti-PD-L1_monoclonal_antibody; UNDEF + anti-PD-L1_monoclonal_antibody	Envafolimab; JSKN003	UNDEF + anti-PD-L1_monoclonal_antibody	JSKN033-101	Phase I/II Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of JSKN033 in Patients With Advanced or Metastatic Solid Malignant Tumors	Advanced Solid Tumor	2031 - Randwick	https://clinicaltrials.gov/ct2/show/NCT06226766
NCT06233942	2023-509958-65-00--BG-C9074-101	Phase 1		NSW, QLD, VIC, WA	2024-01-31	2024-04-12		BG-C9074; BG-C9074 + Tislelizumab; Tislelizumab	anti-PD-1_monoclonal_antibody; anti-B7H4_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody; anti-B7H4_antibody-drug_conjugate	BG-C9074; BG-C9074 + Tislelizumab	anti-B7H4_antibody-drug_conjugate; anti-B7H4_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody	2023-509958-65-00  BG-C9074-101	Phase 1a/1b Study of BG-C9074, an Antibody Drug Conjugate Targeting B7H4, as Monotherapy and in Combination With Tislelizumab in Participants With Advanced Solid Tumors	Advanced Solid Tumor	6009 - Nedlands; 3168 - Clayton; 4102 - Woolloongabba; 2109 - North Ryde; 2500 - Wollongong; 3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT06233942
NCT06236438	LIVIGNO-4	Phase 2		ACT, NSW	2024-02-01	2024-04-10		Budigalimab; Budigalimab + Livmoniplimab + Pemetrexed; Budigalimab + Pemetrexed; Carboplatin; Cisplatin; Livmoniplimab; Pembrolizumab; Pembrolizumab + Pemetrexed; Pemetrexed	antimetabolite; anti-PD-1_monoclonal_antibody + antimetabolite; anti-PD-1_monoclonal_antibody; anti-GARP_monoclonal_antibody; platinum-based_antineoplastic_agent; anti-GARP_monoclonal_antibody + anti-PD-1_monoclonal_antibody + antimetabolite	Budigalimab + Livmoniplimab + Pemetrexed; Budigalimab + Pemetrexed; Pembrolizumab + Pemetrexed; Carboplatin; Cisplatin	anti-GARP_monoclonal_antibody + anti-PD-1_monoclonal_antibody + antimetabolite; anti-PD-1_monoclonal_antibody + antimetabolite; platinum-based_antineoplastic_agent	2023-505773-32-00  M23-721	A Randomized, Phase 2/3 Study to Evaluate the Optimal Dose, Safety, and Efficacy of Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)	Non-Small Cell Lung Cancer	2145 - Westmead; 2605 - Garran; 2747 - Kingswood	https://clinicaltrials.gov/ct2/show/NCT06236438
NCT06238479	EXCEED	Phase 1		SA, VIC	2024-02-02	2024-03-05		LY4101174	anti-NECTIN4_antibody-drug_conjugate	LY4101174	anti-NECTIN4_antibody-drug_conjugate	J5A-OX-JZWA  18836	A Phase 1 Trial Investigating LY4101174, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Recurrent, Advanced or Metastatic Solid Tumors	Triple Negative Breast Cancer; Urinary Bladder Neoplasm; Bladder Cancer; Esophageal Cancer; Non-small Cell Lung Cancer; Renal Pelvis Cancer; Cervical Cancer; Pancreatic Cancer; Metastatic Solid Tumor; Head and Neck Squamous Cell Carcinoma; Prostate Cancer; Advanced Solid Tumor; Ovarian Cancer; Recurrent Solid Tumor	3084 - Heidelberg; 5037 - Kurralta Park	https://clinicaltrials.gov/ct2/show/NCT06238479
NCT06242470	CP-MGC026-01	Phase 1		QLD, SA, VIC	2024-02-05	2024-03-06		MGC026	anti-B7H3_antibody-drug_conjugate	MGC026	anti-B7H3_antibody-drug_conjugate	CP-MGC026-01	A Phase 1/1b First-in-Human, Open Label, Dose Escalation and Cohort Expansion Study of MGC026 in Participants With Advanced Solid Tumors	Squamous Cell Carcinoma of Head and Neck; Gastro-esophageal Cancer; Advanced Solid Tumor; Breast Cancer; Advanced Cancer; Ovarian Cancer; Bladder Cancer; Colorectal Cancer; Platinum-resistant Ovarian Cancer; Pancreas Cancer; Endometrial Cancer; Non Small Cell Lung Cancer; Clear Cell Renal Cell Carcinoma; Gastric Cancer; Castration Resistant Prostatic Cancer; Cervical Cancer; Metastatic Cancer; Esophageal Squamous Cell Cancer (SCC); Sarcoma; Small-cell Lung Cancer; Hepatocellular Carcinoma; Melanoma	4066 - Auchenflower; 5037 - Kurralta Park; 3084 - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT06242470
NCT06242691	2023-508684-68-00--1200-002	Phase 1		VIC	2024-02-05	2024-02-28		MK-1200	anti-CLDN18.2_antibody-drug_conjugate	MK-1200	anti-CLDN18.2_antibody-drug_conjugate	2023-508684-68-00  1200-002	A Phase 1/2 Open-label Study to Evaluate the Safety and Efficacy of MK-1200 in Participants With Advanced Solid Tumors	Advanced Solid Tumors	3004 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT06242691
NCT06247995	NeoB-Cap1	Phase 1		NSW, VIC	2024-02-08	2024-08-14		177Lu-NeoB; 177Lu-NeoB + Capecitabine; Capecitabine	radioligand,GRPR-targeting; fluoropyrimidine + radioligand,GRPR-targeting; fluoropyrimidine	177Lu-NeoB + Capecitabine	fluoropyrimidine + radioligand,GRPR-targeting	2023-506717-21  CAAA603D12101	A Phase I/II, Open-label, Multi-center Trial of [177Lu]Lu-NeoB in Combination With Capecitabine in Adult Patients With Gastrin Releasing Peptide Receptor Positive, Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor-2 Negative Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.	Breast Cancer	3144 - Malvern; 2010 - Darlinghurst	https://clinicaltrials.gov/ct2/show/NCT06247995
NCT06252649	CodeBreaK-301	Phase 3		NSW, QLD, SA, VIC	2024-02-12	2024-07-17		Bevacizumab; Panitumumab; Panitumumab + Sotorasib; Sotorasib	KRAS_G12C_inhibitor; anti-VEGF_monoclonal_antibody; anti-EGFR_monoclonal_antibody; KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody	Bevacizumab; Panitumumab + Sotorasib	KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody; KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody; anti-VEGF_monoclonal_antibody	20210081	Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb for Treatment-naïve Subjects With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (CodeBreaK 301)	Metastatic Colorectal Cancer	5011 - Woodville South; 5042 - Bedford Park; 2050 - Camperdown; 3084 - Heidelberg; 4350 - Toowoomba	https://clinicaltrials.gov/ct2/show/NCT06252649
NCT06253130	IMP1734-101	Phase 1		NSW, QLD, VIC	2024-02-12	2023-12-11		IMP1734	PARP1-selective_inhibitor	IMP1734	PARP1-selective_inhibitor	2023-509230-19  EIK1003-001 (IMP1734-101)	A First-in-human, Phase 1/2, Open-label, Multi-center, Dose-escalation, Dose-optimization, and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of PARP1 Selective Inhibitor, IMP1734, as Monotherapy in Patients With Advanced Solid Tumors	Advanced Solid Tumor	4101 - South Brisbane; 4102 - Woolloongabba; 3199 - Frankston; 2109 - Sydney; 4125 - Southport; 2031 - Randwick	https://clinicaltrials.gov/ct2/show/NCT06253130
NCT06256588	JADE	Phase 3		NSW, QLD, VIC	2024-02-13	2024-03-21		Dostarlimab; Placebo	placebo; anti-PD-1_monoclonal_antibody	Dostarlimab; Placebo	anti-PD-1_monoclonal_antibody; placebo	2023-508613-17  221530	A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate Dostarlimab as Sequential Therapy After Chemoradiation in Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma	Neoplasms, Head and Neck	4814 - Douglas; 2148 - Blacktown; 3004 - Melbourne; 3220 - Geelong; 4029 - Herston; 3350 - Ballarat	https://clinicaltrials.gov/ct2/show/NCT06256588
NCT06257264	CTR20243059--BG-68501-101	Phase 1		NSW, NZ, QLD, SA, VIC	2024-02-13	2024-03-11		BG-68501; BG-68501 + BGB-43395 + Fulvestrant; BG-68501 + Fulvestrant; BGB-43395; Fulvestrant	CDK4_selective_inhibitor; selective_estrogen_receptor_degrader; CDK2_inhibitor + selective_estrogen_receptor_degrader; CDK2_inhibitor + CDK4_selective_inhibitor + selective_estrogen_receptor_degrader; CDK2_inhibitor	BG-68501; BG-68501 + BGB-43395 + Fulvestrant; BG-68501 + Fulvestrant	CDK2_inhibitor; CDK2_inhibitor + CDK4_selective_inhibitor + selective_estrogen_receptor_degrader; CDK2_inhibitor + selective_estrogen_receptor_degrader	CTR20243059  BG-68501-101	A Phase 1a/1b Study of BG-68501, a Selective CDK2 Inhibitor, in Participants With Advanced Solid Tumors	Small Cell Lung Cancer; GastroEsophageal Cancer; Ovarian Cancer; Breast Cancer; Advanced Solid Tumor; Prostate Cancer; Bladder Cancer; Endometrial Cancer; TNBC - Triple-Negative Breast Cancer; Gastric Cancer; Hormone-receptor-positive Breast Cancer; Hormone Receptor Positive HER-2 Negative Breast Cancer	3000 - Melbourne; 2010 - Darlinghurst; 5000 - Adelaide; 2747 - Kingswood; 4102 - Woolloongabba; 3168 - Clayton; 2065 - St Leonards; 2148 - Blacktown; Auckland	https://clinicaltrials.gov/ct2/show/NCT06257264
NCT06267001	SKYSCRAPER-15	Phase 3		QLD, VIC	2024-02-20	2024-03-21		Atezolizumab; Atezolizumab + Tiragolumab; Placebo; Tiragolumab	placebo; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-TIGIT_monoclonal_antibody; anti-PD-L1_monoclonal_antibody	Atezolizumab; Atezolizumab + Tiragolumab; Placebo	anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; placebo	2023-506696-10-00  GO45006	A Phase III, Randomized, Double-blind Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Stage IIB, IIIA, or Select IIIB, PD-L1 Positive, Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy	Non-small Cell Lung Cancer (NSCLC)	4575 - Birtinya; 3168 - Clayton	https://clinicaltrials.gov/ct2/show/NCT06267001
NCT06267729	APOLLO	Phase 1		VIC	2024-02-20	2024-03-12		AZD0754	allogeneic_CAR-T-cell_therapy,STEAP2-targeting	AZD0754	allogeneic_CAR-T-cell_therapy,STEAP2-targeting	D9660C00001	A Phase I/II Open Label Study to Evaluate the Safety, Cellular Kinetics, and Efficacy of AZD0754, a Chimeric Antigen Receptor (CAR) T-cell Therapy Directed Against STEAP2, in Adult Participants With Metastatic Prostate Cancer: APOLLO	Metastatic Prostate Cancer	3002 - East Melbourne	https://clinicaltrials.gov/ct2/show/NCT06267729
NCT06295731	HexAgon-HN	Phase 2		SA	2024-03-06	2024-05-14		Pembrolizumab	anti-PD-1_monoclonal_antibody	Pembrolizumab	anti-PD-1_monoclonal_antibody	EU CT  INBRX106-01-201	A Phase 2/3, Randomized Study of INBRX-106 Combined With Pembrolizumab Versus Pembrolizumab as First Line Treatment for Patients With Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) Expressing PD-L1 (CPS =20) (HexAgon-HN)	Head and Neck Squamous Cell Carcinoma (HNSCC)	5000 - Adelaide	https://clinicaltrials.gov/ct2/show/NCT06295731
NCT06302426	INI-4001-101	Phase 1		NSW, VIC	2024-03-08			Atezolizumab; Avelumab; Cemiplimab; Durvalumab; INI-4001; Nivolumab; Pembrolizumab	anti-PD-L1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; TLR7/TLR8_agonist	INI-4001; Atezolizumab; Avelumab; Cemiplimab; Durvalumab; Nivolumab; Pembrolizumab	TLR7/TLR8_agonist; anti-PD-1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody	INI-4001-101	An Open-label, Multiple-Ascending Dose, Two-Part Dose Ranging and Cohort Expansion Study of INI-4001 in Patients With Advanced Solid Tumours	Advanced Solid Tumor	3144 - Malvern; 2640 - Albury	https://clinicaltrials.gov/ct2/show/NCT06302426
NCT06305962	177Lu-RAD204.2023.0001	Phase 0		NSW, QLD, SA, WA	2024-03-12	2024-06-03		177Lu-RAD204	radioconjugate,PD-L1-targeting	177Lu-RAD204	radioconjugate,PD-L1-targeting	177Lu-RAD204.2023.0001	Phase 0/1 Study of the Safety and Tolerability of 177Lu-RAD204, a Lutetium-177 Radiolabelled Single Domain Antibody Against Programmed Cell Death-Ligand 1 in Patients With Metastatic Solid Tumours	Small Cell Lung Cancer ( SCLC ); Non Small Cell Lung Cancer; Endometrial Cancer; TNBC, Triple Negative Breast Cancer; PDL1 Gene Mutation; HNSCC; Cutaneous Melanoma	2747 - Kingswood; 2500 - Wollongong; 5000 - Adelaide; 4215 - Southport; 6150 - Murdoch; 4509 - North Lakes	https://clinicaltrials.gov/ct2/show/NCT06305962
NCT06312176	MK-2870-010--2870-010	Phase 3		NSW, NZ, VIC, WA	2024-03-15	2024-04-14		Capecitabine; Capecitabine + Nab-paclitaxel + Paclitaxel + Pegylated liposomal doxorubicin; Nab-paclitaxel; Paclitaxel; Pegylated liposomal doxorubicin; Pembrolizumab; Pembrolizumab + Sacituzumab tirumotecan; Sacituzumab tirumotecan	anti-Trop2_antibody-drug_conjugate; anthracycline; fluoropyrimidine; anti-PD-1_monoclonal_antibody; taxane; anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; anthracycline + fluoropyrimidine + taxane	Capecitabine + Nab-paclitaxel + Paclitaxel + Pegylated liposomal doxorubicin; Pembrolizumab + Sacituzumab tirumotecan; Sacituzumab tirumotecan	anthracycline + fluoropyrimidine + taxane; anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; anti-Trop2_antibody-drug_conjugate	MK-2870-010  2870-010	An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer	Breast Neoplasms	Auckland; 2145 - Westmead; 6150 - Murdoch; 2109 - Macquarie University; 3199 - Frankston	https://clinicaltrials.gov/ct2/show/NCT06312176
NCT06318273	2024-516772-15-00--M24-742	Phase 1		NSW, VIC	2024-03-19	2024-03-08		ABBV-969	anti-PSMA∕STEAP1_antibody-drug_conjugate	ABBV-969	anti-PSMA∕STEAP1_antibody-drug_conjugate	2024-516772-15-00  M24-742	A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer	Metastatic Castration-Resistant Prostate Cancer	2050 - Camperdown; 3350 - Ballarat; 3065 - Fitzroy	https://clinicaltrials.gov/ct2/show/NCT06318273
NCT06325748	SENTI-202-101	Phase 1		NSW, VIC	2024-03-22	2024-04-22		SENTI-202	allogeneic_CAR-NK-cell_therapy,CD33/FLT3-targeting	SENTI-202	allogeneic_CAR-NK-cell_therapy,CD33/FLT3-targeting	SENTI-202-101	SENTI-202-101: a Phase 1, Multicenter, Open-Label Study of SENTI-202, a Selective Off-the-Shelf Logic Gated CAR NK Cell Therapy, in Subjects with CD33 And/or FLT3 Expressing Malignancies	FLT3 Expressing Hematological Malignancies; AML/MDS; CD33 Expressing Hematological Malignancies	2050 - Camperdown; 3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT06325748
NCT06326411	NST-628	Phase 1		NSW, QLD, SA, VIC	2024-03-22	2024-04-09		NST-628	pan-RAF/MEK_glue	NST-628	pan-RAF/MEK_glue	NST-628-001	A Phase I, Open Label Single-arm Two-part Study to Investigate Safety, Pharmacokinetics, and Preliminary Efficacy of Pan-RAF/MEK Glue NST-628 Oral Tablets in Subject With Solid Tumors Harboring Genetic Alterations in the MAPK Pathway and With Other Solid Tumors	Solid Tumor, Adult; Oncology; RAF Gene Mutation; Glioma; Ras (KRAS or NRAS) Gene Mutation; NSCLC; Melanoma; MEK Mutation; MAPK Pathway Gene Mutation	3144 - Malvern; 120 - Greenslopes; 5042 - Adelaide; 2010 - Darlinghurst; 2031 - Randwick	https://clinicaltrials.gov/ct2/show/NCT06326411
NCT06330064	2023-509632-26-00--DS7300-203	Phase 2		NSW, QLD, WA	2024-03-26	2024-04-10		Ifinatamab Deruxtecan	anti-B7H3_antibody-drug_conjugate	Ifinatamab Deruxtecan	anti-B7H3_antibody-drug_conjugate	2023-509632-26-00  DS7300-203	A Phase 1B/2 Pan-Tumor, Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)	Recurrent or Metastatic Solid Tumors	2010 - Darlinghurst; 6008 - Subiaco; 4102 - Woolloongabba; 2065 - St Leonards	https://clinicaltrials.gov/ct2/show/NCT06330064
NCT06333951	NCT06333951	Phase 1		NSW, SA	2024-03-27	2024-09-17		AMG 193; AMG 193 + Carboplatin + Paclitaxel + Pembrolizumab; AMG 193 + Carboplatin + Pembrolizumab + Pemetrexed; AMG 193 + Pembrolizumab; AMG 193 + Sotorasib; Carboplatin; Paclitaxel; Pembrolizumab; Pemetrexed; Sotorasib	PRMT5_inhibitor + anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; antimetabolite; PRMT5_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; taxane; PRMT5_inhibitor; KRAS_G12C_inhibitor; platinum-based_antineoplastic_agent; PRMT5_inhibitor + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; KRAS_G12C_inhibitor + PRMT5_inhibitor; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + PRMT5_inhibitor	AMG 193; AMG 193 + Carboplatin + Paclitaxel + Pembrolizumab; AMG 193 + Carboplatin + Pembrolizumab + Pemetrexed; AMG 193 + Pembrolizumab; AMG 193 + Sotorasib	KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + PRMT5_inhibitor; KRAS_G12C_inhibitor + PRMT5_inhibitor; PRMT5_inhibitor; PRMT5_inhibitor + anti-PD-1_monoclonal_antibody; PRMT5_inhibitor + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; PRMT5_inhibitor + anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane	20230167	A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol)	Non-small Cell Lung Cancer; Thoracic Tumors	2800 - Orange; 5011 - Woodville South	https://clinicaltrials.gov/ct2/show/NCT06333951
NCT06336148	ACTM-838-01	Phase 1		NSW, SA, VIC	2024-03-28	2024-06-05		ACTM-838	IL-15/STING_variant,S.Typhimurium-attenuated_bacterial_cancer_therapy	ACTM-838	IL-15/STING_variant,S.Typhimurium-attenuated_bacterial_cancer_therapy	ACTM-838-01	A Phase 1a/1b Open-label, Dose-Escalation and Expansion Study of ACTM-838 as a Single Agent in Patients With Advanced Solid Tumors	Solid Tumor	5042 - Bedford Park; 2145 - Westmead; 3004 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT06336148
NCT06341647	HREC-233-23	Phase 1			2024-04-02			AB-201; Cyclophosphamide; Fludarabine	antimetabolite; alkylating_agent; allogeneic_CAR-NK-cell_therapy,ERBB2-targeting	AB-201; Cyclophosphamide; Fludarabine	allogeneic_CAR-NK-cell_therapy,ERBB2-targeting; alkylating_agent; antimetabolite	103300 (HREC 233/23)  AB-201-01	A Multicenter, Open-label, Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced Human Epidermal Growth Factor Receptor 2 Positive(HER2+) Solid Tumors	Gastric Cancer; Breast Cancer; Gastroesophageal Junction Adenocarcinoma		https://clinicaltrials.gov/ct2/show/NCT06341647
NCT06343402	ONKORAS-101--TBBO8520-101	Phase 1		NSW, SA, VIC	2024-04-02	2024-05-22		BBO-8520; BBO-8520 + Pembrolizumab; Pembrolizumab; Tegafur-gimeracil-oteracil potassium	antimetabolite; orotate_phosphoribosyltransferase_inhibitor; DPD_inhibitor; anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody	BBO-8520; BBO-8520 + Pembrolizumab; Tegafur-gimeracil-oteracil potassium	KRAS_G12C_inhibitor; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody; DPD_inhibitor; antimetabolite; orotate_phosphoribosyltransferase_inhibitor	ONKORAS-101  TBBO8520-101	A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-8520 in Subjects With Advanced KRASG12C Mutant Non-Small Cell Lung Cancer - The ONKORAS-101 Study	KRAS G12C; Advanced Lung Carcinoma; Metastatic Non-Small Cell Lung Cancer; NSCLC; Non-small Cell Lung Cancer; Metastatic Lung Cancer	3199 - Frankston; 2010 - Darlinghurst; 5011 - Woodville South; 5042 - Bedford Park; 3051 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT06343402
NCT06345079	STOPNET	Phase 2		NSW, QLD, VIC, WA	2024-04-03	2024-10-14		Octreotide	somatostatin_analog	Octreotide	somatostatin_analog	AG0219NET	A Randomised Study of Cessation of Somatostatin Analogues After Peptide Receptor Radionuclide Therapy in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours (STOPNET)	Neuroendocrine Tumors	3000 - Melbourne; 6150 - Perth; 2065 - Sydney; 4006 - Brisbane	https://clinicaltrials.gov/ct2/show/NCT06345079
NCT06345729	MK-1084-004--1084-004	Phase 3		NSW, NZ, VIC, WA	2024-04-03	2024-05-24		MK-1084; MK-1084 + Pembrolizumab; Pembrolizumab; Placebo	placebo; KRAS_G12C_inhibitor; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody	MK-1084 + Pembrolizumab; Pembrolizumab; Placebo	KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; placebo	MK-1084-004  1084-004	A Phase 3, Randomized, Double-blind, Multicenter Study of MK-1084 in Combination With Pembrolizumab Compared With Pembrolizumab Plus Placebo as Firstline Treatment of Participants With KRAS G12C-Mutant, Metastatic NSCLC With PD-L1 TPS =50%	Non-small Cell Lung Cancer	2050 - Camperdown; 3199 - Frankston; 6009 - Nedlands; Auckland	https://clinicaltrials.gov/ct2/show/NCT06345729
NCT06346067	ERAS-254-02	Phase 3		NSW, QLD, VIC, WA	2024-04-03	2024-04-29		Dacarbazine; Naporafenib; Naporafenib + Trametinib; Temozolomide; Trametinib	alkylating_agent; RAF_dimer_inhibitor; MEK_inhibitor + RAF_dimer_inhibitor; MEK_inhibitor	Dacarbazine; Naporafenib + Trametinib; Trametinib; Temozolomide	MEK_inhibitor; MEK_inhibitor + RAF_dimer_inhibitor; alkylating_agent	ERAS-254-02	A Randomized, Open-label Phase III Study in Patients With Previously Treated Unresectable or Metastatic NRAS Mutant Cutaneous Melanoma Comparing the Combination of Naporafenib + Trametinib to Physician's Choice of Therapy (Dacarbazine, Temozolomide or Trametinib Monotherapy) With a Dose Optimization lead-in [SEACRAFT-2]	Advanced or Metastatic NRAS-mutant Melanoma	2298 - Waratah; 3004 - Melbourne; 4102 - Woolloongabba; 6009 - Nedlands; 4215 - Southport; 3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT06346067
NCT06349408	CIBI3001A101	Phase 1		NSW, SA	2024-04-05	2025-01-10		IBI3001	bispecific_EGFR/B7H3_antibody-drug_conjugate	IBI3001	bispecific_EGFR/B7H3_antibody-drug_conjugate	CIBI3001A101	A Phase 1 Study of IBI3001 in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors	Locally Advanced Solid Tumor	2500 - Wollongong; 5000 - Adelaide	https://clinicaltrials.gov/ct2/show/NCT06349408
NCT06350097	TROPION-Lung14	Phase 3		NSW, QLD, VIC	2024-04-05	2024-04-29		Datopotamab deruxtecan; Datopotamab deruxtecan + Osimertinib; Osimertinib	anti-Trop2_antibody-drug_conjugate; EGFR_inhibitor,third_generation + anti-Trop2_antibody-drug_conjugate; EGFR_inhibitor,third_generation	Datopotamab deruxtecan + Osimertinib; Osimertinib	EGFR_inhibitor,third_generation; EGFR_inhibitor,third_generation + anti-Trop2_antibody-drug_conjugate	2023-509883-89-00  D516NC00001	A Phase III, Open-label, Randomised Study of Osimertinib With or Without Datopotamab Deruxtecan (Dato-DXd), as First-line Treatment in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation-positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer	Non-small Cell Lung Cancer	4101 - South Brisbane; 3168 - Clayton; 2217 - Kogarah; 2145 - Westmead	https://clinicaltrials.gov/ct2/show/NCT06350097
NCT06351904	RAG-01-01	Phase 1		NSW, VIC	2024-04-08	2024-04-03		Bacillus Calmette-Guérin; RAG-01	BCG_vaccine; saRNA_therapy,CDKN1A-targeting	RAG-01; Bacillus Calmette-Guérin	saRNA_therapy,CDKN1A-targeting; BCG_vaccine	RAG-01-01	A Phase ?, Open Label, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of RAG-01 in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) Who Have Failed Bacillus Calmette Guérin (BCG) Therapy	Non-Muscle-Invasive Bladder Cancer (NMIBC)	2065 - St Leonards; 3199 - Melbourne; 3050 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT06351904
NCT06353386	MK-5684-01A--5684-01A	Phase 1		NSW, NZ, QLD, VIC	2024-04-09	2024-05-20		Cabazitaxel; Cabazitaxel + Dexamethasone + Opevesostat + Prednisone; Dexamethasone; Dexamethasone + Docetaxel + Opevesostat + Prednisone; Dexamethasone + Olaparib + Opevesostat; Dexamethasone + Opevesostat; Docetaxel; Olaparib; Opevesostat; Prednisone	CYP11A1_inhibitor + glucocorticoid + taxane; taxane; CYP11A1_inhibitor; CYP11A1_inhibitor + PARP_inhibitor + glucocorticoid; glucocorticoid; PARP_inhibitor; CYP11A1_inhibitor + glucocorticoid	Cabazitaxel + Dexamethasone + Opevesostat + Prednisone; Dexamethasone + Docetaxel + Opevesostat + Prednisone; Dexamethasone + Olaparib + Opevesostat; Dexamethasone + Opevesostat	CYP11A1_inhibitor + PARP_inhibitor + glucocorticoid; CYP11A1_inhibitor + glucocorticoid; CYP11A1_inhibitor + glucocorticoid + taxane	MK-5684-01A  5684-01A	MK-5684-01A Substudy: A Phase 1/2 Umbrella Substudy of MK-5684-U01 Master Protocol to Evaluate the Safety and Efficacy of MK-5684-based Treatment Combinations or MK-5684 Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC)	Prostatic Neoplasms, Castration-Resistant	Auckland; 2109 - Macquarie University; 4120 - Greenslopes; 3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT06353386
NCT06357533	TROPION-Lung10	Phase 3		NSW, QLD, VIC	2024-04-10	2024-04-11		Datopotamab deruxtecan; Datopotamab deruxtecan + Rilvegostomig; Pembrolizumab; Rilvegostomig	anti-Trop2_antibody-drug_conjugate + bispecific_PD-1/TIGIT_antibody; anti-Trop2_antibody-drug_conjugate; anti-PD-1_monoclonal_antibody; bispecific_PD-1/TIGIT_antibody	Datopotamab deruxtecan + Rilvegostomig; Pembrolizumab; Rilvegostomig	anti-PD-1_monoclonal_antibody; anti-Trop2_antibody-drug_conjugate + bispecific_PD-1/TIGIT_antibody; bispecific_PD-1/TIGIT_antibody	2023-505077-32-00  D7632C00001	A Phase III, Randomised, Open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Pembrolizumab Monotherapy for the First-line Treatment of Participants With Locally-advanced or Metastatic Non-squamous NSCLC With High PD-L1 Expression (TC = 50%) and Without Actionable Genomic Alterations (TROPION-Lung10)	Non-Small Cell Lung Cancer	2148 - Blacktown; 2250 - Gosford; 3168 - Clayton; 3000 - Melbourne; QL 4101 - South Brisbane; 4215 - Southport; 3690 - Wodonga; 4575 - Birtinya	https://clinicaltrials.gov/ct2/show/NCT06357533
NCT06360354	NCT06360354	Phase 1		NSW, SA, VIC	2024-04-11	2024-05-29		AMG 193; AMG 193 + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin; AMG 193 + Gemcitabine + Nab-paclitaxel; Fluorouracil; Gemcitabine; Irinotecan; Leucovorin; Nab-paclitaxel; Oxaliplatin	antimetabolite; topoisomerase_inhibitor; Fluorouracil; taxane; gemcitabine; PRMT5_inhibitor; platinum-based_antineoplastic_agent; folinic_acid; PRMT5_inhibitor + antimetabolite + taxane; PRMT5_inhibitor + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent + topoisomerase_inhibitor	AMG 193 + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin; AMG 193 + Gemcitabine + Nab-paclitaxel	PRMT5_inhibitor + antimetabolite + taxane; PRMT5_inhibitor + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; Fluorouracil; gemcitabine	20230223	A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 in Combination With Other Therapies in Subjects With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous MTAP-deletion	Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers	5011 - Woodville South; 3021 - St Albans; 3000 - Melbourne; 2050 - Camperdown; 3084 - Heidelberg; 2065 - St Leonards	https://clinicaltrials.gov/ct2/show/NCT06360354
NCT06365853	2023-505617-24-00--IMGN853-0424	Phase 2		NSW, VIC	2024-04-15	2024-07-29		Leucovorin; Mirvetuximab Soravtansine; Prednisolone	folinic_acid; glucocorticoid; anti-FR-alpha_antibody-drug_conjugate	Prednisolone; Leucovorin; Mirvetuximab Soravtansine	glucocorticoid; anti-FR-alpha_antibody-drug_conjugate; folinic_acid	2023-505617-24-00  IMGN853-0424	A Randomized Phase 2 Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Patients With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression	Folate Receptor-Alpha Positive; Recurrent Ovarian Cancer	2305 - Lambton Heights; 3168 - Clayton; 2148 - Blacktown	https://clinicaltrials.gov/ct2/show/NCT06365853
NCT06372574	GO44669	Phase 1		VIC	2024-04-18			RO7617991; Tocilizumab	unknown_drug_class; anti-IL-6_monoclonal_antibody	RO7617991; Tocilizumab	unknown_drug_class; anti-IL-6_monoclonal_antibody	GO44669	A Phase I, Open-Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Anti-Tumor Activity of RO7617991 in HLA-A*02-Positive Patients With Locally Advanced and/or Metastatic MAGE-A4-Positive Solid Tumors	Solid Tumor, Adult; Refractory Cancer; Recurrent Cancer	3002 - East Melbourne	https://clinicaltrials.gov/ct2/show/NCT06372574
NCT06380751	EvoPAR-BR01	Phase 3		NSW, VIC	2024-04-24	2024-08-01		Abemaciclib; Anastrozole; Camizestrant; Camizestrant + Saruparib; Exemestane; Fulvestrant; Letrozole; Palbociclib; Ribociclib; Saruparib	aromatase_inhibitor; PARP1-selective_inhibitor; CDK4/6_inhibitor; PARP1-selective_inhibitor + selective_estrogen_receptor_degrader; selective_estrogen_receptor_degrader	Camizestrant; Camizestrant + Saruparib; Abemaciclib; Anastrozole; Exemestane; Fulvestrant; Letrozole; Palbociclib; Ribociclib	PARP1-selective_inhibitor + selective_estrogen_receptor_degrader; selective_estrogen_receptor_degrader; CDK4/6_inhibitor; aromatase_inhibitor	D9722C00001	A Randomised, Open-Label, Phase III Study of Saruparib (AZD5305) Plus Camizestrant Compared With Physician's Choice CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant for the First-Line Treatment of Patients With BRCA1, BRCA2, or PALB2 Mutations and Hormone Receptor Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified) Advanced Breast Cancer (EvoPAR-Breast01)	Advanced Breast Cancer	3144 - Malvern; VIC 3000 - Melbourne; 2139 - Darlinghurst; 2010 - Darlinghurst	https://clinicaltrials.gov/ct2/show/NCT06380751
NCT06384352	YL211-INT-101-01	Phase 1		VIC	2024-04-25	2024-05-01		YL211	anti-cMET_antibody-drug_conjugate	YL211	anti-cMET_antibody-drug_conjugate	YL211-INT-101-01	A Phase 1, Multicenter, Open-Label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors	Advanced Solid Tumors	- Melbourne	https://clinicaltrials.gov/ct2/show/NCT06384352
NCT06400472	2024-511238-11-00--18863	Phase 1		QLD, SA	2024-05-06	2024-05-20		Bevacizumab; Bevacizumab + LY4170156; Carboplatin; Carboplatin + LY4170156; LY4170156	platinum-based_antineoplastic_agent; anti-VEGF_monoclonal_antibody; anti-FR-alpha_antibody-drug_conjugate + anti-VEGF_monoclonal_antibody; anti-FR-alpha_antibody-drug_conjugate; anti-FR-alpha_antibody-drug_conjugate + platinum-based_antineoplastic_agent	Bevacizumab + LY4170156; Carboplatin + LY4170156; LY4170156	anti-FR-alpha_antibody-drug_conjugate; anti-FR-alpha_antibody-drug_conjugate + anti-VEGF_monoclonal_antibody; anti-FR-alpha_antibody-drug_conjugate + platinum-based_antineoplastic_agent	2024-511238-11-00  18863	A First-in-Human, Phase 1a/1b Trial to Assess the Safety, Tolerability and Preliminary Efficacy of LY4170156, an Antibody-Drug Conjugate Targeting Folate Receptor a-Expressing Tumor Cells, in Participants With Selected Advanced Solid Tumors	Ovarian Neoplasms; Pancreatic Neoplasm; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Uterine Cervical Neoplasms; Triple Negative Breast Neoplasms	4066 - South Brisbane; 5000 - Adelaide	https://clinicaltrials.gov/ct2/show/NCT06400472
NCT06400485	AMT-676-01	Phase 0		NSW, New South wWalesQLD, QLD, VIC, WA	2024-05-06	2024-06-18		AMT-676	anti-CDH17_antibody-drug_conjugate	AMT-676	anti-CDH17_antibody-drug_conjugate	AMT-676-01	First-in-Human, Phase 1 Study of AMT-676 in Patients With Advanced Solid Tumors	Advanced Solid Tumors	- Nedlands; - Melbourne; - Greenslopes; - Randwick; - Macquarie	https://clinicaltrials.gov/ct2/show/NCT06400485
NCT06417814	TROPION-Lung15	Phase 3		NSW, QLD, SA, VIC, WA	2024-05-16	2024-10-04		Carboplatin; Carboplatin + Cisplatin + Pemetrexed; Cisplatin; Datopotamab deruxtecan; Datopotamab deruxtecan + Osimertinib; Osimertinib; Pemetrexed	anti-Trop2_antibody-drug_conjugate; antimetabolite; EGFR_inhibitor,third_generation + anti-Trop2_antibody-drug_conjugate; platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; EGFR_inhibitor,third_generation	Carboplatin + Cisplatin + Pemetrexed; Datopotamab deruxtecan; Datopotamab deruxtecan + Osimertinib	EGFR_inhibitor,third_generation + anti-Trop2_antibody-drug_conjugate; anti-Trop2_antibody-drug_conjugate; antimetabolite + platinum-based_antineoplastic_agent	2024-511362-37-00  D516KC00001	A Phase III, Open-label, Sponsor-blind, Randomized Study of Dato-DXd With or Without Osimertinib Versus Platinum-based Doublet Chemotherapy for Participants With EGFR-mutated Locally Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Has Progressed on Prior Osimertinib Treatment (TROPION-Lung15)	Metastatic Non-small Cell Lung Cancer	VIC3065 - Fitzroy; 5011 - Woodville; 2065 - St Leonards; 4102 - Woolloongabba; 6009 - Nedlands; 2145 - Westmead; 2217 - Kogarah; 2444 - Port Macquarie; 2170 - Liverpool; 3084 - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT06417814
NCT06418061	CIBI3005A101	Phase 1			2024-05-16	2025-01-08		IBI3005	unknown_drug_class,bispecific_antibody	IBI3005	unknown_drug_class,bispecific_antibody	CIBI3005A101	A Multicenter, Open-label, Phase Ia/Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of IBI3005 in Subjects With Advanced Malignant Solid Tumors	Locally Advanced or Metastatic Solid Tumors; Unresectable		https://clinicaltrials.gov/ct2/show/NCT06418061
NCT06421935	2024-513492-41-00--MS202659-0001	Phase 1		NSW	2024-05-20	2024-08-07		Abiraterone; Abiraterone + HRS-1167 + Prednisolone + Prednisone; HRS-1167; HRS-1167 + Tuvusertib; Prednisolone; Prednisone; Tuvusertib	PARP1-selective_inhibitor; CYP17A1_inhibitor; CYP17A1_inhibitor + PARP1-selective_inhibitor + glucocorticoid; ATR_inhibitor + PARP1-selective_inhibitor; ATR_inhibitor; glucocorticoid	Abiraterone + HRS-1167 + Prednisolone + Prednisone; HRS-1167; HRS-1167 + Tuvusertib	ATR_inhibitor + PARP1-selective_inhibitor; CYP17A1_inhibitor + PARP1-selective_inhibitor + glucocorticoid; PARP1-selective_inhibitor	2024-513492-41-00  MS202659_0001	An Open Label, Multicenter, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of the PARP1 Inhibitor M9466 Alone or in Combination in Participants With Advanced Solid Tumors	Advanced Solid Tumor	- St Leonards	https://clinicaltrials.gov/ct2/show/NCT06421935
NCT06422520	2024-513280-11-00--BGB-C354-101	Phase 1		NSW, VIC, WA	2024-05-21	2024-07-05		BGB-C354; BGB-C354 + Tislelizumab; Tislelizumab	anti-B7H3_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody; anti-B7H3_antibody-drug_conjugate; anti-PD-1_monoclonal_antibody	BGB-C354; BGB-C354 + Tislelizumab	anti-B7H3_antibody-drug_conjugate; anti-B7H3_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody	2024-513280-11-00  BGB-C354-101	A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-C354, an Antibody-Drug Conjugate Targeting B7H3, Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors	Advanced Solid Tumor	3065 - Fitzroy; 3004 - Melbourne; 6009 - Nedlands; 2145 - Westmead	https://clinicaltrials.gov/ct2/show/NCT06422520
NCT06427941	BGB-B2033-101	Phase 1		NZ	2024-05-24	2024-07-23		BGB-B2033; BGB-B2033 + Tislelizumab; Tislelizumab	anti-GPC3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-GPC3_monoclonal_antibody	BGB-B2033; BGB-B2033 + Tislelizumab	anti-GPC3_monoclonal_antibody; anti-GPC3_monoclonal_antibody + anti-PD-1_monoclonal_antibody	BGB-B2033-101	A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B2033, Alone or in Combination With Tislelizumab, in Participants With Selected Advanced or Metastatic Solid Tumors	Advanced Hepatocellular Carcinoma; Metastatic Solid Tumor; Extragonadal Yolk Sac Tumors; Glypican-3 (GPC3)-Positive Squamous Non-small Cell Lung Cancer; Alpha-fetoprotein (AFP)-Producing Gastric Cancer; Metastatic Hepatocellular Carcinoma	Auckland	https://clinicaltrials.gov/ct2/show/NCT06427941
NCT06428409	MK-9999-02A--9999-02A	Phase 1		NSW, QLD, VIC, WA	2024-05-24	2024-06-20		Fluorouracil; Leucovorin; Sacituzumab tirumotecan	anti-Trop2_antibody-drug_conjugate; folinic_acid; Fluorouracil; fluoropyrimidine	Sacituzumab tirumotecan; Fluorouracil; Leucovorin	anti-Trop2_antibody-drug_conjugate; Fluorouracil; fluoropyrimidine; folinic_acid	MK-9999-02A  9999-02A	A Phase 1/2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers	Pancreatic Ductal Adenocarcinoma; Colorectal Cancer; Biliary Tract Cancer	6009 - Nedlands; 4029 - Brisbane; 2145 - Westmead; 3199 - Frankston; 3002 - East Melbourne	https://clinicaltrials.gov/ct2/show/NCT06428409
NCT06431594	BEHOLD-1	Phase 1		NSW	2024-05-28	2024-07-02		GSK5733584	anti-B7H4_antibody-drug_conjugate	GSK5733584	anti-B7H4_antibody-drug_conjugate	2024-513860-25  222730	A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Subjects With Advanced Solid Tumors	Solid Tumors; Neoplasms	2148 - Blacktown; 2109 - Macquarie University	https://clinicaltrials.gov/ct2/show/NCT06431594
NCT06433219	2024-511202-23-00--MS201924-0002	Phase 2		NSW	2024-05-29	2024-10-30		Lartesertib; Lartesertib + Niraparib + Tuvusertib; Niraparib; Tuvusertib	ATR_inhibitor; ATM_inhibitor; PARP_inhibitor; ATM_inhibitor + ATR_inhibitor + PARP_inhibitor	Lartesertib + Niraparib + Tuvusertib; Tuvusertib	ATM_inhibitor + ATR_inhibitor + PARP_inhibitor; ATR_inhibitor	2024-511202-23-00  MS201924_0002	An Open-label, Multicenter, Randomized Phase 2 Study of the ATR Inhibitor Tuvusertib in Combination With the PARP Inhibitor Niraparib or the ATM Inhibitor Lartesertib in Participants With BRCA Mutant and/or Homologous Recombination de?ciency (HRD)-Positive Epithelial Ovarian Cancer That Progressed on Prior PARP Inhibitor Therapy (DDRiver EOC 302)	Ovarian Cancer	- Liverpool	https://clinicaltrials.gov/ct2/show/NCT06433219
NCT06435429	2023-508960-31-00--JZP598-303	Phase 3		NSW, QLD, SA, VIC, WA	2024-05-30	2024-08-13		Capecitabine; Eribulin; Gemcitabine; Trastuzumab; Trastuzumab Deruxtecan; Vinorelbine; Zanidatamab	antimetabolite; anti-ERBB2_monoclonal_antibody; macrocyclic_ketone_analogue; fluoropyrimidine; gemcitabine; vinca_alkaloid; anti-ERBB2_antibody-drug_conjugate; bispecific_ERBB2/ERBB2_antibody	Trastuzumab; Zanidatamab; Capecitabine; Eribulin; Gemcitabine; Trastuzumab Deruxtecan; Vinorelbine	anti-ERBB2_monoclonal_antibody; bispecific_ERBB2/ERBB2_antibody; anti-ERBB2_antibody-drug_conjugate; antimetabolite; fluoropyrimidine; gemcitabine; macrocyclic_ketone_analogue; vinca_alkaloid	2023-508960-31-00  JZP598-303	A Phase 3, Randomized, Open-label, Multicenter, Controlled Study to Evaluate the Efficacy and Safety of Zanidatamab in Combination With Physician's Choice Chemotherapy Compared to Trastuzumab in Combination With Physician's Choice Chemotherapy for the Treatment of Participants With Metastatic HER2-positive Breast Cancer Who Have Progressed on, or Are Intolerant to, Previous Trastuzumab Deruxtecan Treatment	Metastatic HER2-positive Breast Cancer	5000 - Adelaide; 3149 - Mount Waverly; 4575 - Birtinya; 2080 - Mt Kuring-gai; 3128 - Melbourne; 6008 - Subiaco	https://clinicaltrials.gov/ct2/show/NCT06435429
NCT06441747	BIL-PPP	Phase 2		NSW, QLD, SA, VIC, WA	2024-06-04	2024-09-23		Durvalumab; Durvalumab + Olaparib; Olaparib	PARP_inhibitor + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; PARP_inhibitor	Durvalumab + Olaparib	PARP_inhibitor + anti-PD-L1_monoclonal_antibody	BIL-PPP	Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)	Cholangiocarcinoma	3021 - Saint Albans; 2145 - Westmead; 3168 - Clayton; 4006 - Brisbane; - Bedford Park; 3084 - Melbourne; 4102 - Woolloongabba; 2500 - Wollongong; 2050 - Camperdown; - Perth	https://clinicaltrials.gov/ct2/show/NCT06441747
NCT06449209	BNT327-01	Phase 2		NSW, SA, VIC	2024-06-07	2024-08-05		BNT327; BNT327 + Carboplatin + Etoposide; BNT327 + Paclitaxel; BNT327 + Topotecan; Carboplatin; Etoposide; Paclitaxel; Topotecan	bispecific_PD-L1/VEGFA_antibody + taxane; bispecific_PD-L1/VEGFA_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; topoisomerase_inhibitor; bispecific_PD-L1/VEGFA_antibody; taxane; platinum-based_antineoplastic_agent; bispecific_PD-L1/VEGFA_antibody + topoisomerase_inhibitor	BNT327 + Carboplatin + Etoposide; BNT327 + Paclitaxel; BNT327 + Topotecan	bispecific_PD-L1/VEGFA_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; bispecific_PD-L1/VEGFA_antibody + taxane; bispecific_PD-L1/VEGFA_antibody + topoisomerase_inhibitor	BNT327-01	A Phase II, Multi-site, Open-label, Parallel Group Trial of BNT327 in Combination With Chemotherapy for Participants With Untreated Extensive-stage Small-cell Lung Cancer and Participants With Previously Treated Small-cell Lung Cancer	Extensive-stage Small-cell Lung Cancer; Small-cell Lung Cancer	3199 - Frankston; 5112 - Adelaide; 3065 - Fitzroy; 2065 - St Leonards; 2145 - Westmead	https://clinicaltrials.gov/ct2/show/NCT06449209
NCT06449222	BNT327-02	Phase 2		NSW, QLD, VIC	2024-06-07	2024-08-26		BNT327; BNT327 + Carboplatin + Gemcitabine; BNT327 + Eribulin; BNT327 + Nab-paclitaxel; BNT327 + Paclitaxel; Carboplatin; Eribulin; Gemcitabine; Nab-paclitaxel; Paclitaxel	bispecific_PD-L1/VEGFA_antibody + taxane; antimetabolite; bispecific_PD-L1/VEGFA_antibody + macrocyclic_ketone_analogue; bispecific_PD-L1/VEGFA_antibody; antimetabolite + bispecific_PD-L1/VEGFA_antibody + platinum-based_antineoplastic_agent; macrocyclic_ketone_analogue; taxane; gemcitabine; platinum-based_antineoplastic_agent	BNT327 + Carboplatin + Gemcitabine; BNT327 + Eribulin; BNT327 + Nab-paclitaxel; BNT327 + Paclitaxel	antimetabolite + bispecific_PD-L1/VEGFA_antibody + platinum-based_antineoplastic_agent; bispecific_PD-L1/VEGFA_antibody + macrocyclic_ketone_analogue; bispecific_PD-L1/VEGFA_antibody + taxane; gemcitabine	BNT327-02	A Phase II, Multi-site, Randomized, Open-label Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of BNT327 at Two Dose Levels in Combination With Chemotherapeutic Agents as First- and Second-line Treatment in Triple-negative Breast Cancer	Locally Advanced Breast Cancer; Metastatic Triple Negative Breast Cancers; Triple Negative Breast Cancer	2145 - Westmead; 3199 - Frankston; 4065 - Auchenflower; 3050 - Melbourne; 2065 - Sydney	https://clinicaltrials.gov/ct2/show/NCT06449222
NCT06450106	STM-416p-201	Phase 1		VIC	2024-06-10	2025-05-08						STM-416p-201	A Phase 1 Dose Escalation Study of STM-416p Administered Intraoperatively to Patients Undergoing Radical Prostatectomy	Prostate Cancer	3051 - Melbourne N.	https://clinicaltrials.gov/ct2/show/NCT06450106
NCT06452277	SOHO-02	Phase 3		ACT, NSW, QLD, VIC	2024-06-11	2024-08-28		Carboplatin; Cisplatin; Pembrolizumab; Pemetrexed; Sevabertinib	antimetabolite; platinum-based_antineoplastic_agent; EGFR/ERBB2_inhibitor,mutant-selective,non-covalent; anti-PD-1_monoclonal_antibody	Pembrolizumab; Sevabertinib; Carboplatin; Cisplatin; Pemetrexed	EGFR/ERBB2_inhibitor,mutant-selective,non-covalent; anti-PD-1_monoclonal_antibody; antimetabolite; platinum-based_antineoplastic_agent	2024-511319-91-00  22615	A Phase 3 Open-label, Randomized, Active-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Orally Administered BAY 2927088 Compared With Standard of Care as a First-line Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With HER2-activating Mutations	Advanced Non-small Cell Lung Cancer; HER2 Mutation	2139 - Concord; 3084 - Heidelberg; 2298 - Waratah; 4556 - Buderim; 2148 - Blacktown; 2605 - Garran	https://clinicaltrials.gov/ct2/show/NCT06452277
NCT06459180	MK-2870-020--2870-020	Phase 3		NSW, QLD, VIC, WA	2024-06-14	2024-07-24		Gemcitabine; Gemcitabine + Irinotecan + Pemetrexed + Tisotumab vedotin + Topotecan + Vinorelbine; Irinotecan; Pemetrexed; Sacituzumab tirumotecan; Tisotumab vedotin; Topotecan; Vinorelbine	anti-Trop2_antibody-drug_conjugate; antimetabolite; anti-TF_antibody-drug_conjugate; topoisomerase_inhibitor; anti-TF_antibody-drug_conjugate + antimetabolite + topoisomerase_inhibitor + vinca_alkaloid; gemcitabine; vinca_alkaloid	Gemcitabine + Irinotecan + Pemetrexed + Tisotumab vedotin + Topotecan + Vinorelbine; Sacituzumab tirumotecan	anti-TF_antibody-drug_conjugate + antimetabolite + topoisomerase_inhibitor + vinca_alkaloid; anti-Trop2_antibody-drug_conjugate; gemcitabine	MK-2870-020  2870-020	A Phase 3 Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (TroFuse-020/GOG-3101/ENGOT-cx20)	Cervical Cancer	4029 - Herston; 3000 - Melbourne; 2148 - Sydney; 6009 - Nedlands; 2560 - Sydney; 3168 - Clayton	https://clinicaltrials.gov/ct2/show/NCT06459180
NCT06460961	MK-6837-001--6837-001	Phase 1		NSW, VIC	2024-06-14	2024-07-14		MK-6837; MK-6837 + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody + unknown_drug_class; unknown_drug_class; anti-PD-1_monoclonal_antibody	MK-6837; MK-6837 + Pembrolizumab	anti-PD-1_monoclonal_antibody + unknown_drug_class; unknown_drug_class	MK-6837-001  6837-001	A Phase 1 Open-label, Multicenter Study of MK-6837 as Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors	Neoplasm Metastasis	3004 - Melbourne; 2145 - Westmead	https://clinicaltrials.gov/ct2/show/NCT06460961
NCT06465069	NEXUS-01	Phase 1		NSW, WA	2024-06-18	2024-07-01		LY4052031	anti-NECTIN4_antibody-drug_conjugate	LY4052031	anti-NECTIN4_antibody-drug_conjugate	2024-512927-36-00  18882	A Phase 1a/1b Study of LY4052031, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Advanced or Metastatic Urothelial Carcinoma or Other Solid Tumors	Head and Neck Squamous Cell Carcinoma; Prostate Cancer; Advanced Solid Tumor; Recurrent Solid Tumor; Ovarian Cancer; Urinary Bladder Neoplasm; Triple Negative Breast Cancer; Bladder Cancer; Esophageal Cancer; Non-small Cell Lung Cancer; Renal Pelvis Cancer; Cervical Cancer; Metastatic Solid Tumor; Pancreatic Cancer	6009 - Nedlands; 2010 - Darlinghurst	https://clinicaltrials.gov/ct2/show/NCT06465069
NCT06467357	DESTINY-BTC01	Phase 3		VIC, WA	2024-06-21	2024-08-12		Cisplatin; Cisplatin + Durvalumab + Gemcitabine; Durvalumab; Gemcitabine; Rilvegostomig; Rilvegostomig + Trastuzumab Deruxtecan; Trastuzumab Deruxtecan	antimetabolite; anti-PD-L1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody; gemcitabine; platinum-based_antineoplastic_agent; anti-ERBB2_antibody-drug_conjugate + bispecific_PD-1/TIGIT_antibody; anti-ERBB2_antibody-drug_conjugate; bispecific_PD-1/TIGIT_antibody	Cisplatin + Durvalumab + Gemcitabine; Rilvegostomig + Trastuzumab Deruxtecan; Trastuzumab Deruxtecan	anti-ERBB2_antibody-drug_conjugate; anti-ERBB2_antibody-drug_conjugate + bispecific_PD-1/TIGIT_antibody; anti-PD-L1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; gemcitabine	2023-508057-19-00  D781PC00001	DESTINY-Biliary Tract Cancer-01: A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig Versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab for First Line Locally Advanced or Metastatic HER2-expressing Biliary Tract Cancer	Biliary Tract Cancer	2139 - Concord; 3168 - Clayton; 6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT06467357
NCT06475937	DM001001	Phase 1		QLD, VIC	2024-06-26	2024-10-24		DM001	bispecific-EGFR/Trop2_antibody-drug_conjugate	DM001	bispecific-EGFR/Trop2_antibody-drug_conjugate	DM001001	A Phase I, Multicenter, Open-label, First-in-Human, Dose Escalation and Expansion Study of DM001 in Patients With Advanced Solid Tumors	Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Solid Carcinoma	4215 - Southport; 3168 - Clayton; 4101 - South Brisbane	https://clinicaltrials.gov/ct2/show/NCT06475937
NCT06478693	MTX-GPC3-303	Phase 1		NSW, QLD, VIC, WA	2024-06-27	2024-07-01		MT-303	GPC3-targeting_lipid-nanoparticle_CAR_mRNA; GPC3-targeting_lipid-nanoparticles	MT-303	GPC3-targeting_lipid-nanoparticle_CAR_mRNA; GPC3-targeting_lipid-nanoparticles	MTX-GPC3-303	A Phase 1, Open-Label, First-in-Human, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including Hepatocellular Carcinoma	Hepatocellular Carcinoma	2010 - Sydney; 6150 - Murdoch; 4102 - Woolloongabba; 3004 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT06478693
NCT06486441	ASCENT-GYN-01	Phase 3		NSW, QLD, VIC, WA	2024-07-03	2024-08-28		Doxorubicin; Paclitaxel; Sacituzumab Govitecan	anti-Trop2_antibody-drug_conjugate; anthracycline; doxorubicin; taxane	Sacituzumab Govitecan; Doxorubicin; Paclitaxel	anti-Trop2_antibody-drug_conjugate; anthracycline; doxorubicin; taxane	2024-511957-23  GS-US-682-6769	A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy	Endometrial Cancer	2050 - Camperdown; 3000 - Melbourne; 4101 - South Brisbane; 3168 - Clayton; 6150 - Murdoch	https://clinicaltrials.gov/ct2/show/NCT06486441
NCT06488716	GO45296	Phase 1		NSW	2024-07-05	2024-12-16		Atezolizumab	anti-PD-L1_monoclonal_antibody	Atezolizumab	anti-PD-L1_monoclonal_antibody	GO45296	A Phase Ia/Ib, Open-Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7759065 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors	Solid Tumour	2010 - Darlinghurst	https://clinicaltrials.gov/ct2/show/NCT06488716
NCT06492122	FL-020-001	Phase 1		QLD, WA	2024-07-09	2024-08-30		225Ac-FL-020	anit-PSMA_radionucleotide-drug_conjugate,PSMA-targeting	225Ac-FL-020	anit-PSMA_radionucleotide-drug_conjugate,PSMA-targeting	FL-020-001	A Phase 1, First-in-Human, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of [225Ac]Ac-FL-020 in Participants With mCRPC.	Metastatic Castration-resistant Prostate Cancer	- Murdoch; - Brisbane	https://clinicaltrials.gov/ct2/show/NCT06492122
NCT06496178	2023-510322-32--MCLA-158-CL02	Phase 3		NSW, VIC, WA	2024-07-11	2024-06-25		Petosemtamab	bispecific_EGFR/LGR5_antibody	Petosemtamab	bispecific_EGFR/LGR5_antibody	2023-510322-32  MCLA-158-CL02	A Phase 3 Open-label, Randomized Controlled Study to Evaluate the Efficacy and Safety of Petosemtamab Compared With Investigator's Choice Monotherapy Treatment in Previously Treated Patients With Incurable, Metastatic/Recurrent Head and Neck Squamous Cell Carcinoma	Head and Neck Squamous Cell Carcinoma	2010 - Darlinghurst; 3000 - Melbourne; 2065 - Saint Leonards; 6009 - Nedlands; 2050 - Sydney	https://clinicaltrials.gov/ct2/show/NCT06496178
NCT06501625	2024-514261-19-00--S095031-210	Phase 1		VIC	2024-07-15	2024-12-16		Cisplatin; Durvalumab; Gemcitabine; Ivosidenib	antimetabolite; platinum-based_antineoplastic_agent; IDH1_R132_inhibitor; anti-PD-L1_monoclonal_antibody; gemcitabine	Cisplatin; Durvalumab; Gemcitabine; Ivosidenib	IDH1_R132_inhibitor; anti-PD-L1_monoclonal_antibody; antimetabolite; gemcitabine; platinum-based_antineoplastic_agent	2024-514261-19-00  S095031-210	A Phase 1b/2, Safety Lead-in and Dose-Expansion, Open Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Activity of Ivosidenib in Combination With Durvalumab and Gemcitabine/Cisplatin as First-line Therapy in Participants With Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation	Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation	3004 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT06501625
NCT06509906	2024-514155-15-00--MS202650-0001	Phase 1		NSW, SA, VIC	2024-07-19	2024-10-08		Bevacizumab; Bevacizumab + Fluorouracil + HRS-1167 + Irinotecan + Leucovorin; Fluorouracil; HRS-1167; HRS-1167 + Irinotecan; Irinotecan; Leucovorin	topoisomerase_inhibitor; PARP1-selective_inhibitor; Fluorouracil; fluoropyrimidine; folinic_acid; anti-VEGF_monoclonal_antibody; PARP1-selective_inhibitor + topoisomerase_inhibitor; PARP1-selective_inhibitor + anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid + topoisomerase_inhibitor	Bevacizumab + Fluorouracil + HRS-1167 + Irinotecan + Leucovorin; HRS-1167 + Irinotecan	PARP1-selective_inhibitor + anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid + topoisomerase_inhibitor; PARP1-selective_inhibitor + topoisomerase_inhibitor; Fluorouracil	2024-514155-15-00  MS202650_0001	An Open Label, Multicenter, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of the PARP1 Inhibitor M9466 in Combination With Topoisomerase 1 Inhibitor-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511)	Advanced Solid Tumor	- Parkville; - Elizabeth Vale; - Kogarah	https://clinicaltrials.gov/ct2/show/NCT06509906
NCT06515990	DM005001	Phase 1		QLD	2024-07-23	2024-10-31		DM005	bispecific-EGFR/cMET_antibody-drug_conjugate	DM005	bispecific-EGFR/cMET_antibody-drug_conjugate	DM005001	A Phase 1, Multicenter, Open-label, First-in-human, Dose Escalation and Expansion Study of DM005 in Patients With Advanced Solid Tumors	Solid Carcinoma; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Non-Small-Cell Lung	4101 - South Brisbane	https://clinicaltrials.gov/ct2/show/NCT06515990
NCT06520345	177Lu-TLX591-203	Phase 3		NSW, NZ, VIC, WA	2024-07-25	2024-07-26		177Lu-TLX591; 177Lu-TLX591 + Abiraterone + Docetaxel + Enzalutamide; Abiraterone; Abiraterone + Docetaxel + Enzalutamide; Docetaxel; Enzalutamide	177Lu-anti-PSMA-radioconjugate + CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + taxane; antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor; taxane; 177Lu-anti-PSMA-radioconjugate; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + taxane	177Lu-TLX591 + Abiraterone + Docetaxel + Enzalutamide; Abiraterone + Docetaxel + Enzalutamide	177Lu-anti-PSMA-radioconjugate + CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + taxane; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + taxane	177Lu-TLX591-203	A Multinational, Multicenter, Prospective, Randomized, Controlled, Open-Label, Phase 3 Study of Lutetium (177Lu) Rosopatamab Tetraxetan in Combination With Standard of Care Versus Standard of Care Alone in Patients With PSMA Positive Metastatic Castration-Resistant Prostate Cancer Previously After Androgen Receptor Pathway Inhibitor Treatment	Metastatic Castration-resistant Prostate Cancer	2747 - Sydney; 2143 - Sydney; Auckland; 3051 - Melbourne; 6150 - Perth; 2500 - Wollongong	https://clinicaltrials.gov/ct2/show/NCT06520345
NCT06521554	NVL-330-01	Phase 1		NSW	2024-07-26	2024-07-18		NVL-330	ERBB2_inhibitor,exon_20_selective	NVL-330	ERBB2_inhibitor,exon_20_selective	NVL-330-01	A Phase 1a/1b Study of the Selective Tyrosine Kinase Inhibitor NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)	Locally Advanced Solid Tumor; Metastatic Solid Tumor	2065 - Saint Leonards; NSW 2050 - Camperdown	https://clinicaltrials.gov/ct2/show/NCT06521554
NCT06525220	2023-510323-30-00--MCLA-158-CL03	Phase 3		NSW	2024-07-29	2024-09-25		Pembrolizumab; Pembrolizumab + Petosemtamab; Petosemtamab	bispecific_EGFR/LGR5_antibody; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + bispecific_EGFR/LGR5_antibody	Pembrolizumab; Pembrolizumab + Petosemtamab	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + bispecific_EGFR/LGR5_antibody	2023-510323-30-00  MCLA-158-CL03	A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Recurrent or Metastatic PD-L1+ Head and Neck Squamous Cell Carcinoma	Head and Neck Squamous Cell Carcinoma	2065 - St Leonards; 2148 - Blacktown	https://clinicaltrials.gov/ct2/show/NCT06525220
NCT06533059	2618-001	Phase 1		NSW, QLD, VIC, WA	2024-08-01	2024-08-22		ALTA2618	AKT1_E17K_inhibitor	ALTA2618	AKT1_E17K_inhibitor	2618-001	AKTive-001: A Phase 1/1b Multiple Cohort Trial of ALTA2618 in Patients With Advanced Solid Tumors With AKT1 E17K Mutation	Cancer; Advanced Solid Tumor; Breast Cancer; Metastatic Cancer; Endometrial Cancer	2148 - Blacktown; 6009 - Nedlands; 3144 - Malvern; 4101 - South Brisbane; 2031 - Randwick	https://clinicaltrials.gov/ct2/show/NCT06533059
NCT06533332	ERX-315-101	Phase 1		NSW, SA	2024-08-01	2024-10-14		ERX-315	benzamide,ER_alpha-targeting	ERX-315	benzamide,ER_alpha-targeting	ERX-315-101	A First-in-Human, Phase 1 Safety, Tolerability, Pharmacokinetic, and Preliminary Efficacy Study of Escalating Doses of ERX-315 in Participants With Advanced Solid Tumors	Metastatic Pancreatic Cancer; Advanced Solid Tumor; Metastatic Breast Cancer; Metastatic Ovarian Cancer; Metastatic Endometrial Cancer; Metastatic Liver Cancer	2010 - Sydney; 5000 - Adelaide; 2109 - Sydney	https://clinicaltrials.gov/ct2/show/NCT06533332
NCT06537310	2024-512839-70-00--BP44956	Phase 1		NSW, VIC	2024-08-05	2024-09-16		Atezolizumab	anti-PD-L1_monoclonal_antibody	Atezolizumab	anti-PD-L1_monoclonal_antibody	2024-512839-70-00  BP44956	An Open-label, Multicenter, Dose-escalation, Randomized, Phase I Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Anti-Tumor Activity of RO7567132, as a Single Agent and in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors	Cancer-Neoplasms	2010 - Darlinghurst; 3084 - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT06537310
NCT06542250	TITANium	Phase 1		VIC, WA	2024-08-07	2024-09-18		AZD5492	bispecific_T-cell_engager,CD20-targeting	AZD5492	bispecific_T-cell_engager,CD20-targeting	D9960C00001	A Modular Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With Relapsed or Refractory B-Cell Malignancies (TITANium)	B-cell Malignancies	3000 - Melbourne; 6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT06542250
NCT06544655	EU-2024-513696-40--CA233-0000	Phase 1		NSW, SA	2024-08-09	2024-10-10		BMS-986484; BMS-986484 + Nivolumab; Nivolumab	anti-PD-1_monoclonal_antibody + unknown_drug_class; unknown_drug_class; anti-PD-1_monoclonal_antibody	BMS-986484; BMS-986484 + Nivolumab	anti-PD-1_monoclonal_antibody + unknown_drug_class; unknown_drug_class	EU 2024-513696-40  CA233-0000	A Phase 1/1b First-in-human Trial of BMS-986484 as Monotherapy and Combination Therapy in Participants With Advanced Solid Malignancies	Advanced Solid Tumors	2010 - Darlinghurst; 5112 - Elizabeth Vale	https://clinicaltrials.gov/ct2/show/NCT06544655
NCT06551324	MEVPRO-1	Phase 3		QLD, VIC	2024-08-13	2024-10-21		Abiraterone; Docetaxel; Docetaxel + Enzalutamide; Enzalutamide; Enzalutamide + PF-06821497; PF-06821497	antiandrogen,nonsteroidal,second_generation; EZH2_inhibitor + antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor; taxane; EZH2_inhibitor; antiandrogen,nonsteroidal,second_generation + taxane	Docetaxel + Enzalutamide; Enzalutamide + PF-06821497; Abiraterone	EZH2_inhibitor + antiandrogen,nonsteroidal,second_generation; antiandrogen,nonsteroidal,second_generation + taxane; CYP17A1_inhibitor	2024-511650-50-00  C2321014	A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF PF-06821497 (MEVROMETOSTAT) IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE (MEVPRO-1)	Metastatic Castrate Resistant Prostate Cancer (mCRPC)	4066 - Auchenflower; 3168 - Clayton; 3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT06551324
NCT06554795	DB-1419-O-1001	Phase 1		NSW, WA	2024-08-15	2024-09-03		DB-1419	bispecific_B7H3/PD-L1_antibody	DB-1419	bispecific_B7H3/PD-L1_antibody	DB-1419-O-1001	A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1419 in Participants with Advanced/Metastatic Solid Tumors	Solid Tumor, Adult	- North Ryde; - Randwick; - Nedlands	https://clinicaltrials.gov/ct2/show/NCT06554795
NCT06555744	2024-512299-37-00--ZWI-ZW191-101	Phase 1		NSW, WA	2024-08-15	2024-10-30		ZW191	anti-FR-alpha_antibody-drug_conjugate	ZW191	anti-FR-alpha_antibody-drug_conjugate	2024-512299-37-00  ZWI-ZW191-101	A Phase 1, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of a Folate Receptor Alpha Antibody Drug Conjugate, ZW191, in Participants With Advanced Solid Tumors	Advanced Solid Tumors	NSW 2065 - St Leonards; WA 6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT06555744
NCT06560138	SHR-4602-102	Phase 1		NSW, QLD, SA, VIC	2024-08-19			SHR-4602	anti-ERBB2_antibody-drug_conjugate	SHR-4602	anti-ERBB2_antibody-drug_conjugate	SHR-4602-102	An Open-label, Multi-center Phase I Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SHR-4602 in Subjects With HER2-expressing or HER2-mutated Locally Advanced or Metastatic Solid Tumors	HER2-expressing or HER2-mutated Locally or Metastatic Solid Tumors	500 - Adelaide; 3199 - Frankston; 2109 - Sydney; 4101 - Brisbane; 2031 - Randwick	https://clinicaltrials.gov/ct2/show/NCT06560138
NCT06560645	PRT7732-01	Phase 1		NSW, VIC, WA	2024-08-19	2024-11-04		PRT7732	SMARCA2_degrader	PRT7732	SMARCA2_degrader	PRT7732-01	A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4	Non-small Cell Lung Carcinoma; Advanced Solid Tumor; SMARCA4 Mutation; Metastatic Solid Tumor	6009 - Nedlands; 3168 - Clayton; 2640 - Albury; 2576 - Bowral; 2031 - Randwick	https://clinicaltrials.gov/ct2/show/NCT06560645
NCT06561386	RELATIVITY1093	Phase 3		NSW, NZ, QLD, SA, VIC, WA	2024-08-20	2024-10-07		Carboplatin; Cisplatin; Nivolumab; Pembrolizumab; Pemetrexed; Relatlimab	anti-LAG3_monoclonal_antibody; antimetabolite; platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody	Carboplatin; Cisplatin; Nivolumab; Pembrolizumab; Pemetrexed; Relatlimab	anti-LAG3_monoclonal_antibody; anti-PD-1_monoclonal_antibody; antimetabolite; platinum-based_antineoplastic_agent	2024-513682-40  CA224-1093	A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy as First-line Treatment for Participants With Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and With Tumor Cell PD-L1 Expression = 1%	Non-small Cell Lung Cancer	4120 - Brisbane; 4032 - Brisbane; 5112 - Elizabeth Vale; 3128 - Box Hill; Wellington; Auckland; Dunedin; 6150 - Murdoch; 2065 - St Leonards; 2250 - Gosford	https://clinicaltrials.gov/ct2/show/NCT06561386
NCT06581432	2023-510429-14-00--1479-0009	Phase 2		NSW, QLD, WA	2024-09-03	2024-10-11		Zongertinib	ERBB2_inhibitor,second_generation	Zongertinib	ERBB2_inhibitor,second_generation	2023-510429-14-00  1479-0009	Beamion PANTUMOR-1: A Phase II, Multicentre, Multicohort, Open-label Trial to Evaluate the Efficacy and Safety of Oral Zongertinib (BI 1810631) for the Treatment of Selected HER2-mutated or Overexpressed/Amplified Solid Tumours	Solid Tumours	2109 - Macquarie Park; 2065 - St Leonards; 4102 - Woolloongabba; 6008 - Subiaco	https://clinicaltrials.gov/ct2/show/NCT06581432
NCT06585488	2024-514704-13-00--BGB-53038-101	Phase 1		NSW, NZ, VIC, WA	2024-09-05	2024-11-26		BGB-53038; BGB-53038 + Cetuximab + Tislelizumab; Cetuximab; Tislelizumab	anti-EGFR_monoclonal_antibody + anti-PD-1_monoclonal_antibody + pan-KRAS_inhibitor; pan-KRAS_inhibitor; anti-EGFR_monoclonal_antibody; anti-PD-1_monoclonal_antibody	BGB-53038; BGB-53038 + Cetuximab + Tislelizumab	anti-EGFR_monoclonal_antibody + anti-PD-1_monoclonal_antibody + pan-KRAS_inhibitor; pan-KRAS_inhibitor	2024-514704-13-00  BGB-53038-101	A Phase 1a/1b Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-53038, a Pan-KRAS Inhibitor, as Monotherapy or in Combinations in Patients With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplifications	Metastatic Solid Tumors; Advanced Gastroesophageal Junction Cancer; Advanced Pancreatic Ductal Adenocarcinoma; Advanced Gastric Cancer; Advanced Non-squamous Non-small-cell Lung Cancer; Advanced Colorectal Cancer; Advanced Esophageal Adenocarcinoma	3000 - Melbourne; 3168 - Clayton; 2148 - Blacktown; Auckland; 6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT06585488
NCT06589596	2024-515307-19-00--BGB-58067-101	Phase 1		NSW, VIC, WA	2024-09-19	2024-10-11		BGB-58067	PRMT5_inhibitor,MTA-co-operative	BGB-58067	PRMT5_inhibitor,MTA-co-operative	2024-515307-19-00  BGB-58067-101	A Phase 1a/b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-58067, an MTA-Cooperative PRMT5 Inhibitor in Patients With Advanced Solid Tumors	Advanced Solid Tumor	2148 - Blacktown; 6009 - Nedlands; 3168 - Clayton; 3084 - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT06589596
NCT06593522	NCT06593522	Phase 2		NSW, QLD	2024-09-19	2024-12-26		AMG 193	PRMT5_inhibitor	AMG 193	PRMT5_inhibitor	20230153	A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of AMG 193 in Subjects With Methylthioadenosine Phosphorylase (MTAP)-Deleted Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC)	MTAP-deleted NSCLC	4101 - South Brisbane; 2065 - St Leonards; 2298 - Waratah	https://clinicaltrials.gov/ct2/show/NCT06593522
NCT06596473	CTR20244563--BG-C477-101	Phase 1		NSW, NZ, SA, VIC, WA	2024-09-19	2024-10-03		BG-C477	anti-CEACAM5_antibody-drug_conjugate	BG-C477	anti-CEACAM5_antibody-drug_conjugate	CTR20244563  BG-C477-101	A Multicenter, Open-Label, Phase 1a/b First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-C477 in Patients With Selected Advanced Solid Tumors	Advanced Solid Tumors	5000 - Adelaide; 2148 - Blacktown; 6009 - Nedlands; Auckland; 3004 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT06596473
NCT06596694	MK-1022-011--1022-011	Phase 1		NSW, NZ, VIC, WA	2024-09-19	2024-11-03		Patritumab Deruxtecan	anti-ERBB3_antibody-drug_conjugate	Patritumab Deruxtecan	anti-ERBB3_antibody-drug_conjugate	MK-1022-011  1022-011	A Phase 1/2 Study to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Gastrointestinal Cancers	Gastrointestinal Cancer	2145 - Sydney; 6009 - Mount Pleasant; 3084 - Melbourne; 3004 - Melbourne; Auckland	https://clinicaltrials.gov/ct2/show/NCT06596694
NCT06597721	ADCE-T02-01	Phase 1		NSW, SA, VIC, WA	2024-09-19	2024-11-25		ADCE-T02	anti-TF_antibody-drug_conjugate	ADCE-T02	anti-TF_antibody-drug_conjugate	ADCE-T02-01	First-in-Human, Phase 1 Study of ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors	Advanced Solid Tumor	5042 - Bedford Park; 2031 - Randwick; 3199 - Frankston; 3144 - Malvern; 6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT06597721
NCT06598306	DeLLphi-308	Phase 1		NSW, VIC	2024-09-19	2024-10-07		Tarlatamab	bispecific_T-cell_engager,DLL3-targeting	Tarlatamab	bispecific_T-cell_engager,DLL3-targeting	20230298	A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of Subcutaneous Tarlatamab in Subjects With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)	Extensive Stage Small Cell Lung Cancer	2298 - Waratah; 3004 - Melbourne; 2050 - Camperdown	https://clinicaltrials.gov/ct2/show/NCT06598306
NCT06598800	2024-514944-10-00--BG-T187-101	Phase 1		NSW, VIC, WA	2024-09-19	2024-10-18		BG-T187	trispecific_EGFR/cMET/cMET_antibody	BG-T187	trispecific_EGFR/cMET/cMET_antibody	2024-514944-10-00  BG-T187-101	A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BG-T187, an EGFR×MET Trispecific Antibody, Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors	Advanced Solid Tumor	3144 - Malvern East; 2148 - Blacktown; 6009 - Nedlands; 2109 - North Ryde	https://clinicaltrials.gov/ct2/show/NCT06598800
NCT06599502	ALAFOSS-01	Phase 1		VIC	2024-09-19	2024-10-18		AZD0022; AZD0022 + Cetuximab; Cetuximab	KRAS_G12D_inhibitor + anti-EGFR_monoclonal_antibody; anti-EGFR_monoclonal_antibody; KRAS_G12D_inhibitor	AZD0022; AZD0022 + Cetuximab	KRAS_G12D_inhibitor; KRAS_G12D_inhibitor + anti-EGFR_monoclonal_antibody	D7080C00001	A Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AZD0022 Monotherapy and in Combination With Anti-cancer Agents in Participants With Tumours Harbouring a KRASG12D Mutation (ALAFOSS-01)	Non-Small Cell Lung Cancer (NSCLC); Colorectal Cancer (CRC); Pancreatic Ductal Adenocarcinoma (PDAC); Advanced Solid Tumours	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT06599502
NCT06613009	CIBI3009A101	Phase 1		NSW, VIC	2024-09-25	2024-12-30		IBI3009	anti-DLL3_antibody-drug_conjugate	IBI3009	anti-DLL3_antibody-drug_conjugate	CIBI3009A101	A Phase 1 Multicenter, Open-label Study of IBI3009 in Participants with Unresectable, Metastatic or Extensive-Stage Small Cell Lung Cancer	Small Cell Lung Cancer	2145 - Westmead; 3084 - Heidelberg; 2500 - Wollongong	https://clinicaltrials.gov/ct2/show/NCT06613009
NCT06614192	2024-512804-20-00--M24-064	Phase 3	NOT_RECRUITING	QLD	2024-09-26	2024-11-08		ABBV-400; Bevacizumab; Trifluridine/Tipiracil	antimetabolite; anti-cMET_antibody-drug_conjugate; Tipiracil Hydrochloride; anti-VEGF_monoclonal_antibody; Trifluridine; thymidine_phosphorylase_inhibitor	ABBV-400; Bevacizumab; Trifluridine/Tipiracil	anti-cMET_antibody-drug_conjugate; Tipiracil Hydrochloride; Trifluridine; anti-VEGF_monoclonal_antibody; antimetabolite; thymidine_phosphorylase_inhibitor	2024-512804-20-00  M24-064	AndroMETa-CRC-064: An Open Label, Randomized, Controlled, Global Phase 3 Study Comparing ABBV-400 Monotherapy to LONSURF (Trifluridine and Tipiracil) Plus Bevacizumab in Subjects With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer	Metastatic Colorectal Cancer	4101 - South Brisbane	https://clinicaltrials.gov/ct2/show/NCT06614192
NCT06617169	MNPR101-Lu-1-01	Phase 1		VIC	2024-09-27	2024-10-08		MNPR-101-PCTA-177Lu	177Lu-anti-uPAR_radioconjugate	MNPR-101-PCTA-177Lu	177Lu-anti-uPAR_radioconjugate	MNPR101-Lu-1-01	Open Label, Phase 1a, Dose-Escalation Study Evaluating the Safety of Fractionated MNPR-101-PCTA-177Lu Dosing in the Treatment of Solid Tumor Cancers	Lung Cancer; Solid Tumor, Adult; Ovarian Cancer; Urothelial Carcinoma; Triple-negative Breast Cancer; Bladder Cancer; Colorectal Cancer; Pancreatic Cancer; Gastric Cancer	3051 - North Melbourne	https://clinicaltrials.gov/ct2/show/NCT06617169
NCT06618287	2024-514947-27--CA244-0001	Phase 1		NSW, QLD	2024-10-01	2025-02-04		Izalontamab Brengitecan; Osimertinib; Pembrolizumab	bispecific_EGFR/ERBB3_antibody; anti-PD-1_monoclonal_antibody; EGFR_inhibitor,third_generation	Izalontamab Brengitecan; Osimertinib; Pembrolizumab	EGFR_inhibitor,third_generation; anti-PD-1_monoclonal_antibody; bispecific_EGFR/ERBB3_antibody	2024-514947-27  CA244-0001	A Phase 1/2a, Open-label, Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BMS-986507 (BL-B01D1) Combinations in Adult Participants With Advanced Solid Tumors	Lung Cancer	2170 - Liverpool; 4102 - Woolloongabba	https://clinicaltrials.gov/ct2/show/NCT06618287
NCT06619587	GO45416	Phase 1	_COHORTS_FULL	NSW, VIC	2024-10-01	2024-11-14		GDC-7035	KRAS_G12D_inhibitor	GDC-7035	KRAS_G12D_inhibitor	GO45416	A Phase I/II Dose-Escalation and Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors With a KRAS G12D Mutation	Solid Tumor	3052 - Parkville; 2010 - Darlinghurst	https://clinicaltrials.gov/ct2/show/NCT06619587
NCT06625593	BG-C137-101	Phase 1		NSW, QLD, VIC	2024-10-03	2024-12-09		BG-C137	anti-FGFR2b_antibody-drug_conjugate	BG-C137	anti-FGFR2b_antibody-drug_conjugate	BG-C137-101	A Phase 1a/b, Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-C137, an Antibody-Drug Conjugate Targeting FGFR2b, in Patients With Advanced Solid Tumors	Advanced Solid Tumor	2148 - Blacktown; 4101 - South Brisbane; 3144 - Malvern East; 3168 - Clayton; 2170 - Liverpool	https://clinicaltrials.gov/ct2/show/NCT06625593
NCT06625775	2024-519445-29-00--TBBO10203-101	Phase 1		NSW, VIC	2024-10-03	2024-10-29		BBO-10203; BBO-10203 + Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin; BBO-10203 + Fulvestrant; BBO-10203 + Fulvestrant + Ribociclib; BBO-10203 + Trastuzumab; Bevacizumab; Fluorouracil; Fulvestrant; Leucovorin; Oxaliplatin; Ribociclib; Trastuzumab	PI3K_alpha-RAS_breaker + anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; anti-ERBB2_monoclonal_antibody; CDK4/6_inhibitor; selective_estrogen_receptor_degrader; folinic_acid; anti-VEGF_monoclonal_antibody; Fluorouracil; PI3K_alpha-RAS_breaker; CDK4/6_inhibitor + PI3K_alpha-RAS_breaker + selective_estrogen_receptor_degrader; platinum-based_antineoplastic_agent; PI3K_alpha-RAS_breaker + selective_estrogen_receptor_degrader; PI3K_alpha-RAS_breaker + anti-ERBB2_monoclonal_antibody	BBO-10203; BBO-10203 + Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin; BBO-10203 + Fulvestrant; BBO-10203 + Fulvestrant + Ribociclib; BBO-10203 + Trastuzumab	CDK4/6_inhibitor + PI3K_alpha-RAS_breaker + selective_estrogen_receptor_degrader; PI3K_alpha-RAS_breaker; PI3K_alpha-RAS_breaker + anti-ERBB2_monoclonal_antibody; PI3K_alpha-RAS_breaker + anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; PI3K_alpha-RAS_breaker + selective_estrogen_receptor_degrader; Fluorouracil	2024-519445-29-00  TBBO10203-101	A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-10203 in Subjects With Advanced Solid Tumors (The BREAKER-101 Study)	HER2 Mutation-Related Tumors; Metastatic Lung Cancer; HER2-positive Advanced Breast Cancer; HER2-positive Metastatic Breast Cancer; Metastatic Colorectal Cancer; Metastatic Breast Cancer; Advanced Breast Cancer; HR-positive, HER2-negative Advanced Breast Cancer; KRAS Mutant Metastatic Colorectal Cancer; Solid Tumor, Adult; Advanced Lung Cancer	2031 - Randwick; 3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT06625775
NCT06627647	2024-515008-38-00--D702FC00001	Phase 3		NSW, QLD	2024-10-04	2024-11-27		Carboplatin; Cisplatin; Pembrolizumab; Pembrolizumab + Pemetrexed; Pemetrexed; Pemetrexed + Rilvegostomig; Rilvegostomig	antimetabolite + bispecific_PD-1/TIGIT_antibody; antimetabolite; anti-PD-1_monoclonal_antibody + antimetabolite; anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; bispecific_PD-1/TIGIT_antibody	Pembrolizumab + Pemetrexed; Pemetrexed + Rilvegostomig; Carboplatin; Cisplatin	anti-PD-1_monoclonal_antibody + antimetabolite; antimetabolite + bispecific_PD-1/TIGIT_antibody; platinum-based_antineoplastic_agent	2024-515008-38-00  D702FC00001	A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung03)	Non-squamous Non-small Cell Lung Cancer	4812 - Hyde Park; 2010 - Darlinghurst; 2500 - Wollongong; 4215 - Southport	https://clinicaltrials.gov/ct2/show/NCT06627647
NCT06629779	2024-511652-40-00--C2321003	Phase 3		NZ	2024-10-08	2024-10-22		Enzalutamide; Enzalutamide + PF-06821497; PF-06821497; Placebo	placebo; EZH2_inhibitor; antiandrogen,nonsteroidal,second_generation; EZH2_inhibitor + antiandrogen,nonsteroidal,second_generation	Enzalutamide; Enzalutamide + PF-06821497; Placebo	EZH2_inhibitor + antiandrogen,nonsteroidal,second_generation; antiandrogen,nonsteroidal,second_generation; placebo	2024-511652-40-00  C2321003	A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF PF-06821497 (MEVROMETOSTAT) WITH ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MEVPRO-2)	Metastatic Castration-Resistant Prostate Cancer	Canterbury; Auckland; Waikato	https://clinicaltrials.gov/ct2/show/NCT06629779
NCT06634589	2024-516234-35-00--BGB-16673-104	Phase 1		NSW, NZ, QLD, VIC, WA	2024-10-10	2024-11-27		BGB-16673; BGB-16673 + Glofitamab; BGB-16673 + Glofitamab + Obinutuzumab; BGB-16673 + Mosunetuzumab; BGB-16673 + Sonrotoclax; BGB-16673 + Zanubrutinib; Glofitamab; Mosunetuzumab; Obinutuzumab; Sonrotoclax; Zanubrutinib	BTK_PROTAC_degrader + anti-CD20_monoclonal_antibody + bispecific_T-cell_engager,CD20-targeting; anti-CD20_monoclonal_antibody; BTK_PROTAC_degrader + BTK_inhibitor; BTK_PROTAC_degrader; BTK_PROTAC_degrader + bispecific_T-cell_engager,CD20-targeting; BTK_inhibitor; BTK_PROTAC_degrader + Bcl2_inhibitor; bispecific_T-cell_engager,CD20-targeting; Bcl2_inhibitor	BGB-16673 + Glofitamab; BGB-16673 + Glofitamab + Obinutuzumab; BGB-16673 + Mosunetuzumab; BGB-16673 + Sonrotoclax; BGB-16673 + Zanubrutinib	BTK_PROTAC_degrader + BTK_inhibitor; BTK_PROTAC_degrader + Bcl2_inhibitor; BTK_PROTAC_degrader + anti-CD20_monoclonal_antibody + bispecific_T-cell_engager,CD20-targeting; BTK_PROTAC_degrader + bispecific_T-cell_engager,CD20-targeting	2024-516234-35-00  BGB-16673-104	A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies	B-cell Malignancy; Relapsed Cancer; Refractory Cancer; B-cell Lymphoma	3000 - Melbourne; 2217 - Kogarah; 6009 - Nedlands; Auckland; 3004 - Melbourne; 4101 - South Brisbane; 3168 - Clayton	https://clinicaltrials.gov/ct2/show/NCT06634589
NCT06634849	PTT-4256-01	Phase 1		NSW, SA, VIC, WA	2024-10-10	2024-11-04		PTT-4256	GPR65_inhibitor	PTT-4256	GPR65_inhibitor	PTT-4256-01	A Modular, Open Label, Dose Finding, Phase 1/2 Clinical Trial in Patients With Solid Tumours to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of PTT-4256.	Advanced Solid Tumor	2148 - Blacktown; 5042 - Adelaide; 6009 - Nedlands; 2031 - Randwick; 3084 - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT06634849
NCT06635824	2024-512998-27-00--GCT1046-06	Phase 3		NSW, QLD, SA, VIC, WA	2024-10-10	2024-11-25		Docetaxel; Pembrolizumab	anti-PD-1_monoclonal_antibody; taxane	Docetaxel; Pembrolizumab	anti-PD-1_monoclonal_antibody; taxane	2024-512998-27-00  GCT1046-06	A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06)	PD-L1-positive Metastatic NSCLC	- Southport; - Sydney; - Perth; - Camperdown; - Wendouree; - Fitzroy	https://clinicaltrials.gov/ct2/show/NCT06635824
NCT06644300	BM230-01	Phase 1		QLD	2024-10-16	2024-12-16		BM230	unknown_drug_class	BM230	unknown_drug_class	BM230-01	A Phase I, Multicenter, Non-randomized, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BM230 in Patients With Advanced Solid Tumors	Solid Tumor	4101 - Brisbane	https://clinicaltrials.gov/ct2/show/NCT06644300
NCT06646276	CA245-0001	Phase 3		NSW, QLD, VIC, WA	2024-10-17	2025-02-25		Atezolizumab; BMS-986012; Carboplatin; Etoposide; Nivolumab	topoisomerase_inhibitor; platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-fucosyl-GM1_monoclonal_antibody	Atezolizumab; BMS-986012; Carboplatin; Etoposide; Nivolumab	anti-PD-1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; anti-fucosyl-GM1_monoclonal_antibody; platinum-based_antineoplastic_agent; topoisomerase_inhibitor	CA245-0001	A Randomized, Double Blind, Multicenter Phase 3 Trial of BMS-986489 (BMS-986012+Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide vs Atezolizumab in Combination With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).	Extensive-Stage Small Cell Lung Cancer	2750 - Penrith; 4120 - Brisbane; 3350 - Ballarat Central; 6150 - Murdoch; 2560 - Campbelltown	https://clinicaltrials.gov/ct2/show/NCT06646276
NCT06649708	HX044-I-01	Phase 1		NSW, QLD, VIC	2024-10-21	2024-12-30		HX044	unknown_drug_class	HX044	unknown_drug_class	HX044-I-01	A Phase I/IIa, First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of HX044 in Patients with Advanced Solid Tumor Malignancies	Advanced Solid Tumor Malignancies	4066 - Auchenflower; 2148 - Blacktown; 3144 - Malvern	https://clinicaltrials.gov/ct2/show/NCT06649708
NCT06650566	LM299-01-102	Phase 1		WA, West Australi	2024-10-21	2024-10-09		LM-299	bispecific_PD-1/VEGF_antibody	LM-299	bispecific_PD-1/VEGF_antibody	LM299-01-102	A Phase I/II, Open-label, Dose Escalation and Dose Expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of LM-299 Injection as Monotherapy or in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors	Malignant Tumors	- Perth	https://clinicaltrials.gov/ct2/show/NCT06650566
NCT06651229	90189892AML1001--90189892AML1001	Phase 1		VIC, WA	2024-10-21	2025-03-21		JNJ-90189892	unknown_drug_class	JNJ-90189892	unknown_drug_class	90189892AML1001  90189892AML1001	A Phase 1, First-in-Human, Dose Escalation Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms	Myelodysplastic Neoplasms; Leukemia, Myeloid, Acute	6009 - Nedlands; 2139 - Concord; 3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT06651229
NCT06656390	ALK201-01	Phase 1		NSW	2024-10-24	2024-10-24		ALK-201	anti-FGFR2b_antibody-drug_conjugate	ALK-201	anti-FGFR2b_antibody-drug_conjugate	ALK201-01	A First-in-Human, Open-Label, Multi-Center Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ALK201 for Injection in Adult Participants With Advanced Solid Tumors	Advanced Cancer; Advanced Solid Tumors	2500 - Wollongong	https://clinicaltrials.gov/ct2/show/NCT06656390
NCT06659341	2024-513300-34-00--22676	Phase 1	_COHORTS_FULL	NSW, VIC	2024-10-26	2024-11-08		BAY3498264; Sotorasib	KRAS_G12C_inhibitor; SOS1-KRAS_inhibitor; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor	BAY3498264; Sotorasib	SOS1-KRAS_inhibitor; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor; KRAS_G12C_inhibitor	2024-513300-34-00  22676	Phase 1 Study of a SOS1 Inhibitor, BAY 3498264, in Combination in Participants With Advanced KRASG12C-mutated Solid Tumors	Advanced Solid Tumors Harboring KRAS G12C Mutation	3199 - Frankston; 2109 - Macquarie Park; 2640 - Albury	https://clinicaltrials.gov/ct2/show/NCT06659341
NCT06669975	AP402-101	Phase 1		NSW, SA, WA	2024-11-01	2025-04-22		AP402	bispecific_p95ERBB2/CD137_antibody	AP402	bispecific_p95ERBB2/CD137_antibody	AP402-101	A Phase 1/2, Open-label Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of AP402 in HER2-Positive Patients With Locally or Advanced Solid Tumors	Advanced Solid Tumor	6009 - Perth; 5043 - Bedford Park; 2109 - Macquarie	https://clinicaltrials.gov/ct2/show/NCT06669975
NCT06672185	ARC101-P1-101	Phase 1		QLD, SA, VIC	2024-11-04	2025-02-05		ARC101	bispecific_T-cell_engager,CLDN6-targeting	ARC101	bispecific_T-cell_engager,CLDN6-targeting	ARC101-P1-101	A Phase 1 Study of ARC101 in Advanced Solid Tumors	Advanced Solid Tumor	3144 - Malvern; 4575 - Birtinya; 5000 - Adelaide	https://clinicaltrials.gov/ct2/show/NCT06672185
NCT06682988	IMGN853-0425	Phase 2		QLD	2024-11-12	2025-05-28		Mirvetuximab Soravtansine	anti-FR-alpha_antibody-drug_conjugate	Mirvetuximab Soravtansine	anti-FR-alpha_antibody-drug_conjugate	IMGN853-0425	A Randomized Phase 2, Open-label Study of Mirvetuximab Soravtansine in Patients With Platinum-resistant Advanced High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-alpha Expression Testing 2 Schedules of Administration for Dose Optimization, With a Separate Cohort to Determine Starting Dose in Patients With Moderate Hepatic Impairment	Advanced High-Grade Epithelial Ovarian; Primary Peritoneal; Fallopian Tube Cancers; Platinum Resistant; High Folate Receptor-Alpha Expression	4032 - Chermside	https://clinicaltrials.gov/ct2/show/NCT06682988
NCT06685718	2024-517322-26-00--BG-60366-101	Phase 1		NSW, NZ, QLD, SA, VIC	2024-11-12	2024-11-26		BG-60366; Cladribine	EGFR_CDAC_degrader; antimetabolite	BG-60366; Cladribine	EGFR_CDAC_degrader; antimetabolite	2024-517322-26-00  BG-60366-101	Phase 1a/1b, Open-Label Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of a CDAC Degrading EGFR, BG-60366, in Patients With EGFR-Mutant Non-Small Cell Lung Cancer	EGFR Activating Mutation; Non-Small Cell Lung Cancer; NSCLC (Non-small Cell Lung Carcinoma); Lung Cancer; EGFR Mutation-Related Tumors; NSCLC	2170 - Liverpool; 3000 - Melbourne; 5000 - Adelaide; 3084 - Heidelberg; 4102 - Woolloongabba; 2148 - Blacktown; Auckland	https://clinicaltrials.gov/ct2/show/NCT06685718
NCT06690775	2024-517190-24-00--TORL123-002	Phase 2		MelbourneQLD, QLD, VIC, WA	2024-11-15	2024-11-20		Dexamethasone; Pegfilgrastim	granulocyte_colony_stimulating_factor; glucocorticoid	Pegfilgrastim; Dexamethasone	granulocyte_colony_stimulating_factor; glucocorticoid	2024-517190-24-00  TORL123-002	Catalina-2: A Phase 2 Study Evaluating the Efficacy and Safety of TORL-1-23 in Women With Advanced Platinum-Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal and Fallopian Tube Cancers) Expressing Claudin 6	Endometrioid Ovarian Cancer; Epithelial Ovarian Cancer; Primary Peritoneal; Fallopian Tube Cancer	QLD 4032 - Chermside; WA 6009 - Perth; VIC 3168 - Clayton	https://clinicaltrials.gov/ct2/show/NCT06690775
NCT06691984	2024-513968-25--20230005	Phase 3		NSW, QLD, VIC, WA	2024-11-18	2024-12-09		Abiraterone; Abiraterone + Cabazitaxel + Enzalutamide; Cabazitaxel; Enzalutamide; Xaluritamig	bispecific_T-cell_engager,STEAP1-targeting; antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor; taxane; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + taxane	Abiraterone + Cabazitaxel + Enzalutamide; Xaluritamig	CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + taxane; bispecific_T-cell_engager,STEAP1-targeting	2024-513968-25  20230005	A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Subjects With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Chemotherapy	Metastatic Castration-resistant Prostate Cancer	2050 - Camperdown; 2109 - North Ryde; 6150 - Murdoch; 4102 - Woolloongabba; 3004 - Melbourne; 3168 - Clayton	https://clinicaltrials.gov/ct2/show/NCT06691984
NCT06692738	2024-514281-39-00--D702BC00001	Phase 3		NSW, QLD	2024-11-18	2024-11-18		Carboplatin; Carboplatin + Nab-paclitaxel + Paclitaxel + Pembrolizumab; Carboplatin + Nab-paclitaxel + Paclitaxel + Rilvegostomig; Nab-paclitaxel; Paclitaxel; Pembrolizumab; Rilvegostomig	anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; anti-PD-1_monoclonal_antibody; taxane; platinum-based_antineoplastic_agent; bispecific_PD-1/TIGIT_antibody + platinum-based_antineoplastic_agent + taxane; bispecific_PD-1/TIGIT_antibody	Carboplatin + Nab-paclitaxel + Paclitaxel + Pembrolizumab; Carboplatin + Nab-paclitaxel + Paclitaxel + Rilvegostomig	anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; bispecific_PD-1/TIGIT_antibody + platinum-based_antineoplastic_agent + taxane	2024-514281-39-00  D702BC00001	A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Metastatic Squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung02)	Non-small Cell Lung Cancer	4812 - Hyde Park; 2010 - Darlinghurst; 2500 - Wollongong; 4215 - Southport	https://clinicaltrials.gov/ct2/show/NCT06692738
NCT06697301	KEYNOTE-G04--EIK1001-006	Phase 2		NSW, NZ, QLD	2024-11-20	2025-05-22		EIK1001; EIK1001 + Pembrolizumab; Pembrolizumab; Placebo	placebo; TLR7/TLR8_agonist; TLR7/TLR8_agonist + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody	EIK1001 + Pembrolizumab; Pembrolizumab; Placebo	TLR7/TLR8_agonist + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; placebo	KEYNOTE-G04  EIK1001-006	A Multicenter, Randomized, Double-Blind, Active Comparator-Controlled, Adaptive Phase 2/3 Study to Evaluate the Safety and Efficacy of EIK1001 and Pembrolizumab Versus Placebo and Pembrolizumab as First-Line Therapy in Participants With Advanced Melanoma.	Advanced Melanoma	2500 - Wollongong; 4032 - Chermside; Auckland	https://clinicaltrials.gov/ct2/show/NCT06697301
NCT06707610	ALK202-01	Phase 1		NSW	2024-11-27	2025-02-10		ALK-202	anti_EGFR/cMET_antibody-drug_conjugate	ALK-202	anti_EGFR/cMET_antibody-drug_conjugate	ALK202-01	A First-in-Human, Open-Label, Multi-Center Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ALK202 for Injection in Adult Participants with Advanced Solid Tumors	Advanced Solid Tumor; Advanced Cancer	2109 - Sydney; 2031 - Randwick	https://clinicaltrials.gov/ct2/show/NCT06707610
NCT06710132	2024-517817-34-00--MS202329-0010	Phase 1		NSW, QLD	2024-11-29	2025-01-29		M9140	anti-CEACAM5_antibody-drug_conjugate	M9140	anti-CEACAM5_antibody-drug_conjugate	2024-517817-34-00  MS202329_0010	PROCEADE PanTumor: A Phase 1b/2, Multicenter, Open-Label Study of Anti-CEACAM5 Antibody-Drug Conjugate M9140 in Participants With Advanced Solid Tumors (Master Protocol)	Solid Tumors; Non-Small Cell Lung Cancer (NSCLC); Pancreatic Ductal Adenocarcinoma (PDAC); Pancreatic Cancer; Gastric Cancer	- South Brisbane; - Sydney	https://clinicaltrials.gov/ct2/show/NCT06710132
NCT06712316	2024-515764-31-00--BNT327-06	Phase 2		NSW, QLD, SA, VIC	2024-12-02	2025-01-07		BNT327; BNT327 + Carboplatin + Paclitaxel; BNT327 + Carboplatin + Pemetrexed; Carboplatin; Carboplatin + Paclitaxel + Pembrolizumab; Carboplatin + Pembrolizumab + Pemetrexed; Paclitaxel; Pembrolizumab; Pemetrexed	antimetabolite; bispecific_PD-L1/VEGFA_antibody; antimetabolite + bispecific_PD-L1/VEGFA_antibody + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; anti-PD-1_monoclonal_antibody; taxane; bispecific_PD-L1/VEGFA_antibody + platinum-based_antineoplastic_agent + taxane; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent	BNT327 + Carboplatin + Paclitaxel; BNT327 + Carboplatin + Pemetrexed; Carboplatin + Paclitaxel + Pembrolizumab; Carboplatin + Pembrolizumab + Pemetrexed	anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; antimetabolite + bispecific_PD-L1/VEGFA_antibody + platinum-based_antineoplastic_agent; bispecific_PD-L1/VEGFA_antibody + platinum-based_antineoplastic_agent + taxane	2024-515764-31-00  BNT327-06	A Phase II/III, Multisite, Randomized Master Protocol for a Global Trial of BNT327 in Combination With Chemotherapy and Other Investigational Agents in First-line Non-small Cell Lung Cancer	Non-small Cell Lung Cancer	4812 - Townsville; 4870 - Cairns; 5037 - Kurralta Park; 3021 - St Albans; 2830 - Dubbo; 2500 - Wollongong; 3199 - Frankston	https://clinicaltrials.gov/ct2/show/NCT06712316
NCT06712355	2024-515765-34-00--BNT327-03	Phase 3		SA, VIC	2024-12-02	2025-02-03		Atezolizumab; Atezolizumab + Carboplatin + Etoposide; BNT327; BNT327 + Carboplatin + Etoposide; Carboplatin; Etoposide	anti-PD-L1_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; bispecific_PD-L1/VEGFA_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; topoisomerase_inhibitor; bispecific_PD-L1/VEGFA_antibody; anti-PD-L1_monoclonal_antibody; platinum-based_antineoplastic_agent	Atezolizumab + Carboplatin + Etoposide; BNT327 + Carboplatin + Etoposide	anti-PD-L1_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; bispecific_PD-L1/VEGFA_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor	2024-515765-34-00  BNT327-03	A Phase III, Multisite, Double-blinded Randomized Trial of BNT327 in Combination With Chemotherapy (Etoposide/Carboplatin) Compared to Atezolizumab in Combination With Chemotherapy (Etoposide/Carboplatin) in Participants With First-line Extensive-stage Small-cell Lung Cancer	Extensive-stage Small-cell Lung Cancer	5037 - Kurralta Park; 3199 - Frankston	https://clinicaltrials.gov/ct2/show/NCT06712355
NCT06726148	2024-517281-42--CECI830A12101	Phase 1		VIC	2024-12-10	2025-04-03		ECI830; ECI830 + Fulvestrant; ECI830 + Fulvestrant + Ribociclib; Fulvestrant; Fulvestrant + Ribociclib; Ribociclib	CDK2_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor; CDK2_inhibitor + CDK4/6_inhibitor + selective_estrogen_receptor_degrader; selective_estrogen_receptor_degrader; CDK4/6_inhibitor + selective_estrogen_receptor_degrader; CDK2_inhibitor	ECI830; ECI830 + Fulvestrant; ECI830 + Fulvestrant + Ribociclib; Fulvestrant + Ribociclib	CDK2_inhibitor; CDK2_inhibitor + CDK4/6_inhibitor + selective_estrogen_receptor_degrader; CDK2_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + selective_estrogen_receptor_degrader	2024-517281-42  CECI830A12101	An Open-label, Multi-center, Phase I/II Study of ECI830 as a Single Agent and in Combination With Ribociclib and Endocrine Therapy in Patients With Advanced Hormone Receptor Positive, HER2-negative Breast Cancer and Advanced Solid Tumors	Advanced CCNE1-amplified Solid Tumors; Advanced HR+/HER2- Breast Cancer	3004 - Melbourne; 3168 - Clayton	https://clinicaltrials.gov/ct2/show/NCT06726148
NCT06726265	2024-513621-23-00--TACTI-004	Phase 3		NSW, QLD, SA, VIC	2024-12-10	2025-03-21		Carboplatin; Cisplatin; Eftilagimod Alpha; Paclitaxel; Pembrolizumab; Pemetrexed; Placebo	placebo; antimetabolite; anti-PD-1_monoclonal_antibody; taxane; platinum-based_antineoplastic_agent; T-cell_immunostimulatory_factor	Pembrolizumab; Carboplatin; Cisplatin; Eftilagimod Alpha; Paclitaxel; Pemetrexed; Placebo	anti-PD-1_monoclonal_antibody; T-cell_immunostimulatory_factor; antimetabolite; placebo; platinum-based_antineoplastic_agent; taxane	2024-513621-23-00  TACTI-004	TACTI-004, a Double-Blinded, Randomized Phase 3 Trial in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) Receiving Eftilagimod Alfa (MHC Class II Agonist) in Combination With Pembrolizumab (PD-1 Antagonist) and Chemotherapy.	Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)	- Elizabeth Vale; - Southport; - Greenslopes; - Melbourne; - Waratah; - Wollongong	https://clinicaltrials.gov/ct2/show/NCT06726265
NCT06727565	VELOCITY-HNSCC	Phase 2		NSW, SA, VIC	2024-12-11	2025-02-18		Carboplatin; Carboplatin + Domvanalimab + Paclitaxel + Zimberelimab; Carboplatin + Paclitaxel + Zimberelimab; Domvanalimab; Paclitaxel; Zimberelimab	anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody; taxane; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; platinum-based_antineoplastic_agent	Carboplatin + Domvanalimab + Paclitaxel + Zimberelimab; Carboplatin + Paclitaxel + Zimberelimab	anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane	2024-513121-22  GS-US-699-7184	A Phase 2 Platform Study of Novel Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma	Head and Neck Squamous Cell Carcinoma	5037 - Kurralta Park; 2145 - Sydney; 3004 - Melbourne; 3168 - Clayton	https://clinicaltrials.gov/ct2/show/NCT06727565
NCT06730386	AK138D1-101	Phase 1		NSW, QLD, VIC	2024-12-12	2025-02-24		AK138D1	anti-ERBB3_antibody-drug_conjugate	AK138D1	anti-ERBB3_antibody-drug_conjugate	AK138D1-101	A First-in-human, Phase I Study of Evaluating Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AK138D1 in the Treatment of Advanced Solid Tumors	Solid Cancer	2109 - North Ryde; 4101 - South Brisbane; 3199 - Frankston; 2148 - Blacktown	https://clinicaltrials.gov/ct2/show/NCT06730386
NCT06730750	CA238-0001	Phase 1		QLD	2024-12-12	2025-02-12		BMS-986490; Bevacizumab	anti-VEGF_monoclonal_antibody; unknown_drug_class	BMS-986490; Bevacizumab	anti-VEGF_monoclonal_antibody; unknown_drug_class	CA238-0001	A Phase 1/2a, Multicenter, Open-label, First in Human Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors	Advanced Solid Tumors	4215 - Southport	https://clinicaltrials.gov/ct2/show/NCT06730750
NCT06731478	KEYNOTE-G03--DS8201-724	Phase 3		NSW, SA, VIC, WA	2024-12-12	2025-02-27		Capecitabine; Capecitabine + Cisplatin + Fluorouracil + Oxaliplatin + Pembrolizumab + Trastuzumab; Capecitabine + Cisplatin + Fluorouracil + Oxaliplatin + Trastuzumab; Capecitabine + Fluorouracil + Pembrolizumab + Trastuzumab Deruxtecan; Capecitabine + Fluorouracil + Trastuzumab Deruxtecan; Cisplatin; Fluorouracil; Oxaliplatin; Pembrolizumab; Trastuzumab; Trastuzumab Deruxtecan	anti-ERBB2_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody + fluoropyrimidine; anti-ERBB2_monoclonal_antibody + anti-PD-1_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; anti-ERBB2_antibody-drug_conjugate + fluoropyrimidine; Fluorouracil; anti-ERBB2_monoclonal_antibody; fluoropyrimidine; anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; anti-ERBB2_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; anti-ERBB2_antibody-drug_conjugate	Capecitabine + Cisplatin + Fluorouracil + Oxaliplatin + Pembrolizumab + Trastuzumab; Capecitabine + Cisplatin + Fluorouracil + Oxaliplatin + Trastuzumab; Capecitabine + Fluorouracil + Pembrolizumab + Trastuzumab Deruxtecan; Capecitabine + Fluorouracil + Trastuzumab Deruxtecan	anti-ERBB2_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody + fluoropyrimidine; anti-ERBB2_antibody-drug_conjugate + fluoropyrimidine; anti-ERBB2_monoclonal_antibody + anti-PD-1_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; anti-ERBB2_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; Fluorouracil	KEYNOTE-G03  DS8201-724	A Multicenter, Randomized, Open-Label, Phase 3 Trial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab Versus Chemotherapy Plus Trastuzumab Plus or Minus Pembrolizumab as First-Line Treatment in Participants With Unresectable, Locally Advanced or Metastatic HER2-Positive Gastric Or Gastroesophageal Junction (GEJ) Cancer (Destiny-Gastric05)	Gastric Cancer; Gastroesophageal Junction Cancer	- Bedford Park; - North Melbourne; - Douglas; - St Leonards; - Wollongong; - Clayton; - Subiaco	https://clinicaltrials.gov/ct2/show/NCT06731478
NCT06736704	SNV4818-101	Phase 1		NSW, VIC, W. Australi, WA	2024-12-17	2025-02-20		Fulvestrant; Fulvestrant + SNV4818; SNV4818	PI3K_alpha_inhibitor,allosteric,mutant-selective + selective_estrogen_receptor_degrader; selective_estrogen_receptor_degrader; PI3K_alpha_inhibitor,allosteric,mutant-selective	Fulvestrant + SNV4818; SNV4818	PI3K_alpha_inhibitor,allosteric,mutant-selective; PI3K_alpha_inhibitor,allosteric,mutant-selective + selective_estrogen_receptor_degrader	SNV4818-101	A Phase 1, Open-Label Dose Escalation and Expansion Study of SNV4818 as Monotherapy or in Combination With Other Anticancer Agents in Participants With Advanced Solid Tumors	Advanced Solid Tumors	2031 - Randwick; 3000 - Melbourne; 2050 - Camperdown; 3168 - Clayton; 6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT06736704
NCT06738966	BL0175-102	Phase 1		NSW	2024-12-18			BL0175	unknown_drug_class	BL0175	unknown_drug_class	BL0175-102	An International, Multi-Center, Open-label Phase I Study to Evaluate the Tolerance, Pharmacokinetics, and Anti-Tumor Effects of BL0175 Injection in Postmenopausal Female Adults with HR-positive, Locally Advanced or Metastatic Cancer	Endometrial Cancer; Ovarian Cancer; Breast Cancer	- Sydney	https://clinicaltrials.gov/ct2/show/NCT06738966
NCT06741644	CS2009-101	Phase 1		NSW, QLD, VIC	2024-12-19	2025-02-24		CS2009	trispecific_PD-1/VEGFA/CTLA4_antibody	CS2009	trispecific_PD-1/VEGFA/CTLA4_antibody	CS2009-101	A Phase I, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of CS2009, a Tri-specific Antibody Targeting PD-1/VEGFA/CTLA-4, in Participants With Advanced Solid Tumors	Advanced Solid Tumors	- Sydney; - Melbourne; - South Brisbane	https://clinicaltrials.gov/ct2/show/NCT06741644
NCT06745323	DeLLphi-309	Phase 2		VIC	2024-12-20	2025-02-26		Tarlatamab	bispecific_T-cell_engager,DLL3-targeting	Tarlatamab	bispecific_T-cell_engager,DLL3-targeting	20240092	A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With Small Cell Lung Cancer (SCLC) (DeLLphi-309)	Small Cell Lung Cancer (SCLC)	3084 - Heidelberg; 3168 - Clayton	https://clinicaltrials.gov/ct2/show/NCT06745323
NCT06750094	OrigAMI-3	Phase 3		SA, VIC	2024-12-27	2024-12-12		Amivantamab; Amivantamab + Fluorouracil + Irinotecan + Leucovorin; Bevacizumab; Bevacizumab + Cetuximab; Cetuximab; Fluorouracil; Irinotecan; Leucovorin	topoisomerase_inhibitor; bispecific_cMET/EGFR_antibody + fluoropyrimidine + folinic_acid + topoisomerase_inhibitor; Fluorouracil; anti-EGFR_monoclonal_antibody + anti-VEGF_monoclonal_antibody; fluoropyrimidine; folinic_acid; anti-VEGF_monoclonal_antibody; anti-EGFR_monoclonal_antibody; bispecific_cMET/EGFR_antibody	Amivantamab + Fluorouracil + Irinotecan + Leucovorin; Bevacizumab + Cetuximab	anti-EGFR_monoclonal_antibody + anti-VEGF_monoclonal_antibody; bispecific_cMET/EGFR_antibody + fluoropyrimidine + folinic_acid + topoisomerase_inhibitor; Fluorouracil	61186372COR3002  61186372COR3002	A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Recurrent, Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy	Colorectal Neoplasms	3084 - Heidelberg; 3021 - St Albans; 5011 - South Woodville; 2139 - Concord	https://clinicaltrials.gov/ct2/show/NCT06750094
NCT06750185	BNT317-01	Phase 1		NSW, QLD, VIC	2024-12-27	2025-01-13		BNT317	cancer_therapy,undisclosed_mechanism	BNT317	cancer_therapy,undisclosed_mechanism	BNT317-01	A Phase I, First-in-human, Open-label, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BNT317 in Patients With Advanced Solid Tumors	Advanced Solid Tumor	3168 - Clayton; 4215 - Southport; 2031 - Randwick	https://clinicaltrials.gov/ct2/show/NCT06750185
NCT06751329	DM002001	Phase 1		NSW	2024-12-27	2025-02-17		DM002	bispecific-ERBB3/MUC1_antibody-drug_conjugate	DM002	bispecific-ERBB3/MUC1_antibody-drug_conjugate	DM002001	A Phase I, Multicentre, Open-label, First-in-Human, Dose Escalation and Expansion Study of DM002 in Patients With Advanced Solid Tumors	Colorectal Neoplasms; Endometrial Neoplasms; Prostatic Neoplasms; Ovarian Neoplasms; Solid Carcinoma	2500 - Wollongong	https://clinicaltrials.gov/ct2/show/NCT06751329
NCT06756932	CTR20250114--BGB-21447-102	Phase 1		NSW, QLD, VIC, WA	2025-01-03	2025-02-04		BGB-21447; BGB-21447 + BGB-43395 + Fulvestrant; BGB-21447 + Fulvestrant; BGB-43395; Fulvestrant	CDK4_selective_inhibitor; Bcl2_inhibitor + CDK4_selective_inhibitor + selective_estrogen_receptor_degrader; selective_estrogen_receptor_degrader; Bcl2_inhibitor; Bcl2_inhibitor + selective_estrogen_receptor_degrader	BGB-21447; BGB-21447 + BGB-43395 + Fulvestrant; BGB-21447 + Fulvestrant	Bcl2_inhibitor; Bcl2_inhibitor + CDK4_selective_inhibitor + selective_estrogen_receptor_degrader; Bcl2_inhibitor + selective_estrogen_receptor_degrader	CTR20250114  BGB-21447-102	A Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-21447 (a Bcl-2 Inhibitor) Combinations for Patients With HR+/HER2- Metastatic Breast Cancer	Metastatic Breast Cancer; HER2-negative Breast Cancer; Hormone-receptor-positive Breast Cancer	6009 - Nedlands; 2298 - Waratah; 2010 - Darlinghurst; 3000 - Melbourne; 3021 - St Albans; 4575 - Birtinya	https://clinicaltrials.gov/ct2/show/NCT06756932
NCT06757634	CELC-G-302	Phase 3		NSW, QLD, SA, WA	2025-01-03			Fulvestrant; Fulvestrant + Gedatolisib + Palbociclib + Ribociclib; Fulvestrant + Palbociclib + Ribociclib; Gedatolisib; Palbociclib; Ribociclib	CDK4/6_inhibitor + pan-PI3K/mTORC1/mTORC2_inhibitor + selective_estrogen_receptor_degrader; pan-PI3K/mTORC1/mTORC2_inhibitor; CDK4/6_inhibitor; selective_estrogen_receptor_degrader; CDK4/6_inhibitor + selective_estrogen_receptor_degrader	Fulvestrant + Gedatolisib + Palbociclib + Ribociclib; Fulvestrant + Palbociclib + Ribociclib	CDK4/6_inhibitor + pan-PI3K/mTORC1/mTORC2_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + selective_estrogen_receptor_degrader	CELC-G-302	VIKTORIA-2: A Randomized, Open-Label, Phase 3 Study of Fulvestrant and CDK4/6 Inhibitors With or Without Gedatolisib as First-Line Treatment in Patients With HR-Positive and HER2-Negative Advanced Breast Cancer	Breast Cancer	4215 - Southport; 5000 - Adelaide; 2076 - Wahroonga; 6009 - Nedlands; 2145 - Westmead	https://clinicaltrials.gov/ct2/show/NCT06757634
NCT06760637	FourLight-3	Phase 3		QLD, VIC	2025-01-07	2025-01-06		Abemaciclib; Letrozole; Letrozole + PF-07220060; PF-07220060; Palbociclib; Ribociclib	aromatase_inhibitor; CDK4_selective_inhibitor + aromatase_inhibitor; CDK4/6_inhibitor; CDK4_selective_inhibitor	Letrozole; Letrozole + PF-07220060; Abemaciclib; Palbociclib; Ribociclib	CDK4_selective_inhibitor + aromatase_inhibitor; aromatase_inhibitor; CDK4/6_inhibitor	2024-512925-95-00  C4391024	AN INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER PHASE 3 STUDY OF PF-07220060 PLUS LETROZOLE COMPARED TO CDK4/6 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR (HR)-POSITIVE, HER2-NEGATIVE ADVANCED/METASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCED/METASTATIC DISEASE (FOURLIGHT-3)	Breast Cancer	3940 - Capel Sound; 3000 - Melbourne; 4102 - Woolloongabba; 3052 - Parkville; 3199 - Frankston; 4814 - Douglas	https://clinicaltrials.gov/ct2/show/NCT06760637
NCT06760819	panSOHO	Phase 2		NSW, QLD	2025-01-07	2025-02-13		Sevabertinib	EGFR/ERBB2_inhibitor,mutant-selective,non-covalent	Sevabertinib	EGFR/ERBB2_inhibitor,mutant-selective,non-covalent	2024-517419-62-00  22752	A Phase 2 Open-label Basket Study to Evaluate the Efficacy and Safety of Orally Administered Reversible Tyrosine Kinase Inhibitor BAY 2927088 in Participants With Metastatic or Unresectable Solid Tumors With HER2-activating Mutations	Advanced Solid Tumors; HER2 Mutation	4215 - Southport; 2109 - Sydney; 2148 - Blacktown	https://clinicaltrials.gov/ct2/show/NCT06760819
NCT06764485	rechARge	Phase 3		NSW, QLD, SA, TAS, VIC, WA	2025-01-08	2025-03-13		Abiraterone; Abiraterone + Enzalutamide + Prednisolone + Prednisone; BMS-986365; Docetaxel; Enzalutamide; Prednisolone; Prednisone	CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + glucocorticoid; glucocorticoid; antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor; taxane; dual_AR_degrader_antagonist	Abiraterone + Enzalutamide + Prednisolone + Prednisone; BMS-986365; Docetaxel	CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + glucocorticoid; dual_AR_degrader_antagonist; taxane	CA071-1000	A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 Versus Investigator's Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) - rechARge	Metastatic Castration-resistant Prostate Cancer	3004 - Melbourne; 2076 - Wahroonga; 7000 - Hobart; 3144 - Malvern; 2109 - Macquarie University; 6150 - Murdoch; 2560 - Campbelltown; 4215 - Southport; 5037 - Kurralta Park; 2444 - Port Macquarie; 5112 - Elizabeth Vale; 3000 - Melbourne; 2010 - Darlinghurst; 5000 - Adelaide; 3084 - Heidelberg; 4120 - Greenslopes	https://clinicaltrials.gov/ct2/show/NCT06764485
NCT06764771	CA234-0001	Phase 1		QLD	2025-01-08	2025-03-25		Adagrasib; Adagrasib + BMS-986488; Adagrasib + BMS-986488 + Cetuximab; BMS-986488; BMS-986488 + Nivolumab; Cetuximab; Nivolumab	anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor; anti-EGFR_monoclonal_antibody; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody	Adagrasib + BMS-986488; Adagrasib + BMS-986488 + Cetuximab; BMS-986488; BMS-986488 + Nivolumab	KRAS_G12C_inhibitor; KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody	CA234-0001	A Phase 1/1b Open-label Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors	Advanced Malignant Tumors	4029 - Brisbane	https://clinicaltrials.gov/ct2/show/NCT06764771
NCT06764875	2024-512583-57-00--D702AC00001	Phase 3		NSW, VIC, WA	2025-01-09	2025-03-01		Capecitabine; Capecitabine + Cisplatin + Fluorouracil + Oxaliplatin + Pembrolizumab + Trastuzumab; Capecitabine + Cisplatin + Fluorouracil + Oxaliplatin + Rilvegostomig + Trastuzumab; Capecitabine + Fluorouracil + Rilvegostomig + Trastuzumab Deruxtecan; Cisplatin; Fluorouracil; Oxaliplatin; Pembrolizumab; Rilvegostomig; Trastuzumab; Trastuzumab Deruxtecan	anti-ERBB2_monoclonal_antibody + anti-PD-1_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; Fluorouracil; anti-ERBB2_monoclonal_antibody; fluoropyrimidine; anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; anti-ERBB2_monoclonal_antibody + bispecific_PD-1/TIGIT_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; anti-ERBB2_antibody-drug_conjugate + bispecific_PD-1/TIGIT_antibody + fluoropyrimidine; anti-ERBB2_antibody-drug_conjugate; bispecific_PD-1/TIGIT_antibody	Capecitabine + Cisplatin + Fluorouracil + Oxaliplatin + Pembrolizumab + Trastuzumab; Capecitabine + Cisplatin + Fluorouracil + Oxaliplatin + Rilvegostomig + Trastuzumab; Capecitabine + Fluorouracil + Rilvegostomig + Trastuzumab Deruxtecan	anti-ERBB2_antibody-drug_conjugate + bispecific_PD-1/TIGIT_antibody + fluoropyrimidine; anti-ERBB2_monoclonal_antibody + anti-PD-1_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; anti-ERBB2_monoclonal_antibody + bispecific_PD-1/TIGIT_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; Fluorouracil	2024-512583-57-00  D702AC00001	A Randomized, Phase ? Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan Versus Trastuzumab, Chemotherapy, and Pembrolizumab for the First Line Treatment of HER2-positive Gastric Cancer (ARTEMIDE-Gastric01)	HER2-positive Gastric Cancer; Gastroesophageal Junction Adenocarcinoma	3084 - Heidelberg; 2010 - Darlinghurst; 6150 - Murdoch; 2145 - Westmead	https://clinicaltrials.gov/ct2/show/NCT06764875
NCT06780137	2024-517926-25-00--6070-002	Phase 1		QLD	2025-01-17	2025-02-27		Durvalumab; Ifinatamab Deruxtecan	anti-B7H3_antibody-drug_conjugate; anti-PD-L1_monoclonal_antibody	Durvalumab; Ifinatamab Deruxtecan	anti-PD-L1_monoclonal_antibody; anti-B7H3_antibody-drug_conjugate	2024-517926-25-00  6070-002	A Phase 1b/2 Open-Label Clinical Study to Evaluate the Safety and Efficacy of MK-6070 and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer	Small Cell Lung Cancer	4102 - Wooloongabba	https://clinicaltrials.gov/ct2/show/NCT06780137
NCT06780670	PSMAcTION	Phase 2		NSW, QLD	2025-01-17	2025-02-27						2024-512342-42-00  CAAA817A12201	PSMAcTION: A Phase II/III, Open-label, International, Multicenter, Randomized Study of AAA817 Versus Standard of Care in the Treatment of Adult Participants With PSMA Positive Metastatic Castration-resistant Prostate Cancer Who Progressed on or After [177Lu]Lu-PSMA Targeted Therapy	Prostate Cancer	4029 - Herston; 2010 - Darlinghurst	https://clinicaltrials.gov/ct2/show/NCT06780670
NCT06784193	OP-3136-101	Phase 1		SA	2025-01-20	2024-12-16		OP-3136	KAT6_inhibitor	OP-3136	KAT6_inhibitor	OP-3136-101	A Phase 1 First-in-Human, Open-Label, Multicenter Study of OP-3136 in Adult Participants With Advanced or Metastatic Solid Tumors	Advanced or Metastatic ER+ HER2- Breast Cancer (mBC); Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC); Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC)	5000 - Adelaide	https://clinicaltrials.gov/ct2/show/NCT06784193
NCT06788990	FORTIFI-HN01	Phase 2		NSW, QLD, VIC	2025-01-23	2025-01-28		BCA101; Pembrolizumab; Placebo	placebo; anti-PD-1_monoclonal_antibody; bifunctional_EGFR/TGF-beta_fusion_protein	Pembrolizumab; BCA101; Placebo	anti-PD-1_monoclonal_antibody; bifunctional_EGFR/TGF-beta_fusion_protein; placebo	2024-519654-37-00  BCA101X301	A Multicenter, Randomized, Double-blind, Phase 2/3 Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1-positive, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma	Recurrent Head and Neck Squamous Cell Carcinoma; Metastatic Head and Neck Squamous Cell Carcinoma	2298 - Waratah; 4224 - Tugun; 3051 - North Melbourne	https://clinicaltrials.gov/ct2/show/NCT06788990
NCT06789172	INVOKE	Phase 1		NSW, WA	2025-01-23	2025-01-23		OKN4395; OKN4395 + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody + prostaglandin_EP2/EP4/DP1_receptor_inhibitor; prostaglandin_EP2/EP4/DP1_receptor_inhibitor; anti-PD-1_monoclonal_antibody	OKN4395; OKN4395 + Pembrolizumab	anti-PD-1_monoclonal_antibody + prostaglandin_EP2/EP4/DP1_receptor_inhibitor; prostaglandin_EP2/EP4/DP1_receptor_inhibitor	OKN-4395-121	A Phase 1, Open-label, Multicenter, Dose-escalation and Cohort Expansion Study of OKN4395, a Triple Antagonist of EP2, EP4, and DP1 Prostanoid Receptors, as Monotherapy and in Combination With Pembrolizumab, in Patients With Advanced Solid Tumors	HNSCC; NSCLC; Colorectal Cancer (CRC); Sarcoma; Pancreatic Adenocarcinoma; Dedifferentiated Liposarcoma; Non Small Cell Lung Cancer; Myxofibrosarcoma (MFS); Solitary Fibrous Tumors; Solid Tumours; Undifferentiated Pleomorphic Sarcoma (UPS); Head and Neck Squamous Cell Carcinoma	- Sydney; 6009 - Perth	https://clinicaltrials.gov/ct2/show/NCT06789172
NCT06790693	INAVO123	Phase 3		NSW, SA	2025-01-24	2025-04-09		Inavolisib; Inavolisib + Letrozole; Letrozole; Placebo	placebo; PI3K_alpha_inhibitor; PI3K_alpha_inhibitor + aromatase_inhibitor; aromatase_inhibitor	Inavolisib + Letrozole; Letrozole; Placebo	PI3K_alpha_inhibitor + aromatase_inhibitor; aromatase_inhibitor; placebo	2024-516162-11-00  WO45654	A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib Plus a CDK4/6 Inhibitor and Letrozole Versus Placebo Plus a CDK4/6 Inhibitor and Letrozole in Patients With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer	Breast Cancer	2065 - St Leonards; 5112 - Elizabeth Vale	https://clinicaltrials.gov/ct2/show/NCT06790693
NCT06792695	CANTOR	Phase 2		NSW, SA, VIC	2025-01-27	2025-03-12		Bevacizumab; Bevacizumab + Volrustomig; Fluorouracil; Irinotecan; Leucovorin; Volrustomig	topoisomerase_inhibitor; bispecific_PD-L1/CTLA4_antibody; Fluorouracil; fluoropyrimidine; folinic_acid; anti-VEGF_monoclonal_antibody + bispecific_PD-L1/CTLA4_antibody; anti-VEGF_monoclonal_antibody	Bevacizumab; Bevacizumab + Volrustomig; Fluorouracil; Irinotecan; Leucovorin	anti-VEGF_monoclonal_antibody; anti-VEGF_monoclonal_antibody + bispecific_PD-L1/CTLA4_antibody; Fluorouracil; fluoropyrimidine; folinic_acid; topoisomerase_inhibitor	2024-518469-84  D798VC00001	A Phase II, Open-label, Multicenter, Master Protocol to Evaluate the Safety and Efficacy of Novel Study Interventions and Combinations in Participants With Colorectal Cancer (CANTOR)	Metastatic Colorectal Cancer	2500 - Wollongong; 3002 - East Melbourne; 5011 - Woodville South	https://clinicaltrials.gov/ct2/show/NCT06792695
NCT06797362	NVL-520-EAP			NSW, VIC	2025-01-28			Zidesamtinib	ROS1_inhibitor	Zidesamtinib	ROS1_inhibitor	NVL-520-EAP	Expanded Access Treatment of Zidesamtinib (NVL-520) in Patients With Advanced ROS1+ NSCLC	Non Small Cell Lung Cancer; ROS1-positive Non-Small Cell Lung Cancer (NSCLC)	3000 - Melbourne; 2050 - Camperdown	https://clinicaltrials.gov/ct2/show/NCT06797362
NCT06801834	EVOKE-SCLC-04	Phase 3		NSW	2025-01-30	2025-04-04		Amrubicin; Amrubicin + Topotecan; Sacituzumab Govitecan; Topotecan	anti-Trop2_antibody-drug_conjugate; anthracycline + topoisomerase_inhibitor; topoisomerase_inhibitor; anthracycline	Amrubicin + Topotecan; Sacituzumab Govitecan	anthracycline + topoisomerase_inhibitor; anti-Trop2_antibody-drug_conjugate	2024-515884-69  GS-US-600-6165	A Global, Multicenter, Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Standard of Care (SOC) in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer (ES-SCLC)	Extensive Stage Small Cell Lung Cancer (ES-SCLC)	2500 - New South Wales	https://clinicaltrials.gov/ct2/show/NCT06801834
NCT06803680	2024-512931-64-00--BGB-B455-101	Phase 1		NSW, QLD	2025-01-31	2025-03-18		BGB-B455	bispecific_T-cell_engager,CLDN6-targeting	BGB-B455	bispecific_T-cell_engager,CLDN6-targeting	2024-512931-64-00  BGB-B455-101	A Phase 1, Open-Label Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B455 in Patients With Selected Advanced or Metastatic Solid Tumors	Metastatic Solid Tumor; Advanced Solid Tumor	4101 - South Brisbane; 2148 - Blacktown; 2170 - Liverpool	https://clinicaltrials.gov/ct2/show/NCT06803680
NCT06804824	VVD-159642-01	Phase 1		SA, WA	2025-02-03	2025-02-25		Sotorasib; Sotorasib + VVD-159642; Trametinib; Trametinib + VVD-159642; VVD-159642	RAS-PI3Kalpha_inhibitor; MEK_inhibitor; KRAS_G12C_inhibitor + RAS-PI3Kalpha_inhibitor; KRAS_G12C_inhibitor; MEK_inhibitor + RAS-PI3Kalpha_inhibitor; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + RAS-PI3Kalpha_inhibitor	Sotorasib + VVD-159642; Trametinib + VVD-159642; VVD-159642	KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + RAS-PI3Kalpha_inhibitor; KRAS_G12C_inhibitor + RAS-PI3Kalpha_inhibitor; MEK_inhibitor + RAS-PI3Kalpha_inhibitor; RAS-PI3Kalpha_inhibitor	VVD-159642-01	A Phase 1/1b, Open-Label, Multicenter, First-in-Human Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-Tumor Activity of VVD-159642, a RAS-PI3Ka Inhibitor, as a Single Agent and in Combination in Participants With Advanced Solid Tumors	Advanced Solid Tumors	6009 - Nedlands; 5000 - Adelaide	https://clinicaltrials.gov/ct2/show/NCT06804824
NCT06806852	2024-517091-38-00--1501-0002	Phase 1		NSW, VIC	2025-02-04	2025-05-14		BI 770371; BI 770371 + Cetuximab + Pembrolizumab; BI 770371 + Pembrolizumab; Cetuximab; Pembrolizumab	anti-PD-1_monoclonal_antibody + anti-SIRPa_monoclonal_antibody; anti-EGFR_monoclonal_antibody; anti-SIRPa_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-EGFR_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-SIRPa_monoclonal_antibody	BI 770371 + Cetuximab + Pembrolizumab; BI 770371 + Pembrolizumab; Pembrolizumab	anti-EGFR_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-SIRPa_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-SIRPa_monoclonal_antibody	2024-517091-38-00  1501-0002	A Phase Ib Open Label Randomised Clinical Trial to Evaluate Safety and Efficacy of BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Compared With Pembrolizumab Monotherapy for the First-line Treatment of Patients With Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)	Head and Neck Squamous Cell Carcinoma	3220 - Geelong; 2250 - Gosford	https://clinicaltrials.gov/ct2/show/NCT06806852
NCT06806982	VRN101099-01	Phase 1		NSW	2025-03-25			VRN101099	ERBB2_inhibitor,second_generation	VRN101099	ERBB2_inhibitor,second_generation	VRN101099_01	A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of VRN101099 in Patients With HER2-Positive Solid Tumors	HER2-positive Solid Tumors	2010 - Darlinghurst	https://clinicaltrials.gov/ct2/show/NCT06806982
NCT06815575	RAC-010	Phase 1		NSW	2025-02-07	2025-04-02		Bisantrene; Bisantrene + Doxorubicin; Doxorubicin	antimetabolite; anthracycline; doxorubicin; anthracycline + antimetabolite	Bisantrene + Doxorubicin	anthracycline; anthracycline + antimetabolite; doxorubicin	RAC-010	A Two-part Phase 1 Open-label Safety and Pharmacokinetic Study of Intravenous RC220 in Combination With Doxorubicin in Adult Patients With Solid Tumours.	Solid Tumours; Advanced Solid Tumours	2250 - Gosford; 2228 - Miranda; 2259 - Wyong	https://clinicaltrials.gov/ct2/show/NCT06815575
NCT06816992	ORIC-114-05	Phase 1		VIC	2025-03-25	2025-02-27		Amivantamab; Amivantamab + ORIC-114; ORIC-114	ERBB2_inhibitor,exon_20_selective; bispecific_cMET/EGFR_antibody; ERBB2_inhibitor,exon_20_selective + bispecific_cMET/EGFR_antibody; EGFR_inhibitor,exon_20_selective + bispecific_cMET/EGFR_antibody; EGFR_inhibitor,exon_20_selective	Amivantamab + ORIC-114	EGFR_inhibitor,exon_20_selective + bispecific_cMET/EGFR_antibody; ERBB2_inhibitor,exon_20_selective + bispecific_cMET/EGFR_antibody	ORIC-114-05	Phase 1b Study of ORIC-114 in Combination with Amivantamab in Patients with EGFR Exon20 Insertion Mutant NSCLC	NSCLC; Solid Tumors; EGFR Exon 20 Insertion Mutations; EGFR-mutated NSCLC	03000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT06816992
NCT06819735	DOMISOL	Phase 1		VIC	2025-02-11			DT-7012	anti-CCR8_monoclonal_antibody	DT-7012	anti-CCR8_monoclonal_antibody	DT-7012-CLI-001	A Phase 1/2, Multicentre, Open-label Clinical Trial of DT-7012 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Participants With Selected Advanced Solid Tumors (DOMISOL, DOmain_therapeutics Monoclonal antIbody for SOLid Tumors)	Advanced Solid Tumors	3144 - Malvern; 3199 - Frankston	https://clinicaltrials.gov/ct2/show/NCT06819735
NCT06820463	AndroMETa-CRC	Phase 2		NSW, VIC, WA	2025-02-11	2025-04-24		Bevacizumab; Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin; Fluorouracil; Fluorouracil + Leucovorin + Panitumumab; Fluorouracil + Panitumumab; Leucovorin; Oxaliplatin; Panitumumab	Fluorouracil; anti-EGFR_monoclonal_antibody + fluoropyrimidine; fluoropyrimidine; anti-EGFR_monoclonal_antibody + fluoropyrimidine + folinic_acid; anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent; folinic_acid; anti-VEGF_monoclonal_antibody; anti-EGFR_monoclonal_antibody	Bevacizumab; Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin; Fluorouracil + Leucovorin + Panitumumab; Fluorouracil + Panitumumab; Panitumumab	anti-EGFR_monoclonal_antibody; anti-EGFR_monoclonal_antibody + fluoropyrimidine; anti-EGFR_monoclonal_antibody + fluoropyrimidine + folinic_acid; anti-VEGF_monoclonal_antibody; anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; Fluorouracil	EU CT  M24-533	A Phase 2, Open-Label, Randomized, Master Protocol Study to Evaluate Safety and Efficacy of Multiple Treatment Combinations With Telisotuzumab Adizutecan in Subjects With Metastatic Colorectal Cancer	Metastatic Colorectal Cancer	6009 - Nedlands; 2109 - Sydney; 3084 - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT06820463
NCT06824155	RAD202	Phase 0		NSW, WA	2025-02-13	2025-02-12		177Lu-RAD202	radioconjugate,ERBB2-targeting	177Lu-RAD202	radioconjugate,ERBB2-targeting	RAD202.2022.0002	Phase 0/1 Study of the Safety and Tolerability of 177Lu-RAD202, a Lutetium-177 Radiolabeled Single Domain Antibody Against Human Epidermal Growth Factor Receptor 2 in Patients With Advanced Solid Tumours	HER2 Gene Mutation; Advanced Solid Tumors	2747 - Kingswood; 6150 - Murdoch	https://clinicaltrials.gov/ct2/show/NCT06824155
NCT06824467	MK-2870-022--2870-022	Phase 3		NSW, QLD, VIC	2025-02-13	2025-04-09		Bevacizumab; Bevacizumab + Sacituzumab tirumotecan; Dexamethasone; Sacituzumab tirumotecan	anti-Trop2_antibody-drug_conjugate + anti-VEGF_monoclonal_antibody; anti-Trop2_antibody-drug_conjugate; glucocorticoid; anti-VEGF_monoclonal_antibody	Bevacizumab; Bevacizumab + Sacituzumab tirumotecan; Dexamethasone	anti-Trop2_antibody-drug_conjugate + anti-VEGF_monoclonal_antibody; anti-VEGF_monoclonal_antibody; glucocorticoid	MK-2870-022  2870-022	A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan Maintenance Treatment With or Without Bevacizumab Versus Standard of Care After Second-line Platinum-based Doublet Chemotherapy in Participants With Platinum-sensitive Recurrent Ovarian Cancer (TroFuse-022/ENGOT-ov84/GOG-3103)	Primary Peritoneal Cancer; Fallopian Tube Cancer; Ovarian Cancer	2148 - Sydney; 3002 - East Melbourne; 4120 - Brisbane	https://clinicaltrials.gov/ct2/show/NCT06824467
NCT06830850	HRS-5041-103	Phase 1		NSW, QLD, SA, VIC, WA	2025-02-17	2025-06-15		HRS-5041	AR_PROTAC_degrader	HRS-5041	AR_PROTAC_degrader	HRS-5041-103	A Phase I, Open-label, Multi-Center, Non-Randomized Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-5041 in Subjects With Metastatic Castration-resistant Prostate Cancer	Metastatic Castration Resistant Prostate Cancer	- Sydney; - Wollongong; - Melbourne; - Brisbane; - Adelaide; - Perth	https://clinicaltrials.gov/ct2/show/NCT06830850
NCT06834074	NVL-655-EAP			VIC	2025-02-19			NVL-655; Neladalkib	ALK_inhibitor,fourth_generation	NVL-655; Neladalkib	ALK_inhibitor,fourth_generation	NVL-655-EAP	Expanded Access Treatment of Neladalkib (NVL-655) in Patients With Advanced ALK+ NSCLC	ALK-positive Non-small Cell Lung Cancer (NSCLC); Non Small Cell Lung Cancer	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT06834074
NCT06840119	2023-508090-87-00--IMC-R117C-1004	Phase 1		VIC	2025-03-25	2024-01-10		IMC-R117C	bispecific_T-cell_engager,PIWIL1-targeting	IMC-R117C	bispecific_T-cell_engager,PIWIL1-targeting	2023-508090-87-00  IMC-R117C-1004	A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-R117C (PIWIL1 × CD3 ImmTAC® Bispecific Protein) as a Single Agent and in Combination in HLA-A*02:01-Positive Participants With Selected Advanced PIWIL1-Positive Cancers	Cancer; HLA-A*02:01-positive	- Melbourne	https://clinicaltrials.gov/ct2/show/NCT06840119
NCT06841354	MK-2870-011--2870-011	Phase 3		NZ	2025-02-24	2025-03-16		Carboplatin; Carboplatin + Gemcitabine + Nab-paclitaxel + Paclitaxel; Gemcitabine; Nab-paclitaxel; Paclitaxel; Pembrolizumab; Pembrolizumab + Sacituzumab tirumotecan; Sacituzumab tirumotecan	anti-Trop2_antibody-drug_conjugate; antimetabolite; antimetabolite + platinum-based_antineoplastic_agent + taxane; anti-PD-1_monoclonal_antibody; taxane; gemcitabine; anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; platinum-based_antineoplastic_agent	Carboplatin + Gemcitabine + Nab-paclitaxel + Paclitaxel; Pembrolizumab + Sacituzumab tirumotecan; Sacituzumab tirumotecan	anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; anti-Trop2_antibody-drug_conjugate; antimetabolite + platinum-based_antineoplastic_agent + taxane; gemcitabine	MK-2870-011  2870-011	A Phase 3, Randomized, Open-label Study Comparing Efficacy and Safety of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as a Monotherapy and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With Previously Untreated Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer Expressing PD-L1 at CPS Less Than 10 (TroFuse-011)	Triple Negative Breast Neoplasms	Auckland	https://clinicaltrials.gov/ct2/show/NCT06841354
NCT06855771	2024-519814-29--CA240-0009	Phase 2		NSW, QLD, SA	2025-03-04			BMS-986504	PRMT5_inhibitor,MTA-co-operative	BMS-986504	PRMT5_inhibitor,MTA-co-operative	2024-519814-29  CA240-0009	A Multicenter, Randomized, Open-label, Phase 2 Study Evaluating the Safety and Efficacy of BMS-986504 Monotherapy in Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion After Progression on Prior Therapies	Carcinoma, Non-Small-Cell Lung	5000 - Adelaide; 2560 - Campbelltown; 4102 - Woolloongabba; 2050 - Camperdown	https://clinicaltrials.gov/ct2/show/NCT06855771
NCT06868277	ARTEMIDELung04	Phase 3		QLD, TAS	2025-03-10	2025-04-10		Pembrolizumab; Rilvegostomig	anti-PD-1_monoclonal_antibody; bispecific_PD-1/TIGIT_antibody	Pembrolizumab; Rilvegostomig	anti-PD-1_monoclonal_antibody; bispecific_PD-1/TIGIT_antibody	2024-517780-24-00  D702GC00001	A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab Monotherapy for the First-line Treatment of Patients With PD-L1-high Metastatic Non-small Cell Lung Cancer (ARTEMIDE-Lung04)	Carcinoma, Non-Small Cell Lung	4102 - Woolloongabba; 7000 - Hobart	https://clinicaltrials.gov/ct2/show/NCT06868277
NCT06875310	CA2390004--CA239-0004	Phase 3		ACT, NSW, QLD, SA, VIC, WA	2025-03-13	2025-04-24		Adagrasib; Carboplatin; Cisplatin; Pembrolizumab; Pemetrexed; Placebo	placebo; antimetabolite; KRAS_G12C_inhibitor; platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody	Adagrasib; Carboplatin; Cisplatin; Pembrolizumab; Pemetrexed; Placebo	KRAS_G12C_inhibitor; anti-PD-1_monoclonal_antibody; antimetabolite; placebo; platinum-based_antineoplastic_agent	CA2390004  CA239-0004	A Randomized, Double-Blind, Phase 3 Trial of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated, Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)	Carcinoma, Non-Small-Cell Lung	6027 - Joondalup; 2605 - Canberra; 4102 - Brisbane; 2340 - North Tamworth; 5112 - Elizabeth Vale; 2800 - Orange; 3076 - Melbourne; 3199 - Frankston; 3844 - Traralgon	https://clinicaltrials.gov/ct2/show/NCT06875310
NCT06879041	D7580C00001	Phase 1		VIC	2025-03-17	2025-03-10		225Ac-AZD2284	radioligand,PSMA-targeting	225Ac-AZD2284	radioligand,PSMA-targeting	D7580C00001	A Phase I, First-in-human, Dose Escalation Study Of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer	Metastatic Castration-Resistant Prostate Cancer	3002 - East Melbourne	https://clinicaltrials.gov/ct2/show/NCT06879041
NCT06884618	2024-519622-20-00--YO45758	Phase 1		NZ, VIC	2025-03-19	2025-04-30		RO7673396	pan-KRAS_inhibitor	RO7673396	pan-KRAS_inhibitor	2024-519622-20-00  YO45758	A Phase I Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Clinical Activity of RO7673396 as a Single Agent and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors Harboring RAS Mutation(s)	Neoplasms	3052 - Parkville; Auckland; Christchurch	https://clinicaltrials.gov/ct2/show/NCT06884618
NCT06897735	EDDIS-a1	Phase 1		NZ	2025-03-27			Afatinib	EGFR_inhibitor,second_generation; ERBB2_inhibitor,second_generation	Afatinib	EGFR_inhibitor,second_generation; ERBB2_inhibitor,second_generation	233-1-10AfD	A Phase I Pilot Study to Evaluate the Bioequivalence, Pharmacokinetics, and Safety of Inhaled Afatinib Dimaleate Compared to the Reference Oral Afatinib Dimaleate in Healthy Smoking Volunteers (EDDIS-a1)	Oral Cancer; Melanoma; Lung Cancer	Auckland	https://clinicaltrials.gov/ct2/show/NCT06897735
NCT06909825	CT-2024-CTN-00137-1--FPI-2265-203	Phase 2		NSW, QLD, SA, VIC	2025-04-04	2025-02-26		225Ac-PSMA-I&T; 225Ac-PSMA-I&T + Olaparib; Olaparib	PARP_inhibitor + radioligand,PSMA-targeting; radioligand,PSMA-targeting; PARP_inhibitor	225Ac-PSMA-I&T + Olaparib	PARP_inhibitor + radioligand,PSMA-targeting	CT-2024-CTN-00137-1  FPI-2265-203	A Phase 2, Open-label, Multi-centre Study of FPI-2265 (225Ac-PSMA-I&T) and Olaparib in Participants With Metastatic Castration Resistant Prostate Cancer (mCRPC)	Metastatic Castration-resistant Prostate Cancer	2113 - Macquarie Park; 2010 - Darlinghurst; 3000 - Melbourne; 4102 - Woolloongabba; 3084 - Heidelberg; 5037 - Kurralta Park; 4509 - North Lakes; 5000 - Adelaide	https://clinicaltrials.gov/ct2/show/NCT06909825
NCT06910657	VM-002-101	Phase 1		NSW, VIC	2025-04-04			IDOV-Immune	oncolytic_virus,undisclosed_mechanism	IDOV-Immune	oncolytic_virus,undisclosed_mechanism	VM-002-101	A First-in-human, Phase I, Multi-center, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Evidence of Antitumor Activity of IDOV-Immune in Adult Participants With Advanced Solid Tumors	Lung Cancer; Hepatocellular Carcinoma; Prostate Cancer; Melanoma; Breast Cancer; Adrenal Gland Tumors; Gastric Cancer; Bladder Cancer; Colorectal Cancer; Cervical Cancers; Head and Neck Cancers; Renal Cell Carcinoma; Pancreatic Cancer; Sarcoma; Esophageal Cancer; Ovarian Cancer	3004 - Melbourne; 2145 - Westmead	https://clinicaltrials.gov/ct2/show/NCT06910657
NCT06914128	2025-520623-24-00--22931	Phase 1	RECRUITING	NSW	2025-04-06	2025-03-21		BAY3713372	PRMT5_inhibitor	BAY3713372	PRMT5_inhibitor	2025-520623-24-00  22931	A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of BAY 3713372, a Novel 2nd Generation PRMT5 Inhibitor, in Participants With MTAP-deleted Solid Tumors.	MTAP-deleted Solid Tumors	2139 - Concord; 2050 - Camperdown	https://clinicaltrials.gov/ct2/show/NCT06914128
NCT06921837	BBI-4182-101	Phase 1		NSW, QLD	2025-04-10			BDC-4182	anti-CLDN18.2_immune-stimulating_antibody_conjugate,TLR7/8_agonist	BDC-4182	anti-CLDN18.2_immune-stimulating_antibody_conjugate,TLR7/8_agonist	BBI-4182-101	A Phase 1/2, First-in-Human, Dose Escalation and Expansion Study of BDC-4182 as a Single Agent in Patients With Advanced Gastric and Gastroesophageal Cancer	Gastroesophageal Adenocarcinoma; Gastric Cancer Adenocarcinoma Metastatic	- Birtinya; - Darlinghurst	https://clinicaltrials.gov/ct2/show/NCT06921837
NCT06923761	EMITT-1	Phase 1		NSW, QLD, SA, VIC	2025-04-11	2023-05-21		Cemiplimab; Cemiplimab + GRWD5769; GRWD5769	ERAP1_inhibitor; ERAP1_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody	Cemiplimab + GRWD5769; GRWD5769	ERAP1_inhibitor; ERAP1_inhibitor + anti-PD-1_monoclonal_antibody	GRWD5769-ST-01	A Modular, Multi-part, Multi-arm, Open-label, Phase I/II Study to Evaluate the Safety and Tolerability of GRWD5769 Alone and in Combination With Anticancer Treatments in Patients With Solid Malignancies	Advanced Solid Malignancy	- Adelaide; - South Brisbane; - Bedford Park; - Wollongong; - Blacktown; - Darlinghurst; - Melbourne; - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT06923761
NCT06925737	U1111-1312-2498--2400-001	Phase 3		VIC	2025-04-13	2025-05-13		Docetaxel; Docetaxel + Prednisone; Ifinatamab Deruxtecan; Prednisone	glucocorticoid + taxane; glucocorticoid; anti-B7H3_antibody-drug_conjugate; taxane	Docetaxel + Prednisone; Ifinatamab Deruxtecan	glucocorticoid + taxane; anti-B7H3_antibody-drug_conjugate	U1111-1312-2498  2400-001	A Phase 3, Open-label Study of Ifinatamab Deruxtecan Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (IDeate-Prostate01)	Prostate Cancer; Prostatic Neoplasms	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT06925737
NCT06926075	ADVICE	Phase 1			2025-04-13			Kesonotide	hGIIA-vimentin_inhibitor	Kesonotide	hGIIA-vimentin_inhibitor	FLM-CT002	An Adaptive Phase I/II Study of Kesonotide, a Novel hGIIA-vimentin Inhibitor, in Participants With Solid Tumours	Prostate Cancers; Lung Cancers; Glioblastoma Multiforme (GBM); Breast Cancer; Pancreas Cancer; Ovarian Cancer; Skin Cancer		https://clinicaltrials.gov/ct2/show/NCT06926075
NCT06926868	2024-519871-24--CA244-0008	Phase 2		QLD, VIC, WA	2025-04-15			Capecitabine; Carboplatin; Gemcitabine; Izalontamab Brengitecan; Nab-paclitaxel; Paclitaxel	antimetabolite; fluoropyrimidine; bispecific_EGFR/ERBB3_antibody; taxane; gemcitabine; platinum-based_antineoplastic_agent	Capecitabine; Carboplatin; Gemcitabine; Izalontamab Brengitecan; Nab-paclitaxel	antimetabolite; bispecific_EGFR/ERBB3_antibody; fluoropyrimidine; gemcitabine; platinum-based_antineoplastic_agent; taxane	2024-519871-24  CA244-0008	A Randomized, Open-label, Inferentially Seamless Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) Versus Treatment of Physician's Choice in Patients With Previously Untreated, Locally Advanced, Recurrent Inoperable,or Metastatic Triple-negative Breast Cancer (TNBC)or ER-low, HER2-negative BC Who Are Ineligible for Anti-PD1/PD-L1 Treatment	Breast Neoplasms	3350 - Ballarat Central; 3000 - Melbourne; 6008 - Subiaco; 3084 - Heidelberg; 4029 - Brisbane	https://clinicaltrials.gov/ct2/show/NCT06926868
NCT06926920	2024-519124-25--GS-US-576-7321	Phase 1		NSW	2025-04-15	2025-04-30		Sacituzumab Govitecan	anti-Trop2_antibody-drug_conjugate	Sacituzumab Govitecan	anti-Trop2_antibody-drug_conjugate	2024-519124-25  GS-US-576-7321	A Phase 1/2, Open-label Study of Sacituzumab Govitecan Administered at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer	Triple Negative Breast Cancer	2010 - Darlinghurst	https://clinicaltrials.gov/ct2/show/NCT06926920
NCT06953089	DB-1311-201	Phase 2		NSW	2025-05-01			BNT325; BNT325 + DB-1311; BNT327; BNT327 + DB-1311; DB-1311	anti-Trop2_antibody-drug_conjugate; bispecific_PD-L1/VEGFA_antibody; anti-B7H3_antibody-drug_conjugate + anti-Trop2_antibody-drug_conjugate; anti-B7H3_antibody-drug_conjugate; anti-B7H3_antibody-drug_conjugate + bispecific_PD-L1/VEGFA_antibody	BNT325 + DB-1311; BNT327 + DB-1311	anti-B7H3_antibody-drug_conjugate + anti-Trop2_antibody-drug_conjugate; anti-B7H3_antibody-drug_conjugate + bispecific_PD-L1/VEGFA_antibody	DB-1311-201	A Phase II, Multicenter, Open-Label Trial of DB-1311 in Combination With BNT327 or DB-1305 in Participants With Advanced/Metastatic Solid Tumors	Solid Tumors	2109 - North Ryde BC	https://clinicaltrials.gov/ct2/show/NCT06953089
NCT06956690	ENV-ONC-501	Phase 1		NSW	2025-05-04			ENV-501	anti-ERBB3_antibody-drug_conjugate	ENV-501	anti-ERBB3_antibody-drug_conjugate	ENV-ONC-501	A First-in-Human, Open-label, Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ENV-501 in Patients With Advanced-Stage, Relapsed/Refractory HER3-Expressing Solid Tumors	Non Small Cell Lung Cancer; Melanoma (Skin); Breast Cancer	2560 - Campbelltown; 2228 - Miranda	https://clinicaltrials.gov/ct2/show/NCT06956690
NCT06960395	U1111-1294-8156--VIR-5525-V101	Phase 1		NSW, QLD	2025-05-07			Pembrolizumab; VIR-5525	bispecific_T-cell_engager,EGFR-targeting; anti-PD-1_monoclonal_antibody	VIR-5525; Pembrolizumab	bispecific_T-cell_engager,EGFR-targeting; anti-PD-1_monoclonal_antibody	U1111-1294-8156  VIR-5525-V101	A Phase 1, First-in-Human Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5525 Alone and in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors	EGFR; Solid Tumor Malignancies; EGFR Positive Solid Tumors	4102 - Woolloongabba; 2500 - Wollongong	https://clinicaltrials.gov/ct2/show/NCT06960395
NCT06961006	V940-012--V940-012	Phase 2		NZ, WA	2025-05-07	2025-05-29		Pembrolizumab; Pembrolizumab + mRNA-4157; Placebo; mRNA-4157	placebo; mRNA_personalised_cancer_vaccine; anti-PD-1_monoclonal_antibody + mRNA_personalised_cancer_vaccine; anti-PD-1_monoclonal_antibody	Pembrolizumab; Pembrolizumab + mRNA-4157; Placebo	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + mRNA_personalised_cancer_vaccine; placebo	V940-012  V940-012	A Phase 2, Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Clinical Study of V940 (mRNA-4157) Plus Pembrolizumab Versus Placebo Plus Pembrolizumab in Participants With First-Line Advanced Melanoma (INTerpath-012)	Malignant Melanoma	Auckland; 6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT06961006
NCT06989112	DE-01	Phase 3		NSW, QLD, VIC, WA	2025-05-25	2025-03-27		Carboplatin; Carboplatin + Docetaxel + Paclitaxel + Pembrolizumab; Docetaxel; Paclitaxel; Pembrolizumab; Pembrolizumab + Trastuzumab Deruxtecan; Rilvegostomig; Rilvegostomig + Trastuzumab Deruxtecan; Trastuzumab Deruxtecan	anti-ERBB2_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; anti-PD-1_monoclonal_antibody; taxane; platinum-based_antineoplastic_agent; anti-ERBB2_antibody-drug_conjugate + bispecific_PD-1/TIGIT_antibody; anti-ERBB2_antibody-drug_conjugate; bispecific_PD-1/TIGIT_antibody	Carboplatin + Docetaxel + Paclitaxel + Pembrolizumab; Pembrolizumab + Trastuzumab Deruxtecan; Rilvegostomig + Trastuzumab Deruxtecan	anti-ERBB2_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody; anti-ERBB2_antibody-drug_conjugate + bispecific_PD-1/TIGIT_antibody; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane	2023-508056-19-00  D781DC00001	DESTINY-Endometrial01: An Open-Label, Sponsor-Blinded, Randomized, Controlled, Multicenter, Phase III Study of Trastuzumab Deruxtecan (T-DXd) Plus Rilvegostomig or Pembrolizumab vs Chemotherapy Plus Pembrolizumab as First-Line Therapy of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR), Primary Advanced or Recurrent Endometrial Cancer	Endometrial Cancer	3002 - East Melbourne; 2148 - Blacktown; 6009 - Nedlands; 4101 - South Brisbane	https://clinicaltrials.gov/ct2/show/NCT06989112
NCT07016490	SSGJ-709-101	Phase 1		SA	2025-06-11			SSGJ-709	bispecific_PD-1/LAG3_antibody	SSGJ-709	bispecific_PD-1/LAG3_antibody	SSGJ-709-101	A Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Anti-tumor Activity of SSGJ-709 in Patients With Advanced Malignant Tumors	Advanced Malignant Tumors	- Adelaide	https://clinicaltrials.gov/ct2/show/NCT07016490
NCT07026279	U1111-1298-5990--AMP945-PC-202	Phase 1		NSW, VIC	2025-06-18			Narmafotinib	FAK_inhibitor	Narmafotinib	FAK_inhibitor	U1111-1298-5990  AMP945-PC-202	A Phase 1b/2a, Multicenter, Open Label Study of the Safety, Efficacy and Pharmacokinetics of Narmafotinib in Combination With Modified FOLFIRINOX in Pancreatic Cancer Patients	Pancreatic Cancer Metastatic	2065 - St Leonards; 3121 - Richmond	https://clinicaltrials.gov/ct2/show/NCT07026279
NCT07042100	SBO-154-25-01	Phase 1		QLD	2025-06-27			SBO-154	anti-MUC1_antibody-drug_conjugate	SBO-154	anti-MUC1_antibody-drug_conjugate	SBO-154-25-01	A Phase 1, Multicentre, Open-label, Multiple-dose Study to Determine Safety, Tolerability, and Preliminary Efficacy of SBO-154 in Subjects With Advanced Solid Tumors	Advanced Solid Tumors	4557 - Birtinya	https://clinicaltrials.gov/ct2/show/NCT07042100
NCT07063875	SILVER	Phase 1		NSW, VIC	2025-07-14	2025-06-01		Aldesleukin; Tebentafusp	IL-2_variant; bispecfic_T-cell_engager,gp100-targeting	Aldesleukin; Tebentafusp	IL-2_variant; bispecfic_T-cell_engager,gp100-targeting	SILVER Trial	Supplementing With IL-2 to Verifiably eRadicate Radiological Progression	Metastatic Uveal Melanoma in the Liver; Metastatic Uveal Melanoma; Uveal Melanoma	3004 - Melbourne; 2010 - Sydney	https://clinicaltrials.gov/ct2/show/NCT07063875
